Reactive	O
oxygen	O
intermediate	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
by	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
requires	O
5	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
or	O
NADPH	O
oxidase	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF	O
-	O
kappaB	O
activation	O
by	O
proinflammatory	O
cytokines	O
was	O
cell	O
specific	O
.	O

However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
(	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
)	O
and	O
NADPH	O
oxidase	O
.	O

5	B-PRGE
-	I-PRGE
LOX	I-PRGE
and	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
activating	O
protein	O
(	O
FLAP	B-PRGE
)	O
are	O
coexpressed	O
in	O
lymphoid	O
cells	O
but	O
not	O
in	O
monocytic	O
or	O
epithelial	O
cells	O
.	O

Stimulation	O
of	O
lymphoid	O
cells	O
with	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
led	O
to	O
ROI	O
production	O
and	O
NF	O
-	O
kappaB	O
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B-PRGE
inhibitors	O
,	O
confirming	O
that	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
these	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
stimulation	O
of	O
epithelial	O
cells	O
did	O
not	O
generate	O
any	O
ROIs	O
and	O
NF	O
-	O
kappaB	O
induction	O
was	O
not	O
influenced	O
by	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
inhibitors	O
.	O

However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
monocytic	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
enzyme	O
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

This	O
pathway	O
involves	O
the	O
Rac1	B-PRGE
and	O
Cdc42	B-PRGE
GTPases	O
,	O
two	O
enzymes	O
which	O
are	O
not	O
required	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
in	O
epithelial	O
cells	O
.	O

In	O
conclusion	O
,	O
three	O
different	O
cell	O
-	O
specific	O
pathways	O
lead	O
to	O
NF	O
-	O
kappaB	O
activation	O
by	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
in	O
lymphoid	O
cells	O
,	O
an	O
ROI	O
-	O
and	O
5	B-PRGE
-	I-PRGE
LOX	I-PRGE
-	O
independent	O
pathway	O
in	O
epithelial	O
cells	O
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	O
oxidase	O
in	O
monocytic	O
cells	O
.	O

Activation	O
-	O
dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	O
Fas	B-PRGE
promoter	O
requires	O
NF	O
-	O
kappaB	O
p50	B-PRGE
-	O
p65	B-PRGE
recruitment	O
.	O

Fas	B-PRGE
(	O
CD95	B-PRGE
)	O
and	O
Fas	B-PRGE
ligand	I-PRGE
(	O
CD95L	B-PRGE
)	O
are	O
an	O
interacting	O
receptor	O
-	O
ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-PRGE
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	B-PRGE
-	O
mediated	O
apoptosis	O
.	O

Although	O
Fas	B-PRGE
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation	O
-	O
induced	O
Fas	B-PRGE
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	B-PRGE
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	O
T	O
-	O
cell	O
line	O
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T	O
-	O
cell	O
receptor	O
activation	O
.	O

Although	O
resting	O
Jurkat	O
cells	O
express	O
Fas	B-PRGE
,	O
Fas	B-PRGE
mRNA	O
was	O
induced	O
approximately	O
10	O
-	O
fold	O
in	O
2	O
h	O
upon	O
P	O
/	O
I	O
stimulation	O
.	O

Using	O
sequential	O
deletion	O
mutants	O
of	O
the	O
human	O
fas	B-PRGE
promoter	O
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47	O
-	O
bp	O
sequence	O
(	O
positions	O
-	O
306	O
to	O
-	O
260	O
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation	O
-	O
driven	O
fas	B-PRGE
upregulation	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	O
composite	O
binding	O
site	O
for	O
both	O
the	O
Sp1	B-PRGE
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
at	O
positions	O
-	O
295	O
to	O
-	O
286	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	B-PRGE
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50	B-PRGE
-	O
p65	B-PRGE
NF	O
-	O
kappaB	O
heterodimers	O
after	O
P	O
/	O
I	O
activation	O
.	O

Sp1	B-PRGE
and	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	B-PRGE
and	O
recombinant	O
p50	B-PRGE
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB	O
-	O
Sp1	B-PRGE
composite	O
site	O
in	O
P	O
/	O
I	O
-	O
inducible	O
fas	B-PRGE
promoter	O
activation	O
was	O
verified	O
by	O
using	O
kappaB	O
-	O
Sp1	B-PRGE
concatamers	O
(	O
-	O
295	O
to	O
-	O
286	O
)	O
in	O
a	O
thymidine	O
kinase	O
promoter	O
-	O
driven	O
reporter	O
construct	O
and	O
native	O
promoter	O
constructs	O
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB	O
-	O
Sp1	B-PRGE
element	O
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation	O
-	O
dependent	O
fas	B-PRGE
promoter	O
induction	O
.	O

RFLAT	B-PRGE
-	I-PRGE
1	I-PRGE
:	O
a	O
new	O
zinc	O
finger	O
transcription	O
factor	O
that	O
activates	O
RANTES	B-PRGE
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

RANTES	B-PRGE
(	O
Regulated	B-PRGE
upon	I-PRGE
Activation	I-PRGE
,	I-PRGE
Normal	I-PRGE
T	I-PRGE
cell	I-PRGE
Expressed	I-PRGE
and	I-PRGE
Secreted	I-PRGE
)	O
is	O
a	O
chemoattractant	O
cytokine	O
(	O
chemokine	O
)	O
important	O
in	O
the	O
generation	O
of	O
inflammatory	O
infiltrate	O
and	O
human	O
immunodeficiency	O
virus	O
entry	O
into	O
immune	O
cells	O
.	O

RANTES	B-PRGE
is	O
expressed	O
late	O
(	O
3	O
-	O
5	O
days	O
)	O
after	O
activation	O
in	O
T	O
lymphocytes	O
.	O

Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
"	O
late	O
"	O
T	O
lymphocyte	O
associated	O
transcription	O
factor	O
and	O
named	O
it	O
"	O
RANTES	B-PRGE
Factor	I-PRGE
of	I-PRGE
Late	I-PRGE
Activated	I-PRGE
T	I-PRGE
Lymphocytes	I-PRGE
-	I-PRGE
1	I-PRGE
"	O
(	O
RFLAT	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

RFLAT	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
novel	O
,	O
phosphorylated	O
,	O
zinc	O
finger	O
transcription	O
factor	O
that	O
is	O
expressed	O
in	O
T	O
cells	O
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	B-PRGE
expression	O
.	O

While	O
Rel	O
proteins	O
play	O
the	O
dominant	O
role	O
in	O
RANTES	B-PRGE
gene	O
expression	O
in	O
fibroblasts	O
,	O
RFLAT	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
strong	O
transactivator	O
for	O
RANTES	B-PRGE
in	O
T	O
cells	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
inhibits	O
expression	O
of	O
both	O
interferon	O
alpha	O
-	O
and	O
interferon	B-PRGE
gamma	I-PRGE
-	O
induced	O
genes	O
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-PRGE
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
helps	O
maintain	O
polarized	O
T	O
-	O
helper	O
cells	O
in	O
a	O
T	O
-	O
helper	O
lymphocyte	O
2	O
(	O
Th2	O
)	O
phenotype	O
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	O
cells	O
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	B-PRGE
gamma	I-PRGE
(	O
IFNgamma	B-PRGE
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	O
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Because	O
monocytes	O
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1	O
-	O
type	O
responses	O
,	O
such	O
as	O
delayed	O
-	O
type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma	B-PRGE
-	O
and	O
IFNalpha	O
-	O
induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	B-PRGE
or	O
IFNalpha	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN	O
-	O
induced	O
genes	O
,	O
such	O
as	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
ISG54	B-PRGE
,	O
and	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
to	O
suppress	O
IFN	O
-	O
induced	O
assembly	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
to	O
specific	O
promoter	O
motifs	O
on	O
IFNalpha	O
-	O
and	O
IFNgamma	B-PRGE
-	O
inducible	O
genes	O
.	O

This	O
was	O
accomplished	O
by	O
preventing	O
the	O
IFN	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-PRGE
,	O
a	O
component	O
of	O
both	O
IFNalpha	O
-	O
and	O
IFNgamma	B-PRGE
-	O
induced	O
DNA	O
binding	O
complexes	O
.	O

Therefore	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
can	O
directly	O
inhibit	O
STAT	O
-	O
dependent	O
early	O
response	O
gene	O
expression	O
induced	O
by	O
both	O
IFNalpha	O
and	O
IFNgamma	B-PRGE
in	O
monocytes	O
by	O
suppressing	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-PRGE
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	B-PRGE
of	I-PRGE
cytokine	I-PRGE
signaling	I-PRGE
3	I-PRGE
(	O
SOCS3	B-PRGE
)	O
.	O

The	O
Megakaryocyte	O
/	O
Platelet	O
-	O
specific	O
enhancer	O
of	O
the	O
alpha2beta1	O
integrin	O
gene	O
:	O
two	O
tandem	O
AP1	O
sites	O
and	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
cascade	O
.	O

The	O
alpha2beta1	O
integrin	O
,	O
a	O
collagen	O
receptor	O
on	O
platelets	O
and	O
megakaryocytes	O
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
alpha2	B-PRGE
integrin	I-PRGE
gene	O
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	O
a	O
core	O
promoter	O
between	O
bp	O
-	O
30	O
and	O
-	O
92	O
,	O
a	O
silencer	O
between	O
bp	O
-	O
92	O
and	O
-	O
351	O
,	O
and	O
megakaryocytic	O
enhancers	O
in	O
the	O
distal	O
5	O
'	O
flank	O
.	O

We	O
have	O
now	O
identified	O
a	O
229	O
-	O
bp	O
region	O
of	O
the	O
distal	O
5	O
'	O
flank	O
of	O
the	O
alpha2	B-PRGE
integrin	I-PRGE
gene	O
required	O
for	O
high	O
-	O
level	O
enhancer	O
activity	O
in	O
cells	O
with	O
megakaryocytic	O
features	O
.	O

Two	O
tandem	O
AP1	O
binding	O
sites	O
with	O
dyad	O
symmetry	O
are	O
required	O
for	O
enhancer	O
activity	O
and	O
for	O
DNA	O
-	O
protein	O
complex	O
formation	O
with	O
members	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
family	O
.	O

The	O
requirement	O
for	O
AP1	O
activation	O
suggested	O
a	O
role	O
for	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
in	O
regulating	O
alpha2	B-PRGE
integrin	I-PRGE
gene	O
expression	O
.	O

Inhibition	O
of	O
the	O
MAP	O
kinase	O
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
MAPK	B-PRGE
kinase	I-PRGE
1	I-PRGE
,	O
prevented	O
the	O
expression	O
of	O
the	O
alpha2	B-PRGE
integrin	I-PRGE
subunit	O
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O

We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	O
of	O
the	O
alpha2	B-PRGE
integrin	I-PRGE
gene	O
requires	O
signaling	O
via	O
the	O
MAP	O
kinase	O
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	O
binding	O
sites	O
in	O
the	O
alpha2	B-PRGE
integrin	I-PRGE
enhancer	O
.	O

Differential	O
expression	O
and	O
phosphorylation	O
of	O
CTCF	B-PRGE
,	O
a	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
transcriptional	O
regulator	O
,	O
during	O
differentiation	O
of	O
human	O
myeloid	O
cells	O
.	O

CTCF	B-PRGE
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
gene	O
.	O

Although	O
CTCF	B-PRGE
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	B-PRGE
activity	O
.	O

Therefore	O
we	O
investigated	O
CTCF	B-PRGE
expression	O
and	O
phosphorylation	O
during	O
induced	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O

We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	B-PRGE
mRNA	O
and	O
protein	O
are	O
down	O
-	O
regulated	O
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	B-PRGE
down	O
-	O
regulation	O
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
;	O
(	O
iii	O
)	O
CTCF	B-PRGE
protein	O
is	O
differentially	O
phosphorylated	O
and	O
the	O
phosphorylation	O
profiles	O
depend	O
on	O
the	O
differentiation	O
pathway	O
.	O

We	O
concluded	O
that	O
CTCF	B-PRGE
expression	O
and	O
activity	O
is	O
controlled	O
at	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
levels	O
.	O

T	O
-	O
cell	O
expression	O
of	O
the	O
human	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
is	O
regulated	O
by	O
a	O
non	O
-	O
lineage	O
-	O
specific	O
silencer	O
.	O

The	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
transcription	O
factor	O
is	O
required	O
for	O
development	O
of	O
the	O
T	O
-	O
cell	O
lineage	O
and	O
Th2	O
cytokine	O
gene	O
expression	O
in	O
CD4	B-PRGE
T	O
-	O
cells	O
.	O

We	O
have	O
mapped	O
the	O
DNase	O
-	O
I	O
-	O
hypersensitive	O
(	O
HS	O
)	O
regions	O
of	O
the	O
human	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
in	O
T	O
-	O
cells	O
and	O
non	O
-	O
T	O
-	O
cells	O
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O

HS	O
I	O
-	O
III	O
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	O
initiation	O
site	O
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non	O
-	O
hematopoietic	O
cells	O
,	O
whereas	O
HS	O
IV	O
-	O
VII	O
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	O
start	O
site	O
,	O
were	O
exclusively	O
observed	O
in	O
T	O
-	O
cells	O
.	O

Among	O
these	O
hypersensitive	O
sites	O
,	O
two	O
transcriptional	O
control	O
elements	O
were	O
found	O
,	O
one	O
in	O
the	O
first	O
intron	O
of	O
the	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
and	O
the	O
other	O
between	O
8	O
.	O
3	O
and	O
5	O
.	O
9	O
kilobases	O
5	O
'	O
from	O
the	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
transcriptional	O
initiation	O
site	O
.	O

The	O
first	O
intron	O
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
and	O
with	O
no	O
cell	O
-	O
type	O
specificity	O
.	O

The	O
upstream	O
regulatory	O
element	O
could	O
confer	O
T	O
-	O
cell	O
specificity	O
to	O
the	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707	O
-	O
base	O
pair	O
silencer	O
that	O
drastically	O
inhibited	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
activity	O
in	O
non	O
-	O
T	O
-	O
cells	O
.	O

Two	O
CAGGTG	O
E	O
-	O
boxes	O
,	O
located	O
at	O
the	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
ends	O
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O

The	O
3	O
'	O
-	O
CAGGTG	O
E	O
-	O
box	O
could	O
bind	O
USF	O
proteins	O
,	O
the	O
ubiquitous	O
repressor	O
ZEB	B-PRGE
,	O
or	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
E2A	B-PRGE
and	O
HEB	B-PRGE
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	B-PRGE
and	O
E2A	B-PRGE
/	O
HEB	B-PRGE
proteins	O
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

AML	O
and	O
Ets	O
proteins	O
regulate	O
the	O
I	O
alpha1	O
germ	O
-	O
line	O
promoter	O
.	O

The	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
class	O
switch	O
recombination	O
of	O
B	O
lymphocytes	O
preferentially	O
targets	O
unrearranged	O
IgH	O
genes	O
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O

Transcription	O
of	O
the	O
germ	O
-	O
line	O
IgH	O
genes	O
is	O
controlled	O
by	O
intervening	O
(	O
I	O
)	O
regions	O
upstream	O
of	O
their	O
switch	O
regions	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	O
germ	O
-	O
line	O
C	O
alpha1	O
gene	O
for	O
IgA1	O
and	O
mediates	O
the	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	I-PRGE
TGF	I-PRGE
)	I-PRGE
-	I-PRGE
beta1	I-PRGE
responsiveness	O
of	O
this	O
locus	O
.	O

Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML	O
/	O
PEBP2	O
/	O
CBF	O
family	O
of	O
transcription	O
factors	O
and	O
that	O
AML	O
and	O
Ets	O
proteins	O
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF	O
-	O
beta	O
-	O
inducible	O
promoter	O
activity	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
regulates	O
IgA	O
production	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
isolated	O
from	O
patients	O
with	O
diabetic	O
nephropathy	O
show	O
increased	O
activation	O
of	O
the	O
oxidative	O
-	O
stress	O
sensitive	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O

To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF	O
-	O
kappaB	O
activation	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
examined	O
33	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
Type	O
I	O
and	O
Type	O
II	O
)	O
.	O

Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	O
immunohistological	O
staining	O
for	O
activated	O
NF	B-PRGE
-	I-PRGE
kappaBp65	I-PRGE
than	O
patients	O
without	O
renal	O
complications	O
.	O

NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0	O
.	O
316	O
)	O
and	O
with	O
thrombomodulin	B-PRGE
plasma	O
concentrations	O
(	O
r	O
=	O
0	O
.	O
33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O

In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
38	O
%	O
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
at	O
least	O
in	O
part	O
dependent	O
on	O
oxidative	O
stress	O
since	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
reduced	O
NF	O
-	O
kappaB	O
binding	O
activity	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G	O
.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	O
or	O
protease	O
.	O

G	O
.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

G	O
.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long	O
-	O
terminal	O
repeat	O
transcription	O
in	O
HIV	O
-	O
infected	O
cells	O
and	O
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G	O
.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G	O
.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G	O
.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Interferon	O
-	O
alpha	O
activates	O
multiple	O
STAT	O
proteins	O
and	O
upregulates	O
proliferation	O
-	O
associated	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
and	O
pim	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
in	O
human	O
T	O
cells	O
.	O

Interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
is	O
a	O
pleiotropic	O
cytokine	O
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	O
functions	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN	O
-	O
alpha	O
has	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
and	O
pim	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
in	O
anti	O
-	O
CD3	O
-	O
activated	O
human	O
T	O
lymphocytes	O
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Treatment	O
of	O
T	O
lymphocytes	O
with	O
IFN	O
-	O
alpha	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	O
-	O
12	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
upregulated	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
and	O
pim	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
.	O

IFN	O
-	O
alpha	O
also	O
sensitized	O
T	O
cells	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN	O
-	O
alpha	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
mitogenesis	O
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	O
proteins	O
capable	O
of	O
binding	O
to	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
,	O
pim	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
GAS	O
elements	O
after	O
cytokine	O
stimulation	O
,	O
we	O
observed	O
IFN	O
-	O
alpha	O
-	O
induced	O
binding	O
of	O
STAT1	B-PRGE
,	O
STAT3	B-PRGE
,	O
and	O
STAT4	B-PRGE
,	O
but	O
not	O
STAT5	O
to	O
all	O
of	O
these	O
elements	O
.	O

Yet	O
,	O
IFN	O
-	O
alpha	O
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	O
to	O
the	O
high	O
-	O
affinity	O
IFP53	B-PRGE
GAS	O
site	O
.	O

IFN	O
-	O
alpha	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-PRGE
,	O
STAT3	B-PRGE
,	O
STAT4	B-PRGE
,	O
STAT5a	B-PRGE
,	O
and	O
STAT5b	B-PRGE
.	O

IL	O
-	O
12	O
induced	O
STAT4	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
induced	O
STAT5	O
binding	O
to	O
the	O
GAS	O
elements	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN	O
-	O
alpha	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	O
-	O
12	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O

These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN	O
-	O
alpha	O
as	O
a	O
T	O
-	O
cell	O
regulatory	O
cytokine	O
.	O

Anti	O
-	O
rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
latently	O
infected	O
OM10	O
.	O
1	O
and	O
Ach2	O
cells	O
.	O

NF	O
-	O
kappaB	O
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	O
infected	O
cells	O
.	O

Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA	O
-	O
binding	O
of	O
NF	O
-	O
kappaB	O
in	O
vitro	O
.	O

In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10	O
.	O
1	O
and	O
Ach2	O
cells	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
OM10	O
.	O
1	O
or	O
Ach2	O
cells	O
was	O
significantly	O
inhibited	O
by	O
non	O
-	O
cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10	O
.	O
1	O
cells	O
and	O
>	O
25	O
F	O
.	O
M	O
in	O
Ach2	O
cells	O
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter	O
-	O
anion	O
thioglucose	O
(	O
TG	O
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O

The	O
effect	O
of	O
AuTG	O
on	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	B-PRGE
assay	O
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF	O
-	O
kappaB	O
-	O
DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	O
factor	O
NFAT1	B-PRGE
at	O
its	O
proximal	O
binding	O
element	O
P0	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
associated	O
with	O
enhanced	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
transcription	O
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O

Allergen	O
-	O
specific	O
T	O
cells	O
in	O
atopic	O
patients	O
are	O
polarized	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
producing	O
Th2	O
cells	O
,	O
promoting	O
IgE	B-PRGE
synthesis	O
by	O
B	O
cells	O
.	O

The	O
molecular	O
basis	O
for	O
increased	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
regulation	O
in	O
general	O
involves	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
of	O
which	O
NFAT1	B-PRGE
and	O
NFAT2	B-PRGE
are	O
most	O
prominent	O
in	O
peripheral	O
T	O
cells	O
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	B-PRGE
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA	O
-	O
binding	O
activities	O
at	O
the	O
two	O
NFAT	O
-	O
binding	O
elements	O
P0	O
and	O
P1	O
of	O
the	O
crucial	O
proximal	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

At	O
the	O
most	O
proximal	O
P0	O
site	O
,	O
NFAT	O
-	O
containing	O
complexes	O
devoid	O
of	O
NFAT2	B-PRGE
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	O
clones	O
.	O

In	O
contrast	O
,	O
both	O
in	O
Th1	O
and	O
Th2	O
clones	O
NFAT	O
-	O
containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	O
site	O
,	O
consisting	O
of	O
NFAT2	B-PRGE
and	O
a	O
P0	O
-	O
compatible	O
NFAT	O
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	O
and	O
Th2	O
clones	O
.	O

Like	O
in	O
Th2	O
clones	O
,	O
suppressed	O
NFAT	O
-	O
P0	O
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	B-PRGE
levels	O
,	O
but	O
not	O
in	O
control	O
PBMC	O
.	O

These	O
findings	O
suggest	O
that	O
high	O
-	O
level	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
production	O
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	B-PRGE
activity	O
at	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
P0	O
element	O
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O

OBJECTIVE	O
:	O
The	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
distinctive	O
patterns	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
are	O
seen	O
in	O
different	O
forms	O
of	O
joint	O
disease	O
.	O

METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	O
was	O
examined	O
in	O
purified	O
synovial	O
and	O
peripheral	O
T	O
cells	O
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O

RESULTS	O
:	O
Electrophoretic	O
mobility	O
shift	O
assays	O
disclosed	O
two	O
specific	O
complexes	O
bound	O
to	O
a	O
NF	O
-	O
kappa	O
B	O
specific	O
32P	O
-	O
labelled	O
oligonucleotide	O
in	O
nucleoproteins	O
extracted	O
from	O
purified	O
T	O
cells	O
isolated	O
from	O
synovial	O
fluid	O
and	O
peripheral	O
blood	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
complexes	O
consisted	O
of	O
p50	B-PRGE
/	O
p50	B-PRGE
homodimers	O
and	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

Increased	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
DNA	O
in	O
synovial	O
T	O
cells	O
was	O
observed	O
relative	O
to	O
peripheral	O
T	O
cells	O
.	O

In	O
non	O
-	O
rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
synovial	O
T	O
cells	O
was	O
exclusively	O
mediated	O
by	O
p50	B-PRGE
/	O
p50	B-PRGE
homodimers	O
.	O

CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	O
T	O
cells	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	O
synovial	O
T	O
cells	O
to	O
that	O
in	O
other	O
forms	O
of	O
non	O
-	O
rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
CSF	I-PRGE
.	O

We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS	O
-	O
induced	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
production	O
of	O
cytokines	O
by	O
DC	O
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA	O
-	O
DR	O
,	O
CD86	B-PRGE
(	O
B7	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
and	O
CD40	B-PRGE
molecules	O
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	B-PRGE
engagement	O
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	O
nor	O
their	O
mannose	B-PRGE
receptor	I-PRGE
-	O
mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	O
T	O
cells	O
and	O
allogeneic	O
DC	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	O
as	O
APC	O
-	O
independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O

Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	O
factor	O
-	O
kappaB	O
through	O
interleukin	O
-	O
1	O
signaling	O
mediators	O
in	O
cultured	O
human	O
dermal	O
endothelial	O
cells	O
and	O
mononuclear	O
phagocytes	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram	O
-	O
negative	O
bacteria	O
-	O
induced	O
sepsis	O
syndrome	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS	O
-	O
responsive	O
cells	O
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
signal	O
transducer	O
molecules	O
in	O
LPS	O
signaling	O
in	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
HDMEC	O
)	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

LPS	O
stimulation	O
of	O
HDMEC	O
and	O
THP	O
-	O
1	O
cells	O
initiated	O
an	O
IL	O
-	O
1	O
receptor	O
-	O
like	O
NF	O
-	O
kappaB	O
signaling	O
cascade	O
.	O

In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL	O
-	O
1	O
signaling	O
pathway	O
,	O
including	O
MyD88	B-PRGE
,	O
IRAK	B-PRGE
,	O
IRAK2	B-PRGE
,	O
and	O
TRAF6	B-PRGE
inhibited	O
both	O
IL	O
-	O
1	O
-	O
and	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
-	O
luciferase	O
activity	O
.	O

LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B-PRGE
that	O
is	O
involved	O
in	O
TNF	O
signaling	O
.	O

LPS	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
reporter	O
gene	O
was	O
not	O
inhibited	O
by	O
IL	O
-	O
1	O
receptor	O
antagonist	O
.	O

TLR2	B-PRGE
and	O
TLR4	B-PRGE
were	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
HDMEC	O
and	O
THP	O
-	O
1	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
signal	O
transduction	O
molecule	O
in	O
the	O
LPS	O
receptor	O
complex	O
may	O
belong	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
/	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
super	O
family	O
,	O
and	O
the	O
LPS	O
signaling	O
cascade	O
uses	O
an	O
analogous	O
molecular	O
framework	O
for	O
signaling	O
as	O
IL	O
-	O
1	O
in	O
mononuclear	O
phagocytes	O
and	O
endothelial	O
cells	O
.	O

Selective	O
activation	O
and	O
functional	O
significance	O
of	O
p38alpha	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
neutrophils	O
.	O

Activation	O
of	O
leukocytes	O
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	O
neutrophils	O
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPk	O
)	O
;	O
however	O
,	O
the	O
upstream	O
activator	O
(	O
s	O
)	O
of	O
p38	O
MAPk	O
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	O
MAPk	O
activation	O
remain	O
largely	O
undefined	O
.	O

We	O
investigated	O
the	O
MAPk	O
kinase	O
(	O
MKK	O
)	O
that	O
activates	O
p38	O
MAPk	O
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	O
MAPk	O
isoforms	O
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	O
MAPk	O
activation	O
.	O

Although	O
MKK3	B-PRGE
,	O
MKK4	B-PRGE
,	O
and	O
MKK6	B-PRGE
all	O
activated	O
p38	O
MAPk	O
in	O
experimental	O
models	O
,	O
only	O
MKK3	B-PRGE
was	O
found	O
to	O
activate	O
recombinant	O
p38	O
MAPk	O
in	O
LPS	O
-	O
treated	O
neutrophils	O
.	O

Of	O
p38	O
MAPk	O
isoforms	O
studied	O
,	O
only	O
p38alpha	B-PRGE
and	O
p38delta	B-PRGE
were	O
detected	O
in	O
neutrophils	O
.	O

LPS	O
stimulation	O
selectively	O
activated	O
p38alpha	B-PRGE
.	O

Specific	O
inhibitors	O
of	O
p38alpha	B-PRGE
MAPk	I-PRGE
blocked	O
LPS	O
-	O
induced	O
adhesion	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

Inhibition	O
of	O
p38alpha	B-PRGE
MAPk	I-PRGE
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
accumulation	O
but	O
persistent	O
loss	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
synthesis	O
.	O

These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	O
results	O
in	O
activation	O
of	O
MKK3	B-PRGE
,	O
which	O
in	O
turn	O
activates	O
p38alpha	B-PRGE
MAPk	I-PRGE
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
enhanced	O
gene	O
expression	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
regulation	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
synthesis	O
.	O

Inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
inducible	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
type	O
I	O
and	O
type	O
II	O
interferons	O
.	O

The	O
Th2	O
-	O
type	O
cytokines	O
,	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
13	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	O
monocytes	O
,	O
including	O
FcepsilonRIIb	B-PRGE
(	O
CD23	B-PRGE
)	O
,	O
15	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1ra	I-PRGE
)	O
,	O
and	O
type	O
I	O
and	O
type	O
II	O
IL	O
-	O
1	O
receptors	O
(	O
IL	O
-	O
1R	O
)	O
.	O

Type	O
I	O
interferons	O
(	O
IFN	O
-	O
alpha	O
and	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
and	O
type	O
II	O
interferon	O
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
inhibit	O
induction	O
of	O
these	O
genes	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	O
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

In	O
this	O
overview	O
,	O
we	O
discuss	O
the	O
role	O
of	O
the	O
transcription	O
factor	O
,	O
STAT6	B-PRGE
(	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
-	I-PRGE
6	I-PRGE
)	O
in	O
mediating	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
induced	O
gene	O
expression	O
in	O
monocytes	O
.	O

We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
suppress	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-PRGE
.	O

The	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
inhibit	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
induced	O
STAT6	B-PRGE
activity	O
is	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
is	O
not	O
unique	O
to	O
monocytes	O
because	O
IFNs	O
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	O
.	O

Inhibition	O
of	O
STAT6	B-PRGE
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
h	O
before	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
can	O
be	O
blocked	O
by	O
actinomycin	O
D	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
transcription	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
stimulation	O
of	O
monocytes	O
by	O
IFN	O
activates	O
de	O
novo	O
synthesis	O
of	O
an	O
inhibitory	O
factor	O
,	O
possibly	O
one	O
or	O
more	O
members	O
of	O
the	O
SOCS	O
/	O
SSI	O
/	O
CIS	O
gene	O
family	O
,	O
capable	O
of	O
suppressing	O
activation	O
of	O
STAT6	B-PRGE
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
.	O

Because	O
STAT6	B-PRGE
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
to	O
inhibit	O
STAT6	B-PRGE
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	O
can	O
suppress	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
inducible	O
gene	O
expression	O
.	O

Involvement	O
of	O
NF	O
-	O
kappaB	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimer	O
in	O
activation	O
of	O
the	O
human	O
pro	B-PRGE
-	I-PRGE
interleukin	I-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
at	O
two	O
subregions	O
of	O
the	O
upstream	O
enhancer	O
element	O
.	O

A	O
region	O
between	O
-	O
3134	O
and	O
-	O
2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
site	O
of	O
the	O
human	O
pro	B-PRGE
-	I-PRGE
interleukin	I-PRGE
1beta	I-PRGE
(	O
proIL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
gene	O
was	O
identified	O
as	O
an	O
LPS	O
-	O
responsive	O
enhancer	O
element	O
.	O

In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	O
-	O
3134	O
and	O
-	O
2987	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
in	O
LPS	O
-	O
stimulated	O
Raw	O
264	O
.	O
7	O
cells	O
was	O
examined	O
in	O
detail	O
.	O

The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	B-PRGE
-	O
CAT	B-PRGE
constructs	O
that	O
contained	O
serial	O
5	O
'	O
-	O
deletion	O
mutations	O
showed	O
that	O
the	O
region	O
between	O
-	O
3134	O
and	O
-	O
3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
transcription	O
by	O
LPS	O
.	O

Gel	O
shift	O
assay	O
studies	O
with	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
partial	O
sequences	O
of	O
the	O
latter	O
region	O
and	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
revealed	O
specific	O
protein	O
binding	O
sites	O
between	O
-	O
3110	O
and	O
-	O
3090	O
and	O
between	O
-	O
3079	O
and	O
-	O
3059	O
.	O

These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	O
factors	O
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF	O
-	O
kappaB	O
components	O
p50	B-PRGE
and	O
p65	B-PRGE
,	O
and	O
did	O
not	O
contain	O
other	O
NF	O
-	O
kappaB	O
proteins	O
(	O
p52	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
Rel	B-PRGE
B	I-PRGE
)	O
,	O
AP	O
-	O
1	O
proteins	O
(	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
C	B-PRGE
-	I-PRGE
Jun	I-PRGE
)	O
,	O
CREB	O
or	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
)	O
.	O

Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
in	O
the	O
enhancer	O
element	O
decreased	O
the	O
LPS	O
-	O
stimulated	O
transcriptional	O
activity	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
,	O
which	O
are	O
located	O
between	O
-	O
3134	O
and	O
-	O
3059	O
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
transcription	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Phosphorylation	O
of	O
TRAF2	B-PRGE
inhibits	O
binding	O
to	O
the	O
CD40	B-PRGE
cytoplasmic	O
domain	O
.	O

TRAF2	B-PRGE
is	O
a	O
signal	O
transducing	O
adaptor	O
molecule	O
which	O
binds	O
to	O
the	O
CD40	B-PRGE
cytoplasmic	O
domain	O
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	O
cells	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B-PRGE
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	B-PRGE
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	B-PRGE
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	B-PRGE
cytoplasmic	O
domain	O
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	B-PRGE
and	O
that	O
phosphatase	O
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	B-PRGE
to	O
CD40	B-PRGE
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B-PRGE
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B-PRGE
-	O
TRAF2	B-PRGE
interaction	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cobalt	O
chloride	O
-	O
induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
and	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
is	O
blocked	O
by	O
PAF	B-PRGE
-	I-PRGE
receptor	I-PRGE
antagonist	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
and	O
leukocytes	O
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	O
through	O
the	O
blood	O
vessel	O
increases	O
.	O

However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

We	O
found	O
that	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	O
the	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	O
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	O
.	O

Furthermore	O
,	O
CoCl2	O
also	O
caused	O
time	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
isoform	O
ERK2	B-PRGE
without	O
significantly	O
affecting	O
ERK1	B-PRGE
,	O
indicating	O
ERK2	B-PRGE
is	O
the	O
preferred	O
substrate	O
for	O
upstream	O
kinase	O
of	O
the	O
MAPK	O
pathway	O
.	O

Inhibitors	O
of	O
MAP	O
kinase	O
(	O
PD98059	O
)	O
or	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Augmented	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
led	O
to	O
increased	O
SS	O
RBC	O
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
antibody	O
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two	O
-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecules	O
(	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	O
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Both	O
phosphorylation	O
of	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
transendothelial	O
migration	O
of	O
monocytes	O
in	O
response	O
to	O
CoCl2	O
were	O
inhibited	O
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	O
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O

Our	O
data	O
suggests	O
that	O
CoCl2	O
-	O
induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
HUVEC	O
involve	O
downstream	O
activation	O
of	O
MAP	O
kinase	O
and	O
NF	O
-	O
kappaB	O
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	O
.	O

We	O
conclude	O
that	O
PAF	O
-	O
receptor	O
antagonist	O
inhibits	O
the	O
CoCl2	O
-	O
or	O
hypoxia	O
-	O
induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	O
RBC	O
,	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

Molecular	O
mechanisms	O
of	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
transcriptional	O
regulation	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG	O
/	O
GSH	O
-	O
induced	O
adhesion	O
response	O
.	O

Treatment	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
for	O
6	O
hours	O
with	O
0	O
.	O
2	O
mmol	O
/	O
L	O
diamide	O
and	O
1	O
mmol	O
/	O
L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia	O
/	O
reoxygenation	O
.	O

Diamide	O
plus	O
BSO	O
-	O
induced	O
thiol	O
/	O
disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

N	O
-	O
Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	O
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	O
with	O
the	O
GSSG	O
/	O
GSH	O
ratio	O
,	O
whereas	O
phase	O
2	O
neutrophil	O
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG	O
/	O
GSH	O
ratio	O
but	O
not	O
with	O
GSH	O
levels	O
.	O

Intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
-	O
specific	O
monoclonal	O
antibodies	O
attenuated	O
the	O
increased	O
neutrophil	O
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti	O
-	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
monoclonal	O
antibody	O
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
that	O
contained	O
nuclear	O
factor	O
-	O
kappaB	O
or	O
activator	O
protein	O
-	O
1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Surface	O
expression	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG	O
/	O
GSH	O
cause	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
,	O
which	O
leads	O
to	O
a	O
2	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
adhesion	O
response	O
.	O

Decreased	O
proteasome	O
-	O
mediated	O
degradation	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
:	O
A	O
role	O
in	O
immune	O
senescence	O
.	O

Induction	O
of	O
NFkappaB	O
is	O
a	O
highly	O
regulated	O
process	O
requiring	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
the	O
cytosolic	O
inhibitor	O
IkappaBalpha	B-PRGE
.	O

Analyses	O
of	O
the	O
regulation	O
of	O
IkappaBalpha	B-PRGE
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
treated	O
T	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	O
of	O
IkappaBalpha	B-PRGE
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

Examination	O
of	O
activation	O
-	O
induced	O
phosphorylation	O
and	O
ubiquitination	O
of	O
IkappaBalpha	B-PRGE
did	O
not	O
demonstrate	O
any	O
significant	O
age	O
-	O
related	O
alterations	O
.	O

However	O
,	O
examination	O
of	O
proteasome	O
activity	O
in	O
these	O
T	O
cells	O
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age	O
-	O
related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	O
activity	O
results	O
in	O
a	O
failure	O
to	O
fully	O
degrade	O
IkappaBalpha	B-PRGE
in	O
the	O
elderly	O
.	O

This	O
failure	O
to	O
degrade	O
IkappaBalpha	B-PRGE
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	O
induction	O
and	O
the	O
IL	O
-	O
2	O
receptor	O
expression	O
in	O
TNF	O
-	O
treated	O
T	O
cells	O
during	O
aging	O
.	O

Thus	O
,	O
decreased	O
proteasome	O
-	O
mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Identification	O
of	O
upstream	O
regulatory	O
elements	O
that	O
repress	O
expression	O
of	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
in	O
a	O
primitive	O
erythroid	O
environment	O
.	O

Our	O
investigations	O
have	O
focused	O
on	O
localizing	O
cis	O
-	O
elements	O
responsible	O
for	O
the	O
down	O
regulation	O
of	O
the	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
(	O
delta	B-PRGE
and	O
beta	B-PRGE
)	O
in	O
immature	O
,	O
or	O
primitive	O
erythroid	O
tissues	O
.	O

We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	O
cells	O
,	O
an	O
erythroleukemia	O
cell	O
line	O
with	O
an	O
embryonic	O
-	O
fetal	O
phenotype	O
.	O

Analyzed	O
DNA	O
sequences	O
included	O
delta	B-PRGE
and	O
beta	B-PRGE
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-	O
500	O
to	O
+	O
50bp	O
(	O
promoter	O
regions	O
)	O
,	O
truncated	O
delta	B-PRGE
and	O
beta	B-PRGE
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-	O
250	O
to	O
+	O
50	O
bp	O
,	O
and	O
chimeric	O
promoter	O
constructions	O
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	B-PRGE
or	O
beta	B-PRGE
fragment	O
fused	O
to	O
a	O
proximal	O
beta	B-PRGE
or	O
delta	B-PRGE
sequence	O
.	O

In	O
CAT	B-PRGE
reporter	O
constructions	O
no	O
appreciable	O
level	O
of	O
CAT	B-PRGE
activity	O
was	O
supported	O
by	O
the	O
beta	B-PRGE
globin	I-PRGE
promoter	O
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	B-PRGE
promoter	O
.	O

Truncation	O
of	O
the	O
beta	B-PRGE
globin	I-PRGE
promoter	O
led	O
to	O
a	O
2	O
-	O
3	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	B-PRGE
promoter	O
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O

Coupling	O
of	O
the	O
upstream	O
beta	B-PRGE
globin	I-PRGE
sequence	O
from	O
approximately	O
-	O
500	O
to	O
-	O
250	O
bp	O
to	O
the	O
truncated	O
delta	B-PRGE
promoter	O
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	B-PRGE
globin	I-PRGE
gene	O
upstream	O
element	O
(	O
s	O
)	O
.	O

Fusion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	B-PRGE
promoter	O
to	O
the	O
truncated	O
beta	B-PRGE
globin	I-PRGE
promoter	O
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	O
beta	B-PRGE
gene	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	O
transcriptional	O
element	O
(	O
s	O
)	O
in	O
the	O
upstream	O
delta	B-PRGE
globin	I-PRGE
regulatory	O
region	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	O
proteins	O
BP1	B-PRGE
and	O
BP2	B-PRGE
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	B-PRGE
globin	I-PRGE
gene	O
flanking	O
region	O
led	O
to	O
a	O
4	O
-	O
6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

DNase	B-PRGE
I	I-PRGE
footprinting	O
of	O
the	O
upstream	O
delta	B-PRGE
-	I-PRGE
globin	I-PRGE
region	O
revealed	O
protected	O
sequences	O
corresponding	O
to	O
consensus	O
binding	O
sites	O
for	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
BP2	B-PRGE
.	O

These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	O
promoter	O
region	O
of	O
the	O
adult	O
beta	B-PRGE
globin	I-PRGE
gene	O
contribute	O
to	O
its	O
factor	O
-	O
mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O

Reduction	O
of	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
expression	O
and	O
signalling	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
upon	O
treatment	O
with	O
desferrioxamine	O
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV	O
-	O
1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	O
cells	O
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV	O
-	O
1	O
replication	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
bioavailability	O
from	O
mononuclear	O
cells	O
isolated	O
from	O
10	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
given	O
DFX	O
as	O
compared	O
to	O
10	O
untreated	O
subjects	O
has	O
been	O
evaluated	O
.	O

Evidence	O
is	O
presented	O
showing	O
that	O
DFX	O
treatment	O
reduces	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
bioavailability	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
by	O
inhibiting	O
its	O
steady	O
state	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
by	O
enhancing	O
its	O
inactivation	O
through	O
binding	O
to	O
soluble	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
receptor	I-PRGE
type	I-PRGE
II	I-PRGE
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
both	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
signalling	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

We	O
conclude	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
bioavailability	O
and	O
signalling	O
are	O
impaired	O
in	O
patients	O
upon	O
DFX	O
treatment	O
.	O

This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV	O
-	O
1	O
infection	O
in	O
vivo	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Inhibition	O
of	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
4	O
-	O
trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2	O
-	O
hydroxy	O
-	O
4	O
-	O
trifluoromethylbenzoic	O
acid	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
has	O
been	O
emphasized	O
.	O

When	O
two	O
4	O
-	O
trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2	O
-	O
acetoxy	O
-	O
4	O
-	O
trifluoromethyl	O
-	O
benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2	O
-	O
hydroxy	O
-	O
4	O
-	O
trifluoromethylbenzoic	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide	O
-	O
activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	O
sodium	O
salicylate	O
,	O
inhibited	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0	O
.	O
16	O
,	O
0	O
.	O
18	O
,	O
0	O
.	O
39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O

However	O
,	O
only	O
triflusal	O
and	O
aspirin	O
inhibited	O
purified	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
enzyme	O
.	O

To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
protein	O
expression	O
in	O
peripheral	O
human	O
mononuclear	O
cells	O
.	O

This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18	O
.	O
9	O
and	O
11	O
.	O
4	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal	O
-	O
treated	O
animals	O
showed	O
a	O
decrease	O
in	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

This	O
different	O
behavior	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
ability	O
of	O
HTB	O
and	O
triflusal	O
to	O
block	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
to	O
a	O
higher	O
extent	O
than	O
aspirin	O
and	O
sodium	O
salicylate	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	O
through	O
its	O
metabolite	O
HTB	O
the	O
expression	O
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O

Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	O
factor	O
-	O
kappaB	O
control	O
are	O
up	O
-	O
regulated	O
.	O

Expression	O
of	O
IkappaBalpha	B-PRGE
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O

According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel	O
/	O
NF	O
-	O
kappaB	O
proteins	O
in	O
the	O
cytosol	O
.	O

However	O
,	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
has	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	O
by	O
transient	O
transfection	O
.	O

To	O
gain	O
better	O
insight	O
into	O
the	O
potential	O
role	O
of	O
nuclear	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
in	O
a	O
physiological	O
context	O
we	O
have	O
analysed	O
its	O
presence	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
in	O
PBL	O
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

Low	O
levels	O
of	O
nuclear	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
were	O
detected	O
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O

The	O
nuclear	O
pool	O
of	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
showed	O
a	O
higher	O
stability	O
than	O
cytosolic	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	O
of	O
the	O
protein	O
.	O

Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
did	O
not	O
inhibit	O
NF	O
-	O
kappaB	O
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
IkappaBbeta	B-PRGE
at	O
the	O
nuclear	O
level	O
.	O

Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
and	O
NF	O
-	O
kappaB	O
proteins	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA	O
-	O
activated	O
human	O
PBL	O
,	O
I	B-PRGE
(	I-PRGE
kappa	I-PRGE
)	I-PRGE
B	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF	O
-	O
kappaB	O
binding	O
from	O
DNA	O
.	O

PGG	O
-	O
glucan	O
,	O
a	O
soluble	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
factor	O
in	O
human	O
PMN	O
:	O
evidence	O
for	O
a	O
glycosphingolipid	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
glucan	O
receptor	O
.	O

PGG	O
-	O
Glucan	O
,	O
a	O
soluble	O
beta	O
-	O
(	O
1	O
,	O
6	O
)	O
-	O
branched	O
beta	O
-	O
(	O
1	O
,	O
3	O
)	O
-	O
linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti	O
-	O
infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG	O
-	O
Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	O
isolated	O
blood	O
leukocytes	O
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

No	O
evidence	O
for	O
inflammatory	O
cytokine	O
production	O
was	O
obtained	O
under	O
these	O
conditions	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG	O
-	O
Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
like	O
nuclear	O
transcription	O
factor	O
in	O
purified	O
human	O
neutrophils	O
.	O

The	O
binding	O
of	O
3H	O
-	O
PGG	O
-	O
Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration	O
-	O
dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O

A	O
monoclonal	O
antibody	O
specific	O
to	O
the	O
glycosphingolipid	O
lactosylceramide	O
was	O
able	O
to	O
inhibit	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
like	O
factor	O
by	O
PGG	O
-	O
Glucan	O
,	O
and	O
ligand	O
binding	O
data	O
,	O
including	O
polysaccharide	O
specificity	O
,	O
suggested	O
that	O
the	O
PGG	O
-	O
Glucan	O
binding	O
moiety	O
was	O
lactosylceramide	O
.	O

These	O
results	O
indicate	O
that	O
PGG	O
-	O
Glucan	O
enhances	O
neutrophil	O
anti	O
-	O
microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta	O
-	O
glucan	O
and	O
human	O
neutrophils	O
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

Corticosteroids	O
are	O
most	O
effective	O
in	O
preventing	O
the	O
late	O
phase	O
of	O
allergic	O
reaction	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	O
receptors	O
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

When	O
activated	O
,	O
glucocorticoid	O
receptors	O
form	O
a	O
dimer	O
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP	O
-	O
1	O
(	O
activator	O
protein	O
-	O
1	O
)	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
nuclear	O
factor	O
-	O
kappa	O
B	O
)	O
.	O

Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O

They	O
are	O
in	O
particular	O
able	O
to	O
inhibit	O
most	O
of	O
the	O
pro	O
-	O
inflammatory	O
functions	O
of	O
the	O
eosinophils	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Mycobacterium	O
tuberculosis	O
-	O
induced	O
interleukin	O
-	O
2	O
receptor	O
expression	O
in	O
mononuclear	O
phagocytes	O
.	O

Soluble	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

We	O
investigated	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
using	O
the	O
THP	O
-	O
1	O
mononuclear	O
phagocyte	O
cell	O
line	O
.	O

We	O
found	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
expression	O
to	O
be	O
increased	O
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O

Expression	O
of	O
the	O
alpha	O
-	O
chain	O
of	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
on	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
was	O
induced	O
by	O
M	O
.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Northern	O
analysis	O
demonstrated	O
increased	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
gene	O
expression	O
after	O
stimulation	O
with	O
M	O
.	O
tuberculosis	O
which	O
was	O
further	O
induced	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
promoter	O
containing	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
site	O
was	O
transcriptionally	O
induced	O
by	O
M	O
.	O
tuberculosis	O
and	O
this	O
NF	O
-	O
kappaB	O
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	O
herpes	O
thymidine	O
kinase	O
(	O
TK	O
)	O
promoter	O
by	O
M	O
.	O
tuberculosis	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
to	O
the	O
NF	O
-	O
kappaB	O
site	O
upon	O
induction	O
with	O
M	O
.	O
tuberculosis	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	B-PRGE
and	O
p65	B-PRGE
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B-PRGE
and	O
p65	B-PRGE
proteins	O
was	O
further	O
demonstrated	O
.	O

Functional	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
on	O
mononuclear	O
phagocytes	O
in	O
M	O
.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O

Regulation	O
of	O
the	O
megakaryocytic	O
glycoprotein	B-PRGE
IX	I-PRGE
promoter	O
by	O
the	O
oncogenic	O
Ets	O
transcription	O
factor	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Glycoprotein	B-PRGE
(	I-PRGE
GP	I-PRGE
)	I-PRGE
IX	I-PRGE
is	O
a	O
subunit	O
of	O
the	O
von	O
Willebrand	O
receptor	O
,	O
GPIb	O
-	O
V	O
-	O
IX	O
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O

Previous	O
characterization	O
of	O
the	O
GPIX	B-PRGE
promoter	O
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O

However	O
,	O
the	O
Ets	O
protein	O
(	O
s	O
)	O
that	O
regulated	O
GPIX	B-PRGE
promoter	O
expression	O
was	O
unknown	O
.	O

In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	B-PRGE
promoter	O
/	O
reporter	O
constructs	O
into	O
293T	O
kidney	O
fibroblasts	O
with	O
a	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
vector	O
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
transactivate	O
the	O
GPIX	B-PRGE
promoter	O
when	O
an	O
intact	O
GPIX	B-PRGE
Ets	O
site	O
is	O
present	O
.	O

In	O
addition	O
,	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
of	O
the	O
GPIX	B-PRGE
Ets	O
site	O
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	O
human	O
erythroleukemia	O
cells	O
.	O

Comparative	O
studies	O
showed	O
that	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	B-PRGE
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	B-PRGE
promoter	O
.	O

Immunoblot	O
analysis	O
identified	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
in	O
lysates	O
derived	O
from	O
platelets	O
.	O

In	O
addition	O
,	O
expression	O
of	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
identified	O
immunohistochemically	O
in	O
megakaryocytes	O
derived	O
from	O
CD34	B-PRGE
(	O
+	O
)	O
cells	O
treated	O
with	O
the	O
megakaryocyte	O
differentiation	O
and	O
proliferation	O
factor	O
,	O
thrombopoietin	B-PRGE
.	O

These	O
results	O
suggest	O
that	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
likely	O
to	O
regulate	O
lineage	O
-	O
specific	O
genes	O
during	O
megakaryocytopoiesis	O
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	O
phosphatase	O
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	O
activation	O
in	O
T	O
lymphocytes	O
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
phosphorylation	O
and	O
degradation	O
.	O

Nuclear	O
Factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65	O
-	O
50	O
heterodimer	O
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	O
induction	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
treated	O
T	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
PAO	O
-	O
sensitive	O
phosphatase	O
in	O
the	O
activation	O
of	O
the	O
NFkappaB	O
via	O
this	O
pathway	O
in	O
human	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	O
.	O

Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	O
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
cytosols	O
of	O
TNF	O
-	O
treated	O
T	O
cells	O
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
induced	O
by	O
TNF	O
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	O
,	O
independent	O
of	O
age	O
.	O

A	O
novel	O
lipopolysaccharide	O
-	O
induced	O
transcription	O
factor	O
regulating	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
gene	O
expression	O
:	O
molecular	O
cloning	O
,	O
sequencing	O
,	O
characterization	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	O
and	O
macrophages	O
,	O
causing	O
secretion	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
control	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF	O
-	O
kappaB	O
has	O
been	O
suggested	O
.	O

Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA	O
-	O
binding	O
domain	O
located	O
from	O
-	O
550	O
to	O
-	O
487	O
in	O
the	O
human	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60	O
-	O
kDa	O
protein	O
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino	O
-	O
terminal	O
sequence	O
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	O
probes	O
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP	O
-	O
1	O
cells	O
.	O

A	O
novel	O
cDNA	O
clone	O
(	O
1	O
.	O
8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O

Characterization	O
of	O
this	O
cDNA	O
clone	O
revealed	O
that	O
its	O
induction	O
was	O
dependent	O
on	O
LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
;	O
hence	O
,	O
the	O
name	O
LPS	B-PRGE
-	I-PRGE
induced	I-PRGE
TNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
factor	I-PRGE
(	O
LITAF	B-PRGE
)	O
.	O

Inhibition	O
of	O
LITAF	B-PRGE
mRNA	O
expression	O
in	O
THP	O
-	O
1	O
cells	O
resulted	O
in	O
a	O
reduction	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
transcripts	O
.	O

In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	B-PRGE
mRNA	O
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O

Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	B-PRGE
mapped	O
to	O
chromosome	O
16p12	O
-	O
16p13	O
.	O
3	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	B-PRGE
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
expression	O
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP	O
-	O
1	O
expression	O
in	O
the	O
NKL	O
human	O
NK	O
cell	O
line	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	O
NKL	O
cell	O
line	O
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	O
early	O
activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
transcription	O
factor	O
genes	O
such	O
as	O
JunB	B-PRGE
,	O
FosB	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
.	O

In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	O
-	O
Fos	O
heterodimers	O
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	O
between	O
immunoglobulin	B-PRGE
-	I-PRGE
like	I-PRGE
transcript	I-PRGE
-	I-PRGE
2	I-PRGE
/	O
leukocyte	B-PRGE
Ig	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
1	I-PRGE
on	O
NKL	O
cells	O
and	O
HLA	B-PRGE
-	I-PRGE
B27	I-PRGE
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	O
of	O
JunB	B-PRGE
,	O
FosB	B-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
transcription	O
,	O
as	O
well	O
as	O
an	O
absence	O
of	O
their	O
DNA	O
-	O
binding	O
activity	O
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell	O
-	O
mediated	O
lysis	O
,	O
AP	O
-	O
1	O
transcription	O
factor	O
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	O
cell	O
inhibitory	O
receptors	O
for	O
MHC	O
class	O
I	O
molecules	O
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP	O
-	O
1	O
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	O
monocytes	O
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	O
genes	O
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
A20	B-PRGE
,	O
NF	O
-	O
kappaB	O
-	O
p105	B-PRGE
/	O
p50	B-PRGE
,	O
and	O
IkappaBalpha	B-PRGE
)	O
in	O
unactivated	O
monocytes	O
and	O
that	O
neutralizing	O
Abs	O
to	O
the	O
major	O
HCMV	O
glycoproteins	O
,	O
gB	O
(	O
UL55	O
)	O
and	O
gH	O
(	O
UL75	O
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up	O
-	O
regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	O
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
protein	O
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
promoter	O
regions	O
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up	O
-	O
regulation	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
levels	O
.	O

These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF	O
-	O
kappaB	O
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O

Changes	O
in	O
IkappaBalpha	B-PRGE
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF	O
-	O
kappaB	O
translocation	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	O
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
production	O
and	O
that	O
it	O
was	O
rapidly	O
up	O
-	O
regulated	O
following	O
infection	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory	O
-	O
type	O
conditions	O
.	O

Signal	O
transduction	O
pathways	O
activated	O
in	O
endothelial	O
cells	O
following	O
infection	O
with	O
Chlamydia	O
pneumoniae	O
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C	O
.	O
pneumoniae	O
-	O
mediated	O
activation	O
of	O
endothelial	O
cells	O
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	O
adhesion	O
molecules	O
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	O
(	O
monocytes	O
,	O
granulocytes	O
)	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
mAbs	O
against	O
endothelial	O
and	O
/	O
or	O
leukocyte	O
adhesion	O
molecules	O
(	O
beta1	B-PRGE
and	O
beta2	B-PRGE
integrins	I-PRGE
)	O
.	O

Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C	O
.	O
pneumoniae	O
-	O
infected	O
endothelial	O
cells	O
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up	O
-	O
regulation	O
of	O
phosphorylated	O
p42	B-PRGE
/	O
p44	B-PRGE
mitogen	I-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
activation	O
/	O
translocation	O
occurred	O
within	O
10	O
-	O
15	O
min	O
.	O

Increased	O
mRNA	O
and	O
surface	O
expression	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
noted	O
within	O
hours	O
.	O

Thus	O
,	O
C	O
.	O
pneumoniae	O
triggers	O
a	O
cascade	O
of	O
events	O
that	O
could	O
lead	O
to	O
endothelial	O
activation	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
,	O
which	O
in	O
turn	O
may	O
result	O
in	O
or	O
may	O
promote	O
atherosclerosis	O
.	O

Extracellular	B-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
1	I-PRGE
/	O
2	B-PRGE
,	O
Jun	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
are	O
involved	O
in	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
human	O
monocytes	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
members	O
extracellular	B-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
1	I-PRGE
/	O
2	B-PRGE
(	O
ERK1	B-PRGE
/	O
2	B-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
)	O
in	O
mediating	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
in	O
human	O
monocytes	O
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1	O
/	O
2	O
and	O
JNK	B-PRGE
proteins	O
.	O

The	O
ERK	O
pathway	O
-	O
specific	O
inhibitor	O
PD98059	O
inhibited	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
secretion	O
from	O
monocytes	O
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
JNK1	B-PRGE
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B	O
-	O
dependent	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1	B-PRGE
/	O
MEK1	B-PRGE
/	O
ERK1	O
/	O
2	O
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
.	O

We	O
conclude	O
that	O
okadaic	O
acid	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1	O
/	O
2	O
and	O
JNK	O
pathway	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
capacity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	B-PRGE
pathway	O
may	O
regulate	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

Differential	O
induction	O
of	O
interferon	B-PRGE
(	I-PRGE
IFN	I-PRGE
)	I-PRGE
-	I-PRGE
inducible	I-PRGE
protein	I-PRGE
10	I-PRGE
following	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
and	O
kappaB	O
sites	O
.	O

We	O
examined	O
chemokine	O
gene	O
expression	O
following	O
the	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
.	O

The	O
human	O
monoblastic	O
cell	O
line	O
,	O
U937	O
was	O
differentiated	O
to	O
macrophages	O
by	O
the	O
treatment	O
with	O
either	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
or	O
vitamin	O
D3	O
(	O
VitD3	O
)	O
.	O

The	O
gene	O
expression	O
of	O
interferon	B-PRGE
(	I-PRGE
IFN	I-PRGE
)	I-PRGE
-	I-PRGE
inducible	I-PRGE
protein	I-PRGE
10	I-PRGE
(	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
(	O
a	O
CXC	O
chemokine	O
)	O
was	O
markedly	O
augmented	O
by	O
the	O
IFNgamma	B-PRGE
treatment	O
in	O
PMA	O
-	O
or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3	O
-	O
treated	O
cells	O
.	O

In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
a	O
CC	O
chemokine	O
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	O
factor	O
(	O
FcRFgamma	O
)	O
bound	O
to	O
the	O
gamma	O
response	O
region	O
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	B-PRGE
treatment	O
in	O
PMA	O
-	O
or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
indicating	O
that	O
increased	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
mRNA	O
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	B-PRGE
.	O

Increased	O
expression	O
of	O
IFNgamma	B-PRGE
-	O
induced	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
mRNA	O
following	O
the	O
differentiation	O
of	O
U937	O
cells	O
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation	O
-	O
dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
(	O
ISRE	O
)	O
and	O
kB	O
sites	O
,	O
suggesting	O
that	O
these	O
nuclear	O
proteins	O
may	O
determine	O
the	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
mRNA	O
inducibility	O
by	O
IFNgamma	B-PRGE
.	O

Fludarabine	O
-	O
induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	B-PRGE
signaling	O
.	O

Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

STAT1	B-PRGE
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte	O
-	O
activating	O
cytokines	O
including	O
the	O
interferons	O
,	O
is	O
essential	O
for	O
cell	O
-	O
mediated	O
immunity	O
,	O
as	O
the	O
absence	O
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	O
the	O
cytokine	O
-	O
induced	O
activation	O
of	O
STAT1	B-PRGE
and	O
STAT1	B-PRGE
-	O
dependent	O
gene	O
transcription	O
in	O
normal	O
resting	O
or	O
activated	O
lymphocytes	O
.	O

Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	B-PRGE
protein	O
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	O
.	O

This	O
loss	O
of	O
STAT1	B-PRGE
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Brief	O
exposure	O
to	O
fludarabine	O
led	O
to	O
a	O
sustained	O
loss	O
of	O
STAT1	B-PRGE
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O

Thus	O
,	O
STAT1	B-PRGE
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Suppressive	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
human	O
endothelial	O
cell	O
activation	O
and	O
induction	O
of	O
heat	O
shock	O
proteins	O
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	B-PRGE
shock	I-PRGE
protein	I-PRGE
60	I-PRGE
(	O
Hsp60	B-PRGE
)	O
.	O

The	O
interactions	O
of	O
Hsp60	B-PRGE
-	O
specific	O
T	O
cells	O
with	O
arterial	O
endothelial	O
cells	O
(	O
EC	O
)	O
require	O
expression	O
of	O
both	O
Hsp60	B-PRGE
and	O
certain	O
adhesion	O
molecules	O
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	O
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	O
,	O
respectively	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	O
molecules	O
,	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
and	O
Hsp60	B-PRGE
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
heat	B-PRGE
shock	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
HSF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti	O
-	O
inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	O
virus	O
antigen	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
-	O
induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	O
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
EC	O
.	O

All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	B-PRGE
6	O
hr	O
after	O
application	O
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	O
Hsp70	B-PRGE
expression	O
in	O
HUVECs	O
that	O
correlated	O
with	O
induction	O
of	O
HSF	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	O
molecule	O
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	B-PRGE
in	O
HUVECs	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti	O
-	O
atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	O
T	O
cells	O
to	O
stressed	O
EC	O
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis	O
-	O
promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	O
of	O
Hsp60	B-PRGE
expression	O
and	O
its	O
inability	O
to	O
down	O
-	O
regulate	O
adhesion	O
molecule	O
expression	O
on	O
EC	O
;	O
and	O
(	O
3	O
)	O
that	O
down	O
-	O
regulation	O
of	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	O
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	O
.	O

Amelioration	O
of	O
rat	O
cerulein	O
pancreatitis	O
by	O
guamerin	O
-	O
derived	O
peptide	O
,	O
a	O
novel	O
elastase	O
inhibitor	O
.	O

Increased	O
activity	O
of	O
various	O
proteases	O
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
a	O
novel	O
elastase	O
inhibitor	O
,	O
guamerin	O
-	O
derived	O
synthetic	O
peptide	O
(	O
GDSP	O
)	O
,	O
improves	O
the	O
parameters	O
of	O
cerulein	O
-	O
induced	O
acute	O
pancreatitis	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	O
amylase	O
and	O
lipase	O
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	O
factor	O
KB	O
(	O
NF	O
-	O
KB	O
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g	O
/	O
kg	O
/	O
h	O
)	O
for	O
6	O
h	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	O
human	O
neutrophils	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
compared	O
with	O
those	O
of	O
another	O
elastase	O
inhibitor	O
,	O
elastatinal	O
.	O

GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	O
lipase	O
and	O
amylase	O
increases	O
caused	O
by	O
cerulein	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	O
neutrophils	O
stimulated	O
by	O
N	O
-	O
formyl	O
-	O
methionine	O
-	O
leucine	O
-	O
phenyl	O
-	O
alanine	O
(	O
fMLP	O
)	O
or	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O

Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
targeted	O
hematopoietic	B-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
(	O
HePTP	B-PRGE
)	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
to	O
produce	O
cytokines	O
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein	O
-	O
tyrosine	O
kinases	O
and	O
protein	O
-	O
tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

Overexpression	O
of	O
hematopoietic	B-PRGE
protein	I-PRGE
-	I-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
(	O
HePTP	B-PRGE
)	O
results	O
in	O
suppression	O
of	O
T	O
lymphocyte	O
activation	O
as	O
measured	O
by	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
activation	O
of	O
transcription	O
factors	O
binding	O
to	O
the	O
5	O
'	O
promoter	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	B-PRGE
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	B-PRGE
acts	O
directly	O
on	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
Erk1	B-PRGE
and	O
2	B-PRGE
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
HePTP	B-PRGE
had	O
no	O
effects	O
on	O
N	O
-	O
terminal	O
c	O
-	O
Jun	O
kinase	O
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O

The	O
specificity	O
of	O
HePTP	B-PRGE
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	O
terminus	O
with	O
Erk	O
and	O
another	O
MAP	O
kinase	O
,	O
p38	O
,	O
but	O
not	O
Jnk	O
or	O
other	O
proteins	O
.	O

We	O
propose	O
that	O
HePTP	B-PRGE
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	O
kinases	O
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation	O
-	O
induced	O
expression	O
of	O
nuclear	O
dual	O
-	O
specific	O
MAP	O
kinase	O
phosphatases	O
.	O

Angiotensin	O
II	O
activates	O
the	O
proinflammatory	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
in	O
human	O
monocytes	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

The	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
participates	O
in	O
most	O
signaling	O
pathways	O
involved	O
in	O
inflammation	O
.	O

This	O
study	O
therefore	O
examined	O
the	O
effect	O
of	O
angiotensin	O
(	O
ANG	O
)	O
II	O
on	O
NF	O
-	O
kappaB	O
activation	O
in	O
monocytic	O
cells	O
,	O
a	O
major	O
cellular	O
component	O
of	O
human	O
atheroma	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

ANG	O
II	O
,	O
like	O
TNFalpha	B-PRGE
,	O
caused	O
rapid	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
human	O
mononuclear	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

This	O
ANG	O
II	O
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	B-PRGE
AT1	I-PRGE
receptor	I-PRGE
antagonist	O
losartan	O
.	O

Specificity	O
of	O
ANG	O
II	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O

Moreover	O
,	O
ANG	O
II	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
in	O
human	O
monocytes	O
,	O
but	O
not	O
in	O
lymphocytes	O
from	O
the	O
same	O
preparation	O
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
the	O
ability	O
of	O
the	O
vasoactive	O
peptide	O
ANG	O
II	O
to	O
activate	O
inflammatory	O
pathways	O
in	O
human	O
monocytes	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

SHP2	B-PRGE
-	I-PRGE
interacting	I-PRGE
transmembrane	I-PRGE
adaptor	I-PRGE
protein	I-PRGE
(	O
SIT	B-PRGE
)	O
,	O
a	O
novel	O
disulfide	O
-	O
linked	O
dimer	O
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	O
molecular	O
weight	O
transmembrane	O
adaptor	O
proteins	O
that	O
recruit	O
src	O
homology	O
(	O
SH	O
)	O
2	O
domain	O
-	O
containing	O
intracellular	O
molecules	O
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	B-PRGE
(	O
SHP2	B-PRGE
interacting	I-PRGE
transmembrane	I-PRGE
adaptor	I-PRGE
protein	I-PRGE
)	O
.	O

SIT	B-PRGE
is	O
a	O
disulfide	O
-	O
linked	O
homodimeric	O
glycoprotein	O
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	B-PRGE
and	O
possibly	O
syk	B-PRGE
protein	O
tyrosine	O
kinases	O
SIT	B-PRGE
recruits	O
the	O
SH2	O
domain	O
-	O
containing	O
tyrosine	O
phosphatase	O
SHP2	B-PRGE
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	B-PRGE
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor	O
-	O
and	O
phytohemagglutinin	B-PRGE
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	O
C	O
.	O

However	O
,	O
binding	O
of	O
SHP2	B-PRGE
to	O
SIT	B-PRGE
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	O
-	O
AT	O
induction	O
,	O
suggesting	O
that	O
SIT	B-PRGE
not	O
only	O
regulates	O
NF	O
-	O
AT	O
activity	O
but	O
also	O
controls	O
NF	O
-	O
AT	O
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	B-PRGE
.	O

GrpL	B-PRGE
,	O
a	O
Grb2	B-PRGE
-	O
related	O
adaptor	O
protein	O
,	O
interacts	O
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
to	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	B-PRGE
domain	I-PRGE
-	I-PRGE
containing	I-PRGE
protein	I-PRGE
76	I-PRGE
(	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
)	O
interacts	O
with	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
Vav	B-PRGE
to	O
activate	O
the	O
nuclear	O
factor	O
of	O
activated	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2	B-PRGE
-	O
like	O
adaptor	O
molecule	O
designated	O
as	O
Grb2	B-PRGE
-	I-PRGE
related	I-PRGE
protein	I-PRGE
of	I-PRGE
the	I-PRGE
lymphoid	I-PRGE
system	I-PRGE
(	O
GrpL	B-PRGE
)	O
.	O

Expression	O
of	O
GrpL	B-PRGE
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B-PRGE
by	O
having	O
a	O
proline	O
-	O
rich	O
region	O
.	O

GrpL	B-PRGE
can	O
be	O
coimmunoprecipitated	O
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
but	O
not	O
with	O
Sos1	B-PRGE
or	O
Sos2	B-PRGE
from	O
Jurkat	O
cell	O
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	B-PRGE
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	B-PRGE
and	O
Sos2	B-PRGE
but	O
not	O
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
.	O

Moreover	O
,	O
tyrosine	O
-	O
phosphorylated	O
LAT	B-PRGE
/	O
pp36	B-PRGE
/	I-PRGE
38	I-PRGE
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	B-PRGE
but	O
not	O
GrpL	B-PRGE
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	B-PRGE
and	O
Grb2	B-PRGE
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL	B-PRGE
-	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
complex	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	B-PRGE
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
to	O
augment	O
NF	O
-	O
AT	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Unexpected	O
and	O
coordinated	O
expression	O
of	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
megakaryocytic	O
genes	O
in	O
four	O
Epo	B-PRGE
-	O
dependent	O
cell	O
lines	O
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

Most	O
erythroleukemic	O
cell	O
lines	O
established	O
in	O
vitro	O
coexpress	O
erythrocytic	O
and	O
megakaryocytic	O
markers	O
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
/	O
or	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
factors	O
known	O
as	O
transactivators	O
of	O
megakaryocyte	O
-	O
specific	O
promoters	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	O
cell	O
lines	O
keeping	O
strictly	O
erythroid	O
-	O
specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	O
progenitors	O
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	O
119	O
positive	O
erythroid	O
nucleated	O
cells	O
expressing	O
T	O
antigen	O
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin	B-PRGE
-	O
dependent	O
erythroid	O
progenitors	O
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	O
lines	O
established	O
expressed	O
both	O
erythrocytic	O
(	O
globins	O
)	O
and	O
megakaryocytic	O
markers	O
(	O
glycoprotein	B-PRGE
IIb	I-PRGE
,	O
platelet	B-PRGE
factor	I-PRGE
4	I-PRGE
)	O
as	O
well	O
as	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
transcripts	O
at	O
permissive	O
temperature	O
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	O
gene	O
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
megakaryocytic	O
genes	O
in	O
an	O
erythropoietin	B-PRGE
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
already	O
was	O
detected	O
in	O
the	O
Ter	O
119	O
positive	O
cell	O
population	O
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O

However	O
,	O
like	O
normal	O
Ter	O
119	O
erythroid	O
cells	O
,	O
these	O
Ter	O
119	O
positive	O
cells	O
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	B-PRGE
IIb	I-PRGE
and	O
platelet	B-PRGE
factor	I-PRGE
4	I-PRGE
megakaryocytic	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	O
genes	O
is	O
a	O
specific	O
property	O
of	O
immortalized	O
cells	O
that	O
cannot	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
/	O
or	O
Fli	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
.	O

LPS	O
-	O
Induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
human	O
monocytes	O
are	O
protein	O
tyrosine	O
kinase	O
dependent	O
and	O
protein	O
kinase	O
C	O
independent	O
.	O

BACKGROUND	O
:	O
Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
is	O
an	O
important	O
mediator	O
of	O
septic	O
shock	O
.	O

Endotoxin	O
(	O
LPS	O
)	O
signal	O
transduction	O
in	O
human	O
monocytes	O
leads	O
to	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
.	O

Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
in	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	O
or	O
PTK	O
would	O
decrease	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
human	O
monocytes	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng	O
/	O
ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine	O
/	O
threonine	O
protein	O
kinase	O
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan	O
-	O
PKC	O
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	O
genistein	O
(	O
Gen	O
)	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O

NF	O
-	O
kappaB	O
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
LPS	O
increased	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
human	O
monocytes	O
.	O

Nonspecific	O
protein	O
kinase	O
inhibition	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
,	O
while	O
specific	O
PKC	O
inhibition	O
with	O
Bis	O
had	O
no	O
effect	O
on	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
.	O

PTK	O
inhibition	O
with	O
Gen	O
attenuated	O
both	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
human	O
monocytes	O
.	O

Direct	O
activation	O
of	O
PKC	O
with	O
PMA	O
induced	O
both	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
by	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
human	O
monocytes	O
are	O
independent	O
of	O
PKC	O
activity	O
.	O

Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	O
plays	O
a	O
role	O
in	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
human	O
monocytes	O
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

1	O
.	O

Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically	O
-	O
reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2	O
.	O

Flow	O
cytometry	O
revealed	O
binding	O
of	O
N	O
-	O
hydroxy	O
(	O
SMX	O
-	O
NHOH	O
)	O
and	O
nitroso	O
(	O
SMX	O
-	O
NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O

Cellular	O
haptenation	O
by	O
SMX	O
-	O
NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3	O
.	O

SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	O
bioinactivation	O
mechanism	O
.	O

4	O
.	O

Fluorescence	O
HPLC	O
showed	O
that	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5	O
.	O

Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

Lymphocytes	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX	O
-	O
NO	O
than	O
neutrophils	O
.	O

6	O
.	O

Partitioning	O
of	O
SMX	O
-	O
NHOH	O
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

Tcf	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
-	I-PRGE
3	I-PRGE
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
Armadillo	O
and	O
plays	O
roles	O
in	O
both	O
cell	O
-	O
cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef	O
/	O
Tcf	O
transcription	O
factor	O
family	O
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
explaining	O
how	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
alters	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	O
cells	O
,	O
Tcf	B-PRGE
-	I-PRGE
1	I-PRGE
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	O
lymphocytes	O
as	O
well	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	O
regulatory	O
protein	O
kinase	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
-	I-PRGE
3beta	I-PRGE
(	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
in	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
T	O
cells	O
.	O

That	O
is	O
,	O
a	O
dominant	O
negative	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	B-PRGE
)	O
that	O
inhibit	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
activity	O
also	O
do	O
not	O
activate	O
Tcf	O
reporter	O
genes	O
.	O

Thus	O
,	O
inhibition	O
of	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
is	O
insufficient	O
to	O
activate	O
Tcf	O
-	O
dependent	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	O
GSK	B-PRGE
-	I-PRGE
3beta	I-PRGE
and	O
induces	O
Tcf	B-PRGE
-	O
controlled	O
transcription	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf	O
-	O
responsive	O
genes	O
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	O
and	O
lymphocytes	O
.	O

CIITA	B-PRGE
-	O
induced	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter	O
-	O
bound	O
multi	O
-	O
protein	O
complexes	O
.	O

Precise	O
regulation	O
of	O
MHC	O
class	O
II	O
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O

The	O
transactivator	O
CIITA	B-PRGE
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	O
class	O
II	O
gene	O
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

Activation	O
of	O
MHC	O
class	O
II	O
promoters	O
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi	O
-	O
protein	O
complexes	O
(	O
RFX	O
,	O
X2BP	O
and	O
NF	O
-	O
Y	O
)	O
.	O

It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O

We	O
show	O
here	O
that	O
expression	O
of	O
CIITA	B-PRGE
in	O
MHC	O
class	O
II	O
-	O
cells	O
triggers	O
occupation	O
of	O
the	O
promoters	O
by	O
these	O
complexes	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	B-PRGE
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA	O
-	O
bound	O
multi	O
-	O
protein	O
complexes	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B-PRGE
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher	O
-	O
order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	O
,	O
X2BP	O
and	O
NF	O
-	O
Y	O
.	O

This	O
suggests	O
other	O
mechanisms	O
for	O
CIITA	B-PRGE
-	O
induced	O
promoter	O
occupancy	O
,	O
such	O
as	O
an	O
effect	O
on	O
chromatin	O
structure	O
leading	O
to	O
increased	O
accessibility	O
of	O
MHC	O
class	O
II	O
promoters	O
.	O

This	O
ability	O
of	O
CIITA	B-PRGE
to	O
facilitate	O
promoter	O
occupation	O
is	O
undissociable	O
from	O
its	O
transactivation	O
potential	O
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	B-PRGE
is	O
cell	O
-	O
type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	B-PRGE
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
in	O
B	O
lymphocytes	O
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T	O
-	O
cell	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
at	O
the	O
level	O
of	O
purine	O
-	O
box	O
/	O
nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
and	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O

PG490	O
inhibits	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	O
(	O
IC50	O
of	O
10	O
ng	O
/	O
ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng	O
/	O
ml	O
)	O
.	O

In	O
Jurkat	O
T	O
-	O
cells	O
,	O
PG490	O
inhibits	O
PMA	O
/	O
Iono	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine	O
-	O
box	O
/	O
antigen	O
receptor	O
response	O
element	O
(	O
ARRE	O
)	O
/	O
nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
target	O
sequence	O
but	O
not	O
at	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine	O
-	O
box	O
/	O
ARRE	O
/	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kappaB	O
target	O
DNA	O
sequences	O
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA	O
/	O
Iono	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

PG490	O
also	O
inhibits	O
PMA	O
-	O
stimulated	O
activation	O
of	O
a	O
chimeric	O
transcription	O
factor	O
in	O
which	O
the	O
C	O
-	O
terminal	O
TA1	O
transactivation	O
domain	O
of	O
NF	O
-	O
kappaB	O
p65	B-PRGE
is	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	B-PRGE
.	O

In	O
16HBE	O
human	O
bronchial	O
epithelial	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
is	O
regulated	O
predominantly	O
by	O
NF	O
-	O
kappaB	O
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
purine	O
-	O
box	O
regulator	O
operating	O
at	O
the	O
ARRE	O
/	O
NF	O
-	O
AT	O
site	O
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
lipopolysaccharide	O
in	O
mononuclear	O
leukocytes	O
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
.	O

In	O
monocytes	O
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85	O
-	O
kDa	O
cytosolic	O
phospholipase	O
A2	O
.	O

This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso	O
-	O
phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet	O
-	O
activating	O
-	O
factor	O
.	O

These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	O
factors	O
and	O
expression	O
of	O
cytokine	O
genes	O
indicating	O
a	O
function	O
for	O
cytosolic	O
phospholipase	O
A2	O
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
suppressed	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
protein	O
and	O
steady	O
-	O
state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide	O
-	O
stimulated	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
mechanisms	O
were	O
analyzed	O
by	O
which	O
trifluoromethylketones	O
interfere	O
with	O
gene	O
expression	O
.	O

We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
mRNA	O
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor	B-PRGE
-	I-PRGE
kappaB	I-PRGE
alpha	I-PRGE
.	O

Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA	O
-	O
binding	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
were	O
decreased	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	O
factor	O
-	O
kappaB	O
in	O
the	O
cytosol	O
thereby	O
abrogating	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
transcription	O
.	O

Molecular	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
during	O
the	O
immune	O
response	O
.	O

Cytokine	O
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	O
CD4	B-PRGE
+	O
T	O
helper	O
(	O
Th	O
)	O
cells	O
differentiate	O
into	O
cytokine	O
-	O
producing	O
effector	O
cells	O
.	O

Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	O
profiles	O
have	O
been	O
described	O
.	O

Th1	O
cells	O
produce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
whereas	O
Th2	O
cells	O
produce	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
Th1	O
/	O
Th2	O
-	O
like	O
cytokines	O
has	O
remained	O
elusive	O
.	O

In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O

The	O
evolutionarily	O
conserved	O
sequence	O
upstream	O
of	O
the	O
human	O
Ig	O
heavy	O
chain	O
S	O
gamma	O
3	O
region	O
is	O
an	O
inducible	O
promoter	O
:	O
synergistic	O
activation	O
by	O
CD40	B-PRGE
ligand	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
via	O
cooperative	O
NF	O
-	O
kappa	O
B	O
and	O
STAT	B-PRGE
-	I-PRGE
6	I-PRGE
binding	O
sites	O
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	O
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
B	O
cell	O
differentiation	O
,	O
IgM	O
+	O
IgD	O
+	O
CL	O
-	O
01	O
cells	O
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	B-PRGE
gamma	I-PRGE
3	I-PRGE
evolutionarily	O
conserved	O
sequence	O
(	O
ECS	O
)	O
in	O
the	O
germline	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	B-PRGE
gamma	I-PRGE
3	I-PRGE
gene	O
.	O

The	O
I	B-PRGE
gamma	I-PRGE
3	I-PRGE
ECS	O
lies	O
upstream	O
of	O
the	O
major	O
I	B-PRGE
gamma	I-PRGE
3	I-PRGE
transcription	O
initiation	O
site	O
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	O
I	B-PRGE
gamma	I-PRGE
1	I-PRGE
,	O
I	B-PRGE
gamma	I-PRGE
2	I-PRGE
,	O
and	O
I	B-PRGE
gamma	I-PRGE
4	I-PRGE
regions	O
.	O

Reporter	O
luciferase	O
gene	O
vectors	O
containing	O
the	O
human	O
gamma	O
3	O
ECS	O
were	O
used	O
to	O
transfect	O
CL	O
-	O
01	O
cells	O
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
-	O
-	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	O
of	O
CD40	B-PRGE
by	O
CD40	B-PRGE
ligand	I-PRGE
(	O
CD40L	B-PRGE
)	O
and	O
exposure	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

In	O
these	O
transfected	O
CL	O
-	O
01	O
cells	O
,	O
CD40	B-PRGE
:	O
CD40L	B-PRGE
engagement	O
and	O
exposure	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
synergistically	O
induced	O
gamma	O
3	O
ECS	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
activation	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
motif	O
is	O
critical	O
for	O
the	O
gamma	O
3	O
ECS	O
responsiveness	O
to	O
both	O
CD40L	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
while	O
a	O
STAT	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
binding	O
site	O
is	O
additionally	O
required	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inducibility	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50	B-PRGE
/	O
p65	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
STAT	B-PRGE
-	I-PRGE
6	I-PRGE
are	O
effectively	O
induced	O
by	O
CD40L	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	O
motifs	O
within	O
the	O
ECS	O
.	O

These	O
partially	O
overlapping	O
CD40L	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
responsive	O
elements	O
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O

Thus	O
,	O
the	O
gamma	O
3	O
ECS	O
is	O
an	O
inducible	O
promoter	O
containing	O
cis	O
elements	O
that	O
critically	O
mediate	O
CD40L	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
triggered	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

Thrombin	B-PRGE
-	O
induced	O
p65	B-PRGE
homodimer	O
binding	O
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
promoter	O
mediates	O
endothelial	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
neutrophil	O
adhesion	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	O
mediator	O
,	O
thrombin	B-PRGE
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
CD54	B-PRGE
)	O
expression	O
in	O
endothelial	O
cells	O
.	O

Stimulation	O
of	O
HUVEC	O
with	O
thrombin	B-PRGE
resulted	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
and	O
cell	O
surface	O
expression	O
and	O
in	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	O
leukocytes	O
.	O

Transient	O
transfection	O
of	O
endothelial	O
cells	O
with	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
luciferase	O
reporter	O
gene	O
(	O
ICAM	O
-	O
1LUC	O
)	O
constructs	O
indicated	O
that	O
deletion	O
of	O
upstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-	O
533	O
bases	O
from	O
translation	O
start	O
site	O
)	O
had	O
no	O
effect	O
on	O
thrombin	B-PRGE
responsiveness	O
,	O
whereas	O
mutation	O
/	O
deletion	O
of	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-	O
223	O
bases	O
from	O
the	O
translation	O
start	O
site	O
)	O
prevented	O
the	O
activation	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
,	O
indicating	O
that	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
is	O
critical	O
for	O
thrombin	B-PRGE
inducibility	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
directed	O
luciferase	O
activity	O
increased	O
approximately	O
3	O
-	O
fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	O
pNF	O
-	O
kappa	O
BLUC	O
containing	O
five	O
copies	O
of	O
consensus	O
NF	O
-	O
kappa	O
B	O
site	O
linked	O
to	O
a	O
minimal	O
adenovirus	O
E1B	B-PRGE
promoter	O
-	O
luciferase	O
gene	O
were	O
exposed	O
to	O
thrombin	B-PRGE
,	O
indicating	O
that	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
essential	O
for	O
thrombin	B-PRGE
response	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B-PRGE
induced	O
binding	O
of	O
NF	O
-	O
kappa	O
Bp65	B-PRGE
(	O
Rel	B-PRGE
A	I-PRGE
)	O
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

Thrombin	B-PRGE
receptor	I-PRGE
activation	O
peptide	O
,	O
a	O
14	O
-	O
amino	O
-	O
acid	O
peptide	O
representing	O
the	O
new	O
NH2	O
terminus	O
of	O
proteolytically	B-PRGE
activated	I-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
mimicked	O
thrombin	B-PRGE
'	O
s	O
action	O
in	O
inducing	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

These	O
data	O
indicate	O
that	O
thrombin	B-PRGE
activates	O
endothelial	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF	O
-	O
kappa	O
Bp65	B-PRGE
binding	O
to	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
after	O
proteolytically	B-PRGE
activated	I-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
activation	O
.	O

CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O

CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
engagement	O
by	O
mAbs	O
inhibits	O
,	O
while	O
CD28	B-PRGE
enhances	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4	B-PRGE
+	O
T	O
cells	O
using	O
Ab	O
cross	O
-	O
linking	O
.	O

CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
ligation	O
inhibited	O
CD3	O
/	O
CD28	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
accumulation	O
by	O
inhibiting	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF	O
-	O
AT	O
accumulation	O
in	O
the	O
nuclei	O
.	O

However	O
,	O
CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B-PRGE
-	O
mediated	O
stabilization	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
.	O

Further	O
,	O
CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	B-PRGE
D3	I-PRGE
,	O
cyclin	O
-	O
dependent	O
kinase	O
(	B-PRGE
cdk	I-PRGE
)	I-PRGE
4	I-PRGE
,	O
and	O
cdk6	B-PRGE
when	O
the	O
T	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
and	O
with	O
anti	O
-	O
CD3	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
signaling	O
inhibits	O
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
and	O
at	O
the	O
level	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28	B-PRGE
-	O
mediated	O
costimulation	O
.	O

Fibroblast	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
enhances	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
in	O
FGF	O
receptor	O
-	O
bearing	O
Jurkat	O
T	O
cells	O
.	O

Fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
are	O
heparin	O
-	O
binding	O
proteins	O
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

FGF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune	O
-	O
mediated	O
inflammation	O
.	O

The	O
frequency	O
of	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
responsive	O
T	O
cells	O
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	O
T	O
cells	O
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

To	O
understand	O
the	O
action	O
of	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
T	O
cells	O
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	O
T	O
cells	O
that	O
express	O
the	O
signaling	O
isoform	O
of	O
FGF	B-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

These	O
experiments	O
show	O
that	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
stimulation	O
of	O
Jurkat	O
T	O
cells	O
provides	O
a	O
second	O
signal	O
that	O
augments	O
TCR	O
-	O
mediated	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Analogous	O
to	O
costimulation	O
via	O
CD28	B-PRGE
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel	O
/	O
kappaB	O
,	O
a	O
family	O
of	O
transcription	O
factors	O
known	O
to	O
regulate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
other	O
activation	O
-	O
inducible	O
proteins	O
.	O

FGF	B-PRGE
-	I-PRGE
1	I-PRGE
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB	O
-	O
binding	O
proteins	O
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti	O
-	O
CD3	O
and	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

This	O
NF	O
-	O
kappaB	O
binding	O
complex	O
is	O
composed	O
of	O
transcriptionally	O
active	O
p65	B-PRGE
(	O
RelA	B-PRGE
)	O
/	O
p50	B-PRGE
heterodimers	O
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel	O
/	O
kappaB	O
in	O
the	O
cytoplasm	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
signaling	O
and	O
NF	O
-	O
kappaB	O
activation	O
outside	O
of	O
embryonic	O
development	O
.	O

The	O
signaling	O
events	O
that	O
link	O
FGF	B-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
engagement	O
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
Jurkat	O
are	O
probably	O
distinct	O
from	O
the	O
CD28	B-PRGE
costimulation	O
pathway	O
,	O
since	O
FGF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
induced	O
Rel	O
/	O
kappaB	O
binding	O
proteins	O
do	O
not	O
contain	O
significant	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	B-PRGE
response	O
complex	O
.	O

Signaling	O
through	O
the	O
lymphotoxin	B-PRGE
-	I-PRGE
beta	I-PRGE
receptor	I-PRGE
stimulates	O
HIV	O
-	O
1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane	O
-	O
bound	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
level	O
of	O
ongoing	O
HIV	O
-	O
1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV	O
-	O
1	O
pathogenesis	O
.	O

Among	O
host	O
immune	O
factors	O
,	O
the	O
cytokine	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
has	O
previously	O
been	O
shown	O
to	O
increase	O
HIV	O
-	O
1	O
replication	O
in	O
various	O
monocyte	O
and	O
T	O
cell	O
model	O
systems	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	O
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin	B-PRGE
-	I-PRGE
beta	I-PRGE
(	I-PRGE
LT	I-PRGE
-	I-PRGE
beta	I-PRGE
)	I-PRGE
receptor	I-PRGE
(	O
LT	B-PRGE
-	I-PRGE
betaR	I-PRGE
)	O
,	O
also	O
regulates	O
HIV	O
-	O
1	O
replication	O
.	O

Furthermore	O
,	O
HIV	O
-	O
1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT	B-PRGE
-	I-PRGE
betaR	I-PRGE
and	O
TNF	O
receptor	O
systems	O
are	O
simultaneously	O
engaged	O
by	O
their	O
specific	O
ligands	O
.	O

Moreover	O
,	O
in	O
a	O
physiological	O
coculture	O
cellular	O
assay	O
system	O
,	O
we	O
show	O
that	O
membrane	O
-	O
bound	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
LT	O
-	O
alpha1beta2	O
act	O
virtually	O
identically	O
to	O
their	O
soluble	O
forms	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
receptors	I-PRGE
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV	O
-	O
1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV	O
-	O
1	O
viral	O
burden	O
in	O
monocytes	O
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT	O
-	O
alpha1beta2	O
is	O
up	O
-	O
regulated	O
on	O
a	O
T	O
cell	O
line	O
acutely	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV	O
-	O
1	O
infection	O
,	O
LT	O
-	O
alpha1beta2	O
expression	O
,	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT	O
-	O
alpha1beta2	O
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT	O
-	O
alpha1beta2	O
may	O
be	O
involved	O
in	O
HIV	O
-	O
associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

Resistance	O
to	O
tumor	O
necrosis	O
factor	O
induced	O
apoptosis	O
in	O
vitro	O
correlates	O
with	O
high	O
metastatic	O
capacity	O
of	O
cells	O
in	O
vivo	O
.	O

TNF	O
is	O
one	O
of	O
the	O
cytokines	O
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Our	O
data	O
demonstrate	O
that	O
those	O
cell	O
lines	O
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	O
induced	O
apoptosis	O
in	O
vitro	O
.	O

However	O
,	O
cell	O
lines	O
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	O
lines	O
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	O
proteins	O
secreted	O
by	O
LAK	O
cells	O
.	O

Our	O
data	O
showed	O
that	O
TNF	O
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	O
cells	O
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	O
cells	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
in	O
mononuclear	O
cells	O
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
secretion	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Experiments	O
were	O
conducted	O
to	O
understand	O
the	O
mechanisms	O
for	O
C5a	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
production	O
,	O
which	O
was	O
14	O
-	O
fold	O
greater	O
than	O
that	O
in	O
unstimulated	O
cells	O
by	O
2	O
hours	O
.	O

IL	B-PRGE
-	I-PRGE
8	I-PRGE
secretion	O
was	O
accompanied	O
by	O
accumulation	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
mRNA	O
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	O
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O

AP	O
-	O
1	O
but	O
not	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
DNA	O
binding	O
activity	O
was	O
also	O
detected	O
in	O
C5a	O
-	O
stimulated	O
PBMC	O
;	O
however	O
,	O
its	O
delayed	O
expression	O
(	O
maximal	O
at	O
4	O
hours	O
)	O
suggested	O
a	O
less	O
important	O
role	O
in	O
the	O
rapid	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

The	O
correlation	O
between	O
C5a	O
-	O
induced	O
kappaB	O
binding	O
activity	O
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264	O
.	O
7	O
macrophage	O
cells	O
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	O
sequence	O
from	O
IkappaBalpha	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
promoter	O
regions	O
.	O

C5a	O
-	O
induced	O
reporter	O
gene	O
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	O
sites	O
and	O
by	O
coexpression	O
of	O
a	O
dominant	O
negative	O
IkappaBalpha	B-PRGE
construct	O
resistant	O
to	O
agonist	O
-	O
induced	O
phosphorylation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP	O
-	O
ribosylates	O
the	O
Gi	O
proteins	O
known	O
to	O
couple	O
to	O
the	O
C5a	B-PRGE
receptor	I-PRGE
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a	O
-	O
induced	O
calcium	O
mobilization	O
in	O
RAW264	O
.	O
7	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin	O
-	O
insensitive	O
pathway	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	O
modified	O
hematopoietic	O
stem	O
cells	O
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	O
viral	O
enhancer	O
in	O
the	O
U3	O
region	O
of	O
the	O
3	O
'	O
LTR	O
is	O
replaced	O
by	O
an	O
autoregulatory	O
enhancer	O
of	O
the	O
erythroid	O
-	O
specific	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
factor	O
gene	O
.	O

The	O
replaced	O
enhancer	O
is	O
propagated	O
to	O
the	O
5	O
'	O
LTR	O
upon	O
integration	O
into	O
the	O
target	O
cell	O
genome	O
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
cord	O
blood	O
-	O
derived	O
CD34	O
(	O
+	O
)	O
stem	O
/	O
progenitor	O
cells	O
,	O
and	O
murine	O
bone	O
marrow	O
repopulating	O
stem	O
cells	O
.	O

The	O
expression	O
of	O
appropriate	O
reporter	O
genes	O
(	O
triangle	O
upLNGFR	O
,	O
EGFP	B-PRGE
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	O
stem	O
cells	O
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
autoregulatory	O
enhancer	O
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR	O
-	O
driven	O
proviral	O
transcription	O
unit	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
both	O
human	O
progenitors	O
and	O
mouse	O
-	O
repopulating	O
stem	O
cells	O
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	O
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	O
transgene	O
to	O
a	O
specific	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

An	O
essential	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	B-PRGE
(	O
+	O
)	O
bone	O
marrow	O
cell	O
survival	O
.	O

The	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
,	O
is	O
important	O
for	O
T	O
-	O
cell	O
activation	O
,	O
B	O
-	O
cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	B-PRGE
(	O
+	O
)	O
bone	O
marrow	O
cells	O
has	O
not	O
been	O
described	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	O
CD34	B-PRGE
(	O
+	O
)	O
bone	O
marrow	O
cells	O
express	O
NF	O
-	O
kappaB	O
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
a	O
variety	O
of	O
cytokines	O
,	O
eg	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
may	O
be	O
required	O
for	O
human	O
CD34	B-PRGE
(	O
+	O
)	O
bone	O
marrow	O
cell	O
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Unicellular	O
-	O
unilineage	O
erythropoietic	O
cultures	O
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor	O
/	O
precursor	O
cells	O
growing	O
in	O
culture	O
.	O

We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	O
hematopoietic	O
progenitor	O
cells	O
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	O
factor	O
(	O
GF	O
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
/	O
mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single	O
-	O
cell	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	O
,	O
markers	O
of	O
differentiation	O
,	O
and	O
transcription	O
factors	O
(	O
EKLF	B-PRGE
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
p45	B-PRGE
NF	I-PRGE
-	I-PRGE
E2	I-PRGE
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
and	O
SCL	B-PRGE
/	O
Tal1	B-PRGE
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Freshly	O
isolated	O
CD34	B-PRGE
(	O
+	O
)	O
cells	O
expressed	O
CD34	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
kit	I-PRGE
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
but	O
did	O
not	O
express	O
CD36	B-PRGE
,	O
erythropoietin	B-PRGE
receptor	I-PRGE
(	O
EpoR	B-PRGE
)	O
,	O
SCL	B-PRGE
/	O
Tal1	B-PRGE
,	O
EKLF	B-PRGE
,	O
NF	O
-	O
E2	O
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
or	O
glyocophorin	B-PRGE
A	I-PRGE
(	O
GPA	B-PRGE
)	O
.	O

In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	O
of	O
CD36	B-PRGE
,	O
Tal1	B-PRGE
,	O
EKLF	B-PRGE
,	O
NF	O
-	O
E2	O
,	O
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
that	O
preceeded	O
expression	O
of	O
EpoR	B-PRGE
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	B-PRGE
was	O
upregulated	O
,	O
whereas	O
CD34	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
kit	I-PRGE
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
barely	O
or	O
not	O
detected	O
.	O

In	O
addition	O
,	O
competitive	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
assay	O
CD34	B-PRGE
mRNA	O
transcripts	O
in	O
sibling	O
CD34	B-PRGE
(	O
+	O
)	O
CD38	B-PRGE
(	O
-	O
)	O
cells	O
differentiating	O
in	O
unilineage	O
erythroid	O
cultures	O
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	B-PRGE
mRNA	O
from	O
progenitor	O
cells	O
through	O
their	O
differentiating	O
erythroid	O
progeny	O
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	O
progenitors	O
/	O
precursors	O
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	O
lymphocytes	O
infected	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Infection	O
of	O
human	O
B	O
cells	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	B-PRGE
D2	I-PRGE
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	O
genes	O
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F	B-PRGE
-	I-PRGE
4	I-PRGE
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	B-PRGE
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL	O
-	O
2	O
family	O
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
A20	B-PRGE
.	O

A20	B-PRGE
can	O
be	O
regulated	O
by	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
levels	O
and	O
active	O
NF	O
-	O
kappaB	O
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

Immortalization	O
of	O
CD4	B-PRGE
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
lymphocytes	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-PRGE
mutants	O
expressed	O
in	O
a	O
functional	O
molecular	O
clone	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
transcriptional	O
trans	O
-	O
activator	O
Tax	B-PRGE
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	O
cell	O
culture	O
and	O
transgenic	O
-	O
mouse	O
models	O
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
through	O
the	O
cyclic	O
AMP	O
response	O
element	O
binding	O
protein	O
/	O
activating	O
transcription	O
factor	O
(	O
CREB	O
/	O
ATF	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
Tax	B-PRGE
activates	O
the	O
expression	O
of	O
multiple	O
cellular	O
promoters	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
of	O
transcriptional	O
activation	O
.	O

The	O
Tax	B-PRGE
mutants	O
M22	O
and	O
M47	O
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	B-PRGE
to	O
activate	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
or	O
CREB	O
/	O
ATF	O
pathway	O
,	O
respectively	O
.	O

These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	B-PRGE
gene	O
of	O
the	O
ACH	O
functional	O
molecular	O
clone	O
of	O
HTLV	O
-	O
1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	O
ACH	O
clones	O
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	O
human	O
lymphocytes	O
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	O
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	O
lymphocytes	O
,	O
the	O
M22	O
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
pathway	O
by	O
Tax	B-PRGE
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
1	O
,	O
whereas	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
may	O
be	O
critical	O
.	O

HIV	O
-	O
1	O
reactivation	O
in	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	B-PRGE
cross	O
-	O
linking	O
by	O
ligands	O
of	O
the	O
CDR2	O
-	O
loop	O
in	O
extracellular	O
domain	O
1	O
.	O

HIV	O
-	O
1	O
infects	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross	O
-	O
linking	O
of	O
cell	O
surface	O
CD4	B-PRGE
by	O
gp120	O
-	O
anti	O
-	O
gp120	O
immune	O
complexes	O
or	O
heat	O
-	O
inactivated	O
HIV	O
-	O
1	O
(	O
iHIV	O
-	O
1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV	O
-	O
1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	O
proteins	O
used	O
as	O
exogenous	O
stimuli	O
.	O

Moreover	O
,	O
we	O
further	O
investigated	O
the	O
physiologic	O
relevance	O
of	O
these	O
observations	O
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B-PRGE
cross	O
-	O
linking	O
by	O
iHIV	O
-	O
1	O
,	O
PBMCs	O
from	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	O
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	O
PBMCs	O
infected	O
in	O
vitro	O
with	O
HIV	O
-	O
1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2	O
-	O
loop	O
in	O
domain	O
1	O
(	O
D1	O
)	O
of	O
CD4	B-PRGE
(	O
virus	O
envelope	O
and	O
anti	O
-	O
CD4	B-PRGE
monoclonal	O
antibodies	O
)	O
.	O

In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B-PRGE
oligomerization	O
by	O
antibodies	O
that	O
bind	O
other	O
epitopes	O
in	O
D1	O
,	O
including	O
the	O
D1	O
/	O
CDR3	O
-	O
loop	O
.	O

Finally	O
,	O
soluble	O
CD4	B-PRGE
(	O
sCD4	O
)	O
prevented	O
virus	O
reactivation	O
by	O
D1	O
/	O
CDR2	O
-	O
loop	O
ligands	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	O
by	O
oligomerization	O
of	O
CD4	B-PRGE
at	O
the	O
D1	O
/	O
CDR2	O
-	O
loop	O
can	O
trigger	O
HIV	O
-	O
1	O
upregulation	O
in	O
infected	O
individuals	O
.	O

Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF	O
-	O
kappaB	O
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti	O
-	O
inflammatory	O
mediators	O
.	O

The	O
role	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF	O
-	O
kappaB	O
through	O
overexpression	O
of	O
the	O
inhibitory	O
subunit	O
IkappaBalpha	B-PRGE
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	O
macrophages	O
,	O
fibroblasts	O
,	O
and	O
T	O
cells	O
infected	O
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
and	O
other	O
pro	O
-	O
inflammatory	O
cytokines	O
is	O
NF	O
-	O
kappaB	O
-	O
dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
like	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
-	B-PRGE
11	I-PRGE
,	O
and	O
the	O
IL	O
-	O
1	O
receptor	O
antagonist	O
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B-PRGE
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B-PRGE
metalloproteinases	I-PRGE
1	I-PRGE
and	O
3	B-PRGE
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O

Blocking	O
NF	O
-	O
kappaB	O
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	O
cells	O
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Cell	O
growth	O
-	O
regulated	O
expression	O
of	O
mammalian	O
MCM5	B-PRGE
and	O
MCM6	B-PRGE
genes	O
mediated	O
by	O
the	O
transcription	O
factor	O
E2F	O
.	O

Initiation	O
of	O
DNA	O
replication	O
requires	O
the	O
function	O
of	O
MCM	O
gene	O
products	O
,	O
which	O
participate	O
in	O
ensuring	O
that	O
DNA	O
replication	O
occurs	O
only	O
once	O
in	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
all	O
mammalian	O
genes	O
of	O
the	O
MCM	O
family	O
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1	O
/	O
S	O
boundary	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	O
human	O
MCM	O
gene	O
promoters	O
.	O

Human	O
MCM5	B-PRGE
and	O
MCM6	B-PRGE
promoters	O
with	O
mutation	O
in	O
the	O
E2F	O
sites	O
failed	O
in	O
promoter	O
regulation	O
following	O
serum	O
stimulation	O
and	O
exogenous	O
E2F	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F	O
-	O
like	O
sequence	O
in	O
human	O
MCM6	B-PRGE
promoter	O
which	O
cooperates	O
with	O
the	O
authentic	O
E2F	O
sites	O
in	O
E2F	O
-	O
dependent	O
regulation	O
.	O

Forced	O
expression	O
of	O
E2F1	B-PRGE
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	O
MCM	O
genes	O
in	O
rat	O
embryonal	O
fibroblast	O
REF52	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
growth	O
-	O
regulated	O
expression	O
of	O
mammalian	O
MCM5	B-PRGE
and	O
MCM6	B-PRGE
genes	O
,	O
and	O
presumably	O
other	O
MCM	O
members	O
,	O
is	O
primarily	O
regulated	O
by	O
E2F	O
through	O
binding	O
to	O
multiple	O
E2F	O
sites	O
in	O
the	O
promoters	O
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	O
and	O
induce	O
HSP70	O
in	O
human	O
monocytes	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF1	B-PRGE
)	O
from	O
a	O
latent	O
cytoplasmic	O
form	O
to	O
a	O
nuclear	O
,	O
DNA	O
binding	O
state	O
.	O

As	O
HSF1	B-PRGE
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	O
shock	O
genes	O
and	O
a	O
repressor	O
of	O
non	O
-	O
heat	O
shock	O
genes	O
such	O
as	O
IL1B	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	B-PRGE
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	O
the	O
IL1B	B-PRGE
promoter	O
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	B-PRGE
overexpression	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	B-PRGE
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	O
genes	O
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro	O
-	O
inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	B-PRGE
promoter	O
,	O
repression	O
did	O
not	O
seem	O
to	O
involve	O
another	O
factor	O
whose	O
activity	O
is	O
affected	O
by	O
the	O
NSAIDs	O
,	O
NFkappaB	O
as	O
the	O
IL1B	B-PRGE
promoter	O
fragment	O
used	O
in	O
our	O
studies	O
is	O
not	O
NFkappaB	O
responsive	O
and	O
binds	O
specifically	O
to	O
HSF1	B-PRGE
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	B-PRGE
promoter	O
,	O
sodium	O
salicylate	O
did	O
not	O
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-PRGE
mRNA	O
species	O
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	B-PRGE
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	O
binding	O
forms	O
only	O
one	O
of	O
which	O
activates	O
heat	O
shock	O
promoters	O
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	O
cells	O
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	O
genes	O
and	O
HSF1	B-PRGE
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
protein	O
Id3	B-PRGE
in	O
committed	O
T	O
cell	O
progenitors	O
.	O

Enforced	O
expression	O
of	O
Id3	B-PRGE
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
,	O
in	O
human	O
CD34	B-PRGE
(	O
+	O
)	O
hematopoietic	O
progenitor	O
cells	O
that	O
have	O
not	O
undergone	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
gene	O
rearrangements	O
inhibits	O
development	O
of	O
the	O
transduced	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

Here	O
we	O
document	O
that	O
overexpression	O
of	O
Id3	B-PRGE
,	O
in	O
progenitors	O
that	O
have	O
initiated	O
TCR	O
gene	O
rearrangements	O
(	O
pre	O
-	O
T	O
cells	O
)	O
,	O
inhibits	O
development	O
into	O
TCRalpha	O
beta	O
but	O
not	O
into	O
TCRgamma	O
delta	O
T	O
cells	O
.	O

Furthermore	O
,	O
Id3	B-PRGE
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre	O
-	O
Talpha	O
mRNA	O
.	O

These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	B-PRGE
overexpression	O
can	O
differentially	O
affect	O
development	O
of	O
pre	O
-	O
T	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
.	O

We	O
also	O
observed	O
that	O
cell	O
surface	O
CD4	B-PRGE
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
cells	O
with	O
rearranged	O
TCR	O
genes	O
developed	O
from	O
Id3	B-PRGE
-	O
transduced	O
but	O
not	O
from	O
control	O
-	O
transduced	O
pre	O
-	O
T	O
cells	O
in	O
an	O
FTOC	O
.	O

These	O
cells	O
had	O
properties	O
of	O
both	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
pre	O
-	O
T	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
bHLH	O
factors	O
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T	O
/	O
NK	O
developmental	O
checkpoint	O
.	O

Rel	O
/	O
NF	O
-	O
kappaB	O
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	O
the	O
expression	O
of	O
Jagged1	B-PRGE
,	O
a	O
ligand	O
for	O
Notch	O
receptors	O
.	O

Jagged1	B-PRGE
belongs	O
to	O
the	O
DSL	O
family	O
of	O
ligands	O
for	O
Notch	O
receptors	O
that	O
control	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
cell	O
lineages	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	O
factors	O
that	O
regulate	O
its	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	B-PRGE
is	O
a	O
Rel	O
/	O
NF	O
-	O
kappaB	O
-	O
responsive	O
gene	O
.	O

Both	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
RelA	B-PRGE
induced	O
jagged1	B-PRGE
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O

Importantly	O
,	O
jagged1	B-PRGE
transcripts	O
were	O
also	O
upregulated	O
by	O
endogenous	O
NF	O
-	O
kappaB	O
activation	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	B-PRGE
,	O
a	O
physiological	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Cell	O
surface	O
expression	O
of	O
Jagged1	B-PRGE
in	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
-	O
expressing	O
cell	O
monolayers	O
led	O
to	O
a	O
functional	O
interaction	O
with	O
lymphocytes	O
expressing	O
the	O
Notch1	B-PRGE
/	O
TAN	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	O
.	O

This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	O
levels	O
of	O
HES	B-PRGE
-	I-PRGE
1	I-PRGE
transcripts	O
in	O
co	O
-	O
cultivated	O
T	O
cells	O
and	O
of	O
CD23	B-PRGE
transcripts	O
in	O
co	O
-	O
cultivated	O
B	O
cells	O
.	O

Consistent	O
with	O
its	O
Rel	O
/	O
NF	O
-	O
kappaB	O
-	O
dependent	O
induction	O
,	O
Jagged1	B-PRGE
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	O
B	O
cells	O
where	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
is	O
expressed	O
constitutively	O
.	O

These	O
results	O
demonstrate	O
that	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	O
jagged1	B-PRGE
gene	O
expression	O
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	B-PRGE
in	O
B	O
-	O
cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

Transcriptional	O
control	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
by	O
human	O
helper	O
T	O
cells	O
:	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
is	O
regulated	O
independently	O
from	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
synthesis	O
.	O

BACKGROUND	O
:	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
is	O
fundamentally	O
involved	O
in	O
eosinophilic	O
inflammation	O
.	O

Control	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
find	O
the	O
transcriptional	O
mechanisms	O
that	O
regulate	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
to	O
selectively	O
control	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
-	O
cell	O
clones	O
and	O
T	O
-	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

RESULTS	O
:	O
A	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
/	O
enhancer	O
-	O
luciferase	B-PRGE
gene	O
construct	O
,	O
pIL	O
-	O
5	O
(	O
-	O
511	O
)	O
Luc	O
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
producing	O
T	O
-	O
cell	O
clones	O
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
nonproducing	O
clones	O
.	O

pIL	O
-	O
5	O
(	O
-	O
511	O
)	O
Luc	O
was	O
transcribed	O
by	O
T	O
-	O
cell	O
hybridomas	O
derived	O
from	O
fusion	O
between	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
producing	O
T	O
-	O
cell	O
clones	O
and	O
an	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
-	O
nonexpressing	O
T	O
-	O
cell	O
line	O
,	O
but	O
not	O
by	O
hybridomas	O
derived	O
from	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
nonproducing	O
T	O
-	O
cell	O
clones	O
.	O

IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T	O
-	O
cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
stimulation	O
.	O

Binding	O
of	O
NF	O
-	O
AT	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
AP	O
-	O
1	O
was	O
induced	O
by	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
stimulation	O
,	O
although	O
there	O
was	O
no	O
significant	O
upregulation	O
of	O
binding	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
stimulation	O
.	O

CONCLUSION	O
:	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
by	O
human	O
helper	O
T	O
cells	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

A	O
unique	O
transcriptional	O
mechanism	O
distinct	O
from	O
those	O
regulating	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
genes	O
seems	O
to	O
control	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
.	O

Selective	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
transcription	O
may	O
be	O
useful	O
for	O
treating	O
eosinophlic	O
inflammation	O
.	O

Regulation	O
of	O
low	O
shear	O
flow	O
-	O
induced	O
HAEC	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
monocyte	O
adhesion	O
.	O

We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	O
aortic	O
endothelial	O
cells	O
(	O
HAEC	O
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell	O
-	O
monocyte	O
(	O
EC	O
-	O
Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn	O
/	O
cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	O
were	O
preincubated	O
with	O
or	O
without	O
the	O
antioxidants	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
.	O

PDTC	O
strongly	O
inhibited	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
EC	O
-	O
Mn	O
adhesion	O
.	O

Paradoxically	O
,	O
NAC	O
exerted	O
a	O
positive	O
effect	O
on	O
low	O
shear	O
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
EC	O
-	O
Mn	O
adhesion	O
and	O
only	O
slightly	O
downregulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

However	O
,	O
cytokine	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

These	O
data	O
suggest	O
that	O
NF	O
-	O
kappaB	O
plays	O
a	O
key	O
role	O
in	O
low	O
shear	O
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear	O
-	O
and	O
cytokine	O
-	O
induced	O
EC	O
-	O
Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Nuclear	O
localization	O
and	O
formation	O
of	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
-	O
lymphoid	B-PRGE
enhancer	I-PRGE
factor	I-PRGE
1	I-PRGE
complexes	O
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF	O
/	O
TCF	O
(	O
for	O
lymphoid	O
enhancer	O
factor	O
and	O
T	O
-	O
cell	O
factor	O
)	O
transcription	O
factors	O
to	O
activate	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

We	O
demonstrate	O
here	O
that	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF	O
/	O
TCF	O
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O

We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
(	O
Delta19	O
)	O
that	O
disrupts	O
binding	O
to	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
,	O
and	O
APC	B-PRGE
but	O
not	O
axin	B-PRGE
.	O

This	O
Delta19	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
mutant	O
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	O
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF	O
/	O
TCF	O
factors	O
.	O

beta	B-PRGE
-	I-PRGE
Catenin	I-PRGE
and	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
complexes	O
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
Jurkat	O
)	O
but	O
not	O
in	O
normal	O
T	O
lymphocytes	O
,	O
even	O
though	O
both	O
factors	O
are	O
nuclear	O
.	O

Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

Excess	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
beta	B-PRGE
-	I-PRGE
catenin	I-PRGE
complexes	O
but	O
not	O
activation	O
by	O
the	O
transcription	O
factor	O
VP16	B-PRGE
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
cytokine	O
production	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
is	O
a	O
well	O
-	O
known	O
immunosuppressive	O
and	O
/	O
or	O
anti	O
-	O
inflammatory	O
cytokine	O
.	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
primed	O
leukocytes	O
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	O
human	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
had	O
an	O
enhanced	O
capacity	O
to	O
produce	O
TNF	B-PRGE
in	O
response	O
to	O
LPS	O
.	O

In	O
addition	O
to	O
TNF	B-PRGE
,	O
LPS	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
spontaneous	O
IL	B-PRGE
-	I-PRGE
1ra	I-PRGE
production	O
were	O
also	O
enhanced	O
.	O

When	O
isolated	O
PBMC	O
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
an	O
enhanced	O
release	O
of	O
TNF	B-PRGE
was	O
observed	O
.	O

This	O
was	O
not	O
the	O
case	O
when	O
PBMC	O
were	O
pre	O
-	O
cultured	O
in	O
plastic	O
multidishes	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

TNF	O
mRNA	O
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre	O
-	O
treatment	O
of	O
PBMC	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre	O
-	O
cultured	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
Teflon	O
.	O

Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
pre	O
-	O
treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B-PRGE
and	O
CD68	B-PRGE
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	B-PRGE
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
independently	O
of	O
the	O
pre	O
-	O
culture	O
conditions	O
of	O
the	O
PBMC	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
induced	O
up	O
-	O
regulation	O
of	O
cytokine	O
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	O
cells	O
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	O
on	O
Teflon	O
.	O

In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	O
effect	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
induced	O
modulation	O
of	O
some	O
monocyte	O
surface	O
markers	O
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	O
element	O
upstream	O
of	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
.	O

The	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
required	O
for	O
differentiation	O
of	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis	O
-	O
acting	O
regulatory	O
element	O
,	O
HS	O
I	O
,	O
associated	O
with	O
a	O
hematopoietic	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
,	O
which	O
lies	O
approx	O
.	O
3	O
.	O
7	O
kilobases	O
upstream	O
of	O
the	O
murine	O
hematopoietic	O
-	O
specific	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
IE	O
promoter	O
.	O

HS	O
I	O
directs	O
high	O
-	O
level	O
expression	O
of	O
reporter	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
lacZ	B-PRGE
genes	O
to	O
primitive	O
and	O
definitive	O
erythroid	O
cells	O
and	O
megakaryocytes	O
in	O
transgenic	O
mice	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
HS	O
I	O
between	O
human	O
and	O
mouse	O
shows	O
approx	O
.	O
63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	O
base	O
pairs	O
(	O
86	O
%	O
identity	O
)	O
.	O

This	O
core	O
contains	O
a	O
GATA	O
site	O
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E	O
-	O
box	O
motif	O
.	O

The	O
composite	O
motif	O
binds	O
a	O
multi	O
-	O
protein	O
hematopoietic	O
-	O
specific	O
transcription	O
factor	O
complex	O
which	O
includes	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
SCL	B-PRGE
/	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
E2A	B-PRGE
,	O
Lmo2	B-PRGE
and	O
Ldb	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Point	O
mutations	O
of	O
the	O
GATA	O
site	O
abolishes	O
HS	O
I	O
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E	O
-	O
box	O
motif	O
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O

Strict	O
dependence	O
of	O
HS	O
I	O
activity	O
on	O
a	O
GATA	O
site	O
implies	O
that	O
assembly	O
of	O
a	O
protein	O
complex	O
containing	O
a	O
GATA	O
-	O
factor	O
,	O
presumably	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O

Further	O
dissection	O
of	O
the	O
317	O
base	O
pair	O
region	O
demonstrates	O
that	O
,	O
whereas	O
all	O
317	O
base	O
pairs	O
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	O
,	O
only	O
the	O
5	O
'	O
62	O
base	O
pairs	O
are	O
needed	O
for	O
erythroid	O
-	O
specific	O
reporter	O
expression	O
.	O

These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	O
I	O
element	O
.	O

Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activates	O
transcription	O
of	O
genes	O
encoding	O
endothelial	O
adhesion	O
molecules	O
and	O
chemokines	O
that	O
contribute	O
to	O
monocyte	O
infiltration	O
critical	O
in	O
atherogenesis	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	O
gene	O
transfer	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
have	O
not	O
been	O
studied	O
.	O

We	O
found	O
that	O
overexpression	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
endothelial	O
cells	O
using	O
a	O
recombinant	O
adenovirus	O
prevented	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
-	O
induced	O
degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
suppressed	O
the	O
upregulation	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
mRNA	O
and	O
surface	O
protein	O
expression	O
and	O
the	O
upregulation	O
of	O
transcripts	O
for	O
the	O
chemokines	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
growth	B-PRGE
-	I-PRGE
related	I-PRGE
activity	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
GRO	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
endothelial	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
secretion	O
and	O
GRO	B-PRGE
-	I-PRGE
alpha	I-PRGE
immobilization	O
.	O

Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	O
on	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
overexpression	O
.	O

Inhibition	O
with	O
monoclonal	O
antibodies	O
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	O
specifically	O
involved	O
in	O
these	O
events	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	O
was	O
increased	O
by	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
induction	O
.	O

Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF	O
-	O
kappaB	O
by	O
adenoviral	O
transfer	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	O
gene	O
products	O
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O

SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
,	O
two	O
hematopoietic	O
cell	O
specific	O
molecules	O
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	O
T	O
cell	O
antigen	O
receptor	O
stimulation	O
,	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B-PRGE
and	O
phosphorylated	O
tyrosines	O
of	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
.	O

Furthermore	O
,	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr	O
-	O
113	O
and	O
Tyr	O
-	O
128	O
,	O
of	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	B-PRGE
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
.	O

Overexpression	O
of	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	B-PRGE
leads	O
to	O
enhanced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
activity	O
without	O
affecting	O
AP	O
-	O
1	O
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	B-PRGE
,	O
but	O
not	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
,	O
augments	O
CD28	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
Vav	B-PRGE
in	O
regulating	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
locus	O
assumes	O
a	O
transcriptionally	O
-	O
active	O
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	O
-	O
specific	O
DNase	O
1	O
hypersensitive	O
site	O
-	O
forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF	O
-	O
E2	O
,	O
AP	O
-	O
1	O
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Sp	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B-PRGE
1	I-PRGE
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-	O
300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3	O
-	O
fold	O
increases	O
in	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis	O
-	O
acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
expression	O
.	O

In	O
vivo	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lineage	O
cells	O
leads	O
to	O
a	O
dramatic	O
decrease	O
in	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
and	O
to	O
increased	O
cell	O
apoptosis	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
,	O
but	O
not	O
to	O
abnormal	O
thymopoiesis	O
.	O

To	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
complexes	O
were	O
selectively	O
inhibited	O
in	O
the	O
T	O
-	O
lineage	O
cells	O
by	O
specific	O
expression	O
of	O
a	O
trans	O
-	O
dominant	O
form	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Transgene	O
expression	O
did	O
not	O
affect	O
the	O
thymic	O
development	O
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	O
cells	O
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	O
T	O
lymphocytes	O
.	O

Analysis	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
expression	O
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	O
attributable	O
to	O
an	O
abnormal	O
expression	O
of	O
these	O
genes	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
strongly	O
inhibited	O
in	O
the	O
transgenic	O
T	O
cells	O
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	O
T	O
cells	O
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

These	O
results	O
point	O
out	O
the	O
involvement	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
proteins	O
in	O
growth	O
signaling	O
pathways	O
by	O
either	O
regulating	O
proteins	O
involved	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
signaling	O
or	O
by	O
functionally	O
interfering	O
with	O
the	O
cell	O
cycle	O
progression	O
.	O

CD28	B-PRGE
costimulation	O
augments	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transactivation	O
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	O
propria	O
(	O
LP	O
)	O
T	O
cells	O
are	O
different	O
from	O
peripheral	O
T	O
cells	O
.	O

LP	O
T	O
cells	O
exhibit	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
when	O
activated	O
through	O
the	O
CD2	O
pathway	O
.	O

Coligation	O
of	O
CD28	B-PRGE
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	B-PRGE
augmentation	O
of	O
TCR	O
-	O
mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
CD28	B-PRGE
response	O
element	O
(	O
CD28RE	O
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	B-PRGE
costimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
LP	O
mononuclear	O
cells	O
(	O
LPMC	O
)	O
.	O

LPMC	O
exhibited	O
increased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
response	O
to	O
CD28	B-PRGE
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	O
alone	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
,	O
resulting	O
from	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	O
,	O
EMSA	O
revealed	O
that	O
CD28	B-PRGE
coligation	O
of	O
CD2	O
-	O
activated	O
LPMC	O
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
the	O
CD28RE	O
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I	B-PRGE
-	I-PRGE
kappaBalpha	I-PRGE
or	O
I	B-PRGE
-	I-PRGE
kappaBbeta	I-PRGE
levels	O
following	O
CD28	B-PRGE
coligation	O
.	O

Furthermore	O
,	O
CD28	B-PRGE
coligation	O
fails	O
to	O
enhance	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
reporter	O
or	O
RE	O
/	O
AP	O
construct	O
expression	O
in	O
CD2	O
-	O
activated	O
LPMC	O
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	B-PRGE
cosignaling	O
and	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
in	O
LP	O
T	O
cells	O
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	O
repertoire	O
found	O
in	O
the	O
mucosa	O
.	O

Repression	O
by	O
Ikaros	B-PRGE
and	O
Aiolos	B-PRGE
is	O
mediated	O
through	O
histone	O
deacetylase	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
lineage	O
-	O
determining	O
factors	O
Ikaros	B-PRGE
and	O
Aiolos	B-PRGE
can	O
function	O
as	O
strong	O
transcriptional	O
repressors	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	O
domains	O
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	B-PRGE
proteins	O
correlates	O
with	O
hypo	O
-	O
acetylation	O
of	O
core	O
histones	O
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	O
deacetylase	O
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	B-PRGE
and	O
its	O
repression	O
domains	O
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	O
family	O
of	O
co	O
-	O
repressors	O
which	O
bind	O
to	O
histone	O
deacetylases	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	B-PRGE
and	O
Mi	B-PRGE
-	I-PRGE
2	I-PRGE
-	I-PRGE
HDAC	I-PRGE
,	O
we	O
propose	O
that	O
Ikaros	B-PRGE
family	O
members	O
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	O
deacetylase	O
complexes	O
to	O
specific	O
promoters	O
.	O

New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
proliferation	O
and	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	O
lymphocyte	O
proliferation	O
in	O
vitro	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	O
T	O
cell	O
proliferation	O
in	O
mid	O
-	O
late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	O
,	O
and	O
cyclin	O
-	O
dependent	O
kinases	O
and	O
retinoblastoma	O
phosphorylation	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	O
significantly	O
the	O
induction	O
of	O
either	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
IL	O
-	O
2R	O
alpha	O
-	O
and	O
gamma	O
-	O
chains	O
but	O
inhibits	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
T	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
PNU156804	O
does	O
not	O
inhibit	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
and	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
induction	O
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
.	O

PNU156804	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
beta	I-PRGE
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
PMA	O
in	O
T	O
cells	O
but	O
blocks	O
that	O
induced	O
by	O
CD40	B-PRGE
cross	O
-	O
linking	O
in	O
B	O
lymphocytes	O
.	O

We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O

IL	O
-	O
12	O
induces	O
IFN	B-PRGE
regulating	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
gene	O
expression	O
in	O
human	O
NK	O
and	O
T	O
cells	O
.	O

IL	O
-	O
12	O
is	O
a	O
critical	O
immunoregulatory	O
cytokine	O
that	O
promotes	O
cell	O
-	O
mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4	B-PRGE
+	O
cells	O
to	O
Th1	O
cells	O
;	O
however	O
,	O
relatively	O
few	O
IL	O
-	O
12	O
target	O
genes	O
have	O
been	O
identified	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL	O
-	O
12	O
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up	O
-	O
regulated	O
by	O
IL	O
-	O
12	O
,	O
first	O
by	O
contrasting	O
IL	O
-	O
12	O
-	O
and	O
IFN	O
-	O
alpha	O
-	O
inducible	O
genes	O
.	O

We	O
identified	O
several	O
genes	O
up	O
-	O
regulated	O
by	O
IL	O
-	O
12	O
,	O
namely	O
,	O
MIP	B-PRGE
-	I-PRGE
1alpha	I-PRGE
,	O
MIP	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1RA	I-PRGE
,	O
and	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

IRF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
transcription	O
factor	O
regulated	O
by	O
IFNs	O
that	O
is	O
also	O
essential	O
for	O
Th1	O
responses	O
.	O

We	O
demonstrated	O
that	O
IL	O
-	O
12	O
directly	O
up	O
-	O
regulates	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
the	O
same	O
extent	O
as	O
IFN	O
-	O
alpha	O
in	O
normal	O
human	O
T	O
cells	O
and	O
in	O
NK	O
cells	O
.	O

We	O
showed	O
that	O
IL	O
-	O
12	O
had	O
a	O
direct	O
effect	O
on	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
an	O
effect	O
not	O
mediated	O
indirectly	O
by	O
the	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
.	O

Furthermore	O
,	O
IL	O
-	O
2	O
and	O
IL	O
-	O
12	O
synergistically	O
induced	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
whereas	O
IFN	O
-	O
alpha	O
and	O
IL	O
-	O
12	O
did	O
not	O
.	O

The	O
participation	O
of	O
STAT4	B-PRGE
in	O
the	O
regulation	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
demonstrated	O
in	O
two	O
ways	O
.	O

First	O
,	O
STAT4	B-PRGE
was	O
required	O
for	O
the	O
IL	O
-	O
12	O
-	O
dependent	O
transactivation	O
of	O
an	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
reporter	O
construct	O
,	O
and	O
second	O
,	O
STAT4	B-PRGE
binding	O
to	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
was	O
shown	O
using	O
EMSA	O
.	O

In	O
contrast	O
to	O
IL	O
-	O
12	O
,	O
no	O
up	O
-	O
regulation	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
found	O
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
stimulated	O
cells	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
did	O
not	O
block	O
IL	O
-	O
12	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Therefore	O
,	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
may	O
be	O
an	O
important	O
contributor	O
to	O
IL	O
-	O
12	O
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL	O
-	O
12	O
responses	O
seen	O
in	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
/	O
-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	O
factor	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell	O
-	O
surface	O
receptors	O
,	O
intracellular	O
signaling	O
molecules	O
,	O
and	O
nuclear	O
transcription	O
factors	O
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	O
cell	O
transcription	O
factors	O
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	B-PRGE
,	O
LKLF	B-PRGE
,	O
and	O
GATA3	B-PRGE
zinc	O
-	O
finger	O
proteins	O
;	O
the	O
Ets	O
,	O
CREB	B-PRGE
/	O
ATF	B-PRGE
,	O
and	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
/	O
NFAT	O
transcription	O
factors	O
;	O
the	O
Stat	O
proteins	O
;	O
and	O
HMG	O
box	O
transcription	O
factors	O
such	O
as	O
LEF1	B-PRGE
,	O
TCF1	B-PRGE
,	O
and	O
Sox4	B-PRGE
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

Binding	O
of	O
YY1	B-PRGE
and	O
Oct1	B-PRGE
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
in	O
human	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL	B-PRGE
-	I-PRGE
5	I-PRGE
is	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
hIL	B-PRGE
-	I-PRGE
5	I-PRGE
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-	O
regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
transcription	O
in	O
T	O
cells	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	O
I	O
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	O
of	O
hIL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
activity	O
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	O
and	O
BR4	O
located	O
at	O
positions	O
-	O
102	O
to	O
-	O
73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
expression	O
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	O
regulatory	O
element	O
located	O
at	O
positions	O
-	O
90	O
to	O
-	O
79	O
of	O
the	O
hIL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
,	O
which	O
binds	O
Oct1	B-PRGE
,	O
octamer	O
-	O
like	O
,	O
and	O
YY1	B-PRGE
nuclear	O
factors	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	O
hIL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	B-PRGE
,	O
YY1	B-PRGE
,	O
and	O
octamer	O
-	O
like	O
factors	O
binding	O
to	O
the	O
-	O
90	O
/	O
-	O
79	O
sequence	O
within	O
the	O
proximal	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
are	O
involved	O
in	O
suppression	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
transcription	O
in	O
T	O
cells	O
.	O

Direct	O
interaction	O
of	O
hematopoietic	O
transcription	O
factors	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
:	O
functional	O
antagonism	O
in	O
erythroid	O
cells	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
a	O
hematopoietic	O
-	O
specific	O
Ets	O
family	O
transcription	O
factor	O
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
can	O
also	O
act	O
as	O
an	O
oncoprotein	O
as	O
activation	O
of	O
its	O
expression	O
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O

Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
requires	O
a	O
decline	O
in	O
the	O
level	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
indicating	O
that	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
can	O
block	O
erythroid	O
differentiation	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
interferes	O
with	O
erythroid	O
differentiation	O
.	O

We	O
find	O
that	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
interacts	O
directly	O
with	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
required	O
for	O
erythroid	O
differentiation	O
.	O

Interaction	O
between	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
requires	O
intact	O
DNA	O
-	O
binding	O
domains	O
in	O
both	O
proteins	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
represses	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
transcriptional	O
activation	O
.	O

Both	O
the	O
DNA	O
binding	O
and	O
transactivation	O
domains	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
both	O
MEL	O
cells	O
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	O
factors	O
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live	O
-	O
HIV	O
-	O
1	O
by	O
gain	O
of	O
a	O
proteolysis	O
-	O
resistant	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	B-PRGE
-	I-PRGE
alphaS32	I-PRGE
/	O
36A	O
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live	O
-	O
attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss	O
-	O
of	O
-	O
function	O
(	O
e	O
.	O
g	O
.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	B-PRGE
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication	O
-	O
competent	O
,	O
HIV	O
-	O
1	O
/	O
SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss	O
-	O
of	O
-	O
function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss	O
-	O
of	O
-	O
function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	O
genome	O
.	O

Here	O
,	O
we	O
propose	O
gain	O
-	O
of	O
-	O
function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss	O
-	O
of	O
-	O
function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV	O
-	O
1	O
.	O

We	O
have	O
constructed	O
an	O
HIV	O
-	O
1	O
genome	O
carrying	O
the	O
cDNA	O
of	O
a	O
proteolysis	O
-	O
resistant	O
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	O
(	O
IkappaB	B-PRGE
-	I-PRGE
alphaS32	I-PRGE
/	O
36A	O
)	O
in	O
the	O
nef	B-PRGE
region	O
.	O

HIV	O
-	O
1	O
expressing	O
IkappaB	B-PRGE
-	I-PRGE
alphaS32	I-PRGE
/	O
36A	O
down	O
-	O
regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alphaS32	I-PRGE
/	O
36A	O
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV	O
-	O
1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open	O
-	O
reading	O
frames	O
embedded	O
into	O
HIV	O
/	O
SIV	O
genome	O
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB	B-PRGE
-	I-PRGE
alphaS32	I-PRGE
/	O
36A	O
offers	O
proof	O
-	O
of	O
-	O
principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV	O
-	O
1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain	O
-	O
of	O
-	O
function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live	O
-	O
attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Human	O
alveolar	O
macrophages	O
are	O
markedly	O
deficient	O
in	O
REF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
AP	O
-	O
1	O
DNA	O
binding	O
activity	O
.	O

Although	O
many	O
functions	O
of	O
human	O
alveolar	O
macrophages	O
are	O
altered	O
compared	O
with	O
their	O
precursor	O
cell	O
,	O
the	O
blood	O
monocyte	O
(	O
monocyte	O
)	O
,	O
the	O
reason	O
(	O
s	O
)	O
for	O
these	O
functional	O
changes	O
have	O
not	O
been	O
determined	O
.	O

We	O
recently	O
reported	O
that	O
human	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP	O
-	O
1	O
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M	O
.	O
M	O
.	O
,	O
Carter	O
,	O
A	O
.	O
B	O
.	O
,	O
Gudmundsson	O
,	O
G	O
.	O
,	O
Geist	O
,	O
L	O
.	O
J	O
.	O
,	O
and	O
Hunninghake	O
,	O
G	O
.	O
W	O
.	O
(	O
1998	O
)	O
Am	O
.	O
J	O
.	O
Physiol	O
.	O
275	O
,	O
L389	O
-	O
L397	O
)	O
.	O

To	O
determine	O
why	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP	O
-	O
1	O
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	O
and	O
JUN	O
proteins	O
that	O
make	O
up	O
the	O
AP	O
-	O
1	O
complex	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	O
the	O
amounts	O
of	O
the	O
nuclear	O
protein	O
,	O
REF	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
which	O
regulates	O
AP	O
-	O
1	O
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	O
and	O
JUN	O
proteins	O
)	O
,	O
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	O
to	O
a	O
macrophage	O
-	O
like	O
cell	O
resulted	O
in	O
decreased	O
amounts	O
of	O
REF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Finally	O
,	O
addition	O
of	O
REF	B-PRGE
-	I-PRGE
1	I-PRGE
from	O
activated	O
monocytes	O
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP	O
-	O
1	O
DNA	O
binding	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
the	O
process	O
of	O
differentiation	O
of	O
monocytes	O
into	O
alveolar	O
macrophages	O
is	O
associated	O
with	O
a	O
loss	O
of	O
REF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
AP	O
-	O
1	O
activity	O
.	O

This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
to	O
the	O
TNF	B-PRGE
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	B-PRGE
(	O
encoding	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
,	O
TNF	B-PRGE
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
transcription	O
factor	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	B-PRGE
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
-	O
-	O
although	O
still	O
difficult	O
-	O
-	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O

Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti	O
-	O
TNF	O
antibody	O
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O

The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
-	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
-	O
-	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

PPARalpha	O
activators	O
inhibit	O
cytokine	O
-	O
induced	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	B-PRGE
proliferator	I-PRGE
-	I-PRGE
activated	I-PRGE
receptor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
PPARalpha	B-PRGE
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
family	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	B-PRGE
expression	O
in	O
human	O
ECs	O
and	O
their	O
regulation	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	O
carotid	O
artery	O
ECs	O
express	O
PPARalpha	B-PRGE
.	O

Pretreatment	O
of	O
cultured	O
human	O
ECs	O
with	O
the	O
PPARalpha	B-PRGE
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	B-PRGE
activators	O
.	O

Both	O
PPARalpha	B-PRGE
activators	O
decreased	O
cytokine	O
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half	O
-	O
life	O
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
constructs	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
part	O
by	O
inhibiting	O
NF	O
-	O
kappaB	O
.	O

Finally	O
,	O
PPARalpha	B-PRGE
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	O
cells	O
to	O
cultured	O
human	O
ECs	O
.	O

CONCLUSIONS	O
:	O
Human	O
ECs	O
express	O
PPARalpha	B-PRGE
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid	O
-	O
lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B-PRGE
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	O
inhibitors	O
.	O

The	O
biological	O
significance	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
T	O
.	O
parva	O
-	O
infected	O
cells	O
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T	O
.	O
parva	O
-	O
transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite	O
-	O
mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	O
negative	O
mutant	O
forms	O
of	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B-PRGE
or	O
p65	B-PRGE
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T	O
.	O
parva	O
-	O
transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	O
-	O
kappaB	O
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Downregulation	O
of	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	B-PRGE
)	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O

The	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	B-PRGE
)	O
encodes	O
a	O
transcription	O
factor	O
of	O
the	O
zinc	O
finger	O
type	O
.	O

A	O
high	O
expression	O
of	O
WT1	B-PRGE
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B-PRGE
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	O
cell	O
lines	O
.	O

Overexpression	O
of	O
WT1	B-PRGE
in	O
some	O
myeloid	O
cell	O
lines	O
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	B-PRGE
expression	O
in	O
hematopoietic	O
cells	O
is	O
incompatible	O
with	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-PRGE
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O

K562	O
cells	O
express	O
endogenous	O
WT1	B-PRGE
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
forced	O
exogenous	O
expression	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-PRGE
in	O
K562	O
does	O
not	O
affect	O
the	O
differentiation	O
response	O
,	O
as	O
judged	O
by	O
accumulation	O
of	O
hemoglobin	O
in	O
response	O
to	O
hemin	O
or	O
the	O
expression	O
of	O
megakaryocytic	O
cell	O
surface	O
markers	O
in	O
response	O
to	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

We	O
conclude	O
that	O
downregulation	O
of	O
WT1	B-PRGE
during	O
induced	O
differentiation	O
of	O
K562	O
cells	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
these	O
cells	O
.	O

GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
erythropoietin	B-PRGE
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
expression	O
.	O

The	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O

By	O
examining	O
in	O
vitro	O
-	O
differentiated	O
embryonic	O
stem	O
cells	O
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
committed	O
erythroid	O
precursors	O
fail	O
to	O
complete	O
maturation	O
and	O
instead	O
undergo	O
apoptosis	O
.	O

The	O
mechanisms	O
by	O
which	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
controls	O
cell	O
survival	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
in	O
erythroid	O
cells	O
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
mcl	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Consistent	O
with	O
a	O
role	O
for	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
in	O
mediating	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro	O
-	O
differentiated	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
-	O
/	O
-	O
embryonic	O
stem	O
cells	O
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	O
cells	O
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
disruption	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	B-PRGE
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
stimulate	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
gene	O
expression	O
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O

Together	O
,	O
our	O
data	O
show	O
that	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
is	O
essential	O
for	O
normal	O
erythroid	O
development	O
and	O
suggest	O
a	O
regulatory	O
hierarchy	O
in	O
which	O
bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
is	O
a	O
critical	O
downstream	O
effector	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
erythropoietin	B-PRGE
-	O
mediated	O
signals	O
.	O

NF	O
-	O
kappaB	O
functions	O
as	O
both	O
a	O
proapoptotic	O
and	O
antiapoptotic	O
regulatory	O
factor	O
within	O
a	O
single	O
cell	O
type	O
.	O

Recently	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O

In	O
T	O
cell	O
hybridomas	O
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
using	O
a	O
dominant	O
negative	O
IkappaBalpha	B-PRGE
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-PRGE
Ligand	I-PRGE
(	O
FasL	B-PRGE
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
inhibits	O
the	O
P	O
/	O
I	O
mediated	O
induction	O
of	O
FasL	B-PRGE
mRNA	O
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF	O
-	O
kappaB	O
as	O
a	O
proapoptotic	O
factor	O
in	O
this	O
context	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF	O
-	O
kappaB	O
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappaB	O
is	O
a	O
context	O
-	O
dependent	O
apoptosis	O
regulator	O
.	O

Our	O
data	O
suggests	O
that	O
NF	O
-	O
kappaB	O
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	O
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	O
peripheral	O
T	O
cells	O
.	O

3	O
-	O
deazaadenosine	O
,	O
a	O
S	B-PRGE
-	I-PRGE
adenosylhomocysteine	I-PRGE
hydrolase	I-PRGE
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF	O
-	O
kappaB	O
regulation	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B-PRGE
degradation	O
.	O

Previously	O
we	O
reported	O
that	O
3	O
-	O
deazaadenosine	O
(	O
DZA	O
)	O
,	O
a	O
potent	O
inhibitor	O
and	O
substrate	O
for	O
S	B-PRGE
-	I-PRGE
adenosylhomocysteine	I-PRGE
hydrolase	I-PRGE
inhibits	O
bacterial	O
lipopolysaccharide	O
-	O
induced	O
transcription	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
in	O
mouse	O
macrophage	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
regulation	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
through	O
the	O
hindrance	O
of	O
p65	B-PRGE
(	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Taken	O
together	O
,	O
DZA	O
promotes	O
the	O
proteolytic	O
degradation	O
of	O
IkappaBalpha	B-PRGE
,	O
but	O
not	O
IkappaBbeta	B-PRGE
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
its	O
transcriptional	O
activity	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

The	O
reduction	O
of	O
IkappaBalpha	B-PRGE
by	O
DZA	O
is	O
neither	O
involved	O
in	O
IkappaB	O
kinase	O
complex	O
activation	O
nor	O
modulated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

This	O
study	O
strongly	O
suggests	O
that	O
DZA	O
may	O
be	O
a	O
potent	O
drug	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
NF	O
-	O
kappaB	O
plays	O
a	O
central	O
pathogenic	O
role	O
,	O
as	O
well	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
regulation	O
and	O
physiological	O
functions	O
of	O
NF	O
-	O
kappaB	O
.	O

STAT1	B-PRGE
activation	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
:	O
role	O
of	O
adhesion	O
molecules	O
.	O

Human	O
monocytes	O
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time	O
-	O
dependent	O
differentiation	O
into	O
macrophages	O
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time	O
-	O
dependent	O
,	O
activation	O
of	O
STAT1	B-PRGE
protein	O
starting	O
at	O
day	O
0	O
/	O
1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O

STAT1	B-PRGE
activity	O
was	O
evident	O
on	O
the	O
STAT	O
binding	O
sequences	O
(	O
SBE	O
)	O
present	O
in	O
the	O
promoters	O
of	O
genes	O
which	O
are	O
up	O
-	O
regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	B-PRGE
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	O
factor	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	B-PRGE
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	B-PRGE
activation	O
.	O

Compared	O
with	O
monocytes	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin	B-PRGE
-	O
or	O
laminin	O
-	O
coated	O
flasks	O
exhibited	O
an	O
increased	O
STAT1	B-PRGE
binding	O
activity	O
both	O
in	O
control	O
and	O
in	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
treated	O
cells	O
.	O

The	O
molecular	O
events	O
leading	O
to	O
enhanced	O
STAT1	B-PRGE
activation	O
and	O
cytokine	O
responsiveness	O
concerned	O
both	O
Y701	O
and	O
S727	O
STAT1	B-PRGE
phosphorylation	O
.	O

Exogenous	O
addition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
some	O
monocytic	O
differentiation	O
markers	O
,	O
inhibited	O
macrophage	O
maturation	O
,	O
integrin	O
expression	O
and	O
STAT1	B-PRGE
binding	O
activity	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
STAT1	B-PRGE
plays	O
a	O
pivotal	O
role	O
in	O
the	O
differentiation	O
/	O
maturation	O
process	O
of	O
monocytes	O
as	O
an	O
early	O
transcription	O
factor	O
initially	O
activated	O
by	O
adherence	O
and	O
then	O
able	O
to	O
modulate	O
the	O
expression	O
of	O
functional	O
genes	O
,	O
such	O
as	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
FcgammaRI	B-PRGE
.	O

Stimulation	O
of	O
neutrophil	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
production	O
by	O
eosinophil	B-PRGE
granule	I-PRGE
major	I-PRGE
basic	I-PRGE
protein	I-PRGE
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B-PRGE
granule	I-PRGE
major	I-PRGE
basic	I-PRGE
protein	I-PRGE
(	O
MBP	B-PRGE
)	O
to	O
stimulate	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
8	I-PRGE
production	O
by	O
neutrophils	O
.	O

MBP	B-PRGE
over	O
the	O
concentration	O
range	O
of	O
0	O
.	O
1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng	O
/	O
ml	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

Incubation	O
with	O
2	O
microM	O
MBP	B-PRGE
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
release	O
increased	O
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	B-PRGE
cationic	I-PRGE
protein	I-PRGE
,	O
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
and	O
eosinophil	B-PRGE
peroxidase	I-PRGE
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
production	O
.	O

MBP	B-PRGE
stimulated	O
2	O
-	O
fold	O
increases	O
in	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
messenger	O
RNA	O
(	O
mRNA	O
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation	O
,	O
which	O
were	O
blocked	O
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O

However	O
,	O
stimulation	O
with	O
MBP	B-PRGE
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
or	O
activator	O
protein	O
-	O
1	O
.	O

No	O
NF	O
-	O
IL	O
-	O
6	O
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O

In	O
addition	O
,	O
stimulation	O
with	O
MBP	B-PRGE
prolonged	O
the	O
stability	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
mRNA	O
.	O

MBP	B-PRGE
also	O
induced	O
transient	O
increases	O
in	O
mRNA	O
for	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
(	I-PRGE
MIP	I-PRGE
)	I-PRGE
-	I-PRGE
1alpha	I-PRGE
and	O
MIP	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	O
.	O

These	O
findings	O
indicate	O
that	O
MBP	B-PRGE
is	O
selective	O
among	O
the	O
eosinophil	O
granule	O
proteins	O
as	O
a	O
stimulus	O
for	O
neutrophil	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
release	O
and	O
,	O
further	O
,	O
that	O
stimulation	O
of	O
neutrophil	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
release	O
by	O
MBP	B-PRGE
involves	O
both	O
transcriptional	O
and	O
posttranscriptional	O
regulation	O
.	O

We	O
postulate	O
that	O
MBP	B-PRGE
-	O
induced	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
by	O
neutrophils	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
acute	O
asthma	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O

PPARgamma	B-PRGE
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	B-PRGE
fatty	I-PRGE
acid	I-PRGE
binding	I-PRGE
protein	I-PRGE
gene	O
in	O
human	O
monocytes	O
.	O

The	O
peroxisome	B-PRGE
-	I-PRGE
proliferator	I-PRGE
activated	I-PRGE
receptor	I-PRGE
gamma	I-PRGE
(	O
PPARgamma	B-PRGE
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
of	O
ligand	O
activated	O
transcription	O
factors	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti	O
-	O
diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O

PPARgamma	B-PRGE
induces	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	B-PRGE
fatty	I-PRGE
acid	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
aP2	B-PRGE
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	O
differentiation	O
.	O

PPARgamma	B-PRGE
is	O
also	O
expressed	O
in	O
hematopoietic	O
cells	O
and	O
is	O
up	O
-	O
regulated	O
in	O
activated	O
monocytes	O
/	O
macrophages	O
.	O

Activation	O
of	O
PPARgamma	B-PRGE
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	O
to	O
foam	O
cells	O
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
increases	O
in	O
aP2	B-PRGE
mRNA	O
in	O
both	O
primary	O
human	O
monocytes	O
and	O
the	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
.	O

These	O
data	O
suggest	O
that	O
PPARgamma	B-PRGE
activation	O
may	O
play	O
a	O
role	O
in	O
monocyte	O
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well	O
-	O
characterized	O
role	O
in	O
adipocytes	O
.	O

Reactive	O
oxygen	O
intermediate	O
-	O
release	O
of	O
fibre	O
-	O
exposed	O
monocytes	O
increases	O
inflammatory	O
cytokine	O
-	O
mRNA	O
level	O
,	O
protein	O
tyrosine	O
kinase	O
and	O
NF	O
-	O
kappaB	O
activity	O
in	O
co	O
-	O
cultured	O
bronchial	O
epithelial	O
cells	O
(	O
BEAS	O
-	O
2B	O
)	O
.	O

Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Alveolar	O
macrophages	O
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	O
cells	O
and	O
macrophages	O
regarding	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
.	O

For	O
measuring	O
the	O
contribution	O
of	O
macrophages	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
by	O
bronchial	O
epithelial	O
cells	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co	O
-	O
cultured	O
blood	O
monocytes	O
(	O
BM	O
)	O
and	O
BEAS	O
-	O
2B	O
cells	O
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O

BM	O
were	O
exposed	O
to	O
Chrysotile	O
B	O
and	O
soot	O
particle	O
FR	O
101	O
in	O
a	O
concentration	O
of	O
100	O
microg	O
/	O
10	O
(	O
6	O
)	O
cells	O
.	O

After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
measure	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
protein	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
cytokine	O
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
specific	O
mRNA	O
levels	O
in	O
BEAS	O
-	O
2B	O
cells	O
.	O

We	O
observed	O
an	O
increase	O
in	O
protein	O
tyrosine	O
kinase	O
activity	O
(	O
up	O
to	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
-	O
fold	O
)	O
and	O
NF	O
-	O
kappaB	O
protein	O
activity	O
in	O
BEAS	O
-	O
2B	O
cells	O
after	O
particle	O
or	O
fibre	O
exposure	O
of	O
co	O
-	O
cultured	O
BM	O
.	O

Consecutive	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
-	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mRNA	O
were	O
elevated	O
(	O
up	O
to	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
58	O
-	O
fold	O
)	O
.	O

Protein	O
tyrosine	O
kinase	O
activity	O
,	O
NF	O
-	O
kappaB	O
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine	O
-	O
specific	O
mRNA	O
were	O
inhibited	O
by	O
antioxidants	O
.	O

These	O
data	O
suggest	O
a	O
ROI	O
-	O
dependent	O
NF	O
-	O
kappaB	O
mediated	O
transcription	O
of	O
inflammatory	O
cytokines	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	O
lipoproteins	O
through	O
toll	O
-	O
like	O
receptors	O
.	O

The	O
generation	O
of	O
cell	O
-	O
mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin	B-PRGE
-	I-PRGE
12	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
production	O
by	O
macrophages	O
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	O
lipoproteins	O
are	O
potent	O
stimulators	O
of	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
production	O
by	O
human	O
macrophages	O
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
.	O

Several	O
lipoproteins	O
stimulated	O
TLR	O
-	O
dependent	O
transcription	O
of	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O

Activation	O
of	O
TLRs	O
by	O
microbial	O
lipoproteins	O
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O

Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	O
lipoproteins	O
through	O
toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

All	O
bacterial	O
pathogens	O
produce	O
lipoproteins	O
(	O
BLPs	O
)	O
,	O
which	O
trigger	O
the	O
innate	O
immune	O
response	O
.	O

BLPs	O
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
through	O
human	B-PRGE
Toll	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
hTLR2	B-PRGE
)	O
.	O

BLPs	O
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	O
cell	O
line	O
transfected	O
with	O
hTLR2	B-PRGE
.	O

In	O
addition	O
,	O
BLPs	O
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
a	O
transcriptional	O
activator	O
of	O
multiple	O
host	O
defense	O
genes	O
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	B-PRGE
.	O

Thus	O
,	O
hTLR2	B-PRGE
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O

Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
ecto	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
-	I-PRGE
nucleotidase	I-PRGE
promoter	O
.	O

Role	O
of	O
the	O
camp	O
response	O
element	O
site	O
in	O
mediating	O
repression	O
by	O
the	O
upstream	O
regulatory	O
region	O
.	O

We	O
have	O
isolated	O
the	O
5	O
'	O
region	O
of	O
the	O
ecto	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
-	I-PRGE
nucleotidase	I-PRGE
(	O
low	O
K	O
(	O
m	O
)	O
5	B-PRGE
'	I-PRGE
-	I-PRGE
NT	I-PRGE
)	O
gene	O
and	O
established	O
that	O
a	O
969	O
-	O
base	O
pair	O
(	O
bp	O
)	O
fragment	O
confers	O
cell	O
-	O
specific	O
expression	O
of	O
a	O
CAT	B-PRGE
reporter	O
gene	O
that	O
correlates	O
with	O
the	O
expression	O
of	O
endogenous	O
ecto	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
-	I-PRGE
NT	I-PRGE
mRNA	O
and	O
enzymatic	O
activity	O
.	O

A	O
768	O
-	O
bp	O
upstream	O
negative	O
regulatory	O
region	O
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte	O
-	O
specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244	O
-	O
bp	O
deoxycytidine	O
kinase	O
core	O
promoter	O
.	O

DNase	B-PRGE
I	I-PRGE
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	B-PRGE
,	O
Sp1	B-PRGE
/	O
AP	O
-	O
2	O
,	O
and	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
binding	O
sites	O
within	O
the	O
201	O
-	O
bp	O
core	O
promoter	O
region	O
and	O
Sp1	B-PRGE
,	O
NRE	B-PRGE
-	I-PRGE
2a	I-PRGE
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
Sp1	B-PRGE
/	O
NF	O
-	O
AT	O
binding	O
sites	O
in	O
the	O
upstream	O
regulatory	O
region	O
.	O

Whereas	O
the	O
CRE	O
site	O
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	O
regulatory	O
region	O
in	O
Jurkat	O
but	O
not	O
in	O
HeLa	O
cells	O
,	O
mutation	O
of	O
the	O
Sp1	B-PRGE
/	O
AP	O
-	O
2	O
site	O
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	O
to	O
the	O
CRE	O
site	O
identified	O
both	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ATF	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
Jurkat	O
cells	O
.	O

Finally	O
,	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969	O
-	O
bp	O
promoter	O
fragments	O
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	O
site	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue	O
-	O
specific	O
regulatory	O
region	O
5	O
'	O
of	O
the	O
ecto	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
-	I-PRGE
NT	I-PRGE
core	O
promoter	O
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	O
site	O
within	O
the	O
basal	O
promoter	O
for	O
its	O
suppressive	O
activity	O
.	O

NF	O
-	O
kappaB	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
and	O
Bfl	B-PRGE
-	I-PRGE
1	I-PRGE
/	I-PRGE
A1	I-PRGE
is	O
required	O
for	O
CD40	B-PRGE
survival	O
signaling	O
in	O
B	O
lymphocytes	O
.	O

Activation	O
of	O
CD40	B-PRGE
is	O
essential	O
for	O
thymus	O
-	O
dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	O
cells	O
from	O
apoptosis	O
.	O

Many	O
of	O
the	O
effects	O
of	O
CD40	B-PRGE
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O

In	O
addition	O
to	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
,	O
a	O
known	O
CD40	B-PRGE
-	O
regulated	O
antiapoptotic	O
molecule	O
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	O
molecule	O
,	O
A1	B-PRGE
/	I-PRGE
Bfl	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
as	O
a	O
CD40	B-PRGE
-	O
inducible	O
gene	O
.	O

Inhibition	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
overexpression	O
of	O
a	O
dominant	O
-	O
active	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
abolished	O
CD40	B-PRGE
-	O
induced	O
up	O
-	O
regulation	O
of	O
both	O
the	O
Bfl	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	B-PRGE
to	O
rescue	O
Fas	B-PRGE
-	O
induced	O
cell	O
death	O
.	O

Within	O
the	O
upstream	O
promoter	O
region	O
of	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
,	O
a	O
potential	O
NF	O
-	O
kappaB	O
-	O
binding	O
sequence	O
was	O
found	O
to	O
support	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
protected	O
B	O
cells	O
from	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	B-PRGE
-	O
mediated	O
cell	O
survival	O
proceeds	O
through	O
NF	O
-	O
kappaB	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Bcl	O
-	O
2	O
family	O
members	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	O
mammary	O
epithelial	O
cells	O
and	O
breast	O
cancers	O
.	O

cDNA	O
microarrays	O
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	O
mammary	O
epithelial	O
cells	O
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

Clusters	O
of	O
coexpressed	O
genes	O
identified	O
through	O
manipulations	O
of	O
mammary	O
epithelial	O
cells	O
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O

Clusters	O
of	O
genes	O
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	O
cells	O
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	O
-	O
regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

Clusters	O
of	O
genes	O
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
(	O
NFAT	O
)	O
-	O
induced	O
Fas	B-PRGE
ligand	I-PRGE
transcription	O
.	O

Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
such	O
as	O
Bax	B-PRGE
and	O
Bad	B-PRGE
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B-PRGE
/	O
Fas	B-PRGE
ligand	I-PRGE
(	O
FasL	B-PRGE
)	O
-	O
dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B-PRGE
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-	O
induced	O
expression	O
of	O
FasL	B-PRGE
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
,	O
a	O
transcription	O
factor	O
activated	O
by	O
microtubule	O
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium	O
-	O
dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	O
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	O
nuclear	O
translocation	O
,	O
the	O
FasL	B-PRGE
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	B-PRGE
.	O

Furthermore	O
,	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	O
activation	O
,	O
blocking	O
NFAT	O
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B-PRGE
expression	O
.	O

The	O
effects	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Phosphorylated	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
cannot	O
bind	O
calcineurin	B-PRGE
,	O
and	O
NFAT	O
activation	O
,	O
FasL	B-PRGE
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
phosphorylation	O
.	O

Retinoblastoma	B-PRGE
protein	O
expression	O
leads	O
to	O
reduced	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
DNA	O
binding	O
activity	O
and	O
enhances	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
.	O

Tumor	O
cell	O
lines	O
with	O
a	O
defective	O
retinoblastoma	B-PRGE
gene	O
are	O
unable	O
to	O
transcribe	O
the	O
HLA	O
class	O
II	O
genes	O
in	O
response	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	B-PRGE
rescues	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
class	O
II	O
gene	O
expression	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	B-PRGE
rescue	O
of	O
the	O
class	O
II	O
genes	O
is	O
unknown	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	B-PRGE
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA	O
-	O
DRA	O
,	O
the	O
prototype	O
class	O
II	O
gene	O
.	O

Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
POU	O
domain	O
transcription	O
factor	O
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA	O
-	O
DRA	O
promoter	O
activity	O
in	O
the	O
Rb	B-PRGE
-	O
defective	O
cells	O
.	O

Rb	B-PRGE
expression	O
led	O
to	O
phosphorylation	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
thus	O
relieving	O
its	O
repressive	O
effect	O
.	O

Oct	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
also	O
been	O
shown	O
to	O
repress	O
interleukin	B-PRGE
8	I-PRGE
promoter	O
activity	O
.	O

Consistent	O
with	O
reduced	O
levels	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
DNA	O
binding	O
activity	O
in	O
the	O
Rb	B-PRGE
-	O
transformed	O
cell	O
lines	O
,	O
interleukin	B-PRGE
8	I-PRGE
expression	O
is	O
higher	O
in	O
these	O
cell	O
lines	O
.	O

Protein	O
kinase	O
C	O
and	O
calcineurin	O
synergize	O
to	O
activate	O
IkappaB	O
kinase	O
and	O
NF	O
-	O
kappaB	O
in	O
T	O
lymphocytes	O
.	O

The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
cross	O
-	O
linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-PRGE
.	O

By	O
using	O
Jurkat	O
and	O
primary	O
human	O
T	O
lymphocytes	O
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	O
-	O
initiated	O
signal	O
transduction	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
calcineurin	O
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	O
kinase	O
(	O
IKK	O
)	O
complex	O
but	O
not	O
of	O
another	O
putative	O
IkappaBalpha	B-PRGE
kinase	I-PRGE
,	O
p90	B-PRGE
(	I-PRGE
rsk	I-PRGE
)	I-PRGE
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	O
complex	O
,	O
but	O
not	O
p90	B-PRGE
(	I-PRGE
rsk	I-PRGE
)	I-PRGE
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B-PRGE
mediated	O
by	O
the	O
co	O
-	O
activation	O
of	O
PKC	O
and	O
calcineurin	O
.	O

Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	O
the	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
IkappaBalpha	B-PRGE
phosphorylation	O
in	O
vivo	O
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	B-PRGE
and	O
-	B-PRGE
beta	I-PRGE
demonstrates	O
that	O
only	O
IKKbeta	B-PRGE
is	O
the	O
target	O
for	O
PKC	O
and	O
calcineurin	O
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	O
/	O
CD3	O
signal	O
transduction	O
pathway	O
both	O
PKC	O
and	O
calcineurin	O
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
NF	O
-	O
kappaB	O
in	O
T	O
lymphocytes	O
.	O

C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
synergistically	O
regulate	O
activity	O
of	O
the	O
eosinophil	B-PRGE
granule	I-PRGE
major	I-PRGE
basic	I-PRGE
protein	I-PRGE
promoter	O
:	O
implication	O
for	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O

Eosinophil	B-PRGE
granule	I-PRGE
major	I-PRGE
basic	I-PRGE
protein	I-PRGE
(	O
MBP	B-PRGE
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	O
regulatory	O
role	O
for	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
a	O
negative	O
regulatory	O
role	O
for	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
MBP	B-PRGE
gene	O
transcription	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	B-PRGE
promoter	O
region	O
identified	O
a	O
C	O
/	O
EBP	O
(	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA	O
-	O
binding	O
site	O
in	O
the	O
MBP	B-PRGE
gene	O
.	O

In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C	B-PRGE
/	I-PRGE
EBPalpha	I-PRGE
mRNA	O
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
expression	O
was	O
markedly	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
protein	O
could	O
bind	O
to	O
the	O
potential	O
C	O
/	O
EBP	O
-	O
binding	O
site	O
(	O
bp	O
-	O
90	O
to	O
-	O
82	O
)	O
in	O
the	O
MBP	B-PRGE
promoter	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
bind	O
simultaneously	O
to	O
the	O
C	O
/	O
EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
in	O
the	O
MBP	B-PRGE
promoter	O
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C	O
/	O
EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
stimulate	O
the	O
MBP	B-PRGE
promoter	O
in	O
the	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
negative	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

Cotransfection	O
with	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
vectors	O
produced	O
a	O
5	O
-	O
fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
or	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
vectors	O
individually	O
.	O

In	O
addition	O
,	O
GST	O
pull	O
-	O
down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
.	O

Expression	O
of	O
FOG	O
(	O
riend	O
ATA	O
)	O
,	O
which	O
binds	O
to	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA	O
-	O
binding	O
proteins	O
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
for	O
the	O
MBP	B-PRGE
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
synergistically	O
transactivate	O
the	O
promoter	O
of	O
an	O
eosinophil	O
-	O
specific	O
granule	O
protein	O
gene	O
and	O
that	O
FOG	O
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	O
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O

Thymocyte	O
-	O
thymic	O
epithelial	O
cell	O
interaction	O
leads	O
to	O
high	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
exclusively	O
in	O
mature	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
:	O
a	O
critical	O
role	O
for	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
.	O

This	O
work	O
aims	O
at	O
identifying	O
the	O
thymocyte	O
subpopulation	O
able	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
under	O
the	O
biological	O
stimuli	O
of	O
the	O
thymic	O
microenvironment	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
induces	O
a	O
high	O
-	O
level	O
replication	O
of	O
the	O
T	O
-	O
tropic	O
primary	O
isolate	O
HIV	O
-	O
1	O
(	O
B	O
-	O
LAIp	O
)	O
exclusively	O
in	O
the	O
mature	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	O
long	O
terminal	O
repeat	O
transactivation	O
through	O
NF	O
-	O
kappaB	O
-	O
dependent	O
activation	O
.	O

TNF	B-PRGE
is	O
the	O
major	O
inducer	O
of	O
NF	O
-	O
kappaB	O
and	O
particularly	O
of	O
the	O
p50	B-PRGE
-	O
p65	B-PRGE
complex	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
acts	O
as	O
a	O
cofactor	O
by	O
sustaining	O
the	O
expression	O
of	O
the	O
p75	B-PRGE
TNF	I-PRGE
receptor	I-PRGE
.	O

The	O
requirement	O
for	O
TNF	B-PRGE
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
thymocytes	O
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B-PRGE
production	O
during	O
their	O
interaction	O
with	O
TEC	O
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
activity	O
in	O
these	O
freshly	O
isolated	O
thymocytes	O
.	O

Addition	O
of	O
exogenous	O
TNF	B-PRGE
to	O
the	O
intermediate	O
thymocyte	O
cultures	O
induces	O
NF	O
-	O
kappaB	O
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B-PRGE
receptor	O
,	O
namely	O
,	O
the	O
double	O
-	O
positive	O
(	O
DP	O
)	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
CD3	O
(	O
+	O
/	O
-	O
)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	B-PRGE
(	O
+	O
)	O
subpopulations	O
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	O
CD4	B-PRGE
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
subset	O
of	O
thymocytes	O
.	O

However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	B-PRGE
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	O
thymocyte	O
compartment	O
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
activation	O
and	O
proliferation	O
in	O
human	O
T	O
cells	O
induced	O
by	O
CD28	B-PRGE
.	O

Although	O
the	O
role	O
of	O
CD28	B-PRGE
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O

In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	B-PRGE
from	O
subsequent	O
actions	O
of	O
cytokines	O
,	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
on	O
T	O
cell	O
proliferation	O
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	B-PRGE
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	O
ligand	O
CD80	B-PRGE
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
as	O
evidenced	O
by	O
both	O
cytokine	O
production	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
stimulation	O
.	O

Promoter	O
assays	O
revealed	O
CD28	B-PRGE
-	O
dependent	O
effects	O
on	O
both	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
,	O
but	O
not	O
on	O
NF	O
-	O
AT	O
or	O
the	O
intact	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	O
Abs	O
to	O
both	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
IL	O
-	O
2	O
receptor	O
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	B-PRGE
was	O
independent	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	O
cell	O
blasts	O
with	O
CD80	B-PRGE
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
this	O
system	O
.	O

We	O
conclude	O
that	O
CD28	B-PRGE
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	O
factor	O
independent	O
of	O
NF	O
-	O
AT	O
transactivation	O
.	O

Suppression	O
of	O
TNFalpha	B-PRGE
-	O
mediated	O
NFkappaB	O
activity	O
by	O
myricetin	O
and	O
other	O
flavonoids	O
through	O
downregulating	O
the	O
activity	O
of	O
IKK	O
in	O
ECV304	O
cells	O
.	O

Flavonoids	O
are	O
a	O
group	O
of	O
naturally	O
-	O
occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O

Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O

In	O
view	O
of	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	O
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB	O
/	O
inhibitor	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
system	O
in	O
ECV304	O
cells	O
activated	O
with	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
were	O
examined	O
.	O

We	O
investigated	O
the	O
inhibitory	O
action	O
of	O
six	O
flavonoids	O
on	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
activity	O
,	O
an	O
enzyme	O
recently	O
found	O
to	O
phosphorylate	O
critical	O
serine	O
residues	O
of	O
IkappaB	O
for	O
degradation	O
.	O

Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	O
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	B-PRGE
and	O
IkappaBbeta	B-PRGE
in	O
activated	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	O
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	O
cells	O
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB	O
/	O
IkappaB	O
system	O
.	O

Copyright	O
1999	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
in	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
M2	O
-	O
type	O
leukemic	O
blast	O
cells	O
.	O

Different	O
types	O
of	O
acute	O
myeloid	O
leukemia	O
blast	O
cells	O
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0	O
/	O
M1	O
leukemic	O
cells	O
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	O
leukemic	O
cells	O
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

M2	O
leukemic	O
blast	O
cells	O
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2	O
-	O
type	O
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	O
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi	O
-	O
1	O
cells	O
(	O
an	O
acute	O
myeloid	O
leukemia	O
M2	O
-	O
type	O
cell	O
line	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	B-PRGE
is	O
functionally	O
active	O
in	O
ATRA	O
-	O
treated	O
Kasumi	O
-	O
1	O
cells	O
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	B-PRGE
X	I-PRGE
receptor	I-PRGE
,	O
binds	O
to	O
a	O
DR3	O
-	O
type	O
vitamin	O
D	O
-	O
responsive	O
element	O
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
element	O
-	O
regulated	O
reporter	O
gene	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD	O
-	O
responsive	O
genes	O
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi	O
-	O
1	O
cells	O
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B-PRGE
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	O
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	B-PRGE
receptor	I-PRGE
(	O
CD23	B-PRGE
)	O
in	O
human	O
monocytes	O
lead	O
to	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
.	O

BACKGROUND	O
:	O
Alveolar	O
macrophages	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O

Alveolar	O
macrophages	O
and	O
peripheral	O
blood	O
monocytes	O
are	O
activated	O
when	O
IgE	O
/	O
allergen	O
immune	O
complexes	O
bind	O
to	O
the	O
CD23	B-PRGE
receptor	I-PRGE
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	B-PRGE
in	O
human	O
monocytes	O
and	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

METHODS	O
:	O
CD23	B-PRGE
was	O
cross	O
-	O
linked	O
in	O
human	O
monocytes	O
and	O
U937	O
cells	O
with	O
IgE	O
immune	O
complexes	O
.	O

Surface	O
expression	O
of	O
CD23	B-PRGE
was	O
determined	O
by	O
FACS	O
analysis	O
.	O

Transcription	O
factor	O
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel	O
-	O
shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O

IkappaBalpha	B-PRGE
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
gene	O
activation	O
that	O
follows	O
CD23	B-PRGE
cross	O
-	O
linking	O
in	O
monocytes	O
.	O

CD23	B-PRGE
-	O
induced	O
NF	O
-	O
kappaB	O
is	O
a	O
heterodimer	O
composed	O
of	O
p65	B-PRGE
/	O
p50	B-PRGE
subunits	O
.	O

NF	O
-	O
kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
molecule	O
IkappaBalpha	B-PRGE
.	O

Tyrosine	O
kinase	O
-	O
dependent	O
,	O
and	O
not	O
protein	O
kinase	O
C	O
-	O
dependent	O
,	O
pathways	O
mediate	O
CD23	B-PRGE
-	O
triggered	O
NF	O
-	O
kappaB	O
activation	O
but	O
do	O
not	O
participate	O
in	O
the	O
direct	O
phosphorylation	O
of	O
IkappaBalpha	B-PRGE
.	O

IkappaBalpha	B-PRGE
degradation	O
and	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	O
activation	O
of	O
the	O
inflammatory	O
cytokines	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

CONCLUSIONS	O
:	O
NF	O
-	O
kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	B-PRGE
in	O
monocytes	O
.	O

Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF	O
-	O
kappaB	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	O
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

However	O
,	O
the	O
action	O
of	O
dopamine	O
on	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
immune	O
system	O
has	O
not	O
yet	O
been	O
examined	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	O
T	O
cells	O
and	O
in	O
primary	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

HIV	O
-	O
1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV	O
-	O
1	O
transactivation	O
.	O

Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
element	O
present	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

The	O
importance	O
of	O
NF	O
-	O
kappaB	O
sites	O
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild	O
-	O
type	O
or	O
mutant	O
kappaB	O
sites	O
in	O
a	O
heterologous	O
promoter	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine	O
-	O
induced	O
transcriptional	O
activation	O
.	O

We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
known	O
to	O
activate	O
NF	O
-	O
kappaB	O
.	O

The	O
combination	O
of	O
dopamine	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
led	O
to	O
a	O
stimulation	O
of	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

However	O
,	O
in	O
contrast	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
dopamine	O
treatment	O
did	O
not	O
affect	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
nor	O
the	O
concentrations	O
of	O
p50	B-PRGE
,	O
p65	B-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
proteins	O
,	O
which	O
suggests	O
a	O
distinct	O
NF	O
-	O
kappaB	O
activation	O
mechanism	O
.	O

These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	O
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
T	O
cells	O
and	O
PBMC	O
.	O

AML1	B-PRGE
(	O
CBFalpha2	B-PRGE
)	O
cooperates	O
with	O
B	B-PRGE
cell	I-PRGE
-	I-PRGE
specific	I-PRGE
activating	I-PRGE
protein	I-PRGE
(	O
BSAP	B-PRGE
/	O
PAX5	B-PRGE
)	O
in	O
activation	O
of	O
the	O
B	O
cell	O
-	O
specific	O
BLK	B-PRGE
gene	O
promoter	O
.	O

AML1	B-PRGE
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	B-PRGE
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

To	O
understand	O
the	O
function	O
of	O
AML1	B-PRGE
during	O
B	O
cell	O
differentiation	O
,	O
we	O
analyzed	O
regulatory	O
regions	O
of	O
B	O
cell	O
-	O
specific	O
genes	O
for	O
potential	O
AML1	B-PRGE
-	O
binding	O
sites	O
and	O
have	O
identified	O
a	O
putative	O
AML1	B-PRGE
-	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
the	O
B	B-PRGE
cell	I-PRGE
-	I-PRGE
specific	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
gene	O
,	O
blk	B-PRGE
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	B-PRGE
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	B-PRGE
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	B-PRGE
promoter	O
activity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	B-PRGE
runt	O
DNA	O
-	O
binding	O
domain	O
physically	O
interacts	O
with	O
the	O
paired	O
DNA	O
-	O
binding	O
domain	O
of	O
BSAP	B-PRGE
,	O
a	O
B	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

BSAP	B-PRGE
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
regulation	O
of	O
the	O
blk	B-PRGE
gene	O
.	O

Physical	O
interaction	O
of	O
AML1	B-PRGE
with	O
BSAP	B-PRGE
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B-PRGE
and	O
BSAP	B-PRGE
synergistically	O
activate	O
blk	B-PRGE
promoter	O
transcription	O
by	O
more	O
than	O
50	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B-PRGE
and	O
BSAP	B-PRGE
and	O
suggest	O
that	O
AML1	B-PRGE
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	O
cell	O
-	O
specific	O
gene	O
,	O
blk	B-PRGE
.	O

c	B-PRGE
-	I-PRGE
Maf	I-PRGE
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O

The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony	O
-	O
forming	O
unit	O
granulocyte	O
-	O
macrophage	O
(	O
CFU	O
-	O
GM	O
)	O
myeloid	O
progenitors	O
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	O
or	O
monocytic	O
lineage	O
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
shown	O
that	O
the	O
c	B-PRGE
-	I-PRGE
Maf	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
transcription	O
factors	O
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
target	O
genes	O
through	O
direct	O
binding	O
to	O
Myb	O
consensus	O
sites	O
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	O
stage	O
,	O
or	O
in	O
cell	O
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

Because	O
the	O
elevated	O
Myb	O
:	O
Maf	O
status	O
seen	O
in	O
differentiating	O
cells	O
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c	B-PRGE
-	I-PRGE
Maf	I-PRGE
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c	B-PRGE
-	I-PRGE
Maf	I-PRGE
cDNA	O
in	O
2	O
bipotent	O
human	O
myeloid	O
progenitor	O
cells	O
.	O

Elevated	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Maf	I-PRGE
protein	O
led	O
to	O
marked	O
increases	O
in	O
Myb	O
:	O
Maf	O
complexes	O
and	O
the	O
accumulation	O
of	O
monocyte	O
/	O
macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c	B-PRGE
-	I-PRGE
Maf	I-PRGE
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
regulated	O
targets	O
,	O
such	O
as	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
CD13	B-PRGE
/	O
APN	B-PRGE
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation	O
-	O
promoting	O
genes	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
-	O
dependent	O
induction	O
of	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	O
activating	O
pathway	O
distinct	O
from	O
nuclear	O
translocation	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	O
cytokine	O
cascade	O
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	O
chemokine	O
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha	B-PRGE
-	O
inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
by	O
"	O
monocyte	O
-	O
like	O
"	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O

TNFalpha	B-PRGE
is	O
a	O
rapid	O
activator	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
by	O
U937	O
,	O
producing	O
a	O
50	O
-	O
fold	O
induction	O
of	O
mRNA	O
within	O
1	O
hour	O
of	O
treatment	O
.	O

In	O
gene	O
transfection	O
assays	O
,	O
the	O
effect	O
of	O
TNFalpha	B-PRGE
requires	O
the	O
presence	O
of	O
an	O
inducible	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
(	O
Rel	B-PRGE
A	I-PRGE
)	O
binding	O
site	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
promoter	O
.	O

TNFalpha	B-PRGE
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	O
kD	O
transcriptional	O
activator	O
NF	O
-	O
kappaB	O
subunit	O
,	O
Rel	B-PRGE
A	I-PRGE
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	B-PRGE
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol	O
/	O
vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
.	O

Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	O
on	O
inducible	O
Rel	B-PRGE
A	I-PRGE
binding	O
.	O

Similar	O
selective	O
effects	O
on	O
NF	O
-	O
kappaB	O
transcription	O
are	O
seen	O
with	O
the	O
unrelated	O
antioxidants	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
and	O
vitamin	O
C	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	B-PRGE
induces	O
a	O
delayed	O
ROS	O
-	O
dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	B-PRGE
signalling	O
.	O

Neutrophil	O
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O

Neutrophil	O
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	O
markers	O
associated	O
with	O
neutrophil	O
function	O
.	O

A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	O
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	O
receptors	O
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	O
genes	O
.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	O
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources	O
.	O

Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	O
acid	O
receptor	O
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	O
maturation	O
.	O

Induction	O
of	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
(	I-PRGE
L	I-PRGE
)	I-PRGE
expression	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-PRGE
through	O
NF	O
-	O
kappaB	O
in	O
apoptosis	O
-	O
resistant	O
T	O
-	O
cell	O
transfectants	O
with	O
Tax	B-PRGE
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-PRGE
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	B-PRGE
protected	O
the	O
mouse	O
T	O
-	O
cell	O
line	O
CTLL	O
-	O
2	O
against	O
apoptosis	O
induced	O
by	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
dependent	O
to	O
being	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl	B-PRGE
-	I-PRGE
xl	I-PRGE
but	O
not	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
bcl	B-PRGE
-	I-PRGE
xs	I-PRGE
,	O
bak	B-PRGE
,	O
bad	B-PRGE
,	O
or	O
bax	B-PRGE
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
in	O
CTLL	O
-	O
2	O
cells	O
that	O
expressed	O
Tax	B-PRGE
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	B-PRGE
-	I-PRGE
x	I-PRGE
promoter	O
was	O
transactivated	O
by	O
wild	O
-	O
type	O
Tax	B-PRGE
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	B-PRGE
retaining	O
transactivating	O
ability	O
through	O
NF	O
-	O
kappaB	O
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	O
NF	O
-	O
kappaB	O
binding	O
site	O
identified	O
in	O
the	O
bcl	B-PRGE
-	I-PRGE
x	I-PRGE
promoter	O
significantly	O
decreased	O
Tax	B-PRGE
-	O
induced	O
transactivation	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF	O
-	O
kappaB	O
family	O
proteins	O
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	B-PRGE
-	O
induced	O
transactivation	O
of	O
the	O
bcl	B-PRGE
-	I-PRGE
x	I-PRGE
promoter	O
was	O
also	O
diminished	O
by	O
the	O
mutant	O
IkappaBalpha	B-PRGE
,	O
which	O
specifically	O
inhibits	O
NF	O
-	O
kappaB	O
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
x	I-PRGE
(	I-PRGE
L	I-PRGE
)	I-PRGE
induced	O
by	O
Tax	B-PRGE
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL	O
-	O
2	O
cells	O
after	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
.	O

Interferons	O
inhibit	O
activation	O
of	O
STAT6	B-PRGE
by	O
interleukin	B-PRGE
4	I-PRGE
in	O
human	O
monocytes	O
by	O
inducing	O
SOCS	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
.	O

Interferons	O
(	O
IFNs	O
)	O
inhibit	O
induction	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
of	O
multiple	O
genes	O
in	O
human	O
monocytes	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	O
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	O
transcription	O
factor	O
,	O
STAT6	B-PRGE
(	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
-	I-PRGE
6	I-PRGE
)	O
.	O

STAT6	B-PRGE
-	O
responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
inducible	O
genes	O
.	O

Because	O
STAT6	B-PRGE
activation	O
is	O
essential	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
regulate	O
activation	O
of	O
STAT6	B-PRGE
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
primary	O
human	O
monocytes	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
or	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
beta	I-PRGE
suppressed	O
activation	O
of	O
STAT6	B-PRGE
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-PRGE
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
hr	O
before	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
by	O
IFN	O
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	O
of	O
the	O
JAK	O
/	O
STAT	O
inhibitory	O
gene	O
,	O
SOCS	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Forced	O
expression	O
of	O
SOCS	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
a	O
macrophage	O
cell	O
line	O
,	O
RAW264	O
,	O
markedly	O
suppressed	O
trans	O
-	O
activation	O
of	O
an	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
inducible	O
reporter	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
reporter	O
gene	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	O
inhibit	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
activation	O
of	O
STAT6	B-PRGE
and	O
STAT6	B-PRGE
-	O
dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Increased	O
IkappaB	O
expression	O
and	O
diminished	O
nuclear	O
NF	O
-	O
kappaB	O
in	O
human	O
mononuclear	O
cells	O
following	O
hydrocortisone	O
injection	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	O
(	O
MNC	O
)	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
/	O
IkappaB	O
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	O
genes	O
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	O
production	O
thus	O
inhibiting	O
NF	O
-	O
kappaB	O
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	O
,	O
in	O
vivo	O
.	O

One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	O
by	O
standard	O
techniques	O
.	O

IkappaB	O
levels	O
in	O
MNC	O
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

NF	O
-	O
kappaB	O
in	O
MNC	O
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

The	O
total	O
protein	O
content	O
of	O
NF	O
-	O
kappaB	O
subunit	O
(	O
P65	B-PRGE
)	O
in	O
MNC	O
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O

This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

ROS	O
generation	O
inhibition	O
paralleled	O
NF	O
-	O
kappaB	O
levels	O
in	O
the	O
nucleus	O
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	O
and	O
suppresses	O
NF	O
-	O
kappaB	O
expression	O
in	O
MNC	O
in	O
parallel	O
.	O

IkappaB	O
further	O
reduces	O
the	O
translocation	O
of	O
NF	O
-	O
kappaB	O
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	O
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus	O
-	O
induced	O
degradation	O
of	O
the	O
cytoplasmic	O
factor	O
IkappaBalpha	B-PRGE
.	O

Tumor	O
-	O
derived	O
soluble	O
products	O
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	O
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus	O
-	O
induced	O
IkappaBalpha	B-PRGE
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	O
but	O
not	O
protease	O
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	O
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	O
expression	O
of	O
the	O
cytokines	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor	O
-	O
derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

Affinity	O
-	O
driven	O
peptide	O
selection	O
of	O
an	O
NFAT	O
inhibitor	O
more	O
selective	O
than	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

The	O
flow	O
of	O
information	O
from	O
calcium	O
-	O
mobilizing	O
receptors	O
to	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-	O
dependent	O
genes	O
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	O
calcineurin	O
and	O
the	O
transcription	O
factor	O
NFAT	O
.	O

A	O
high	O
-	O
affinity	O
calcineurin	O
-	O
binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	O
docking	O
motif	O
of	O
NFAT	O
.	O

This	O
peptide	O
potently	O
inhibited	O
NFAT	O
activation	O
and	O
NFAT	O
-	O
dependent	O
expression	O
of	O
endogenous	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
without	O
affecting	O
the	O
expression	O
of	O
other	O
cytokines	O
that	O
require	O
calcineurin	O
but	O
not	O
NFAT	O
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	O
docking	O
site	O
increased	O
the	O
calcineurin	O
responsiveness	O
of	O
NFAT	O
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	O
-	O
NFAT	O
interaction	O
without	O
affecting	O
calcineurin	O
phosphatase	O
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs	O
.	O

Leukotriene	O
B4	O
stimulates	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
transcription	O
and	O
AP	O
-	O
1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	O
of	O
the	O
proto	O
-	O
oncogenes	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP	O
-	O
1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral	O
-	O
blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
7	O
-	O
fold	O
and	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
1	O
.	O
4	O
-	O
fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP	O
-	O
1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	O
by	O
modulating	O
the	O
yield	O
and	O
/	O
or	O
the	O
function	O
of	O
transcription	O
factors	O
such	O
as	O
AP	O
-	O
1	O
-	O
binding	O
proto	O
-	O
oncogene	O
products	O
.	O

Transcription	O
factor	O
activation	O
and	O
functional	O
stimulation	O
of	O
human	O
monocytes	O
.	O

Activation	O
of	O
expression	O
of	O
genes	O
encoding	O
transcription	O
factors	O
:	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
formation	O
of	O
AP1	O
transcriptional	O
complex	O
in	O
human	O
monocytes	O
was	O
investigated	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
as	O
well	O
as	O
AP1	O
formation	O
.	O

Interferon	B-PRGE
gamma	I-PRGE
activated	O
strongly	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
weakly	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
AP1	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
induced	O
slightly	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
had	O
almost	O
no	O
effect	O
on	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
AP1	O
.	O

The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	O
by	O
all	O
three	O
factors	O
may	O
be	O
dependent	O
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon	O
-	O
stimulated	O
genes	O
induced	O
by	O
interferon	O
-	O
alpha	O
in	O
U937	O
cells	O
.	O

Binding	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
to	O
specific	O
receptors	O
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN	O
-	O
alpha	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
human	O
fibroblasts	O
and	O
HeLa	O
and	O
Daudi	O
cell	O
lines	O
.	O

The	O
binding	O
of	O
ISGF3	O
(	O
IFN	O
-	O
stimulated	O
gene	O
factor	O
3	O
)	O
to	O
the	O
conserved	O
IFN	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
results	O
in	O
transcriptional	O
activation	O
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA	O
-	O
binding	O
protein	O
(	O
ISGF3	B-PRGE
gamma	I-PRGE
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN	O
-	O
alpha	O
-	O
activated	O
proteins	O
which	O
preexist	O
as	O
latent	O
cytoplasmic	O
precursors	O
(	O
ISGF3	O
alpha	O
)	O
.	O

We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	O
U937	O
cell	O
line	O
differs	O
from	O
most	O
cell	O
lines	O
previously	O
examined	O
.	O

U937	O
cells	O
express	O
both	O
type	O
I	O
and	O
type	O
II	O
IFN	O
receptors	O
,	O
but	O
only	O
IFN	O
-	O
alpha	O
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O

Pretreatment	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
potentiates	O
the	O
IFN	O
-	O
alpha	O
-	O
induced	O
protection	O
,	O
but	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O

ISG15	B-PRGE
mRNA	O
accumulation	O
in	O
U937	O
cells	O
is	O
not	O
detectable	O
before	O
6	O
h	O
of	O
IFN	O
-	O
alpha	O
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O

Although	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O

Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	O
binding	O
factors	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	O
is	O
induced	O
by	O
IFN	O
-	O
alpha	O
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	O
cells	O
.	O

Activation	O
of	O
ISGF3	O
alpha	O
,	O
the	O
latent	O
component	O
of	O
ISGF3	O
,	O
occurs	O
rapidly	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	O
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	B-PRGE
gamma	I-PRGE
induced	O
by	O
IFN	O
-	O
alpha	O
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	O
factor	O
containing	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
-	O
like	O
proteins	O
preferentially	O
interacts	O
with	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
-	O
related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto	O
-	O
oncoprotein	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
is	O
a	O
member	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
transcription	O
factor	O
family	O
,	O
which	O
includes	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
binds	O
to	O
kappa	O
B	O
sites	O
as	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
p50	B-PRGE
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA	O
-	O
binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	O
B	O
motifs	O
.	O

In	O
particular	O
,	O
the	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
homodimer	O
has	O
a	O
high	O
affinity	O
for	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
beta	B-PRGE
interferon	I-PRGE
kappa	O
B	O
sites	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	B-PRGE
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	O
factor	O
in	O
vivo	O
that	O
contains	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
but	O
not	O
p50	B-PRGE
epitopes	O
;	O
this	O
factor	O
,	O
termed	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
binding	O
factor	O
II	O
,	O
appears	O
to	O
contain	O
the	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
homodimer	O
and	O
preferentially	O
recognizes	O
several	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
motif	O
functions	O
as	O
a	O
potent	O
IL	O
-	O
1	O
/	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	O
responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
binding	O
factor	O
II	O
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O

The	O
promoter	O
of	O
the	O
CD19	B-PRGE
gene	O
is	O
a	O
target	O
for	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	B-PRGE
.	O

The	O
CD19	B-PRGE
protein	O
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B	O
-	O
lymphoid	O
cells	O
with	O
the	O
exception	O
of	O
terminally	O
differentiated	O
plasma	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
signal	O
-	O
transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	B-PRGE
gene	O
and	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	B-PRGE
in	O
a	O
large	O
panel	O
of	O
B	O
-	O
lymphoid	O
cell	O
lines	O
.	O

The	O
human	O
CD19	B-PRGE
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP	B-PRGE
-	O
binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein	O
-	O
DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high	O
-	O
affinity	O
BSAP	B-PRGE
-	O
binding	O
site	O
instead	O
of	O
a	O
TATA	O
sequence	O
is	O
located	O
in	O
the	O
-	O
30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	B-PRGE
in	O
vivo	O
in	O
a	O
CD19	B-PRGE
-	O
expressing	O
B	O
-	O
cell	O
line	O
but	O
not	O
in	O
plasma	O
or	O
HeLa	O
cells	O
.	O

This	O
high	O
-	O
affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	B-PRGE
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B	O
-	O
cell	O
specificity	O
to	O
a	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
reporter	I-PRGE
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	B-PRGE
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA	O
-	O
binding	O
activity	O
of	O
B	O
-	O
cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B-PRGE
promoter	O
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	B-PRGE
in	O
the	O
regulation	O
of	O
the	O
CD19	B-PRGE
gene	O
.	O

SRC	O
-	O
related	O
proto	O
-	O
oncogenes	O
and	O
transcription	O
factors	O
in	O
primary	O
human	O
T	O
cells	O
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
transcription	O
of	O
genes	O
encoding	O
for	O
lymphokines	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans	O
-	O
activating	O
factors	O
that	O
bind	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
T	O
lymphocytes	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

A	O
member	O
of	O
the	O
src	O
gene	O
family	O
,	O
the	O
lymphocyte	O
-	O
specific	O
protein	O
tyrosine	O
kinase	O
,	O
p56lck	B-PRGE
,	O
has	O
been	O
implicated	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B-PRGE
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	B-PRGE
gene	O
product	O
.	O

However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
sites	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
.	O

Since	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans	O
-	O
activating	O
factors	O
.	O

The	O
development	O
of	O
functionally	O
responsive	O
T	O
cells	O
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	O
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O

This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	O
gene	O
rearrangement	O
.	O

The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	O
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O

It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	O
gamma	O
loci	O
in	O
the	O
gamma	O
delta	O
lineage	O
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	O
beta	O
in	O
the	O
alpha	O
beta	O
lineage	O
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O

In	O
the	O
TCR	O
alpha	O
beta	O
lineage	O
,	O
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O

Whereas	O
peripheral	O
T	O
cells	O
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen	O
-	O
driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O

Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	O
of	O
antigen	O
responsiveness	O
:	O
instead	O
of	O
turning	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
,	O
the	O
activated	O
cell	O
destroys	O
its	O
own	O
chromatin	O
.	O

The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	O
thymocytes	O
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
provided	O
.	O

Perhaps	O
murine	O
thymocytes	O
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
chain	I-PRGE
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
deficient	O
(	O
cf	O
.	O
Sentman	O
et	O
al	O
.	O
,	O
1991	O
;	O
Strasser	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

Even	O
so	O
,	O
medullary	O
thymocytes	O
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

Regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B-PRGE
1	I-PRGE
and	O
2A	B-PRGE
protein	I-PRGE
phosphatases	I-PRGE
,	O
on	O
the	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
leukemia	O
cells	O
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac	B-PRGE
-	I-PRGE
1	I-PRGE
cell	I-PRGE
surface	I-PRGE
antigen	I-PRGE
expression	O
;	O
(	O
c	O
)	O
down	O
-	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
transcripts	O
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	O
necrosis	O
factor	O
gene	O
expression	O
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
.	O

Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
in	O
U	O
-	O
937	O
cells	O
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40	O
-	O
fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid	O
-	O
induced	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
.	O

The	O
half	O
-	O
life	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
was	O
similar	O
(	O
45	O
-	O
50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	O
acid	O
-	O
induced	O
cells	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1	O
/	O
2	O
=	O
90	O
min	O
)	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
is	O
autoinduced	O
by	O
Jun	O
/	O
AP	O
-	O
1	O
,	O
we	O
also	O
studied	O
transcription	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
promoter	O
(	O
positions	O
-	O
132	O
/	O
+	O
170	O
)	O
-	O
reporter	O
gene	O
constructs	O
with	O
and	O
without	O
a	O
mutated	O
AP	O
-	O
1	O
element	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
interleukin	B-PRGE
2	I-PRGE
in	O
human	O
blood	O
monocytes	O
.	O

We	O
report	O
here	O
that	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
acts	O
on	O
human	O
blood	O
monocytes	O
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
p55	B-PRGE
)	O
.	O

Similarly	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
activates	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	O
in	O
resting	O
human	O
T	O
-	O
cells	O
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
is	O
mediated	O
by	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
(	O
-	O
291	O
to	O
-	O
245	O
)	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
gene	O
is	O
activated	O
.	O

In	O
addition	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B-PRGE
gene	O
coding	O
for	O
the	O
p50	B-PRGE
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
gene	O
remained	O
unchanged	O
.	O

The	O
regulation	O
of	O
the	O
human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
promoter	O
region	O
in	O
macrophage	O
,	O
T	O
cell	O
,	O
and	O
B	O
cell	O
lines	O
.	O

The	O
1311	O
-	O
base	O
pair	O
human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
alpha	I-PRGE
promoter	O
region	O
was	O
fused	O
to	O
the	O
luciferase	O
(	O
Luc	O
)	O
reporter	O
gene	O
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	O
producing	O
cell	O
lines	O
,	O
the	O
U937	O
macrophage	O
cell	O
line	O
,	O
the	O
MLA	O
144	O
T	O
cell	O
line	O
,	O
and	O
the	O
729	O
-	O
6	O
B	O
cell	O
line	O
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5	O
'	O
-	O
truncations	O
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-	O
95	O
and	O
-	O
36	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Within	O
this	O
region	O
,	O
single	O
AP	O
-	O
2	O
-	O
and	O
AP	O
-	O
1	O
-	O
like	O
consensus	O
sequences	O
were	O
noted	O
.	O

These	O
AP	O
-	O
2	O
and	O
AP	O
-	O
1	O
sites	O
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

A	O
modest	O
(	O
20	O
-	O
50	O
%	O
)	O
reduction	O
in	O
TNF	B-PRGE
promoter	O
activity	O
was	O
observed	O
with	O
the	O
AP	O
-	O
2	O
site	O
mutation	O
.	O

However	O
,	O
mutation	O
of	O
the	O
AP	O
-	O
1	O
site	O
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA	O
-	O
activated	O
promoter	O
activity	O
.	O

Also	O
co	O
-	O
transfections	O
of	O
the	O
wild	O
-	O
type	O
promoter	O
construct	O
with	O
an	O
AP	O
-	O
1	O
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
vector	O
resulted	O
in	O
augmented	O
basal	O
and	O
PMA	O
-	O
induced	O
promoter	O
activity	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF	O
-	O
kappa	O
B	O
translocation	O
and	O
HIV	O
long	O
terminal	O
repeat	O
activity	O
in	O
human	O
T	O
and	O
monocytic	O
cell	O
lines	O
.	O

We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	O
lymphocytes	O
and	O
monocytes	O
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O

We	O
used	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha	O
-	O
tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA	O
-	O
or	O
TNF	O
-	O
stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA	O
-	O
or	O
TNF	O
-	O
induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV	O
-	O
enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
both	O
lymphoblastoid	O
T	O
(	O
J	O
.	O
Jhan	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	B-PRGE
homodimer	O
)	O
binding	O
activity	O
in	O
U937	O
cells	O
.	O

Secretion	O
of	O
TNF	O
,	O
the	O
product	O
of	O
another	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA	O
-	O
stimulated	O
U937	O
cells	O
.	O

The	O
anti	O
-	O
oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	O
and	O
unstimulated	O
T	O
cell	O
,	O
whereas	O
TNF	O
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J	O
.	O
Jhan	O
or	O
U937	O
cells	O
could	O
not	O
by	O
itself	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	O
and	O
PMA	O
do	O
not	O
lead	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

Rather	O
,	O
TNF	O
and	O
PMA	O
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
.	O

Natural	O
variants	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
-	O
1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV	O
-	O
1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	B-PRGE
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG	O
-	O
motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	B-PRGE
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	B-PRGE
sites	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	O
-	O
motif	O
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild	O
-	O
type	O
plasmid	O
were	O
cotransfected	O
into	O
T	O
-	O
cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	B-PRGE
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	B-PRGE
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG	O
-	O
monomer	O
virus	O
outcompeted	O
the	O
CTG	O
-	O
dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

In	O
the	O
human	O
genome	O
,	O
the	O
erythroid	O
-	O
specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	O
the	O
transcription	O
of	O
the	O
downstream	O
beta	B-PRGE
-	I-PRGE
like	I-PRGE
globin	I-PRGE
genes	O
10	O
-	O
50	O
kilobases	O
away	O
.	O

The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
plasmids	O
.	O

In	O
erythroid	O
K562	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	O
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis	O
-	O
linked	O
CAT	B-PRGE
gene	O
.	O

In	O
nonerythroid	O
HL	O
-	O
60	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	O
detectable	O
.	O

Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis	O
-	O
linked	O
CAT	B-PRGE
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	O
structure	O
of	O
a	O
gene	O
domain	O
and	O
(	O
ii	O
)	O
deliver	O
enhancer	O
binding	O
proteins	O
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	O
site	O
.	O

Phorbol	O
ester	O
reduces	O
constitutive	O
nuclear	O
NF	O
kappa	O
B	O
and	O
inhibits	O
HIV	O
-	O
1	O
production	O
in	O
mature	O
human	O
monocytic	O
cells	O
.	O

NF	O
kappa	O
B	O
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	O
kappa	O
B	O
to	O
cytokines	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
have	O
used	O
a	O
32P	O
-	O
labeled	O
oligonucleotide	O
derived	O
from	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
long	O
terminal	O
repeat	O
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	O
kappa	O
B	O
binding	O
sequence	O
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	O
factor	O
.	O

Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	O
kappa	O
B	O
in	O
extracts	O
of	O
nuclei	O
from	O
normal	O
human	O
monocytes	O
.	O

Treatment	O
of	O
normal	O
monocytes	O
with	O
12	O
-	O
0	O
-	O
tetradecanoyl	O
phorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
for	O
4	O
-	O
24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O

A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
.	O

The	O
constitutive	O
transcription	O
factor	O
SP1	B-PRGE
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O

The	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng	O
/	O
ml	O
of	O
phorbol	O
ester	O
.	O

In	O
THP	O
-	O
1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster	O
-	O
migrating	O
NF	O
kappa	O
B	O
species	O
not	O
induced	O
in	O
monocytes	O
.	O

Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	O
cyclic	O
nucleotide	O
-	O
dependent	O
protein	O
kinase	O
inhibitor	O
HA	O
-	O
1004	O
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	O
infected	O
with	O
HIV	O
-	O
1	O
inhibited	O
HIV	O
-	O
1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	O
transcriptase	O
assays	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	O
kappa	O
B	O
and	O
HIV	O
-	O
1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	O
leukemia	O
cells	O
U937	O
and	O
HL	O
-	O
60	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	O
regulation	O
of	O
HIV	O
-	O
1	O
in	O
normal	O
monocytes	O
.	O

Targeted	O
degradation	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
but	O
not	O
v	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
signal	O
on	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

The	O
proto	O
-	O
oncogene	O
products	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
heterodimerize	O
through	O
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
isolated	O
from	O
phorbol	O
ester	O
-	O
induced	O
cells	O
did	O
not	O
target	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O

v	B-PRGE
-	I-PRGE
Fos	I-PRGE
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

Alpha	O
-	O
lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
proviral	O
DNA	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
and	O
this	O
transcriptional	O
activator	O
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O

Incubation	O
of	O
Jurkat	O
T	O
cells	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha	O
-	O
lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
25	O
ng	O
/	O
ml	O
)	O
or	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
50	O
ng	O
/	O
ml	O
)	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha	O
-	O
lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N	O
-	O
acetylcysteine	O
.	O

These	O
results	O
indicate	O
that	O
alpha	O
-	O
lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O

Activation	O
of	O
lymphokine	O
genes	O
in	O
T	O
cells	O
:	O
role	O
of	O
cis	O
-	O
acting	O
DNA	O
elements	O
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

Activation	O
of	O
T	O
cells	O
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	O
presenting	O
cells	O
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	O
(	O
lymphokine	O
)	O
secretion	O
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell	O
-	O
mediated	O
immunity	O
.	O

Although	O
lymphokine	O
genes	O
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O

For	O
most	O
lymphokine	O
genes	O
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	O
.	O

The	O
production	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis	O
-	O
acting	O
region	O
spanning	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
region	O
(	O
positions	O
-	O
95	O
to	O
+	O
27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	O
,	O
GC	O
-	O
box	O
and	O
conserved	O
lymphokine	O
element	O
(	O
CLE0	O
)	O
.	O

GM2	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

One	O
protein	O
,	O
NF	O
-	O
GM2	O
is	O
similar	O
to	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
.	O

GC	O
-	O
box	O
is	O
a	O
binding	O
site	O
for	O
constitutively	O
bound	O
proteins	O
.	O

CLEO	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

Viral	O
trans	O
-	O
activators	O
such	O
as	O
Tax	B-PRGE
(	O
human	O
T	O
cell	O
leukemia	O
virus	O
-	O
1	O
,	O
HTLV	O
-	O
1	O
)	O
and	O
E2	B-PRGE
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	O
gene	O
expression	O
by	O
bypassing	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
mediated	O
signaling	O
.	O

The	O
trans	O
-	O
activation	O
domain	O
of	O
E2	B-PRGE
and	O
Tax	B-PRGE
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O

The	O
viral	O
trans	O
-	O
activators	O
appear	O
to	O
target	O
specific	O
DNA	O
binding	O
protein	O
such	O
as	O
NF	O
-	O
kB	O
and	O
Sp1	B-PRGE
to	O
cis	O
-	O
acting	O
DNA	O
site	O
and	O
promote	O
lymphokine	O
gene	O
expression	O
without	O
TCR	O
-	O
mediated	O
stimulation	O
.	O

I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
and	O
requires	O
the	O
transactivation	O
domain	O
to	O
inhibit	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
DNA	O
binding	O
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	O
is	O
composed	O
of	O
two	O
DNA	O
binding	O
subunits	O
,	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
and	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
,	O
both	O
of	O
which	O
share	O
extensive	O
N	O
-	O
terminal	O
sequence	O
homology	O
with	O
the	O
v	B-PRGE
-	I-PRGE
rel	I-PRGE
oncogene	O
product	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
subunit	O
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
termed	O
I	O
kappa	O
B	O
.	O

In	O
contrast	O
,	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
alone	O
fails	O
to	O
stimulate	O
kappa	O
B	O
-	O
directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	O
kappa	O
B	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF	O
-	O
kappa	O
B	O
and	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
a	O
series	O
of	O
human	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
mutants	O
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	O
,	O
and	O
I	O
kappa	O
B	O
-	O
induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	O
factor	O
.	O

Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
mutants	O
revealed	O
the	O
following	O
:	O
1	O
)	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
completely	O
inhibits	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
-	O
dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
kappa	O
B	O
enhancer	O
in	O
human	O
T	O
lymphocytes	O
,	O
2	O
)	O
the	O
binding	O
of	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
to	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
is	O
sufficient	O
to	O
retarget	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	O
homology	O
domain	O
of	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
disrupts	O
its	O
ability	O
to	O
engage	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
4	O
)	O
the	O
unique	O
C	O
-	O
terminus	O
of	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
DNA	O
binding	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
of	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	O
kappa	O
B	O
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
binds	O
directly	O
to	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C	O
-	O
terminal	O
domain	O
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
.	O

Simple	O
derivation	O
of	O
TFIID	O
-	O
dependent	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	O
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	O
polymerase	O
II	O
promoters	O
.	O

This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	O
lymphocytes	O
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

TFIIDs	O
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O

The	O
S	O
.	O
cerevisiae	O
and	O
Sch	O
.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	O
activator	O
proteins	O
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S	O
.	O
cerevisiae	O
is	O
supplied	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	O
initiation	O
factors	O
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	O
activators	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
dependent	O
induction	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
subunit	O
gene	O
promoter	O
underlies	O
self	O
-	O
perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
observed	O
in	O
U937	O
monocytic	O
cells	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	O
regulating	O
the	O
synthesis	O
of	O
the	O
p105	B-PRGE
precursor	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
subunit	O
was	O
enhanced	O
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	O
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
but	O
not	O
the	O
AP	O
-	O
1	O
-	O
binding	O
motif	O
,	O
by	O
bona	O
fide	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF	O
-	O
kappa	O
B	O
levels	O
were	O
increased	O
in	O
HIV	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF	O
-	O
kappa	O
B	O
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B-PRGE
isoenzymes	I-PRGE
alpha	I-PRGE
and	O
beta	B-PRGE
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	O
cells	O
,	O
continuous	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
translocation	O
results	O
in	O
p105	B-PRGE
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

This	O
HIV	O
-	O
mediated	O
mechanism	O
results	O
in	O
a	O
self	O
-	O
perpetuating	O
loop	O
of	O
NF	O
-	O
kappa	O
B	O
production	O
.	O

TAR	O
-	O
independent	O
transactivation	O
by	O
Tat	B-PRGE
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV	O
-	O
1	O
gene	O
regulation	O
.	O

The	O
Tat	B-PRGE
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	B-PRGE
,	O
a	O
potent	O
activator	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	B-PRGE
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV	O
-	O
1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS	O
-	O
derived	O
cells	O
Tat	B-PRGE
is	O
capable	O
of	O
activating	O
HIV	O
-	O
1	O
through	O
a	O
TAR	O
-	O
independent	O
pathway	O
.	O

A	O
Tat	B-PRGE
-	O
responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial	O
-	O
derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat	B-PRGE
-	O
responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV	O
-	O
1	O
enhancer	O
,	O
or	O
NF	O
-	O
kappa	O
B	O
domain	O
.	O

DNA	O
band	O
-	O
shift	O
analysis	O
reveals	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	O
-	O
deleted	O
mutants	O
of	O
HIV	O
-	O
1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	O
p24	B-PRGE
antigen	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mitogen	O
stimulation	O
of	O
T	O
-	O
cells	O
increases	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
levels	O
,	O
AP	O
-	O
1	O
binding	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Both	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
levels	O
were	O
increased	O
after	O
Con	B-PRGE
A	I-PRGE
and	O
PHA	O
stimulation	O
.	O

Since	O
T	O
-	O
cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2	O
+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	O
of	O
these	O
intracellular	O
messengers	O
in	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
induction	O
was	O
tested	O
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	B-PRGE
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2	O
+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O

The	O
mitogen	O
-	O
induced	O
increase	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
immunoreactivity	O
was	O
inhibited	O
by	O
H	O
-	O
7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	B-PRGE
,	O
and	O
less	O
efficiently	O
by	O
H	O
-	O
8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	B-PRGE
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide	O
-	O
dependent	O
kinases	O
.	O

Con	B-PRGE
A	I-PRGE
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP	O
-	O
1	O
to	O
the	O
AP	O
-	O
1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP	O
-	O
1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	O
cells	O
.	O

PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2	O
+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
levels	O
,	O
AP	O
-	O
1	O
binding	O
and	O
AP	O
-	O
1	O
enhancer	O
activity	O
in	O
Jurkat	O
cells	O
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	B-PRGE
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	B-PRGE
1	I-PRGE
and	O
2A	B-PRGE
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
,	O
AP	O
-	O
1	O
and	O
a	O
marked	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
levels	O
.	O

In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	O
binding	O
proteins	O
,	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
were	O
found	O
.	O

Since	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
gene	O
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	O
secretion	O
.	O

A	O
novel	O
Ets	O
-	O
related	O
transcription	O
factor	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
binds	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
regulatory	O
elements	O
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
and	O
HIV	O
-	O
2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human	O
-	O
peripheral	O
-	O
blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV	O
-	O
2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV	O
-	O
1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T	O
-	O
cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV	O
-	O
1	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
to	O
activate	O
HIV	O
-	O
2	O
transcription	O
in	O
infected	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets	O
-	O
related	O
transcription	O
factor	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
binds	O
specifically	O
to	O
two	O
purine	O
-	O
rich	O
motifs	O
in	O
the	O
HIV	O
-	O
2	O
enhancer	O
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
sites	O
are	O
required	O
for	O
induction	O
of	O
HIV	O
-	O
2	O
transcription	O
following	O
T	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
T	O
-	O
cell	O
activation	O
.	O

Moreover	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
novel	O
transcription	O
factor	O
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
trans	O
activation	O
of	O
HIV	O
-	O
2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV	O
-	O
2	O
infection	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	B-PRGE
protein	O
inhibits	O
NF	O
-	O
kappa	O
B	O
induction	O
in	O
human	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4	B-PRGE
+	O
T	O
lymphocytes	O
(	O
W	O
.	O
C	O
.	O
Greene	O
,	O
N	O
.	O
Engl	O
.	O
J	O
.	O
Med	O
.	O
324	O
:	O
308	O
-	O
317	O
,	O
1991	O
;	O
S	O
.	O
M	O
.	O
Schnittman	O
,	O
M	O
.	O
C	O
.	O
Psallidopoulos	O
,	O
H	O
.	O
C	O
.	O
Lane	O
,	O
L	O
.	O
Thompson	O
,	O
M	O
.	O
Baseler	O
,	O
F	O
.	O
Massari	O
,	O
C	O
.	O
H	O
.	O
Fox	O
,	O
N	O
.	O
P	O
.	O
Salzman	O
,	O
and	O
A	O
.	O
S	O
.	O
Fauci	O
,	O
Science	O
245	O
:	O
305	O
-	O
308	O
,	O
1989	O
)	O
.	O

Production	O
of	O
HIV	O
-	O
1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T	O
-	O
cell	O
mitogens	O
(	O
T	O
.	O
Folks	O
,	O
D	O
.	O
M	O
.	O
Powell	O
,	O
M	O
.	O
M	O
.	O
Lightfoote	O
,	O
S	O
.	O
Benn	O
,	O
M	O
.	O
A	O
.	O
Martin	O
,	O
and	O
A	O
.	O
S	O
.	O
Fauci	O
,	O
Science	O
231	O
:	O
600	O
-	O
602	O
,	O
1986	O
;	O
D	O
.	O
Zagury	O
,	O
J	O
.	O
Bernard	O
,	O
R	O
.	O
Leonard	O
,	O
R	O
.	O
Cheynier	O
,	O
M	O
.	O
Feldman	O
,	O
P	O
.	O
S	O
.	O
Sarin	O
,	O
and	O
R	O
.	O
C	O
.	O
Gallo	O
,	O
Science	O
231	O
:	O
850	O
-	O
853	O
,	O
1986	O
)	O
.	O

This	O
activation	O
is	O
mediated	O
by	O
the	O
host	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
[	O
G	O
.	O
Nabel	O
and	O
D	O
.	O
Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711	O
-	O
717	O
,	O
1987	O
]	O
.	O

We	O
report	O
here	O
that	O
the	O
HIV	O
-	O
1	O
-	O
encoded	O
Nef	B-PRGE
protein	O
inhibits	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
by	O
T	O
-	O
cell	O
mitogens	O
.	O

However	O
,	O
Nef	B-PRGE
does	O
not	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
other	O
transcription	O
factors	O
implicated	O
in	O
HIV	O
-	O
1	O
regulation	O
,	O
including	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
USF	O
,	O
URS	O
,	O
and	O
NF	O
-	O
AT	O
.	O

Additionally	O
,	O
Nef	B-PRGE
inhibits	O
the	O
induction	O
of	O
HIV	O
-	O
1	O
-	O
and	O
interleukin	B-PRGE
2	I-PRGE
-	O
directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
.	O

These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF	O
-	O
kappa	O
B	O
may	O
underlie	O
Nef	B-PRGE
'	O
s	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV	O
-	O
1	O
and	O
interleukin	B-PRGE
2	I-PRGE
promoters	O
.	O

Further	O
evidence	O
suggests	O
that	O
Nef	B-PRGE
inhibits	O
NF	O
-	O
kappa	O
B	O
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
complex	O
.	O

A	O
novel	O
mitogen	O
-	O
inducible	O
gene	O
product	O
related	O
to	O
p50	B-PRGE
/	O
p105	B-PRGE
-	O
NF	O
-	O
kappa	O
B	O
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O

A	O
Rel	O
-	O
related	O
,	O
mitogen	O
-	O
inducible	O
,	O
kappa	O
B	O
-	O
binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate	O
-	O
early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97	O
-	O
kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105	O
-	O
kDa	O
precursor	O
polypeptide	O
of	O
p50	B-PRGE
-	O
NF	O
-	O
kappa	O
B	O
.	O

Like	O
the	O
105	O
-	O
kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino	O
-	O
terminal	O
Rel	O
-	O
related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy	O
-	O
terminal	O
domain	O
containing	O
six	O
full	O
cell	O
cycle	O
or	O
ankyrin	O
repeats	O
.	O

In	O
vitro	O
-	O
translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	O
B	O
-	O
binding	O
,	O
truncated	O
protein	O
as	O
p50B	B-PRGE
by	O
analogy	O
with	O
p50	B-PRGE
-	O
NF	O
-	O
kappa	O
B	O
and	O
to	O
the	O
full	O
-	O
length	O
protein	O
as	O
p97	B-PRGE
.	O

p50B	B-PRGE
is	O
able	O
to	O
form	O
heteromeric	O
kappa	O
B	O
-	O
binding	O
complexes	O
with	O
RelB	B-PRGE
,	O
as	O
well	O
as	O
with	O
p65	B-PRGE
and	O
p50	B-PRGE
,	O
the	O
two	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Transient	O
-	O
transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B-PRGE
and	O
RelB	B-PRGE
or	O
p65	B-PRGE
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
transcription	O
factors	O
.	O

Transcriptional	O
regulation	O
during	O
T	O
-	O
cell	O
development	O
:	O
the	O
alpha	B-PRGE
TCR	I-PRGE
gene	O
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T	O
-	O
cell	O
-	O
specific	O
gene	O
,	O
alpha	B-PRGE
TCR	I-PRGE
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T	O
-	O
cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T	O
-	O
cell	O
activation	O
,	O
are	O
described	O
.	O

An	O
11	O
-	O
base	O
-	O
pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	B-PRGE
4	I-PRGE
gene	O
confers	O
responsiveness	O
to	O
T	O
-	O
cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
4	I-PRGE
gene	O
in	O
Jurkat	O
cells	O
.	O

The	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis	O
-	O
acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O
no	O
additional	O
DNA	O
segments	O
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-	O
79	O
and	O
-	O
69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base	O
-	O
substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
were	O
identified	O
by	O
DNA	O
-	O
mobility	O
-	O
shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	O
(	O
P	O
)	O
interaction	O
is	O
sequence	O
-	O
specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
expression	O
in	O
vivo	O
.	O

The	O
P	O
sequence	O
does	O
not	O
share	O
homology	O
with	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
share	O
high	O
homology	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
genes	O
.	O

Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	O
dependent	O
on	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
function	O
of	O
a	O
putative	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O

The	O
putative	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
region	O
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti	O
-	O
CD3	O
or	O
to	O
mitogens	O
in	O
T	O
-	O
cell	O
,	O
B	O
-	O
cell	O
,	O
or	O
monocyte	O
/	O
macrophage	O
leukemia	O
lines	O
,	O
nor	O
is	O
it	O
a	O
cis	O
-	O
acting	O
negative	O
regulatory	O
element	O
.	O

Interleukin	B-PRGE
6	I-PRGE
-	O
induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM	O
-	O
secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
.	O

The	O
role	O
of	O
the	O
protooncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
in	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
6	I-PRGE
-	O
induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6	O
.	O
4	O
cells	O
with	O
IL	B-PRGE
6	I-PRGE
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
sense	O
mRNA	O
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
significantly	O
inhibited	O
IL	B-PRGE
6	I-PRGE
-	O
induced	O
IgM	O
production	O
by	O
SKW	O
6	O
.	O
4	O
cells	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
is	O
involved	O
in	O
IL	B-PRGE
6	I-PRGE
-	O
induced	O
differentiation	O
of	O
SKW	O
6	O
.	O
4	O
cells	O
into	O
IgM	O
-	O
secreting	O
cells	O
.	O

Binding	O
of	O
erythroid	O
and	O
non	O
-	O
erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
-	O
encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	O
-	O
encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-	O
392	O
to	O
-	O
177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
-	O
encoding	O
gene	O
[	O
Cao	O
et	O
al	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
86	O
(	O
1989	O
)	O
5306	O
-	O
5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-	O
cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-	O
294	O
to	O
-	O
251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B-PRGE
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
-	O
encoding	O
gene	O
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

T	O
cell	O
-	O
specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	O
cytokine	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	O
cytokine	O
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

A	O
novel	O
T	O
cell	O
-	O
specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein	O
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
:	O
-	O
311CTCCCTTCT	O
-	O
303	O
(	O
NRE	O
-	O
I	O
)	O
and	O
-	O
288CTTTTTGCTT	O
-	O
TGC	O
-	O
300	O
(	O
NRE	O
-	O
II	O
)	O
.	O

A	O
T	O
cell	O
-	O
specific	O
protein	O
Neg	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
a	O
ubiquitous	O
protein	O
Neg	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
to	O
NRE	O
-	O
I	O
and	O
NRE	O
-	O
II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O

These	O
data	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activity	O
is	O
normally	O
down	O
-	O
regulated	O
by	O
an	O
NRE	O
via	O
repression	O
of	O
the	O
enhancer	O
positive	O
regulatory	O
element	O
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
expression	O
in	O
T	O
cells	O
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation	B-PRGE
-	I-PRGE
inducer	I-PRGE
molecule	I-PRGE
/	O
CD69	B-PRGE
enhances	O
the	O
activity	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
.	O

The	O
induction	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP	O
-	O
1	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	B-PRGE
inducer	I-PRGE
molecule	I-PRGE
(	O
AIM	B-PRGE
)	O
/	O
CD69	B-PRGE
activation	O
pathway	O
.	O

Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM	B-PRGE
/	O
CD69	B-PRGE
cell	O
-	O
surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti	O
-	O
AIM	B-PRGE
mAb	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti	O
-	O
AIM	B-PRGE
mAb	O
to	O
PMA	O
-	O
treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP	O
-	O
1	O
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	O
ester	O
response	O
element	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
AIM	B-PRGE
mAb	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	O
kinase	O
C	O
.	O

The	O
increase	O
in	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
but	O
not	O
that	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
.	O

Blockade	O
of	O
the	O
DNA	O
-	O
binding	O
complexes	O
with	O
an	O
anti	O
-	O
Fos	B-PRGE
mAb	O
demonstrated	O
a	O
direct	O
participation	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
in	O
the	O
AP	O
-	O
1	O
complexes	O
induced	O
by	O
anti	O
-	O
AIM	B-PRGE
mAb	O
.	O

Most	O
of	O
the	O
AP	O
-	O
1	O
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti	O
-	O
AIM	B-PRGE
mAb	O
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	B-PRGE
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP	O
-	O
1	O
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

The	O
B	O
cell	O
-	O
specific	O
nuclear	O
factor	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
positively	O
regulates	O
transcription	O
of	O
the	O
human	O
class	O
II	O
transplantation	O
gene	O
,	O
DRA	B-PRGE
.	O

The	O
promoter	O
of	O
the	O
major	O
histocompatibility	O
class	O
II	O
gene	O
DRA	B-PRGE
contains	O
an	O
octamer	O
element	O
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	B-PRGE
expression	O
in	O
B	O
cells	O
.	O

Several	O
DNA	O
-	O
binding	O
proteins	O
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	O
cell	O
-	O
specific	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
ubiquitous	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

This	O
report	O
directly	O
demonstrates	O
that	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
but	O
not	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
regulates	O
the	O
DRA	B-PRGE
gene	O
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer	O
-	O
binding	O
protein	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
DRA	B-PRGE
gene	O
transcription	O
.	O

In	O
contrast	O
,	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
enriched	O
protein	O
fractions	O
did	O
not	O
affect	O
DRA	B-PRGE
gene	O
transcription	O
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Recombinant	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
protein	O
produced	O
by	O
in	O
vitro	O
transcription	O
/	O
translation	O
could	O
also	O
enhance	O
DRA	B-PRGE
gene	O
transcription	O
in	O
vitro	O
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
vector	O
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
protein	O
enhanced	O
DRA	B-PRGE
gene	O
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	O
element	O
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid	O
-	O
specific	O
octamer	O
-	O
binding	O
factor	O
in	O
DRA	B-PRGE
gene	O
transcription	O
.	O

Specific	O
NF	O
-	O
kappa	O
B	O
subunits	O
act	O
in	O
concert	O
with	O
Tat	B-PRGE
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
protein	O
complex	O
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	B-PRGE
-	I-PRGE
I	I-PRGE
gene	O
product	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF	O
-	O
kappa	O
B	O
subunits	O
to	O
act	O
with	O
Tat	B-PRGE
-	I-PRGE
I	I-PRGE
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	B-PRGE
(	I-PRGE
100	I-PRGE
)	I-PRGE
DNA	O
binding	O
subunit	O
,	O
together	O
with	O
p65	B-PRGE
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	B-PRGE
-	I-PRGE
I	I-PRGE
to	O
stimulate	O
the	O
expression	O
of	O
HIV	O
-	O
CAT	B-PRGE
plasmid	O
.	O

Little	O
effect	O
was	O
observed	O
with	O
50	O
-	O
kDa	O
forms	O
of	O
p105	B-PRGE
NF	O
-	O
kappa	O
B	O
or	O
rel	B-PRGE
,	O
in	O
combination	O
with	O
p65	B-PRGE
or	O
full	O
-	O
length	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B-PRGE
(	I-PRGE
100	I-PRGE
)	I-PRGE
and	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
can	O
act	O
in	O
concert	O
with	O
the	O
tat	B-PRGE
-	I-PRGE
I	I-PRGE
gene	O
product	O
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF	O
-	O
kappa	O
B	O
proteins	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
proteins	O
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B-PRGE
related	O
polypeptides	O
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

In	O
this	O
study	O
multiple	O
NF	O
-	O
kappa	O
B	O
related	O
polypeptides	O
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	O
regulatory	O
element	O
of	O
interferon	O
beta	O
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF	O
-	O
kappa	O
B	O
site	O
and	O
form	O
multiple	O
DNA	O
binding	O
homo	O
-	O
and	O
heterodimer	O
complexes	O
in	O
co	O
-	O
renaturation	O
experiments	O
.	O

Furthermore	O
,	O
using	O
DNA	O
templates	O
containing	O
two	O
copies	O
of	O
the	O
PRDII	O
domain	O
linked	O
to	O
the	O
rabbit	O
beta	O
globin	O
gene	O
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF	O
-	O
kappa	O
B	O
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B-PRGE
homodimers	O
.	O

These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	O
proteins	O
.	O

Oct2	B-PRGE
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B	O
-	O
cell	O
-	O
restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte	O
-	O
specific	O
transcription	O
factor	O
Oct2	B-PRGE
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	B-PRGE
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	O
octamer	O
enhancer	O
element	O
in	O
HeLa	O
cells	O
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B-PRGE
isoforms	O
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B	O
-	O
cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-PRGE
isoforms	O
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B	O
-	O
cell	O
-	O
specific	O
cofactor	O
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	O
or	O
the	O
Oct2	B-PRGE
protein	O
in	O
Oct2	B-PRGE
-	O
mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
Oct2	B-PRGE
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B-PRGE
protein	O
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine	O
-	O
rich	O
activation	O
domain	O
present	O
in	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Oct2	B-PRGE
and	O
the	O
POU	O
domain	O
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

Transcription	O
factor	O
AP	O
-	O
2	O
activates	O
gene	O
expression	O
of	O
HTLV	O
-	O
I	O
.	O

The	O
HTLV	O
-	O
I	O
LTR	O
contains	O
three	O
conserved	O
regulatory	O
elements	O
known	O
as	O
21	O
base	O
pair	O
repeats	O
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	O
protein	O
tax	B-PRGE
.	O

Mutagenesis	O
indicates	O
that	O
the	O
21	O
bp	O
repeats	O
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B-PRGE
activation	O
.	O

The	O
A	O
site	O
in	O
the	O
21	O
bp	O
repeat	O
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
AP	O
-	O
2	O
.	O

We	O
demonstrated	O
that	O
AP	O
-	O
2	O
mRNA	O
was	O
present	O
in	O
T	O
-	O
lymphocytes	O
and	O
that	O
cellular	O
factors	O
from	O
both	O
non	O
-	O
transformed	O
and	O
transformed	O
T	O
-	O
lymphocytes	O
specifically	O
bound	O
to	O
the	O
consensus	O
motif	O
for	O
AP	O
-	O
2	O
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP	O
-	O
2	O
in	O
the	O
regulation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
gene	O
expression	O
,	O
we	O
used	O
an	O
AP	O
-	O
2	O
cDNA	O
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	O
produced	O
AP	O
-	O
2	O
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	O
bp	O
repeats	O
,	O
and	O
that	O
it	O
required	O
the	O
core	O
sequence	O
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP	O
-	O
2	O
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB	O
/	O
ATF	O
family	O
to	O
an	O
adjacent	O
regulatory	O
motif	O
in	O
the	O
21	O
bp	O
repeat	O
.	O

Transfection	O
of	O
an	O
AP	O
-	O
2	O
expression	O
construct	O
into	O
T	O
-	O
lymphocytes	O
activated	O
gene	O
expression	O
from	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

At	O
least	O
two	O
21	O
bp	O
repeats	O
were	O
required	O
for	O
high	O
levels	O
of	O
AP	O
-	O
2	O
activation	O
and	O
mutagenesis	O
of	O
the	O
AP	O
-	O
2	O
consensus	O
binding	O
sequences	O
in	O
the	O
21	O
bp	O
repeats	O
eliminate	O
this	O
activation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
human	O
myelomonocytic	O
cell	O
line	O
U	O
-	O
937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid	O
-	O
induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide	O
-	O
stimulated	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
messenger	O
RNA	O
levels	O
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte	O
/	O
macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U	O
-	O
937	O
,	O
THP	O
-	O
1	O
,	O
and	O
HL	O
-	O
60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
mRNA	O
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
protein	O
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
and	O
had	O
increased	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
in	O
response	O
to	O
LPS	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
levels	O
only	O
in	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U	O
-	O
937	O
was	O
chosen	O
over	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U	O
-	O
937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12	O
-	O
24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
appearance	O
in	O
response	O
to	O
LPS	O
.	O

However	O
,	O
exposure	O
of	O
U	O
-	O
937	O
cells	O
to	O
1	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U	O
-	O
937	O
cells	O
not	O
preincubated	O
with	O
the	O
hormone	O
.	O
2	O
+	O
o	O

NF	O
-	O
kappa	O
B	O
activation	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
regulated	O
kinases	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
DNA	O
-	O
binding	O
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	O
cells	O
,	O
NF	O
-	O
kappa	O
B	O
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
TNF	B-PRGE
alpha	I-PRGE
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B-PRGE
alpha	I-PRGE
were	O
able	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2	O
+	O
influx	O
while	O
TNF	B-PRGE
alpha	I-PRGE
activation	O
was	O
not	O
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B-PRGE
alpha	I-PRGE
effect	O
was	O
unchanged	O
.	O

TNF	B-PRGE
alpha	I-PRGE
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O

Moreover	O
,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF	O
-	O
kappa	O
B	O
in	O
Jurkat	O
cells	O
.	O

Thus	O
,	O
TNF	B-PRGE
alpha	I-PRGE
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal	O
-	O
mediating	O
kinases	O
such	O
as	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
protein	O
kinase	O
A	O
,	O
or	O
Ca	O
(	O
2	O
+	O
)	O
-	O
regulated	O
kinases	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
both	O
TNF	B-PRGE
alpha	I-PRGE
and	O
PKC	O
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF	O
-	O
kappa	O
B	O
/	O
I	O
kappa	O
B	O
dissociation	O
without	O
affecting	O
the	O
NF	O
-	O
kappa	O
B	O
translocation	O
step	O
.	O

USF	B-PRGE
-	O
related	O
transcription	O
factor	O
,	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
.	O

The	O
transcription	O
factor	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O

HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Binding	O
of	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O

The	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
-	O
binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	B-PRGE
stimulatory	I-PRGE
factor	I-PRGE
(	O
USF	B-PRGE
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O

DNA	O
-	O
binding	O
properties	O
of	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
suggested	O
that	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
might	O
be	O
identical	O
or	O
related	O
to	O
USF	B-PRGE
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
by	O
phosphatase	O
greatly	O
reduced	O
its	O
DNA	O
-	O
binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
was	O
essential	O
for	O
DNA	O
binding	O
.	O

The	O
disruption	O
of	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
-	O
binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV	B-PRGE
-	I-PRGE
TF1	I-PRGE
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV	O
-	O
1	O
.	O

Nuclear	O
transcription	O
factors	O
that	O
bind	O
to	O
elements	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
AP	O
-	O
3	O
,	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
NF	O
-	O
AT	O
.	O

The	O
latter	O
"	O
nuclear	O
factor	O
for	O
activated	O
T	O
cells	O
"	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	O
factors	O
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	O
but	O
not	O
with	O
exogenous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
growth	O
factor	O
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i	O
.	O
e	O
.	O
,	O
PMA	O
plus	O
either	O
lectin	O
or	O
antibody	O
to	O
the	O
CD3	O
or	O
CD28	B-PRGE
surface	O
molecules	O
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	O
,	O
antibody	O
,	O
and	O
/	O
or	O
PMA	O
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
.	O

An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell	O
-	O
type	O
specific	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA	O
-	O
1	O
genes	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
to	O
the	O
SV40	O
promoter	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
site	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor	O
-	O
induced	O
genes	O
with	O
almost	O
identical	O
zinc	O
-	O
finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS	O
-	O
like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc	O
-	O
finger	O
sequences	O
of	O
the	O
type	O
Cys2	O
-	O
Xaa12	O
-	O
His2	O
.	O

This	O
zinc	O
-	O
finger	O
region	O
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	O
factors	O
pAT	O
225	O
/	O
EGR1	B-PRGE
and	O
pAT	O
591	O
/	O
EGR2	B-PRGE
.	O

Except	O
for	O
the	O
conserved	O
zinc	O
-	O
finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc	O
-	O
finger	O
-	O
encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	O
225	O
/	O
EGR1	B-PRGE
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591	O
/	O
EGR2	B-PRGE
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i	O
.	O
e	O
.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer	O
/	O
promoter	O
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	O
kappa	O
enhancer	O
(	O
or	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer	O
/	O
promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility	O
/	O
cell	O
type	O
specificity	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T	O
-	O
cell	O
-	O
specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T	O
-	O
cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T	O
-	O
cell	O
phenotype	O
by	O
functioning	O
as	O
'	O
master	O
regulators	O
of	O
T	O
-	O
cell	O
differentiation	O
'	O
.	O

Transcription	O
factor	O
requirements	O
for	O
U2	O
snRNA	O
-	O
encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O

Transcription	O
of	O
a	O
human	O
U2	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
-	O
encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	B-PRGE
1	I-PRGE
-	O
binding	O
sites	O
.	O

To	O
study	O
the	O
transcription	O
factor	O
requirement	O
in	O
B	O
-	O
cells	O
,	O
different	O
U2	O
enhancer	O
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA	O
-	O
B	O
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B	O
-	O
cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	O
1	O
-	O
binding	O
site	O
.	O

Deletion	O
of	O
all	O
the	O
Sp	B-PRGE
1	I-PRGE
-	O
binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80	O
-	O
90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer	O
-	O
binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	O
snRNA	O
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
expressed	O
,	O
and	O
in	O
BJA	O
-	O
B	O
cells	O
in	O
which	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
the	O
predominantly	O
expressed	O
octamer	O
-	O
binding	O
factor	O
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	O
factor	O
,	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
,	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
can	O
activate	O
U2	O
snRNA	O
transcription	O
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	B-PRGE
1	I-PRGE
-	O
binding	O
site	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	O
expresses	O
wild	O
-	O
type	O
levels	O
of	O
U2	O
snRNA	O
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer	O
-	O
binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	B-PRGE
1	I-PRGE
-	O
binding	O
site	O
.	O

Kappa	O
B	O
-	O
specific	O
DNA	O
binding	O
proteins	O
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	O
B	O
(	O
kappa	O
B	O
)	O
enhancer	O
binding	O
proteins	O
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	O
complexes	O
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
gene	O
.	O

These	O
two	O
DNA	O
-	O
protein	O
complexes	O
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B-PRGE
,	O
p55	B-PRGE
,	O
p75	B-PRGE
,	O
p85	B-PRGE
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v	B-PRGE
-	I-PRGE
rel	I-PRGE
oncogene	O
product	O
.	O

Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	O
cells	O
(	O
p55	B-PRGE
/	O
p75	B-PRGE
early	O
and	O
p50	B-PRGE
/	O
p85	B-PRGE
late	O
)	O
.	O

DNA	O
-	O
protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	O
complex	O
contains	O
both	O
p50	B-PRGE
and	O
p55	B-PRGE
while	O
the	O
more	O
slowly	O
migrating	O
B1	O
complex	O
is	O
composed	O
of	O
p50	B-PRGE
,	O
p55	B-PRGE
,	O
p75	B-PRGE
,	O
and	O
p85	B-PRGE
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
wild	O
-	O
type	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	B-PRGE
and	O
p55	B-PRGE
(	O
B2	O
complex	O
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	O
'	O
triplet	O
of	O
deoxyguanosine	O
residues	O
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	O
complex	O
,	O
reflecting	O
the	O
binding	O
of	O
p75	B-PRGE
and	O
p85	B-PRGE
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	O
element	O
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel	O
-	O
related	O
factors	O
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	O
B	O
element	O
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N	O
-	O
ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B-PRGE
oxidase	I-PRGE
selectively	O
inhibits	O
p75	B-PRGE
and	O
p85	B-PRGE
binding	O
while	O
not	O
blocking	O
p50	B-PRGE
and	O
p55	B-PRGE
interactions	O
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel	O
-	O
related	O
transcription	O
factors	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	O
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
two	O
nuclear	O
proteins	O
NF	O
-	O
kappa	O
B	O
(	O
consisting	O
of	O
subunits	O
p50	B-PRGE
and	O
p65	B-PRGE
)	O
and	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-PRGE
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T	O
-	O
cell	O
line	O
IARC	O
301	O
.	O
5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301	O
.	O
5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B-PRGE
and	O
NF	O
-	O
kappa	O
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B-PRGE
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
)	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	B-PRGE
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	B-PRGE
is	O
a	O
competitive	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
genes	O
during	O
the	O
immune	O
response	O
.	O

Stimulation	O
of	O
interferon	B-PRGE
beta	I-PRGE
gene	O
transcription	O
in	O
vitro	O
by	O
purified	O
NF	O
-	O
kappa	O
B	O
and	O
a	O
novel	O
TH	O
protein	O
.	O

The	O
human	O
interferon	B-PRGE
beta	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	O
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
mediating	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
induction	O
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	O
T	O
-	O
cells	O
and	O
from	O
IFN	O
primed	O
,	O
cycloheximide	O
/	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
treated	O
HeLa	O
S3	O
cells	O
.	O

From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T	O
-	O
cells	O
,	O
four	O
proteins	O
-	O
-	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43	O
-	O
47	O
kD	O
-	O
-	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
ISGF2	B-PRGE
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B-PRGE
beta	I-PRGE
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2	O
-	O
4	O
-	O
fold	O
increase	O
in	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4	O
-	O
fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
transcription	O
.	O

Characterization	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	O
kappa	O
B	O
-	O
like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O

One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	O
tandem	O
repeats	O
of	O
the	O
cdc10	O
/	O
ankyrin	O
motif	O
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	O
repeat	O
region	O
of	O
the	O
precursor	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
KBF1	B-PRGE
p50	B-PRGE
.	O

The	O
C	O
-	O
terminus	O
has	O
a	O
putative	O
protein	O
kinase	O
C	O
phosphorylation	O
site	O
.	O

In	O
vitro	O
translated	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
protein	O
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
p50	B-PRGE
/	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
complex	O
but	O
not	O
that	O
of	O
the	O
p50	B-PRGE
/	O
p50	B-PRGE
KBF1	B-PRGE
factor	O
or	O
of	O
other	O
DNA	O
-	O
binding	O
proteins	O
.	O

The	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
cDNA	O
encodes	O
an	O
I	O
kappa	O
B	O
-	O
like	O
protein	O
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF	O
-	O
kappa	O
B	O
,	O
including	O
adhesion	O
-	O
dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O

Platelet	O
-	O
activating	O
factor	O
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Platelet	O
-	O
activating	O
factor	O
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet	O
-	O
activating	O
factor	O
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet	O
-	O
activating	O
factor	O
on	O
B	O
lymphocytes	O
.	O

Employing	O
the	O
EBV	O
-	O
transformed	O
human	O
B	O
cell	O
line	O
SKW6	O
.	O
4	O
,	O
we	O
demonstrate	O
that	O
platelet	O
-	O
activating	O
factor	O
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-	O
9	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso	O
-	O
platelet	O
-	O
activating	O
factor	O
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-	O
7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O

We	O
also	O
show	O
that	O
platelet	O
-	O
activating	O
factor	O
from	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso	O
-	O
platelet	O
-	O
activating	O
factor	O
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet	O
-	O
activating	O
factor	O
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet	O
-	O
activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
and	O
5	O
-	O
hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Moreover	O
,	O
platelet	O
-	O
activating	O
factor	O
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	O
proto	O
-	O
oncogenes	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5	O
-	O
hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
activity	O
modulates	O
platelet	O
-	O
activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B-PRGE
A2	I-PRGE
.	O

In	O
summary	O
,	O
platelet	O
-	O
activating	O
factor	O
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O

Inhibition	O
of	O
protein	O
phosphatases	O
by	O
okadaic	O
acid	O
induces	O
AP1	O
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	O
phosphatases	O
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
phosphatases	O
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	O
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	O
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto	O
-	O
oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B-PRGE
further	O
enhanced	O
the	O
induction	O
of	O
AP1	O
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto	O
-	O
oncogenes	O
including	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
junD	B-PRGE
,	O
and	O
junB	B-PRGE
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
fra	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
.	O

The	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B-PRGE
phosphatases	I-PRGE
1	I-PRGE
and	O
2A	B-PRGE
(	O
PP1	O
and	O
PP2A	O
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	O
factor	O
AP1	O
.	O

Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
strains	O
GS	O
and	O
Z	O
-	O
29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV	O
-	O
infected	O
human	O
T	O
cells	O
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV	O
-	O
6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O

Two	O
different	O
strains	O
of	O
HHV	O
-	O
6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O

A	O
21	O
.	O
4	O
-	O
kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6	O
.	O
2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8	O
.	O
7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	O
kappa	O
B	O
site	O
.	O

However	O
,	O
this	O
mutated	O
NF	O
kappa	O
B	O
promoter	O
was	O
not	O
transactivated	O
during	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	O
or	O
pZVB10	O
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	O
kappa	O
B	O
sites	O
of	O
the	O
HIV	O
promoter	O
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV	O
-	O
6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV	O
-	O
6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	O
human	O
T	O
cells	O
.	O

Regulation	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
expression	O
by	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
:	O
role	O
of	O
protein	O
kinase	O
C	O
and	O
transcription	O
factor	O
NF	O
kappa	O
B	O
.	O

Macrophage	B-PRGE
-	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
also	O
referred	O
to	O
as	O
CSF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fms	I-PRGE
protooncogene	O
.	O

The	O
detection	O
of	O
both	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fms	I-PRGE
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

We	O
show	O
that	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
activates	O
and	O
translocates	O
PKC	O
.	O

Inhibition	O
of	O
PKC	O
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
by	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	O
was	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	O
kappa	O
B	O
protein	O
in	O
nuclear	O
extracts	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
induced	O
blood	O
monocytes	O
but	O
not	O
in	O
monocytes	O
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

The	O
results	O
suggest	O
that	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
induction	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
involves	O
G	O
proteins	O
,	O
PKC	O
and	O
NF	O
kappa	O
B	O
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF	O
-	O
KB	O
-	O
related	O
factors	O
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	O
,	O
B2	O
and	O
B3	O
)	O
with	O
affinity	O
for	O
the	O
KB	O
-	O
enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
.	O

The	O
B2	O
factor	O
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1	O
-	O
infected	O
macrophages	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	O
factor	O
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA	O
-	O
binding	O
protein	O
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1	O
-	O
infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Induction	O
of	O
NF	O
-	O
kappa	O
B	O
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV	O
-	O
gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte	O
-	O
macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF	O
-	O
kappa	O
B	O
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B-PRGE
alpha	I-PRGE
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	O
esters	O
or	O
TNF	B-PRGE
alpha	I-PRGE
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O

Expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
B	I-PRGE
and	O
jun	B-PRGE
D	I-PRGE
proto	O
-	O
oncogenes	O
in	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto	O
-	O
oncogenes	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
B	I-PRGE
and	O
jun	B-PRGE
D	I-PRGE
mRNA	O
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	O
beta	O
-	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
B	I-PRGE
and	O
jun	B-PRGE
D	I-PRGE
transcripts	O
were	O
increased	O
.	O

The	O
three	O
jun	O
genes	O
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	O
that	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
B	I-PRGE
and	O
jun	B-PRGE
D	I-PRGE
genes	O
might	O
be	O
involved	O
in	O
terminal	O
granulocyte	O
differentiation	O
or	O
in	O
regulating	O
granulocyte	O
functionality	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
suppresses	O
human	O
B	O
lymphocyte	O
Ig	O
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
inhibits	O
B	O
cell	O
Ig	O
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	O
expression	O
.	O

The	O
addition	O
of	O
TGF	O
-	O
beta	O
to	O
human	O
B	O
lymphocyte	O
cultures	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
completely	O
inhibited	O
B	O
cell	O
Ig	O
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	B-PRGE
L	I-PRGE
chain	I-PRGE
,	O
and	O
lambda	B-PRGE
L	I-PRGE
chain	I-PRGE
expression	O
.	O

In	O
contrast	O
,	O
TGF	O
-	O
beta	O
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	O
cell	O
membrane	O
proteins	O
,	O
HLA	O
-	O
DR	O
and	O
CD20	B-PRGE
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti	O
-	O
IgM	O
,	O
anti	O
-	O
kappa	B-PRGE
,	O
and	O
anti	O
-	O
lambda	B-PRGE
antibodies	O
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	B-PRGE
L	I-PRGE
chain	I-PRGE
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	B-PRGE
L	I-PRGE
chain	I-PRGE
and	O
microH	O
chain	O
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF	O
-	O
beta	O
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	B-PRGE
and	O
lambda	B-PRGE
L	I-PRGE
chain	I-PRGE
mRNA	O
levels	O
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	B-PRGE
L	I-PRGE
chain	I-PRGE
.	O

The	O
effects	O
of	O
TGF	O
-	O
beta	O
on	O
two	O
transcriptional	O
regulatory	O
factors	O
,	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappa	O
B	O
,	O
known	O
to	O
be	O
important	O
in	O
Ig	O
gene	O
transcription	O
were	O
examined	O
.	O

Oct	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
levels	O
and	O
both	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF	O
-	O
beta	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	O
factor	O
AP	O
-	O
1	O
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	O
cell	O
Ig	O
production	O
,	O
were	O
reduced	O
by	O
TGF	O
-	O
beta	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF	O
-	O
beta	O
decreases	O
B	O
lymphocyte	O
Ig	O
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O

The	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
or	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
their	O
respective	O
target	O
sequences	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

HIV	O
-	O
1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

HIV	O
-	O
1	O
-	O
infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV	O
-	O
1	O
replication	O
and	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV	O
-	O
1	O
replication	O
in	O
persistently	O
infected	O
Molt	O
-	O
4	O
and	O
U937	O
cells	O
.	O

However	O
,	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
-	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
expression	O
under	O
control	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O

This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
individuals	O
may	O
cause	O
an	O
over	O
-	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
and	O
enhance	O
HIV	O
-	O
1	O
replication	O
.	O

NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
individuals	O
.	O

A	O
nuclear	O
factor	O
NF	O
-	O
GM2	O
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T	O
-	O
cell	O
activation	O
:	O
purification	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	O
,	O
or	O
a	O
combination	O
of	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
at	O
positions	O
between	O
-	O
95	O
and	O
-	O
73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA	O
/	O
A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA	O
-	O
binding	O
motifs	O
,	O
GM2	O
and	O
GC	O
-	O
box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	O
NF	O
-	O
GM2	O
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	O
NF	O
-	O
GM2	O
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
purified	O
NF	O
-	O
GM2	O
consists	O
of	O
50	O
(	O
p50	B-PRGE
)	O
and	O
65	O
kDa	O
(	O
p65	B-PRGE
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	O
p50	B-PRGE
alone	O
can	O
form	O
a	O
protein	O
-	O
DNA	O
complex	O
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B-PRGE
associates	O
preferentially	O
with	O
p65	B-PRGE
to	O
form	O
the	O
NF	O
-	O
GM2	O
complex	O
.	O

In	O
addition	O
,	O
p65	B-PRGE
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein	O
-	O
DNA	O
complex	O
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF	O
-	O
GM2	O
complex	O
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B-PRGE
(	O
identical	O
to	O
50	O
kDa	O
NF	O
-	O
kappa	O
B	O
protein	O
)	O
reacted	O
with	O
the	O
p50	B-PRGE
of	O
NF	O
-	O
GM2	O
,	O
indicating	O
that	O
the	O
NF	O
-	O
GM2	O
polypeptide	O
cannot	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	O
kDa	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
purified	O
NF	O
-	O
GM2	O
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
harboring	O
the	O
GM2	O
sequence	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
through	O
the	O
GM2	O
/	O
GC	O
-	O
box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	O
B	O
enhancer	O
alone	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans	O
-	O
activator	O
of	O
HTLV	O
-	O
I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
using	O
the	O
human	O
T	O
-	O
cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV	O
-	O
I	O
,	O
and	O
MT	O
-	O
2	O
and	O
TL	O
-	O
Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV	O
-	O
I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
.	O

One	O
is	O
the	O
21	O
-	O
base	O
-	O
pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans	O
-	O
activation	O
by	O
the	O
HTLV	O
-	O
I	O
trans	O
-	O
activator	O
p40tax	B-PRGE
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic	B-PRGE
-	I-PRGE
AMP	I-PRGE
responsive	I-PRGE
element	I-PRGE
binding	I-PRGE
factor	I-PRGE
(	O
CREB	B-PRGE
)	O
-	O
like	O
factor	O
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21	O
-	O
bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21	O
-	O
bp	O
elements	O
is	O
involved	O
in	O
trans	O
-	O
activation	O
by	O
p40tax	B-PRGE
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
nuclear	O
factor	O
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein	O
-	O
DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	B-PRGE
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	B-PRGE
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21	O
-	O
bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	B-PRGE
.	O

However	O
,	O
the	O
C26	O
element	O
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	B-PRGE
,	O
unlike	O
other	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV	O
-	O
I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB	B-PRGE
-	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
factors	O
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
in	O
response	O
to	O
p40tax	B-PRGE
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA	O
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O

Inhibition	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
(	O
AP	O
-	O
1	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
early	O
response	O
genes	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA	O
-	O
induced	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
levels	O
in	O
U	O
-	O
937	O
leukemia	O
cells	O
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA	O
-	O
induced	O
increases	O
in	O
lamin	B-PRGE
A	I-PRGE
,	O
lamin	B-PRGE
C	I-PRGE
,	O
and	O
vimentin	B-PRGE
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA	O
-	O
induced	O
activation	O
of	O
PKC	B-PRGE
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
.	O

Increases	O
in	O
CAT	B-PRGE
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA	O
-	O
treated	O
U	O
-	O
937	O
cells	O
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-	O
97	O
to	O
-	O
20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP	O
-	O
1	O
binding	O
site	O
.	O

This	O
induction	O
of	O
CAT	B-PRGE
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	O
down	O
-	O
regulates	O
TPA	O
-	O
induced	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP	O
-	O
1	O
site	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
human	O
glucocorticoid	O
receptor	O
.	O

We	O
have	O
used	O
a	O
DNA	O
-	O
binding	O
/	O
immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
indistinguishable	O
from	O
native	O
hGR	O
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	O
antibodies	O
generated	O
against	O
hGR	O
.	O

In	O
addition	O
,	O
cell	O
-	O
free	O
synthesized	O
hGR	O
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
-	O
containing	O
DNA	O
fragments	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	O
receptors	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA	O
-	O
binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3	O
-	O
fold	O
over	O
that	O
of	O
heat	O
-	O
activated	O
unliganded	O
receptors	O
.	O

Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O

DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
GR	O
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA	O
-	O
receptor	O
complex	O
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell	O
-	O
free	O
synthesized	O
hGR	O
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid	O
-	O
repressible	O
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	O
that	O
hGR	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	O
-	O
specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	O
receptor	O
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	O
cells	O
and	O
tissues	O
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell	O
-	O
restricted	O
activity	O
of	O
a	O
kB	O
-	O
like	O
proto	O
-	O
enhancer	O
element	O
from	O
the	O
interleukin	B-PRGE
2	I-PRGE
promoter	O
.	O

The	O
inducible	O
,	O
T	O
cell	O
-	O
specific	O
enhancers	O
of	O
murine	O
and	O
human	O
Interleukin	B-PRGE
2	I-PRGE
(	O
Il	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
genes	O
contain	O
the	O
kB	O
-	O
like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis	O
-	O
acting	O
enhancer	O
motif	O
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so	O
-	O
called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto	O
-	O
enhancer	O
element	O
in	O
E14	O
T	O
lymphoma	O
cells	O
,	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il	B-PRGE
-	I-PRGE
2	I-PRGE
secreting	O
El4	O
cells	O
three	O
individual	O
protein	O
factors	O
bind	O
to	O
TCEd	O
DNA	O
.	O

The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
T	B-PRGE
cell	I-PRGE
factor	I-PRGE
1	I-PRGE
)	O
,	O
is	O
correlated	O
with	O
the	O
proto	O
-	O
enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF	B-PRGE
-	I-PRGE
1	I-PRGE
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	O
kD	O
polypeptide	O
of	O
NF	O
-	O
kB	O
.	O

Purified	O
NF	O
-	O
kB	O
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
binds	O
stronger	O
than	O
NF	O
-	O
kB	O
to	O
TCEd	O
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'	O
perfect	O
'	O
NF	O
-	O
kB	O
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF	O
-	O
kB	O
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'	O
converted	O
'	O
TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell	O
-	O
restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
lymphocyte	O
-	O
specific	O
factors	O
binding	O
to	O
the	O
TCEd	O
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific	O
-	O
transcription	O
of	O
the	O
Il	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65	B-PRGE
-	I-PRGE
kDa	I-PRGE
plus	O
50	B-PRGE
-	I-PRGE
kDa	I-PRGE
NF	O
-	O
kappa	O
B	O
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

In	O
THP	O
-	O
1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA	O
-	O
protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV	O
-	O
1	O
promoter	O
-	O
enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
region	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
;	O
the	O
65	B-PRGE
-	I-PRGE
kDa	I-PRGE
plus	O
50	B-PRGE
-	I-PRGE
kDa	I-PRGE
NF	O
-	O
kappa	O
B	O
heterodimer	O
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	O
NF	O
-	O
kappa	O
B	O
protein	O
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Antiserum	O
specific	O
for	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
,	O
but	O
not	O
c	O
-	O
rel	O
-	O
specific	O
antiserum	O
,	O
disrupted	O
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
complexes	O
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65	B-PRGE
-	I-PRGE
kDa	I-PRGE
plus	O
50	B-PRGE
-	I-PRGE
kDa	I-PRGE
heterodimer	O
to	O
the	O
HIV	O
-	O
1	O
enhancer	O
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor	O
/	O
activator	O
,	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
(	O
YY	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
delta	B-PRGE
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
mu	O
E1	O
site	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
(	O
kappa	O
E3	O
'	O
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive	O
-	O
and	O
negative	O
-	O
acting	O
elements	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	O
E3	O
'	O
enhancer	O
is	O
active	O
at	O
the	O
pre	O
-	O
B	O
-	O
cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative	O
-	O
acting	O
elements	O
.	O

The	O
negative	O
-	O
acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
at	O
the	O
pre	O
-	O
B	O
-	O
cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	O
finger	O
protein	O
(	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
)	O
that	O
binds	O
to	O
the	O
negative	O
-	O
acting	O
segment	O
of	O
the	O
kappa	O
E3	O
'	O
enhancer	O
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
mu	O
E1	O
site	O
.	O

NF	B-PRGE
-	I-PRGE
E1	I-PRGE
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
,	O
which	O
binds	O
to	O
the	O
adeno	O
-	O
associated	O
virus	O
P5	O
promoter	O
.	O

NF	B-PRGE
-	I-PRGE
E1	I-PRGE
is	O
also	O
the	O
human	O
homologue	O
of	O
the	O
mouse	O
delta	B-PRGE
protein	O
,	O
which	O
binds	O
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	O
activators	O
as	O
well	O
as	O
transcriptional	O
repressors	O
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	O
that	O
it	O
can	O
repress	O
basal	O
promoter	O
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

Regulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide	O
-	O
induced	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate	O
-	O
induced	O
production	O
was	O
increased	O
3	O
-	O
10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA	O
-	O
induced	O
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate	O
-	O
induced	O
signal	O
(	O
prolonged	O
protein	O
kinase	O
C	O
activation	O
?	O
)	O
cannot	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Identification	O
of	O
transcriptional	O
suppressor	O
proteins	O
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus	O
-	O
infected	O
human	O
T	O
cell	O
line	O
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV	O
-	O
1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	O
retinoblastoma	O
gene	O
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus	O
-	O
uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	O
AP	O
-	O
1	O
recognition	O
sequence	O
predicted	O
for	O
the	O
HIV	O
-	O
1	O
NRE	O
.	O

However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP	O
-	O
1	O
site	O
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one	O
-	O
tenth	O
or	O
one	O
-	O
third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
transcription	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kB	O
in	O
human	O
thymocytes	O
.	O

NF	O
-	O
kB	O
is	O
a	O
eukaryotic	O
transcription	O
regulatory	O
factor	O
.	O

In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF	O
-	O
kB	O
is	O
bound	O
to	O
a	O
cytoplasmic	O
proteic	O
inhibitor	O
,	O
the	O
IkB	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	O
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
induces	O
NF	O
-	O
kB	O
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF	O
-	O
kB	O
dependent	O
T	O
cell	O
genes	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF	O
-	O
kB	O
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2	O
+	O
)	O
i	O
requirement	O
for	O
NF	O
-	O
kB	O
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	O
have	O
a	O
constitutively	O
active	O
form	O
of	O
NF	O
-	O
kB	O
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV	O
-	O
I	O
Tax	B-PRGE
protein	O
.	O

Transient	O
short	O
-	O
term	O
expression	O
of	O
the	O
Tax	B-PRGE
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
nucleus	O
of	O
Namalwa	O
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	O
Tax	B-PRGE
.	O

In	O
contrast	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long	O
-	O
term	O
expression	O
of	O
Tax	B-PRGE
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
was	O
also	O
blocked	O
in	O
Jurkat	O
cells	O
constitutively	O
expressing	O
Tax	B-PRGE
.	O

However	O
,	O
the	O
activation	O
of	O
other	O
mitogen	O
-	O
inducible	O
transcription	O
factors	O
,	O
such	O
as	O
Fos	B-PRGE
and	O
Jun	B-PRGE
,	O
was	O
unaffected	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short	O
-	O
and	O
long	O
-	O
term	O
effects	O
of	O
Tax	B-PRGE
expression	O
can	O
be	O
quite	O
different	O
.	O

Consequently	O
,	O
one	O
function	O
of	O
Tax	B-PRGE
in	O
cells	O
infected	O
with	O
HTLV	O
-	O
I	O
might	O
involve	O
cell	O
-	O
type	O
-	O
specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV	O
-	O
2	O
transactivator	O
gene	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV	O
-	O
1	O
replication	O
and	O
pathogenesis	O
.	O

The	O
transactivator	O
(	O
IE	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV	O
-	O
2	O
as	O
well	O
as	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
vitro	O
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV	O
-	O
2	O
tat	B-PRGE
gene	O
and	O
T	O
-	O
cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	O
CD4	B-PRGE
+	O
lymphocytes	O
.	O

While	O
the	O
HIV	O
-	O
2	O
and	O
HIV	O
-	O
1	O
tat	B-PRGE
genes	O
and	O
T	O
-	O
cell	O
activators	O
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	O
transactivator	O
in	O
combination	O
with	O
the	O
HIV	O
-	O
2	O
tat	B-PRGE
or	O
T	O
-	O
cell	O
activators	O
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O

Both	O
HIV	O
-	O
2	O
and	O
CMV	O
transactivators	O
enhance	O
HIV	O
-	O
2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	O
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	O
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV	O
-	O
2	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	O
CD4	B-PRGE
+	O
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV	O
-	O
2	O
enhancer	O
element	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
2	O
gene	O
expression	O
:	O
two	O
enhancers	O
and	O
their	O
activation	O
by	O
T	O
-	O
cell	O
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	O
elements	O
in	O
the	O
HIV	O
-	O
2	O
LTR	O
.	O

The	O
HIV	O
-	O
2	O
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	O
.	O

One	O
of	O
these	O
enhancers	O
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV	O
-	O
1	O
enhancer	O
.	O

This	O
enhancer	O
in	O
HIV	O
-	O
1	O
is	O
the	O
T	O
-	O
cell	O
activation	O
response	O
element	O
;	O
in	O
HIV	O
-	O
2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T	O
-	O
cell	O
activators	O
.	O

The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	O
binding	O
proteins	O
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV	O
-	O
2	O
.	O

Induction	O
of	O
NF	O
-	O
KB	O
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	O
transactivation	O
factor	O
NF	O
-	O
KB	O
to	O
the	O
double	O
repeat	O
-	O
KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	O
cells	O
acts	O
in	O
inducing	O
NF	O
-	O
KB	O
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF	O
-	O
KB	O
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
no	O
induction	O
of	O
NF	O
-	O
KB	O
factor	O
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV	O
-	O
1	O
could	O
mimic	O
some	O
differentiation	O
/	O
activation	O
stimuli	O
allowing	O
nuclear	O
NF	O
-	O
KB	O
expression	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
by	O
a	O
novel	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
.	O

A	O
new	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
enhancer	O
.	O

Tandem	O
copies	O
of	O
this	O
67	O
-	O
bp	O
MnlI	O
-	O
AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
gene	O
driven	O
by	O
the	O
conalbumin	O
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
or	O
HeLa	O
cells	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B-PRGE
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B	O
-	O
cell	O
-	O
specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B-PRGE
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	O
in	O
Jurkat	O
or	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
a	O
mutant	O
E6	B-PRGE
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	O
Ig	O
heavy	O
-	O
chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer	O
-	O
binding	O
proteins	O
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O

Interestingly	O
,	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
could	O
suppress	O
the	O
basal	O
-	O
level	O
activity	O
of	O
the	O
conalbumin	O
promoter	O
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	O
and	O
negative	O
factors	O
.	O

The	O
NF	O
kappa	O
B	O
independent	O
cis	O
-	O
acting	O
sequences	O
in	O
HIV	O
-	O
1	O
LTR	O
responsive	O
to	O
T	O
-	O
cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
NF	O
kappa	O
B	O
.	O

The	O
rate	O
of	O
LTR	O
-	O
directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
if	O
either	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
NF	O
kappa	O
B	O
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O

The	O
HIV	O
-	O
1	O
mutant	O
virus	O
containing	O
both	O
NF	O
kappa	O
B	O
and	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O

Neither	O
deletion	O
of	O
NF	O
kappa	O
B	O
nor	O
deletion	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B	O
-	O
related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
tax	B-PRGE
gene	O
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B	O
-	O
related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
gene	O
and	O
the	O
beta	B-PRGE
-	I-PRGE
interferon	I-PRGE
gene	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B	O
-	O
related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B	O
-	O
cell	O
-	O
derived	O
NF	O
-	O
kappa	O
B	O
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	O
2	O
receptor	O
or	O
T	O
-	O
cell	O
receptor	O
genes	O
in	O
S194	O
cells	O
.	O

However	O
,	O
in	O
either	O
EL	O
-	O
4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower	O
-	O
affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	B-PRGE
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF	O
-	O
kappa	O
B	O
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B	O
-	O
cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Isolation	O
of	O
a	O
rel	O
-	O
related	O
human	O
cDNA	O
that	O
potentially	O
encodes	O
the	O
65	O
-	O
kD	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto	O
-	O
oncogene	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
the	O
Drosophila	O
morphogen	O
dorsal	O
,	O
and	O
the	O
p50	B-PRGE
DNA	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel	O
-	O
related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2	O
.	O
6	O
-	O
kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	O
kilodaltons	O
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein	O
-	O
DNA	O
complex	O
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	O
human	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
subunit	O
and	O
binding	O
was	O
inhibited	O
by	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
beta	I-PRGE
proteins	O
.	O

In	O
addition	O
,	O
the	O
65	O
-	O
kD	O
protein	O
associated	O
with	O
the	O
p50	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
complex	O
.	O

Therefore	O
the	O
rel	O
-	O
related	O
65	O
-	O
kD	O
protein	O
may	O
represent	O
the	O
p65	B-PRGE
subunit	O
of	O
the	O
active	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	O
.	O

Murine	O
and	O
human	O
T	O
-	O
lymphocyte	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
factors	O
mediate	O
transcription	O
through	O
a	O
cis	O
-	O
regulatory	O
element	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	O
finger	O
DNA	O
-	O
binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
factors	O
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T	O
-	O
cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue	O
-	O
specific	O
GATA	O
-	O
binding	O
site	O
identified	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

We	O
infer	O
that	O
the	O
murine	O
and	O
human	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
proteins	O
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
regulation	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
the	O
HIV	O
-	O
1	O
protease	B-PRGE
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	O
factors	O
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O

T	O
-	O
cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA	O
-	O
binding	O
subunits	O
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	O
subunits	O
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	O
cytoplasmic	O
complex	O
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50K	B-PRGE
subunit	I-PRGE
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	O
105K	O
precursor	O
(	O
p105	B-PRGE
)	O
(	O
V	O
.	O
B	O
.	O
,	O
P	O
.	O
K	O
.	O
and	O
A	O
.	O
I	O
.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	O
expression	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B-PRGE
.	O

Because	O
HIV	O
-	O
1	O
requires	O
active	O
NF	O
-	O
kappa	O
B	O
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV	O
-	O
1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	O
105K	O
precursor	O
.	O

We	O
show	O
here	O
that	O
the	O
HIV	O
-	O
1	O
protease	B-PRGE
can	O
process	O
p105	B-PRGE
and	O
increases	O
levels	O
of	O
active	O
nuclear	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF	O
-	O
kappa	O
B	O
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	O
necrosis	O
factor	O
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
the	O
platelet	O
GPIIb	B-PRGE
gene	O
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O

Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B-PRGE
IIb	I-PRGE
(	O
GPIIb	B-PRGE
)	O
gene	O
;	O
GPIIb	B-PRGE
,	O
the	O
alpha	O
subunit	O
of	O
the	O
platelet	O
cytoadhesin	O
GPIIb	O
-	O
IIIa	O
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B-PRGE
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
GPIIb	B-PRGE
gene	O
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA	O
-	O
binding	O
nuclear	O
factors	O
.	O

A	O
fragment	O
extending	O
from	O
-	O
643	O
to	O
+	O
33	O
is	O
capable	O
of	O
controlling	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
CAT	B-PRGE
gene	O
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	O
I	O
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-	O
54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	B-PRGE
factor	I-PRGE
E1	I-PRGE
-	O
binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-	O
233	O
contains	O
a	O
CCAAT	O
motif	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-	O
345	O
and	O
-	O
540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-	O
460	O
and	O
-	O
510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte	O
-	O
specific	O
nuclear	O
proteins	O
acting	O
as	O
positive	O
transcription	O
factors	O
.	O

Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
messenger	O
ribonucleic	O
acid	O
in	O
wild	O
-	O
type	O
and	O
dexamethasone	O
-	O
resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild	O
-	O
type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)	O
-	O
resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild	O
-	O
type	O
CEM	O
cells	O
but	O
not	O
in	O
a	O
dex	O
-	O
resistant	O
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
-	O
defective	O
clone	O
ICR	O
-	O
27	O
TK	O
-	O
3	O
,	O
dex	O
induces	O
GR	B-PRGE
mRNA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex	O
-	O
resistant	O
cells	O
by	O
making	O
use	O
of	O
the	O
residual	O
GR	B-PRGE
found	O
there	O
,	O
wild	O
-	O
type	O
and	O
dex	O
-	O
resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	B-PRGE
mRNA	O
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	O
GR	B-PRGE
mRNA	O
in	O
the	O
normal	O
CEM	O
-	O
C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex	O
-	O
resistant	O
clones	O
,	O
although	O
the	O
dex	O
-	O
resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	B-PRGE
mRNA	O
induction	O
.	O

Increased	O
levels	O
of	O
GR	B-PRGE
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	B-PRGE
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex	O
-	O
resistant	O
cells	O
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	B-PRGE
mRNA	O
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	O
and	O
dex	O
-	O
resistant	O
CEM	O
cells	O
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex	O
-	O
resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex	O
-	O
resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O

Human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

The	O
minimal	O
region	O
of	O
the	O
human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
gene	O
promoter	O
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-	O
52	O
and	O
+	O
89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
'	O
s	O
transcriptional	O
start	O
site	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF	O
-	O
kappa	O
B	O
binding	O
activities	O
displayed	O
by	O
different	O
T	O
and	O
B	O
cell	O
lines	O
.	O

Moreover	O
,	O
kappa	O
1	O
-	O
kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
with	O
little	O
effect	O
on	O
the	O
gene	O
'	O
s	O
inducibility	O
by	O
PMA	O
.	O

Therefore	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	O
not	O
primarily	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	O
factors	O
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1	O
-	O
kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	O
a	O
T	O
(	O
HUT78	O
)	O
cell	O
line	O
.	O

However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
and	O
HIV	O
-	O
1	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	O
cytoplasmic	O
form	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
H2O2	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
cycloheximide	O
,	O
double	O
-	O
stranded	O
RNA	O
,	O
calcium	O
ionophore	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
active	O
phorbol	O
ester	O
,	O
interleukin	O
-	O
1	O
,	O
lipopolysaccharide	O
and	O
lectin	O
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	O
subunit	O
I	O
kappa	O
B	O
from	O
NF	O
-	O
kappa	O
B	O
.	O

Contribution	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T	O
-	O
cell	O
types	O
.	O

Starting	O
with	O
a	O
replication	O
-	O
incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
binding	O
sites	O
present	O
in	O
the	O
native	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
elements	O
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection	O
-	O
cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T	O
-	O
cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF	O
-	O
kappa	O
B	O
elements	O
(	O
and	O
no	O
Sp1	B-PRGE
binding	O
sites	O
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second	O
-	O
site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T	O
-	O
cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	O
factors	O
present	O
.	O

Purification	O
of	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
that	O
activates	O
the	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
receptor	I-PRGE
C	I-PRGE
alpha	I-PRGE
gene	O
enhancer	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O

The	O
differentiation	O
of	O
T	O
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
.	O

TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV	O
-	O
1	O
promoter	O
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-PRGE
alpha	I-PRGE
enhancer	O
and	O
to	O
promoters	O
for	O
several	O
genes	O
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T	O
-	O
cell	O
development	O
than	O
the	O
TCR	B-PRGE
alpha	I-PRGE
gene	O
(	O
e	O
.	O
g	O
.	O
,	O
p56lck	B-PRGE
and	O
CD3	B-PRGE
delta	I-PRGE
)	O
.	O

Sequences	O
related	O
to	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
binding	O
motif	O
(	O
5	O
'	O
-	O
GGCACCCTTTGA	O
-	O
3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	O
TCR	B-PRGE
delta	I-PRGE
(	O
and	O
possibly	O
TCR	B-PRGE
beta	I-PRGE
)	O
enhancers	O
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57	O
-	O
to	O
53	O
-	O
kD	O
proteins	O
that	O
are	O
abundantly	O
expressed	O
in	O
mature	O
and	O
immature	O
T	O
-	O
cell	O
lines	O
(	O
Jurkat	O
,	O
CCRF	O
-	O
CEM	O
)	O
and	O
not	O
in	O
mature	O
B	O
cells	O
(	O
JY	O
,	O
Namalwa	O
)	O
or	O
nonlymphoid	O
(	O
HeLa	O
)	O
cell	O
lines	O
.	O

A	O
small	O
95	O
-	O
bp	O
fragment	O
of	O
the	O
TCR	B-PRGE
alpha	I-PRGE
control	O
region	O
that	O
contains	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
binding	O
site	O
juxtaposed	O
between	O
a	O
cAMP	O
-	O
response	O
element	O
(	O
the	O
CRE	O
or	O
T	O
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	O
site	O
for	O
a	O
distinct	O
lymphoid	O
-	O
specific	O
protein	O
(	O
TCF	B-PRGE
-	I-PRGE
2	I-PRGE
alpha	I-PRGE
)	O
behaved	O
as	O
a	O
potent	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
in	O
vivo	O
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	O
(	O
Jurkat	O
)	O
T	O
-	O
cell	O
lines	O
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	O
(	O
CCRF	O
-	O
CEM	O
)	O
T	O
-	O
cell	O
lines	O
.	O

Mutation	O
of	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	O
enhancer	O
repeats	O
.	O

The	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
binding	O
site	O
was	O
also	O
required	O
for	O
TCR	B-PRGE
alpha	I-PRGE
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Curiously	O
,	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B-PRGE
alpha	I-PRGE
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
.	O

Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
appears	O
to	O
depend	O
on	O
the	O
TCF	B-PRGE
-	I-PRGE
2	I-PRGE
alpha	I-PRGE
and	O
T	B-PRGE
alpha	I-PRGE
1	I-PRGE
(	O
CREB	B-PRGE
)	O
transcription	O
factors	O
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B-PRGE
alpha	I-PRGE
enhancer	O
.	O

A	O
novel	O
T	O
-	O
cell	O
trans	O
-	O
activator	O
that	O
recognizes	O
a	O
phorbol	O
ester	O
-	O
inducible	O
element	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

The	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
promoter	O
is	O
recognized	O
by	O
several	O
cell	O
-	O
type	O
-	O
specific	O
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
T	O
-	O
cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein	O
-	O
DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
activator	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
for	O
T	B-PRGE
-	I-PRGE
Cell	I-PRGE
Factor	I-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
which	O
recognizes	O
a	O
T	O
-	O
cell	O
-	O
specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	O
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
distinct	O
from	O
NF	O
kappa	O
B	O
.	O

However	O
,	O
like	O
NF	O
kappa	O
B	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T	O
-	O
cell	O
activators	O
.	O

Two	O
distinct	O
transcription	O
factors	O
that	O
bind	O
the	O
immunoglobulin	O
enhancer	O
microE5	O
/	O
kappa	O
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	O
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ITF	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5	O
/	O
kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ITF	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix	O
-	O
loop	O
-	O
helix	O
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	O
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	O
factors	O
.	O

Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non	O
-	O
B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF	B-PRGE
-	I-PRGE
muE3	I-PRGE
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non	O
-	O
B	O
cells	O
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell	O
-	O
type	O
-	O
specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell	O
-	O
specific	O
factors	O
such	O
as	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2B	I-PRGE
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	O
factors	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	O
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non	O
-	O
permissive	O
chromatin	O
structure	O
of	O
the	O
Ig	O
heavy	O
chain	O
locus	O
.	O

Transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

AP	O
-	O
1	O
,	O
the	O
polypeptide	O
product	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
expression	O
in	O
HL	O
-	O
60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
were	O
detectable	O
in	O
untreated	O
HL	O
-	O
60	O
leukemic	O
cells	O
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	O
U	O
-	O
937	O
and	O
THP	O
-	O
1	O
monocytic	O
leukemia	O
cells	O
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	O
kinase	O
C	O
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
0	O
.	O
5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL	O
-	O
60	O
monocytic	O
differentiation	O
,	O
increased	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
.	O

TPA	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
.	O

Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
transcription	O
in	O
untreated	O
HL	O
-	O
60	O
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3	O
.	O
3	O
-	O
fold	O
.	O

Treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
.	O

The	O
half	O
-	O
life	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
RNA	O
as	O
determined	O
by	O
treating	O
HL	O
-	O
60	O
cells	O
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half	O
-	O
life	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
RNA	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
RNA	O
observed	O
during	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

Identification	O
of	O
a	O
novel	O
factor	O
that	O
interacts	O
with	O
an	O
immunoglobulin	O
heavy	O
-	O
chain	O
promoter	O
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	O
cell	O
-	O
specific	O
factor	O
OTF2	B-PRGE
.	O

The	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
MOPC	O
141	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B	O
-	O
cell	O
-	O
specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	O
element	O
5	O
'	O
-	O
ATGCAAAG	O
-	O
3	O
'	O
,	O
located	O
in	O
the	O
upstream	O
region	O
of	O
this	O
promoter	O
and	O
in	O
the	O
promoters	O
of	O
all	O
other	O
immunoglobulin	O
heavy	O
-	O
and	O
light	O
-	O
chain	O
genes	O
.	O

The	O
interaction	O
of	O
purified	O
octamer	B-PRGE
transcription	I-PRGE
factors	I-PRGE
1	I-PRGE
and	O
2	B-PRGE
(	O
OTF1	B-PRGE
and	O
OTF2	B-PRGE
)	O
with	O
the	O
MOPC	O
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
.	O

Purified	O
OTF1	B-PRGE
from	O
HeLa	O
cells	O
and	O
OTF1	B-PRGE
and	O
OTF2	B-PRGE
from	O
B	O
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy	O
-	O
chain	O
promoter	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	O
element	O
5	O
'	O
-	O
CTCAGGA	O
-	O
3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	O
factors	O
involves	O
cooperation	O
between	O
octamer	O
and	O
heptamer	O
sites	O
in	O
this	O
promoter	O
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	O
element	O
,	O
the	O
N	O
element	O
with	O
the	O
sequence	O
5	O
'	O
-	O
GGAACCTCCCCC	O
-	O
3	O
'	O
.	O

The	O
N	O
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B	O
-	O
cell	O
and	O
HeLa	O
-	O
cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	O
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B	O
-	O
cell	O
extracts	O
.	O

The	O
N	O
element	O
bound	O
a	O
transcription	O
factor	O
,	O
NTF	O
,	O
that	O
is	O
ubiquitous	O
in	O
cell	O
-	O
type	O
distribution	O
,	O
and	O
NTF	O
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	O
described	O
proteins	O
that	O
bind	O
to	O
similar	O
sequences	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	O
and	O
OTF2	B-PRGE
interactions	O
(	O
both	O
with	O
their	O
cognate	O
DNA	O
elements	O
and	O
possibly	O
at	O
the	O
protein	O
-	O
protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B	O
-	O
cell	O
-	O
specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid	O
-	O
specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-	O
nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	O
site	O
for	O
a	O
putative	O
additional	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
,	O
designated	O
NF	B-PRGE
-	I-PRGE
microB	I-PRGE
,	O
in	O
the	O
murine	O
IgH	O
enhancer	O
.	O

We	O
demonstrate	O
that	O
the	O
NF	B-PRGE
-	I-PRGE
microB	I-PRGE
-	O
binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	O
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
enhancer	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
lineage	O
but	O
not	O
in	O
nonlymphoid	O
cells	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70	O
-	O
base	O
-	O
pair	O
fragment	O
of	O
the	O
IgH	O
enhancer	O
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid	O
-	O
specific	O
protein	O
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O

The	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
genes	O
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	O
lymphoid	O
cells	O
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	O
protooncogenes	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
was	O
studied	O
in	O
human	O
lymphoid	O
cells	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
levels	O
in	O
pre	O
-	O
B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND	O
-	O
41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	O
in	O
Hyon	O
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	O
transcription	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
genes	O
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	O
cells	O
stabilized	O
the	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
level	O
by	O
increasing	O
its	O
half	O
-	O
life	O
from	O
24	O
to	O
45	O
min	O
.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	O
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	O
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	O
cells	O
.	O

Tandem	O
AP	O
-	O
1	O
-	O
binding	O
sites	O
within	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18	O
-	O
bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
within	O
the	O
dominant	O
control	O
or	O
locus	O
-	O
activating	O
region	O
.	O

This	O
enhancer	O
is	O
inducible	O
in	O
K562	O
human	O
erythroleukemia	O
cells	O
,	O
increasing	O
linked	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
/	O
luciferase	B-PRGE
gene	O
expression	O
to	O
170	O
-	O
fold	O
over	O
an	O
enhancerless	O
construct	O
.	O

The	O
enhancer	O
consists	O
of	O
tandem	O
AP	O
-	O
1	O
-	O
binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O

DNA	O
-	O
protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	O
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	O
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP	O
-	O
1	O
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	O
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	O
and	O
fos	O
families	O
to	O
tandem	O
AP	O
-	O
1	O
consensus	O
sequences	O
.	O

Adherence	O
-	O
dependent	O
increase	O
in	O
human	O
monocyte	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
is	O
associated	O
with	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
EGR2	B-PRGE
mRNA	O
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	O
growth	O
factors	O
such	O
as	O
platelet	B-PRGE
-	I-PRGE
derived	I-PRGE
growth	I-PRGE
factor	I-PRGE
B	I-PRGE
subunit	I-PRGE
(	O
PDGF	B-PRGE
[	I-PRGE
B	I-PRGE
]	I-PRGE
)	O
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	O
increase	O
in	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
mRNA	O
was	O
observed	O
.	O

The	O
6	O
-	O
h	O
increase	O
in	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6	O
-	O
h	O
increase	O
in	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	B-PRGE
or	O
collagen	O
-	O
coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
accumulation	O
.	O

The	O
increased	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	O
of	O
the	O
early	O
growth	O
response	O
genes	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
EGR2	B-PRGE
(	O
maximal	O
at	O
6	O
-	O
24	O
h	O
)	O
.	O

The	O
increase	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
EGR2	B-PRGE
,	O
but	O
not	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
EGR2	B-PRGE
,	O
and	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
mRNA	O
.	O

In	O
addition	O
,	O
the	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
EGR2	B-PRGE
,	O
and	O
PDGF	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	O
,	O
may	O
help	O
explain	O
the	O
gender	O
-	O
specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	O
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	O
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
to	O
quantitate	O
beta	B-PRGE
-	I-PRGE
galactosidase	I-PRGE
(	O
beta	B-PRGE
-	I-PRGE
gal	I-PRGE
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF	O
-	O
AT	O
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	B-PRGE
gene	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta	B-PRGE
-	I-PRGE
gal	I-PRGE
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta	B-PRGE
-	I-PRGE
gal	I-PRGE
and	O
others	O
express	O
high	O
levels	O
.	O

This	O
expression	O
pattern	O
cannot	O
be	O
accounted	O
for	O
by	O
cell	O
-	O
cycle	O
position	O
or	O
heritable	O
variation	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta	B-PRGE
-	I-PRGE
gal	I-PRGE
activity	O
is	O
correlated	O
with	O
NF	O
-	O
AT	O
-	O
binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF	O
-	O
AT	O
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF	O
-	O
AT	O
concentration	O
-	O
dependent	O
assembly	O
of	O
transcription	O
complexes	O
at	O
the	O
promoter	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF	O
-	O
kappa	O
B	O
or	O
the	O
entire	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	O
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	O
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	O
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	O
receptor	O
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
'	O
s	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	O
(	O
immunosuppressant	O
binding	O
protein	O
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	O
binding	O
protein	O
FKBP	O
(	O
Kd	O
=	O
0	O
.	O
2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	O
(	O
Kd	O
=	O
0	O
.	O
4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506	O
-	O
mediated	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF	O
-	O
AT	O
,	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
necessary	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
activation	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin	O
-	O
mediated	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	O
FKBP	O
.	O

FKBP	O
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis	O
-	O
and	O
trans	O
-	O
rotamers	O
of	O
the	O
peptidyl	O
-	O
prolyl	O
amide	O
bond	O
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	O
(	O
Ki	O
=	O
0	O
.	O
2	O
nM	O
)	O
.	O

Neither	O
FKBP	O
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	O
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	O
receptor	O
-	O
induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	O
interferes	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
signals	O
.	O

Transcriptional	O
down	O
-	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
expression	O
by	O
protein	O
synthesis	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
in	O
a	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O

We	O
show	O
that	O
in	O
the	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
Molt4	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
and	O
protein	O
expression	O
is	O
down	O
-	O
regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
transcription	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

The	O
calcium	O
ionophore	O
-	O
induced	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium	O
-	O
dependent	O
induced	O
gene	O
product	O
.	O

Induction	O
of	O
immediate	O
early	O
response	O
genes	O
by	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	O
normal	O
human	O
monocytes	O
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	O
,	O
cytoskeletal	O
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	O
factor	O
-	O
stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage	B-PRGE
-	I-PRGE
CSF	I-PRGE
(	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
in	O
human	O
monocytes	O
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	O
monocytes	O
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum	O
-	O
containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	O
cells	O
were	O
stimulated	O
with	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	O
cells	O
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
fibronectin	O
receptor	O
,	O
and	O
actin	O
mRNA	O
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

The	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
gene	O
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
addition	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	O
and	O
fibronectin	O
receptor	O
mRNA	O
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	O
specific	O
tyrosine	O
kinase	O
hck	B-PRGE
gene	O
simultaneously	O
with	O
the	O
other	O
immediate	O
early	O
response	O
genes	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super	O
-	O
induced	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
hck	B-PRGE
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
hck	B-PRGE
,	O
and	O
actin	O
genes	O
.	O

Therefore	O
,	O
in	O
normal	O
human	O
monocytes	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
induces	O
immediate	O
early	O
response	O
genes	O
without	O
inducing	O
cell	O
proliferation	O
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	O
.	O

Stimulation	O
of	O
a	O
human	O
T	O
-	O
cell	O
clone	O
with	O
anti	O
-	O
CD3	O
or	O
tumor	O
necrosis	O
factor	O
induces	O
NF	O
-	O
kappa	O
B	O
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-	O
dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	O
enhancer	O
-	O
binding	O
protein	O
NF	O
-	O
kappa	O
B	O
were	O
analyzed	O
in	O
two	O
human	O
T	O
-	O
cell	O
clones	O
stimulated	O
through	O
their	O
T	O
-	O
cell	O
receptor	O
complex	O
or	O
by	O
tumor	O
necrosis	O
factor	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF	O
-	O
kappa	O
B	O
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O

Interleukin	B-PRGE
2	I-PRGE
induced	O
proliferation	O
but	O
not	O
NF	O
-	O
kappa	O
B	O
translocation	O
or	O
LTR	O
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band	O
-	O
shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
is	O
not	O
sufficient	O
to	O
induce	O
HIV	O
enhancer	O
-	O
dependent	O
transcription	O
in	O
cloned	O
T	O
cells	O
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	O
T	O
-	O
cell	O
lines	O
and	O
indicates	O
that	O
normal	O
T	O
lymphocytes	O
differ	O
from	O
tumoral	O
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	O
LTR	O
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T	O
-	O
cell	O
activation	O
,	O
in	O
addition	O
to	O
NF	O
-	O
kappa	O
B	O
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
with	O
the	O
HIV	O
enhancer	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	O
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
binding	O
motifs	O
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	O
control	O
elements	O
and	O
the	O
cellular	O
factors	O
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	O
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	O
early	O
region	O
3	O
(	O
ES	O
)	O
gene	O
products	O
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	O
I	O
MHC	O
antigens	O
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	O
factors	O
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	O
as	O
compared	O
with	O
HeLa	O
cells	O
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	O
promoter	O
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	O
domains	O
referred	O
to	O
as	O
L1	O
and	O
L2	O
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Transfections	O
of	O
E3	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L2	O
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	O
cells	O
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	O
cells	O
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L1	O
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	O
cells	O
and	O
lymphoid	O
cells	O
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	O
cells	O
when	O
coupled	O
to	O
the	O
L2	O
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	O
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	O
promoter	O
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Characterization	O
of	O
defensin	O
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	O
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	O
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP	B-PRGE
/	O
phoQ	B-PRGE
two	O
-	O
component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	O
defensins	O
NP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NP	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	B-PRGE
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	B-PRGE
[	O
membrane	O
sensor	O
kinase	O
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	O
.	O

The	O
predicted	O
periplasmic	O
domain	O
of	O
the	O
PhoQ	B-PRGE
protein	O
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	O
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	O
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	B-PRGE
are	O
polar	O
on	O
phoQ	B-PRGE
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-PRGE
protein	O
in	O
the	O
absence	O
of	O
PhoP	B-PRGE
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B-PRGE
gene	O
product	O
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B-PRGE
without	O
PhoP	B-PRGE
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	O
.	O

This	O
implied	O
that	O
a	O
pag	O
(	O
phoP	O
-	O
activated	O
gene	O
)	O
product	O
is	O
responsible	O
for	O
defensin	O
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	O
NP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
NP	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
and	O
HNP	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
activate	O
pag	O
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP	B-PRGE
-	O
PhoQ	B-PRGE
regulon	O
because	O
mutations	O
in	O
pagC	B-PRGE
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-PRGE
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	O
activation	O
(	O
phenotype	O
PhoPc	O
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	O
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-PRGE
-	O
phoQ	B-PRGE
two	O
-	O
component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	O
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S	O
.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O

Involvement	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
-	O
responsive	O
cells	O
blocked	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-PRGE
immunoglobulin	I-PRGE
enhancer	O
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	O
kinase	O
C	O
-	O
mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte	O
/	O
macrophage	O
-	O
specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
-	O
long	O
terminal	O
repeat	O
(	O
HIV	O
-	O
1	O
-	O
LTR	O
)	O
CAT	B-PRGE
constructs	O
transfected	O
into	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cell	O
lines	O
but	O
not	O
a	O
T	O
cell	O
line	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF	O
-	O
kappa	O
B	O
in	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV	O
-	O
1	O
production	O
from	O
a	O
chronically	O
infected	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cloned	O
cell	O
line	O
,	O
U1	O
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV	O
-	O
1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV	O
-	O
1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV	O
-	O
1	O
RNA	O
and	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV	O
-	O
1	O
production	O
in	O
a	O
cloned	O
T	O
cell	O
line	O
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV	O
-	O
1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Inducible	O
nuclear	O
factor	O
binding	O
to	O
the	O
kappa	O
B	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T	O
-	O
cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	O
factors	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen	O
-	O
inducible	O
DNA	O
-	O
binding	O
complexes	O
,	O
the	O
kappa	O
B	O
complex	O
within	O
the	O
HIV	O
enhancer	O
and	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
complex	O
within	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B	O
-	O
binding	O
activity	O
with	O
the	O
HIV	O
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	O
phytohemagglutinin	O
whereas	O
phorbol	O
myristate	O
acetate	O
-	O
mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	O
B	O
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

Cell	O
-	O
specific	O
differences	O
in	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
regulatory	O
elements	O
of	O
human	O
immunodeficiency	O
virus	O
and	O
beta	O
interferon	O
promoters	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
mRNA	O
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9	O
-	O
IIIB	O
)	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
RNA	O
was	O
undetectable	O
in	O
U937	O
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9	O
-	O
IIIB	O
cells	O
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5	O
-	O
to	O
10	O
-	O
fold	O
increase	O
in	O
the	O
steady	O
-	O
state	O
level	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
RNA	O
in	O
U9	O
-	O
IIIB	O
cells	O
compared	O
with	O
U937	O
cells	O
,	O
suggesting	O
that	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
produced	O
higher	O
levels	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
plasmids	O
linked	O
to	O
regulatory	O
elements	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
the	O
beta	B-PRGE
interferon	I-PRGE
promoter	O
.	O

In	O
U937	O
and	O
Jurkat	O
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	O
promoters	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type	O
-	O
and	O
promoter	O
context	O
-	O
specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	B-PRGE
interferon	I-PRGE
promoter	O
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
multimers	O
of	O
the	O
PRDII	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	O
LTR	O
in	O
T	O
cells	O
,	O
but	O
in	O
monocytic	O
cells	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
did	O
not	O
induce	O
the	O
HIV	O
LTR	O
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

This	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
and	O
viral	O
RNA	O
production	O
in	O
U937	O
cells	O
.	O

However	O
,	O
in	O
Jurkat	O
cells	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV	O
-	O
1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	O
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	O
cells	O
HIV	O
-	O
1	O
multiplication	O
was	O
stimulated	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
treatment	O
.	O

Astrocytes	O
and	O
glioblastoma	O
cells	O
express	O
novel	O
octamer	O
-	O
DNA	O
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
B	O
cell	O
type	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
proteins	O
.	O

The	O
'	O
octamer	O
'	O
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	O
genes	O
in	O
B	O
-	O
lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer	O
-	O
binding	O
protein	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B	O
-	O
cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
seems	O
to	O
control	O
general	O
octamer	O
site	O
-	O
dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin	O
-	O
1	O
and	O
MHC	O
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer	O
-	O
binding	O
proteins	O
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	O
binding	O
proteins	O
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	O
glioblastoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nervous	O
system	O
-	O
derived	O
(	O
N	O
-	O
Oct	O
)	O
proteins	O
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
proteins	O
.	O

The	O
relationship	O
of	O
the	O
N	O
-	O
Oct	O
proteins	O
to	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
proteins	O
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N	O
-	O
Oct	O
-	O
factors	O
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
lymphoid	O
-	O
specific	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
proteins	O
.	O

In	O
melanoma	O
cells	O
that	O
contain	O
the	O
N	B-PRGE
-	I-PRGE
Oct	I-PRGE
-	I-PRGE
3	I-PRGE
factor	O
,	O
a	O
transfected	O
lymphocyte	O
-	O
specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
expression	O
vector	O
.	O

We	O
therefore	O
speculate	O
that	O
N	B-PRGE
-	I-PRGE
Oct	I-PRGE
-	I-PRGE
3	I-PRGE
and	O
other	O
N	O
-	O
Oct	O
factors	O
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Cloning	O
of	O
a	O
mitogen	O
-	O
inducible	O
gene	O
encoding	O
a	O
kappa	O
B	O
DNA	O
-	O
binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	O
oncogene	O
and	O
to	O
cell	O
-	O
cycle	O
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen	O
-	O
inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino	O
-	O
terminal	O
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	O
rel	O
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O

The	O
carboxy	O
-	O
terminal	O
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell	O
-	O
cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	O
oncogene	O
bcl	O
-	O
3	O
and	O
in	O
the	O
ankyrin	O
protein	O
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA	O
-	O
binding	O
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-	O
stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	O
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
proteins	O
was	O
achieved	O
with	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	O
transcription	O
factor	O
or	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	O
cell	O
line	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti	O
-	O
viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV	O
-	O
1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV	O
-	O
2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	O
kappa	O
B	O
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV	O
-	O
2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV	O
-	O
1	O
or	O
HIV	O
-	O
2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	O
kappa	O
B	O
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV	O
-	O
2	O
transcriptional	O
enhancer	O
.	O

Instead	O
of	O
NF	O
kappa	O
B	O
,	O
the	O
activator	B-PRGE
protein	I-PRGE
3	I-PRGE
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV	O
-	O
2	O
.	O

In	O
conclusion	O
,	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV	O
-	O
2	O
than	O
with	O
HIV	O
-	O
1	O
infection	O
.	O

An	O
in	O
vitro	O
globin	O
gene	O
switching	O
model	O
based	O
on	O
differentiated	O
embryonic	O
stem	O
cells	O
.	O

We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	O
gene	O
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES	O
-	O
derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	O
embryonic	O
globin	O
genes	O
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal	O
/	O
adult	O
genes	O
.	O

In	O
addition	O
,	O
the	O
erythroid	O
-	O
specific	O
transcription	O
factor	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	O
in	O
embryoid	O
bodies	O
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	O
epsilon	O
-	O
or	O
beta	O
-	O
globin	O
genes	O
driven	O
by	O
the	O
dominant	O
control	O
region	O
(	O
DCR	O
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
,	O
in	O
contrast	O
to	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	O
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	O
gene	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
.	O

Functional	O
analysis	O
of	O
cis	O
-	O
linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	O
proteins	O
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA	O
-	O
DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
"	O
octamer	O
"	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell	O
-	O
specific	O
transcription	O
.	O

This	O
"	O
octamer	O
"	O
in	O
the	O
context	O
of	O
DRA	O
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	O
(	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
lymphoid	O
-	O
specific	O
(	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
"	O
octamer	O
"	O
binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
"	O
octamer	O
"	O
complex	O
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-	O
acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II	O
-	O
negative	O
HeLa	O
cells	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
"	O
octamer	O
"	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
"	O
octamer	O
"	O
does	O
not	O
utilize	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Characterization	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
-	O
binding	O
proteins	O
from	O
the	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	O
proteins	O
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Among	O
the	O
protein	O
-	O
binding	O
regions	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
is	O
the	O
transcription	O
-	O
enhancer	O
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	B-PRGE
,	O
and	O
one	O
constitutive	O
,	O
C2	B-PRGE
,	O
protein	O
can	O
bind	O
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2	O
+	O
and	O
Zn2	O
+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV	O
-	O
enhancer	O
domain	O
.	O

Both	O
C1	B-PRGE
and	O
C2	B-PRGE
proteins	O
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
-	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
subunit	I-PRGE
enhancer	O
.	O

The	O
inducible	O
C1	B-PRGE
protein	O
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u	O
.	O
v	O
.	O
cross	O
-	O
linking	O
as	O
a	O
47	O
kDa	O
protein	O
.	O

The	O
ubiquitous	O
octamer	O
-	O
binding	O
protein	O
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O

All	O
immunoglobulin	O
genes	O
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer	O
-	O
binding	O
proteins	O
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
yet	O
still	O
express	O
high	O
levels	O
of	O
steady	O
-	O
state	O
immunoglobulin	O
heavy	O
-	O
chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	O
gene	O
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
made	O
from	O
one	O
of	O
these	O
pre	O
-	O
B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	O
gene	O
.	O

Furthermore	O
,	O
OFT	B-PRGE
-	I-PRGE
1	I-PRGE
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
without	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
and	O
that	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
alone	O
is	O
not	O
responsible	O
for	O
the	O
B	O
-	O
cell	O
-	O
specific	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Tax	B-PRGE
-	O
independent	O
binding	O
of	O
multiple	O
cellular	O
factors	O
to	O
Tax	B-PRGE
-	O
response	O
element	O
DNA	O
of	O
HTLV	O
-	O
I	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21	O
-	O
base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	O
(	O
Tax	O
-	O
response	O
element	O
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	O
encoded	O
transactivator	O
protein	O
Tax	B-PRGE
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	O
proteins	O
from	O
C81	O
-	O
66	O
-	O
45	O
cells	O
,	O
an	O
HTLV	O
-	O
I	O
immortalized	O
Tax	B-PRGE
-	O
expressing	O
human	O
T	O
-	O
lymphocyte	O
line	O
(	O
Salahuddin	O
et	O
al	O
.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE	O
-	O
DNA	O
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax	B-PRGE
-	O
protein	O
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O

First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	O
proteins	O
were	O
specifically	O
cross	O
-	O
linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE	O
-	O
DNA	O
fragment	O
.	O

Second	O
,	O
TRE	O
-	O
DNA	O
binding	O
proteins	O
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	O
kD	O
protein	O
was	O
retained	O
on	O
a	O
biotinylated	O
DNA	O
-	O
streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE	O
-	O
DNA	O
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	O
-	O
DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	O
,	O
36	O
to	O
42	O
and	O
110	O
kD	O
proteins	O
and	O
to	O
less	O
extent	O
the	O
50	O
kD	O
factor	O
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I	O
-	O
C	O
)	O
]	O
in	O
all	O
reactions	O
.	O

The	O
cAMP	O
-	O
response	O
element	O
CRE	O
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	O
base	O
-	O
pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein	O
-	O
TRE	O
-	O
DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
'	O
s	O
destroys	O
this	O
complex	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
,	O
CREB	B-PRGE
,	O
is	O
involved	O
in	O
the	O
protein	O
-	O
TRE	O
-	O
DNA	O
complex	O
and	O
in	O
mediating	O
the	O
Tax	B-PRGE
response	O
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	O
factor	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
transcription	O
factor	O
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T	O
-	O
cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
motif	O
that	O
directs	O
transcription	O
of	O
SV40	O
T	O
-	O
antigen	O
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T	O
-	O
lymphocytes	O
upon	O
release	O
of	O
intracellular	O
calcium	O
.	O

By	O
targeting	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
.	O

Besides	O
in	O
T	O
-	O
lymphocytes	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
could	O
also	O
be	O
induced	O
in	O
T	O
-	O
lymphocyte	O
-	O
depleted	O
spleen	O
cells	O
and	O
purified	O
B	O
-	O
lymphocytes	O
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	O
kinase	O
C	O
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
between	O
T	O
-	O
lymphocytes	O
and	O
non	O
-	O
T	O
-	O
lymphocytes	O
was	O
revealed	O
.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV	O
-	O
LTR	O
/	O
tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J	O
.	O
,	O
Hinrichs	O
,	O
S	O
.	O
H	O
.	O
,	O
Reynolds	O
,	O
R	O
.	O
K	O
.	O
,	O
Luciw	O
,	O
P	O
.	O
A	O
.	O
,	O
and	O
Jay	O
,	O
G	O
.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606	O
-	O
611	O
)	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
been	O
shown	O
to	O
bind	O
functional	O
sequences	O
in	O
HIV	O
-	O
LTR	O
suggest	O
a	O
role	O
for	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
dermal	O
activation	O
of	O
the	O
HIV	O
-	O
LTR	O
.	O

Octamer	O
transcription	O
factors	O
and	O
the	O
cell	O
type	O
-	O
specificity	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Antibodies	O
are	O
produced	O
exclusively	O
in	O
B	O
lymphocytes	O
.	O

The	O
expression	O
of	O
the	O
antibody	O
-	O
encoding	O
genes	O
,	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	O
and	O
the	O
enhancer	O
of	O
Ig	O
genes	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue	O
-	O
specific	O
expression	O
.	O

This	O
sequence	O
motif	O
is	O
a	O
binding	O
site	O
for	O
nuclear	O
proteins	O
,	O
the	O
so	O
-	O
called	O
octamer	O
transcription	O
factors	O
(	O
Oct	O
or	O
OTF	O
factors	O
)	O
.	O

The	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2B	I-PRGE
are	O
found	O
mainly	O
in	O
B	O
lymphocytes	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell	O
-	O
specific	O
expression	O
of	O
Ig	O
genes	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type	O
-	O
specific	O
Oct	O
factors	O
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
factors	O
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	O
factor	O
variants	O
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	O
transcript	O
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

Thrombin	B-PRGE
and	O
thrombin	O
receptor	O
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	O
cross	O
-	O
linking	O
for	O
CD69	B-PRGE
expression	O
and	O
interleukin	B-PRGE
2	I-PRGE
production	O
.	O

Thrombin	B-PRGE
stimulation	O
of	O
the	O
T	O
leukemic	O
cell	O
line	O
Jurkat	O
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	O
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	O
fluorophosphate	O
-	O
thrombin	B-PRGE
failed	O
to	O
increase	O
[	O
Ca2	O
+	O
]	O
i	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti	O
-	O
thrombin	B-PRGE
III	I-PRGE
inhibited	O
the	O
thrombin	B-PRGE
-	O
induced	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
synthetic	O
thrombin	O
receptor	O
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-PRGE
for	O
[	O
Ca2	O
+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2	O
+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	B-PRGE
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	O
mass	O
40	O
,	O
42	O
,	O
70	O
,	O
120	O
,	O
and	O
130	O
kDa	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B-PRGE
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2	O
+	O
mobilization	O
.	O

Thrombin	B-PRGE
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	O
kinase	O
C	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B-PRGE
activated	O
the	O
nuclear	O
factor	O
NF	O
-	O
kB	O
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	O
T	O
cell	O
line	O
HPB	O
.	O
ALL	O
and	O
the	O
erythroleukemic	O
cell	O
line	O
K562	O
were	O
responsive	O
to	O
thrombin	B-PRGE
,	O
whereas	O
others	O
such	O
as	O
THP1	O
,	O
a	O
myelomonocytic	O
cell	O
line	O
,	O
and	O
BL2	O
,	O
a	O
Burkitt	O
lymphoma	O
were	O
refractory	O
to	O
thrombin	B-PRGE
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	B-PRGE
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-PRGE
receptor	I-PRGE
mRNA	O
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	O
T	O
cells	O
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-PRGE
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-PRGE
receptor	I-PRGE
mRNA	O
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-PRGE
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B-PRGE
and	O
TRP	O
enhanced	O
CD69	B-PRGE
expression	O
and	O
interleukin	B-PRGE
2	I-PRGE
production	O
induced	O
by	O
T	O
cell	O
receptor	O
cross	O
-	O
linking	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B-PRGE
as	O
a	O
potential	O
regulator	O
of	O
T	O
lymphocyte	O
activation	O
.	O

Sp1	B-PRGE
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	O
CD14	B-PRGE
.	O

CD14	B-PRGE
is	O
a	O
membrane	O
glycoprotein	O
expressed	O
specifically	O
on	O
monocytes	O
and	O
macrophages	O
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	O
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	B-PRGE
gene	O
regulation	O
,	O
the	O
human	O
CD14	B-PRGE
gene	O
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	B-PRGE
digested	O
chromosome	O
5	O
library	O
.	O

A	O
5	O
.	O
5	O
-	O
kilobase	O
genomic	O
clone	O
contained	O
the	O
full	O
-	O
length	O
CD14	B-PRGE
coding	O
sequence	O
and	O
4	O
.	O
2	O
kilobases	O
of	O
5	O
'	O
-	O
upstream	O
sequence	O
.	O

One	O
major	O
and	O
one	O
minor	O
transcription	O
start	O
site	O
were	O
identified	O
101	O
and	O
130	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
,	O
respectively	O
,	O
from	O
the	O
protein	O
translation	O
start	O
ATG	O
.	O

A	O
DNA	O
fragment	O
containing	O
128	O
bp	O
of	O
upstream	O
sequence	O
had	O
strong	O
,	O
monocyte	O
-	O
specific	O
promoter	O
activity	O
in	O
the	O
CD14	B-PRGE
positive	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	O
cell	O
lines	O
HeLa	O
and	O
REX	O
.	O

Four	O
regions	O
in	O
this	O
DNA	O
fragment	O
interact	O
with	O
nuclear	O
proteins	O
isolated	O
from	O
monocytic	O
cells	O
.	O

The	O
Sp1	B-PRGE
transcription	O
factor	O
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	B-PRGE
promoter	O
.	O

Mutation	O
of	O
the	O
major	O
Sp1	B-PRGE
binding	O
site	O
(	O
-	O
110	O
bp	O
)	O
decreased	O
tissue	O
-	O
specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	B-PRGE
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
CD14	B-PRGE
in	O
monocytic	O
cells	O
.	O

CD14	B-PRGE
Sp1	B-PRGE
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105	O
-	O
kDa	O
Sp1	B-PRGE
species	O
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	O
than	O
non	O
-	O
monocytic	O
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	B-PRGE
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	B-PRGE
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	O
factor	O
kappa	O
B	O
with	O
predominance	O
of	O
p50	B-PRGE
homodimers	O
.	O

Stimulation	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	O
like	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng	O
/	O
ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram	O
/	O
ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	O
gene	O
is	O
minimal	O
,	O
i	O
.	O
e	O
.	O
the	O
cells	O
are	O
tolerant	O
.	O

In	O
nuclear	O
run	O
-	O
on	O
analysis	O
,	O
such	O
tolerant	O
cells	O
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	B-PRGE
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up	O
-	O
regulated	O
(	O
not	O
down	O
-	O
regulated	O
)	O
in	O
tolerant	O
cells	O
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	O
cells	O
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Resolution	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	O
protein	O
,	O
mobilized	O
in	O
naive	O
Mono	O
Mac	O
6	O
cells	O
,	O
consists	O
mainly	O
of	O
p50	B-PRGE
-	O
p65	B-PRGE
heterodimers	O
,	O
while	O
in	O
tolerant	O
cells	O
,	O
the	O
p50	B-PRGE
homodimer	O
is	O
predominant	O
.	O

This	O
increase	O
in	O
p50	B-PRGE
homodimers	O
coincides	O
with	O
an	O
increase	O
in	O
p105	B-PRGE
mRNA	O
,	O
suggestive	O
of	O
a	O
transcriptional	O
up	O
-	O
regulation	O
of	O
p50	B-PRGE
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
mobilized	O
in	O
tolerant	O
cells	O
is	O
functionally	O
inactive	O
in	O
that	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
luciferase	O
constructs	O
containing	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
or	O
the	O
TNF	O
5	O
'	O
-	O
region	O
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

Similar	O
to	O
Mono	O
Mac	O
6	O
cells	O
,	O
primary	O
blood	O
monocytes	O
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	O
after	O
LPS	O
stimulation	O
.	O

The	O
tolerant	O
blood	O
monocytes	O
also	O
up	O
-	O
regulate	O
CD14	B-PRGE
,	O
and	O
they	O
mobilize	O
NF	O
-	O
kappa	O
B	O
with	O
a	O
predominance	O
of	O
p50	B-PRGE
homodimers	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post	O
-	O
receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

Evidence	O
for	O
a	O
trans	O
-	O
acting	O
activator	O
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	O
CD5	B-PRGE
antigen	O
.	O

Interspecies	O
somatic	O
cell	O
hybrids	O
were	O
generated	O
by	O
fusing	O
the	O
mouse	O
T	O
-	O
lymphoma	O
cell	O
line	O
,	O
BW5147	O
,	O
with	O
normal	O
human	O
T	O
lymphocytes	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O

Thymocytes	O
,	O
activated	O
peripheral	O
T	O
lymphocytes	O
,	O
or	O
an	O
activated	O
T	O
-	O
cell	O
clone	O
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	O
lost	O
CD5	B-PRGE
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	B-PRGE
expression	O
was	O
due	O
neither	O
to	O
segregation	O
of	O
human	O
autosome	O
11	O
,	O
on	O
which	O
the	O
CD5	B-PRGE
gene	O
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	B-PRGE
structural	O
gene	O
.	O

Furthermore	O
,	O
loss	O
of	O
CD5	B-PRGE
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	O
.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non	O
-	O
syntenic	O
trans	O
-	O
active	O
locus	O
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	O
CD5	B-PRGE
gene	O
.	O

Alpha	O
-	O
tocopherol	O
inhibits	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	O
human	O
endothelial	O
cells	O
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti	O
-	O
atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Human	O
umbilical	O
vein	O
ECs	O
were	O
pretreated	O
with	O
alpha	O
-	O
tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL	O
-	O
1	O
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
thrombin	O
(	O
30	O
U	O
/	O
ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

Agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
alpha	O
-	O
tcp	O
.	O

The	O
IC50	O
of	O
alpha	O
-	O
tcp	O
on	O
an	O
IL	O
-	O
1	O
-	O
induced	O
response	O
was	O
45	O
microM	O
.	O

The	O
inhibition	O
correlated	O
with	O
a	O
decrease	O
in	O
steady	O
state	O
levels	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	O
antibody	O
to	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N	O
-	O
acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha	O
-	O
tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	O
substrates	O
was	O
observed	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
expression	O
in	O
EC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha	O
-	O
tcp	O
-	O
induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	O
factor	O
after	O
cytokine	O
stimulation	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha	O
-	O
tcp	O
acts	O
as	O
an	O
anti	O
-	O
atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
-	O
-	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha	O
-	O
tcp	O
.	O

Upregulation	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
by	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	B-PRGE
:	O
a	O
B	O
-	O
cell	O
-	O
specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
to	O
induction	O
of	O
cell	O
surface	O
markers	O
.	O

An	O
ability	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	B-PRGE
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	O
of	O
the	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1	B-PRGE
+	O
clones	O
(	O
S	O
.	O
Henderson	O
,	O
M	O
.	O
Rowe	O
,	O
C	O
.	O
Gregory	O
,	O
F	O
.	O
Wang	O
,	O
E	O
.	O
Kieff	O
,	O
and	O
A	O
.	O
Rickinson	O
,	O
Cell	O
65	O
:	O
1107	O
-	O
1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B-PRGE
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B-PRGE
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B-PRGE
-	O
induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
and	O
upregulation	O
of	O
the	O
cell	O
adhesion	O
molecule	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B-PRGE
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B	O
-	O
cell	O
lines	O
carrying	O
an	O
LMP1	B-PRGE
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	O
to	O
express	O
LMP1	B-PRGE
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK	O
-	O
kappa	O
B	O
and	O
upregulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B-PRGE
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B	O
-	O
cell	O
lines	O
tested	O
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
LMP1	B-PRGE
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non	O
-	O
B	O
-	O
cell	O
lines	O
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

We	O
therefore	O
conclude	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	B-PRGE
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B-PRGE
signal	O
transduction	O
,	O
other	O
cell	O
-	O
specific	O
factors	O
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	O
protein	O
.	O

CD14	B-PRGE
-	O
mediated	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	O
kinase	O
activity	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

CD14	B-PRGE
,	O
a	O
glycosylphosphatidylinositol	O
-	O
linked	O
antigen	O
,	O
functions	O
as	O
an	O
LPS	O
signaling	O
receptor	O
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B-PRGE
,	O
which	O
has	O
no	O
transmembrane	O
domain	O
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	B-PRGE
-	O
mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor	O
-	O
associated	O
tyrosine	O
kinase	O
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Wild	O
-	O
type	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-	O
K1	O
cells	O
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	O
with	O
human	O
CD14	B-PRGE
(	O
CHO	O
/	O
CD14	B-PRGE
)	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS	O
-	O
inducible	O
responses	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO	O
/	O
CD14	B-PRGE
cells	O
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
to	O
the	O
CD14	B-PRGE
receptor	O
system	O
.	O

LPS	O
-	O
stimulated	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO	O
/	O
CD14	B-PRGE
cells	O
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	O
cytokines	O
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO	O
/	O
CD14	B-PRGE
or	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
demonstrating	O
that	O
NF	O
-	O
kappa	O
B	O
translocation	O
is	O
an	O
early	O
event	O
.	O

Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
LPS	O
-	O
induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO	O
/	O
CD14	B-PRGE
cells	O
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CHO	O
/	O
CD14	B-PRGE
or	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS	O
-	O
induced	O
TK	O
activity	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	B-PRGE
-	O
mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Regulation	O
of	O
CD14	B-PRGE
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

CD14	B-PRGE
,	O
a	O
monocyte	O
/	O
macrophage	O
receptor	O
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	O
binding	O
protein	O
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	B-PRGE
expression	O
during	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up	O
-	O
regulation	O
of	O
CD14	B-PRGE
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B-PRGE
induction	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	B-PRGE
5	O
'	O
upstream	O
sequence	O
and	O
demonstrated	O
its	O
tissue	O
-	O
specific	O
promoter	O
activity	O
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	O
U937	O
cell	O
line	O
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	B-PRGE
5	O
'	O
upstream	O
sequence	O
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	O
-	O
128	O
to	O
-	O
70	O
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	B-PRGE
expression	O
.	O

This	O
region	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
Sp1	B-PRGE
transcription	O
factor	O
.	O

A	O
3	O
-	O
bp	O
mutation	O
at	O
the	O
distal	O
Sp1	B-PRGE
-	O
binding	O
site	O
not	O
only	O
eliminates	O
Sp1	B-PRGE
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B-PRGE
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	O
detect	O
a	O
direct	O
interaction	O
of	O
the	O
CD14	B-PRGE
distal	O
Sp1	B-PRGE
-	O
binding	O
site	O
with	O
the	O
vitamin	B-PRGE
D3	I-PRGE
receptor	I-PRGE
and	O
its	O
partner	O
,	O
the	O
retinoid	O
X	O
receptor	O
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	B-PRGE
indirectly	O
through	O
some	O
intermediary	O
factor	O
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	B-PRGE
in	O
this	O
process	O
.	O

Calcium	O
signalling	O
in	O
T	O
cells	O
stimulated	O
by	O
a	O
cyclophilin	B-PRGE
B	I-PRGE
-	O
binding	O
protein	O
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium	O
-	O
dependent	O
signal	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
that	O
normally	O
leads	O
to	O
T	O
-	O
cell	O
activation	O
.	O

When	O
bound	O
to	O
cyclophilin	O
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	O
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-PRGE
B	I-PRGE
-	O
binding	O
-	O
proteins	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
,	O
by	O
activating	O
the	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factors	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
IL2A	O
.	O

This	O
protein	O
,	O
termed	O
calcium	B-PRGE
-	I-PRGE
signal	I-PRGE
modulating	I-PRGE
cyclophilin	I-PRGE
ligand	I-PRGE
(	O
CAML	B-PRGE
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	O
and	O
upstream	O
of	O
calcineurin	O
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O

CAML	B-PRGE
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium	O
-	O
signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B-PRGE
B	I-PRGE
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O

Antioxidants	O
inhibit	O
monocyte	O
adhesion	O
by	O
suppressing	O
nuclear	O
factor	O
-	O
kappa	O
B	O
mobilization	O
and	O
induction	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
in	O
endothelial	O
cells	O
stimulated	O
to	O
generate	O
radicals	O
.	O

Cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
)	O
is	O
due	O
to	O
induction	O
of	O
surface	O
receptors	O
,	O
such	O
as	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

The	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
specifically	O
inhibits	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Since	O
kappa	O
B	O
motifs	O
are	O
present	O
in	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
promoters	O
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
TNF	B-PRGE
-	O
treated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

PDTC	O
or	O
N	O
-	O
acetylcysteine	O
dose	O
dependently	O
reduced	O
TNF	B-PRGE
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
not	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
surface	O
protein	O
(	O
also	O
in	O
human	O
umbilical	O
arterial	O
endothelial	O
cells	O
)	O
and	O
mRNA	O
expression	O
(	O
by	O
70	O
%	O
at	O
100	O
mumol	O
/	O
L	O
PDTC	O
)	O
in	O
HUVECs	O
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O

Gel	O
-	O
shift	O
analysis	O
in	O
HUVECs	O
demonstrated	O
that	O
PDTC	O
prevented	O
NF	O
-	O
kappa	O
B	O
mobilization	O
by	O
TNF	B-PRGE
,	O
suggesting	O
that	O
only	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
was	O
controlled	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

Since	O
HUVECs	O
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	B-PRGE
,	O
and	O
H2O2	O
induces	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

Although	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	O
oxidase	O
(	O
apocynin	O
)	O
or	O
cytochrome	O
P	O
-	O
450	O
(	O
SKF525a	O
)	O
suppressed	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
by	O
TNF	B-PRGE
,	O
revealing	O
that	O
several	O
radical	O
-	O
generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O

PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	O
U937	O
cells	O
to	O
TNF	B-PRGE
-	O
treated	O
HUVECs	O
(	O
by	O
75	O
%	O
at	O
100	O
mumol	O
/	O
L	O
PDTC	O
)	O
.	O

Inhibition	O
by	O
anti	O
-	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
monoclonal	O
antibody	O
1G11	O
indicated	O
that	O
U937	O
adhesion	O
was	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inducible	O
binding	O
to	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine	O
-	O
containing	O
protein	O
.	O

The	O
proto	O
-	O
oncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
is	O
an	O
immediate	O
-	O
early	O
gene	O
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

Fos	B-PRGE
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand	O
-	O
receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

The	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
in	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
regulatory	O
region	O
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	O
factors	O
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	O
complex	O
(	O
Band	O
A	O
)	O
binds	O
to	O
SRE	O
DNA	O
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	O
PBL	O
-	O
T	O
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O

Band	O
A	O
contains	O
the	O
serum	O
response	O
factor	O
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	O
PBL	O
-	O
T	O
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	O
A	O
to	O
the	O
SRE	O
motif	O
.	O

Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	O
longer	O
prevents	O
binding	O
of	O
DNA	O
by	O
Band	O
A	O
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein	O
-	O
protein	O
interaction	O
.	O

Steel	B-PRGE
factor	I-PRGE
affects	O
SCL	B-PRGE
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	B-PRGE
factor	I-PRGE
is	O
one	O
of	O
the	O
growth	O
factors	O
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
and	O
SCL	B-PRGE
,	O
also	O
known	O
as	O
Tcl	B-PRGE
-	I-PRGE
5	I-PRGE
or	O
Tal	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	B-PRGE
in	O
the	O
proliferation	O
of	O
human	O
peripheral	O
blood	O
burst	O
-	O
forming	O
unit	O
-	O
erythroid	O
(	O
BFU	O
-	O
E	O
)	O
and	O
the	O
effects	O
of	O
Steel	B-PRGE
factor	I-PRGE
on	O
SCL	B-PRGE
expression	O
in	O
proliferating	O
erythroid	O
cells	O
.	O

BFU	O
-	O
E	O
-	O
derived	O
colonies	O
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10	O
-	O
fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	B-PRGE
protein	O
levels	O
in	O
BFU	O
-	O
E	O
-	O
derived	O
cells	O
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	B-PRGE
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	B-PRGE
mRNA	O
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	B-PRGE
protein	O
observed	O
.	O

The	O
role	O
of	O
SCL	B-PRGE
in	O
Steel	B-PRGE
factor	I-PRGE
-	O
induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU	O
-	O
E	O
-	O
derived	O
colonies	O
cultured	O
with	O
Steel	B-PRGE
factor	I-PRGE
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	O
precursors	O
cultured	O
with	O
Steel	B-PRGE
factor	I-PRGE
,	O
SCL	B-PRGE
protein	O
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	O
in	O
SCL	B-PRGE
protein	O
levels	O
in	O
early	O
erythroid	O
precursors	O
stimulated	O
with	O
Steel	B-PRGE
factor	I-PRGE
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B-PRGE
factor	I-PRGE
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	B-PRGE
mRNA	O
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	B-PRGE
factor	I-PRGE
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	B-PRGE
protein	O
observed	O
in	O
response	O
to	O
Steel	B-PRGE
.	O

Cross	O
-	O
linking	O
CD40	B-PRGE
on	O
B	O
cells	O
rapidly	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

The	O
B	O
cell	O
-	O
associated	O
surface	O
molecule	O
CD40	B-PRGE
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross	O
-	O
linking	O
CD40	B-PRGE
on	O
B	O
cells	O
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	O
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	B-PRGE
cross	O
-	O
linking	O
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
transcription	O
factors	O
are	O
activated	O
after	O
cross	O
-	O
linking	O
CD40	B-PRGE
on	O
resting	O
human	O
tonsillar	O
B	O
cells	O
and	O
on	O
B	O
cell	O
lines	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	B-PRGE
,	O
p65	B-PRGE
(	O
RelA	B-PRGE
)	O
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross	O
-	O
linking	O
CD40	B-PRGE
supports	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	B-PRGE
signaling	O
and	O
suggest	O
that	O
the	O
CD40	B-PRGE
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	O
cell	O
-	O
associated	O
genes	O
with	O
NF	O
-	O
kappa	O
B	O
consensus	O
sites	O
.	O

Separation	O
of	O
oxidant	O
-	O
initiated	O
and	O
redox	O
-	O
regulated	O
steps	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli	O
-	O
specific	O
pathways	O
through	O
which	O
cytokines	O
(	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
distinguish	O
the	O
stimuli	O
-	O
specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
only	O
one	O
of	O
two	O
human	O
T	O
-	O
cell	O
lines	O
(	O
Wurzburg	O
but	O
not	O
Jurkat	O
)	O
,	O
whereas	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox	O
-	O
regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
(	O
in	O
which	O
oxidants	O
don	O
'	O
t	O
activate	O
NF	O
-	O
kappa	O
B	O
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	O
-	O
stimulated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Transcription	O
-	O
independent	O
turnover	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
levels	O
.	O

We	O
identified	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
as	O
an	O
immediate	O
-	O
early	O
gene	O
in	O
human	O
monocytes	O
that	O
is	O
expressed	O
in	O
response	O
to	O
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
protein	O
is	O
markedly	O
diminished	O
but	O
is	O
rapidly	O
replaced	O
in	O
a	O
cycloheximide	O
-	O
sensitive	O
manner	O
within	O
20	O
min	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
protein	O
is	O
simultaneous	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
transcription	O
factors	O
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O

The	O
demonstration	O
that	O
NF	O
-	O
kappa	O
B	O
can	O
regulate	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady	O
-	O
state	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
.	O

Nuclear	O
run	O
-	O
on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate	O
-	O
early	O
cytokine	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
gene	O
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
transcription	O
remained	O
constant	O
.	O

The	O
adherence	O
-	O
dependent	O
increase	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	O
stabilization	O
events	O
.	O

Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	O
monocytes	O
,	O
cytoplasmic	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
did	O
not	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
levels	O
.	O

We	O
propose	O
that	O
adherent	O
monocytes	O
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
transcription	O
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
without	O
stimulating	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
transcription	O
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
mRNA	O
are	O
maintained	O
by	O
a	O
translation	O
-	O
dependent	O
degradation	O
mechanism	O
.	O

E2F	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
a	O
cyclin	O
-	O
like	O
DNA	O
repair	O
enzyme	O
,	O
uracil	B-PRGE
-	I-PRGE
DNA	I-PRGE
glycosylase	I-PRGE
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	O
cycle	O
-	O
dependent	O
transcription	O
factor	O
,	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
regulates	O
the	O
cyclin	O
-	O
like	O
species	O
of	O
the	O
DNA	O
repair	O
enzyme	O
uracil	B-PRGE
-	I-PRGE
DNA	I-PRGE
glycosylase	I-PRGE
(	O
UDG	B-PRGE
)	O
gene	O
in	O
human	O
osteosarcoma	O
(	O
Saos	O
-	O
2	O
)	O
cells	O
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	O
UDG	B-PRGE
promoter	O
sequences	O
,	O
that	O
expression	O
of	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
activates	O
the	O
UDG	B-PRGE
promoter	O
through	O
several	O
E2F	O
sites	O
.	O

The	O
major	O
putative	O
downstream	O
site	O
for	O
E2F	O
,	O
located	O
in	O
the	O
first	O
exon	O
,	O
serves	O
as	O
a	O
target	O
for	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
DP1	B-PRGE
complex	O
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin	O
-	O
like	O
UDG	B-PRGE
gene	O
product	O
and	O
E2F	O
.	O

High	O
levels	O
of	O
UDG	B-PRGE
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	O
specific	O
for	O
E2F	O
-	O
mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	B-PRGE
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	O
.	O

This	O
implicates	O
E2F	O
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B-PRGE
on	O
E2F	O
-	O
mediated	O
transcriptional	O
activity	O
.	O

Aspirin	O
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	O
kappa	O
B	O
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel	O
-	O
shift	O
analyses	O
demonstrated	O
dose	O
-	O
dependent	O
inhibition	O
of	O
TNF	B-PRGE
-	O
induced	O
NF	O
-	O
kappa	O
B	O
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol	O
/	O
L	O
.	O

Induction	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
surface	O
expression	O
by	O
TNF	B-PRGE
was	O
dose	O
-	O
dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
was	O
hardly	O
affected	O
.	O

Aspirin	O
appeared	O
to	O
prevent	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
,	O
since	O
it	O
dose	O
-	O
dependently	O
inhibited	O
induction	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
by	O
TNF	B-PRGE
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	O
monocytes	O
to	O
TNF	B-PRGE
-	O
stimulated	O
HUVECs	O
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
upregulation	O
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	O
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF	O
-	O
kappa	O
B	O
mobilization	O
,	O
induction	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	B-PRGE
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Danazol	O
decreases	O
transcription	O
of	O
estrogen	B-PRGE
receptor	I-PRGE
gene	O
in	O
human	O
monocytes	O
.	O

1	O
.	O

Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	B-PRGE
receptor	I-PRGE
(	O
ER	B-PRGE
)	O
and	O
its	O
mRNA	O
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	O
.	O

2	O
.	O

Danazol	O
did	O
not	O
alter	O
the	O
degradation	O
rate	O
of	O
ER	B-PRGE
mRNA	O
in	O
monocytes	O
.	O

3	O
.	O

Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B-PRGE
gene	O
to	O
approximately	O
50	O
%	O
in	O
monocytes	O
in	O
a	O
run	O
-	O
on	O
assay	O
.	O

4	O
.	O

Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	B-PRGE
gene	O
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	B-PRGE
mRNA	O
and	O
ER	B-PRGE
expressions	O
in	O
monocytes	O
.	O

Cross	O
-	O
linking	O
of	O
CD30	B-PRGE
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	O
cells	O
.	O

CD30	B-PRGE
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
)	O
-	O
1	O
.	O

We	O
demonstrate	O
that	O
cross	O
-	O
linking	O
CD30	B-PRGE
with	O
an	O
anti	O
-	O
CD30	B-PRGE
-	O
specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-PRGE
ligand	I-PRGE
(	O
CD30L	B-PRGE
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	B-PRGE
cross	O
-	O
linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH	O
-	O
2	O
cells	O
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	B-PRGE
alpha	I-PRGE
/	O
beta	B-PRGE
.	O

Furthermore	O
,	O
cross	O
-	O
linking	O
of	O
CD30	B-PRGE
leads	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	B-PRGE
-	O
CD30L	B-PRGE
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B	O
-	O
dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	O
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4	B-PRGE
+	O
T	O
cells	O
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor	O
-	O
ligand	O
interactions	O
.	O

Integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	O
message	O
induction	O
in	O
monocytic	O
cells	O
.	O

A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-PRGE
tyrosine	O
kinase	O
.	O

Activation	O
of	O
cytoplasmic	O
tyrosine	O
kinases	O
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	O
.	O

In	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
,	O
either	O
integrin	O
-	O
dependent	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
ligation	O
of	O
beta	B-PRGE
1	I-PRGE
integrins	I-PRGE
with	O
antibodies	O
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65	O
-	O
75	O
and	O
120	O
-	O
125	O
kDa	O
.	O

In	O
addition	O
,	O
integrin	O
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-PRGE
and	O
p65	B-PRGE
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
,	O
to	O
activation	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
containing	O
NF	O
-	O
kappa	O
B	O
sites	O
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	O
for	O
immediate	O
-	O
early	O
genes	O
,	O
including	O
the	O
cytokine	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B-PRGE
,	O
pp125FAK	B-PRGE
,	O
and	O
the	O
SH2	O
domain	O
containing	O
tyrosine	O
kinase	O
Syk	B-PRGE
.	O

In	O
contrast	O
,	O
integrin	O
ligation	O
with	O
antibodies	O
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B-PRGE
but	O
not	O
of	O
FAK	O
or	O
paxillin	B-PRGE
.	O

In	O
adhering	O
cells	O
,	O
pre	O
-	O
treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	O
and	O
paxillin	B-PRGE
but	O
not	O
of	O
Syk	B-PRGE
,	O
while	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
message	O
induction	O
is	O
unaffected	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	B-PRGE
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	O
signaling	O
pathway	O
in	O
monocytic	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
to	O
increased	O
levels	O
of	O
cytokine	O
messages	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine	O
-	O
induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	O
molecules	O
and	O
proinflammatory	O
cytokines	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine	O
-	O
stimulated	O
human	O
saphenous	O
vein	O
endothelial	O
cells	O
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

In	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
by	O
35	O
-	O
55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	O
adhesion	O
molecules	O
(	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
secretable	O
cytokines	O
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L	O
-	O
N	O
-	O
monomethyl	O
-	O
arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
did	O
not	O
augment	O
cytokine	O
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
reporter	O
gene	O
constructs	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
propose	O
that	O
NO	O
'	O
s	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-PRGE
epitopes	O
.	O

The	O
CD4	B-PRGE
coreceptor	O
interacts	O
with	O
non	O
-	O
polymorphic	O
regions	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
on	O
antigen	O
-	O
presenting	O
cells	O
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-PRGE
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
which	O
recognize	O
different	O
CD4	B-PRGE
epitopes	O
.	O

We	O
demonstrate	O
that	O
CD4	B-PRGE
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF	O
-	O
AT	O
transcription	O
factor	O
which	O
is	O
required	O
for	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
.	O

Whereas	O
different	O
anti	O
-	O
CD4	B-PRGE
mAb	O
or	O
HIV	O
-	O
1	O
gp120	B-PRGE
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	B-PRGE
and	O
p59fyn	B-PRGE
and	O
phosphorylation	O
of	O
the	O
Shc	O
adaptor	O
protein	O
,	O
which	O
mediates	O
signals	O
to	O
Ras	O
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF	O
-	O
AT	O
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF	O
-	O
AT	O
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	O
on	O
the	O
CD4	B-PRGE
coreceptor	O
involved	O
in	O
activation	O
of	O
the	O
Ras	O
/	O
protein	O
kinase	O
C	O
and	O
calcium	O
pathways	O
.	O

Lipopolysaccharide	O
-	O
induced	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal	O
/	O
permeability	O
-	O
increasing	O
protein	O
.	O

Endothelial	O
cells	O
stimulated	O
by	O
LPS	O
express	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	O
adhesion	O
during	O
inflammation	O
.	O

E	B-PRGE
-	I-PRGE
selectin	I-PRGE
is	O
induced	O
within	O
1	O
-	O
2	O
h	O
,	O
peaks	O
at	O
4	O
-	O
6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	O
,	O
a	O
recombinant	O
N	O
-	O
terminal	O
fragment	O
of	O
human	O
bactericidal	B-PRGE
/	I-PRGE
permeability	I-PRGE
-	I-PRGE
increasing	I-PRGE
protein	I-PRGE
(	O
BPI	B-PRGE
)	O
,	O
inhibited	O
LPS	O
-	O
induced	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	O
also	O
affected	O
LPS	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF	O
-	O
kappa	O
B	O
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	O
resulted	O
in	O
marked	O
reduction	O
of	O
NF	O
-	O
kappa	O
B	O
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	O
acts	O
to	O
reverse	O
LPS	O
-	O
mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on	O
-	O
going	O
LPS	O
signal	O
.	O

Costimulation	O
of	O
human	O
CD4	B-PRGE
+	O
T	O
cells	O
with	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
B7	B-PRGE
induce	O
distinct	O
effects	O
on	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	O
CD4	B-PRGE
+	O
T	O
cells	O
with	O
SEA	O
presented	O
on	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-	O
DR	O
transfectants	O
coexpressing	O
either	O
B7	B-PRGE
or	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
resulted	O
in	O
distinct	O
cytokine	O
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	B-PRGE
,	O
but	O
not	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
strongly	O
costimulated	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

Maximal	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
was	O
recorded	O
with	O
CHO	O
-	O
DR	O
/	O
B7	B-PRGE
/	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	B-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
at	O
the	O
transcriptional	O
level	O
.	O

Gel	O
-	O
shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4	B-PRGE
+	O
T	O
cells	O
with	O
CHO	O
-	O
DR	O
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP	O
-	O
1	O
binding	O
proteins	O
required	O
costimulation	O
.	O

LFA	B-PRGE
-	I-PRGE
3	I-PRGE
induced	O
moderate	O
levels	O
of	O
AP	O
-	O
1	O
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
while	O
B7	B-PRGE
costimulation	O
strongly	O
induced	O
both	O
AP	O
-	O
1	O
and	O
substantially	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
.	O

The	O
CHO	O
-	O
DR	O
/	O
B7	B-PRGE
/	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
triple	O
transfectant	O
induced	O
a	O
further	O
increase	O
in	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
compared	O
with	O
the	O
double	O
transfectants	O
.	O

The	O
level	O
of	O
Oct	O
-	O
1	O
binding	O
proteins	O
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super	O
-	O
shift	O
analysis	O
revealed	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
of	O
costimulated	O
CD4	B-PRGE
+	O
T	O
cells	O
contained	O
large	O
amounts	O
of	O
p50	B-PRGE
,	O
substantial	O
amounts	O
of	O
p65	B-PRGE
,	O
and	O
marginal	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
proteins	O
.	O

The	O
AP	O
-	O
1	O
binding	O
proteins	O
contained	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
Jun	B-PRGE
-	I-PRGE
D	I-PRGE
,	O
and	O
Fra	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
marginal	O
amounts	O
of	O
Jun	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
costimulation	O
on	O
the	O
activity	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	B-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
costimulation	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Regulation	O
of	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
expression	O
in	O
endothelial	O
cells	O
by	O
cyclosporin	O
A	O
and	O
the	O
T	O
-	O
cell	O
transcription	O
factor	O
NFAT	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
was	O
originally	O
described	O
as	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
athat	O
supported	O
the	O
activation	O
of	O
cytokine	O
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	O
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

As	O
we	O
observed	O
that	O
activated	O
endothelial	O
cells	O
also	O
expressed	O
NFAT	O
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	O
cells	O
.	O

Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
gene	O
regulatory	O
elements	O
that	O
use	O
NFAT	O
by	O
60	O
%	O
.	O

CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65	O
%	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
mRNA	O
and	O
protein	O
expression	O
in	O
activated	O
endothelial	O
cells	O
.	O

CsA	O
also	O
suppressed	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
but	O
not	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
expression	O
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
promoter	O
is	O
activated	O
by	O
NF	O
-	O
kappa	O
B	O
rather	O
than	O
NFAT	O
.	O

Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	O
adhesion	O
molecule	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	O
adhesion	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	O
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	O
structure	O
level	O
,	O
as	O
DNasel	B-PRGE
hypersensitive	O
sites	O
within	O
both	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
enhancer	O
and	O
the	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
promoter	O
were	O
suppressed	O
by	O
CsA	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Signalling	O
via	O
CD28	B-PRGE
of	O
human	O
naive	O
neonatal	O
T	O
lymphocytes	O
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B-PRGE
in	O
modulating	O
the	O
'	O
naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti	O
-	O
CD2	O
-	O
mediated	O
activation	O
.	O

To	O
compare	O
the	O
role	O
of	O
CD28	B-PRGE
,	O
neonatal	O
and	O
adult	O
T	O
cells	O
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	O
anti	O
-	O
CD2	O
antibodies	O
in	O
the	O
presence	O
or	O
absence	O
of	O
anti	O
-	O
CD28	B-PRGE
MoAb	O
.	O

With	O
anti	O
-	O
CD2	O
alone	O
,	O
neonatal	O
T	O
cells	O
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
whereas	O
adult	O
T	O
cells	O
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Costimulation	O
with	O
anti	O
-	O
CD28	B-PRGE
MoAb	O
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	O
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	O
T	O
cells	O
,	O
whereas	O
adult	O
T	O
cells	O
showed	O
only	O
slight	O
increases	O
.	O

Although	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti	O
-	O
CD28	B-PRGE
MoAb	O
,	O
neonatal	O
T	O
cell	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O

In	O
contrast	O
,	O
enhancement	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O

Anti	O
-	O
CD28	B-PRGE
MoAb	O
costimulation	O
increased	O
NF	O
kappa	O
B	O
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	O
T	O
lymphocytes	O
to	O
anti	O
-	O
CD2	O
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	O
kappa	O
B	O
induction	O
,	O
reduced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
expression	O
and	O
deficient	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Although	O
anti	O
-	O
CD28	B-PRGE
MoAb	O
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

N	O
-	O
and	O
C	O
-	O
terminal	O
sequences	O
control	O
degradation	O
of	O
MAD3	B-PRGE
/	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
in	O
response	O
to	O
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	O
protein	O
MAD3	B-PRGE
/	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
protein	O
in	O
stable	O
transfectants	O
of	O
mouse	O
70Z	O
/	O
3	O
cells	O
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	O
inhibitor	O
N	O
-	O
Ac	O
-	O
Leu	O
-	O
Leu	O
-	O
norleucinal	O
inhibits	O
this	O
ligand	O
-	O
induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
protein	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	O
line	O
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand	O
-	O
induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	O
terminus	O
of	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
molecule	O
up	O
to	O
amino	O
acid	O
279	O
abolishes	O
constitutive	O
but	O
not	O
ligand	O
-	O
inducible	O
phosphorylation	O
and	O
inhibits	O
ligand	O
-	O
inducible	O
degradation	O
.	O

Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
maps	O
to	O
two	O
serines	O
in	O
the	O
N	O
terminus	O
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand	O
-	O
induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Transcriptional	O
repression	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp	B-PRGE
/	O
AP	O
-	O
1	O
complex	O
formation	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
.	O

T	O
-	O
lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
Jurkat	O
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
the	O
vitamin	B-PRGE
D3	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3	O
-	O
mediated	O
repression	O
of	O
activated	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
cotransfecting	O
Jurkat	O
cells	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
/	O
reporter	O
constructs	O
and	O
a	O
VDR	B-PRGE
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40	O
-	O
bp	O
region	O
encompassing	O
an	O
important	O
positive	O
regulatory	O
element	O
,	O
NF	B-PRGE
-	I-PRGE
AT	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
is	O
bound	O
by	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
,	O
NFATp	B-PRGE
,	O
as	O
well	O
as	O
by	O
AP	O
-	O
1	O
.	O

VDR	B-PRGE
DNA	O
-	O
binding	O
mutants	O
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-PRGE
DNA	O
-	O
binding	O
domain	O
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-PRGE
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
repression	O
.	O

By	O
combining	O
partially	O
purified	O
proteins	O
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp	B-PRGE
/	O
AP	O
-	O
1	O
-	O
DNA	O
complex	O
upon	O
inclusion	O
of	O
VDR	B-PRGE
or	O
VDR	B-PRGE
-	O
retinoid	O
X	O
receptor	O
.	O

Order	O
of	O
addition	O
and	O
off	O
-	O
rate	O
experiments	O
indicate	O
that	O
the	O
VDR	B-PRGE
-	O
retinoid	O
X	O
receptor	O
heterodimer	O
blocks	O
NFATp	B-PRGE
/	O
AP	O
-	O
1	O
complex	O
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF	B-PRGE
-	I-PRGE
AT	I-PRGE
-	I-PRGE
1	I-PRGE
element	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	O
activators	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

An	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
sequence	O
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-PRGE
Fc	I-PRGE
receptor	I-PRGE
type	I-PRGE
IC	I-PRGE
gene	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Expression	O
of	O
the	O
IgG	B-PRGE
Fc	I-PRGE
receptor	I-PRGE
type	I-PRGE
I	I-PRGE
(	O
Fc	B-PRGE
gamma	I-PRGE
RI	I-PRGE
)	O
on	O
myeloid	O
cells	O
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
.	O

We	O
observed	O
that	O
Fc	B-PRGE
gamma	I-PRGE
RI	I-PRGE
transcript	O
levels	O
in	O
monoblast	O
-	O
like	O
U937	O
cells	O
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Treatment	O
of	O
U937	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super	O
-	O
induction	O
of	O
Fc	B-PRGE
gamma	I-PRGE
RI	I-PRGE
expression	O
.	O

Nuclear	O
run	O
-	O
on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	B-PRGE
gamma	I-PRGE
RI	I-PRGE
transcription	O
was	O
increased	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-PRGE
gamma	I-PRGE
RIC	I-PRGE
gene	O
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	O
initiation	O
site	O
without	O
a	O
TATA	O
box	O
.	O

Transient	O
transfections	O
of	O
CAT	B-PRGE
reporter	O
gene	O
constructs	O
containing	O
various	O
Fc	B-PRGE
gamma	I-PRGE
RIC	I-PRGE
promoter	O
sequences	O
into	O
U937	O
cells	O
revealed	O
that	O
a	O
20	O
-	O
bp	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-	O
7	O
to	O
+	O
13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
responsive	O
element	O
(	O
GIRE	O
)	O
was	O
present	O
within	O
74	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
17	O
-	O
bp	O
sequence	O
between	O
positions	O
-	O
51	O
and	O
-	O
35	O
conferred	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

Double	O
-	O
stranded	O
GIRE	O
sequence	O
,	O
but	O
not	O
a	O
scrambled	O
sequence	O
,	O
was	O
specifically	O
bound	O
by	O
nuclear	O
proteins	O
from	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
treated	O
U937	O
cells	O
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B-PRGE
alpha	I-PRGE
protein	O
bound	O
to	O
the	O
Fc	B-PRGE
gamma	I-PRGE
RIC	I-PRGE
GIRE	O
in	O
response	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
treatment	O
of	O
U937	O
cells	O
.	O

The	O
Fc	B-PRGE
gamma	I-PRGE
RIC	I-PRGE
GIRE	O
is	O
homologous	O
to	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
sequence	O
(	O
GAS	O
)	O
of	O
the	O
guanylate	O
binding	O
protein	O
and	O
to	O
X	O
box	O
elements	O
of	O
class	O
II	O
MHC	O
genes	O
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	B-PRGE
gamma	I-PRGE
RIC	I-PRGE
gene	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
involves	O
the	O
binding	O
of	O
STAT1	B-PRGE
alpha	I-PRGE
to	O
a	O
17	O
-	O
bp	O
GAS	O
homology	O
in	O
the	O
proximal	O
promoter	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
through	O
induction	O
of	O
I	O
kappa	O
B	O
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	O
and	O
of	O
several	O
cell	O
surface	O
molecules	O
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear	O
.	O

Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
in	O
mice	O
and	O
cultured	O
cells	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
inactive	O
cytoplasmic	O
complexes	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
activates	O
many	O
immunoregulatory	O
genes	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
priming	O
of	O
monocytes	O
enhances	O
LPS	O
-	O
induced	O
TNF	O
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
by	O
bacterial	O
endotoxin	O
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	B-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	O
monocytes	O
.	O

Priming	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	O
mRNA	O
accumulation	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
pre	O
-	O
treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
but	O
not	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

Primed	O
monocytes	O
transcribed	O
TNF	O
mRNA	O
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	O
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	O
NF	O
-	O
kappa	O
B	O
oligonucleotide	O
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	O
mRNA	O
induced	O
in	O
primed	O
cells	O
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	O
cells	O
(	O
T1	O
/	O
2	O
increased	O
6	O
-	O
8	O
-	O
fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	O
stability	O
,	O
the	O
duration	O
of	O
mRNA	O
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	O
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H	O
-	O
89	O
.	O

H	O
-	O
89	O
substantially	O
suppressed	O
LPS	O
-	O
induced	O
TNF	O
mRNA	O
accumulation	O
in	O
unprimed	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
primed	O
monocytes	O
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
myeloid	O
zinc	O
finger	O
gene	O
,	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
regulates	O
the	O
CD34	B-PRGE
promoter	O
in	O
vitro	O
.	O

MZF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
C2H2	O
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	O
transcriptional	O
regulator	O
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
contains	O
13	O
C2H2	O
zinc	O
fingers	O
arranged	O
in	O
bipartite	O
DNA	O
binding	O
domains	O
containing	O
zinc	O
fingers	O
through	O
4	O
and	O
,	O
in	O
the	O
carboxy	O
-	O
terminus	O
,	O
5	O
through	O
13	O
.	O

We	O
previously	O
identified	O
the	O
DNA	O
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	O
binding	O
domains	O
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
full	O
-	O
length	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
GAL4	B-PRGE
.	O

The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
gene	O
regulated	O
by	O
the	O
thymidine	B-PRGE
kinase	I-PRGE
promoter	O
containing	O
GAL4	B-PRGE
DNA	O
binding	O
sites	O
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

MZF	B-PRGE
-	I-PRGE
1	I-PRGE
represses	O
CAT	B-PRGE
reporter	O
gene	O
expression	O
via	O
GAL4	B-PRGE
binding	O
sites	O
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O

In	O
contrast	O
,	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
activates	O
CAT	B-PRGE
reporter	O
gene	O
expression	O
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O

The	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B-PRGE
promoter	O
.	O

MZF	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
regulation	O
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
lines	O
.	O

Recombinant	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
specifically	O
binds	O
to	O
the	O
consensus	O
binding	O
sites	O
in	O
the	O
CD34	B-PRGE
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O

MZF	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	O
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	B-PRGE
promoter	O
into	O
both	O
nonhematopoietic	O
and	O
hematopoietic	O
cell	O
lines	O
.	O

As	O
with	O
the	O
heterologous	O
DNA	O
binding	O
domain	O
,	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O

Activation	O
of	O
CD34	B-PRGE
expression	O
in	O
hematopoietic	O
cell	O
lines	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
sites	O
.	O

The	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
CD34	B-PRGE
promoter	O
by	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
suggests	O
the	O
presence	O
of	O
tissue	O
-	O
specific	O
regulators	O
/	O
adapters	O
or	O
differential	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
modifications	O
that	O
determine	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
regulatory	O
function	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	O
B	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

B	O
lymphocytes	O
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non	O
-	O
proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	O
cell	O
lines	O
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	O
B	O
lymphocytes	O
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	O
cycle	O
-	O
associated	O
genes	O
in	O
quiescent	O
and	O
stimulated	O
cells	O
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	O
genes	O
,	O
cdc	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
cyclin	B-PRGE
E	I-PRGE
,	O
CD23	B-PRGE
,	O
and	O
cyclin	B-PRGE
D2	I-PRGE
,	O
are	O
up	O
-	O
regulated	O
approximately	O
100	O
-	O
fold	O
as	O
a	O
result	O
of	O
EBV	O
-	O
mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	O
B	O
lymphocytes	O
with	O
either	O
a	O
cocktail	O
of	O
anti	O
-	O
CD40	B-PRGE
,	O
anti	O
-	O
IgM	O
,	O
and	O
IL4	B-PRGE
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
activation	O
.	O

CD30	B-PRGE
ligation	O
induces	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
cell	O
lines	O
.	O

CD30	B-PRGE
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
/	O
nerve	O
growth	O
factor	O
receptor	O
superfamily	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	O
cells	O
(	O
Hodgkin	O
'	O
s	O
disease	O
-	O
derived	O
,	O
T	O
cell	O
-	O
like	O
,	O
CD30	B-PRGE
+	O
cells	O
)	O
with	O
the	O
agonistic	O
anti	O
-	O
CD30	B-PRGE
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
M44	O
and	O
M67	O
,	O
two	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

The	O
effect	O
of	O
the	O
mAb	O
towards	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O

By	O
comparison	O
,	O
an	O
isotype	O
-	O
matched	O
antibody	O
had	O
no	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Moreover	O
,	O
in	O
human	O
T	O
helper	O
(	O
Th	O
)	O
clones	O
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30	O
+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	B-PRGE
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30	B-PRGE
+	O
cells	O
.	O

In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
complexes	O
induced	O
following	O
CD30	B-PRGE
engagement	O
were	O
shown	O
to	O
contain	O
p50	B-PRGE
NF	I-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
,	O
p65	B-PRGE
RelA	I-PRGE
,	O
and	O
possibly	O
other	O
transcription	O
factors	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
rank	O
among	O
the	O
short	O
-	O
term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B-PRGE
ligation	O
.	O

Constitutive	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
deficient	O
mice	O
.	O

Transcription	O
factors	O
belonging	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
are	O
controlled	O
by	O
inhibitory	O
I	O
kappa	O
B	O
proteins	O
,	O
mainly	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
.	O

Apparently	O
normal	O
at	O
birth	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
/	O
-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	O
NF	O
-	O
kappa	O
B	O
and	O
mRNAs	O
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

NF	O
-	O
kappa	O
B	O
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
the	O
p50	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O

In	O
contrast	O
to	O
hematopoietic	O
cells	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
/	O
-	O
embryonic	O
fibroblasts	O
show	O
minimal	O
constitutive	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
well	O
as	O
normal	O
signal	O
-	O
dependent	O
NF	O
-	O
kappa	O
B	O
activation	O
that	O
is	O
concomitant	O
with	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
degradation	O
.	O

Our	O
results	O
indicate	O
that	O
I	B-PRGE
kappa	I-PRGE
b	I-PRGE
beta	I-PRGE
,	O
but	O
not	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
is	O
required	O
for	O
the	O
signal	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
fibroblasts	O
.	O

However	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
fibroblasts	O
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	O
kappa	O
B	O
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4	O
-	O
induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activity	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	O
cytokines	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water	O
-	O
soluble	O
emulsion	O
of	O
alpha	O
-	O
tocopherol	O
.	O

Alpha	O
-	O
tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
and	O
an	O
increase	O
in	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
messenger	O
RNA	O
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha	O
-	O
tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
caused	O
by	O
free	O
radical	O
production	O
/	O
oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	O
cytokine	O
synthesis	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	O
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-PRGE
with	O
TCR	O
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
in	O
a	O
primary	O
TCR	O
-	O
mediated	O
activation	O
of	O
T	O
cells	O
have	O
been	O
explored	O
.	O

In	O
purified	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
nuclear	O
STAT	O
proteins	O
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross	O
-	O
linked	O
anti	O
-	O
CD3	B-PRGE
Abs	O
.	O

These	O
STAT	O
proteins	O
were	O
detected	O
by	O
using	O
the	O
IFN	O
-	O
gamma	O
-	O
activated	O
sequence	O
(	O
GAS	O
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti	O
-	O
STAT	O
Abs	O
indicated	O
that	O
they	O
contained	O
STAT	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	O
family	O
.	O

The	O
induction	O
of	O
STAT	O
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	O
factor	O
produced	O
by	O
the	O
activated	O
T	O
cells	O
.	O

As	O
neutralizing	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
Abs	O
effectively	O
down	O
-	O
regulated	O
the	O
early	O
induction	O
of	O
STAT	O
proteins	O
and	O
as	O
exogenously	O
added	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	O
-	O
mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	O
proteins	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Regulation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
by	O
PKC	O
-	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
phosphatase	O
calcineurin	O
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	O
-	O
induced	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
T	O
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
calcineurin	O
is	O
also	O
sufficient	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
PKC	O
-	O
dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
.	O

While	O
PKC	O
-	O
dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
in	O
T	O
cell	O
lines	O
,	O
co	O
-	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and	O
/	O
or	O
degradation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
in	O
Jurkat	O
T	O
or	O
in	O
U937	O
cells	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	O
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA	O
-	O
induced	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
/	O
degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-PRGE
alpha	I-PRGE
induced	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
a	O
PKC	O
-	O
independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathways	O
synergize	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
not	O
at	O
the	O
level	O
of	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	O
calcineurin	O
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-PRGE
alpha	I-PRGE
phosphorylation	O
and	O
degradation	O
.	O

Triggering	O
of	O
complement	O
receptors	O
CR1	B-PRGE
(	O
CD35	B-PRGE
)	O
and	O
CR3	O
(	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
)	O
induces	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
in	O
human	O
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
.	O

Monocyte	O
/	O
macrophages	O
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	O
such	O
as	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA	O
-	O
binding	O
heterodimer	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV	O
-	O
long	O
terminal	O
repeat	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	O
receptors	O
CR1	B-PRGE
(	O
CD35	B-PRGE
)	O
and	O
CR3	O
(	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
)	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
human	O
monocytic	O
cells	O
.	O

Monocytic	O
cell	O
lines	O
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragments	O
of	O
monoclonal	O
anti	O
-	O
CR1	B-PRGE
or	O
anti	O
-	O
CR3	O
Abs	O
or	O
with	O
C3	O
fragments	O
.	O

Stimulation	O
of	O
CR1	B-PRGE
or	O
CR3	O
induces	O
a	O
two	O
-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell	O
-	O
associated	O
and	O
released	O
p24	B-PRGE
Ag	O
in	O
cell	O
cultures	O
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	O
cultures	O
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	B-PRGE
or	O
CR3	O
induces	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
/	O
p65	B-PRGE
in	O
infected	O
cells	O
.	O

Translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
/	O
p65	B-PRGE
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B-PRGE
or	O
CR3	O
of	O
uninfected	O
peripheral	O
blood	O
monocytes	O
from	O
HIV	O
-	O
seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF	O
-	O
alpha	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
/	O
p65	B-PRGE
induced	O
by	O
triggering	O
of	O
complement	O
receptors	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	O
monocytes	O
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement	O
-	O
opsonized	O
particles	O
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	O
receptor	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

Nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
IL6	I-PRGE
activates	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
in	O
T	O
cells	O
.	O

Positive	O
regulatory	O
element	O
I	O
(	O
PRE	O
-	O
I	O
)	O
is	O
a	O
strong	O
enhancer	O
element	O
essential	O
for	O
expression	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
.	O

To	O
identify	O
transcription	O
factors	O
binding	O
to	O
PRE	O
-	O
I	O
,	O
we	O
screened	O
a	O
cDNA	O
expression	O
library	O
from	O
Jurkat	O
T	O
cells	O
and	O
isolated	O
a	O
cDNA	O
encoding	O
nuclear	O
factor	O
(	B-PRGE
NF	I-PRGE
)	I-PRGE
-	I-PRGE
IL6	I-PRGE
(	O
also	O
known	O
as	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
)	O
.	O

NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
mRNA	O
was	O
found	O
in	O
human	O
Jurkat	O
T	O
cells	O
and	O
in	O
the	O
mouse	O
Th2	O
clone	O
D10	O
,	O
but	O
not	O
in	O
Th1	O
clone	O
29	O
.	O

rNF	B-PRGE
-	I-PRGE
IL6	I-PRGE
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE	O
-	O
I	O
.	O

PRE	O
-	O
I	O
forms	O
multiple	O
DNA	O
-	O
protein	O
complexes	O
with	O
nuclear	O
extracts	O
from	O
Jurkat	O
cells	O
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
by	O
using	O
anti	O
-	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
Abs	O
.	O

Overexpression	O
of	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
reporter	O
gene	O
linked	O
to	O
the	O
PRE	O
-	O
I	O
-	O
thymidine	O
kinase	O
or	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
more	O
than	O
10	O
-	O
fold	O
in	O
Jurkat	O
cells	O
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
binding	O
sites	O
located	O
at	O
positions	O
-	O
44	O
to	O
-	O
36	O
(	O
C	O
/	O
EBP	O
proximal	O
)	O
and	O
-	O
87	O
to	O
-	O
79	O
(	O
C	O
/	O
EBP	O
medial	O
)	O
,	O
respectively	O
.	O

Our	O
results	O
demonstrate	O
that	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
in	O
T	O
cells	O
.	O

The	O
peri	O
-	O
kappa	O
B	O
site	O
mediates	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
enhancer	O
activation	O
in	O
monocytes	O
but	O
not	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV	O
-	O
2	O
)	O
,	O
like	O
HIV	O
-	O
1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer	O
/	O
promoter	O
region	O
of	O
HIV	O
-	O
2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV	O
-	O
1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
following	O
T	O
-	O
cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
two	O
adjacent	O
kappa	O
B	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
,	O
activation	O
of	O
the	O
HIV	O
-	O
2	O
enhancer	O
in	O
monocytes	O
and	O
T	O
cells	O
is	O
dependent	O
on	O
four	O
cis	O
-	O
acting	O
elements	O
:	O
a	O
single	O
kappa	O
B	O
site	O
,	O
two	O
purine	O
-	O
rich	O
binding	O
sites	O
,	O
PuB1	O
and	O
PuB2	O
,	O
and	O
a	O
pets	O
site	O
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
within	O
the	O
HIV	O
-	O
2	O
enhancer	O
,	O
immediately	O
upstream	O
of	O
the	O
kappa	O
B	O
site	O
,	O
designated	O
peri	O
-	O
kappa	O
B	O
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV	O
-	O
2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV	O
-	O
2	O
enhancer	O
activation	O
following	O
stimulation	O
of	O
monocytic	O
but	O
not	O
T	O
-	O
cell	O
lines	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV	O
-	O
2	O
enhancer	O
element	O
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	O
element	O
has	O
been	O
clearly	O
defined	O
for	O
HIV	O
-	O
1	O
.	O

While	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
from	O
both	O
peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
binds	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	O
versus	O
T	O
cells	O
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	O
element	O
undergoes	O
differential	O
modification	O
in	O
monocytes	O
and	O
T	O
cells	O
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
is	O
seen	O
in	O
monocytes	O
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte	O
-	O
specific	O
function	O
of	O
the	O
peri	O
-	O
kappa	O
B	O
factor	O
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	O
and	O
T	O
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O

Thapsigargin	O
induces	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
in	O
human	O
peripheral	O
and	O
Jurkat	O
T	O
cells	O
via	O
a	O
protein	O
kinase	O
C	O
-	O
independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
ATPase	O
,	O
depletes	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2	O
+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
Jurkat	O
T	O
cells	O
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
protein	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
mRNA	O
in	O
Jurkat	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	O
kappa	O
B	O
in	O
Jurkat	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
through	O
distinct	O
pathways	O
.	O

PMA	O
-	O
but	O
not	O
TG	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
is	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
H7	O
,	O
whereas	O
TG	O
-	O
but	O
not	O
PMA	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9	O
-	O
dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
in	O
human	O
T	O
cells	O
through	O
a	O
PKC	O
-	O
independent	O
pathway	O
.	O

A	O
functional	O
T	O
-	O
cell	O
receptor	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-PRGE
activity	O
.	O

Stimulation	O
of	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	O
kinases	O
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	B-PRGE
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O

It	O
contains	O
a	O
number	O
of	O
structural	O
motifs	O
,	O
including	O
Src	O
homology	O
2	O
,	O
Src	O
homology	O
3	O
,	O
and	O
pleckstrin	O
homology	O
domains	O
and	O
a	O
putative	O
guanine	O
nucleotide	O
exchange	O
domain	O
.	O

The	O
role	O
of	O
p95vav	B-PRGE
in	O
TCR	O
-	O
mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B-PRGE
alone	O
in	O
Jurkat	O
T	O
cells	O
leads	O
to	O
activation	O
of	O
the	O
nuclear	O
factors	O
,	O
including	O
NFAT	O
,	O
involved	O
in	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Furthermore	O
,	O
p95vav	B-PRGE
synergizes	O
with	O
TCR	O
stimulation	O
in	O
inducing	O
NFAT	O
-	O
and	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	O
activation	O
by	O
a	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
is	O
not	O
modulated	O
by	O
p95vav	B-PRGE
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	O
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	O
67	O
amino	O
acids	O
of	O
p95vav	B-PRGE
activates	O
its	O
transforming	O
potential	O
in	O
NIH	O
3T3	O
cells	O
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-PRGE
-	O
induced	O
NFAT	O
activation	O
is	O
not	O
mimicked	O
by	O
Ras	O
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	O
and	O
Raf	O
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B-PRGE
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B-PRGE
.	O

To	O
further	O
dissect	O
p95vav	B-PRGE
involvement	O
in	O
TCR	O
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	O
mutants	O
deficient	O
in	O
TCR	O
signaling	O
function	O
or	O
TCR	O
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-PRGE
to	O
function	O
.	O

However	O
,	O
overexpression	O
of	O
p95vav	B-PRGE
does	O
not	O
appear	O
to	O
influence	O
TCR	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	B-PRGE
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	O
signaling	O
cascade	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
phosphatase	O
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
at	O
phosphatase	O
2A	O
-	O
sensitive	O
sites	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine	O
/	O
threonine	O
phosphatases	O
in	O
the	O
regulation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	O
T	O
cells	O
with	O
low	O
concentrations	O
(	O
approximately	O
1	O
-	O
5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	O
phosphatase	O
type	O
1	O
(	O
PP	O
-	O
1	O
)	O
and	O
type	O
2A	O
(	O
PP	O
-	O
2A	O
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA	B-PRGE
.	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
phosphorylation	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
from	O
calyculin	O
A	O
-	O
treated	O
cells	O
,	O
but	O
not	O
that	O
from	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
cells	O
,	O
is	O
sensitive	O
to	O
PP	O
-	O
2A	O
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
induced	O
by	O
the	O
two	O
different	O
NF	O
-	O
kappa	O
B	O
inducers	O
.	O

However	O
,	O
induction	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
phosphorylation	O
by	O
both	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

We	O
further	O
demonstrate	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
and	O
calyculin	O
A	O
-	O
induced	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
mediated	O
through	O
both	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
inducible	O
and	O
the	O
PP	O
-	O
2A	O
-	O
opposing	O
kinases	O
,	O
may	O
serve	O
to	O
target	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
for	O
proteasome	O
-	O
mediated	O
degradation	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	O
factor	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
and	O
the	O
high	O
mobility	O
group	O
protein	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
.	O

The	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
HLA	O
-	O
DRA	O
is	O
expressed	O
in	O
B	O
cells	O
,	O
activated	O
T	O
lymphocytes	O
,	O
and	O
in	O
antigen	O
-	O
presenting	O
cells	O
.	O

In	O
addition	O
,	O
HLA	O
-	O
DRA	O
gene	O
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
plays	O
a	O
critical	O
role	O
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
in	O
class	O
II	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
that	O
the	O
high	O
mobility	O
group	O
protein	O
(	O
HMG	O
)	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	O
promoter	O
,	O
including	O
the	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
binding	O
site	O
.	O

Coexpression	O
of	O
HMG	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
cell	O
lines	O
lacking	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
results	O
in	O
high	O
levels	O
of	O
HLA	O
-	O
DRA	O
gene	O
expression	O
,	O
and	O
in	O
vitro	O
DNA	O
-	O
binding	O
studies	O
reveal	O
that	O
HMG	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
stimulates	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
binding	O
to	O
the	O
HLA	O
-	O
DRA	O
promoter	O
.	O

Thus	O
,	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
and	O
HMG	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
may	O
synergize	O
to	O
activate	O
HLA	O
-	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O

By	O
contrast	O
,	O
Oct	B-PRGE
-	I-PRGE
2A	I-PRGE
is	O
not	O
involved	O
in	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
in	O
HeLa	O
cells	O
,	O
but	O
antisense	O
HMG	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA	O
-	O
DRA	O
expression	O
,	O
and	O
that	O
HMG	O
I	B-PRGE
/	I-PRGE
Y	I-PRGE
may	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
.	O

Interleukin	B-PRGE
4	I-PRGE
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
which	O
interacts	O
with	O
an	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
site	O
-	O
like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
Stat	O
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
the	O
human	O
B	O
cell	O
line	O
,	O
BL	O
-	O
2	O
.	O

Utilizing	O
a	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
site	O
-	O
like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL	O
-	O
2	O
cells	O
.	O

This	O
factor	O
was	O
designated	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
NAF	O
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
nuclear	O
-	O
activating	O
factors	O
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	O
phosphoprotein	O
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
,	O
we	O
determined	O
whether	O
antibodies	O
to	O
Stat	O
proteins	O
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
Stat	I-PRGE
,	O
also	O
known	O
as	O
Stat6	B-PRGE
,	O
but	O
not	O
antibodies	O
to	O
other	O
Stat	O
proteins	O
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
NAF	O
complex	O
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	O
protein	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
induced	O
robust	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
(	O
JAK3	B-PRGE
)	O
activity	O
in	O
BL	O
-	O
2	O
cells	O
.	O

Cotransfection	O
of	O
JAK3	B-PRGE
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
Stat	O
into	O
COS	O
-	O
7	O
cells	O
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
site	O
-	O
like	O
sequence	O
and	O
comigrated	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
NAF	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
NAF	O
is	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
Stat	O
,	O
which	O
is	O
activated	O
by	O
JAK3	B-PRGE
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
receptor	O
engagement	O
.	O

An	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
pathway	O
of	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
mitogen	O
-	O
activated	O
T	O
lymphocytes	O
.	O

Lymphocytes	O
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'	O
altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
tumour	O
suppressor	O
p53	B-PRGE
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	O
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	B-PRGE
-	O
independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen	O
-	O
activated	O
mature	O
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
these	O
T	O
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	O
transcription	O
factor	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
(	I-PRGE
IRF	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Thus	O
two	O
different	O
anti	O
-	O
onco	O
-	O
genic	O
transcription	O
factors	O
,	O
p53	B-PRGE
and	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ICE	B-PRGE
)	O
gene	O
,	O
a	O
mammalian	O
homologue	O
of	O
the	O
Caenorhabditis	O
elegans	O
cell	O
death	O
gene	O
ced	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
is	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
.	O

Ectopic	O
overexpression	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	O
gene	O
for	O
ICE	B-PRGE
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation	O
-	O
induced	O
apoptosis	O
.	O

Regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
expression	O
by	O
hydroxyurea	O
in	O
human	O
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	O
hemoglobin	O
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

HU	O
induced	O
a	O
dose	O
-	O
dependent	O
stimulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
synthesis	O
.	O

The	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
was	O
elevated	O
4	O
to	O
7	O
.	O
5	O
-	O
fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Both	O
nuclear	O
run	O
-	O
on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	O
protein	O
was	O
elevated	O
by	O
2	O
to	O
5	O
-	O
fold	O
within	O
4	O
h	O
in	O
HU	O
treated	O
cells	O
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP	O
-	O
1	O
/	O
CAT	O
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post	O
-	O
transcription	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
during	O
erythroid	O
differentiation	O
.	O

Characterization	O
of	O
5	O
'	O
end	O
of	O
human	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	O
kinase	O
C	O
-	O
-	O
responsive	O
elements	O
regulating	O
expression	O
in	O
platelets	O
.	O

Platelet	O
thromboxane	B-PRGE
receptors	I-PRGE
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	B-PRGE
receptors	I-PRGE
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	O
genomic	O
DNA	O
clones	O
containing	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
.	O

The	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
5	O
'	O
portion	O
of	O
the	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	O
uterine	O
thromboxane	B-PRGE
receptor	I-PRGE
cDNA	O
that	O
extended	O
the	O
mRNA	O
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	O
placental	O
cDNA	O
.	O

A	O
major	O
transcription	O
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
and	O
380	O
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	O
initiation	O
site	O
.	O

The	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
has	O
neither	O
a	O
TATA	O
nor	O
a	O
CAAT	O
consensus	O
site	O
.	O

Promoter	O
function	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
promoter	O
/	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
chimera	O
plasmids	O
into	O
platelet	O
-	O
like	O
K562	O
cells	O
.	O

Thromboxane	B-PRGE
receptor	I-PRGE
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	B-PRGE
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5	O
'	O
deletion	O
constructs	O
in	O
transfected	O
K562	O
cells	O
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester	O
-	O
responsive	O
motifs	O
in	O
the	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	O
protein	O
-	O
2	O
(	O
AP	O
-	O
2	O
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1	O
.	O
8	O
kb	O
5	O
'	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
and	O
demonstrate	O
that	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	O
kinase	O
C	O
via	O
induction	O
of	O
an	O
AP	O
-	O
2	O
-	O
like	O
nuclear	O
factor	O
binding	O
to	O
upstream	O
promoter	O
elements	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	O
thromboxane	B-PRGE
receptors	I-PRGE
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B-PRGE
receptor	I-PRGE
gene	O
transcription	O
in	O
platelet	O
-	O
progenitor	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
through	O
CD28	B-PRGE
requires	O
reactive	O
oxygen	O
production	O
by	O
5	O
-	O
lipoxygenase	O
.	O

Activation	O
of	O
the	O
CD28	B-PRGE
surface	O
receptor	O
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	O
T	O
lymphocytes	O
we	O
show	O
that	O
CD28	B-PRGE
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-PRGE
-	O
mediated	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
CD28	B-PRGE
-	O
responsive	O
complex	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-PRGE
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	O
A2	O
and	O
5	O
-	O
lipoxygenase	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
via	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-PRGE
costimulatory	O
pathway	O
.	O

Infection	O
and	O
replication	O
of	O
Tat	B-PRGE
-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	O
and	O
tat	B-PRGE
mutations	O
in	O
primary	O
and	O
long	O
-	O
term	O
human	O
lymphoid	O
cells	O
.	O

Tat	B-PRGE
is	O
an	O
essential	O
regulatory	O
protein	O
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	B-PRGE
gene	O
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B-PRGE
releases	O
an	O
elongation	O
block	O
to	O
the	O
transcription	O
of	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
when	O
Tat	B-PRGE
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	B-PRGE
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-PRGE
mutants	O
,	O
including	O
two	O
stop	O
codon	O
mutants	O
and	O
one	O
deletion	O
mutant	O
using	O
replication	O
-	O
competent	O
HIV	O
-	O
1	O
constructs	O
carrying	O
wild	O
-	O
type	O
or	O
mutant	O
LTRs	O
with	O
modifications	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
/	O
or	O
Sp1	B-PRGE
binding	O
sites	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat	B-PRGE
-	O
HIV	O
-	O
1	O
with	O
wild	O
-	O
type	O
LTRs	O
can	O
replicate	O
in	O
HeLa	O
cells	O
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	O
cells	O
can	O
infect	O
primary	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B-PRGE
mutants	O
containing	O
wild	O
-	O
type	O
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR	O
-	O
modified	O
Tat	B-PRGE
mutants	O
.	O

Large	O
amounts	O
of	O
viral	O
RNA	O
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B-PRGE
mutants	O
that	O
contain	O
modified	O
LTRs	O
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR	O
-	O
modified	O
tat	B-PRGE
mutants	O
was	O
restricted	O
to	O
some	O
lymphoid	O
cell	O
lines	O
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	O
block	O
,	O
Tat	B-PRGE
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full	O
-	O
length	O
HIV	O
transcripts	O
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	O
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild	O
-	O
type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-PRGE
-	O
virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV	O
-	O
1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	B-PRGE
function	O
are	O
discussed	O
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	O
factors	O
of	O
activated	O
T	O
cells	O
,	O
NFATp	B-PRGE
and	O
NFATc	B-PRGE
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	O
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	O
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFATp	B-PRGE
)	O
,	O
a	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
-	O
sensitive	O
factor	O
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	O
,	O
mediates	O
CD16	O
-	O
induced	O
activation	O
of	O
cytokine	O
genes	O
in	O
human	O
NK	O
cells	O
.	O

CD16	O
(	O
Fc	B-PRGE
gamma	I-PRGE
RIIIA	I-PRGE
)	O
-	O
induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	O
ligands	O
induces	O
NFAT	O
-	O
like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	O
cell	O
NFAT	O
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP	O
-	O
1	O
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	B-PRGE
and	O
NFATc	B-PRGE
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	O
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp	B-PRGE
-	O
and	O
NFATc	B-PRGE
-	O
specific	O
antibodies	O
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	O
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B-PRGE
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	O
express	O
NFATc	B-PRGE
constitutively	O
,	O
but	O
NFATc	B-PRGE
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	O
recognizing	O
the	O
T	O
cell	O
NFATc	B-PRGE
revealed	O
no	O
detectable	O
NFATc	B-PRGE
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16	O
-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
cells	O
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	O
-	O
sensitive	O
transcription	O
factors	O
,	O
NFATp	B-PRGE
and	O
NFATc	B-PRGE
,	O
are	O
expressed	O
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	O
and	O
/	O
or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B-PRGE
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B-PRGE
mRNA	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	O
tyrosine	O
kinases	O
in	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
tax	B-PRGE
protein	O
or	O
virus	O
-	O
transformed	O
cells	O
.	O

HTLV	O
-	O
1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	O
encoded	O
protein	O
tax	B-PRGE
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B-PRGE
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B-PRGE
transforms	O
mouse	O
fibroblasts	O
but	O
not	O
thymocytes	O
,	O
despite	O
comparable	O
levels	O
of	O
tax	B-PRGE
expression	O
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130	O
-	O
kD	O
protein	O
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B-PRGE
transformed	O
fibroblast	O
B	O
line	O
and	O
in	O
HTLV	O
-	O
1	O
transformed	O
human	O
lymphoid	O
lines	O
,	O
but	O
not	O
in	O
thymocytes	O
from	O
Thy	O
-	O
tax	O
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	O
kinase	O
specific	O
antibodies	O
,	O
identified	O
p130	O
as	O
Jak2	B-PRGE
in	O
the	O
tax	B-PRGE
transformed	O
mouse	O
fibroblastic	O
cell	O
line	O
and	O
Jak3	B-PRGE
in	O
HTLV	O
-	O
1	O
transformed	O
human	O
T	O
cell	O
lines	O
.	O

Phosphorylation	O
of	O
Jak2	B-PRGE
in	O
tax	B-PRGE
transformed	O
cells	O
resulted	O
from	O
high	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb	O
/	O
c3T3	O
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	O
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
neutralizing	O
antibodies	O
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	O
kinases	O
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV	O
-	O
1	O
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	O
erythropoietin	B-PRGE
receptor	I-PRGE
gene	O
by	O
proteins	O
binding	O
to	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Sp1	B-PRGE
motifs	O
.	O

Erythropoietin	B-PRGE
(	O
Epo	B-PRGE
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	O
surface	O
receptor	O
(	O
EpoR	B-PRGE
)	O
on	O
erythroid	O
progenitors	O
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
EpoR	B-PRGE
gene	O
.	O

In	O
erythroid	O
cells	O
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	O
bp	O
promoter	O
fragment	O
with	O
binding	O
sites	O
for	O
transcription	O
factors	O
AP2	O
,	O
Sp1	B-PRGE
and	O
the	O
erythroid	O
-	O
specific	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
150	O
bp	O
hEpoR	B-PRGE
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	O
and	O
K562	O
cells	O
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-PRGE
expression	O
.	O

The	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Sp1	B-PRGE
binding	O
sites	O
in	O
this	O
promoter	O
lacking	O
a	O
TATA	O
sequence	O
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein	O
-	O
DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	B-PRGE
and	O
two	O
other	O
CCGCCC	O
binding	O
proteins	O
from	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
could	O
bind	O
to	O
the	O
Sp1	B-PRGE
binding	O
motif	O
.	O

By	O
increasing	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
via	O
co	O
-	O
transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-PRGE
promoter	O
in	O
K562	O
cells	O
and	O
non	O
-	O
erythroid	O
cells	O
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	O
cells	O
,	O
although	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
levels	O
were	O
comparable	O
in	O
OCIM1	O
and	O
K562	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B-PRGE
site	O
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B-PRGE
promoter	O
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
in	O
OCIM1	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
transactivate	O
the	O
EpoR	B-PRGE
promoter	O
,	O
the	O
level	O
of	O
hEpoR	B-PRGE
gene	O
expression	O
does	O
not	O
depend	O
on	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
alone	O
.	O

Rather	O
,	O
hEpoR	B-PRGE
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
with	O
other	O
cell	O
-	O
specific	O
factors	O
,	O
including	O
possibly	O
other	O
Sp1	B-PRGE
-	O
like	O
binding	O
proteins	O
,	O
to	O
provide	O
high	O
level	O
,	O
tissue	O
-	O
specific	O
expression	O
.	O

TCL1	B-PRGE
oncogene	O
activation	O
in	O
preleukemic	O
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia	O
-	O
telangiectasia	O
.	O

The	O
TCL1	B-PRGE
oncogene	O
on	O
human	O
chromosome	O
14q32	O
.	O
1	O
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32	O
.	O
1	O
)	O
and	O
t	O
(	O
7	O
;	O
14	O
)	O
(	O
q35	O
;	O
q32	O
.	O
1	O
)	O
]	O
and	O
inversions	O
[	O
inv14	O
(	O
q11	O
;	O
q32	O
.	O
1	O
)	O
]	O
with	O
TCR	O
alpha	O
/	O
beta	O
loci	O
in	O
T	O
-	O
cell	O
leukemias	O
,	O
such	O
as	O
T	O
-	O
prolymphocytic	O
(	O
T	O
-	O
PLL	O
)	O
.	O

It	O
is	O
also	O
involved	O
in	O
T	O
-	O
acute	O
and	O
-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia	O
-	O
telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O

Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	O
cells	O
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B-PRGE
mRNA	O
and	O
protein	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	B-PRGE
gene	O
was	O
overexpressed	O
in	O
the	O
PBLs	O
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T	O
-	O
cell	O
population	O
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	O
of	O
the	O
other	O
cases	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-PRGE
genomic	O
locus	O
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T	O
-	O
cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-PRGE
locus	O
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	O
part	O
of	O
chromosome	O
14	O
.	O

These	O
data	O
indicate	O
that	O
TCL1	B-PRGE
is	O
activated	O
in	O
preleukemic	O
clonal	O
cells	O
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	O
locus	O
at	O
14q11	O
.	O

Deregulation	O
of	O
TCL1	B-PRGE
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
B	O
lymphocytes	O
is	O
controlled	O
by	O
nuclear	O
factor	O
-	O
chi	O
B	O
.	O

The	O
regulation	O
of	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	O
lymphocytes	O
,	O
the	O
predominant	O
producers	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

However	O
,	O
B	O
cells	O
can	O
also	O
synthesize	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
the	O
Ca2	O
+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	O
constructs	O
with	O
multiples	O
of	O
transcription	O
factor	O
binding	O
sites	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
[	O
distal	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
AT	O
,	O
proximal	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
/	O
Octamer	O
(	O
UPS	O
)	O
or	O
NF	O
-	O
chi	O
B	O
(	O
TCEd	O
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV	O
-	O
transformed	O
B	O
clones	O
,	O
the	O
chi	O
B	O
site	O
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	O
T	O
cells	O
.	O

An	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
bearing	O
a	O
defective	O
NF	O
-	O
chi	O
B	O
site	O
was	O
completely	O
inactive	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
seven	O
EBV	O
-	O
B	O
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
the	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
.	O

Similarly	O
,	O
a	O
human	O
immunodeficiency	O
virus	O
promoter	O
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	O
B	O
factors	O
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
producing	O
EBV	O
-	O
B	O
cells	O
,	O
but	O
inactive	O
in	O
the	O
non	O
-	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
producing	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV	O
-	O
B	O
cells	O
and	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
NF	O
-	O
chi	O
B	O
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	O
B	O
complexes	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
secreting	O
cells	O
consisting	O
mainly	O
of	O
heterodimeric	O
p50	B-PRGE
/	O
p65	B-PRGE
complexes	O
.	O

A	O
weaker	O
chi	O
B	O
complex	O
formation	O
and	O
faster	O
-	O
migrating	O
complexes	O
were	O
detected	O
in	O
non	O
-	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
secreting	O
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
NF	O
-	O
chi	O
B	O
site	O
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
,	O
whereas	O
other	O
transcription	O
factors	O
appear	O
to	O
be	O
less	O
important	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
these	O
cells	O
.	O

Ubiquitin	B-PRGE
-	O
mediated	O
processing	O
of	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
activator	O
precursor	O
p105	B-PRGE
.	O

Reconstitution	O
of	O
a	O
cell	O
-	O
free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin	B-PRGE
-	O
carrier	O
protein	O
,	O
E2	B-PRGE
,	O
and	O
a	O
novel	O
ubiquitin	B-PRGE
-	O
protein	O
ligase	O
,	O
E3	B-PRGE
,	O
involved	O
in	O
conjugation	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
heterodimer	O
consisting	O
of	O
two	O
subunits	O
,	O
p50	B-PRGE
and	O
p65	B-PRGE
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	O
family	O
.	O

p50	B-PRGE
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	O
kDa	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	O
p50	B-PRGE
subunit	O
consisted	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
molecule	O
.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	B-PRGE
is	O
not	O
known	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	O
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V	O
.	O
J	O
.	O
,	O
Rando	O
,	O
O	O
.	O
J	O
.	O
,	O
Goldberg	O
,	O
A	O
.	O
L	O
.	O
,	O
and	O
Maniatis	O
,	O
T	O
.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773	O
-	O
785	O
)	O
have	O
shown	O
that	O
ubiquitin	B-PRGE
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell	O
-	O
free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60	O
-	O
kDa	O
precursor	O
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	O
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell	O
-	O
free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B-PRGE
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	O
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin	B-PRGE
-	O
carrier	O
protein	O
,	O
E2	B-PRGE
-	I-PRGE
F1	I-PRGE
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B-PRGE
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B-PRGE
precursor	O
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320	O
-	O
kDa	O
species	O
of	O
ubiquitin	B-PRGE
-	O
protein	O
ligase	O
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6	B-PRGE
-	I-PRGE
AP	I-PRGE
,	O
the	O
p53	B-PRGE
-	O
conjugating	O
ligase	O
,	O
and	O
from	O
E3	B-PRGE
alpha	I-PRGE
,	O
the	O
"	O
N	O
-	O
end	O
rule	O
"	O
ligase	O
.	O

The	O
hematopoietic	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
downregulated	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
a	O
hematopoietic	O
transcription	O
factor	O
belonging	O
to	O
the	O
Ets	O
-	O
family	O
.	O

It	O
is	O
identical	O
to	O
the	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
oncogene	O
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus	O
-	O
forming	O
virus	O
-	O
induced	O
murine	O
erythroleukemias	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	O
hematopoietic	O
lineages	O
,	O
but	O
its	O
expression	O
in	O
mature	O
cells	O
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
-	O
and	O
monocyte	O
/	O
macrophage	O
-	O
differentiation	O
lineage	O
.	O

It	O
binds	O
the	O
so	O
-	O
called	O
Pu	O
box	O
,	O
an	O
important	O
tissue	O
-	O
specific	O
regulatory	O
DNA	O
element	O
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
during	O
human	O
B	O
-	O
cell	O
development	O
using	O
a	O
panel	O
of	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	O
precursors	O
to	O
differentiated	O
plasma	O
cells	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
mRNA	O
expression	O
and	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	O
lines	O
representing	O
pro	O
-	O
B	O
,	O
pre	O
-	O
B	O
,	O
and	O
mature	O
B	O
cells	O
.	O

We	O
could	O
also	O
show	O
Pu	O
box	O
-	O
dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	O
myeloma	O
cell	O
lines	O
,	O
representing	O
differentiated	O
,	O
plasma	O
cell	O
-	O
like	O
B	O
cells	O
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	O
box	O
-	O
dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

The	O
findings	O
in	O
the	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	O
cells	O
with	O
downregulated	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	O
cell	O
lines	O
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
expression	O
and	O
activity	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represents	O
a	O
malignancy	O
-	O
associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	O
differentiated	O
B	O
cells	O
.	O

A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	B-PRGE
2	I-PRGE
gene	O
promoter	O
is	O
a	O
binding	O
site	O
for	O
the	O
zinc	O
finger	O
proteins	O
Sp1	B-PRGE
and	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Activation	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	O
factors	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	O
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	B-PRGE
and	O
the	O
inducible	O
early	O
growth	O
response	O
protein	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
only	O
Sp1	B-PRGE
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secreting	O
cells	O
the	O
inducible	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	O
site	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	B-PRGE
and	O
CD23	B-PRGE
expression	O
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
cells	O
.	O

1	O
,	O
25	O
alpha	O
-	O
Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte	O
-	O
macrophage	O
Ag	O
,	O
CD14	B-PRGE
,	O
and	O
the	O
low	O
affinity	O
Fc	O
receptor	O
for	O
IgE	O
,	O
CD23	B-PRGE
,	O
were	O
inversely	O
regulated	O
during	O
VitD3	O
-	O
and	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
human	O
U	O
-	O
937	O
monoblasts	O
.	O

PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	B-PRGE
and	O
CD23	B-PRGE
mRNA	O
and	O
protein	O
.	O

Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	B-PRGE
mRNA	O
and	O
protein	O
.	O

The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	O
the	O
VitD3	O
induction	O
of	O
CD14	B-PRGE
mRNA	O
expression	O
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	O
on	O
ongoing	O
protein	O
synthesis	O
.	O

While	O
inducing	O
CD14	B-PRGE
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA	O
-	O
,	O
and	O
RA	O
-	O
inducible	O
CD23	B-PRGE
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
U	O
-	O
937	O
cells	O
induced	O
by	O
RA	O
strongly	O
increased	O
their	O
expression	O
of	O
CD23	B-PRGE
mRNA	O
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	O
detectable	O
CD14	B-PRGE
cell	O
surface	O
or	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
the	O
VitD3	O
-	O
and	O
the	O
PMA	O
-	O
induced	O
CD14	B-PRGE
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA	O
-	O
induced	O
differentiation	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	B-PRGE
and	O
CD23	B-PRGE
gene	O
expression	O
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Cytokines	O
,	O
the	O
peptide	O
hormones	O
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Conversely	O
,	O
several	O
cytokines	O
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	O
lymphocytic	O
and	O
mononuclear	O
phagocytic	O
lineage	O
.	O

Activated	O
mononuclear	O
cells	O
,	O
particularly	O
B	O
cells	O
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV	O
-	O
inductive	O
cytokines	O
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O

The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

HIV	O
-	O
1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	O
cell	O
lines	O
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O

However	O
,	O
activation	O
of	O
the	O
T	O
cell	O
lines	O
leading	O
to	O
enhanced	O
HIV	O
-	O
1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	O
,	O
mitogens	O
,	O
and	O
cytokines	O
(	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
[	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
]	O
,	O
interleukin	O
1	O
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
.	O

Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV	O
-	O
1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV	O
-	O
6	O
)	O
can	O
also	O
enhance	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
reporter	O
gene	O
activity	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV	O
-	O
1	O
harbored	O
in	O
chronically	O
infected	O
T	O
lymphocytes	O
,	O
monocytes	O
,	O
or	O
macrophages	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV	O
-	O
1	O
latency	O
reactivation	O
.	O

ACH	O
-	O
2	O
,	O
derived	O
from	O
a	O
human	O
T	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O

ACH	O
-	O
2	O
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	O
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O

Therefore	O
the	O
ACH	O
-	O
2	O
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV	O
-	O
1	O
activation	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV	O
-	O
1	O
IIIB	O
replication	O
in	O
phytohemagglutinin	B-PRGE
-	O
stimulated	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Nitric	O
oxide	O
-	O
stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-PRGE
.	O

The	O
protooncogene	O
p21ras	B-PRGE
,	O
a	O
monomeric	O
G	O
protein	O
family	O
member	O
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B-PRGE
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP	O
-	O
bound	O
p21ras	B-PRGE
.	O

In	O
vitro	O
studies	O
using	O
pure	O
recombinant	O
p21ras	B-PRGE
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-PRGE
in	O
association	O
with	O
GDP	O
/	O
GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S	O
-	O
nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-PRGE
is	O
essential	O
for	O
NO	O
-	O
induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-PRGE
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-PRGE
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-PRGE
as	O
a	O
target	O
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-PRGE
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	O
nucleotide	O
exchange	O
factors	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	O
H	O
(	O
+	O
)	O
-	O
ATPase	O
B2	B-PRGE
subunit	O
gene	O
in	O
differentiating	O
THP	O
-	O
1	O
cells	O
.	O

Monocyte	O
-	O
macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	O
vacuolar	O
H	O
(	O
+	O
)	O
-	O
ATPase	O
(	O
V	O
-	O
ATPase	O
)	O
.	O

We	O
examined	O
mRNA	O
levels	O
of	O
various	O
V	O
-	O
ATPase	O
subunits	O
during	O
differentiation	O
of	O
both	O
native	O
monocytes	O
and	O
the	O
cell	O
line	O
THP	O
-	O
1	O
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V	O
-	O
ATPase	O
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-PRGE
isoform	O
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-PRGE
subunit	O
promoter	O
region	O
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	O
exon	O
and	O
5	O
'	O
-	O
flanking	O
region	O
of	O
this	O
gene	O
reveal	O
a	O
TATA	O
-	O
less	O
promoter	O
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	O
protection	O
analyses	O
indicate	O
a	O
single	O
major	O
transcriptional	O
start	O
site	O
.	O

We	O
transfected	O
promoter	O
-	O
luciferase	O
reporter	O
plasmids	O
into	O
THP	O
-	O
1	O
cells	O
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP	O
-	O
1	O
differentiation	O
.	O

DNase	B-PRGE
I	I-PRGE
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	O
and	O
Sp1	B-PRGE
binding	O
sites	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
and	O
proximal	O
coding	O
regions	O
.	O

Functional	O
characterization	O
of	O
novel	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcriptional	O
inhibitors	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
complex	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
is	O
essential	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
regulatory	O
element	O
linked	O
to	O
a	O
lac	B-PRGE
-	I-PRGE
Z	I-PRGE
reporter	O
gene	O
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
beta	B-PRGE
-	I-PRGE
galactosidase	I-PRGE
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta	B-PRGE
-	I-PRGE
galactosidase	I-PRGE
mRNA	O
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	O
line	O
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
linked	O
lac	B-PRGE
-	I-PRGE
Z	I-PRGE
transfectants	O
,	O
and	O
in	O
human	O
lymphocytes	O
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

WIN	O
53071	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
induced	O
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium	O
-	O
independent	O
anti	O
-	O
CD28	O
Ab	O
and	O
PMA	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
complex	O
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
transcription	O
.	O

cDNA	O
cloning	O
of	O
a	O
NGFI	B-PRGE
-	I-PRGE
B	I-PRGE
/	O
nur77	B-PRGE
-	O
related	O
transcription	O
factor	O
from	O
an	O
apoptotic	O
human	O
T	O
cell	O
line	O
.	O

A	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	O
,	O
TINUR	B-PRGE
,	O
was	O
cloned	O
from	O
apoptotic	O
PEER	O
cells	O
.	O

The	O
expression	O
of	O
the	O
TINUR	B-PRGE
gene	O
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross	O
-	O
linking	O
of	O
the	O
T	O
cell	O
Ag	O
receptor	O
complex	O
.	O

TINUR	B-PRGE
belongs	O
to	O
the	O
NGFI	B-PRGE
-	I-PRGE
B	I-PRGE
/	O
nur77	B-PRGE
family	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
and	O
is	O
an	O
orphan	O
receptor	O
.	O

TINUR	B-PRGE
binds	O
to	O
the	O
same	O
DNA	O
sequence	O
as	O
NGFI	B-PRGE
-	I-PRGE
B	I-PRGE
/	O
nur77	B-PRGE
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI	B-PRGE
-	I-PRGE
B	I-PRGE
/	O
nur77	B-PRGE
family	O
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Platelet	O
-	O
activating	O
factor	O
stimulates	O
transcription	O
of	O
the	O
heparin	B-PRGE
-	I-PRGE
binding	I-PRGE
epidermal	I-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
like	I-PRGE
growth	I-PRGE
factor	I-PRGE
in	O
monocytes	O
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
with	O
up	O
-	O
regulation	O
of	O
the	O
transcript	O
for	O
heparin	B-PRGE
-	I-PRGE
binding	I-PRGE
epidermal	I-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
like	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
)	O
,	O
a	O
potent	O
mitogen	O
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
function	O
of	O
PAF	O
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	O
surface	O
PAF	O
receptors	O
,	O
as	O
two	O
PAF	O
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L	O
-	O
659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up	O
-	O
regulation	O
of	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	O
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	O
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
markedly	O
reduced	O
PAF	O
-	O
stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up	O
-	O
regulation	O
of	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
mRNA	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	O
in	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

IL	O
-	O
1	O
receptor	O
and	O
TCR	O
signals	O
synergize	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL	O
-	O
1	O
receptor	O
(	O
IL	O
-	O
1R	O
)	O
-	O
and	O
TCR	O
-	O
initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	B-PRGE
I	I-PRGE
IL	I-PRGE
-	I-PRGE
1R	I-PRGE
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
synergistic	O
antigen	O
receptor	O
initiated	O
signals	O
are	O
mediated	O
through	O
protein	O
kinase	O
C	O
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL	O
-	O
1	O
rather	O
than	O
by	O
antigen	O
receptor	O
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
functional	O
activity	O
is	O
independent	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
(	O
MAD3	B-PRGE
)	O
-	O
NF	O
-	O
kappa	O
B	O
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	O
kappa	O
B	O
nuclear	O
translocation	O
.	O

The	O
IL	O
-	O
1	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL	O
-	O
1	O
induces	O
both	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL	O
-	O
1	O
-	O
induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
-	O
DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL	O
-	O
1	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
transcription	O
.	O

Induction	O
of	O
transcription	O
factors	O
in	O
human	O
T	O
lymphocytes	O
by	O
aspirin	O
-	O
like	O
drugs	O
.	O

Aspirin	O
-	O
like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	O
the	O
biosynthesis	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD	O
-	O
treated	O
T	O
cells	O
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	O
kinase	O
(	O
PKC	O
)	O
but	O
have	O
no	O
effect	O
(	O
in	O
comparison	O
to	O
anti	O
-	O
CD3	O
antibodies	O
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	B-PRGE
gamma	I-PRGE
1	I-PRGE
tyrosine	O
phosphorylation	O
.	O

ALD	O
-	O
induced	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
are	O
independent	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
of	O
herbimycin	O
,	O
a	O
tyrosine	O
-	O
protein	O
kinase	O
-	O
specific	O
inhibitor	O
.	O

Although	O
we	O
detected	O
no	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
in	O
ALD	O
-	O
treated	O
cells	O
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	O
sequences	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
region	O
:	O
NFAT	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
.	O

These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	O
T	O
cells	O
.	O

The	O
expression	O
of	O
AP	O
-	O
1	O
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
ALD	O
cause	O
transient	O
but	O
significant	O
changes	O
in	O
T	O
cell	O
transmembrane	O
signaling	O
,	O
although	O
some	O
events	O
induced	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	O
antibodies	O
are	O
not	O
induced	O
by	O
ALD	O
.	O

The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA	O
-	O
binding	O
activity	O
by	O
several	O
transcription	O
factors	O
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O

Interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
10	I-PRGE
inhibits	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
activation	O
in	O
human	O
monocytes	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
suppress	O
cytokine	O
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	O
monocytes	O
have	O
demonstrated	O
that	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
10	I-PRGE
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
expression	O
of	O
inflammatory	O
cytokine	O
genes	O
.	O

Several	O
other	O
transcription	O
factors	O
including	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
AP	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
GR	B-PRGE
,	O
CREB	B-PRGE
,	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
Sp	B-PRGE
-	I-PRGE
1	I-PRGE
are	O
not	O
affected	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

This	O
selective	O
inhibition	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
of	O
NF	O
kappa	O
B	O
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
'	O
s	O
cytokine	O
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	O
kappa	O
B	O
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	O
kappa	O
B	O
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
another	O
cytokine	O
that	O
inhibits	O
cytokine	O
mRNA	O
accumulation	O
in	O
monocytes	O
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS	O
-	O
induced	O
NF	O
kappa	O
B	O
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
enhances	O
mRNA	O
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inhibit	O
cytokine	O
production	O
by	O
different	O
mechanisms	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
(	O
YY1	B-PRGE
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	O
DR	B-PRGE
alpha	I-PRGE
gene	O
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	O
site	O
of	O
transcription	O
in	O
the	O
first	O
exon	O
of	O
the	O
DR	B-PRGE
alpha	I-PRGE
gene	O
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA	O
-	O
binding	O
site	O
abolished	O
binding	O
of	O
a	O
nuclear	O
factor	O
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	B-PRGE
alpha	I-PRGE
promoter	O
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	O
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	B-PRGE
beta	I-PRGE
,	O
DP	O
alpha	O
and	O
-	O
beta	O
,	O
and	O
DQ	B-PRGE
alpha	I-PRGE
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B-PRGE
alpha	I-PRGE
and	O
DP	B-PRGE
alpha	I-PRGE
element	O
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B-PRGE
alpha	I-PRGE
gene	O
.	O

It	O
was	O
identified	O
as	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
(	O
YY1	B-PRGE
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
Ig	O
heavy	O
chain	O
mu	O
E1	O
site	O
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Coupling	O
of	O
a	O
signal	O
response	O
domain	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
to	O
multiple	O
pathways	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T	O
-	O
cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	O
subunit	O
called	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
inducing	O
agents	O
,	O
including	O
T	O
-	O
cell	O
mitogens	O
,	O
proinflammatory	O
cytokines	O
,	O
and	O
viral	O
transactivators	O
such	O
as	O
the	O
Tax	B-PRGE
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
dependent	O
mechanisms	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal	O
-	O
transducing	O
functions	O
in	O
human	O
T	O
lymphocytes	O
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
36	O
amino	O
acids	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
from	O
NF	O
-	O
kappa	O
B	O
in	O
Tax	B-PRGE
-	O
expressing	O
cells	O
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N	O
-	O
terminal	O
regulatory	O
region	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B-PRGE
-	O
induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	O
and	O
cytokine	O
receptors	O
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	O
inhibitor	O
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

HIV	B-PRGE
type	I-PRGE
1	I-PRGE
protease	I-PRGE
activation	O
of	O
NF	O
-	O
kappa	O
B	O
within	O
T	O
lymphoid	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
nuclear	O
protein	O
of	O
the	O
rel	O
oncogene	O
family	O
capable	O
of	O
enhancing	O
transcription	O
of	O
several	O
cellular	O
genes	O
,	O
including	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
IL	O
-	O
2	O
receptor	O
,	O
and	O
viral	O
genes	O
transcribed	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

It	O
has	O
been	O
reported	O
that	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
protease	I-PRGE
may	O
cleave	O
the	O
NF	O
-	O
kappa	O
B	O
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
HIV	B-PRGE
protease	I-PRGE
on	O
NF	O
-	O
kappa	O
B	O
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	O
cells	O
by	O
introducing	O
a	O
protease	O
expression	O
vector	O
into	O
the	O
cells	O
.	O

Increased	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
viral	O
protease	O
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	O
-	O
CAT	B-PRGE
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV	B-PRGE
-	I-PRGE
protease	I-PRGE
expressing	O
cells	O
,	O
while	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
expression	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
were	O
not	O
affected	O
.	O

The	O
limited	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
HIV	B-PRGE
protease	I-PRGE
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

Expression	O
of	O
Ah	B-PRGE
receptor	I-PRGE
(	O
TCDD	B-PRGE
receptor	I-PRGE
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	O
Ah	B-PRGE
receptor	I-PRGE
(	O
TCDD	B-PRGE
receptor	I-PRGE
)	O
mRNA	O
in	O
peripheral	O
blood	O
cells	O
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	O
cells	O
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	O
cells	O
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-PRGE
receptor	I-PRGE
gene	O
in	O
the	O
monocyte	O
fraction	O
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	B-PRGE
mRNA	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	O
and	O
P450IA1	B-PRGE
.	O

AhR	B-PRGE
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	O
U937	O
,	O
THP1	O
,	O
and	O
HEL	O
/	O
S	O
cells	O
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	O
HL60	O
cells	O
and	O
erythroblastic	O
HEL	O
cells	O
.	O

However	O
,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	O
cells	O
MOLT4	O
(	O
T	O
cell	O
)	O
and	O
BALL1	O
(	O
B	O
cell	O
)	O
,	O
nor	O
in	O
K562	O
erythroblasts	O
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-PRGE
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	O
and	O
HEL	O
cells	O
.	O

HL60	O
cells	O
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes	O
-	O
macrophages	O
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5	O
-	O
to	O
2	O
-	O
fold	O
increase	O
of	O
AhR	B-PRGE
mRNA	O
.	O

The	O
incubation	O
with	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
beta	I-PRGE
1	I-PRGE
and	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5	O
-	O
to	O
7	O
-	O
fold	O
increase	O
of	O
AhR	B-PRGE
mRNA	O
.	O

The	O
HEL	O
cells	O
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-PRGE
mRNA	O
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte	O
-	O
macrophage	O
cells	O
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	O
HL60	O
cells	O
with	O
3	O
-	O
methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	B-PRGE
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	B-PRGE
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	B-PRGE
mRNA	O
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	O
cells	O
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	B-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	O
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
positively	O
auto	O
-	O
regulates	O
the	O
expression	O
of	O
human	O
PAF	B-PRGE
receptor	I-PRGE
transcript	O
1	O
(	O
leukocyte	O
-	O
type	O
)	O
through	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
human	O
platelet	B-PRGE
-	I-PRGE
activating	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
PAFR	B-PRGE
)	O
gene	O
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	O
(	O
promoter	O
1	O
and	O
promoter	O
2	O
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	B-PRGE
transcript	O
1	O
and	O
PAFR	B-PRGE
transcript	O
2	O
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	B-PRGE
transcript	O
1	O
(	O
leukocyte	O
-	O
type	O
)	O
,	O
but	O
not	O
PAFR	B-PRGE
transcript	O
2	O
(	O
tissue	O
-	O
type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	O
as	O
well	O
as	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	O
stomach	O
cancer	O
cell	O
line	O
(	O
JR	O
-	O
St	O
cells	O
)	O
which	O
expresses	O
both	O
functional	O
PAFR	B-PRGE
transcript	O
1	O
and	O
PAFR	B-PRGE
transcript	O
2	O
endogenously	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
1	O
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	O
and	O
TPA	O
activated	O
the	O
promoter	O
1	O
but	O
not	O
the	O
deleted	O
promoter	O
lacking	O
the	O
three	O
consensus	O
binding	O
sites	O
for	O
NF	O
-	O
kappa	O
B	O
located	O
from	O
-	O
571	O
bp	O
to	O
-	O
459	O
bp	O
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	B-PRGE
gene	O
expression	O
by	O
PAF	O
through	O
NF	O
-	O
kappa	O
B	O
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	O
kinase	O
C	O
by	O
PAF	O
.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
and	O
PAS	O
domains	O
.	O

The	O
intracellular	O
dioxin	O
receptor	O
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand	O
-	O
activated	O
transcription	O
factor	O
.	O

It	O
contains	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
motif	O
contiguous	O
with	O
a	O
Per	O
-	O
Arnt	O
-	O
Sim	O
(	O
PAS	O
)	O
homology	O
region	O
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
hsp90	O
)	O
,	O
a	O
molecular	O
chaperone	O
.	O

We	O
have	O
reconstituted	O
ligand	O
-	O
dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA	O
-	O
binding	O
form	O
by	O
using	O
the	O
dioxin	O
receptor	O
and	O
its	O
bHLH	O
-	O
PAS	O
partner	O
factor	O
Arnt	O
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O

Deletion	O
of	O
the	O
PAS	O
domain	O
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	O
.	O

In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element	O
-	O
binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	O
domain	O
may	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
affinity	O
and	O
/	O
or	O
specificity	O
of	O
the	O
receptor	O
.	O

It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	O
receptor	O
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	O
receptor	O
with	O
hsp90	O
.	O

At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	O
:	O
the	O
ligand	O
-	O
binding	O
domain	O
located	O
within	O
the	O
PAS	O
region	O
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	O
domain	O
.	O

Whereas	O
ligand	O
-	O
binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	O
,	O
bHLH	O
-	O
hsp90	O
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

Several	O
distinct	O
roles	O
for	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
,	O
interference	O
with	O
Arnt	O
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA	O
-	O
binding	O
conformation	O
of	O
the	O
bHLH	O
domain	O
.	O

Thus	O
,	O
the	O
dioxin	O
receptor	O
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	O
factors	O
by	O
hsp90	O
.	O

T	O
-	O
cell	O
functional	O
regions	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
proximal	O
promoter	O
.	O

The	O
human	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
gene	O
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	O
cells	O
.	O

Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
with	O
phytohemaglutinin	B-PRGE
(	O
PHA	B-PRGE
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
5	O
'	O
and	O
3	O
'	O
flanking	O
sequences	O
.	O

Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
.	O

The	O
promoter	O
region	O
between	O
-	O
173	O
and	O
-	O
60	O
contained	O
the	O
strongest	O
activating	O
elements	O
.	O

The	O
transcription	O
factor	O
AP	O
-	O
1	O
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
CK	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CK	B-PRGE
-	I-PRGE
2	I-PRGE
elements	O
that	O
are	O
present	O
in	O
many	O
cytokine	O
genes	O
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/	O
PHA	B-PRGE
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	B-PRGE
transcription	O
induced	O
by	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
the	O
B	O
cell	O
hybridoma	O
7TD1	O
.	O

We	O
have	O
measured	O
the	O
level	O
of	O
junB	B-PRGE
mRNA	O
in	O
the	O
B	O
hybridoma	O
cell	O
line	O
7TD1	O
,	O
under	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
stimulation	O
.	O

IL	B-PRGE
-	I-PRGE
6	I-PRGE
increases	O
junB	B-PRGE
mRNA	O
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early	O
-	O
induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B-PRGE
mRNA	O
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	O
factors	O
,	O
including	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	B-PRGE
mRNA	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	B-PRGE
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	B-PRGE
mRNA	O
and	O
JunB	B-PRGE
protein	O
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	B-PRGE
transcription	O
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
induced	O
junB	B-PRGE
transcription	O
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early	O
-	O
induced	O
burst	O
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	B-PRGE
mRNA	O
peak	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-PRGE
mRNA	O
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
controls	O
junB	B-PRGE
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

Biphasic	O
control	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
complex	O
:	O
role	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
.	O

The	O
regulation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
/	O
CD3	O
complex	O
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
protein	O
bound	O
the	O
kappa	O
B	O
element	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2R	I-PRGE
)	I-PRGE
alpha	I-PRGE
chain	I-PRGE
promoter	O
on	O
resting	O
T	O
cells	O
.	O

However	O
,	O
immediately	O
after	O
TcR	O
/	O
CD3	O
cross	O
-	O
linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50	B-PRGE
.	O
p65	B-PRGE
heterodimers	O
was	O
observed	O
.	O

p50	B-PRGE
.	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
heterodimers	O
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7	O
-	O
16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
and	O
p105	B-PRGE
/	O
p50	B-PRGE
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	B-PRGE
mRNA	O
whose	O
expression	O
was	O
constitutive	O
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti	O
-	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
monoclonal	O
antibody	O
.	O

Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
prevented	O
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR	O
/	O
CD3	O
signals	O
is	O
biphasic	O
:	O
TcR	O
/	O
CD3	O
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
is	O
present	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF	O
-	O
kappa	O
B	O
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
and	O
new	O
mRNA	O
synthesis	O
for	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
and	O
p105	B-PRGE
/	O
p50	B-PRGE
.	O

Protein	O
kinase	O
C	O
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B-PRGE
in	O
activated	O
T	O
cells	O
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
downstream	O
of	O
p21ras	B-PRGE
,	O
in	O
activating	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	O
is	O
an	O
effector	O
of	O
p21ras	B-PRGE
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	O
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	O
is	O
not	O
downstream	O
of	O
p21ras	O
in	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	B-PRGE
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	O
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	O
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
during	O
T	O
cell	O
activation	O
.	O

Association	O
of	O
alterations	O
in	O
NF	O
-	O
kappa	O
B	O
moieties	O
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	O
encoded	O
and	O
cellular	O
proteins	O
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV	O
-	O
1	O
proviral	O
latency	O
in	O
the	O
monocytic	O
cell	O
line	O
U1	O
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
moieties	O
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross	O
-	O
linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
moieties	O
and	O
possibly	O
p50	B-PRGE
homodimers	O
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50	B-PRGE
-	O
p56	B-PRGE
heterodimer	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
is	O
the	O
predominant	O
NF	O
-	O
kappa	O
B	O
species	O
in	O
most	O
T	O
lymphocytic	O
and	O
monocytic	O
cells	O
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	O
cells	O
.	O

This	O
pattern	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
moieties	O
differs	O
from	O
the	O
latently	O
infected	O
T	O
lymphocytic	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
and	O
from	O
the	O
U937	O
monocytic	O
line	O
,	O
the	O
parental	O
cell	O
line	O
of	O
the	O
U1	O
cellular	O
clone	O
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

Overexpression	O
of	O
protein	B-PRGE
kinase	I-PRGE
C	I-PRGE
-	I-PRGE
zeta	I-PRGE
stimulates	O
leukemic	O
cell	O
differentiation	O
.	O

A	O
function	O
for	O
protein	B-PRGE
kinase	I-PRGE
C	I-PRGE
-	I-PRGE
zeta	I-PRGE
(	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	O
atypical	O
protein	O
kinase	O
C	O
subfamily	O
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	O
U937	O
cell	O
.	O

Transfected	O
U937	O
cells	O
stably	O
overexpressing	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	O
cells	O
.	O

PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	O
enzyme	O
activities	O
and	O
were	O
distinct	O
from	O
parental	O
U937	O
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

In	O
contrast	O
to	O
parental	O
U937	O
cells	O
,	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
cells	O
constitutively	O
expressed	O
mRNA	O
transcripts	O
for	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
a	O
low	O
mobility	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

Thus	O
,	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	O
subfamilies	O
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Increased	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
protooncogene	O
and	O
an	O
increase	O
in	O
AP	O
-	O
1	O
binding	O
activity	O
in	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
cells	O
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	B-PRGE
factor	I-PRGE
expression	O
by	O
antioxidants	O
.	O

Tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
expression	O
by	O
cells	O
of	O
monocyte	O
/	O
macrophage	O
lineage	O
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	O
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	O
factors	O
,	O
including	O
nuclear	O
factor	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
TF	B-PRGE
expression	O
was	O
examined	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
monocytes	O
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	O
LPS	O
-	O
stimulated	O
TF	B-PRGE
mRNA	O
accumulation	O
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O

Immunofluorescence	O
studies	O
of	O
human	O
monocytes	O
using	O
polyclonal	O
anti	O
-	O
TF	B-PRGE
antibody	O
showed	O
that	O
N	O
-	O
acetyl	O
-	O
cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	B-PRGE
antigen	O
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N	O
-	O
acetyl	O
-	O
cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47	O
-	O
kD	O
mature	O
glycoprotein	O
in	O
LPS	O
-	O
treated	O
cells	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	O
in	O
an	O
accumulation	O
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	B-PRGE
.	O

When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and	O
/	O
or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	O
protein	O
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	O
necrosis	O
factor	O
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS	O
-	O
induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	O
monocytes	O
.	O

The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B-PRGE
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	O
/	O
macrophage	O
activation	O
.	O

Regulation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
p105	B-PRGE
in	O
monocytes	O
and	O
macrophages	O
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	O
/	O
macrophages	O
are	O
partially	O
understood	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	O
monocytic	O
cells	O
results	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Whether	O
virus	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	O
remains	O
unknown	O
.	O

To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
HIV	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O

First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	O
.	O

In	O
HIV	O
-	O
infected	O
cells	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

This	O
parallels	O
the	O
increased	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
synthesis	O
secondary	O
to	O
increased	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
,	O
i	O
.	O
e	O
.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter	O
-	O
enhancer	O
.	O

Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	B-PRGE
,	O
is	O
also	O
modified	O
in	O
HIV	O
-	O
infected	O
cells	O
:	O
p105	B-PRGE
and	O
p50	B-PRGE
steady	O
-	O
state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	B-PRGE
.	O

Transcriptional	O
activity	O
of	O
p105	B-PRGE
is	O
also	O
increased	O
in	O
infected	O
cells	O
and	O
is	O
also	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
through	O
a	O
specific	O
kappa	O
B	O
motif	O
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	O
autoregulatory	O
loop	O
in	O
monocytes	O
and	O
macrophages	O
involving	O
HIV	O
,	O
p105	B-PRGE
and	O
p50	B-PRGE
,	O
and	O
MAD3	B-PRGE
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O

Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	O
and	O
macrophages	O
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	O
kappa	O
B	O
molecules	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
(	O
C	B-PRGE
-	I-PRGE
FMS	I-PRGE
)	O
,	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
gene	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
FMS	B-PRGE
and	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	O
of	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	O
clones	O
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	B-PRGE
and	O
the	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
FMS	B-PRGE
genes	O
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	O
growth	O
factors	O
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

OBF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
novel	O
B	O
cell	O
-	O
specific	O
coactivator	O
that	O
stimulates	O
immunoglobulin	O
promoter	O
activity	O
through	O
association	O
with	O
octamer	O
-	O
binding	O
proteins	O
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer	O
-	O
binding	O
proteins	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
other	O
B	O
cell	O
components	O
are	O
required	O
for	O
lymphoid	O
-	O
restricted	O
,	O
octamer	O
site	O
-	O
mediated	O
immunoglobulin	O
gene	O
promoter	O
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	O
cell	O
-	O
derived	O
cDNAs	O
encoding	O
Oct	B-PRGE
-	I-PRGE
binding	I-PRGE
factor	I-PRGE
1	I-PRGE
(	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
no	O
intrinsic	O
DNA	O
-	O
binding	O
activity	O
and	O
recognizes	O
the	O
POU	O
domains	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
but	O
not	O
those	O
of	O
Oct	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

The	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
is	O
expressed	O
in	O
a	O
highly	O
cell	O
-	O
specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

Furthermore	O
,	O
expression	O
of	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
HeLa	O
cells	O
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	O
promoter	O
in	O
an	O
octamer	O
site	O
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	O
cell	O
-	O
specific	O
transcriptional	O
coactivator	O
protein	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
human	O
leukemic	O
cells	O
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	O
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so	O
-	O
called	O
'	O
lysis	O
genes	O
'	O
by	O
the	O
activated	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation	O
-	O
deficient	O
glucocorticoid	B-PRGE
receptor	I-PRGE
mutant	O
is	O
as	O
effective	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
in	O
repression	O
of	O
AP	O
-	O
1	O
activity	O
,	O
inhibition	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
inhibition	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	O
acid	O
receptor	O
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	O
factors	O
required	O
for	O
cell	O
survival	O
.	O

HIV	O
-	O
1	O
Tat	B-PRGE
potentiates	O
TNF	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	B-PRGE
protein	O
amplifies	O
the	O
activity	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV	O
-	O
1	O
replication	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

In	O
HeLa	O
cells	O
stably	O
transfected	O
with	O
the	O
HIV	O
-	O
1	O
tat	O
gene	O
(	O
HeLa	O
-	O
tat	O
cells	O
)	O
,	O
expression	O
of	O
the	O
Tat	B-PRGE
protein	O
enhanced	O
both	O
TNF	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
TNF	O
-	O
mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	O
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	O
cells	O
treated	O
with	O
soluble	O
Tat	B-PRGE
protein	O
.	O

TNF	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	B-PRGE
-	O
mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	O
cells	O
and	O
HeLa	O
cells	O
HIV	O
-	O
1	O
Tat	B-PRGE
suppressed	O
the	O
expression	O
of	O
Mn	B-PRGE
-	I-PRGE
dependent	I-PRGE
superoxide	I-PRGE
dismutase	I-PRGE
(	O
Mn	B-PRGE
-	I-PRGE
SOD	I-PRGE
)	O
,	O
a	O
mitochondrial	O
enzyme	O
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn	B-PRGE
-	I-PRGE
SOD	I-PRGE
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B-PRGE
.	O

Decreased	O
Mn	B-PRGE
-	I-PRGE
SOD	I-PRGE
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	B-PRGE
protein	O
(	O
Tat1	O
-	O
72	O
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
no	O
longer	O
affected	O
Mn	B-PRGE
-	I-PRGE
SOD	I-PRGE
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	O
-	O
mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
HIV	O
-	O
1	O
Tat	B-PRGE
is	O
required	O
to	O
suppress	O
Mn	B-PRGE
-	I-PRGE
SOD	I-PRGE
expression	O
and	O
to	O
induce	O
pro	O
-	O
oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Expression	O
of	O
the	O
Runt	O
domain	O
-	O
encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	O
cells	O
during	O
thymic	O
development	O
.	O

The	O
PEBP2	B-PRGE
alpha	I-PRGE
A	I-PRGE
and	O
PEBP2	B-PRGE
alpha	I-PRGE
B	I-PRGE
genes	O
encode	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
a	O
murine	O
transcription	O
factor	O
,	O
PEBP2	O
,	O
which	O
is	O
implicated	O
as	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
regulator	O
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	O
domain	O
.	O

PEBP2	B-PRGE
alpha	I-PRGE
B	I-PRGE
is	O
the	O
murine	O
counterpart	O
of	O
human	O
AML1	B-PRGE
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	O
;	O
21	O
and	O
3	O
;	O
21	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	B-PRGE
alpha	I-PRGE
A	I-PRGE
and	O
mouse	O
AML1	B-PRGE
/	I-PRGE
PEBP2	I-PRGE
alpha	I-PRGE
B	I-PRGE
were	O
detected	O
in	O
T	O
lymphocytes	O
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4	O
-	O
week	O
-	O
old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4	B-PRGE
-	O
CD8	O
-	O
,	O
CD4	B-PRGE
+	O
CD8	O
+	O
,	O
CD4	B-PRGE
+	O
CD8	O
-	O
,	O
and	O
CD4	B-PRGE
-	O
CD8	O
+	O
cell	O
populations	O
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	O
cells	O
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Transcripts	O
of	O
mouse	O
AML1	B-PRGE
/	I-PRGE
PEBP2	I-PRGE
alpha	I-PRGE
B	I-PRGE
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	O
marrow	O
cells	O
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1	B-PRGE
/	I-PRGE
PEBP2	I-PRGE
alpha	I-PRGE
B	I-PRGE
expression	O
in	O
hematopoietic	O
cells	O
other	O
than	O
those	O
of	O
T	O
-	O
cell	O
lineage	O
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Regulation	O
of	O
cell	O
-	O
type	O
-	O
specific	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
,	O
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

The	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	O
enhancer	O
between	O
nucleotides	O
-	O
299	O
and	O
-	O
228	O
that	O
contains	O
NF	O
-	O
kappa	O
B	O
and	O
CArG	O
motifs	O
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	O
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
that	O
binds	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Transcription	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
was	O
inhibited	O
when	O
either	O
the	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
the	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
binding	O
site	O
was	O
mutated	O
.	O

Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-	O
137	O
to	O
-	O
64	O
element	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Elf	B-PRGE
-	I-PRGE
1	I-PRGE
physically	O
associated	O
with	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
with	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
in	O
vitro	O
,	O
suggesting	O
that	O
protein	O
-	O
protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
DNA	O
interactions	O
that	O
regulate	O
cell	O
-	O
type	O
-	O
specific	O
and	O
inducible	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
family	O
proteins	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	O
factor	O
binding	O
to	O
DNA	O
.	O

The	O
interaction	O
of	O
the	O
transcription	O
factors	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
and	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
with	O
DNA	O
and	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
GR	B-PRGE
)	O
was	O
analyzed	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP	O
-	O
1	O
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	O
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60	O
-	O
min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	O
response	O
element	O
binding	O
and	O
a	O
concomitant	O
40	O
-	O
50	O
%	O
decrease	O
in	O
AP	O
-	O
1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	O
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	B-PRGE
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	O
factors	O
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	B-PRGE
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine	O
-	O
stimulated	O
transcription	O
factors	O
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Isolation	O
of	O
cDNA	O
clones	O
for	O
42	O
different	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
proteins	O
expressed	O
in	O
the	O
human	O
monoblast	O
cell	O
line	O
U	O
-	O
937	O
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	O
finger	O
proteins	O
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	O
zinc	O
finger	O
peptide	O
domain	O
was	O
used	O
to	O
isolate	O
63	O
cDNA	O
clones	O
for	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
from	O
the	O
human	O
monoblast	O
cell	O
line	O
U	O
-	O
937	O
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	O
clones	O
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-PRGE
1	I-PRGE
-	O
42	B-PRGE
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U	O
-	O
937	O
and	O
HeLa	O
cells	O
.	O

The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non	O
-	O
cell	O
-	O
type	O
-	O
specific	O
expression	O
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O

In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	O
(	O
HZF	B-PRGE
1	I-PRGE
-	O
10	B-PRGE
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	B-PRGE
11	I-PRGE
-	O
42	B-PRGE
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
proteins	O
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	O
fingers	O
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy	O
-	O
terminal	O
regions	O
of	O
the	O
proteins	O
.	O

In	O
addition	O
,	O
several	O
novel	O
KRAB	O
-	O
containing	O
zinc	O
finger	O
genes	O
and	O
a	O
novel	O
conserved	O
sequence	O
element	O
were	O
identified	O
.	O

Calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
-	O
mediated	O
pathways	O
for	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
.	O

Engagement	O
of	O
the	O
T	O
cell	O
receptor	O
for	O
antigen	O
activates	O
phospholipase	O
C	O
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

Increased	O
[	O
Ca2	O
+	O
]	O
i	O
activates	O
Ca2	O
+	O
/	O
calmodulin	B-PRGE
-	O
dependent	O
kinases	O
including	O
the	O
multifunctional	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
CaM	O
-	O
K	O
II	O
)	O
,	O
as	O
well	O
as	O
calcineurin	O
,	O
a	O
type	O
2B	O
protein	O
phosphatase	O
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	O
as	O
a	O
key	O
enzyme	O
for	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activation	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM	O
-	O
K	O
II	O
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	O
and	O
phosphatases	O
(	O
gamma	O
B	O
*	O
CaM	O
-	O
K	O
and	O
delta	O
CaM	O
-	O
AI	O
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	O
gene	O
transcription	O
and	O
their	O
interactions	O
with	O
PKC	O
-	O
dependent	O
signaling	O
systems	O
.	O
gamma	O
B	O
*	O
CaM	O
-	O
K	O
and	O
delta	O
CaM	O
-	O
AI	O
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	O
T	O
cells	O
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
reporter	O
gene	O
.	O

Cotransfection	O
of	O
gamma	O
B	O
*	O
CaM	O
-	O
K	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
construct	O
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	O
effect	O
of	O
CaM	O
-	O
K	O
II	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
transactivating	O
pathways	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	O
CaM	O
-	O
AI	O
superinduced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	O
B	O
*	O
CaM	O
-	O
K	O
inhibited	O
the	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
by	O
delta	O
CaM	O
-	O
AI	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
also	O
was	O
used	O
.	O
gamma	O
B	O
*	O
CaM	O
-	O
K	O
also	O
downregulated	O
the	O
activation	O
of	O
AP	O
-	O
1	O
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	O
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM	O
-	O
K	O
II	O
may	O
exert	O
negative	O
influences	O
on	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross	O
-	O
talk	O
with	O
the	O
calcineurin	O
-	O
and	O
PKC	O
-	O
dependent	O
signaling	O
systems	O
.	O

Control	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
proteolysis	O
by	O
site	O
-	O
specific	O
,	O
signal	O
-	O
induced	O
phosphorylation	O
.	O

I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
inhibits	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

This	O
liberates	O
NF	O
-	O
kappa	O
B	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	O
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
correlates	O
with	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine	O
-	O
32	O
or	O
serine	O
-	O
36	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal	O
-	O
induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

HIV	O
-	O
1	O
Nef	B-PRGE
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	O
cells	O
depending	O
on	O
its	O
intracellular	O
localization	O
.	O

Nef	B-PRGE
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	B-PRGE
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	O
CD8	O
-	O
Nef	B-PRGE
protein	O
in	O
Jurkat	O
cells	O
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	B-PRGE
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	O
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
.	O

Activated	O
Jurkat	O
cells	O
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	B-PRGE
genes	O
expressing	O
truncated	O
Nefs	B-PRGE
survived	O
,	O
which	O
rendered	O
Nef	B-PRGE
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	B-PRGE
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	B-PRGE
and	O
suggest	O
a	O
role	O
for	O
its	O
N	O
-	O
terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	B-PRGE
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

LMP	B-PRGE
-	I-PRGE
1	I-PRGE
activates	O
NF	O
-	O
kappa	O
B	O
by	O
targeting	O
the	O
inhibitory	O
molecule	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

LMP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
an	O
Epstein	O
-	O
Barr	O
virus	O
membrane	O
protein	O
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

LMP	B-PRGE
-	I-PRGE
1	I-PRGE
induces	O
the	O
expression	O
of	O
bcl2	B-PRGE
,	O
an	O
oncogene	O
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	O
factors	O
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	O
genes	O
.	O

NF	O
-	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
controlling	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B	O
-	O
lymphoid	O
cells	O
stably	O
or	O
transiently	O
expressing	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
selectively	O
modified	O
in	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
expressing	O
B	O
cells	O
.	O

A	O
phosphorylated	O
form	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
increased	O
protein	O
turnover	O
-	O
degradation	O
correlate	O
with	O
increased	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
-	O
genes	O
,	O
including	O
those	O
encoding	O
p105	B-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
(	O
MAD3	B-PRGE
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
activates	O
NF	O
-	O
kappa	O
B	O
in	O
B	O
-	O
cell	O
lines	O
by	O
targeting	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus	O
-	O
host	O
cell	O
protein	O
interaction	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
mediated	O
oncogenesis	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV	O
-	O
1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	O
receptors	O
(	O
RARs	O
)	O
in	O
T	O
-	O
lymphoid	O
and	O
monocytoid	O
cell	O
lines	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all	O
-	O
trans	O
and	O
9	O
-	O
cis	O
RA	O
on	O
HIV	O
-	O
1	O
production	O
in	O
T	O
-	O
lymphoid	O
(	O
H9	O
,	O
CEM	O
)	O
and	O
monocytoid	O
(	O
U937	O
,	O
THP	O
-	O
1	O
)	O
cell	O
lines	O
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	O
levels	O
of	O
human	O
RAR	B-PRGE
alpha	I-PRGE
(	O
hRAR	B-PRGE
alpha	I-PRGE
,	O
receptor	O
for	O
all	O
-	O
trans	O
RA	O
)	O
and	O
the	O
human	O
retinoid	B-PRGE
-	I-PRGE
X	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
hRXR	B-PRGE
alpha	I-PRGE
receptor	O
for	O
9	O
-	O
cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all	O
-	O
trans	O
and	O
9	O
-	O
cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV	O
-	O
1	O
IIIB	O
-	O
infected	O
monocytoid	O
cells	O
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co	O
-	O
stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T	O
-	O
cell	O
lines	O
.	O

HIV	O
production	O
by	O
PMA	O
-	O
stimulated	O
T	O
-	O
cell	O
lines	O
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9	O
-	O
cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all	O
-	O
trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	O
RAR	O
alpha	O
was	O
expressed	O
in	O
H9	O
,	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
,	O
but	O
almost	O
undetectable	O
in	O
CEM	O
cells	O
.	O

Human	O
RXR	B-PRGE
alpha	I-PRGE
was	O
significantly	O
expressed	O
in	O
U937	O
and	O
THP	O
-	O
1	O
cells	O
,	O
weakly	O
expressed	O
in	O
H9	O
cells	O
and	O
not	O
detectable	O
in	O
CEM	O
cells	O
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	B-PRGE
alpha	I-PRGE
expression	O
increased	O
in	O
H9	O
and	O
U937	O
cells	O
but	O
not	O
in	O
CEM	O
cells	O
.	O

Human	O
RAR	B-PRGE
alpha	I-PRGE
expression	O
was	O
unchanged	O
in	O
H9	O
and	O
CEM	O
cells	O
,	O
and	O
elevated	O
in	O
U937	O
cells	O
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV	O
-	O
1	O
expression	O
was	O
cell	O
-	O
type	O
-	O
dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	O
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Identification	O
of	O
human	O
TR2	O
orphan	O
receptor	O
response	O
element	O
in	O
the	O
transcriptional	O
initiation	O
site	O
of	O
the	O
simian	O
virus	O
40	O
major	O
late	O
promoter	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	O
response	O
element	O
(	O
TR2RE	O
-	O
SV40	O
)	O
for	O
the	O
TR2	O
orphan	O
receptor	O
,	O
a	O
member	O
of	O
the	O
steroid	O
-	O
thyroid	O
hormone	O
receptor	O
superfamily	O
,	O
has	O
been	O
identified	O
in	O
the	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
+	O
55	O
region	O
(	O
nucleotide	O
numbers	O
368	O
-	O
389	O
,	O
5	O
'	O
-	O
GTTAAGGTTCGTAGGTCATGGA	O
-	O
3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	O
orphan	O
receptor	O
with	O
a	O
molecular	O
mass	O
of	O
67	O
kilodaltons	O
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA	O
-	O
swap	O
experiments	O
using	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
-	I-PRGE
transferase	I-PRGE
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	O
early	O
promoter	O
via	O
the	O
interaction	O
between	O
this	O
TR2RE	O
-	O
SV40	O
and	O
the	O
chimeric	O
receptor	O
AR	O
/	O
TR2	O
/	O
AR	O
with	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
TR2	O
orphan	O
receptor	O
flanked	O
by	O
the	O
N	O
-	O
terminal	O
and	O
androgen	O
-	O
binding	O
domains	O
of	O
the	O
androgen	O
receptor	O
.	O

In	O
addition	O
,	O
this	O
TR2RE	O
-	O
SV40	O
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	O
early	O
and	O
late	O
promoters	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE	O
-	O
SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	O
response	O
element	O
for	O
the	O
TR2	O
orphan	O
receptor	O
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Mapping	O
of	O
the	O
interaction	O
site	O
of	O
the	O
defective	O
transcription	O
factor	O
in	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
mutant	O
cell	O
line	O
clone	O
-	O
13	O
to	O
the	O
divergent	O
X2	O
-	O
box	O
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Clone	O
-	O
13	O
,	O
that	O
expresses	O
HLA	O
-	O
DQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
-	O
DP	O
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype	O
-	O
specific	O
transcription	O
factor	O
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA	O
-	O
DRA	O
and	O
DQB	O
reporter	O
constructs	O
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis	O
-	O
elements	O
located	O
between	O
-	O
141	O
base	O
pairs	O
and	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
series	O
of	O
hybrid	O
DRA	O
/	O
DQB	O
reporter	O
constructs	O
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis	O
-	O
elements	O
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	O
X	O
-	O
box	O
(	O
but	O
not	O
the	O
DQB	O
-	O
W	O
region	O
or	O
the	O
DQB	O
Y	O
-	O
box	O
)	O
upstream	O
of	O
-	O
141	O
in	O
a	O
DRA	O
reporter	O
plasmid	O
rescued	O
expression	O
to	O
nearly	O
wild	O
-	O
type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X	O
-	O
box	O
,	O
or	O
only	O
the	O
X1	O
-	O
or	O
X2	O
-	O
boxes	O
of	O
HLA	B-PRGE
-	I-PRGE
DRA	I-PRGE
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA	O
-	O
DQB	O
.	O

The	O
DQB	O
X2	O
-	O
box	O
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	O
DRA	O
reporter	O
construct	O
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	O
X2	O
-	O
box	O
with	O
the	O
DRA	O
X2	O
-	O
box	O
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	O
promoter	O
in	O
the	O
mutant	O
cell	O
.	O

None	O
of	O
the	O
hybrid	O
reporter	O
constructs	O
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild	O
-	O
type	O
,	O
HLA	O
-	O
DR	O
/	O
-	O
DQ	O
positive	O
parental	O
cell	O
line	O
,	O
Jijoye	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	O
X2	O
-	O
box	O
of	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	O
class	O
II	O
isotypes	O
.	O

[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
B	O
-	O
lymphocytes	O
]	O

Since	O
most	O
B	O
cell	O
clones	O
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
a	O
typical	O
T	O
cell	O
cytokine	O
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	O
clones	O
tested	O
.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	O
cells	O
of	O
the	O
Jurkat	O
line	O
.	O

The	O
NFATd	O
element	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	O
clone	O
and	O
not	O
at	O
all	O
in	O
another	O
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
different	O
cells	O
.	O

Effects	O
of	O
CD45	B-PRGE
on	O
NF	O
-	O
kappa	O
B	O
.	O

Implications	O
for	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	O
T	O
cells	O
through	O
the	O
TCR	O
.	O

However	O
,	O
anti	O
-	O
CD45	B-PRGE
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	B-PRGE
and	O
HIV	O
-	O
1	O
further	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
T	O
cell	O
lines	O
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	B-PRGE
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	O
of	O
CD45	B-PRGE
on	O
their	O
surfaces	O
.	O

First	O
,	O
anti	O
-	O
CD45	B-PRGE
antibodies	O
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

Second	O
,	O
T	O
cells	O
,	O
which	O
lack	O
CD45	B-PRGE
and	O
cannot	O
signal	O
via	O
the	O
TCR	O
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
complexes	O
in	O
the	O
nucleus	O
of	O
CD45	B-PRGE
-	O
T	O
cells	O
.	O

Additionally	O
,	O
infected	O
T	O
cells	O
displayed	O
lower	O
levels	O
of	O
CD45	B-PRGE
on	O
their	O
surfaces	O
.	O

Thus	O
,	O
CD45	B-PRGE
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	O
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

ERP	B-PRGE
,	O
a	O
new	O
member	O
of	O
the	O
ets	O
transcription	O
factor	O
/	O
oncoprotein	O
family	O
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B	O
-	O
lymphocyte	O
development	O
.	O

The	O
ets	O
gene	O
family	O
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	O
factors	O
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
,	O
pi	O
and	O
microB	O
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	O
sites	O
for	O
ets	O
-	O
related	O
proteins	O
.	O

To	O
identify	O
ets	O
-	O
related	O
transcriptional	O
regulators	O
expressed	O
in	O
pre	O
-	O
B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	O
or	O
the	O
microB	O
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	O
family	O
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets	O
-	O
related	O
transcription	O
factor	O
,	O
ERP	B-PRGE
(	O
ets	B-PRGE
-	I-PRGE
related	I-PRGE
protein	I-PRGE
)	O
,	O
from	O
the	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	B-PRGE
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA	O
-	O
binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	O
transcription	O
factor	O
/	O
oncoprotein	O
family	O
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
SAP	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	O
gene	O
family	O
that	O
interacts	O
with	O
the	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
.	O

Full	O
-	O
length	O
ERP	B-PRGE
expresses	O
only	O
negligible	O
DNA	O
-	O
binding	O
activity	O
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	O
terminus	O
enables	O
ERP	B-PRGE
to	O
interact	O
with	O
a	O
variety	O
of	O
ets	O
-	O
binding	O
sites	O
including	O
the	O
E74	O
site	O
,	O
the	O
IgH	O
enhancer	O
pi	O
site	O
,	O
and	O
the	O
lck	B-PRGE
promoter	O
ets	O
site	O
,	O
suggesting	O
a	O
carboxy	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
.	O

At	O
least	O
three	O
ERP	B-PRGE
-	O
related	O
transcripts	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B	O
-	O
cell	O
lineage	O
,	O
ERP	B-PRGE
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B	O
-	O
lymphocyte	O
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B	O
-	O
cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	O
pi	O
site	O
.	O

These	O
data	O
suggest	O
that	O
ERP	B-PRGE
might	O
play	O
a	O
role	O
in	O
B	O
-	O
cell	O
development	O
and	O
in	O
IgH	O
gene	O
regulation	O
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pharmacological	O
modification	O
of	O
cytokine	O
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

Dr	O
.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
a	O
cytokine	O
known	O
to	O
influence	O
HIV	O
-	O
1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr	O
.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV	O
-	O
1	O
infection	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	B-PRGE
molecule	O
on	O
T	O
lymphocytes	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
-	O
1	O
,	O
gp160	B-PRGE
can	O
induce	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-PRGE
are	O
mediated	O
through	O
the	O
CD4	B-PRGE
molecule	O
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B-PRGE
abrogates	O
its	O
activity	O
.	O

The	O
gp160	B-PRGE
-	O
induced	O
NF	O
-	O
kappa	O
B	O
complex	O
consists	O
of	O
p65	B-PRGE
,	O
p50	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
proteins	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	B-PRGE
on	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
gp160	B-PRGE
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
CD4	B-PRGE
positive	O
T	O
cells	O
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e	O
.	O
g	O
.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	O
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

Role	O
of	O
HIV	O
-	O
1	O
Nef	B-PRGE
expression	O
in	O
activation	O
pathways	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

The	O
role	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
Nef	B-PRGE
protein	O
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	O
CD4	B-PRGE
+	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
Nef	B-PRGE
expression	O
vector	O
.	O

Secretion	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
surface	O
expression	O
of	O
IL	O
-	O
2R	O
,	O
and	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
(	O
Fos	B-PRGE
/	O
Jun	B-PRGE
)	O
complex	O
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	O
were	O
monitored	O
.	O

These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B-PRGE
expression	O
in	O
Jurkat	O
cells	O
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	O
activation	O
in	O
Nef	B-PRGE
+	O
Jurkat	O
cells	O
.	O

This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	B-PRGE
phosphorylation	O
on	O
Thr	O
-	O
15	O
or	O
GTP	O
-	O
binding	O
activity	O
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O

Analysis	O
of	O
truncated	O
LTRs	O
confirmed	O
that	O
inhibition	O
of	O
LTR	O
activation	O
was	O
not	O
mediated	O
through	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	O
responding	O
elements	O
(	O
NREs	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Nef	B-PRGE
downmodulates	O
LTR	O
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
respond	O
to	O
immunological	O
activations	O
.	O

A	O
low	O
NM23	B-PRGE
.	I-PRGE
H1	I-PRGE
gene	O
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis	O
-	O
suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	O
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	O
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	O
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23	B-PRGE
.	I-PRGE
H1	I-PRGE
gene	O
in	O
cell	O
lines	O
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease	O
-	O
free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	O
lines	O
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	O
lines	O
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24	O
-	O
58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	O
lines	O
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6	O
-	O
15	O
months	O
)	O
.	O

T	O
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T	O
-	O
cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	O
cells	O
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	O
patient	O
T	O
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	O
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	O
to	O
kappa	O
B	O
/	O
Rel	O
family	O
proteins	O
,	O
the	O
kappa	O
B	O
-	O
binding	O
activity	O
constitutively	O
expressed	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
(	O
p50	B-PRGE
)	O
subunit	O
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	B-PRGE
,	O
a	O
member	O
of	O
the	O
Rel	O
homology	O
family	O
which	O
is	O
part	O
of	O
the	O
normal	O
NF	O
-	O
kappa	O
B	O
complex	O
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	B-PRGE
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	O
cells	O
.	O

The	O
altered	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O

The	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF	O
-	O
kappa	O
B	O
/	O
I	O
kappa	O
B	O
components	O
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF	O
-	O
kappa	O
B	O
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
I	O
kappa	O
B	O
protein	O
families	O
.	O

In	O
HeLa	O
cells	O
as	O
well	O
as	O
in	O
B	O
cells	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50	B-PRGE
-	O
p65	B-PRGE
,	O
but	O
not	O
of	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
.	O

Both	O
NF	O
-	O
kappa	O
B	O
precursors	O
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	O
lymphocytes	O
containing	O
constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
revealed	O
constitutively	O
phosphorylated	O
p65	B-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	B-PRGE
and	O
p105	B-PRGE
and	O
by	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	B-PRGE
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Surprisingly	O
,	O
even	O
p65	B-PRGE
,	O
but	O
not	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
selectively	O
activates	O
only	O
specific	O
NF	O
-	O
kappa	O
B	O
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	O
kappa	O
B	O
molecules	O
but	O
also	O
NF	O
-	O
kappa	O
B	O
molecules	O
.	O

In	O
fact	O
,	O
cellular	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
phosphorylation	O
-	O
dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-PRGE
-	O
containing	O
NF	O
-	O
kappa	O
B	O
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF	O
-	O
kappa	O
B	O
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
vivo	O
.	O

An	O
active	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
tyrosine	O
kinase	O
blocks	O
immunoglobulin	O
light	O
-	O
chain	O
gene	O
rearrangement	O
.	O

Lymphoid	O
cells	O
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B	O
-	O
cell	O
development	O
and	O
immunoglobulin	O
rearrangement	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy	O
-	O
chain	O
locus	O
but	O
not	O
their	O
light	O
chain	O
genes	O
,	O
suggesting	O
that	O
an	O
active	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
interferes	O
with	O
this	O
differentiation	O
step	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light	O
-	O
chain	O
gene	O
structure	O
was	O
examined	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	O
BCL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
tyrosine	O
kinase	O
triggers	O
high	O
-	O
frequency	O
rearrangement	O
of	O
kappa	B-PRGE
and	O
lambda	B-PRGE
light	I-PRGE
-	I-PRGE
chain	I-PRGE
genes	O
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
RAG	B-PRGE
-	I-PRGE
2	I-PRGE
RNAs	O
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
tyrosine	O
kinase	O
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al	O
.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
also	O
suppresses	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
rel	O
and	O
expression	O
controlled	O
by	O
the	O
kappa	O
intron	O
enhancer	O
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
protein	O
specifically	O
interferes	O
with	O
light	O
-	O
chain	O
gene	O
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	O
gene	O
expression	O
.	O

[	O
An	O
overexpression	O
of	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
blocks	O
myeloid	O
cell	O
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	O
receptors	O
(	O
RARs	O
)	O
.	O

RARs	O
are	O
members	O
of	O
the	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
superfamily	O
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA	O
-	O
binding	O
and	O
RA	O
(	O
ligand	O
)	O
-	O
binding	O
domains	O
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	O
,	O
predominantly	O
RAR	B-PRGE
alpha	I-PRGE
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
progenitors	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	O
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B-PRGE
alpha	I-PRGE
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	O
RAR	B-PRGE
alpha	I-PRGE
(	O
hRAR	B-PRGE
alpha	I-PRGE
)	O
into	O
murine	O
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	O
resistant	O
marker	O
(	O
Neo	O
(	O
r	O
)	O
)	O
cultured	O
on	O
the	O
stroma	O
cell	O
line	O
(	O
PA6	O
-	O
neo	O
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	O
cells	O
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	B-PRGE
alpha	I-PRGE
exhibited	O
promyelocytic	O
morphology	O
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	O
cells	O
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

RAR	B-PRGE
alpha	I-PRGE
infected	O
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	O
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	O
colony	O
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	B-PRGE
alpha	I-PRGE
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	O
cell	O
differentiation	O
and	O
RAR	B-PRGE
alpha	I-PRGE
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	O
genes	O
for	O
differentiation	O
of	O
normal	O
bone	O
marrow	O
cells	O
.	O

Regulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
expression	O
and	O
nuclear	O
factor	O
.	O
kappa	O
B	O
activation	O
by	O
protein	O
kinase	O
C	O
in	O
T	O
lymphocytes	O
.	O

Autocrine	O
role	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
.	O

The	O
regulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
expression	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
activation	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
resting	O
T	O
cells	O
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
the	O
activation	O
of	O
NF	O
.	O
kappa	O
B	O
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
NF	O
.	O
kappa	O
B	O
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	O
B	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
either	O
as	O
p50	B-PRGE
.	O
p65	B-PRGE
or	O
as	O
p50	B-PRGE
.	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
heterodimers	O
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	O
anti	O
-	O
TNF	B-PRGE
alpha	I-PRGE
monoclonal	O
antibody	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	B-PRGE
alpha	I-PRGE
production	O
induced	O
by	O
PKC	O
,	O
strongly	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
NF	O
.	O
kappa	O
B	O
activation	O
.	O

The	O
addition	O
of	O
either	O
TNF	B-PRGE
alpha	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
partially	O
recovered	O
cyclosporin	O
A	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
inhibition	O
,	O
but	O
only	O
TNF	B-PRGE
alpha	I-PRGE
completely	O
recovered	O
NF	O
.	O
kappa	O
B	O
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	O
T	O
cells	O
,	O
PKC	O
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B-PRGE
alpha	I-PRGE
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
chain	I-PRGE
or	O
NF	O
.	O
kappa	O
B	O
activation	O
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

Tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
is	O
expressed	O
rapidly	O
by	O
human	O
monocytes	O
exposed	O
to	O
bacterial	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
in	O
the	O
TF	B-PRGE
promoter	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
and	O
other	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

The	O
protease	O
inhibitors	O
N	O
alpha	O
-	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
proteins	O
by	O
preventing	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-PRGE
expression	O
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-PRGE
protein	O
,	O
TF	B-PRGE
mRNA	O
and	O
TF	B-PRGE
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
nuclear	O
translocation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
encoding	O
the	O
transcription	O
factor	O
,	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
prevented	O
LPS	O
induction	O
of	O
TF	B-PRGE
gene	O
transcription	O
in	O
monocytic	O
cells	O
.	O

A	O
family	O
of	O
serine	O
proteases	O
expressed	O
exclusively	O
in	O
myelo	O
-	O
monocytic	O
cells	O
specifically	O
processes	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
subunit	O
p65	B-PRGE
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O

Two	O
groups	O
of	O
U937	O
promonocytic	O
cells	O
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
.	O

"	O
Plus	O
"	O
clones	O
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
"	O
minus	O
"	O
clones	O
did	O
not	O
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

Stimulation	O
of	O
plus	O
clones	O
liberated	O
the	O
classical	O
p50	B-PRGE
-	O
p65	B-PRGE
complex	O
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	O
clones	O
produced	O
an	O
apparently	O
novel	O
,	O
faster	O
-	O
migrating	O
complex	O
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster	O
-	O
migrating	O
complex	O
was	O
composed	O
also	O
of	O
p50	B-PRGE
and	O
p65	B-PRGE
.	O

However	O
,	O
the	O
p65	B-PRGE
subunit	O
was	O
COOH	O
-	O
terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O

The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	B-PRGE
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	O
serine	O
proteases	O
,	O
such	O
as	O
elastase	O
,	O
cathepsin	B-PRGE
G	I-PRGE
,	O
and	O
proteinase	B-PRGE
3	I-PRGE
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	O
U937	O
clones	O
,	O
but	O
not	O
in	O
the	O
plus	O
clones	O
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B-PRGE
G	I-PRGE
.	O

In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	O
in	O
certain	O
subclones	O
of	O
THP	O
-	O
1	O
and	O
HL	O
-	O
60	O
cells	O
and	O
in	O
primary	O
monocytes	O
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	B-PRGE
.	O

We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	B-PRGE
by	O
purified	O
elastase	O
and	O
cathepsin	B-PRGE
G	I-PRGE
.	O

It	O
is	O
possible	O
that	O
particular	O
serine	O
proteases	O
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
myelo	O
-	O
monocytic	O
cells	O
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo	O
-	O
monocytic	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-PRGE
activation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
-	O
mediated	O
induction	O
of	O
the	O
c	O
-	O
rel	O
gene	O
.	O

The	O
tax	B-PRGE
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
potent	O
transcriptional	O
activator	O
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	O
genes	O
involved	O
in	O
T	O
-	O
cell	O
growth	O
.	O

Tax	B-PRGE
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
enhancer	O
-	O
binding	O
proteins	O
.	O

In	O
resting	O
T	O
cells	O
,	O
many	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
factors	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin	O
-	O
rich	O
inhibitory	O
proteins	O
,	O
including	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

HTLV	O
-	O
I	O
Tax	B-PRGE
expression	O
leads	O
to	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
biologically	O
active	O
NF	O
-	O
kappa	O
B	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
complexes	O
;	O
however	O
,	O
the	O
biochemical	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
response	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	B-PRGE
-	O
stimulated	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
both	O
HTLV	O
-	O
I	O
-	O
infected	O
and	O
Tax	B-PRGE
-	O
transfected	O
human	O
T	O
cells	O
is	O
associated	O
with	O
the	O
phosphorylation	O
and	O
rapid	O
proteolytic	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
remains	O
physically	O
associated	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

We	O
further	O
demonstrate	O
that	O
Tax	B-PRGE
induction	O
of	O
nuclear	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
expression	O
is	O
activated	O
by	O
the	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
activates	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
gene	O
through	O
an	O
intrinsic	O
kappa	O
B	O
enhancer	O
element	O
.	O

In	O
normal	O
cells	O
,	O
the	O
subsequent	O
accumulation	O
of	O
nuclear	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
acts	O
to	O
inhibit	O
its	O
own	O
continued	O
production	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
autoregulatory	O
loop	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Arrested	O
development	O
:	O
understanding	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
.	O

The	O
protein	O
tyrosine	O
kinase	O
activity	O
of	O
the	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
oncogene	O
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	O
cells	O
for	O
growth	O
and	O
differentiation	O
.	O

Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	O
cell	O
lineage	O
cells	O
arrested	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	O
gene	O
expression	O
.	O

These	O
observations	O
suggest	O
that	O
v	B-PRGE
-	I-PRGE
abl	I-PRGE
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	O
cells	O
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Distinct	O
DNase	B-PRGE
-	I-PRGE
I	I-PRGE
hypersensitive	O
sites	O
are	O
associated	O
with	O
TAL	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
erythroid	O
and	O
T	O
-	O
cell	O
lines	O
.	O

The	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
,	O
frequently	O
activated	O
in	O
human	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mast	O
cell	O
lineages	O
during	O
normal	O
hematopoiesis	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
we	O
investigated	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
chromatin	O
structure	O
in	O
erythroid	O
/	O
megakaryocytic	O
cell	O
lines	O
and	O
in	O
T	O
-	O
cell	O
lines	O
either	O
with	O
or	O
without	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
rearrangements	O
.	O

Tal	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
expresses	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal	B-PRGE
-	I-PRGE
15	I-PRGE
'	O
GC	O
-	O
rich	O
region	O
behaves	O
like	O
a	O
CpG	O
island	O
,	O
hypomethylated	O
in	O
normal	O
cells	O
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	O
inactive	O
alleles	O
in	O
established	O
cell	O
lines	O
.	O

Five	O
major	O
DNase	B-PRGE
-	I-PRGE
I	I-PRGE
hypersensitive	O
sites	O
(	O
HS	O
)	O
were	O
mapped	O
in	O
the	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
locus	O
.	O

HS	O
I	O
,	O
IV	O
,	O
and	O
V	O
were	O
exclusively	O
observed	O
in	O
the	O
erythroid	O
/	O
megakaryocytic	O
cell	O
lines	O
that	O
express	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
from	O
the	O
promoters	O
1a	O
and	O
1b	O
.	O

HS	O
II	O
was	O
weak	O
in	O
hematopoietic	O
cell	O
lines	O
,	O
absent	O
in	O
Hela	O
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	O
,	O
suggesting	O
that	O
this	O
region	O
might	O
be	O
implicated	O
in	O
the	O
cis	O
-	O
activation	O
of	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
1b	O
in	O
this	O
cell	O
line	O
.	O

HS	O
III	O
was	O
weak	O
in	O
HEL	O
and	O
Jurkat	O
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
bears	O
a	O
t	O
(	O
1	O
;	O
14	O
)	O
and	O
initiates	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
within	O
exon	O
4	O
.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
promoters	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	O
cells	O
cannot	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	B-PRGE
(	O
TRX	B-PRGE
)	O
.	O

As	O
the	O
protein	O
tyrosine	O
kinase	O
activities	O
p56lck	B-PRGE
and	O
p59fyn	B-PRGE
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O

These	O
redox	O
-	O
regulated	O
enzymes	O
trigger	O
signal	O
cascades	O
for	O
NF	O
kappa	O
B	O
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
,	O
from	O
CD4	B-PRGE
and	O
CD8	O
molecules	O
,	O
and	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well	O
-	O
known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV	O
-	O
infected	O
patients	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

Erythropoietin	B-PRGE
-	O
dependent	O
induction	O
of	O
hemoglobin	O
synthesis	O
in	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
M	O
-	O
TAT	O
.	O

M	O
-	O
TAT	O
is	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

We	O
cultured	O
M	O
-	O
TAT	O
cells	O
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	B-PRGE
(	O
EPO	B-PRGE
)	O
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
or	O
stem	B-PRGE
cell	I-PRGE
factor	I-PRGE
(	O
SCF	B-PRGE
)	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M	O
-	O
TAT	O
/	O
EPO	O
,	O
M	O
-	O
TAT	O
/	O
GM	O
-	O
CSF	O
,	O
and	O
M	O
-	O
TAT	O
/	O
SCF	O
cells	O
,	O
respectively	O
.	O

Hemoglobin	O
concentration	O
and	O
gamma	O
-	O
globin	O
and	O
erythroid	B-PRGE
delta	I-PRGE
-	I-PRGE
aminolevulinate	I-PRGE
synthase	I-PRGE
mRNA	O
levels	O
were	O
significantly	O
higher	O
in	O
M	O
-	O
TAT	O
/	O
EPO	B-PRGE
cells	O
than	O
in	O
M	O
-	O
TAT	O
/	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
cells	O
.	O

When	O
the	O
supplemented	O
cytokine	O
was	O
switched	O
from	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
to	O
EPO	B-PRGE
,	O
hemoglobin	O
synthesis	O
in	O
M	O
-	O
TAT	O
/	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
cells	O
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
increased	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
to	O
the	O
M	O
-	O
TAT	O
/	O
EPO	B-PRGE
cell	O
culture	O
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	B-PRGE
,	O
indicating	O
that	O
the	O
EPO	B-PRGE
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

Thus	O
,	O
erythroid	O
development	O
of	O
M	O
-	O
TAT	O
cells	O
is	O
promoted	O
by	O
EPO	B-PRGE
and	O
suppressed	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	B-PRGE
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	O
progenitor	O
cell	O
differentiation	O
.	O

One	O
gene	O
,	O
two	O
transcripts	O
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B-PRGE
La	I-PRGE
/	O
SS	B-PRGE
-	I-PRGE
B	I-PRGE
from	O
a	O
cDNA	O
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	O
library	O
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	O
autoantigen	B-PRGE
La	I-PRGE
/	O
SS	B-PRGE
-	I-PRGE
B	I-PRGE
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	B-PRGE
mRNA	O
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	B-PRGE
mRNA	O
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	O
1	O
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	O
5	O
'	O
-	O
end	O
is	O
a	O
part	O
of	O
the	O
intron	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	O
promoter	O
site	O
,	O
which	O
exists	O
within	O
the	O
intron	O
downstream	O
of	O
the	O
exon	O
1	O
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	O
La	B-PRGE
mRNA	O
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	O
factor	O
binding	O
sites	O
,	O
including	O
a	O
NF	O
-	O
kappa	O
B	O
element	O
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	O
autoantigen	B-PRGE
La	I-PRGE
/	O
SS	B-PRGE
-	I-PRGE
B	I-PRGE
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Functional	O
Myc	B-PRGE
-	O
Max	B-PRGE
heterodimer	O
is	O
required	O
for	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O

T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
protein	O
in	O
the	O
phenomenon	O
of	O
activation	O
-	O
induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	B-PRGE
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation	O
-	O
induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	O
mutant	O
Myc	B-PRGE
protein	O
capable	O
of	O
forming	O
functional	O
heterodimers	O
with	O
the	O
mutant	O
Max	B-PRGE
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation	O
-	O
induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	B-PRGE
promotes	O
activation	O
-	O
induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	B-PRGE
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

DNA	O
-	O
binding	O
studies	O
of	O
the	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
(	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	O
membrane	O
protein	O
gene	O
promoter	O
-	O
binding	O
proteins	O
in	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
positive	O
cell	O
lines	O
.	O

The	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
(	I-PRGE
EBV	I-PRGE
)	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
(	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O

EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
trans	O
-	O
activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
fgr	I-PRGE
,	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
and	O
terminal	B-PRGE
protein	I-PRGE
1	I-PRGE
(	O
TP1	B-PRGE
)	O
.	O

Trans	O
-	O
activation	O
of	O
the	O
TP1	B-PRGE
promoter	O
and	O
of	O
the	O
BamHI	B-PRGE
C	I-PRGE
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein	O
-	O
protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
type	O
A	O
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
able	O
to	O
trans	O
-	O
activate	O
the	O
expression	O
of	O
the	O
LMP	B-PRGE
gene	O
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
LMP	B-PRGE
promoter	O
through	O
which	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
mediates	O
trans	O
-	O
activation	O
.	O

To	O
determine	O
whether	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
also	O
trans	O
-	O
activates	O
the	O
LMP	B-PRGE
promoter	O
by	O
protein	O
-	O
protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	B-PRGE
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein	O
-	O
binding	O
region	O
on	O
the	O
LMP	B-PRGE
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-	O
135	O
to	O
-	O
176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
with	O
the	O
DNA	O
via	O
protein	O
-	O
protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
positive	O
and	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA	B-PRGE
-	I-PRGE
2A	I-PRGE
to	O
the	O
TP1	B-PRGE
promoter	O
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B-PRGE
promoter	O
-	O
binding	O
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
positive	O
cell	O
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
positive	O
cells	O
might	O
indeed	O
contain	O
specific	O
complexes	O
bound	O
to	O
the	O
LMP	B-PRGE
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	O
factor	O
kappa	O
B	O
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O

LTR	O
-	O
directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	O
reporter	O
constructs	O
that	O
were	O
transiently	O
transfected	O
into	O
cultured	O
cells	O
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2	O
-	O
to	O
4	O
.	O
5	O
-	O
fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	O
from	O
a	O
non	O
-	O
acutely	O
pathogenic	O
strain	O
.	O

These	O
LTRs	O
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22	O
-	O
bp	O
duplication	O
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
site	O
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	O
were	O
further	O
enhanced	O
by	O
two	O
-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
or	O
by	O
cotransfection	O
with	O
plasmids	O
expressing	O
NF	O
kappa	O
B	O
subunits	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22	O
-	O
bp	O
sequence	O
duplication	O
and	O
the	O
NF	O
kappa	O
B	O
site	O
contained	O
within	O
it	O
.	O

Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	O
were	O
generated	O
.	O

The	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O

Inclusion	O
of	O
this	O
LTR	O
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two	O
-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	O
simian	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	O
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony	B-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
1	I-PRGE
(	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
)	I-PRGE
receptor	I-PRGE
promoter	O
and	O
binds	O
PEBP2	O
/	O
CBF	O
(	O
AML1	B-PRGE
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
or	O
colony	B-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
1	I-PRGE
[	O
CSF	B-PRGE
-	I-PRGE
1	I-PRGE
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	O
cells	O
and	O
placental	O
trophoblasts	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte	O
-	O
specific	O
expression	O
of	O
the	O
CSF	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue	O
-	O
specific	O
promoter	O
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte	O
/	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
(	O
D	O
.	O
-	O
E	O
.	O
Zhang	O
,	O
C	O
.	O
J	O
.	O
Hetherington	O
,	O
H	O
.	O
-	O
M	O
.	O
Chen	O
,	O
and	O
D	O
.	O
G	O
.	O
Tenen	O
,	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
14	O
:	O
373	O
-	O
381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	O
II	O
(	O
bp	O
-	O
88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	O
bp	O
upstream	O
from	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
-	O
binding	O
site	O
.	O

When	O
analyzed	O
by	O
DNase	O
footprinting	O
,	O
region	O
II	O
was	O
protected	O
preferentially	O
in	O
monocytic	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	O
II	O
interacts	O
specifically	O
with	O
nuclear	O
proteins	O
from	O
monocytic	O
cells	O
.	O

Two	O
gel	O
shift	O
complexes	O
(	O
Mono	O
A	O
and	O
Mono	O
B	O
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	O
B	O
contains	O
a	O
member	O
of	O
the	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2	O
/	O
core	O
-	O
binding	O
factor	O
(	O
PEBP2	O
/	O
CBF	O
)	O
family	O
,	O
which	O
includes	O
the	O
AML1	B-PRGE
gene	O
product	O
,	O
while	O
Mono	O
A	O
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	O
cells	O
.	O

Promoter	O
constructs	O
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	O
.	O

Furthermore	O
,	O
multimerized	O
region	O
II	O
sequence	O
elements	O
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	O
cells	O
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte	O
/	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
the	O
Mono	O
A	O
and	O
Mono	O
B	O
protein	O
complexes	O
act	O
in	O
concert	O
to	O
regulate	O
monocyte	O
-	O
specific	O
transcription	O
of	O
the	O
CSF	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
DPA	B-PRGE
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	O
finger	O
proteins	O
that	O
includes	O
a	O
Drosophila	O
developmental	O
control	O
protein	O
.	O

A	O
novel	O
DNA	O
sequence	O
element	O
termed	O
the	O
J	O
element	O
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
was	O
recently	O
described	O
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	O
II	O
gene	O
regulation	O
further	O
,	O
a	O
cDNA	O
library	O
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	O
element	O
and	O
the	O
nearby	O
J	O
element	O
of	O
the	O
human	O
DPA	B-PRGE
gene	O
.	O

Several	O
DNA	O
clones	O
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	O
18	O
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	O
finger	O
motifs	O
of	O
the	O
C2H2	O
type	O
in	O
the	O
C	O
-	O
terminal	O
region	O
,	O
that	O
are	O
Kruppel	O
-	O
like	O
in	O
the	O
conservation	O
of	O
the	O
H	O
/	O
C	O
link	O
sequence	O
connecting	O
them	O
.	O

The	O
160	O
N	O
-	O
terminal	O
amino	O
acids	O
in	O
the	O
nonfinger	O
region	O
of	O
clone	O
18	O
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	O
,	O
mouse	O
,	O
and	O
Drosophila	O
sequences	O
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel	O
-	O
like	O
zinc	O
finger	O
proteins	O
termed	O
TAB	O
(	O
tramtrack	O
[	O
ttk	O
]	O
-	O
associated	O
box	O
)	O
here	O
.	O

One	O
of	O
the	O
Drosophila	O
sequences	O
,	O
ttk	O
,	O
is	O
a	O
developmental	O
control	O
gene	O
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	O
finger	O
region	O
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

An	O
acidic	O
activation	O
domain	O
is	O
located	O
between	O
the	O
N	O
-	O
terminal	O
conserved	O
region	O
of	O
clone	O
18	O
and	O
its	O
zinc	O
fingers	O
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	O
and	O
J	O
elements	O
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

Antisense	O
cDNA	O
to	O
clone	O
18	O
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	B-PRGE
promoter	O
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	O
II	O
gene	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	O
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid	O
-	O
induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat	B-PRGE
-	O
activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
-	O
infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	O
(	O
IFN	O
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
,	O
HIV	O
-	O
1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
significantly	O
inhibited	O
Tat	B-PRGE
-	O
mediated	O
transactivation	O
in	O
T	O
-	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	O
line	O
,	O
U937	O
.	O

Replacement	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
in	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
IFN	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN	O
-	O
stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat	B-PRGE
-	O
mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	B-PRGE
gene	O
directed	O
high	O
levels	O
of	O
IFN	O
synthesis	O
in	O
Tat	B-PRGE
-	O
expressing	O
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
-	O
mediated	O
activation	O
.	O

ISG15	O
-	O
LTR	O
-	O
IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	O
and	O
U937	O
cells	O
.	O

Selected	O
transfected	O
clones	O
produced	O
low	O
levels	O
of	O
IFN	B-PRGE
A	I-PRGE
(	O
IFNA	B-PRGE
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
interleukin	O
-	O
2	O
receptor	O
upon	O
stimulation	O
with	O
phytohemagglutinin	B-PRGE
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B-PRGE
synthesis	O
observed	O
upon	O
HIV	O
-	O
1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA	B-PRGE
-	O
producing	O
cells	O
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	O
cells	O
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	O
cells	O
transduced	O
with	O
the	O
IFNA	B-PRGE
gene	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	O
synthesis	O
to	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	O
synthesis	O
results	O
in	O
a	O
long	O
-	O
lasting	O
and	O
permanent	O
suppression	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	O
leukemia	O
HL	O
-	O
60	O
cells	O
and	O
thymocytes	O
.	O

We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O

Treatment	O
of	O
a	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
,	O
HL	O
-	O
60	O
,	O
with	O
10	O
micrograms	O
/	O
mL	O
etoposide	O
or	O
2	O
microM	O
1	O
-	O
beta	O
-	O
D	O
-	O
arabinofuranosylcytosine	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3	O
-	O
4	O
hr	O
.	O

The	O
simultaneous	O
addition	O
of	O
50	O
-	O
500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O

However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	O
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-	O
and	O
dexamethasone	O
-	O
induced	O
apoptosis	O
in	O
human	O
thymocytes	O
at	O
a	O
concentration	O
of	O
1	O
-	O
10	O
microM	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal	O
-	O
ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o	O
-	O
phenanthroline	O
(	O
OP	O
)	O
(	O
metal	O
-	O
ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

Pretreatment	O
of	O
HL	O
-	O
60	O
cells	O
or	O
thymocytes	O
with	O
100	O
-	O
500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10	O
-	O
60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	O
hematopoietic	O
cells	O
.	O

Differential	O
regulation	O
of	O
proto	O
-	O
oncogenes	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
in	O
T	O
lymphocytes	O
activated	O
through	O
CD28	B-PRGE
.	O

The	O
T	O
cell	O
surface	O
molecule	O
CD28	B-PRGE
binds	O
to	O
ligands	O
on	O
accessory	O
cells	O
and	O
APCs	O
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	O
cells	O
to	O
Ags	O
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

In	O
addition	O
to	O
activation	O
of	O
phospholipase	B-PRGE
C	I-PRGE
gamma	I-PRGE
1	I-PRGE
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium	O
-	O
independent	O
,	O
CD28	B-PRGE
-	O
specific	O
pathway	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross	O
-	O
linking	O
of	O
CD28	B-PRGE
(	O
but	O
not	O
CD2	O
,	O
CD5	B-PRGE
,	O
LFA	O
-	O
1	O
,	O
or	O
CD7	B-PRGE
)	O
leads	O
to	O
an	O
elevation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
,	O
with	O
only	O
minimal	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
.	O

CD28	B-PRGE
-	O
dependent	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
requires	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
does	O
not	O
depend	O
on	O
activation	O
of	O
a	O
phorbol	O
ester	O
-	O
responsive	O
protein	O
kinase	O
C	O
or	O
elevation	O
of	O
cytosolic	O
calcium	O
.	O

Furthermore	O
,	O
CD28	B-PRGE
-	O
dependent	O
elevation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
does	O
not	O
appear	O
to	O
be	O
mediated	O
at	O
the	O
level	O
of	O
mRNA	O
stability	O
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
junB	B-PRGE
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	O
family	O
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	O
cells	O
caused	O
by	O
ligation	O
of	O
CD28	B-PRGE
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

Constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

In	O
monocytes	O
,	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	O
factor	O
in	O
the	O
expression	O
of	O
cytokine	O
genes	O
,	O
of	O
cell	O
-	O
surface	O
receptors	O
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O

In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	O
monocytic	O
line	O
Mono	O
Mac	O
6	O
,	O
cultured	O
in	O
medium	O
containing	O
fetal	O
-	O
calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'	O
constitutive	O
'	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
demonstrated	O
by	O
mobility	O
-	O
shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

This	O
nuclear	O
NF	O
-	O
kappa	O
B	O
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Protein	O
-	O
DNA	O
complexes	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	B-PRGE
subunit	I-PRGE
of	O
NF	O
-	O
kappa	O
B	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
not	O
the	O
constitutive	O
binding	O
protein	O
.	O

Using	O
LPS	O
-	O
free	O
and	O
serum	O
-	O
free	O
conditions	O
,	O
constitutive	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
in	O
different	O
cell	O
lines	O
of	O
the	O
monocytic	O
lineage	O
(	O
HL60	O
,	O
U937	O
,	O
THP	O
-	O
1	O
,	O
Mono	O
Mac	O
1	O
and	O
Mono	O
Mac	O
6	O
)	O
,	O
but	O
not	O
in	O
Molt	O
4	O
T	O
cells	O
or	O
K562	O
stem	O
cells	O
.	O

When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	O
amount	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
was	O
not	O
increased	O
in	O
more	O
mature	O
cell	O
lines	O
.	O

Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
with	O
vitamin	O
D3	O
,	O
no	O
change	O
in	O
constitutive	O
or	O
inducible	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
detected	O
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
blood	O
monocytes	O
,	O
pleural	O
macrophages	O
and	O
alveolar	O
macrophages	O
.	O

The	O
constitutive	O
NF	O
-	O
kappa	O
B	O
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
transcript	O
is	O
detectable	O
in	O
monocytes	O
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

The	O
level	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	O
macrophages	O
.	O

Constitutive	O
NF	O
-	O
kappa	O
B	O
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	O
TNF	O
,	O
interleukin	B-PRGE
6	I-PRGE
,	O
interleukin	B-PRGE
10	I-PRGE
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
or	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA	O
-	O
binding	O
activity	O
.	O

Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	O
affect	O
constitutive	O
NF	O
-	O
kappa	O
B	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Function	O
and	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
immune	O
system	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Among	O
these	O
properties	O
are	O
NF	O
-	O
kappa	O
B	O
'	O
s	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic	O
/	O
nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	O
relevant	O
proteins	O
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	O
binding	O
subunits	O
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type	O
-	O
and	O
cell	O
stage	O
-	O
specific	O
distribution	O
.	O

The	O
activity	O
of	O
DNA	O
binding	O
NF	O
-	O
kappa	O
B	O
dimers	O
is	O
tightly	O
controlled	O
by	O
accessory	O
proteins	O
called	O
I	O
kappa	O
B	O
subunits	O
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

I	O
kappa	O
B	O
proteins	O
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF	O
-	O
kappa	O
B	O
complexes	O
.	O

An	O
exception	O
is	O
the	O
Bcl	B-PRGE
-	I-PRGE
3	I-PRGE
protein	O
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	O
activating	O
subunit	O
in	O
th	O
nucleus	O
.	O

Other	O
I	O
kappa	O
B	O
proteins	O
are	O
rather	O
involved	O
in	O
terminating	O
NF	O
-	O
kappa	O
B	O
'	O
s	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	O
kappa	O
B	O
,	O
i	O
.	O
e	O
.	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
are	O
complex	O
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic	O
/	O
septic	O
shock	O
,	O
graft	O
-	O
vs	O
-	O
host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O

The	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

Increased	O
interleukin	B-PRGE
2	I-PRGE
transcription	O
in	O
murine	O
lymphocytes	O
by	O
ciprofloxacin	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
in	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	O
cell	O
mitogens	O
or	O
alloantigens	O
)	O
murine	O
splenocytes	O
and	O
in	O
the	O
stimulated	O
murine	O
T	O
cell	O
line	O
EL	O
-	O
4	O
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5	O
-	O
80	O
micrograms	O
/	O
ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	O
lymphocytes	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
was	O
inhibited	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	O
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	O
splenocytes	O
incubated	O
with	O
cipro	O
(	O
20	O
micrograms	O
/	O
ml	O
)	O
.	O

EL	O
-	O
4	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
enhancer	O
region	O
linked	O
to	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
gene	O
.	O

Analysis	O
of	O
CAT	B-PRGE
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
induction	O
.	O

In	O
addition	O
,	O
EL	O
-	O
4	O
cells	O
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

Cipro	O
did	O
not	O
affect	O
the	O
nuclear	O
transcription	O
factors	O
AP	O
-	O
1	O
or	O
NFIL	B-PRGE
-	I-PRGE
2A	I-PRGE
.	O

Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
synthesis	O
,	O
but	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
murine	O
lymphocytes	O
by	O
means	O
of	O
influencing	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
causing	O
an	O
increased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
.	O

Multiple	O
prolactin	B-PRGE
-	O
responsive	O
elements	O
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
.	O

The	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
gene	O
is	O
both	O
an	O
immediate	O
-	O
early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	O
by	O
PRL	B-PRGE
in	O
rat	O
Nb2	O
T	O
lymphocytes	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B-PRGE
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
we	O
cloned	O
the	O
rat	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
and	O
functionally	O
characterized	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	O
T	O
cells	O
,	O
1	O
.	O
7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
5	O
'	O
-	O
flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
gene	O
mediated	O
a	O
30	O
-	O
fold	O
induction	O
of	O
CAT	B-PRGE
enzyme	O
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B-PRGE
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1	O
.	O
3	O
,	O
0	O
.	O
6	O
,	O
and	O
0	O
.	O
2	O
kb	O
5	O
'	O
-	O
flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0	O
.	O
2	O
kb	O
still	O
mediated	O
a	O
12	O
-	O
fold	O
induction	O
by	O
PRL	B-PRGE
.	O

The	O
sequence	O
between	O
-	O
1	O
.	O
7	O
and	O
-	O
0	O
.	O
2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	O
to	O
respond	O
to	O
PRL	B-PRGE
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	O
PRL	B-PRGE
response	O
elements	O
may	O
require	O
an	O
interaction	O
with	O
promoter	O
-	O
proximal	O
elements	O
.	O

By	O
assaying	O
CAT	B-PRGE
enzyme	O
activity	O
across	O
a	O
24	O
-	O
h	O
PRL	B-PRGE
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs	O
.	O
S	O
phase	O
PRL	B-PRGE
responses	O
of	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
5	O
'	O
-	O
flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0	O
.	O
2	O
-	O
kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
induced	O
by	O
PRL	B-PRGE
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1	O
.	O
7	O
-	O
kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
inducible	O
by	O
PRL	B-PRGE
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	B-PRGE
-	O
induced	O
biphasic	O
expression	O
of	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL	B-PRGE
-	O
responsive	O
elements	O
:	O
elements	O
in	O
the	O
first	O
0	O
.	O
2	O
kb	O
of	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
region	O
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0	O
.	O
2	O
-	O
kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

Nonpituitary	O
human	O
prolactin	B-PRGE
gene	O
transcription	O
is	O
independent	O
of	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
differentially	O
controlled	O
in	O
lymphocytes	O
and	O
in	O
endometrial	O
stroma	O
.	O

Expression	O
of	O
the	O
human	O
PRL	B-PRGE
(	O
hPRL	B-PRGE
)	O
gene	O
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	O
lineage	O
is	O
directed	O
by	O
an	O
alternative	O
promoter	O
which	O
is	O
located	O
approximately	O
6	O
kilobases	O
(	O
kb	O
)	O
upstream	O
of	O
the	O
pituitary	O
-	O
specific	O
start	O
site	O
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue	O
-	O
specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	B-PRGE
gene	O
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	O
kb	O
5	O
'	O
-	O
flanking	O
DNA	O
of	O
the	O
upstream	O
decidual	O
/	O
lymphoid	O
(	O
dPRL	B-PRGE
)	O
promoter	O
.	O

Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	O
motifs	O
for	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
seven	O
half	O
-	O
sites	O
for	O
glucocorticoid	B-PRGE
receptor	I-PRGE
/	O
progesterone	B-PRGE
receptor	I-PRGE
(	O
PR	B-PRGE
)	O
binding	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
of	O
PR	B-PRGE
as	O
potential	O
transcriptional	O
regulators	O
,	O
since	O
the	O
POU	O
domain	O
protein	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	B-PRGE
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	B-PRGE
gene	O
is	O
activated	O
.	O

We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	O
and	O
endometrial	O
stroma	O
,	O
that	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
dPRL	B-PRGE
promoter	O
/	O
reporter	O
gene	O
constructs	O
carrying	O
3	O
kb	O
5	O
'	O
-	O
flanking	O
DNA	O
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B-PRGE
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	B-PRGE
promoter	O
.	O

When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	B-PRGE
promoter	O
in	O
PRL	B-PRGE
-	O
secreting	O
and	O
nonsecreting	O
lymphoid	O
cells	O
,	O
we	O
found	O
that	O
the	O
3	O
kb	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
dPRL	O
promoter	O
did	O
not	O
contain	O
elements	O
restricting	O
expression	O
to	O
only	O
those	O
lymphocytes	O
that	O
produce	O
PRL	B-PRGE
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	B-PRGE
gene	O
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5	O
'	O
-	O
flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	B-PRGE
promoter	O
in	O
decidualized	O
endometrial	O
stromal	O
cells	O
actively	O
secreting	O
PRL	B-PRGE
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non	O
-	O
PRL	B-PRGE
-	O
secreting	O
endometrial	O
stromal	O
cells	O
.	O

Activation	O
of	O
the	O
dPRL	B-PRGE
promoter	O
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	O
of	O
progesterone	O
,	O
suggesting	O
that	O
a	O
signal	O
transduced	O
through	O
the	O
cAMP	O
signaling	O
pathway	O
is	O
a	O
primary	O
inducer	O
of	O
decidual	O
PRL	B-PRGE
gene	O
expression	O
.	O

Activation	O
of	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
1	I-PRGE
gene	O
transcription	O
and	O
pp90rsk	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	O
of	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
1	I-PRGE
(	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
gene	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U	O
-	O
937	O
myeloid	O
leukemia	O
cells	O
.	O

Differentiation	O
of	O
U	O
-	O
937	O
cells	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine	O
/	O
threonine	O
protein	O
kinase	O
C	O
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
-	O
reporter	O
constructs	O
.	O

The	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
contains	O
six	O
CC	O
(	O
A	O
/	O
T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O

The	O
two	O
5	O
'	O
-	O
most	O
distal	O
CArG	O
sequences	O
conferred	O
TPA	O
inducibility	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
a	O
TPA	O
-	O
resistant	O
U	O
-	O
937	O
cell	O
variant	O
,	O
designated	O
TUR	O
.	O

Treatment	O
of	O
both	O
U	O
-	O
937	O
and	O
TUR	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
1	O
and	O
2A	O
,	O
was	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
through	O
the	O
5	O
'	O
-	O
most	O
CArG	O
element	O
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
serine	O
/	O
threonine	O
kinases	O
,	O
pp70S6K	O
and	O
pp90rsk	O
.	O

Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
of	O
pp70S6K	O
during	O
TPA	O
-	O
or	O
okadaic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	O
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	O
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	O
protein	O
demonstrated	O
stimulation	O
of	O
this	O
kinase	O
in	O
TPA	O
-	O
treated	O
U	O
-	O
937	O
,	O
and	O
not	O
TUR	O
,	O
cells	O
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	O
.	O

Effects	O
of	O
prostaglandin	O
E2	O
on	O
Th0	O
-	O
type	O
human	O
T	O
cell	O
clones	O
:	O
modulation	O
of	O
functions	O
of	O
nuclear	O
proteins	O
involved	O
in	O
cytokine	O
production	O
.	O

The	O
effects	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
on	O
cytokine	O
production	O
and	O
proliferation	O
of	O
the	O
CD4	B-PRGE
+	O
human	O
helper	O
T	O
cell	O
clone	O
SP	O
-	O
B21	O
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
,	O
PGE2	O
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	O
examined	O
.	O

Addition	O
of	O
rIL	O
-	O
2	O
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/	O
A23187	O
,	O
PGE2	O
enhanced	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	O
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
are	O
regulated	O
differently	O
from	O
other	O
cytokines	O
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p50	B-PRGE
)	O
homodimer	O
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	O
B	O
sequence	O
in	O
unstimulated	O
SP	O
-	O
B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA	O
/	O
A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
heterodimer	O
with	O
the	O
kappa	O
B	O
sequence	O
was	O
induced	O
.	O

Interestingly	O
,	O
PGE2	O
or	O
di	O
-	O
butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
heterodimer	O
to	O
the	O
kappa	O
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
but	O
not	O
with	O
PMA	O
/	O
A23187	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	O
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	O
is	O
selective	O
.	O

PGE2	O
enhanced	O
the	O
complex	O
formation	O
with	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
and	O
CLE0	O
sequences	O
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA	O
/	O
A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	O
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF	O
-	O
kappa	O
B	O
but	O
not	O
for	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
or	O
CLE0	O
binding	O
protein	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
down	O
-	O
regulates	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
a	O
product	O
of	O
the	O
T	O
-	O
helper	O
0	O
(	O
Th0	O
)	O
and	O
2	O
(	O
Th2	O
)	O
subset	O
,	O
was	O
originally	O
described	O
as	O
a	O
B	O
-	O
cell	O
stimulatory	O
factor	O
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
expression	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
,	O
and	O
to	O
upregulate	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
(	B-PRGE
IL1	I-PRGE
-	I-PRGE
RA	I-PRGE
)	O
gene	O
expression	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
on	O
the	O
expression	O
of	O
cytokine	O
genes	O
in	O
monocytes	O
evoked	O
by	O
other	O
T	O
-	O
helper	O
cell	O
cytokines	O
:	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
down	O
-	O
regulated	O
mRNA	O
accumulation	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
monocytes	O
stimulated	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
also	O
suppressed	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
.	O

Temporal	O
analysis	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
down	O
-	O
regulatory	O
effect	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
,	O
or	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	O
provided	O
evidence	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
acts	O
predominantly	O
on	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down	O
-	O
regulatory	O
capacity	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
did	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
induction	O
of	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
RA	I-PRGE
or	O
various	O
CSFs	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Long	O
-	O
term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	O
kinase	O
activity	O
,	O
correlates	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
and	O
NF	O
-	O
AT	O
induction	O
in	O
anti	O
-	O
CD3	O
-	O
activated	O
peripheral	O
human	O
T	O
lymphocytes	O
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	O
cell	O
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	O
cell	O
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
peripheral	O
T	O
cells	O
has	O
not	O
been	O
demonstrated	O
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3	O
-	O
mediated	O
stimulation	O
in	O
peripheral	O
T	O
cells	O
,	O
we	O
used	O
two	O
anti	O
-	O
CD3	O
mAbs	O
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	O
T	O
cells	O
:	O
OKT3	O
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	O
cells	O
without	O
a	O
second	O
signal	O
,	O
and	O
64	O
.	O
1	O
,	O
which	O
stimulates	O
T	O
cell	O
proliferation	O
on	O
its	O
own	O
.	O

We	O
found	O
that	O
tyrosine	O
kinase	O
activity	O
was	O
similar	O
for	O
both	O
mAbs	O
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64	O
.	O
1	O
than	O
for	O
OKT3	O
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
activity	O
in	O
the	O
nucleus	O
after	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
components	O
(	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
p65	B-PRGE
(	O
RelA	B-PRGE
)	O
,	O
and	O
p50	B-PRGE
(	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
)	O
)	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
only	O
64	O
.	O
1	O
induced	O
NF	O
-	O
AT	O
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	O
cells	O
.	O

Thus	O
,	O
NF	O
-	O
AT	O
induction	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	O
kinase	O
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O

On	O
the	O
other	O
hand	O
,	O
NF	O
-	O
kappa	O
B	O
induction	O
and	O
IL	O
-	O
2	O
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	O
.	O

ZAP	B-PRGE
-	I-PRGE
70	I-PRGE
tyrosine	O
kinase	O
,	O
CD45	B-PRGE
,	O
and	O
T	O
cell	O
receptor	O
involvement	O
in	O
UV	O
-	O
and	O
H2O2	O
-	O
induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	O
lymphocytes	O
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2	O
+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Normal	O
T	O
lymphocytes	O
whose	O
surface	O
expression	O
of	O
CD3	O
was	O
depleted	O
showed	O
impaired	O
UV	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2	O
+	O
signals	O
.	O

Similarly	O
,	O
Jurkat	O
T	O
cell	O
lines	O
deficient	O
in	O
CD3	O
or	O
CD45	B-PRGE
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2	O
+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	O
ZAP	B-PRGE
-	I-PRGE
70	I-PRGE
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

ZAP	B-PRGE
-	I-PRGE
70	I-PRGE
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	O
and	O
CD45	B-PRGE
,	O
whereas	O
only	O
CD3	O
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

UV	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
blocked	O
by	O
CD3	O
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	O
surface	O
molecules	O
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
nonlymphoid	O
cells	O
,	O
the	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

These	O
results	O
suggest	O
that	O
UV	O
-	O
induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	O
surface	O
receptors	O
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

The	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
adhesion	O
molecules	O
.	O

The	O
anti	O
-	O
inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
therefore	O
NF	O
-	O
kappa	O
B	O
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
transcription	O
from	O
the	O
Ig	B-PRGE
kappa	I-PRGE
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
is	O
an	O
important	O
lymphokine	O
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis	O
-	O
acting	O
regulatory	O
sites	O
are	O
required	O
for	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
sites	O
in	O
the	O
context	O
of	O
the	O
native	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
and	O
promoter	O
sequence	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	O
(	O
-	O
276	O
to	O
-	O
261	O
)	O
,	O
the	O
distal	O
octamer	O
(	O
-	O
256	O
to	O
-	O
248	O
)	O
and	O
the	O
proximal	O
octamer	O
(	O
-	O
75	O
to	O
-	O
66	O
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
in	O
different	O
T	O
leukemia	O
cell	O
lines	O
:	O
the	O
distal	O
purine	O
box	O
(	O
-	O
291	O
to	O
-	O
277	O
)	O
and	O
the	O
proximal	O
purine	O
box	O
sites	O
(	O
-	O
145	O
to	O
-	O
128	O
)	O
.	O

Finally	O
,	O
the	O
AP	O
-	O
1	O
(	O
-	O
186	O
to	O
-	O
176	O
)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-	O
206	O
to	O
-	O
195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	O
cells	O
.	O

The	O
AP	O
-	O
1	O
site	O
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	O
B	O
site	O
responded	O
to	O
IL	O
-	O
1	O
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis	O
-	O
acting	O
regulatory	O
sites	O
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	O
cells	O
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Superantigens	O
activate	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	O
class	O
II	O
molecules	O
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	O
superantigens	O
toxic	B-PRGE
shock	I-PRGE
syndrome	I-PRGE
toxin	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
TSST	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
staphylococcal	B-PRGE
enterotoxin	I-PRGE
A	I-PRGE
(	O
SEA	B-PRGE
)	O
activate	O
HIV	O
-	O
1	O
-	O
LTR	O
-	O
driven	O
transcription	O
of	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

Induction	O
of	O
HIV	O
-	O
1	O
-	O
LTR	O
-	O
driven	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
by	O
superantigens	O
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
.	O

Superantigens	O
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
-	O
pretreated	O
chronically	O
infected	O
human	O
monocytic	O
cell	O
line	O
U1	O
.	O

Induction	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
by	O
superantigens	O
occurred	O
via	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
superantigens	O
and	O
other	O
MHC	O
class	O
II	O
ligands	O
may	O
activate	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Inhibition	O
of	O
activation	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
by	O
CD28	B-PRGE
signalling	O
in	O
human	O
T	O
-	O
cells	O
.	O

Co	O
-	O
stimulation	O
of	O
T	O
-	O
lymphocytes	O
by	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B-PRGE
surface	O
molecule	O
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
production	O
.	O

The	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
triggered	O
by	O
CD28	B-PRGE
involves	O
a	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
,	O
called	O
CD28	B-PRGE
-	O
responsive	O
element	O
.	O

Stimulation	O
of	O
T	O
-	O
cells	O
by	O
agonistic	O
anti	O
-	O
CD28	B-PRGE
antibodies	O
in	O
conjunction	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	O
-	O
derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Here	O
we	O
report	O
that	O
CD28	B-PRGE
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
.	O

Whereas	O
anti	O
-	O
CD28	B-PRGE
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans	O
-	O
activation	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
PMA	O
-	O
induced	O
activation	O
of	O
AP	O
-	O
1	O
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti	O
-	O
CD28	B-PRGE
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter	O
-	O
gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	O
factors	O
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Induction	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
in	O
T	O
cells	O
uses	O
the	O
CD28	B-PRGE
costimulatory	O
pathway	O
.	O

IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
a	O
potent	O
chemotactic	O
factor	O
for	O
neutrophil	O
granulocytes	O
and	O
lymphocytes	O
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	O
cells	O
.	O

Stimulation	O
of	O
the	O
CD28	B-PRGE
cell	O
surface	O
molecule	O
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	O
production	O
in	O
activated	O
T	O
cells	O
via	O
a	O
conserved	O
sequence	O
element	O
found	O
in	O
the	O
promoter	O
of	O
several	O
lymphokine	O
genes	O
.	O

Anti	O
-	O
CD28	B-PRGE
-	O
stimulated	O
T	O
cells	O
produced	O
significant	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
;	O
additionally	O
,	O
costimulation	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-PRGE
Abs	O
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
secretion	O
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti	O
-	O
CD28	B-PRGE
Ab	O
stimulation	O
studies	O
established	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
promoter	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
functioned	O
as	O
a	O
CD28	B-PRGE
response	O
element	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
achieved	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-PRGE
costimulation	O
.	O

The	O
involvement	O
of	O
a	O
CD28	B-PRGE
response	O
element	O
in	O
the	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
expression	O
in	O
activated	O
T	O
cells	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	O
to	O
undergo	O
X	O
inactivation	O
.	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X	O
/	O
46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	B-PRGE
locus	O
on	O
their	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O

As	O
XIST	B-PRGE
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	O
chromosome	O
in	O
female	O
somatic	O
cells	O
and	O
spermatogonia	O
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	O
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	O
chromosomes	O
lacking	O
XIST	B-PRGE
expression	O
(	O
XISTE	O
-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
two	O
tiny	O
ring	O
X	O
chromosomes	O
studied	O
with	O
an	O
antibody	O
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B-PRGE
H4	I-PRGE
marking	O
transcribed	O
chromatin	O
domains	O
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE	O
-	O
ring	O
chromosomes	O
to	O
determine	O
whether	O
genes	O
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	O
X	O
are	O
expressed	O
from	O
these	O
chromosomes	O
.	O

Analyses	O
of	O
hybrid	O
cells	O
show	O
that	O
TIMP	O
,	O
ZXDA	B-PRGE
,	O
and	O
ZXDB	B-PRGE
loci	O
on	O
the	O
proximal	O
short	O
arm	O
,	O
and	O
AR	O
and	O
PHKA1	B-PRGE
loci	O
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	O
from	O
the	O
tiny	O
ring	O
X	O
chromosome	O
lacking	O
XIST	B-PRGE
DNA	O
.	O

Studies	O
of	O
the	O
ring	O
chromosome	O
that	O
has	O
XIST	B-PRGE
DNA	O
but	O
does	O
not	O
transcribe	O
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Signals	O
and	O
nuclear	O
factors	O
that	O
regulate	O
the	O
expression	O
of	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
genes	O
in	O
helper	O
T	O
cells	O
.	O

Mouse	O
thymoma	O
line	O
EL	O
-	O
4	O
cells	O
produce	O
cytokines	O
such	O
as	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
in	O
response	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

EL	O
-	O
4	O
cells	O
also	O
produce	O
low	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
when	O
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	O
PMA	O
-	O
dependent	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
production	O
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
.	O

In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	O
the	O
PMA	O
-	O
dependent	O
activation	O
of	O
the	O
endogenous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
as	O
well	O
as	O
the	O
transfected	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

These	O
results	O
indicate	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
is	O
positively	O
regulated	O
by	O
cAMP	O
in	O
a	O
manner	O
opposite	O
to	O
that	O
for	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

One	O
of	O
the	O
nuclear	O
factors	O
(	O
NFs	O
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	O
for	O
activated	O
t	O
cell	O
.	O

The	O
P	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
,	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
activated	O
T	O
cell	O
binding	O
sites	O
.	O

We	O
attempted	O
to	O
determine	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
nuclear	O
factor	O
for	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
.	O

In	O
electromobility	O
shift	O
assays	O
both	O
NF	O
-	O
kappa	O
B	O
(	O
P65	B-PRGE
or	O
P65	B-PRGE
/	O
P50	B-PRGE
heterodimer	O
)	O
and	O
NF	O
-	O
AT	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF	O
-	O
AT	O
was	O
more	O
similar	O
to	O
that	O
of	O
NF	O
(	O
P	O
)	O
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-PRGE
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
.	O

These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF	O
-	O
AT	O
have	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
,	O
whereas	O
NF	O
-	O
kappa	O
B	O
alone	O
does	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
Jurkat	O
crude	O
extract	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
AT	O
-	O
like	O
factors	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
genes	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
human	O
GATA3	B-PRGE
gene	O
.	O

GATA3	B-PRGE
,	O
a	O
member	O
of	O
the	O
GATA	O
family	O
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
lineage	O
,	O
is	O
thought	O
to	O
participate	O
in	O
T	O
-	O
cell	O
receptor	O
gene	O
activation	O
through	O
binding	O
to	O
enhancers	O
.	O

To	O
understand	O
GATA3	B-PRGE
gene	O
regulation	O
,	O
we	O
cloned	O
the	O
human	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	O
GATA3	B-PRGE
gene	O
.	O

We	O
show	O
that	O
the	O
human	O
GATA3	B-PRGE
gene	O
contains	O
six	O
exons	O
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	O
GATA3	B-PRGE
zinc	O
fingers	O
are	O
encoded	O
by	O
two	O
separate	O
exons	O
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B-PRGE
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	O
and	O
mouse	O
GATA3	B-PRGE
transcription	O
units	O
start	O
at	O
a	O
major	O
initiation	O
site	O
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	O
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	O
of	O
housekeeping	O
genes	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	O
fragment	O
containing	O
the	O
human	O
GATA3	B-PRGE
transcription	O
unit	O
,	O
3	O
kb	O
upstream	O
from	O
the	O
initiation	O
site	O
and	O
4	O
kb	O
downstream	O
from	O
the	O
polyadenylation	O
site	O
,	O
displays	O
T	O
-	O
cell	O
specificity	O
.	O

Characterization	O
of	O
NF	O
(	O
P	O
)	O
,	O
the	O
nuclear	O
factor	O
that	O
interacts	O
with	O
the	O
regulatory	O
P	O
sequence	O
(	O
5	O
'	O
-	O
CGAAAATTTCC	O
-	O
3	O
'	O
)	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
:	O
relationship	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

The	O
P	O
sequence	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
gene	O
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	O
T	O
cells	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
.	O

We	O
examined	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

NF	O
-	O
kappa	O
B	O
(	O
P65	B-PRGE
or	O
P65	B-PRGE
/	O
P50	B-PRGE
heterodimer	O
)	O
bound	O
to	O
the	O
P	O
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	O
sequence	O
when	O
expression	O
plasmids	O
were	O
cotransfected	O
with	O
P	O
sequence	O
-	O
driven	O
reporter	O
plasmids	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
EMSAs	O
,	O
NF	O
(	O
P	O
)	O
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	O
NF	O
-	O
AT	O
binding	O
site	O
but	O
not	O
by	O
the	O
unlabeled	O
AP1	O
binding	O
site	O
and	O
purified	O
NF	O
-	O
AT	O
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF	O
-	O
AT	O
were	O
similar	O
to	O
those	O
of	O
NF	O
(	O
P	O
)	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-PRGE
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF	O
-	O
AT	O
has	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
whereas	O
NF	O
-	O
kappa	O
B	O
alone	O
cannot	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
crude	O
extracts	O
.	O

Unlike	O
NF	O
-	O
AT	O
,	O
NF	O
(	O
P	O
)	O
does	O
not	O
contain	O
AP1	O
as	O
its	O
DNA	O
binding	O
component	O
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
through	O
the	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	O
regulatory	O
proteins	O
such	O
as	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	O
response	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0	O
.	O
02	O
%	O
O2	O
)	O
results	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
degradation	O
,	O
increased	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	O
gene	O
construct	O
containing	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
sites	O
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	O
kinase	O
inhibitors	O
and	O
the	O
dominant	O
negative	O
allele	O
of	O
c	O
-	O
Raf	O
-	O
1	O
(	O
Raf	O
301	O
)	O
inhibited	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
degradation	O
,	O
NF	O
-	O
kappa	O
B	O
binding	O
,	O
and	O
transactivation	O
of	O
kappa	O
B	O
reporter	O
constructs	O
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
with	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
we	O
immunoprecipitated	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
prevented	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
degradation	O
and	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF	O
-	O
kappa	O
B	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	O
necrosis	O
factor	O
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
transcriptional	O
regulatory	O
element	O
is	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	B-PRGE
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
genome	O
has	O
previously	O
revealed	O
a	O
major	O
constitutive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
associated	O
with	O
the	O
pol	B-PRGE
gene	O
(	O
E	O
.	O
Verdin	O
,	O
J	O
.	O
Virol	O
.	O
65	O
:	O
6790	O
-	O
6799	O
,	O
1991	O
)	O
.	O

In	O
the	O
present	O
report	O
,	O
high	O
-	O
resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	B-PRGE
I	I-PRGE
and	O
micrococcal	B-PRGE
nuclease	I-PRGE
identified	O
a	O
nucleosome	O
-	O
free	O
region	O
centered	O
around	O
nucleotides	O
(	O
nt	O
)	O
4490	O
to	O
4766	O
.	O

A	O
500	O
-	O
bp	O
fragment	O
encompassing	O
this	O
hypersensitive	O
site	O
(	O
nt	O
4481	O
to	O
4982	O
)	O
exhibited	O
transcription	O
-	O
enhancing	O
activity	O
(	O
two	O
-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV	O
-	O
1	O
promoter	O
after	O
transient	O
transfection	O
in	O
U937	O
and	O
CEM	O
cells	O
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	O
sites	O
for	O
nuclear	O
proteins	O
within	O
this	O
positive	O
regulatory	O
element	O
.	O

Site	O
B	O
(	O
nt	O
4519	O
to	O
4545	O
)	O
specifically	O
bound	O
four	O
distinct	O
nuclear	O
protein	O
complexes	O
:	O
a	O
ubiquitous	O
factor	O
,	O
a	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
,	O
a	O
B	O
-	O
cell	O
-	O
specific	O
factor	O
,	O
and	O
the	O
monocyte	O
/	O
macrophage	O
-	O
and	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
most	O
HIV	O
-	O
1	O
isolates	O
in	O
which	O
this	O
PU	O
box	O
was	O
not	O
conserved	O
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	O
site	O
for	O
the	O
related	O
factor	O
Ets1	B-PRGE
.	O

Factors	O
binding	O
to	O
site	O
C	O
(	O
nt	O
4681	O
to	O
4701	O
)	O
had	O
a	O
DNA	O
-	O
binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	O
B	O
,	O
except	O
for	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

A	O
GC	O
box	O
containing	O
a	O
binding	O
site	O
for	O
Sp1	B-PRGE
was	O
identified	O
(	O
nt	O
4623	O
to	O
4631	O
)	O
.	O

Site	O
D	O
(	O
nt	O
4816	O
to	O
4851	O
)	O
specifically	O
bound	O
a	O
ubiquitously	O
expressed	O
factor	O
.	O

These	O
results	O
identify	O
a	O
transcriptional	O
regulatory	O
element	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	B-PRGE
gene	O
of	O
HIV	O
-	O
1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis	O
-	O
regulatory	O
elements	O
.	O

Expression	O
of	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
in	O
T	O
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
rapidly	O
inducible	O
transcriptional	O
activator	O
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	O
kinases	O
transmit	O
signals	O
from	O
cytokine	O
and	O
immune	O
receptors	O
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	O
molecules	O
.	O

We	O
now	O
demonstrate	O
that	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	O
B	O
binding	O
complex	O
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	O
B	O
sites	O
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	O
kinase	O
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
-	O
induced	O
complex	O
comprised	O
the	O
p50	B-PRGE
and	O
p65	B-PRGE
components	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co	O
-	O
transfection	O
of	O
HIV	O
-	O
1	O
LTR	O
reporter	O
constructs	O
in	O
a	O
different	O
T	O
cell	O
line	O
demonstrated	O
that	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
activated	O
this	O
promoter	O
in	O
a	O
kappa	O
B	O
-	O
dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
v	B-PRGE
-	I-PRGE
src	I-PRGE
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	O
B	O
element	O
.	O

The	O
implications	O
for	O
T	O
cell	O
receptor	O
signaling	O
and	O
HIV	O
-	O
1	O
gene	O
expression	O
are	O
considered	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	B-PRGE
protein	O
down	O
-	O
regulates	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
human	O
T	O
cells	O
in	O
vitro	O
after	O
T	O
-	O
cell	O
receptor	O
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
negative	B-PRGE
factor	I-PRGE
(	O
Nef	B-PRGE
)	O
has	O
been	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
vitro	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B-PRGE
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	O
cells	O
by	O
constitutive	O
expression	O
of	O
the	O
nef	B-PRGE
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	O
-	O
1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	O
complex	O
resulted	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
cells	O
expressing	O
the	O
nef	B-PRGE
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O

Because	O
the	O
Nef	B-PRGE
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	O
-	O
TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	B-PRGE
protein	O
down	O
-	O
regulates	O
the	O
transcriptional	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
in	O
T	O
cells	O
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
eukaryotic	O
transcription	O
factor	O
.	O

In	O
B	O
cells	O
and	O
macrophages	O
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF	O
-	O
kappa	O
B	O
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	O
cell	O
lines	O
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	O
cells	O
NF	O
-	O
kappa	O
B	O
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	B-PRGE
alpha	I-PRGE
treatment	O
.	O

The	O
TNF	B-PRGE
alpha	I-PRGE
-	O
activated	O
NF	O
-	O
kappa	O
B	O
was	O
transcriptionally	O
functional	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
by	O
TNF	B-PRGE
alpha	I-PRGE
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cell	O
line	O
,	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
only	O
in	O
that	O
particular	O
cell	O
line	O
.	O

In	O
a	O
NGF	O
-	O
responsive	O
rat	O
pheochromocytoma	O
cell	O
line	O
,	O
PC12	O
,	O
PMA	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
whereas	O
NGF	O
did	O
not	O
.	O

In	O
other	O
neuroblastoma	O
cell	O
lines	O
,	O
such	O
as	O
SK	O
-	O
N	O
-	O
Be	O
(	O
2	O
)	O
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK	O
-	O
N	O
-	O
Be	O
(	O
2	O
)	O
cells	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	O
cell	O
line	O
and	O
that	O
the	O
low	O
PKC	O
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	O
protein	O
expression	O
.	O

NF	O
-	O
kappa	O
B	O
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	O
cell	O
lines	O
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	O
cell	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	B-PRGE
alpha	I-PRGE
proved	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	O
differentiation	O
.	O

Genes	O
encoding	O
general	O
initiation	O
factors	O
for	O
RNA	O
polymerase	O
II	O
transcription	O
are	O
dispersed	O
in	O
the	O
human	O
genome	O
.	O

General	O
transcription	O
factors	O
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

Human	O
cDNAs	O
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	O
encoding	O
the	O
TATA	B-PRGE
-	I-PRGE
box	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
TBP	B-PRGE
)	O
,	O
TFIIB	B-PRGE
,	O
TFIIE	B-PRGE
alpha	I-PRGE
,	O
TFIIE	B-PRGE
beta	I-PRGE
,	O
RAP30	B-PRGE
,	O
RAP74	B-PRGE
and	O
the	O
62	O
kDa	O
subunit	O
,	O
of	O
TFIIH	O
are	O
located	O
at	O
the	O
human	O
chromosomal	O
bands	O
6q26	O
-	O
27	O
,	O
1p21	O
-	O
22	O
,	O
3q21	O
-	O
24	O
,	O
8p12	O
,	O
13q14	O
,	O
19p13	O
.	O
3	O
and	O
11p14	O
-	O
15	O
.	O
1	O
,	O
respectively	O
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	O
genome	O
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

A	O
novel	O
heterodimerization	O
partner	O
for	O
thyroid	O
hormone	O
receptor	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
.	O

Retinoid	O
-	O
like	O
receptors	O
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	O
with	O
other	O
nuclear	O
hormone	O
receptors	O
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
as	O
a	O
new	O
thyroid	O
hormone	O
receptor	O
(	O
THR	O
)	O
auxiliary	O
nuclear	O
protein	O
,	O
heterodimerizing	O
with	O
THR	O
in	O
solution	O
.	O

Although	O
these	O
heterodimers	O
do	O
not	O
recognize	O
a	O
classical	O
thyroid	O
hormone	O
response	O
element	O
(	O
TRE	O
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR	O
+	O
4	O
)	O
,	O
PPAR	O
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH	O
-	O
dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	O
beta	O
-	O
PPAR	O
but	O
not	O
the	O
THR	O
alpha	O
-	O
PPAR	O
heterodimer	O
with	O
a	O
novel	O
TRE	O
(	O
DR	O
+	O
2	O
)	O
.	O

The	O
critical	O
region	O
of	O
THR	O
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	O
box	O
of	O
the	O
DNA	O
binding	O
domain	O
.	O

Hence	O
,	O
PPAR	O
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	O
isotype	O
.	O

Hypoxic	O
induction	O
of	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte	O
-	O
mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia	O
/	O
reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14	O
-	O
18	O
Torr	O
,	O
led	O
to	O
time	O
-	O
dependent	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

Production	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
transcription	O
,	O
based	O
on	O
nuclear	O
run	O
-	O
on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	O
for	O
macrophage	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
another	O
member	O
of	O
the	O
chemokine	O
superfamily	O
of	O
proinflammatory	O
cytokines	O
.	O

IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF	O
-	O
kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
antigen	O
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30	O
-	O
40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B-PRGE
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	O
family	O
related	O
to	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Function	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
in	O
the	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
II	I-PRGE
invariant	I-PRGE
chain	I-PRGE
promoter	O
is	O
dependent	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
different	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
subunits	O
.	O

The	O
promoter	O
of	O
the	O
human	O
major	O
histocompatibility	B-PRGE
complex	I-PRGE
class	I-PRGE
II	I-PRGE
-	I-PRGE
associated	I-PRGE
invariant	I-PRGE
-	I-PRGE
chain	I-PRGE
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
located	O
at	O
-	O
109	O
to	O
-	O
118	O
(	O
Ii	O
kappa	O
B	O
-	O
1	O
)	O
and	O
-	O
163	O
to	O
-	O
172	O
(	O
Ii	O
kappa	O
B	O
-	O
2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
transcription	O
factors	O
.	O

Ii	O
kappa	O
B	O
-	O
1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
-	O
cell	O
lines	O
and	O
in	O
the	O
Ii	O
-	O
expressing	O
T	O
-	O
cell	O
line	O
,	O
H9	O
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	O
and	O
glia	O
cell	O
lines	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	O
B	O
-	O
1	O
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA	O
-	O
binding	O
complexes	O
that	O
contain	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
p65	B-PRGE
,	O
and	O
cRel	B-PRGE
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B-PRGE
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	O
kappa	O
B	O
-	O
2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	O
-	O
cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	O
T	O
-	O
cell	O
line	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
p65	B-PRGE
,	O
and	O
cRel	B-PRGE
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	B-PRGE
and	O
p52	B-PRGE
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
.	O

Positive	O
regulators	O
of	O
the	O
lineage	O
-	O
specific	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
differentiating	O
erythroid	O
cells	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
and	O
mast	O
cell	O
lineages	O
.	O

GATA	B-PRGE
-	I-PRGE
1	I-PRGE
binds	O
to	O
WGATAR	O
consensus	O
motifs	O
in	O
the	O
regulatory	O
regions	O
of	O
virtually	O
all	O
erythroid	O
cell	O
-	O
specific	O
genes	O
.	O

Analyses	O
with	O
cultured	O
cells	O
and	O
cell	O
-	O
free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
involved	O
in	O
control	O
of	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
embryonic	O
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	O
element	O
in	O
the	O
distal	O
promoter	O
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
.	O

To	O
examine	O
whether	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
involves	O
additional	O
regulatory	O
factors	O
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	O
factors	O
to	O
activate	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	O
and	O
mature	O
erythroid	O
cells	O
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	O
cells	O
.	O

Nuclei	O
from	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mutant	O
embryonic	O
stem	O
cells	O
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	O
genes	O
in	O
erythroid	O
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
not	O
required	O
for	O
globin	O
gene	O
activation	O
following	O
cell	O
fusion	O
.	O

Patterns	O
of	O
Pan	O
expression	O
and	O
role	O
of	O
Pan	O
proteins	O
in	O
endocrine	O
cell	O
type	O
-	O
specific	O
complex	O
formation	O
.	O

The	O
Pan	B-PRGE
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Pan	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
also	O
known	O
as	O
E47	B-PRGE
and	O
E12	B-PRGE
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	B-PRGE
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	B-PRGE
proteins	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	O
lines	O
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B-PRGE
proteins	O
have	O
suggested	O
that	O
significant	O
E2A	B-PRGE
protein	O
expression	O
is	O
restricted	O
to	O
B	O
-	O
lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	O
antibody	O
,	O
Yae	O
,	O
which	O
is	O
specific	O
for	O
Pan	B-PRGE
/	O
E2A	B-PRGE
proteins	O
,	O
and	O
have	O
used	O
the	O
Yae	O
antibody	O
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan	B-PRGE
/	O
E2A	B-PRGE
protein	O
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan	B-PRGE
/	O
E2A	B-PRGE
proteins	O
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-PRGE
proteins	O
in	O
GH	B-PRGE
/	O
PRL	O
-	O
and	O
insulin	B-PRGE
-	O
producing	O
,	O
B	O
-	O
and	O
T	O
-	O
lymphocyte	O
cells	O
.	O

IEF	O
-	O
1	O
,	O
a	O
pancreatic	O
beta	O
-	O
cell	O
type	O
-	O
specific	O
complex	O
believed	O
to	O
regulate	O
insulin	B-PRGE
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B-PRGE
molecules	O
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta	O
-	O
cells	O
share	O
identical	O
Pan	B-PRGE
/	O
E2A	B-PRGE
complexes	O
,	O
native	O
-	O
Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta	O
-	O
cells	O
detect	O
Pan	B-PRGE
proteins	O
in	O
distinct	O
cell	O
type	O
-	O
specific	O
complexes	O
.	O

Functional	O
block	O
for	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
-	O
mediated	O
gene	O
regulation	O
in	O
human	O
B	O
lymphocytes	O
.	O

Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	O
receptors	O
(	O
vitamin	B-PRGE
D3	I-PRGE
receptors	I-PRGE
(	O
VDR	B-PRGE
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone	O
-	O
activated	O
receptor	O
binding	O
to	O
regulatory	O
regions	O
of	O
target	O
genes	O
.	O

These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
human	O
B	O
cells	O
and	O
compared	O
with	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
-	O
responsive	O
cells	O
of	O
the	O
T	O
and	O
monocytic	O
lineages	O
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	B-PRGE
mRNA	O
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
induced	O
VDR	B-PRGE
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
.	O

As	O
indicators	O
of	O
hormone	O
-	O
mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	O
of	O
CD23	B-PRGE
,	O
a	O
common	O
B	O
cell	O
/	O
monocyte	O
surface	O
antigen	O
,	O
and	O
24	B-PRGE
-	I-PRGE
hydroxylase	I-PRGE
.	O

1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-PRGE
expression	O
in	O
U937	O
cells	O
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-PRGE
expression	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
induced	O
24	B-PRGE
-	I-PRGE
hydroxylase	I-PRGE
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	O
cells	O
and	O
lectin	O
-	O
activated	O
T	O
cells	O
,	O
yet	O
failed	O
to	O
induce	O
24	B-PRGE
-	I-PRGE
hydroxylase	I-PRGE
mRNA	O
or	O
its	O
metabolic	O
activity	O
in	O
B	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	O
B	O
lymphocytes	O
can	O
express	O
VDR	B-PRGE
mRNA	O
and	O
protein	O
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D	O
-	O
dependent	O
gene	O
regulation	O
.	O

Effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto	O
-	O
oncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
.	O

The	O
transcription	O
factor	O
AP	O
-	O
1	O
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	O
factors	O
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
-	O
phorbol	O
-	O
13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP	O
-	O
1	O
complex	O
consists	O
of	O
distinct	O
protein	O
heterodimers	O
encoded	O
by	O
the	O
proto	O
-	O
oncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	O
factors	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	O
kinase	O
C	O
leading	O
to	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
.	O

To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0	O
.	O
2	O
mM	O
)	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0	O
.	O
5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha	O
-	O
lipoic	O
acid	O
(	O
0	O
.	O
2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	O
p105	B-PRGE
NF	I-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
gene	O
generates	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
isoforms	O
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105	O
-	O
kDa	O
protein	O
(	O
p105	B-PRGE
)	O
precursor	O
of	O
the	O
p50	B-PRGE
subunit	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
also	O
encodes	O
a	O
p70	B-PRGE
I	I-PRGE
kappa	I-PRGE
B	I-PRGE
protein	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
,	O
which	O
is	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
607	O
amino	O
acids	O
of	O
p105	O
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
isoforms	O
with	O
properties	O
different	O
from	O
those	O
of	O
p70	O
.	O

One	O
63	O
-	O
kDa	O
isoform	O
,	O
termed	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C	O
-	O
terminal	O
to	O
ankyrin	O
repeat	O
7	O
,	O
has	O
a	O
novel	O
35	O
-	O
amino	O
acid	O
C	O
terminus	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
of	O
the	O
p105	B-PRGE
gene	O
.	O

A	O
55	O
-	O
kDa	O
isoform	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
lacks	O
the	O
190	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
p70I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
.	O

In	O
contrast	O
to	O
p70I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
1	I-PRGE
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
2	I-PRGE
is	O
predominantly	O
nuclear	O
.	O

The	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
isoforms	O
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
.	O

While	O
p70I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
inhibits	O
p50	B-PRGE
-	O
,	O
p65	B-PRGE
-	O
,	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
-	O
mediated	O
transactivation	O
and	O
/	O
or	O
DNA	O
binding	O
,	O
both	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
2	I-PRGE
are	O
specific	O
for	O
p50	B-PRGE
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
-	I-PRGE
2	I-PRGE
of	O
a	O
protein	O
kinase	O
A	O
site	O
whose	O
phosphorylation	O
modulates	O
p70I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
isoforms	O
that	O
respond	O
differently	O
to	O
intracellular	O
signals	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
lymphoblastoid	O
cells	O
by	O
low	O
-	O
dose	O
ionizing	O
radiation	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
pleiotropic	O
transcription	O
factor	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2	O
-	O
50	O
Gy	O
results	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
KG	O
-	O
1	O
myeloid	O
leukemia	O
cells	O
and	O
human	O
B	O
-	O
lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0	O
.	O
25	O
-	O
2	O
.	O
0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
EBV	O
-	O
transformed	O
244B	O
human	O
lymphoblastoid	O
cells	O
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1	O
.	O
17	O
Gy	O
/	O
min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0	O
.	O
5	O
-	O
Gy	O
exposure	O
.	O

Time	O
-	O
course	O
studies	O
revealed	O
a	O
biphasic	O
time	O
-	O
dependent	O
expression	O
after	O
0	O
.	O
5	O
-	O
,	O
1	O
-	O
and	O
2	O
-	O
Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
maximum	O
after	O
the	O
0	O
.	O
5	O
-	O
Gy	O
exposure	O
.	O

The	O
expression	O
of	O
the	O
p50	B-PRGE
and	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
subunits	O
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
Gy	O
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co	O
-	O
ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11	O
-	O
dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O

Inhibition	O
of	O
cytokine	O
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

Inhibition	O
of	O
cytokine	O
production	O
by	O
PBMC	O
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
-	O
-	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha	O
-	O
tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5	O
-	O
lipoxygenase	O
inhibitor	O
zileuton	O
-	O
-	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	O
.	O

The	O
active	O
compounds	O
did	O
not	O
inhibit	O
IL	O
-	O
1	O
-	O
induced	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
fibroblasts	O
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Antioxidant	O
-	O
mediated	O
inhibition	O
of	O
cytokine	O
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	O
RNAs	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
gene	O
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	O
factors	O
and	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	O
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O

Calcineurin	O
potentiates	O
activation	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
gene	O
in	O
T	O
cells	O
:	O
involvement	O
of	O
the	O
conserved	O
lymphokine	O
element	O
0	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	O
T	O
cell	O
leukemia	O
Jurkat	O
cells	O
.	O

The	O
expression	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2	O
+	O
/	O
calmodulin	B-PRGE
-	O
dependent	O
protein	O
phosphatase	O
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
through	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	O
for	O
CN	B-PRGE
A	I-PRGE
(	O
catalytic	O
)	O
and	O
CN	B-PRGE
B	I-PRGE
(	O
regulatory	O
)	O
subunits	O
also	O
augments	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B-PRGE
A	I-PRGE
subunit	O
,	O
which	O
lacks	O
the	O
auto	O
-	O
inhibitory	O
and	O
calmodulin	O
-	O
binding	O
domains	O
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	O
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

By	O
multimerizing	O
the	O
regulatory	O
elements	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	O
sites	O
for	O
the	O
CN	O
action	O
is	O
the	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
located	O
at	O
positions	O
between	O
-	O
54	O
and	O
-	O
40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	O
sequence	O
has	O
an	O
AP1	O
-	O
binding	O
site	O
and	O
is	O
associated	O
with	O
an	O
NF	O
-	O
AT	O
-	O
like	O
factor	O
,	O
termed	O
NF	B-PRGE
-	I-PRGE
CLE0	I-PRGE
gamma	I-PRGE
.	O

NF	B-PRGE
-	I-PRGE
CLE0	I-PRGE
gamma	I-PRGE
binding	O
is	O
induced	O
by	O
PMA	O
/	O
A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	O
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
genes	O
and	O
that	O
the	O
CLE0	O
sequence	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Central	O
nervous	O
system	O
-	O
derived	O
cells	O
express	O
a	O
kappa	O
B	O
-	O
binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	O
-	O
independent	O
transactivation	O
by	O
Tat	B-PRGE
.	O

The	O
Tat	B-PRGE
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	O
terminal	O
repeat	O
-	O
directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	B-PRGE
with	O
the	O
unusual	O
transcription	O
element	O
TAR	O
,	O
astrocytic	O
glial	O
cells	O
support	O
TAR	O
-	O
independent	O
transactivation	O
of	O
HIV	O
-	O
1	O
transcription	O
by	O
Tat	B-PRGE
.	O

This	O
alternative	O
pathway	O
of	O
Tat	B-PRGE
activation	O
is	O
mediated	O
by	O
the	O
viral	O
enhancer	O
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	O
lymphocytes	O
.	O

Tat	B-PRGE
transactivation	O
mediated	O
by	O
the	O
kappa	O
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	O
-	O
deleted	O
mutant	O
HIV	O
-	O
1	O
in	O
astrocytes	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	O
B	O
-	O
specific	O
binding	O
factors	O
present	O
in	O
human	O
glial	O
astrocytes	O
that	O
differ	O
from	O
prototypical	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
novel	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV	O
-	O
1	O
Tat	B-PRGE
affinity	O
column	O
,	O
while	O
prototypical	O
NF	O
-	O
kappa	O
B	O
from	O
Jurkat	O
T	O
cells	O
is	O
not	O
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
factors	O
activate	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	O
B	O
domain	O
.	O

Moreover	O
,	O
TAR	O
-	O
independent	O
transactivation	O
of	O
HIV	O
-	O
1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor	O
-	O
dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B	O
-	O
binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	O
nervous	O
system	O
-	O
enriched	O
kappa	O
B	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
HIV	O
-	O
1	O
expression	O
is	O
discussed	O
.	O

An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
regulates	O
activity	O
of	O
the	O
alpha	B-PRGE
4	I-PRGE
integrin	I-PRGE
gene	O
promoter	O
.	O

alpha	B-PRGE
4	I-PRGE
integrins	I-PRGE
mediate	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	B-PRGE
4	I-PRGE
expression	O
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	O
'	O
deletion	O
mutants	O
of	O
the	O
alpha	B-PRGE
4	I-PRGE
gene	O
promoter	O
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	O
lines	O
that	O
express	O
alpha	B-PRGE
4	I-PRGE
and	O
cell	O
lines	O
that	O
do	O
not	O
.	O

The	O
sequence	O
between	O
position	O
-	O
42	O
and	O
-	O
76	O
base	O
pairs	O
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B-PRGE
4	I-PRGE
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	O
cells	O
,	O
which	O
do	O
not	O
express	O
alpha	B-PRGE
4	I-PRGE
.	O

Three	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-	O
50	O
and	O
-	O
54	O
bp	O
and	O
a	O
more	O
5	O
'	O
site	O
at	O
position	O
-	O
67	O
bp	O
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3	O
'	O
-	O
most	O
site	O
alone	O
was	O
sufficient	O
for	O
binding	O
GA	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
alpha	I-PRGE
(	O
GABP	B-PRGE
alpha	I-PRGE
)	O
/	O
GABP	O
beta	O
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
"	O
a	O
"	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	O
family	O
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell	O
-	O
type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O

Deletion	O
of	O
the	O
5	O
'	O
-	O
most	O
Ets	O
site	O
had	O
no	O
effect	O
on	O
binding	O
to	O
GABP	B-PRGE
alpha	I-PRGE
/	O
GABP	O
beta	O
,	O
but	O
it	O
eliminated	O
a	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	O
Ets	O
-	O
1	O
-	O
containing	O
complex	O
"	O
c	O
"	O
appeared	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O

We	O
conclude	O
that	O
although	O
neither	O
of	O
the	O
two	O
5	O
'	O
-	O
most	O
Ets	O
sites	O
alone	O
binds	O
nuclear	O
protein	O
,	O
they	O
appear	O
to	O
act	O
as	O
modulators	O
which	O
control	O
the	O
pattern	O
of	O
Ets	O
proteins	O
that	O
bind	O
the	O
alpha	B-PRGE
4	I-PRGE
gene	O
promoter	O
.	O

This	O
arrangement	O
of	O
Ets	O
sites	O
,	O
coupled	O
with	O
the	O
tissue	O
-	O
and	O
developmental	O
-	O
specific	O
expression	O
of	O
Ets	O
members	O
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	B-PRGE
4	I-PRGE
integrin	I-PRGE
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
monocytic	O
cells	O
is	O
mediated	O
by	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
.	O

Exposure	O
of	O
monocytic	O
cells	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	O
gene	O
products	O
,	O
including	O
tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
.	O

TF	B-PRGE
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	O
protease	O
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	O
complex	O
from	O
human	O
monocytic	O
cells	O
that	O
bound	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
,	O
5	O
'	O
-	O
CGGAGTTTCC	O
-	O
3	O
'	O
,	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	O
TF	B-PRGE
gene	O
.	O

This	O
nuclear	O
complex	O
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B-PRGE
gene	O
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	B-PRGE
site	O
bound	O
translated	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p65	B-PRGE
homodimers	O
but	O
not	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimers	O
or	O
p50	B-PRGE
homodimers	O
.	O

Base	O
-	O
pair	O
substitutions	O
in	O
the	O
TF	B-PRGE
site	O
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	O
1	O
precluded	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

In	O
fact	O
,	O
under	O
low	O
-	O
ionic	O
-	O
strength	O
conditions	O
,	O
the	O
TF	B-PRGE
complex	O
did	O
not	O
migrate	O
with	O
translated	O
p50	B-PRGE
/	O
p65	B-PRGE
dimers	O
but	O
instead	O
comigrated	O
with	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
dimers	O
.	O

Antibodies	O
against	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p65	B-PRGE
and	O
the	O
absence	O
of	O
p50	B-PRGE
in	O
the	O
TF	B-PRGE
complex	O
and	O
further	O
showed	O
that	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
selectively	O
bound	O
to	O
the	O
TF	B-PRGE
kappa	O
B	O
-	O
like	O
site	O
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	B-PRGE
site	O
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
and	O
was	O
transactivated	O
by	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
or	O
p65	B-PRGE
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
to	O
a	O
novel	O
kappa	O
B	O
-	O
like	O
site	O
mediated	O
LPS	O
induction	O
of	O
TF	B-PRGE
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	O
phagocytes	O
by	O
leukemia	B-PRGE
inhibitory	I-PRGE
factor	I-PRGE
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	B-PRGE
inhibitory	I-PRGE
factor	I-PRGE
(	O
LIF	B-PRGE
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	O
phagocytes	O
(	O
MNP	O
)	O
.	O

LIF	B-PRGE
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
p24	B-PRGE
antigen	I-PRGE
production	O
in	O
the	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
U1	O
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	B-PRGE
effects	O
were	O
similar	O
to	O
interleukin	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	B-PRGE
effects	O
,	O
levels	O
of	O
HIV	O
mRNA	O
,	O
activation	O
of	O
the	O
DNA	O
binding	O
protein	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kB	O
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	O
were	O
analyzed	O
.	O

LIF	B-PRGE
increased	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
mRNA	O
at	O
2	O
.	O
0	O
,	O
4	O
.	O
3	O
,	O
and	O
9	O
.	O
2	O
kB	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O

The	O
DNA	O
binding	O
protein	O
NF	O
-	O
kB	O
is	O
a	O
central	O
mediator	O
in	O
cytokine	O
activation	O
of	O
HIV	O
transcription	O
.	O

NF	O
-	O
kB	O
levels	O
were	O
higher	O
in	O
unstimulated	O
U1	O
cells	O
as	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
U937	O
.	O

In	O
both	O
cell	O
lines	O
LIF	B-PRGE
increased	O
NF	O
-	O
kB	O
activity	O
.	O

Induction	O
of	O
NF	O
-	O
kB	O
and	O
HIV	O
replication	O
by	O
cytokines	O
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
oxygen	O
radical	O
scavenger	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
,	O
inhibited	O
LIF	B-PRGE
-	O
induced	O
HIV	O
replication	O
.	O

LIF	B-PRGE
induces	O
the	O
production	O
of	O
other	O
cytokines	O
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	O
to	O
IL	O
-	O
1	O
,	O
TNF	O
,	O
or	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

These	O
results	O
identify	O
LIF	B-PRGE
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Tat	B-PRGE
upregulates	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
in	O
activated	O
T	O
cells	O
.	O

Dysregulation	O
of	O
cytokines	O
secreted	O
by	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	B-PRGE
on	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
expression	O
,	O
we	O
used	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
constructs	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
secreting	O
Jurkat	O
T	O
cells	O
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV	O
-	O
1	O
Tat	B-PRGE
induced	O
a	O
five	O
-	O
to	O
eightfold	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
phytohemagglutinin	B-PRGE
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
primary	O
T	O
cells	O
stimulated	O
by	O
extracellular	O
HIV	O
-	O
1	O
Tat	B-PRGE
protein	O
.	O

Analysis	O
of	O
mRNA	O
suggested	O
that	O
Tat	B-PRGE
exerts	O
its	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
site	O
at	O
positions	O
-	O
206	O
to	O
-	O
195	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B-PRGE
effect	O
.	O

The	O
Tat	B-PRGE
-	O
mediated	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	B-PRGE
or	O
-	O
unlike	O
the	O
analogous	O
effect	O
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	B-PRGE
-	O
by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	O
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T	O
-	O
helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

The	O
macrophage	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
directs	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
receptor	I-PRGE
.	O

The	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	I-PRGE
M	I-PRGE
-	I-PRGE
CSF	I-PRGE
)	I-PRGE
receptor	I-PRGE
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
from	O
two	O
distinct	O
promoters	O
in	O
monocytes	O
/	O
macrophages	O
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	O
progenitors	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
monocytic	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	O
factors	O
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	O
genes	O
is	O
the	O
macrophage	O
-	O
and	O
B	O
-	O
cell	O
-	O
specific	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
transcription	O
factor	O
,	O
we	O
investigated	O
whether	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
binds	O
and	O
activates	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro	O
-	O
translated	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
promoter	O
just	O
upstream	O
from	O
the	O
major	O
transcription	O
initiation	O
site	O
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
binding	O
decrease	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
promoter	O
activity	O
significantly	O
in	O
macrophage	O
cell	O
lines	O
only	O
.	O

Furthermore	O
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
transactivates	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
promoter	O
in	O
nonmacrophage	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	O
macrophage	O
growth	O
factor	O
.	O

Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	B-PRGE
expression	O
in	O
purified	O
adult	O
-	O
progenitor	O
culture	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

In	O
clonogenetic	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS	O
+	O
)	O
or	O
-	O
nonsupplemented	O
(	O
FCS	O
-	O
)	O
culture	O
treated	O
with	O
saturating	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
and	O
erythropoietin	B-PRGE
(	O
Ep	B-PRGE
)	O
(	O
combined	O
with	O
c	B-PRGE
-	I-PRGE
kit	I-PRGE
ligand	I-PRGE
in	O
FCS	O
(	O
-	O
)	O
-	O
culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose	O
-	O
dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	O
clones	O
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS	O
+	O
culture	O
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

In	O
FCS	O
-	O
liquid	O
-	O
suspension	O
culture	O
supplemented	O
with	O
saturating	O
Ep	B-PRGE
level	O
and	O
low	O
-	O
dose	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
/	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
adult	O
HPC	O
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high	O
-	O
dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Studies	O
on	O
RA	O
time	O
-	O
response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	O
are	O
sensitive	O
to	O
its	O
action	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	O
GATA1	B-PRGE
gene	O
,	O
which	O
encodes	O
a	O
finger	O
transcription	O
factor	O
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	O
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	B-PRGE
mRNA	O
induction	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	O
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	B-PRGE
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

Comparative	O
analysis	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
complex	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
is	O
a	O
transcriptional	O
activator	O
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
promoter	O
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell	O
-	O
specific	O
inducibility	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	O
binding	O
activity	O
could	O
also	O
be	O
induced	O
in	O
human	O
B	O
cells	O
.	O

The	O
B	O
cell	O
NFAT	O
complex	O
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT	O
-	O
driven	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
construct	O
.	O

Competition	O
with	O
an	O
AP	O
-	O
1	O
motif	O
or	O
with	O
anti	O
-	O
Jun	O
and	O
anti	O
-	O
Fos	O
antibodies	O
abolished	O
binding	O
to	O
the	O
NFAT	O
motif	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	O
complex	O
formation	O
in	O
both	O
cell	O
types	O
.	O

Purified	O
recombinant	O
Jun	O
and	O
Fos	O
proteins	O
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	O
motif	O
.	O

However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full	O
-	O
length	O
,	O
but	O
not	O
truncated	O
,	O
Jun	O
/	O
Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	O
complex	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	O
expressed	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
B	O
and	O
T	O
cells	O
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	O
complex	O
in	O
both	O
cell	O
types	O
.	O

An	O
NFAT	O
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	O
'	O
purine	O
-	O
rich	O
part	O
of	O
the	O
NFAT	O
sequence	O
failed	O
to	O
form	O
a	O
complex	O
and	O
to	O
compete	O
with	O
the	O
wild	O
type	O
motif	O
for	O
NFAT	O
complex	O
formation	O
in	O
both	O
T	O
and	O
B	O
cells	O
.	O

We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	O
complex	O
consisting	O
of	O
Jun	O
,	O
Fos	O
,	O
and	O
a	O
constitutive	O
nuclear	O
factor	O
is	O
formed	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
but	O
an	O
additional	O
factor	O
and	O
/	O
or	O
post	O
-	O
translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	O
cells	O
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	O
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
expression	O
in	O
human	O
T	O
-	O
and	O
B	O
-	O
cell	O
lines	O
.	O

Regulation	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
expression	O
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid	O
-	O
sensitive	O
human	O
leukemic	O
T	O
-	O
cell	O
line	O
6TG1	O
.	O
1	O
and	O
in	O
the	O
human	O
B	O
-	O
cell	O
line	O
IM	O
-	O
9	O
.	O

In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	B-PRGE
mRNA	O
seen	O
in	O
IM	O
-	O
9	O
cells	O
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16	O
-	O
18	O
h	O
,	O
treatment	O
of	O
6TG1	O
.	O
1	O
cells	O
resulted	O
in	O
an	O
8	O
-	O
fold	O
increase	O
in	O
GR	B-PRGE
mRNA	O
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	O
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
GR	B-PRGE
protein	O
.	O

Half	O
-	O
maximal	O
induction	O
of	O
GR	B-PRGE
mRNA	O
and	O
protein	O
in	O
6TG1	O
.	O
1	O
cells	O
was	O
observed	O
between	O
10	O
-	O
100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	B-PRGE
expression	O
in	O
6TG1	O
.	O
1	O
cells	O
is	O
a	O
receptor	O
-	O
mediated	O
response	O
.	O

Positive	O
autoregulation	O
of	O
GR	B-PRGE
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid	O
-	O
resistant	O
CEM	O
-	O
C1	O
cells	O
,	O
which	O
contain	O
functional	O
GR	B-PRGE
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	O
a	O
consequence	O
nor	O
the	O
sole	O
cause	O
of	O
growth	O
arrest	O
.	O

The	O
degree	O
of	O
negative	O
autoregulation	O
in	O
IM	O
-	O
9	O
cells	O
and	O
positive	O
autoregulation	O
in	O
6TG1	O
.	O
1	O
cells	O
was	O
unaffected	O
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O

Measurement	O
of	O
GR	B-PRGE
mRNA	O
turnover	O
in	O
6TG1	O
.	O
1	O
cells	O
treated	O
with	O
actinomycin	O
-	O
D	O
revealed	O
a	O
half	O
-	O
life	O
of	O
2	O
.	O
5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O

A	O
similar	O
half	O
-	O
life	O
was	O
determined	O
in	O
IM	O
-	O
9	O
cells	O
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid	O
-	O
mediated	O
autoregulation	O
of	O
GR	B-PRGE
expression	O
is	O
a	O
tissue	O
-	O
specific	O
primary	O
transcriptional	O
response	O
.	O

Occurrence	O
of	O
a	O
silencer	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
naive	O
but	O
not	O
in	O
memory	O
resting	O
T	O
helper	O
lymphocytes	O
.	O

In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	O
T	O
cell	O
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self	O
-	O
tolerance	O
.	O

In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
activation	O
shows	O
that	O
naive	O
human	O
helper	O
T	O
cells	O
(	O
cord	O
blood	O
CD4	B-PRGE
+	O
T	O
cells	O
,	O
adult	O
CD4	B-PRGE
+	O
CD45RO	B-PRGE
-	O
T	O
cells	O
)	O
regulate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	O
and	O
an	O
activator	O
acting	O
on	O
the	O
purine	O
-	O
rich	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
elements	O
(	O
NF	O
-	O
AT	O
binding	O
sites	O
)	O
.	O

By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	O
activated	O
helper	O
T	O
cells	O
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4	B-PRGE
+	O
T	O
(	O
memory	O
)	O
clones	O
,	O
or	O
CD4	B-PRGE
+	O
CD45RO	B-PRGE
+	O
T	O
cells	O
isolated	O
ex	O
vivo	O
,	O
no	O
longer	O
have	O
a	O
silencer	O
.	O

Their	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	O
transcription	O
factor	O
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	O
memory	O
T	O
cells	O
the	O
activator	O
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	O
cells	O
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	O
cell	O
growth	O
factor	O
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O

It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	O
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

Stimulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
production	O
in	O
human	O
monocytes	O
by	O
protein	B-PRGE
phosphatase	I-PRGE
1	I-PRGE
and	O
2A	B-PRGE
inhibitors	O
.	O

Protein	B-PRGE
phosphatases	I-PRGE
1	I-PRGE
and	O
2A	B-PRGE
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O

In	O
human	O
monocytes	O
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	O
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
.	O

The	O
increased	O
mRNA	O
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin	O
-	O
1	O
genes	O
.	O

Stimulation	O
of	O
interleukin	O
-	O
1	O
gene	O
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	O
factor	O
activities	O
,	O
including	O
those	O
of	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
by	O
these	O
protein	O
phosphatase	O
inhibitors	O
.	O

Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
convertase	I-PRGE
mRNA	O
accumulation	O
.	O

The	O
stimulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
cytokine	O
was	O
increased	O
.	O

These	O
results	O
show	O
that	O
protein	B-PRGE
phosphatase	I-PRGE
1	I-PRGE
and	O
2A	B-PRGE
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	O
monocytes	O
and	O
suggest	O
that	O
these	O
two	O
phosphatases	O
play	O
important	O
roles	O
in	O
regulating	O
interleukin	O
-	O
1	O
production	O
.	O

Human	O
CD3	B-PRGE
-	O
CD16	B-PRGE
+	O
natural	O
killer	O
cells	O
express	O
the	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
T	O
cell	O
transcription	O
factor	O
and	O
an	O
unrearranged	O
2	O
.	O
3	O
-	O
kb	O
TcR	B-PRGE
delta	I-PRGE
transcript	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
(	I-PRGE
TcR	I-PRGE
)	I-PRGE
delta	I-PRGE
transcripts	O
expressed	O
by	O
CD3	B-PRGE
-	O
CD16	B-PRGE
+	O
cells	O
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
T	O
cell	O
transcription	O
factor	O
and	O
the	O
recombination	B-PRGE
-	I-PRGE
activating	I-PRGE
gene	I-PRGE
(	I-PRGE
RAG	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Multiple	O
TcR	B-PRGE
delta	I-PRGE
transcripts	O
deriving	O
from	O
an	O
unrearranged	O
TcR	B-PRGE
delta	I-PRGE
gene	O
were	O
detected	O
in	O
both	O
polyclonal	O
and	O
clonal	O
CD3	B-PRGE
-	O
CD16	B-PRGE
+	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O

Two	O
unrearranged	O
TcR	B-PRGE
delta	I-PRGE
transcripts	O
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	B-PRGE
delta	I-PRGE
mRNA	O
(	O
2	O
.	O
3	O
and	O
1	O
.	O
3	O
kb	O
)	O
found	O
in	O
TcR	B-PRGE
gamma	I-PRGE
/	O
delta	B-PRGE
+	O
T	O
lymphocytes	O
.	O

Sequence	O
analysis	O
of	O
nine	O
different	O
2	O
.	O
3	O
-	O
kb	O
cDNA	O
clones	O
obtained	O
from	O
NK	O
-	O
derived	O
polyA	O
+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	B-PRGE
delta	I-PRGE
gene	O
.	O

These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	O
bp	O
upstream	O
from	O
the	O
J	O
delta	O
1	O
segment	O
.	O

The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	O
delta	O
1	O
segment	O
corresponded	O
to	O
the	O
previously	O
reported	O
germ	O
-	O
line	O
sequence	O
.	O

The	O
J	O
delta	O
1	O
segment	O
was	O
correctly	O
spliced	O
to	O
C	O
delta	O
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	O
C	O
delta	O
exon	O
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2	O
.	O
3	O
-	O
kb	O
cDNA	O
.	O

The	O
expression	O
of	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
a	O
T	O
cell	O
-	O
specific	O
factor	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	B-PRGE
delta	I-PRGE
locus	O
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	O
cell	O
population	O
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O

All	O
NK	O
clones	O
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
specific	O
mRNA	O
,	O
suggesting	O
that	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	B-PRGE
delta	I-PRGE
gene	O
expression	O
in	O
NK	O
cells	O
.	O

Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
could	O
be	O
detected	O
in	O
all	O
NK	O
cell	O
lines	O
or	O
clones	O
analyzed	O
.	O

Involvement	O
of	O
Alu	O
sequences	O
in	O
the	O
cell	O
-	O
specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	O
chain	O
of	O
Fc	O
and	O
T	O
cell	O
receptors	O
.	O

The	O
Fc	B-PRGE
epsilon	I-PRGE
RI	I-PRGE
-	I-PRGE
gamma	I-PRGE
chains	I-PRGE
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	O
cells	O
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

They	O
are	O
part	O
of	O
the	O
high	O
affinity	O
IgE	O
receptor	O
in	O
mast	O
cells	O
,	O
basophils	O
,	O
Langerhans	O
cells	O
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	O
(	O
Fc	B-PRGE
gamma	I-PRGE
RIIIA	I-PRGE
or	O
CD16	B-PRGE
)	O
in	O
natural	O
killer	O
cells	O
and	O
macrophages	O
;	O
and	O
part	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
in	O
subsets	O
of	O
T	O
cells	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	O
chain	O
gene	O
by	O
analyzing	O
the	O
2	O
.	O
5	O
-	O
kilobase	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

This	O
sequence	O
contains	O
a	O
promoter	O
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O

However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	O
Fc	B-PRGE
epsilon	I-PRGE
RI	I-PRGE
-	I-PRGE
gamma	I-PRGE
chain	I-PRGE
transcripts	O
.	O

We	O
have	O
identified	O
two	O
adjacent	O
cis	O
-	O
acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O

The	O
first	O
(	O
-	O
445	O
/	O
-	O
366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	O
and	O
T	O
cells	O
.	O

The	O
second	O
(	O
-	O
365	O
/	O
-	O
264	O
)	O
binds	O
to	O
nuclear	O
factors	O
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	O
and	O
T	O
cells	O
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	O
and	O
as	O
a	O
positive	O
one	O
in	O
T	O
cells	O
.	O

Thus	O
,	O
this	O
Alu	O
repeat	O
(	O
90	O
%	O
identical	O
to	O
Alu	O
consensus	O
sequences	O
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O

Interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
expression	O
by	O
activated	O
T	O
cells	O
involves	O
an	O
inducible	O
,	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
and	O
an	O
octamer	O
binding	O
protein	O
.	O

Interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
exclusively	O
expressed	O
by	O
activated	O
T	O
and	O
natural	O
killer	O
cells	O
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage	O
-	O
specific	O
and	O
in	O
a	O
stimulation	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT	O
-	O
1	O
-	O
activating	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
.	O

This	O
region	O
binds	O
an	O
inducible	O
,	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
over	O
its	O
5	O
'	O
end	O
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

Over	O
its	O
3	O
'	O
end	O
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O

This	O
factor	O
is	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
an	O
immunologically	O
related	O
octamer	O
-	O
binding	O
protein	O
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	O
elements	O
.	O

These	O
characteristics	O
make	O
the	O
ACT	O
-	O
1	O
site	O
analogous	O
to	O
the	O
activating	O
ARRE	O
-	O
1	O
site	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
these	O
genes	O
.	O

ras	O
protein	O
activity	O
is	O
essential	O
for	O
T	O
-	O
cell	O
antigen	O
receptor	O
signal	O
transduction	O
.	O

In	O
a	O
Jurkat	O
cell	O
model	O
of	O
T	O
-	O
cell	O
activation	O
an	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
/	O
reporter	O
gene	O
construct	O
was	O
activated	O
by	O
antigen	O
receptor	O
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	O
interleukin	O
-	O
1	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	O
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin	O
-	O
1	O
.	O

Activated	O
ras	O
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	O
stimulation	O
in	O
activation	O
of	O
the	O
T	O
-	O
cell	O
transcription	O
factor	O
NF	O
-	O
AT	O
.	O

A	O
dominant	O
inhibitory	O
ras	O
mutant	O
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	O
activity	O
is	O
required	O
for	O
antigen	O
receptor	O
signaling	O
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	O
blocked	O
both	O
activated	O
ras	O
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	O
upstream	O
of	O
PKC	O
.	O

Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid	O
-	O
specific	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
complex	O
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
complex	O
,	O
NF	O
-	O
AT	O
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	O
cells	O
and	O
is	O
assembled	O
from	O
a	O
pre	O
-	O
existing	O
,	O
T	O
cell	O
restricted	O
cytoplasmic	O
factor	O
and	O
an	O
inducible	O
ubiquitous	O
nuclear	O
component	O
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	O
receptor	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	O
factors	O
as	O
components	O
of	O
the	O
murine	O
NF	O
-	O
AT	O
complex	O
.	O

Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	O
NF	O
-	O
AT	O
contains	O
the	O
phorbol	O
ester	O
-	O
inducible	O
transcription	O
factor	O
AP1	O
(	O
Jun	O
/	O
Fos	O
)	O
.	O

We	O
further	O
characterize	O
which	O
AP1	O
family	O
members	O
can	O
assume	O
this	O
role	O
.	O

Antisera	O
to	O
Fos	O
inhibits	O
NF	O
-	O
AT	O
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	O
site	O
for	O
AP1	O
.	O

Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF	O
-	O
AT	O
-	O
directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O

Overexpression	O
of	O
cJun	B-PRGE
or	O
JunD	B-PRGE
,	O
but	O
not	O
JunB	B-PRGE
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	O
that	O
many	O
but	O
not	O
all	O
Jun	O
-	O
and	O
Fos	O
-	O
related	O
proteins	O
functionally	O
activate	O
NF	O
-	O
AT	O
-	O
dependent	O
transcription	O
in	O
the	O
presence	O
of	O
the	O
cytoplasmic	O
component	O
.	O

NF	O
-	O
AT	O
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi	O
-	O
purified	O
AP1	O
proteins	O
mixed	O
with	O
cytosol	O
from	O
T	O
lymphocytes	O
.	O

Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	B-PRGE
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF	O
-	O
AT	O
DNA	O
binding	O
complex	O
.	O

Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF	O
-	O
AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	O
II	O
MHC	O
X1	O
box	O
DNA	O
-	O
binding	O
proteins	O
in	O
wild	O
-	O
type	O
and	O
class	O
II	O
-	O
deficient	O
B	O
cells	O
.	O

The	O
X	O
box	O
region	O
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
in	O
B	O
lymphocytes	O
.	O

Although	O
several	O
class	O
II	O
promoter	O
-	O
specific	O
DNA	O
binding	O
factors	O
have	O
been	O
described	O
,	O
only	O
the	O
X	O
box	O
region	O
factor	O
,	O
RFX	O
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
class	O
II	O
-	O
deficient	O
congenital	O
immunodeficiency	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	O
box	O
DNA	O
-	O
binding	O
proteins	O
in	O
class	O
II	O
gene	O
expression	O
,	O
the	O
role	O
of	O
the	O
X	O
box	O
region	O
was	O
examined	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-	O
negative	O
lymphoid	O
cells	O
.	O

In	O
addition	O
to	O
the	O
wild	O
-	O
type	O
B	O
cell	O
line	O
Raji	O
,	O
two	O
class	O
II	O
transcriptional	O
mutant	O
cell	O
lines	O
,	O
SJO	O
and	O
RJ2	O
.	O
2	O
.	O
5	O
,	O
and	O
Jurkat	O
,	O
a	O
class	O
II	O
negative	O
T	O
cell	O
line	O
,	O
were	O
examined	O
.	O

In	O
contrast	O
to	O
wild	O
-	O
type	O
B	O
cells	O
,	O
neither	O
of	O
the	O
class	O
II	O
mutant	O
cell	O
lines	O
could	O
use	O
the	O
X	O
box	O
region	O
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	O
gene	O
,	O
indicating	O
that	O
the	O
X	O
box	O
-	O
dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	O
box	O
DNA	O
-	O
binding	O
protein	O
RFX	O
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild	O
-	O
type	O
B	O
cells	O
and	O
the	O
mutant	O
RJ2	O
.	O
2	O
.	O
5	O
but	O
was	O
absent	O
in	O
SJO	O
and	O
Jurkat	O
.	O

However	O
,	O
other	O
X1	O
box	O
-	O
specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	O
lines	O
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	O
binding	O
proteins	O
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	O
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA	O
-	O
binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1	O
-	O
specific	O
factors	O
.	O

One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	O
activity	O
.	O

A	O
similar	O
comparison	O
with	O
protease	O
-	O
treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	O
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box	O
-	O
specific	O
DNA	O
-	O
binding	O
activities	O
exist	O
in	O
all	O
lymphoid	O
cells	O
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	O
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

The	O
human	B-PRGE
prointerleukin	I-PRGE
1	I-PRGE
beta	I-PRGE
gene	O
requires	O
DNA	O
sequences	O
both	O
proximal	O
and	O
distal	O
to	O
the	O
transcription	O
start	O
site	O
for	O
tissue	O
-	O
specific	O
induction	O
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	O
sequences	O
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	B-PRGE
prointerleukin	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
proIL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
gene	O
.	O

A	O
cell	O
-	O
type	O
-	O
independent	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
responsive	O
enhancer	O
element	O
located	O
between	O
-	O
3757	O
and	O
-	O
2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
cap	O
site	O
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	O
monocytes	O
.	O

The	O
enhancer	O
also	O
appeared	O
to	O
mediate	O
phorbol	O
myristate	O
acetate	O
induction	O
in	O
monocytes	O
and	O
IL	O
-	O
1	O
responsiveness	O
in	O
fibroblasts	O
.	O

Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	O
binding	O
sequences	O
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	O
for	O
gene	O
induction	O
.	O

One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C	O
/	O
EBP	O
family	O
of	O
transcription	O
factors	O
required	O
for	O
both	O
IL	O
-	O
1	O
-	O
and	O
LPS	O
-	O
specific	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
proteins	O
)	O
.	O

When	O
ligated	O
to	O
the	O
proIL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
cap	O
site	O
-	O
proximal	O
region	O
(	O
located	O
between	O
-	O
131	O
to	O
+	O
12	O
)	O
,	O
both	O
the	O
proIL	O
-	O
1	O
beta	O
and	O
the	O
simian	O
virus	O
40	O
enhancer	O
elements	O
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
expression	O
.	O

When	O
ligated	O
to	O
the	O
murine	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
promoter	O
,	O
however	O
,	O
the	O
proIL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
enhancer	O
was	O
inducible	O
in	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
HeLa	O
cells	O
,	O
suggesting	O
the	O
existence	O
of	O
a	O
proIL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
promoter	O
-	O
proximal	O
requirement	O
for	O
tissue	O
specificity	O
.	O

Expression	O
of	O
PILOT	B-PRGE
,	O
a	O
putative	O
transcription	O
factor	O
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	O
cells	O
.	O

Few	O
known	O
genes	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
members	O
of	O
the	O
IL	O
-	O
8	O
family	O
,	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
are	O
induced	O
in	O
T	O
cells	O
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	O
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

We	O
have	O
identified	O
a	O
putative	O
transcription	O
factor	O
,	O
designated	O
PILOT	B-PRGE
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	O
for	O
expression	O
.	O

Induction	O
of	O
the	O
PILOT	B-PRGE
gene	O
is	O
detectable	O
in	O
human	O
T	O
cells	O
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	O
by	O
CyA	O
.	O

The	O
PILOT	B-PRGE
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42	O
.	O
6	O
kDa	O
and	O
contains	O
three	O
zinc	O
fingers	O
of	O
the	O
C2H2	O
-	O
type	O
at	O
the	O
carboxyl	O
-	O
terminus	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	O
finger	O
regions	O
of	O
the	O
transcription	O
factors	O
EGR1	B-PRGE
,	O
EGR2	B-PRGE
,	O
and	O
pAT	B-PRGE
133	I-PRGE
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	B-PRGE
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O

This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2	O
+	O
signal	O
-	O
dependent	O
regulatory	O
element	O
obligatory	O
for	O
expression	O
of	O
some	O
genes	O
in	O
T	O
cells	O
but	O
not	O
in	O
fibroblasts	O
.	O

This	O
differential	O
expression	O
model	O
will	O
be	O
valuable	O
in	O
the	O
dissection	O
of	O
the	O
dual	O
signal	O
pathway	O
in	O
T	O
cells	O
and	O
the	O
effects	O
of	O
CyA	O
upon	O
it	O
.	O

Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell	O
-	O
specific	O
transcription	O
factor	O
(	O
NF	O
-	O
E2	O
)	O
to	O
an	O
enhancer	O
element	O
required	O
for	O
expression	O
of	O
an	O
erythroid	O
-	O
specific	O
gene	O
.	O

Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid	O
-	O
specific	O
gene	O
expression	O
in	O
the	O
human	O
cell	O
line	O
K562	O
.	O

We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	O
factors	O
at	O
a	O
regulatory	O
element	O
found	O
within	O
the	O
transcriptional	O
regulatory	O
sequences	O
of	O
many	O
erythroid	O
-	O
specific	O
genes	O
.	O

TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	O
AP	O
-	O
1	O
factors	O
to	O
this	O
element	O
.	O

TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF	O
-	O
E2	O
to	O
this	O
transcriptional	O
control	O
element	O
.	O

Hemin	O
induction	O
of	O
K562	O
cells	O
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF	O
-	O
E2	O
to	O
its	O
recognition	O
site	O
.	O

Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	O
cells	O
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	O
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF	O
-	O
E2	O
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	O
cells	O
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	O
factor	O
NF	O
-	O
E2	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid	O
-	O
specific	O
promoter	O
.	O

Mammal	O
pyruvate	O
kinases	O
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	B-PRGE
gene	O
produces	O
the	O
erythroid	O
(	O
R	B-PRGE
-	I-PRGE
PK	I-PRGE
)	O
or	O
the	O
hepatic	O
(	O
L	B-PRGE
-	I-PRGE
PK	I-PRGE
)	O
isozymes	O
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
elements	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	O
of	O
the	O
L	B-PRGE
gene	O
erythroid	O
promoter	O
.	O

A	O
R	B-PRGE
-	I-PRGE
PK	I-PRGE
DNA	O
fragment	O
extending	O
from	O
-	O
870	O
to	O
+	O
54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-	O
62	O
to	O
+	O
54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-	O
50	O
,	O
binds	O
members	O
of	O
the	O
CCACC	O
/	O
Sp1	O
family	O
and	O
the	O
other	O
,	O
located	O
at	O
-	O
20	O
,	O
binds	O
the	O
erythroid	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Although	O
the	O
-	O
20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	O
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC	O
/	O
Sp1	O
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
R	B-PRGE
-	I-PRGE
PK	I-PRGE
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA	B-PRGE
-	I-PRGE
1	I-PRGE
transactivation	O
of	O
the	O
R	B-PRGE
-	I-PRGE
PK	I-PRGE
promoter	O
in	O
HeLa	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
interleukin	B-PRGE
3	I-PRGE
(	O
IL3	B-PRGE
)	O
in	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Role	O
of	O
AP	O
-	O
1	O
-	O
and	O
octamer	O
-	O
binding	O
proteins	O
in	O
control	O
of	O
IL3	B-PRGE
gene	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B-PRGE
3	I-PRGE
(	O
IL3	B-PRGE
)	O
gene	O
expression	O
in	O
primary	O
human	O
T	O
lymphocytes	O
following	O
CD3	O
and	O
CD2	B-PRGE
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B-PRGE
plus	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	O
T	O
lymphocytes	O
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
,	O
we	O
found	O
that	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
and	O
octamer	O
-	O
binding	O
proteins	O
play	O
a	O
major	O
role	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL3	B-PRGE
gene	O
via	O
their	O
interaction	O
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	B-PRGE
5	O
'	O
-	O
flanking	O
sequence	O
.	O

Additionally	O
,	O
the	O
region	O
between	O
bases	O
-	O
107	O
and	O
-	O
59	O
of	O
the	O
IL3	B-PRGE
promoter	O
containing	O
putative	O
AP	O
-	O
2	O
and	O
Sp1	B-PRGE
binding	O
motifs	O
appears	O
necessary	O
for	O
basal	O
level	O
expression	O
of	O
the	O
IL3	B-PRGE
gene	O
.	O

The	O
data	O
also	O
indicate	O
that	O
CD2	B-PRGE
receptor	O
activation	O
and	O
phytohemagglutinin	B-PRGE
plus	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B-PRGE
gene	O
expression	O
through	O
the	O
same	O
cis	O
-	O
and	O
trans	O
-	O
activating	O
signals	O
.	O

These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	B-PRGE
gene	O
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O

Transcriptional	O
activation	O
of	O
human	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
by	O
the	O
alpha	B-PRGE
globin	I-PRGE
regulatory	O
element	O
(	O
HS	O
-	O
40	O
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	O
factor	O
-	O
DNA	O
complexes	O
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
and	O
the	O
alpha	B-PRGE
globin	I-PRGE
regulatory	O
element	O
(	O
HS	O
-	O
40	O
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
gene	O
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS	O
-	O
40	O
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high	O
-	O
level	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and	O
/	O
or	O
fetal	O
origin	O
.	O

Although	O
sequences	O
located	O
between	O
-	O
559	O
and	O
-	O
88	O
of	O
the	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
gene	O
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	O
plasmids	O
,	O
they	O
were	O
required	O
for	O
the	O
HS	O
-	O
40	O
enhancer	O
-	O
mediated	O
activity	O
of	O
the	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS	O
-	O
40	O
enhancer	O
-	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
factor	O
binding	O
motifs	O
located	O
at	O
-	O
230	O
and	O
-	O
104	O
,	O
respectively	O
.	O

The	O
functional	O
domains	O
of	O
HS	O
-	O
40	O
were	O
also	O
mapped	O
.	O

Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF	O
-	O
E2	O
/	O
AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS	O
-	O
40	O
in	O
the	O
erythroid	O
-	O
specific	O
activation	O
of	O
the	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
promoter	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	O
function	O
of	O
one	O
of	O
the	O
two	O
NF	O
-	O
E2	O
/	O
AP1	O
motifs	O
of	O
HS	O
-	O
40	O
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF	O
-	O
E2	O
but	O
not	O
AP1	O
transcription	O
factor	O
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS	O
-	O
40	O
enhancer	O
region	O
in	O
K562	O
cells	O
,	O
adult	O
nucleated	O
erythroblasts	O
,	O
and	O
different	O
nonerythroid	O
cells	O
.	O

All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS	O
-	O
40	O
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
living	O
K562	O
cells	O
but	O
not	O
in	O
nonerythroid	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	O
sequence	O
motifs	O
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

In	O
comparison	O
to	O
K562	O
,	O
nucleated	O
erythroblasts	O
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	O
factor	O
binding	O
in	O
vivo	O
at	O
the	O
HS	O
-	O
40	O
region	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	O
embryonic	O
zeta	B-PRGE
2	I-PRGE
globin	I-PRGE
gene	O
and	O
the	O
fetal	O
/	O
adult	O
alpha	B-PRGE
globin	I-PRGE
genes	O
is	O
mediated	O
by	O
erythroid	O
cell	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
nuclear	O
factor	O
-	O
DNA	O
complexes	O
which	O
form	O
at	O
the	O
enhancer	O
(	O
HS	O
-	O
40	O
)	O
and	O
the	O
globin	O
promoters	O
.	O

Costimulation	O
of	O
peripheral	O
blood	O
T	O
cell	O
activation	O
by	O
human	O
endothelial	O
cells	O
.	O

Enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
correlates	O
with	O
increased	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
synthesis	O
and	O
increased	O
Fos	O
content	O
of	O
AP	O
-	O
1	O
.	O

Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

We	O
previously	O
reported	O
that	O
human	O
umbilical	O
vein	O
EC	O
provide	O
costimulatory	O
signals	O
to	O
PHA	B-PRGE
-	O
stimulated	O
PBL	O
via	O
CD2	B-PRGE
:	O
lymphocyte	B-PRGE
function	I-PRGE
-	I-PRGE
associated	I-PRGE
Ag	I-PRGE
-	I-PRGE
3	I-PRGE
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three	O
-	O
to	O
eight	O
-	O
fold	O
enhancement	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	O
to	O
PBL	O
suboptimally	O
stimulated	O
with	O
mAb	O
OKT3	O
.	O

We	O
now	O
report	O
that	O
EC	O
costimulation	O
causes	O
increased	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
as	O
a	O
result	O
of	O
increased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
in	O
PBL	O
.	O

We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	O
on	O
T	O
cell	O
nuclear	O
factors	O
known	O
to	O
regulate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
,	O
including	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
-	O
two	O
components	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
others	O
.	O

PBL	O
constitutively	O
express	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
,	O
and	O
the	O
level	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
is	O
not	O
altered	O
by	O
PHA	B-PRGE
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	O
.	O

In	O
contrast	O
,	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
is	O
absent	O
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	O
on	O
PHA	B-PRGE
activation	O
.	O

EC	O
alone	O
do	O
not	O
induce	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
but	O
augment	O
the	O
level	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
in	O
PHA	B-PRGE
-	O
activated	O
T	O
cells	O
by	O
3	O
-	O
to	O
10	O
-	O
fold	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	B-PRGE
:	O
lymphocyte	B-PRGE
function	I-PRGE
-	I-PRGE
associated	I-PRGE
Ag	I-PRGE
-	I-PRGE
3	I-PRGE
pathway	O
.	O

Gel	O
-	O
shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	O
PBL	O
that	O
bind	O
to	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
that	O
contain	O
immunoreactive	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
but	O
not	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
protein	O
.	O

In	O
contrast	O
,	O
AP	O
-	O
1	O
from	O
PHA	B-PRGE
-	O
activated	O
cells	O
contains	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
and	O
low	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
.	O

Strikingly	O
,	O
costimulation	O
with	O
EC	O
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15	O
-	O
fold	O
)	O
in	O
the	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
content	O
of	O
AP	O
-	O
1	O
.	O

Levels	O
of	O
other	O
nuclear	O
factors	O
involved	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
regulation	O
were	O
not	O
altered	O
by	O
EC	O
,	O
although	O
NFAT	O
-	O
DNA	O
complexes	O
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	O
.	O

Negative	O
transcriptional	O
regulation	O
of	O
human	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
is	O
affected	O
by	O
several	O
nuclear	O
proteins	O
.	O

We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	O
proteins	O
that	O
bind	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

Nuclear	O
extracts	O
from	O
primary	O
human	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
,	O
but	O
not	O
of	O
NF	O
-	O
kB	O
and	O
OCT	O
-	O
1	O
/	O
OAF	O
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
promoter	O
.	O

To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
plasmids	O
containing	O
either	O
the	O
intact	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
or	O
its	O
AP	O
-	O
1	O
,	O
NF	O
-	O
AT	O
,	O
and	O
NF	O
-	O
kB	O
motifs	O
.	O

Dex	O
inhibited	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
the	O
AP	O
-	O
1	O
,	O
but	O
not	O
the	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
the	O
NF	O
-	O
AT	O
,	O
but	O
not	O
the	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
through	O
interference	O
with	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O

Cell	O
-	O
specific	O
expression	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factors	O
encoded	O
by	O
the	O
E2A	B-PRGE
gene	O
.	O

The	O
E2A	B-PRGE
gene	O
encodes	O
transcription	O
factors	O
of	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
family	O
that	O
are	O
implicated	O
in	O
cell	O
-	O
specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	O
complexes	O
that	O
interact	O
with	O
E	O
box	O
enhancer	O
elements	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	B-PRGE
gene	O
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

We	O
have	O
now	O
examined	O
expression	O
of	O
the	O
mouse	O
E2A	B-PRGE
gene	O
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	B-PRGE
protein	O
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O

A	O
73	O
kDa	O
protein	O
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	O
lines	O
of	O
B	O
lymphoid	O
origin	O
as	O
compared	O
to	O
pancreatic	O
beta	O
-	O
cells	O
and	O
fibroblast	O
cells	O
.	O

The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	O
cells	O
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	O
box	O
-	O
binding	O
activity	O
LEF1	O
/	O
BCF1	O
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	B-PRGE
gene	O
products	O
.	O

Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-PRGE
cDNA	O
leads	O
to	O
appearance	O
of	O
protein	O
co	O
-	O
migrating	O
with	O
the	O
73	O
kDa	O
protein	O
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co	O
-	O
migrating	O
with	O
LEF1	O
/	O
BCF1	O
on	O
mobility	O
shift	O
analysis	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA	O
-	O
binding	O
activity	O
LEF1	O
/	O
BCF1	O
is	O
a	O
homodimer	O
of	O
E2A	B-PRGE
proteins	O
;	O
the	O
selective	O
appearance	O
of	O
this	O
putative	O
cell	O
-	O
specific	O
transcription	O
factor	O
in	O
B	O
lymphoid	O
cells	O
seems	O
to	O
be	O
attributable	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	O
E2A	B-PRGE
protein	O
concentrations	O
in	O
these	O
cells	O
.	O

HIV	O
-	O
1	O
Nef	B-PRGE
protein	O
inhibits	O
the	O
recruitment	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
in	O
human	O
T	O
-	O
cells	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
HIV	O
-	O
1	O
-	O
LTR	O
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
the	O
HIV	O
-	O
1	O
-	O
encoded	O
Nef	B-PRGE
protein	O
suggested	O
that	O
Nef	B-PRGE
may	O
be	O
an	O
inhibitor	O
HIV	O
-	O
1	O
transcription	O
.	O

To	O
determine	O
whether	O
Nef	B-PRGE
affects	O
the	O
binding	O
of	O
cellular	O
factors	O
implicated	O
in	O
HIV	O
-	O
1	O
regulation	O
,	O
32P	O
-	O
labeled	O
oligonucleotides	O
corresponding	O
to	O
the	O
binding	O
sites	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
prepared	O
from	O
Nef	B-PRGE
-	O
expressing	O
T	O
-	O
cell	O
lines	O
that	O
were	O
not	O
stimulated	O
or	O
were	O
stimulated	O
with	O
T	O
-	O
cell	O
mitogens	O
.	O

We	O
found	O
that	O
Nef	B-PRGE
inhibited	O
the	O
recruitment	O
of	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
in	O
mitogen	O
-	O
stimulated	O
human	O
T	O
-	O
cells	O
.	O

Additionally	O
,	O
Nef	B-PRGE
expressing	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV	O
-	O
1	O
AP	O
-	O
1	O
DNA	O
recognition	O
sequences	O
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
.	O

Mitogen	O
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
CAT	B-PRGE
gene	O
in	O
this	O
construct	O
was	O
inhibited	O
in	O
Nef	B-PRGE
-	O
expressing	O
cells	O
but	O
not	O
in	O
control	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
,	O
by	O
inhibiting	O
AP	O
-	O
1	O
activation	O
,	O
Nef	B-PRGE
may	O
play	O
a	O
role	O
in	O
regulating	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
infected	O
T	O
-	O
cells	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
early	B-PRGE
B	I-PRGE
-	I-PRGE
cell	I-PRGE
factor	I-PRGE
,	O
a	O
regulator	O
of	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O

Early	B-PRGE
B	I-PRGE
-	I-PRGE
cell	I-PRGE
factor	I-PRGE
(	O
EBF	B-PRGE
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue	O
-	O
specific	O
and	O
differentiation	O
stage	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre	O
-	O
B	O
and	O
B	O
lymphocyte	O
-	O
specific	O
mb	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
.	O

Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	B-PRGE
were	O
used	O
to	O
isolate	O
cDNA	O
clones	O
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	B-PRGE
.	O

The	O
recombinant	O
polypeptide	O
formed	O
sequence	O
-	O
specific	O
complexes	O
with	O
the	O
EBF	B-PRGE
-	O
binding	O
site	O
in	O
the	O
mb	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

The	O
cDNA	O
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lines	O
,	O
but	O
transcripts	O
were	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
plasmacytoma	O
,	O
T	O
-	O
cell	O
,	O
and	O
nonlymphoid	O
cell	O
lines	O
.	O

Expression	O
of	O
recombinant	O
EBF	B-PRGE
in	O
transfected	O
nonlymphoid	O
cells	O
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF	B-PRGE
-	O
binding	O
sites	O
.	O

Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	B-PRGE
identified	O
an	O
amino	O
-	O
terminal	O
cysteine	O
-	O
rich	O
DNA	O
-	O
binding	O
domain	O
lacking	O
obvious	O
sequence	O
similarity	O
to	O
known	O
transcription	O
factors	O
.	O

DNA	O
-	O
binding	O
assays	O
with	O
cotranslated	O
wild	O
-	O
type	O
and	O
truncated	O
forms	O
of	O
EBF	B-PRGE
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	O
.	O

Deletions	O
delineated	O
a	O
carboxy	O
-	O
terminal	O
dimerization	O
region	O
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	O
domains	O
of	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-PRGE
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O

Regulation	O
of	O
the	O
Ets	O
-	O
related	O
transcription	O
factor	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
binding	O
to	O
the	O
retinoblastoma	B-PRGE
protein	I-PRGE
.	O

The	O
retinoblastoma	B-PRGE
gene	O
product	O
(	O
Rb	B-PRGE
)	O
is	O
a	O
nuclear	O
phosphoprotein	O
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O

Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
lymphoid	O
-	O
specific	O
Ets	O
transcription	O
factor	O
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	B-PRGE
binding	O
sites	O
of	O
several	O
viral	O
oncoproteins	O
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	B-PRGE
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Elf	B-PRGE
-	I-PRGE
1	I-PRGE
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	B-PRGE
and	O
fails	O
to	O
bind	O
to	O
Rb	B-PRGE
mutants	O
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Rb	B-PRGE
in	O
resting	O
normal	O
human	O
T	O
cells	O
.	O

After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	O
of	O
Rb	B-PRGE
results	O
in	O
the	O
release	O
of	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
transcription	O
.	O

Overexpression	O
of	O
a	O
phosphorylation	O
-	O
defective	O
form	O
of	O
Rb	B-PRGE
inhibited	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
transcription	O
during	O
T	O
cell	O
activation	O
.	O

These	O
results	O
demonstrate	O
that	O
Rb	B-PRGE
interacts	O
specifically	O
with	O
a	O
lineage	O
-	O
restricted	O
Ets	O
transcription	O
factor	O
.	O

This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage	O
-	O
specific	O
effector	O
functions	O
such	O
as	O
lymphokine	O
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	O
T	O
cells	O
.	O

Expression	O
levels	O
of	O
the	O
thyrotropin	B-PRGE
receptor	I-PRGE
gene	O
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	O
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	O
histocompatibility	O
complex	O
classes	O
I	O
and	O
II	O
.	O

Using	O
a	O
human	O
TSH	B-PRGE
receptor	I-PRGE
(	O
TSH	B-PRGE
-	I-PRGE
R	I-PRGE
)	O
cDNA	O
probe	O
,	O
we	O
investigated	O
TSH	B-PRGE
-	I-PRGE
R	I-PRGE
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
'	O
s	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O

TSH	B-PRGE
-	I-PRGE
R	I-PRGE
expression	O
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	O
of	O
thyroid	B-PRGE
peroxidase	I-PRGE
(	O
r	O
=	O
0	O
.	O
703	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
thyroglobulin	B-PRGE
(	O
r	O
=	O
0	O
.	O
817	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
nuclear	O
oncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
(	O
r	O
=	O
0	O
.	O
935	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
.	O

Overall	O
,	O
TSH	B-PRGE
-	I-PRGE
R	I-PRGE
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
(	O
MHC	O
I	O
or	O
II	O
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	O
I	O
,	O
r	O
=	O
-	O
0	O
.	O
791	O
;	O
P	O
<	O
0	O
.	O
01	O
;	O
MHC	O
II	O
,	O
r	O
=	O
-	O
0	O
.	O
784	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	O
,	O
thyroid	O
cells	O
themselves	O
were	O
the	O
source	O
of	O
MHC	O
II	O
transcripts	O
.	O

gamma	B-PRGE
-	I-PRGE
Interferon	I-PRGE
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
'	O
s	O
goiter	O
.	O

Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	O
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH	B-PRGE
-	I-PRGE
R	I-PRGE
,	O
thyroid	B-PRGE
peroxidase	I-PRGE
,	O
thyroglobulin	B-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
)	O
and	O
immunological	O
markers	O
(	O
MHC	O
I	O
and	O
II	O
)	O
.	O

Regulation	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
.	O

Transcription	O
of	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
cluster	O
depends	O
upon	O
upstream	O
regulatory	O
sequences	O
,	O
which	O
are	O
collectively	O
termed	O
the	O
locus	O
control	O
region	O
.	O

Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	O
through	O
development	O
.	O

The	O
crux	O
of	O
transcriptional	O
activation	O
is	O
how	O
the	O
locus	O
control	O
region	O
communicates	O
with	O
the	O
gene	O
-	O
proximal	O
regulatory	O
elements	O
.	O

Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
estrogen	B-PRGE
receptor	I-PRGE
chimera	O
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone	O
-	O
dependent	O
manner	O
.	O

The	O
GATA	O
factors	O
are	O
a	O
family	O
of	O
transcriptional	O
regulatory	O
proteins	O
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA	O
-	O
binding	O
domains	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	O
factor	O
expression	O
is	O
that	O
several	O
GATA	O
proteins	O
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA	O
-	O
binding	O
site	O
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	O
factors	O
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
human	O
estrogen	B-PRGE
receptor	I-PRGE
(	O
ER	B-PRGE
)	O
.	O

These	O
GATA	O
/	O
ER	B-PRGE
chimeric	O
factors	O
were	O
shown	O
to	O
be	O
hormone	O
-	O
inducible	O
trans	O
-	O
activating	O
proteins	O
in	O
transient	O
transfection	O
assays	O
.	O

When	O
stably	O
introduced	O
into	O
primary	O
erythroblasts	O
or	O
conditionally	O
transformed	O
erythroid	O
progenitors	O
cells	O
,	O
exogenous	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
ER	B-PRGE
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen	O
-	O
dependent	O
manner	O
.	O

These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
ER	B-PRGE
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	O
progenitors	O
expressing	O
either	O
Gal	O
/	O
ER	B-PRGE
or	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
/	O
ER	B-PRGE
do	O
not	O
display	O
a	O
hormone	O
-	O
responsive	O
block	O
in	O
differentiation	O
.	O

Thus	O
,	O
the	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
factor	O
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self	O
-	O
renewal	O
capacity	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	O
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	B-PRGE
,	O
IL3	B-PRGE
,	O
IL4	B-PRGE
,	O
and	O
IL5	B-PRGE
,	O
which	O
encode	O
interleukins	B-PRGE
2	I-PRGE
,	O
3	B-PRGE
,	O
4	B-PRGE
,	O
and	O
5	B-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
-	B-PRGE
3	I-PRGE
,	O
-	B-PRGE
4	I-PRGE
,	O
and	O
-	B-PRGE
5	I-PRGE
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
involved	O
a	O
trans	O
-	O
acting	O
factor	O
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	O
factors	O
from	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	B-PRGE
.	O

Nuclear	O
factor	O
NF	O
-	O
kB	O
,	O
activation	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
NF	O
-	O
IL	O
-	O
2B	O
binding	O
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B-PRGE
enhancer	O
and	O
to	O
an	O
NF	O
-	O
AT	O
-	O
like	O
response	O
element	O
present	O
in	O
the	O
IL4	B-PRGE
enhancer	O
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF	O
-	O
AT	O
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	B-PRGE
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O

CAT	B-PRGE
expression	O
directed	O
by	O
the	O
IL2	B-PRGE
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	B-PRGE
gene	O
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
proximal	O
(	O
OCT	O
-	O
1p	O
)	O
-	O
binding	O
site	O
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of	O
/	O
or	O
influencing	O
NF	O
-	O
AT	O
may	O
underlie	O
the	O
multiple	O
lymphokine	O
deficiency	O
in	O
this	O
patient	O
.	O

Expression	O
of	O
mRNA	O
for	O
the	O
GATA	O
-	O
binding	O
proteins	O
in	O
human	O
eosinophils	O
and	O
basophils	O
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O

The	O
expression	O
of	O
the	O
hematopoietic	O
transcription	O
factors	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
studied	O
in	O
eosinophils	O
and	O
basophils	O
.	O

Eosinophils	O
express	O
mRNA	O
for	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Basophils	O
express	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Treatment	O
of	O
HL	O
-	O
60	O
eosinophilic	O
sublines	O
with	O
either	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil	O
-	O
specific	O
genes	O
,	O
whereas	O
levels	O
of	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
remained	O
relatively	O
constant	O
.	O

The	O
presence	O
of	O
mRNA	O
for	O
these	O
proteins	O
in	O
eosinophils	O
and	O
basophils	O
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA	O
-	O
binding	O
proteins	O
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B-PRGE
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	O
hematopoietic	O
cell	O
line	O
,	O
UT	O
-	O
7	O
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	O
genes	O
and	O
the	O
erythropoietin	B-PRGE
receptor	I-PRGE
(	O
Epo	B-PRGE
-	I-PRGE
R	I-PRGE
)	O
gene	O
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
response	O
to	O
Epo	B-PRGE
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Epo	B-PRGE
-	I-PRGE
R	I-PRGE
and	O
globin	O
genes	O
in	O
an	O
Epo	B-PRGE
-	O
dependent	O
human	O
cell	O
line	O
,	O
UT	O
-	O
7	O
Epo	O
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
-	O
dependent	O
cell	O
line	O
,	O
UT	O
-	O
7	O
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	B-PRGE
.	O

UT	O
-	O
7	O
Epo	O
and	O
UT	O
-	O
7	O
expressed	O
similar	O
levels	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
and	O
binding	O
activity	O
.	O

The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo	B-PRGE
-	I-PRGE
R	I-PRGE
mRNA	O
while	O
the	O
number	O
of	O
Epo	B-PRGE
-	O
binding	O
sites	O
on	O
UT	O
-	O
7	O
Epo	O
cells	O
was	O
one	O
-	O
sixth	O
the	O
number	O
of	O
UT	O
-	O
7	O
cells	O
(	O
2400	O
+	O
/	O
-	O
3	O
vs	O
.	O
13	O
,	O
800	O
+	O
/	O
-	O
300	O
)	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT	O
-	O
7	O
cells	O
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT	O
-	O
7	O
cells	O
)	O
or	O
in	O
receptor	O
turnover	O
.	O

By	O
Northern	O
analysis	O
,	O
UT	O
-	O
7	O
cells	O
expressed	O
detectable	O
levels	O
of	O
beta	O
-	O
and	O
gamma	O
-	O
globin	O
but	O
not	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
.	O

In	O
comparison	O
,	O
UT	O
-	O
7	O
Epo	O
cells	O
expressed	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
and	O
higher	O
levels	O
of	O
gamma	O
-	O
globin	O
(	O
5	O
-	O
fold	O
)	O
and	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O

Globin	B-PRGE
chains	I-PRGE
(	I-PRGE
alpha	I-PRGE
,	O
beta	B-PRGE
and	O
gamma	B-PRGE
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT	O
-	O
7	O
Epo	O
but	O
not	O
in	O
UT	O
-	O
7	O
cells	O
.	O

The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta	O
-	O
and	O
gamma	O
-	O
globin	O
genes	O
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta	O
-	O
and	O
gamma	O
-	O
specific	O
antibodies	O
.	O

The	O
number	O
of	O
gamma	O
-	O
positive	O
cells	O
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT	O
-	O
7	O
Epo	O
than	O
in	O
UT	O
-	O
7	O
cells	O
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	O
mRNA	O
observed	O
in	O
UT	O
-	O
7	O
Epo	O
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma	O
-	O
globin	O
.	O

The	O
levels	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Epo	B-PRGE
-	I-PRGE
R	I-PRGE
and	O
globin	O
mRNA	O
expressed	O
were	O
not	O
affected	O
by	O
a	O
24	O
-	O
hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	B-PRGE
,	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
or	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Protein	B-PRGE
kinase	I-PRGE
C	I-PRGE
-	I-PRGE
zeta	I-PRGE
mediates	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
immunodeficiency	O
virus	O
-	O
infected	O
monocytes	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	O
remain	O
unknown	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
and	O
is	O
selectively	O
activated	O
following	O
HIV	O
infection	O
of	O
human	O
macrophages	O
.	O

Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
monocytes	O
-	O
macrophages	O
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
isoenzymes	O
were	O
not	O
involved	O
in	O
the	O
HIV	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	O
isoenzymes	O
.	O

PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
other	O
cell	O
systems	O
.	O

Immunoblotting	O
experiments	O
with	O
U937	O
cells	O
demonstrate	O
that	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
is	O
present	O
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	O
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O

The	O
HIV	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
.	O

In	O
addition	O
,	O
cotransfection	O
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
(	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
mut	O
)	O
with	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV	O
-	O
but	O
not	O
phorbol	O
myristate	O
acetate	O
-	O
or	O
lipopolysaccharide	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

That	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
is	O
specific	O
in	O
regulating	O
NF	O
-	O
kappa	O
B	O
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC	B-PRGE
-	I-PRGE
zeta	I-PRGE
(	O
mut	O
)	O
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate	O
-	O
inducible	O
CREB	B-PRGE
-	O
or	O
AP1	O
-	O
dependent	O
transcriptional	O
activity	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	O
production	O
by	O
HIV	O
-	O
infected	O
human	O
macrophages	O
when	O
treated	O
with	O
AO	O
to	O
PKC	O
-	O
zeta	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	O
PKC	O
isoenzymes	O
,	O
including	O
PKC	O
-	O
zeta	O
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
monocytic	O
cells	O
and	O
macrophages	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
-	O
dependent	O
transcription	O
by	O
NF	O
-	O
kappa	O
B	O
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	O
helper	O
cell	O
subsets	O
.	O

Activation	O
of	O
individual	O
CD4	B-PRGE
+	O
T	O
cells	O
results	O
in	O
differential	O
lymphokine	O
expression	O
:	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
is	O
preferentially	O
produced	O
by	O
T	O
helper	O
type	O
1	O
(	O
TH1	O
)	O
cells	O
,	O
which	O
are	O
involved	O
in	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
is	O
synthesized	O
by	O
TH2	O
cells	O
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
factor	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	O
genes	O
.	O

However	O
,	O
while	O
IL2	B-PRGE
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
protein	O
kinase	O
C	O
-	O
dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	O
IL4	B-PRGE
transcription	O
through	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
pathway	O
is	O
diminished	O
by	O
protein	O
kinase	O
C	O
stimulation	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
P	O
sequence	O
,	O
an	O
element	O
located	O
69	O
bp	O
upstream	O
of	O
the	O
IL4	B-PRGE
transcription	O
initiation	O
site	O
.	O

Human	O
IL4	B-PRGE
promoter	O
-	O
mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	O
cells	O
stimulated	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
activating	O
cytokine	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
and	O
suppressed	O
in	O
RelA	B-PRGE
-	O
overexpressing	O
cells	O
.	O

In	O
contrast	O
,	O
protein	O
kinase	O
C	O
stimulation	O
or	O
RelA	B-PRGE
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	O
IL4	B-PRGE
promoter	O
containing	O
a	O
mouse	O
P	O
sequence	O
,	O
which	O
is	O
a	O
higher	O
-	O
affinity	O
site	O
for	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
and	O
a	O
lower	O
-	O
affinity	O
site	O
for	O
RelA	B-PRGE
.	O

Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	O
activators	O
,	O
RelA	B-PRGE
and	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	O
kinase	O
C	O
stimulation	O
on	O
IL4	B-PRGE
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	O
cells	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
B	O
cell	O
-	O
specific	O
coactivator	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
.	O

B	O
cell	O
-	O
specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	O
motif	O
requires	O
the	O
Oct1	B-PRGE
or	O
Oct2	B-PRGE
protein	O
and	O
additional	O
B	O
cell	O
-	O
restricted	O
cofactors	O
.	O

One	O
such	O
cofactor	O
,	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
was	O
recently	O
isolated	O
from	O
human	O
B	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	O
homolog	O
.	O

Full	O
-	O
length	O
cDNAs	O
and	O
genomic	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	O
and	O
human	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
.	O

The	O
NH2	O
-	O
terminal	O
126	O
amino	O
acids	O
of	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	O
domains	O
of	O
either	O
Oct1	B-PRGE
or	O
Oct2	B-PRGE
.	O

This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	O
proteins	O
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	O
-	O
DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
to	O
Oct1	B-PRGE
or	O
Oct2	B-PRGE
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
can	O
efficiently	O
activate	O
octamer	O
-	O
dependent	O
promoters	O
in	O
fibroblasts	O
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
activity	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
with	O
the	O
GAL4	B-PRGE
DNA	O
binding	O
domain	O
reveals	O
that	O
both	O
NH2	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
of	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full	O
-	O
length	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
elements	O
in	O
non	O
B	O
cells	O
,	O
the	O
GAL4	B-PRGE
fusions	O
likewise	O
only	O
stimulate	O
from	O
a	O
promoter	O
-	O
proximal	O
position	O
.	O

Polymorphic	O
nucleotides	O
within	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
that	O
mediate	O
overexpression	O
of	O
the	O
gene	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	O
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	O
gene	O
and	O
multiple	O
minor	O
susceptibility	O
genes	O
.	O

A	O
recent	O
sib	O
-	O
pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31	O
.	O
1	O
and	O
a	O
major	O
susceptibility	O
gene	O
controlling	O
total	O
serum	O
IgE	O
levels	O
.	O

Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	O
cell	O
differentiation	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	O
gene	O
.	O

In	O
one	O
model	O
,	O
polymorphisms	O
within	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
regulatory	O
elements	O
might	O
result	O
in	O
overexpression	O
of	O
the	O
gene	O
,	O
amplifying	O
Th2	O
cell	O
differentiation	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
positive	O
T	O
cells	O
.	O

A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	O
transcriptional	O
activity	O
.	O

A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	O
element	O
located	O
just	O
upstream	O
of	O
an	O
NF	O
-	O
AT	O
site	O
(	O
P	O
sequence	O
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence	O
-	O
specific	O
complexes	O
exhibiting	O
an	O
AP	O
-	O
1	O
specificity	O
.	O

The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	O
in	O
overexpression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
cooperates	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
to	O
activate	O
HIV	O
-	O
1	O
from	O
latently	O
and	O
acutely	O
infected	O
cells	O
of	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
is	O
elevated	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
the	O
activation	O
of	O
HIV	O
-	O
1	O
from	O
infected	O
monocytes	O
and	O
macrophages	O
.	O

Although	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
alone	O
did	O
not	O
induce	O
HIV	O
-	O
1	O
replication	O
,	O
in	O
the	O
presence	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
(	O
U1	O
)	O
and	O
in	O
acutely	O
infected	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Neutralizing	O
mAbs	O
to	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
indicated	O
that	O
both	O
cytokines	O
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O

The	O
effects	O
of	O
the	O
two	O
cytokines	O
were	O
distinguishable	O
functionally	O
since	O
pretreatment	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
attenuated	O
the	O
cytokine	O
cooperativity	O
,	O
while	O
pretreatment	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
potentiated	O
their	O
cooperativity	O
,	O
suggesting	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
play	O
different	O
roles	O
in	O
the	O
activation	O
of	O
virus	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	O
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up	O
-	O
regulation	O
of	O
TNF	O
-	O
alpha	O
receptors	O
.	O

In	O
combination	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
stimulated	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV	O
-	O
1	O
steady	O
-	O
state	O
mRNA	O
levels	O
and	O
enhance	O
long	O
terminal	O
repeat	O
-	O
directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
,	O
suggesting	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
results	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
in	O
addition	O
to	O
down	O
-	O
regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV	O
-	O
1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

The	O
promoter	O
and	O
5	O
'	O
flanking	O
sequences	O
controlling	O
human	O
B29	B-PRGE
gene	O
expression	O
.	O

The	O
product	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
B29	B-PRGE
gene	O
(	O
B29	B-PRGE
,	O
Ig	B-PRGE
beta	I-PRGE
,	O
CD79b	B-PRGE
)	O
is	O
essential	O
for	O
Ig	O
-	O
mediated	O
B	O
-	O
cell	O
activation	O
via	O
the	O
B	O
-	O
cell	O
antigen	O
receptor	O
complex	O
(	O
BCR	O
)	O
on	O
human	O
and	O
murine	O
B	O
lymphocytes	O
.	O

To	O
better	O
understand	O
the	O
regulation	O
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	O
genomic	O
DNA	O
sequence	O
upstream	O
of	O
the	O
B29	B-PRGE
ATG	O
start	O
codon	O
for	O
transcriptional	O
control	O
activity	O
.	O

The	O
human	O
B29	B-PRGE
gene	O
lacks	O
either	O
a	O
TATA	O
or	O
a	O
CAAT	O
box	O
and	O
transcription	O
is	O
initiated	O
at	O
multiple	O
sites	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
human	O
B29	B-PRGE
gene	O
is	O
contained	O
within	O
a	O
193	O
-	O
bp	O
region	O
5	O
'	O
of	O
these	O
multiple	O
start	O
sites	O
.	O

This	O
minimal	O
promoter	O
exhibits	O
B	O
-	O
cell	O
-	O
specific	O
activity	O
and	O
contains	O
SP1	O
,	O
ETS	O
,	O
OCT	O
,	O
and	O
IKAROS	O
/	O
LYF	O
-	O
1	O
transcription	O
factor	O
motifs	O
.	O

All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	O
B29	B-PRGE
promoter	O
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	B-PRGE
minimal	O
promoter	O
activity	O
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	B-PRGE
conserved	O
sequence	O
(	O
BCS	O
)	O
,	O
found	O
upstream	O
of	O
both	O
human	O
and	O
murine	O
B29	B-PRGE
promoters	O
,	O
appears	O
to	O
stimulate	O
B29	B-PRGE
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O

A	O
single	O
BCS	O
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	B-PRGE
promoter	O
or	O
on	O
a	O
heterologous	O
promoter	O
.	O

Instead	O
,	O
the	O
BCS	O
stimulated	O
transcription	O
by	O
counteracting	O
5	O
'	O
negative	O
regulatory	O
DNA	O
sequences	O
that	O
block	O
the	O
activity	O
of	O
the	O
B29	B-PRGE
minimal	O
promoter	O
in	O
its	O
absence	O
.	O

These	O
findings	O
indicate	O
that	O
B29	B-PRGE
gene	O
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

MEK1	B-PRGE
and	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
in	O
T	O
cells	O
.	O

TCR	O
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Active	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
phosphorylates	O
and	O
activates	O
the	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
(	I-PRGE
MAP	I-PRGE
)	I-PRGE
kinase	I-PRGE
/	I-PRGE
extracellular	I-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
MEK1	B-PRGE
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	O
kinases	O
/	O
extracellular	O
signal	O
regulated	O
kinases	O
,	O
ERK1	B-PRGE
and	O
ERK2	B-PRGE
.	O

Raf	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
promotes	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	B-PRGE
and	O
ERK	O
activities	O
also	O
stimulate	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
MEK1	B-PRGE
in	O
Jurkat	O
T	O
cells	O
enhanced	O
the	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF	O
-	O
AT	O
activity	O
.	O

Expression	O
of	O
MEK1	B-PRGE
-	O
interfering	O
mutants	O
inhibited	O
the	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	O
and	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
costimulate	O
NF	O
-	O
AT	O
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	O
kinase	O
-	O
specific	O
phosphatase	O
,	O
MKP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
blocks	O
ERK	O
activation	O
,	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
NF	O
-	O
AT	O
-	O
driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP	B-PRGE
-	I-PRGE
1	I-PRGE
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
MEK1	B-PRGE
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	O
kinase	O
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
MEK1	B-PRGE
,	O
and	O
ERK1	B-PRGE
and	O
ERK2	B-PRGE
functions	O
in	O
the	O
stimulation	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Cross	O
-	O
linking	O
of	O
Fc	O
gamma	O
receptors	O
activates	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
in	O
human	O
monocytes	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	O
immune	O
complexes	O
frequently	O
accompanies	O
HIV	O
-	O
1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross	O
-	O
linking	O
of	O
Fc	B-PRGE
gamma	I-PRGE
RI	I-PRGE
or	O
Fc	B-PRGE
gamma	I-PRGE
RII	I-PRGE
by	O
adherent	O
human	O
IgG	O
or	O
by	O
specific	O
anti	O
-	O
Fc	O
gamma	O
R	O
mAb	O
activates	O
HIV	O
-	O
1	O
gene	O
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
BF24	O
and	O
increased	O
HIV	O
RNA	O
expression	O
in	O
monocytes	O
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

In	O
THP	O
-	O
1	O
cells	O
,	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
induced	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
and	O
to	O
activate	O
HIV	O
-	O
1	O
transcription	O
.	O

Anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	O
but	O
not	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
antibody	O
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV	O
-	O
1	O
-	O
LTR	O
-	O
driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	O
gamma	O
R	O
can	O
mediate	O
a	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
dependent	O
induction	O
of	O
HIV	O
-	O
1	O
gene	O
transcription	O
and	O
suggest	O
that	O
immune	O
complexes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV	O
-	O
1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	O
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	O
mononuclear	O
cells	O
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	O
peripheral	O
mononuclear	O
cells	O
.	O

After	O
short	O
-	O
term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P	O
-	O
glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	B-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long	O
-	O
term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

Identification	O
of	O
an	O
ionomycin	O
/	O
cyclosporin	O
A	O
-	O
responsive	O
element	O
within	O
the	O
human	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
gamma	I-PRGE
enhancer	O
.	O

Activation	O
through	O
the	O
Ca2	O
+	O
/	O
calcineurin	O
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	O
genes	O
.	O

The	O
conserved	O
cis	O
-	O
acting	O
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	O
factors	O
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2	O
+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non	O
-	O
cytokine	O
gene	O
,	O
the	O
human	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
gamma	I-PRGE
(	O
TCRG	B-PRGE
)	O
enhancer	O
.	O

Results	O
from	O
site	O
-	O
directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin	O
-	O
induced	O
activation	O
of	O
the	O
TCRG	B-PRGE
enhancer	O
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B-PRGE
mRNA	O
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	O
cell	O
receptor	O
alpha	O
and	O
-	O
beta	O
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
-	O
cell	O
lines	O
by	O
anetholdithiolthione	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
is	O
a	O
redox	O
sensitive	O
cytosolic	O
transcription	O
factor	O
.	O

Redox	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno	O
-	O
deficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Therefore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

Anetholdithiolthione	O
(	O
ADT	O
,	O
5	O
-	O
[	O
p	O
-	O
methoxyphenyl	O
]	O
-	O
3H	O
-	O
1	O
,	O
2	O
-	O
dithiol	O
-	O
3	O
-	O
thione	O
)	O
is	O
an	O
antioxidant	O
which	O
has	O
been	O
used	O
to	O
protect	O
against	O
acetaminophen	O
-	O
and	O
CCl4	O
-	O
induced	O
hepatotoxicity	O
,	O
lipid	O
peroxidation	O
,	O
radiation	O
injury	O
,	O
and	O
also	O
has	O
been	O
used	O
clinically	O
as	O
an	O
anti	O
-	O
choleretic	O
agent	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
ADT	O
pretreatment	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
such	O
as	O
H2O2	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
.	O

PMA	O
and	O
TNF	B-PRGE
alpha	I-PRGE
induced	O
activation	O
of	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
human	O
Jurkat	O
T	O
-	O
cells	O
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0	O
.	O
1	O
mM	O
)	O
pretreatment	O
.	O

ADT	O
(	O
0	O
.	O
1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	O
factor	O
in	O
the	O
peroxide	O
sensitive	O
human	O
Wurzburg	O
T	O
-	O
cells	O
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	O
cells	O
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	O
cells	O
.	O

H2O2	O
induced	O
lipid	O
peroxidation	O
in	O
Wurzburg	O
cells	O
was	O
remarkably	O
inhibited	O
by	O
ADT	O
pretreatment	O
.	O

ADT	O
,	O
a	O
pro	O
-	O
glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
vivo	O
anergized	O
CD4	B-PRGE
+	O
T	O
cells	O
express	O
perturbed	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen	O
-	O
specific	O
tolerance	O
in	O
T	O
lymphocytes	O
in	O
the	O
adult	O
.	O

In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
T	O
-	O
cell	O
-	O
activating	O
superantigen	O
staphylococcal	B-PRGE
enterotoxin	I-PRGE
A	I-PRGE
(	O
SEA	B-PRGE
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T	O
-	O
lymphocyte	O
anergy	O
in	O
vivo	O
.	O

Injection	O
of	O
SEA	B-PRGE
to	O
adult	O
mice	O
activates	O
CD4	B-PRGE
+	O
T	O
cells	O
expressing	O
certain	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
variable	O
region	O
beta	O
-	O
chain	O
families	O
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
.	O

In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	B-PRGE
cause	O
CD4	B-PRGE
+	O
T	O
-	O
cell	O
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4	B-PRGE
+	O
T	O
cells	O
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
at	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
analyzed	O
expression	O
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
,	O
and	O
octamer	O
binding	O
transcription	O
factors	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
promoter	O
activity	O
.	O

Large	O
amounts	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
and	O
significant	O
quantities	O
of	O
NF	O
-	O
AT	O
were	O
induced	O
in	O
SEA	B-PRGE
-	O
activated	O
CD4	B-PRGE
+	O
spleen	O
T	O
cells	O
,	O
whereas	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
CD4	B-PRGE
+	O
T	O
cells	O
contained	O
severely	O
reduced	O
levels	O
of	O
AP	O
-	O
1	O
and	O
Fos	B-PRGE
/	O
Jun	B-PRGE
-	O
containing	O
NF	O
-	O
AT	O
complexes	O
but	O
expressed	O
significant	O
amounts	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Oct	O
binding	O
proteins	O
after	O
SEA	B-PRGE
stimulation	O
.	O

Resolution	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
demonstrated	O
predominant	O
expression	O
of	O
p50	B-PRGE
-	O
p65	B-PRGE
heterodimers	O
in	O
activated	O
CD4	B-PRGE
+	O
T	O
cells	O
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	B-PRGE
homodimer	O
.	O

These	O
alterations	O
of	O
transcription	O
factors	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
anergic	O
T	O
cells	O
.	O

Surfactant	O
suppresses	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
monocytic	O
cells	O
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	O
endotoxin	O
-	O
stimulated	O
inflammatory	O
cytokine	O
mRNA	O
levels	O
and	O
protein	O
products	O
(	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
[	O
TNF	B-PRGE
]	O
,	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
beta	I-PRGE
[	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
]	O
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
[	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
]	O
)	O
in	O
human	O
alveolar	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	B-PRGE
mRNA	O
and	O
secretion	O
(	O
85	O
+	O
/	O
-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+	O
/	O
-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+	O
/	O
-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin	O
-	O
stimulated	O
THP	O
-	O
1	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Because	O
surfactant	O
downregulated	O
inflammatory	O
cytokine	O
production	O
similarly	O
in	O
both	O
normal	O
human	O
alveolar	O
macrophages	O
and	O
the	O
THP	O
-	O
1	O
cell	O
line	O
,	O
we	O
used	O
this	O
cell	O
line	O
to	O
investigate	O
whether	O
surfactant	O
affected	O
transcriptional	O
mechanisms	O
.	O

Specifically	O
,	O
we	O
examined	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
because	O
it	O
is	O
crucial	O
in	O
transcriptional	O
regulation	O
of	O
many	O
inflammatory	O
cytokine	O
genes	O
including	O
TNF	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
presence	O
of	O
both	O
p65	B-PRGE
and	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
components	O
in	O
LPS	O
-	O
activated	O
THP	O
-	O
1	O
cells	O
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
'	O
s	O
suppressive	O
effects	O
on	O
inflammatory	O
cytokine	O
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

A	O
mammalian	O
histone	O
deacetylase	O
related	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	B-PRGE
[	O
see	O
comments	O
]	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	O
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	O
deacetylase	O
activity	O
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	O
DNA	O
encoding	O
the	O
histone	O
deacetylase	O
catalytic	O
subunit	O
(	O
HD1	B-PRGE
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

As	O
the	O
predicted	O
protein	O
is	O
very	O
similar	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	B-PRGE
,	O
these	O
results	O
support	O
a	O
role	O
for	O
histone	O
deacetylase	O
as	O
a	O
key	O
regulator	O
of	O
eukaryotic	O
transcription	O
.	O

Coexpression	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
13	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
genes	O
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	O
gene	O
cluster	O
on	O
human	O
chromosome	O
5q23	O
-	O
31	O
.	O

Interleukin	B-PRGE
-	I-PRGE
13	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
)	O
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23	O
-	O
31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
investigate	O
the	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
gene	O
expression	O
by	O
T	O
cells	O
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
gene	O
,	O
analyzed	O
its	O
5	O
'	O
-	O
flanking	O
region	O
for	O
potential	O
transcriptional	O
activation	O
elements	O
,	O
and	O
examined	O
its	O
expression	O
in	O
nontransformed	O
T	O
-	O
lineage	O
cell	O
populations	O
.	O

The	O
human	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
gene	O
was	O
located	O
12	O
.	O
5	O
-	O
kb	O
upstream	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
and	O
2	O
-	O
kb	O
downstream	O
of	O
a	O
CpG	O
island	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
gene	O
5	O
'	O
flank	O
region	O
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	O
elements	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
involved	O
in	O
transcriptional	O
activation	O
in	O
T	O
cells	O
.	O

Mutation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
P	O
element	O
site	O
significantly	O
reduced	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
promoter	O
activity	O
in	O
response	O
to	O
T	O
-	O
cell	O
activation	O
.	O

Oligonucleotides	O
containing	O
the	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
P	O
element	O
sites	O
specifically	O
bound	O
the	O
transcriptional	O
activator	O
protein	O
,	O
nuclear	O
factor	O
-	O
activated	O
T	O
cells	O
,	O
preformed	O
(	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	O
T	O
cells	O
.	O

Similar	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
mRNA	O
expression	O
was	O
highest	O
in	O
T	O
-	O
cell	O
populations	O
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
genes	O
in	O
a	O
coordinate	O
manner	O
.	O

Because	O
the	O
primed	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
nuclear	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
,	O
capable	O
of	O
binding	O
to	O
P	O
elements	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
promoters	O
,	O
than	O
do	O
freshly	O
-	O
isolated	O
T	O
cells	O
,	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
P	O
elements	O
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	O
genes	O
.	O

Transactivation	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
type	O
II	O
Tax	B-PRGE
proteins	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
constitutively	O
produce	O
high	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
1alpha	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
)	O
.	O

To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
in	O
HTLV	O
-	O
I	O
-	O
infected	O
cell	O
lines	O
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
involved	O
in	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
gene	O
.	O

IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
constructs	O
drive	O
transcription	O
of	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
gene	O
in	O
HTLV	O
-	O
I	O
-	O
positive	O
MT	O
-	O
2	O
cells	O
,	O
which	O
constitutively	O
produce	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B-PRGE
protein	O
of	O
both	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
in	O
an	O
uninfected	O
Jurkat	O
cell	O
line	O
.	O

A	O
mutant	O
Tax	B-PRGE
protein	O
deficient	O
in	O
transactivation	O
of	O
genes	O
by	O
the	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
pathway	O
was	O
unable	O
to	O
induce	O
transcriptional	O
activity	O
of	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
-	O
CAT	B-PRGE
constructs	O
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65	B-PRGE
/	O
p50	B-PRGE
NF	O
-	O
kappaB	O
.	O

We	O
found	O
that	O
two	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
kappaB	O
-	O
like	O
sites	O
(	O
positions	O
-	O
1	O
,	O
065	O
to	O
-	O
1	O
,	O
056	O
and	O
+	O
646	O
to	O
+	O
655	O
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF	O
-	O
kappaB	O
-	O
containing	O
nuclear	O
extract	O
from	O
MT	O
-	O
2	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	O
'	O
NF	O
-	O
kappaB	O
binding	O
site	O
than	O
to	O
the	O
5	O
'	O
NF	O
-	O
kappaB	O
site	O
.	O

Moreover	O
,	O
deletion	O
of	O
either	O
5	O
'	O
or	O
3	O
'	O
NF	O
-	O
kappaB	O
sites	O
reduced	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
activity	O
in	O
MT	O
-	O
2	O
cells	O
and	O
transactivation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
promoter	O
by	O
exogenous	O
NF	O
-	O
kappaB	O
and	O
Tax	B-PRGE
in	O
Jurkat	O
cells	O
.	O

These	O
data	O
suggest	O
a	O
general	O
role	O
for	O
Tax	B-PRGE
induction	O
of	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
gene	O
transcription	O
by	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

Expression	O
of	O
IL	B-PRGE
-	I-PRGE
1alpha	I-PRGE
by	O
HTLV	O
-	O
I	O
productively	O
infected	O
cells	O
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV	O
-	O
I	O
-	O
induced	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
.	O

Soluble	O
tumor	O
necrosis	O
factor	O
receptors	O
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
binding	O
protein	O
-	O
1	O
(	O
r	O
-	O
h	O
TBP	O
-	O
1	O
)	O
and	O
recombinant	O
human	O
soluble	O
dimeric	O
TNF	O
receptor	O
(	O
rhu	O
TNFR	O
:	O
Fc	O
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine	O
-	O
induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
promonocytic	O
U1	O
cells	O
with	O
r	O
-	O
h	O
-	O
TBP	O
-	O
1	O
or	O
rhu	O
TNFR	O
:	O
Fc	O
reduced	O
PMA	O
-	O
induced	O
HIV	O
-	O
1	O
p24	B-PRGE
antigen	O
production	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	B-PRGE
antigen	O
production	O
in	O
T	O
-	O
lymphocytic	O
ACH	O
-	O
2	O
cells	O
was	O
47	O
%	O
with	O
r	O
-	O
hTBP	O
-	O
1	O
and	O
42	O
%	O
with	O
rhu	O
TNFR	O
:	O
Fc	O
.	O

r	O
-	O
hTBP	O
-	O
1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
also	O
decreased	O
p24	B-PRGE
antigen	O
synthesized	O
by	O
U1	O
cells	O
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
induced	O
supernatant	O
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
TNF	O
.	O

Addition	O
of	O
r	O
-	O
hTBP	O
-	O
1	O
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B-PRGE
antigen	O
production	O
by	O
15	O
%	O
.	O

U1	O
cells	O
stimulated	O
with	O
10	O
(	O
-	O
7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng	O
/	O
ml	O
endogenous	O
TBP	B-PRGE
-	I-PRGE
1	I-PRGE
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r	O
-	O
hTBP	O
-	O
1	O
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r	O
-	O
hTBP	O
-	O
1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
blocked	O
PMA	O
induction	O
of	O
nuclear	O
factor	O
(	O
NK	O
)	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
U1	O
cells	O
in	O
association	O
with	O
decreases	O
in	O
HIV	O
-	O
1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli	O
-	O
induced	O
HIV	O
-	O
1	O
expression	O
and	O
NK	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto	O
-	O
differentiating	O
effects	O
on	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	O
cells	O
express	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
type	I-PRGE
alpha	I-PRGE
(	O
RAR	B-PRGE
alpha	I-PRGE
)	O
derived	O
from	O
the	O
leukemia	O
-	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B-PRGE
alpha	I-PRGE
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	O
,	O
an	O
APL	O
-	O
derived	O
cell	O
line	O
,	O
and	O
in	O
freshly	O
isolated	O
APL	O
blasts	O
.	O

After	O
treatment	O
of	O
APL	O
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	B-PRGE
alkaline	I-PRGE
phosphatase	I-PRGE
,	O
CD11b	B-PRGE
,	O
CD33	B-PRGE
,	O
and	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10	O
-	O
to	O
100	O
-	O
fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	O
markers	O
in	O
the	O
HL	O
-	O
60	O
cell	O
line	O
and	O
in	O
freshly	O
isolated	O
granulocytes	O
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	O
cells	O
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	B-PRGE
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	B-PRGE
beta	I-PRGE
-	O
or	O
RAR	B-PRGE
gamma	I-PRGE
-	O
specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS	O
-	O
7	O
cells	O
transiently	O
transfected	O
with	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
and	O
the	O
normal	O
RAR	B-PRGE
alpha	I-PRGE
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	O
acid	O
-	O
responsive	O
element	O
-	O
containing	O
promoters	O
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	B-PRGE
alpha	I-PRGE
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto	O
-	O
differentiating	O
potential	O
of	O
AM580	O
in	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
-	O
containing	O
leukemic	O
cells	O
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
gene	O
to	O
lipopolysaccharide	O
/	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

The	O
work	O
reported	O
here	O
resolves	O
,	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
,	O
the	O
controversy	O
as	O
to	O
whether	O
or	O
not	O
human	O
monocytes	O
/	O
macrophages	O
can	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
when	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
with	O
or	O
without	O
co	O
-	O
stimulation	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
.	O

Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	B-PRGE
NO	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
genes	O
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	B-PRGE
promoter	O
regions	O
in	O
response	O
to	O
LPS	O
+	O
/	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	O
B	O
response	O
elements	O
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
iNOS	B-PRGE
promoter	O
to	O
LPS	O
+	O
/	O
-	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	O
element	O
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS	O
/	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induced	O
expression	O
of	O
the	O
mouse	O
iNOS	B-PRGE
gene	O
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	O
factors	O
in	O
human	O
macrophages	O
(	O
e	O
.	O
g	O
.	O
,	O
an	O
LPS	O
-	O
inducible	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
complex	O
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O

GATA	O
transcription	O
factors	O
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	O
and	O
megakaryocytes	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	O
transcription	O
factors	O
in	O
murine	O
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

Specific	O
bright	O
foci	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	O
cells	O
and	O
primary	O
murine	O
erythroblasts	O
and	O
megakaryocytes	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
consensus	O
sites	O
in	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
loci	O
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
foci	O
seen	O
by	O
immunofluorescence	O
.	O

The	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co	O
-	O
localization	O
with	O
nuclear	O
antigens	O
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	O
(	O
Spl	O
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
and	O
TBP	B-PRGE
)	O
or	O
haemopoietic	O
(	O
NF	O
-	O
E2	O
)	O
transcription	O
factors	O
.	O

Interestingly	O
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
proteins	O
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co	O
-	O
expressing	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
-	B-PRGE
2	I-PRGE
or	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
-	B-PRGE
3	I-PRGE
gene	O
products	O
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	O
transcription	O
factors	O
and	O
suggests	O
a	O
protein	O
-	O
protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	O
zinc	O
finger	O
domain	O
.	O

Permanent	O
occupancy	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
by	O
NF	O
-	O
kappa	O
B	O
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	O
.	O

This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB	O
-	O
responsive	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
enhancer	O
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long	O
-	O
term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor	O
-	O
induced	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	O
tumor	O
necrosis	O
factor	O
.	O

This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
and	O
endogenous	O
long	O
terminal	O
repeat	O
transcriptional	O
activity	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF	O
-	O
kappaB	O
translocation	O
induced	O
by	O
HIV	O
-	O
1	O
replication	O
itself	O
in	O
chronically	O
infected	O
U937	O
cells	O
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z	O
-	O
LLL	O
-	O
H	O
)	O
.	O

As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
HIV	O
-	O
1	O
genome	O
expression	O
.	O

The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	O
cells	O
of	O
an	O
infectious	O
HIV	O
-	O
1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB	O
-	O
responsive	O
elements	O
of	O
both	O
long	O
terminal	O
repeats	O
.	O

Compared	O
with	O
its	O
wild	O
-	O
type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z	O
-	O
LLL	O
-	O
H	O
-	O
insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	O
monocytes	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	O
enhancer	O
by	O
NF	O
-	O
kappaB	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
heterodimers	O
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	O
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	O
Tat	B-PRGE
protein	O
.	O

Thus	O
,	O
the	O
ability	O
of	O
HIV	O
-	O
1	O
replication	O
to	O
activate	O
NF	O
-	O
kappaB	O
is	O
crucial	O
to	O
the	O
intense	O
self	O
-	O
perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	B-PRGE
binding	O
elements	O
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF	O
-	O
kappaB	O
and	O
/	O
or	O
Sp1	B-PRGE
binding	O
elements	O
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF	O
-	O
kappaB	O
and	O
four	O
Spl	B-PRGE
binding	O
elements	O
,	O
replicated	O
with	O
wild	O
-	O
type	O
kinetics	O
and	O
to	O
a	O
wild	O
-	O
type	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
cultures	O
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	O
cells	O
(	O
2xNFKappaB	O
>	O
or	O
=	O
SlVmac239	O
approximately	O
deltaNFkappaB	O
approximately	O
deltaSpl234	O
approximately	O
substNFkappaB	O
approximately	O
substSpl2	O
approximately	O
substSp23	O
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	O
cells	O
(	O
SIVmac239	O
>	O
substSp34	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSp1	O
>	O
substSpl234	O
)	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	O
and	O
R	O
regions	O
of	O
proviral	O
DNA	O
from	O
CEMxl74	O
cells	O
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage	O
-	O
competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
CEMx174	O
cultures	O
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	O
approximately	O
substNFkappaB	O
>	O
deltaNFkappaB	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSpl	O
>	O
deltaSpl234	O
approximately	O
substSpl2	O
>	O
substSp23	O
approximately	O
substSp34	O
approximately	O
substSpl234	O
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	B-PRGE
binding	O
sites	O
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	O
macrophage	O
cultures	O
.	O

Analysis	O
of	O
long	O
terminal	O
repeat	O
-	O
driven	O
secreted	O
alkaline	O
phosphatase	O
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	O
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	B-PRGE
sites	O
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B-PRGE
.	O

In	O
addition	O
,	O
the	O
SIV	O
TATA	O
box	O
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	B-PRGE
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer	O
/	O
promoter	O
region	O
.	O

Inactivation	O
of	O
IkappaBbeta	B-PRGE
by	O
the	O
tax	B-PRGE
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
resting	O
T	O
lymphocytes	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	O
kappa	O
B	O
family	O
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	B-PRGE
and	O
IkappaBbeta	B-PRGE
.	O

During	O
normal	O
T	O
-	O
cell	O
activation	O
,	O
IkappaBalpha	B-PRGE
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	O
proteasome	O
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF	O
-	O
kappaB	O
.	O

In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF	O
-	O
kappaB	O
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	B-PRGE
transforming	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
1	O
)	O
.	O

Recent	O
studies	O
indicate	O
that	O
HTLV	O
-	O
1	O
Tax	B-PRGE
targets	O
IkappaBalpha	B-PRGE
to	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	O
protein	O
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF	O
-	O
kappaB	O
response	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
addition	O
to	O
acting	O
on	O
IkappaBalpha	B-PRGE
,	O
Tax	B-PRGE
stimulates	O
the	O
turnover	O
Of	O
IkappaBbeta	B-PRGE
via	O
a	O
related	O
targeting	O
mechanism	O
.	O

Like	O
IkappaBalpha	B-PRGE
,	O
Tax	B-PRGE
-	O
mediated	O
breakdown	O
of	O
IkappaBbeta	B-PRGE
in	O
transfected	O
T	O
lymphocytes	O
is	O
blocked	O
either	O
by	O
cell	O
-	O
permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	B-PRGE
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N	O
-	O
terminal	O
region	O
.	O

Despite	O
the	O
dual	O
specificity	O
of	O
HTLV	O
-	O
1	O
Tax	B-PRGE
for	O
IkappaBalpha	B-PRGE
and	O
IkappaBbeta	B-PRGE
at	O
the	O
protein	O
level	O
,	O
Tax	B-PRGE
selectively	O
stimulates	O
NF	O
-	O
kappaB	O
-	O
directed	O
transcription	O
of	O
the	O
IkappaBalpha	B-PRGE
gene	O
.	O

Consequently	O
,	O
IkappaBbeta	B-PRGE
protein	O
expression	O
is	O
chronically	O
downregulated	O
in	O
HTLV	O
-	O
1	O
-	O
infected	O
T	O
lymphocytes	O
.	O

These	O
findings	O
with	O
IkappaBbeta	B-PRGE
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Tax	B-PRGE
-	O
expressing	O
cells	O
.	O

Role	O
of	O
EGR1	B-PRGE
in	O
regulation	O
of	O
stimulus	O
-	O
dependent	O
CD44	B-PRGE
transcription	O
in	O
B	O
lymphocytes	O
.	O

The	O
immediate	O
-	O
early	O
gene	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
encodes	O
a	O
transcription	O
factor	O
(	O
EGR1	B-PRGE
)	O
that	O
links	O
B	O
-	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	O
genes	O
.	O

Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	O
homing	O
and	O
migration	O
protein	O
CD44	B-PRGE
as	O
a	O
target	O
of	O
EGR1	B-PRGE
regulation	O
in	O
B	O
cells	O
.	O

BCR	O
-	O
induced	O
increases	O
in	O
CD44	B-PRGE
mRNA	O
expression	O
and	O
transcription	O
levels	O
are	O
shown	O
to	O
occur	O
in	O
EGR1	B-PRGE
-	O
expressing	O
but	O
not	O
in	O
nonexpressing	O
subclones	O
of	O
the	O
B	O
-	O
cell	O
line	O
WEHI	O
-	O
231	O
.	O

Kinetics	O
of	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
and	O
the	O
appearance	O
of	O
nuclear	O
EGR1	B-PRGE
protein	O
precede	O
CD44	B-PRGE
induction	O
and	O
occur	O
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1	B-PRGE
-	O
expressing	O
subclone	O
.	O

A	O
single	O
EGR1	B-PRGE
binding	O
motif	O
is	O
demonstrated	O
at	O
bp	O
-	O
301	O
of	O
the	O
human	O
CD44	B-PRGE
promoter	O
.	O

Cotransfection	O
of	O
a	O
CD44	B-PRGE
promoter	O
-	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
reporter	O
construct	O
with	O
an	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
vector	O
resulted	O
in	O
a	O
6	O
.	O
5	O
-	O
to	O
8	O
.	O
5	O
-	O
fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	O
expression	O
vector	O
.	O

The	O
EGR1	B-PRGE
binding	O
motif	O
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus	O
-	O
induced	O
expression	O
of	O
a	O
CD44	B-PRGE
promoter	O
-	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
reporter	O
construct	O
in	O
nontransformed	O
B	O
lymphocytes	O
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	B-PRGE
expression	O
vector	O
in	O
a	O
B	O
-	O
cell	O
line	O
.	O

These	O
studies	O
identify	O
EGR1	B-PRGE
as	O
an	O
intermediary	O
linking	O
BCR	O
-	O
derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B-PRGE
.	O

The	O
relevance	O
of	O
these	O
molecular	O
events	O
to	O
BCR	O
signal	O
transduction	O
and	O
antigen	O
-	O
stimulated	O
B	O
-	O
cell	O
-	O
mediated	O
immune	O
responses	O
is	O
discussed	O
.	O

Identification	O
of	O
an	O
inducible	O
regulator	O
of	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Resting	O
T	O
cells	O
express	O
very	O
low	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
protein	O
.	O

During	O
T	O
-	O
cell	O
activation	O
,	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
5	O
'	O
flanking	O
sequence	O
that	O
increased	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O

In	O
vivo	O
footprinting	O
by	O
ligation	O
-	O
mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
5	O
'	O
flanking	O
sequence	O
in	O
activated	O
T	O
cells	O
but	O
not	O
in	O
unactivated	O
T	O
cells	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	O
T	O
cells	O
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein	O
-	O
DNA	O
complex	O
,	O
referred	O
to	O
as	O
CMAT	O
for	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
in	O
activated	O
T	O
cells	O
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	O
T	O
cells	O
.	O

Because	O
the	O
binding	O
site	O
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
binding	O
site	O
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	O
EMSA	O
binding	O
complex	O
appeared	O
earlier	O
than	O
the	O
CMAT	O
complex	O
.	O

The	O
NFAT	O
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
than	O
the	O
CMAT	O
protein	O
did	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	O
did	O
not	O
cross	O
-	O
react	O
with	O
the	O
CMAT	O
protein	O
.	O

The	O
appearance	O
of	O
the	O
CMAT	O
binding	O
complex	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

The	O
CMAT	O
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
CD36	B-PRGE
gene	O
promoter	O
:	O
identification	O
of	O
a	O
proximal	O
PEBP2	O
/	O
CBF	O
site	O
.	O

CD36	B-PRGE
is	O
a	O
cell	O
surface	O
glycoprotein	O
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	O
with	O
thrombospondin	O
,	O
collagens	O
type	O
I	O
and	O
IV	O
,	O
oxidized	O
low	O
density	O
lipoprotein	O
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	O
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O

Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte	O
/	O
macrophages	O
.	O

In	O
these	O
cells	O
,	O
CD36	B-PRGE
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	O
low	O
density	O
lipoprotein	O
.	O

To	O
study	O
the	O
molecular	O
mechanisms	O
that	O
control	O
the	O
transcription	O
of	O
the	O
CD36	B-PRGE
gene	O
in	O
monocytic	O
cells	O
we	O
have	O
isolated	O
and	O
analyzed	O
the	O
CD36	B-PRGE
promoter	O
.	O

Transient	O
expression	O
experiments	O
of	O
5	O
'	O
-	O
deletion	O
fragments	O
of	O
the	O
CD36	B-PRGE
promoter	O
coupled	O
to	O
luciferase	O
demonstrated	O
that	O
as	O
few	O
as	O
158	O
base	O
pairs	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
were	O
sufficient	O
to	O
direct	O
the	O
monocyte	O
-	O
specific	O
transcription	O
of	O
the	O
reporter	O
gene	O
.	O

Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	O
-	O
158	O
to	O
-	O
90	O
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	O
cells	O
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-	O
158	O
/	O
-	O
90	O
revealed	O
a	O
binding	O
site	O
for	O
transcription	O
factors	O
of	O
the	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2	O
/	O
core	O
-	O
binding	O
factor	O
(	O
PEBP2	O
/	O
CBF	O
)	O
family	O
at	O
position	O
-	O
103	O
.	O

Disruption	O
of	O
the	O
PEBP2	O
/	O
CBF	O
site	O
markedly	O
diminished	O
the	O
role	O
of	O
the	O
PEBP2	O
/	O
CBF	O
factors	O
in	O
the	O
constitutive	O
transcription	O
of	O
the	O
CD36	B-PRGE
gene	O
.	O

The	O
involvement	O
of	O
members	O
of	O
the	O
PEBP2	O
/	O
CBF	O
family	O
in	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
myeloid	O
-	O
specific	O
genes	O
encoding	O
for	O
myeloperoxidase	B-PRGE
,	O
elastase	O
,	O
and	O
the	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
,	O
highlights	O
the	O
relevance	O
of	O
the	O
regulation	O
of	O
the	O
CD36	B-PRGE
gene	O
promoter	O
in	O
monocytic	O
cells	O
by	O
members	O
of	O
the	O
PEBP2	O
/	O
CBF	O
family	O
.	O

CNI	O
-	O
1493	O
inhibits	O
monocyte	O
/	O
macrophage	O
tumor	O
necrosis	O
factor	O
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI	O
-	O
1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	O
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M	O
.	O
,	O
Ulrich	O
,	O
P	O
.	O
,	O
Bloom	O
,	O
O	O
.	O
,	O
Meistrell	O
,	O
M	O
.	O
,	O
Zimmerman	O
,	O
G	O
.	O
A	O
.	O
,	O
Schmidtmayerova	O
,	O
H	O
.	O
,	O
Bukrinsky	O
,	O
M	O
.	O
,	O
Donnelley	O
,	O
T	O
.	O
,	O
Bucala	O
,	O
R	O
.	O
,	O
Sherry	O
,	O
B	O
.	O
,	O
Manogue	O
,	O
K	O
.	O
R	O
.	O
,	O
Tortolani	O
,	O
A	O
.	O
J	O
.	O
,	O
Cerami	O
,	O
A	O
.	O
&	O
Tracey	O
,	O
K	O
.	O
J	O
.	O
(	O
1995	O
)	O
Mol	O
.	O
Med	O
.	O
1	O
,	O
254	O
-	O
266	O
,	O
and	O
Bianchi	O
,	O
M	O
.	O
,	O
Bloom	O
,	O
O	O
.	O
,	O
Raabe	O
,	O
T	O
.	O
,	O
Cohen	O
,	O
P	O
.	O

S	O
.	O
,	O
Chesney	O
,	O
J	O
.	O
,	O
Sherry	O
,	O
B	O
.	O
,	O
Schmidtmayerova	O
,	O
H	O
.	O
,	O
Zhang	O
,	O
X	O
.	O
,	O
Bukrinsky	O
,	O
M	O
.	O
,	O
Ulrich	O
,	O
P	O
.	O
,	O
Cerami	O
,	O
A	O
.	O
&	O
Tracey	O
,	O
J	O
.	O
(	O
1996	O
)	O
J	O
.	O
Exp	O
.	O
Med	O
.	O
,	O
in	O
press	O
]	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI	O
-	O
1493	O
inhibits	O
macrophage	O
TNF	O
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	O
translation	O
efficiency	O
.	O

CNI	O
-	O
1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	O
mRNA	O
nor	O
the	O
translocation	O
of	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
nucleus	O
in	O
macrophages	O
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI	O
-	O
1493	O
does	O
not	O
interfere	O
with	O
early	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
transcriptional	O
regulation	O
of	O
TNF	O
.	O

However	O
,	O
synthesis	O
of	O
the	O
26	O
-	O
kDa	O
membrane	O
form	O
of	O
TNF	O
was	O
effectively	O
blocked	O
by	O
CNI	O
-	O
1493	O
.	O

Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	O
is	O
given	O
by	O
experiments	O
using	O
chloram	B-PRGE
-	I-PRGE
phenicol	I-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
constructs	O
containing	O
elements	O
of	O
the	O
TNF	O
gene	O
that	O
are	O
involved	O
in	O
TNF	O
translational	O
regulation	O
.	O

Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
TNF	O
gene	O
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI	O
-	O
1493	O
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI	O
-	O
1493	O
inhibits	O
TNF	O
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

STAT	O
-	O
related	O
transcription	O
factors	O
are	O
constitutively	O
activated	O
in	O
peripheral	O
blood	O
cells	O
from	O
acute	O
leukemia	O
patients	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	O
has	O
recently	O
been	O
elaborated	O
.	O

The	O
JAK	O
kinases	O
and	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	O
factors	O
in	O
peripheral	O
blood	O
cells	O
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
and	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
promoters	O
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
acute	O
leukemia	O
cells	O
in	O
bandshift	O
assays	O
.	O

Specific	O
DNA	O
protein	O
complex	O
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
and	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
promoters	O
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O

Specific	O
antibodies	O
directed	O
against	O
the	O
individual	O
STAT	O
proteins	O
were	O
used	O
in	O
supershift	O
experiments	O
.	O

STAT5	B-PRGE
-	O
and	O
STAT1	B-PRGE
-	O
related	O
factors	O
were	O
detected	O
in	O
ALL	O
and	O
STAT1	B-PRGE
-	O
,	O
STAT3	B-PRGE
-	O
,	O
and	O
STAT5	B-PRGE
-	O
related	O
proteins	O
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	O
before	O
the	O
nuclear	O
proteins	O
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	O
proteins	O
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

Reversible	O
differentiation	O
of	O
human	O
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML	O
-	O
9	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
.	O

Human	O
monoblastic	O
leukemia	O
U937	O
cells	O
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1	O
-	O
(	O
5	O
-	O
chloronaphthalene	O
-	O
1	O
-	O
sulfonyl	O
)	O
-	O
1H	O
-	O
hexahydro	O
-	O
1	O
,	O
4	O
-	O
diazepine	O
hydrochloride	O
(	O
ML	O
-	O
9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
,	O
induces	O
differentiation	O
of	O
monocytoid	O
leukemia	O
cell	O
lines	O
U937	O
and	O
THP	O
-	O
1	O
but	O
not	O
of	O
myeloblastic	O
leukemic	O
ML	O
-	O
1	O
cell	O
or	O
erythroleukemia	O
K562	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML	O
-	O
9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML	O
-	O
9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-	O
reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML	O
-	O
9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML	O
-	O
9	O
also	O
induced	O
alpha	O
-	O
naphthyl	O
acetate	O
esterase	O
(	O
ANAE	O
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML	O
-	O
9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML	O
-	O
9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML	O
-	O
9	O
'	O
s	O
induction	O
of	O
expression	O
of	O
differentiation	O
-	O
associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	O
cells	O
by	O
ML	O
-	O
9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	O
monoblastic	O
cells	O
,	O
THP	O
-	O
1	O
.	O

ML	O
-	O
9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	O
cells	O
but	O
increased	O
the	O
expression	O
of	O
monocyte	O
-	O
macrophage	O
lineage	O
-	O
associated	O
surface	O
antigen	O
,	O
CD14	B-PRGE
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
but	O
ML	O
-	O
9	O
did	O
not	O
affect	O
the	O
expression	O
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML	O
-	O
9	O
-	O
induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML	O
-	O
9	O
plus	O
an	O
anti	O
-	O
cancer	O
drug	O
such	O
as	O
1	O
-	O
beta	O
-	O
D	O
-	O
arabino	O
-	O
furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	O
cells	O
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML	O
-	O
9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
modulates	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	O
monocytes	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
modulates	O
the	O
expression	O
of	O
several	O
cytokines	O
by	O
human	O
monocytes	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
the	O
expression	O
of	O
different	O
transcription	O
factors	O
in	O
activated	O
human	O
monocytes	O
.	O

Priming	O
of	O
human	O
monocytes	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
resulted	O
in	O
the	O
down	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone	O
.	O

Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
AP	O
-	O
1	O
in	O
the	O
presence	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

LPS	O
-	O
stimulated	O
monocytes	O
showed	O
an	O
increased	O
expression	O
of	O
p105	B-PRGE
mRNA	O
,	O
the	O
precursor	O
of	O
the	O
p50	B-PRGE
subunit	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
while	O
no	O
effect	O
was	O
noticed	O
on	O
the	O
expression	O
of	O
p65	B-PRGE
mRNA	O
.	O

In	O
contrast	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
priming	O
did	O
not	O
affect	O
the	O
expression	O
of	O
p105	B-PRGE
transcripts	O
but	O
enhanced	O
the	O
expression	O
of	O
p65	B-PRGE
mRNA	O
(	O
two	O
-	O
fold	O
)	O
.	O

Priming	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	B-PRGE
mRNA	O
.	O

This	O
was	O
due	O
to	O
an	O
increase	O
in	O
the	O
half	O
-	O
life	O
of	O
p65	B-PRGE
mRNA	O
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
with	O
LPS	O
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
resulted	O
in	O
the	O
expression	O
of	O
p50	B-PRGE
and	O
p65	B-PRGE
subunits	O
,	O
while	O
the	O
combination	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
plus	O
LPS	O
caused	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	O
contained	O
p50	B-PRGE
and	O
p65	B-PRGE
protein	O
in	O
response	O
to	O
LPS	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
stimulation	O
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	O
p50	B-PRGE
and	O
p65	B-PRGE
protein	O
expression	O
.	O

The	O
effects	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
the	O
transcription	O
factors	O
were	O
specific	O
,	O
since	O
no	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
or	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
the	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
the	O
expression	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
the	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

Expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
proteins	O
and	O
AP	O
-	O
1	O
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	O
cells	O
and	O
phytohemagglutinin	B-PRGE
-	O
stimulated	O
lymphocytes	O
.	O

The	O
protein	O
products	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
(	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
(	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
)	O
genes	O
are	O
members	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
family	O
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	O
systems	O
:	O
a	O
continuously	O
growing	O
myeloid	O
leukemic	O
cell	O
line	O
,	O
HL60	O
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto	B-PRGE
-	I-PRGE
hemagglutinin	I-PRGE
(	O
PHA	B-PRGE
)	O
-	O
stimulated	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	O
and	O
Jun	O
family	O
proteins	O
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
AP	O
-	O
1	O
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	O
cells	O
and	O
in	O
PHA	B-PRGE
-	O
stimulated	O
PBL	O
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP	O
-	O
1	O
binding	O
activity	O
from	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
and	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
AP	O
-	O
1	O
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1	O
-	O
and	O
G2	O
/	O
M	O
-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S	O
-	O
phase	O
enriched	O
samples	O
of	O
HL60	O
cells	O
,	O
while	O
levels	O
of	O
nuclear	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
but	O
AP	O
-	O
1	O
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	B-PRGE
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP	O
-	O
1	O
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
were	O
present	O
in	O
HL60	O
cells	O
and	O
PHA	B-PRGE
-	O
stimulated	O
PBL	O
.	O

However	O
,	O
no	O
cytoplasmic	O
p62c	B-PRGE
-	I-PRGE
fos	I-PRGE
was	O
detected	O
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	O
p39c	B-PRGE
-	I-PRGE
jun	I-PRGE
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteinsmay	O
occur	O
under	O
certain	O
circumstances	O
.	O

Involvement	O
of	O
intracellular	O
Ca2	O
+	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
human	O
Jurkat	O
T	O
cells	O
and	O
its	O
subclone	O
Wurzburg	O
cells	O
oxidant	O
challenge	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
mobilizing	O
Ca2	O
+	O
from	O
intracellular	O
stores	O
.	O

In	O
Jurkat	O
cells	O
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	O
cells	O
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

H2O2	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
Wurzburg	O
cells	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

In	O
Jurkat	O
cells	O
that	O
are	O
not	O
sensitive	O
to	O
H2O2	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
H2O2	O
potentiated	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

NF	O
-	O
kappaB	O
regulatory	O
effect	O
of	O
alpha	O
-	O
lipoate	O
and	O
N	O
-	O
acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
cell	O
type	O
-	O
specific	O
enhancer	O
in	O
the	O
human	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
gene	O
regulated	O
by	O
NF	O
-	O
kappaB	O
.	O

The	O
costimulatory	O
molecule	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

The	O
distribution	O
of	O
this	O
integral	O
membrane	O
protein	O
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	O
is	O
modulated	O
by	O
multiple	O
exogenous	O
stimuli	O
.	O

To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	O
configuration	O
of	O
the	O
human	O
B7	O
.	O
1	O
gene	O
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O

The	O
identification	O
of	O
a	O
tissue	O
-	O
specific	O
deoxyribonuclease	B-PRGE
I	I-PRGE
hypersensitive	O
site	O
approximately	O
3kb	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
led	O
to	O
the	O
characterization	O
of	O
a	O
cell	O
type	O
-	O
specific	O
enhancer	O
region	O
.	O

This	O
183	O
-	O
bp	O
region	O
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
expression	O
.	O

Deletional	O
and	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	O
elements	O
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
consensus	O
sequence	O
.	O

In	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
-	O
positive	O
B	O
cells	O
,	O
this	O
element	O
bound	O
several	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
,	O
transcription	O
factors	O
already	O
implicated	O
in	O
signal	O
transduction	O
pathways	O
relevant	O
to	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
expression	O
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	O
costimulatory	O
molecule	O
.	O

Heat	O
shock	O
induces	O
HIV	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	O
cell	O
line	O
OM10	O
.	O
1	O
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
.	O

OM10	O
.	O
1	O
,	O
a	O
promyelocyte	O
cell	O
line	O
latently	O
infected	O
with	O
HIV	O
-	O
1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV	O
-	O
1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	O
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	O
and	O
various	O
inhibitors	O
.	O

Although	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV	O
-	O
1	O
production	O
.	O

Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5	O
-	O
3335	O
(	O
HIV	O
-	O
1	O
Tat	B-PRGE
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O

In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV	O
-	O
1	O
antigen	O
expression	O
in	O
heat	O
shock	O
-	O
treated	O
OM10	O
.	O
1	O
at	O
a	O
non	O
-	O
toxic	O
concentration	O
.	O

Although	O
the	O
mechanism	O
of	O
HIV	O
-	O
1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	O
plays	O
an	O
important	O
role	O
in	O
HIV	O
-	O
1	O
activation	O
.	O

Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infections	O
.	O

Abundant	O
expression	O
of	O
erythroid	B-PRGE
transcription	I-PRGE
factor	I-PRGE
P45	I-PRGE
NF	I-PRGE
-	I-PRGE
E2	I-PRGE
mRNA	O
in	O
human	O
peripheral	O
granurocytes	O
.	O

Transcription	O
factor	O
NF	O
-	O
E2	O
is	O
crucial	O
for	O
regulation	O
of	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O

p45	B-PRGE
subunit	O
of	O
NF	O
-	O
E2	O
contains	O
a	O
basic	O
-	O
leucine	O
zipper	O
domain	O
and	O
dimerizes	O
with	O
the	O
small	O
Maf	O
family	O
protein	O
to	O
form	O
functional	O
NF	O
-	O
E2	O
complex	O
.	O

While	O
p45	B-PRGE
expression	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
erythroid	O
cells	O
,	O
megakaryocytes	O
and	O
mast	O
cells	O
in	O
hematopoietic	O
lineage	O
,	O
we	O
found	O
in	O
this	O
study	O
that	O
p45	B-PRGE
mRNA	O
is	O
abundantly	O
transcribed	O
in	O
the	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	O
p45	B-PRGE
is	O
most	O
likely	O
to	O
be	O
neutrophils	O
.	O

p45	B-PRGE
mRNA	O
is	O
also	O
expressed	O
in	O
HL	O
-	O
60	O
promyelocytes	O
,	O
albeit	O
the	O
expression	O
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	O
fraction	O
.	O

HL	O
-	O
60	O
cells	O
were	O
found	O
to	O
express	O
mafK	B-PRGE
mRNA	O
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF	O
-	O
E2	O
complex	O
in	O
the	O
cells	O
.	O

Although	O
p45	B-PRGE
mRNA	O
is	O
transcribed	O
from	O
two	O
different	O
promoters	O
,	O
aNF	O
-	O
E2	O
promoter	O
and	O
fNF	O
-	O
E2	O
promoter	O
,	O
in	O
erythroid	O
and	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	B-PRGE
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF	O
-	O
E2	O
promoter	O
.	O

The	O
expression	O
of	O
p45	B-PRGE
megakaryocytic	O
lineage	O
cells	O
,	O
p45	B-PRGE
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF	O
-	O
E2	O
promoter	O
.	O

The	O
expression	O
of	O
p45	B-PRGE
mRNA	O
in	O
the	O
neutrophils	O
declined	O
rapidly	O
after	O
transfer	O
of	O
the	O
cells	O
to	O
in	O
vitro	O
culture	O
and	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
could	O
not	O
sustain	O
the	O
expression	O
from	O
the	O
down	O
-	O
regulation	O
,	O
suggesting	O
the	O
E2	O
may	O
also	O
participate	O
in	O
the	O
regulation	O
of	O
neutrophil	O
-	O
specific	O
gene	O
expression	O
.	O

Identification	O
of	O
a	O
human	O
LIM	O
-	O
Hox	O
gene	O
,	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
aberrantly	O
expressed	O
in	O
chronic	O
myelogenous	O
leukaemia	O
and	O
located	O
on	O
9q33	O
-	O
34	O
.	O
1	O
.	O

We	O
describe	O
the	O
isolation	O
of	O
human	O
LH	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
a	O
putative	O
transcription	O
factor	O
containing	O
two	O
cysteine	O
-	O
rich	O
regions	O
(	O
LIM	O
domains	O
)	O
and	O
a	O
homeobox	O
(	O
Hox	O
)	O
DNA	O
-	O
binding	O
domain	O
.	O

High	O
levels	O
of	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
were	O
observed	O
in	O
all	O
cases	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
tested	O
,	O
regardless	O
of	O
disease	O
status	O
.	O

hLH	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
mapped	O
to	O
chromosome	O
9Q33	O
-	O
34	O
.	O
1	O
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR	B-PRGE
-	O
ABL	B-PRGE
chimera	O
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
retained	O
on	O
the	O
derivative	O
9	O
chromosome	O
and	O
is	O
therefore	O
centromeric	O
of	O
c	B-PRGE
-	I-PRGE
ABL	I-PRGE
.	O

The	O
proximity	O
of	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
the	O
breakpoint	O
on	O
chromosome	O
9	O
raises	O
the	O
possibility	O
of	O
cis	O
-	O
activation	O
by	O
the	O
t	O
(	O
9	O
;	O
22	O
)	O
(	O
q34	O
;	O
q11	O
)	O
translocation	O
.	O

In	O
addition	O
to	O
finding	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	O
cell	O
lines	O
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O

The	O
role	O
of	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O

However	O
,	O
hLH	B-PRGE
-	I-PRGE
2	I-PRGE
may	O
prove	O
useful	O
as	O
a	O
marker	O
of	O
CML	O
for	O
monitoring	O
residual	O
disease	O
.	O

BCL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
during	O
B	O
-	O
cell	O
activation	O
.	O

Translocations	O
involving	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Invariably	O
,	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	O
'	O
untranslated	O
region	O
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	O
partner	O
.	O

The	O
present	O
study	O
shows	O
that	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
is	O
regulated	O
in	O
lymphocytes	O
during	O
mitogenic	O
stimulation	O
.	O

Resting	O
B	O
and	O
T	O
lymphocytes	O
contain	O
high	O
levels	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
.	O

Stimulation	O
of	O
mouse	O
B	O
cells	O
with	O
anti	O
-	O
IgM	O
or	O
IgD	O
antibodies	O
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-PRGE
ligand	I-PRGE
led	O
to	O
a	O
five	O
-	O
fold	O
to	O
35	O
-	O
fold	O
decrease	O
in	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
levels	O
.	O

Similar	O
downregulation	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
was	O
seen	O
in	O
human	O
B	O
cells	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
anti	O
-	O
IgM	O
antibodies	O
and	O
in	O
human	O
T	O
lymphocytes	O
stimulated	O
with	O
phytohemagglutinin	B-PRGE
.	O

BCL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	O
cells	O
in	O
vitro	O
invariably	O
decreased	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
MRNA	O
expression	O
,	O
activated	O
B	O
cells	O
from	O
human	O
germinal	O
centers	O
expressed	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O

Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
expression	O
was	O
threefold	O
to	O
34	O
-	O
fold	O
higher	O
in	O
germinal	O
center	O
B	O
cells	O
than	O
in	O
resting	O
B	O
cells	O
,	O
suggesting	O
that	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
levels	O
are	O
controlled	O
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	O
cells	O
that	O
allow	O
for	O
continued	O
,	O
high	O
-	O
level	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
.	O

A	O
novel	O
interferon	O
regulatory	O
factor	O
family	O
transcription	O
factor	O
,	O
ICSAT	B-PRGE
/	O
Pip	B-PRGE
/	O
LSIRF	B-PRGE
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon	O
-	O
regulated	O
genes	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
cDNA	O
clone	O
encoding	O
interferon	B-PRGE
(	I-PRGE
IFN	I-PRGE
)	I-PRGE
consensus	I-PRGE
sequence	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
in	I-PRGE
adult	I-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
leukemia	I-PRGE
cell	I-PRGE
line	I-PRGE
or	I-PRGE
activated	I-PRGE
T	I-PRGE
cells	I-PRGE
(	O
ICSAT	B-PRGE
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip	B-PRGE
/	O
LSIRF	B-PRGE
.	O

ICSAT	B-PRGE
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	B-PRGE
,	O
a	O
member	O
of	O
the	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
proteins	O
that	O
binds	O
to	O
interferon	O
consensus	O
sequences	O
(	O
ICSs	O
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN	O
-	O
regulated	O
genes	O
.	O

Among	O
T	O
-	O
cell	O
lines	O
investigated	O
,	O
ICSAT	B-PRGE
was	O
abundantly	O
expressed	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
infected	O
T	O
cells	O
.	O

When	O
the	O
HTLV	O
-	O
1	O
tax	B-PRGE
gene	O
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate	O
-	O
A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	B-PRGE
expression	O
was	O
induced	O
in	O
Jurkat	O
cells	O
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	B-PRGE
.	O

When	O
the	O
binding	O
of	O
ICSAT	B-PRGE
to	O
four	O
different	O
ICSs	O
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	O
were	O
determined	O
.	O

To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	B-PRGE
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	O
embryonal	O
carcinoma	O
cell	O
line	O
N	O
-	O
Tera2	O
.	O

ICSAT	B-PRGE
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	O
stimulation	O
or	O
by	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
cotransfection	O
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
ICSBP	B-PRGE
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B-PRGE
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
ICSBP	B-PRGE
in	O
some	O
IFN	O
-	O
responsive	O
reporter	O
constructs	O
.	O

These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
"	O
differential	O
repression	O
"	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	O
proteins	O
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN	O
-	O
responsive	O
genes	O
.	O

Transcription	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
-	O
-	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	O
factors	O
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	O
and	O
enhancers	O
by	O
nuclear	O
trans	O
-	O
acting	O
factors	O
in	O
lymphocytes	O
.	O

The	O
structural	O
classes	O
of	O
transcription	O
factors	O
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	O
factors	O
are	O
detailed	O
.	O

Furthermore	O
,	O
the	O
most	O
important	O
trans	O
-	O
acting	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
(	O
e	O
.	O
g	O
.	O
NF	O
-	O
kB	O
,	O
NF	O
-	O
AT	O
and	O
STAT	O
families	O
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O

Several	O
methods	O
for	O
specific	O
down	O
-	O
regulation	O
of	O
transcription	O
factors	O
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O

The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
gene	O
expression	O
in	O
human	O
T	O
cells	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

Although	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

An	O
NF	O
-	O
kappaB	O
/	O
Rel	O
binding	O
site	O
within	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
,	O
termed	O
the	O
kappaB	O
element	O
appears	O
to	O
be	O
important	O
for	O
controlling	O
expression	O
in	O
reporter	O
gene	O
assays	O
in	O
response	O
to	O
a	O
number	O
of	O
stimuli	O
in	O
T	O
cells	O
.	O

We	O
investigated	O
oligonucleotide	O
-	O
directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	O
sequence	O
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
transcription	O
.	O

A	O
15	O
-	O
base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine	O
-	O
rich	O
region	O
in	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
proximal	O
promoter	O
,	O
which	O
overlaps	O
the	O
kappaB	O
element	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
DNase	B-PRGE
I	I-PRGE
footprinting	O
demonstrated	O
that	O
GM3	O
formed	O
a	O
sequence	O
-	O
specific	O
collinear	O
triplex	O
with	O
its	O
double	O
-	O
stranded	O
DNA	O
target	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	O
and	O
nuclear	O
NF	O
-	O
kappaB	O
proteins	O
binding	O
to	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
element	O
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	O
T	O
-	O
cell	O
lymphotrophic	O
virus	O
-	O
1	O
Tax	B-PRGE
transactivator	O
-	O
induced	O
luciferase	O
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
in	O
Jurkat	O
T	O
cells	O
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
mRNA	O
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	O
T	O
cells	O
but	O
did	O
not	O
affect	O
interleukin	B-PRGE
3	I-PRGE
mRNA	O
levels	O
in	O
the	O
same	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
kappaB	O
element	O
in	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
plays	O
a	O
central	O
role	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
endogenous	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O

Cooperation	O
between	O
core	O
binding	O
factor	O
and	O
adjacent	O
promoter	O
elements	O
contributes	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
mediated	O
via	O
cis	O
-	O
acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP	O
-	O
1	O
and	O
Elf	O
-	O
1	O
sites	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell	O
-	O
specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act	O
-	O
1	O
.	O

Together	O
the	O
Act	O
-	O
1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	O
in	O
fibroblasts	O
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
between	O
nucleotide	O
-	O
180	O
and	O
-	O
210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
not	O
specified	O
by	O
the	O
activity	O
of	O
a	O
single	O
tissue	O
-	O
specific	O
element	O
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

Octamer	O
binding	O
factors	O
and	O
their	O
coactivator	O
can	O
activate	O
the	O
murine	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
(	O
spi	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
promoter	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
(	O
spi	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
a	O
member	O
of	O
the	O
Ets	O
transcription	O
factor	O
family	O
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	O
and	O
B	O
cells	O
,	O
activates	O
many	O
B	O
cell	O
and	O
myeloid	O
genes	O
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O

Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H	O
.	O
M	O
.	O
,	O
Ray	O
-	O
Gallet	O
,	O
D	O
.	O
,	O
Zhang	O
,	O
P	O
.	O
,	O
Hetherington	O
,	O
C	O
.	O
J	O
.	O
,	O
Gonzalez	O
,	O
D	O
.	O
A	O
.	O
,	O
Zhang	O
,	O
D	O
.	O
-	O
E	O
.	O
,	O
Moreau	O
-	O
Gachelin	O
,	O
F	O
.	O
,	O
and	O
Tenen	O
,	O
D	O
.	O
G	O
.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549	O
-	O
1560	O
)	O
demonstrate	O
that	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
promoter	O
directs	O
cell	O
type	O
-	O
specific	O
reporter	O
gene	O
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
activates	O
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O

Here	O
we	O
show	O
that	O
the	O
murine	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
promoter	O
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	O
cell	O
lines	O
as	O
well	O
.	O

Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
can	O
bind	O
specifically	O
to	O
a	O
site	O
at	O
base	O
pair	O
-	O
55	O
in	O
vitro	O
,	O
and	O
this	O
site	O
is	O
specifically	O
protected	O
in	O
B	O
cells	O
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
two	O
other	O
sites	O
contribute	O
to	O
promoter	O
activity	O
in	O
B	O
cells	O
;	O
an	O
Sp1	B-PRGE
binding	O
site	O
adjacent	O
to	O
the	O
octamer	O
site	O
,	O
and	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
autoregulatory	O
site	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Bob1	B-PRGE
/	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
is	O
only	O
expressed	O
in	O
B	O
cells	O
and	O
not	O
in	O
myeloid	O
cells	O
,	O
and	O
that	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
Bob1	B-PRGE
/	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
can	O
transactivate	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
promoter	O
in	O
HeLa	O
and	O
myeloid	O
cells	O
.	O

This	O
B	O
cell	O
restricted	O
coactivator	O
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
mediated	O
by	O
the	O
octamer	O
site	O
.	O

Tissue	O
-	O
specific	O
activity	O
of	O
the	O
gammac	O
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	O
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA	O
-	O
binding	O
protein	O
.	O

The	O
gammac	B-PRGE
chain	O
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	O
receptors	O
(	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	O
lineages	O
.	O

A	O
defect	O
in	O
gammac	B-PRGE
leads	O
to	O
the	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	O
gammac	B-PRGE
promoter	O
and	O
define	O
the	O
minimal	O
tissue	O
-	O
specific	O
promoter	O
region	O
,	O
progressive	O
5	O
'	O
-	O
deletion	O
constructs	O
of	O
a	O
segment	O
extending	O
1053	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
types	O
.	O

The	O
-	O
1053	O
/	O
+	O
34	O
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-	O
90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	O
binding	O
sites	O
conserved	O
in	O
the	O
murine	O
gammac	B-PRGE
promoter	O
gene	O
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	O
binding	O
site	O
was	O
found	O
to	O
bind	O
Ets	O
family	O
proteins	O
,	O
principally	O
GA	O
-	O
binding	O
protein	O
and	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	O
and	O
-	O
beta	O
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B-PRGE
promoter	O
,	O
GA	O
-	O
binding	O
protein	O
is	O
an	O
essential	O
component	O
of	O
gammac	B-PRGE
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	B-PRGE
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	O
lineage	O
,	O
its	O
interaction	O
with	O
other	O
specific	O
factors	O
may	O
contribute	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
gammac	B-PRGE
gene	O
.	O

Multiple	O
transcription	O
factors	O
are	O
required	O
for	O
activation	O
of	O
human	O
interleukin	B-PRGE
9	I-PRGE
gene	O
in	O
T	O
cells	O
.	O

The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	O
for	O
human	O
interleukin	B-PRGE
9	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
)	O
gene	O
expression	O
in	O
a	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
transformed	O
human	O
T	O
cell	O
line	O
,	O
C5MJ2	O
,	O
were	O
investigated	O
.	O

We	O
demonstrated	O
that	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
expression	O
is	O
controlled	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	O
reporter	O
gene	O
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
has	O
revealed	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
in	O
C5MJ2	O
cells	O
.	O

An	O
AP	O
-	O
1	O
site	O
at	O
-	O
146	O
to	O
-	O
140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
.	O

A	O
proximal	O
region	O
between	O
-	O
46	O
and	O
-	O
80	O
was	O
identified	O
as	O
the	O
minimum	O
sequence	O
for	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
in	O
C5MJ2	O
cells	O
.	O

Within	O
this	O
region	O
,	O
an	O
NF	O
-	O
kappaB	O
site	O
at	O
-	O
59	O
to	O
-	O
50	O
and	O
its	O
adjacent	O
20	O
-	O
base	O
pair	O
upstream	O
sequence	O
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
promoter	O
activity	O
.	O

DNA	O
-	O
protein	O
binding	O
studies	O
indicated	O
that	O
NF	O
-	O
kappaB	O
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
and	O
potentially	O
novel	O
proteins	O
(	O
around	O
35	O
kDa	O
)	O
can	O
bind	O
to	O
this	O
important	O
sequence	O
.	O

Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	O
promoter	O
region	O
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
different	O
transcription	O
factors	O
is	O
essential	O
for	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
gene	O
expression	O
in	O
T	O
cells	O
.	O

Mapping	O
of	O
the	O
transcriptional	O
repression	O
domain	O
of	O
the	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
oct	B-PRGE
-	I-PRGE
2A	I-PRGE
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
is	O
implicated	O
in	O
B	O
cell	O
-	O
specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure	O
/	O
function	O
analysis	O
of	O
various	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
effector	O
regions	O
in	O
the	O
context	O
of	O
the	O
GAL4	B-PRGE
DNA	O
-	O
binding	O
domain	O
revealed	O
that	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
contains	O
two	O
functionally	O
different	O
activation	O
domains	O
at	O
the	O
N	O
and	O
the	O
C	O
termini	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	O
cell	O
-	O
specific	O
coactivators	O
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	O
domain	O
located	O
within	O
the	O
N	O
terminus	O
of	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
(	O
amino	O
acids	O
2	O
-	O
99	O
)	O
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
to	O
determine	O
the	O
minimal	O
repression	O
domain	O
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	O
present	O
in	O
the	O
reporter	O
plasmid	O
as	O
well	O
as	O
on	O
the	O
cell	O
line	O
tested	O
.	O

The	O
possibility	O
that	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
can	O
act	O
as	O
an	O
activator	O
and	O
/	O
or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct	B-PRGE
-	I-PRGE
2a	I-PRGE
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

The	O
role	O
of	O
BSAP	B-PRGE
(	O
Pax	B-PRGE
-	I-PRGE
5	I-PRGE
)	O
in	O
B	O
-	O
cell	O
development	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B	O
-	O
cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

In	O
this	O
manner	O
,	O
the	O
paired	O
box	O
containing	O
gene	O
Pax	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
encoding	O
the	O
B	B-PRGE
cell	I-PRGE
specific	I-PRGE
transcription	I-PRGE
factor	I-PRGE
BSAP	B-PRGE
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B-PRGE
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
at	O
late	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
receptor	I-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
controls	O
responsiveness	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	O
cells	O
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O

Therefore	O
,	O
any	O
event	O
that	O
enables	O
T	O
cells	O
to	O
become	O
less	O
responsive	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	O
peripheral	O
blood	O
T	O
cells	O
that	O
are	O
stimulated	O
through	O
the	O
TCR	O
and	O
expanded	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
unresponsive	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	O
of	O
jak	O
kinases	O
and	O
the	O
transcription	O
factor	O
,	O
STAT1	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O

This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta	O
-	O
chain	O
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN	O
-	O
gamma	O
receptor	O
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
expression	O
.	O

Expression	O
of	O
the	O
beta	O
-	O
chain	O
can	O
be	O
restored	O
by	O
secondary	O
TCR	O
ligation	O
or	O
PMA	O
treatment	O
.	O

T	O
cell	O
blasts	O
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	O
cells	O
are	O
examined	O
for	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
express	O
beta	O
-	O
chain	O
.	O

Therefore	O
,	O
as	O
T	O
cells	O
progress	O
from	O
primary	O
TCR	O
activation	O
through	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	O
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O

Induction	O
of	O
CIITA	B-PRGE
and	O
modification	O
of	O
in	O
vivo	O
HLA	O
-	O
DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA	O
-	O
DR	O
-	O
constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	O
class	O
II	O
induction	O
is	O
studied	O
in	O
a	O
"	O
physiologic	O
"	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B-PRGE
trans	O
-	O
activator	O
,	O
a	O
crucial	O
MHC	O
class	O
II	O
gene	O
regulatory	O
factor	O
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	O
factors	O
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	O
I	O
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	O
factors	O
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II	O
-	O
constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	O
lymphoma	O
line	O
Raji	O
and	O
normal	O
tonsil	O
-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	O
,	O
either	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	B-PRGE
trans	O
-	O
activator	O
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Recombinant	O
NFAT1	B-PRGE
(	O
NFATp	B-PRGE
)	O
is	O
regulated	O
by	O
calcineurin	O
in	O
T	O
cells	O
and	O
mediates	O
transcription	O
of	O
several	O
cytokine	O
genes	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
identified	O
two	O
new	O
isoforms	O
of	O
the	O
transcription	O
factor	O
NFAT1	B-PRGE
(	O
previously	O
termed	O
NFATp	B-PRGE
)	O
that	O
are	O
the	O
predominant	O
isoforms	O
expressed	O
in	O
murine	O
and	O
human	O
T	O
cells	O
.	O

When	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
recombinant	O
NFAT1	B-PRGE
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin	B-PRGE
-	O
dependent	O
phosphatase	O
calcineurin	O
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Transactivation	O
by	O
recombinant	O
NFAT1	B-PRGE
in	O
Jurkat	O
T	O
cells	O
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
;	O
this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	O
and	O
is	O
inhibited	O
by	O
CsA	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	B-PRGE
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	O
transfected	O
T	O
cells	O
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

When	O
expressed	O
in	O
COS	O
cells	O
,	O
however	O
,	O
NFAT1	B-PRGE
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	O
cells	O
with	O
ionomycin	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Recombinant	O
NFAT1	B-PRGE
can	O
mediate	O
transcription	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
promoters	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
NFAT1	B-PRGE
contributes	O
to	O
the	O
CsA	O
-	O
sensitive	O
transcription	O
of	O
these	O
genes	O
during	O
the	O
immune	O
response	O
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
transcription	O
factor	O
.	O

Spi	B-PRGE
-	I-PRGE
B	I-PRGE
is	O
an	O
Ets	O
transcription	O
factor	O
related	O
to	O
the	O
oncoprotein	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
highly	O
expressed	O
in	O
B	O
lymphoid	O
cells	O
.	O

The	O
Ets	O
proteins	O
share	O
a	O
conserved	O
Ets	O
domain	O
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O

Spi	B-PRGE
-	I-PRGE
B	I-PRGE
binds	O
DNA	O
sequences	O
containing	O
a	O
core	O
5	O
'	O
-	O
GGAA	O
-	O
3	O
'	O
and	O
activates	O
transcription	O
through	O
this	O
motif	O
.	O

Up	O
to	O
date	O
,	O
the	O
biological	O
function	O
of	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
remains	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
named	O
deltaSpi	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
which	O
has	O
lost	O
the	O
Ets	O
domain	O
.	O

In	O
B	O
lymphoid	O
cells	O
,	O
deltaspi	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
spi	B-PRGE
-	I-PRGE
B	I-PRGE
mRNAs	O
were	O
present	O
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O

DeltaSpi	B-PRGE
-	I-PRGE
B	I-PRGE
product	O
was	O
not	O
able	O
to	O
bind	O
DNA	O
and	O
was	O
recovered	O
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	B-PRGE
Spi	I-PRGE
-	I-PRGE
B	I-PRGE
might	O
affect	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
activity	O
.	O

Activation	O
protein	O
1	O
-	O
dependent	O
transcriptional	O
activation	O
of	O
interleukin	B-PRGE
2	I-PRGE
gene	O
by	O
Ca2	B-PRGE
+	I-PRGE
/	I-PRGE
calmodulin	I-PRGE
kinase	I-PRGE
type	I-PRGE
IV	I-PRGE
/	I-PRGE
Gr	I-PRGE
.	O

The	O
Ca2	B-PRGE
+	I-PRGE
/	I-PRGE
calmodulin	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	I-PRGE
CaMK	I-PRGE
)	I-PRGE
type	I-PRGE
IV	I-PRGE
/	I-PRGE
Gr	I-PRGE
is	O
selectively	O
expressed	O
in	O
T	O
lymphocytes	O
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	O
engagement	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV	B-PRGE
/	I-PRGE
Gr	I-PRGE
induces	O
the	O
transcription	O
factor	O
activation	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	O
cell	O
mitogens	O
and	O
with	O
the	O
p21ras	B-PRGE
oncoprotein	O
.	O

CaMKIV	B-PRGE
/	I-PRGE
Gr	I-PRGE
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
but	O
is	O
independent	O
of	O
p21ras	B-PRGE
or	O
calcineurin	O
.	O

AP	O
-	O
1	O
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
transcriptional	O
complex	O
,	O
which	O
is	O
required	O
for	O
interleukin	B-PRGE
2	I-PRGE
gene	O
expression	O
in	O
T	O
cells	O
.	O

We	O
demonstrate	O
that	O
CaMKIV	B-PRGE
/	I-PRGE
Gr	I-PRGE
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	O
to	O
direct	O
transcription	O
from	O
NFAT	O
sites	O
in	O
non	O
-	O
T	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV	B-PRGE
/	I-PRGE
Gr	I-PRGE
as	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B-PRGE
factor	I-PRGE
of	I-PRGE
activated	I-PRGE
T	I-PRGE
cells	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
family	O
proteins	O
(	O
NFAT1	B-PRGE
/	O
NFATp	B-PRGE
,	O
NFATc	B-PRGE
,	O
NFAT3	B-PRGE
,	O
and	O
NFAT4	B-PRGE
/	O
NFATx	B-PRGE
/	O
NFATc3	B-PRGE
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
defined	O
the	O
mechanisms	O
of	O
transactivation	O
by	O
NFAT1	B-PRGE
.	O

NFAT1	B-PRGE
possesses	O
two	O
transactivation	O
domains	O
whose	O
sequences	O
are	O
not	O
conserved	O
in	O
the	O
other	O
NFAT	O
-	O
family	O
proteins	O
,	O
and	O
a	O
conserved	O
DNA	O
-	O
binding	O
domain	O
that	O
mediates	O
the	O
recruitment	O
of	O
cooperating	O
nuclear	O
transcription	O
factors	O
even	O
when	O
it	O
is	O
expressed	O
in	O
the	O
absence	O
of	O
other	O
regions	O
of	O
the	O
protein	O
.	O

The	O
activity	O
of	O
the	O
NH2	O
-	O
terminal	O
transactivation	O
domain	O
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	O
region	O
that	O
contains	O
several	O
conserved	O
sequence	O
motifs	O
represented	O
only	O
in	O
the	O
NFAT	O
family	O
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT	O
-	O
dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	O
complexes	O
containing	O
different	O
NFAT	O
-	O
family	O
proteins	O
.	O

BCL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
a	O
POZ	O
/	O
zinc	O
-	O
finger	O
protein	O
,	O
is	O
a	O
sequence	O
-	O
specific	O
transcriptional	O
repressor	O
.	O

Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	O
the	O
expression	O
of	O
the	O
BCL6	B-PRGE
gene	O
by	O
juxtaposing	O
heterologous	O
promoters	O
to	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
coding	O
domain	O
.	O

The	O
BCL6	B-PRGE
gene	O
encodes	O
a	O
95	O
-	O
kDa	O
protein	O
containing	O
six	O
C	O
-	O
terminal	O
zinc	O
-	O
finger	O
motifs	O
and	O
an	O
N	O
-	O
terminal	O
POZ	O
domain	O
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	O
factor	O
.	O

By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
is	O
present	O
in	O
DNA	O
-	O
binding	O
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B	O
-	O
cell	O
lines	O
.	O

In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	B-PRGE
can	O
repress	O
transcription	O
from	O
promoters	O
linked	O
to	O
its	O
DNA	O
target	O
sequence	O
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA	O
-	O
binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
.	O

We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	B-PRGE
molecule	O
contains	O
an	O
autonomous	O
transrepressor	O
domain	O
and	O
that	O
two	O
noncontiguous	O
regions	O
,	O
including	O
the	O
POZ	O
motif	O
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
can	O
function	O
as	O
a	O
sequence	O
-	O
specific	O
transcriptional	O
repressor	O
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B-PRGE
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	O
isotypes	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	O
U937	O
cells	O
.	O

Constitutive	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha5	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	O
mRNA	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	O
product	O
.	O

The	O
activated	O
form	O
of	O
the	O
interferon	O
-	O
induced	O
transcription	O
factor	O
complex	O
ISGF3	O
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	O
cells	O
.	O

Culture	O
supernatants	O
from	O
uninduced	O
U937	O
cells	O
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	O
cloned	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
,	O
indicating	O
the	O
presence	O
of	O
endogenous	O
IFN	O
activity	O
equivalent	O
to	O
approximately	O
0	O
.	O
3	O
to	O
0	O
.	O
5	O
IU	O
/	O
mL	O
.	O

This	O
endogenous	O
IFN	O
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	O
histocompatibility	O
class	O
I	O
genes	O
in	O
lymphoid	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
IFN	B-PRGE
-	I-PRGE
alpha5	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
gene	O
family	O
member	O
NFATc	B-PRGE
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
/	O
FK506	O
-	O
sensitive	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	O
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non	O
-	O
T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	O
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	O
proteins	O
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc	B-PRGE
.	I-PRGE
beta	I-PRGE
,	O
of	O
the	O
NFAT	O
gene	O
family	O
member	O
NFATc	B-PRGE
(	O
designated	O
here	O
NFATc	B-PRGE
.	I-PRGE
alpha	I-PRGE
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
NFATc	B-PRGE
.	I-PRGE
beta	I-PRGE
differs	O
from	O
that	O
of	O
NFATc	B-PRGE
.	I-PRGE
alpha	I-PRGE
in	O
the	O
first	O
NH2	O
-	O
terminal	O
29	O
residues	O
and	O
contains	O
an	O
additional	O
region	O
of	O
142	O
residues	O
at	O
the	O
COOH	O
terminus	O
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2	O
.	O
7	O
and	O
4	O
.	O
5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc	B-PRGE
.	I-PRGE
beta	I-PRGE
-	O
specific	O
probe	O
detected	O
only	O
the	O
4	O
.	O
5	O
-	O
kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc	B-PRGE
.	I-PRGE
beta	I-PRGE
was	O
capable	O
of	O
activating	O
an	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
NFAT	O
-	O
driven	O
reporter	O
gene	O
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc	B-PRGE
.	I-PRGE
beta	I-PRGE
neither	O
bound	O
to	O
the	O
kappa3	O
element	O
(	O
an	O
NFAT	O
-	O
binding	O
site	O
)	O
in	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
nor	O
activated	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

Cytokine	O
-	O
modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase	O
/	O
5	O
-	O
lipoxygenase	O
anti	O
-	O
inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O

It	O
has	O
been	O
shown	O
to	O
possess	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induced	O
signal	O
transduction	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	O
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O

In	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
with	O
OKT3	O
/	O
PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	B-PRGE
(	O
IC50	O
=	O
0	O
.	O
5	O
microM	O
)	O
and	O
the	O
cytokines	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
alpha	I-PRGE
(	O
IC50	O
=	O
10	O
-	O
12	O
microM	O
)	O
.	O

Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O

Add	O
-	O
back	O
experiments	O
with	O
either	O
cytokines	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
,	O
LTB4	B-PRGE
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O

However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
which	O
acts	O
on	O
several	O
cytokine	O
genes	O
.	O

Tepoxalin	O
'	O
s	O
effect	O
on	O
NF	O
kappa	O
B	O
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	O
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	O
kappa	O
B	O
and	O
subsequent	O
inhibition	O
of	O
cytokine	O
production	O
.	O

oriP	B-PRGE
is	O
essential	O
for	O
EBNA	O
gene	O
promoter	O
activity	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
.	O

During	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	O
nuclear	O
antigens	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	B-PRGE
or	O
Wp	B-PRGE
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Upon	O
infection	O
,	O
Wp	B-PRGE
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	B-PRGE
for	O
the	O
duration	O
of	O
latency	O
.	O

In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	B-PRGE
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	O
gene	O
promoters	O
in	O
established	O
in	O
vitro	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

It	O
was	O
determined	O
that	O
oriP	B-PRGE
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	B-PRGE
or	O
Wp	B-PRGE
in	O
LCLs	O
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	O
'	O
s	O
lymphoma	O
cell	O
lines	O
.	O

Deletion	O
of	O
the	O
EBNA2	B-PRGE
-	O
dependent	O
enhancer	O
located	O
upstream	O
of	O
Cp	B-PRGE
resulted	O
in	O
a	O
ca	O
.	O
two	O
-	O
to	O
fivefold	O
reduction	O
in	O
Cp	B-PRGE
activity	O
in	O
the	O
LCLs	O
assayed	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	B-PRGE
,	O
including	O
the	O
EBNA2	B-PRGE
-	O
dependent	O
enhancer	O
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	B-PRGE
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	O
boxes	O
,	O
a	O
proximal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-	O
61	O
to	O
-	O
65	O
and	O
a	O
distal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-	O
253	O
to	O
-	O
257	O
,	O
upstream	O
of	O
Cp	B-PRGE
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
these	O
cis	O
elements	O
demonstrated	O
that	O
Cp	B-PRGE
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	O
box	O
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	O
CCAAT	O
box	O
apparent	O
only	O
when	O
the	O
proximal	O
CCAAT	O
box	O
was	O
deleted	O
or	O
mutated	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca	O
.	O

bp	O
-	O
850	O
upstream	O
of	O
Cp	B-PRGE
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	B-PRGE
activity	O
resulted	O
in	O
induction	O
of	O
Wp	B-PRGE
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	B-PRGE
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	B-PRGE
.	O

The	O
identification	O
of	O
oriP	B-PRGE
and	O
the	O
EBNA2	B-PRGE
-	O
dependent	O
enhancer	O
as	O
the	O
major	O
positive	O
cis	O
elements	O
involved	O
in	O
regulating	O
Cp	B-PRGE
activity	O
in	O
LCL	O
suggests	O
that	O
EBNA	O
gene	O
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	B-PRGE
1	I-PRGE
and	O
EBNA	B-PRGE
2	I-PRGE
.	O

Various	O
modes	O
of	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
protein	O
-	O
mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

The	O
transcriptionally	O
regulatory	O
regions	O
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3	O
-	O
3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E	O
-	O
box	O
consensus	O
motifs	O
,	O
CAGATG	O
.	O

One	O
type	O
,	O
EA	O
/	O
S	O
,	O
is	O
located	O
in	O
the	O
upstream	O
promoter	O
region	O
,	O
and	O
the	O
other	O
,	O
E	O
(	O
gre	O
)	O
,	O
is	O
located	O
in	O
a	O
tandem	O
repeat	O
with	O
enhancer	O
properties	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E	O
-	O
boxes	O
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
lymphoid	O
cell	O
lines	O
only	O
,	O
the	O
E	O
(	O
gre	O
)	O
-	O
binding	O
protein	O
complexes	O
included	O
ALF1	B-PRGE
or	O
HEB	B-PRGE
and	O
E2A	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
.	O

Ectopic	O
ALF1	B-PRGE
and	O
E2A	O
proteins	O
required	O
intact	O
E	O
(	O
gre	O
)	O
motifs	O
for	O
mediating	O
transcriptional	O
activation	O
.	O

ALF1	B-PRGE
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	O
(	O
gre	O
)	O
motifs	O
equally	O
,	O
whereas	O
E2A	O
protein	O
required	O
the	O
promoter	O
-	O
proximal	O
E	O
(	O
gre	O
)	O
motif	O
.	O

In	O
T	O
-	O
and	O
B	O
-	O
cell	O
lines	O
,	O
the	O
E	O
(	O
gre	O
)	O
motifs	O
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA	O
/	O
S	O
motif	O
had	O
some	O
effect	O
.	O

In	O
contrast	O
,	O
neither	O
E	O
(	O
gre	O
)	O
nor	O
EA	O
/	O
S	O
motifs	O
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	O
3T3	O
cells	O
lacking	O
DNA	O
-	O
binding	O
ALF1	B-PRGE
or	O
HEB	B-PRGE
and	O
E2A	O
proteins	O
.	O

The	O
Id1	B-PRGE
protein	O
was	O
found	O
to	O
repress	O
ALF1	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
ectopic	O
Id1	B-PRGE
repressed	O
E	O
(	O
gre	O
)	O
-	O
directed	O
but	O
not	O
EA	O
/	O
S	O
-	O
directed	O
MLV	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

In	O
conclusion	O
,	O
E	O
(	O
gre	O
)	O
motifs	O
and	O
interacting	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	O
cell	O
lines	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G	O
-	O
protein	O
-	O
coupled	O
chemoattractant	O
receptors	O
.	O

Receptors	O
for	O
leukocyte	O
chemoattractants	O
,	O
including	O
chemokines	O
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G	O
-	O
protein	O
-	O
coupled	O
serpentine	O
receptors	O
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
NF	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G	O
-	O
protein	O
coupling	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate	O
-	O
early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	O
and	O
chemokine	O
gene	O
expression	O
.	O

Regulation	O
of	O
gene	O
expression	O
at	O
early	O
stages	O
of	O
B	O
-	O
cell	O
and	O
T	O
-	O
cell	O
differentiation	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B	O
-	O
lymphocyte	O
and	O
T	O
-	O
lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	O
factors	O
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	O
order	O
nucleoprotein	O
complexes	O
and	O
other	O
protein	O
-	O
protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	O
regulators	O
in	O
lymphocytes	O
.	O

Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	O
adhesion	O
molecule	O
induction	O
.	O

Induction	O
of	O
endothelial	O
adhesion	O
molecules	O
by	O
the	O
cytokine	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
)	O
can	O
occur	O
independently	O
of	O
protein	O
kinase	O
C	O
and	O
activation	O
of	O
a	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
by	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
on	O
endothelial	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
PTK	O
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	O
induction	O
of	O
endothelial	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	B-PRGE
.	O

Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	O
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
,	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
expression	O
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e	O
.	O
g	O
.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Application	O
of	O
a	O
"	O
formamide	O
free	O
"	O
and	O
thus	O
"	O
material	O
preserving	O
"	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	O
of	O
the	O
myf3	B-PRGE
gene	O
revealed	O
the	O
following	O
results	O
:	O
Human	O
rhabdomyosarcoma	O
cells	O
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	B-PRGE
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O

RNase	O
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	O
lymphocytes	O
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly	O
,	O
RNase	O
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Precise	O
alignment	O
of	O
sites	O
required	O
for	O
mu	O
enhancer	O
activation	O
in	O
B	O
cells	O
.	O

The	O
lymphocyte	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
-	O
chain	O
gene	O
intronic	O
enhancer	O
is	O
regulated	O
by	O
multiple	O
nuclear	O
factors	O
.	O

The	O
previously	O
defined	O
minimal	O
enhancer	O
containing	O
the	O
muA	O
,	O
muE3	O
,	O
and	O
muB	O
sites	O
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS	O
-	O
domain	O
proteins	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
nonlymphoid	O
cells	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	O
proteins	O
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	O
by	O
using	O
mutated	O
enhancers	O
with	O
altered	O
spacings	O
.	O

A	O
4	O
-	O
or	O
10	O
-	O
bp	O
insertion	O
between	O
muE3	O
and	O
muB	O
inactivated	O
the	O
mu	O
enhancer	O
in	O
S194	O
plasma	O
cells	O
but	O
did	O
not	O
affect	O
in	O
vitro	O
binding	O
of	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
or	O
the	O
muE3	O
-	O
binding	O
protein	O
TFE3	B-PRGE
,	O
alone	O
or	O
in	O
pairwise	O
combinations	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
binding	O
but	O
not	O
TFE3	B-PRGE
or	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
bends	O
mu	O
enhancer	O
DNA	O
toward	O
the	O
major	O
groove	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
.	O

Alpha	B-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
(	I-PRGE
CD49d	I-PRGE
/	I-PRGE
CD29	I-PRGE
)	I-PRGE
integrin	I-PRGE
costimulation	O
of	O
human	O
T	O
cells	O
enhances	O
transcription	O
factor	O
and	O
cytokine	O
induction	O
in	O
the	O
absence	O
of	O
altered	O
sensitivity	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

The	O
integrin	B-PRGE
alpha	I-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
can	O
provide	O
a	O
costimulus	O
to	O
induce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
expression	O
leading	O
to	O
enhanced	O
proliferation	O
of	O
purified	O
,	O
peripheral	O
blood	O
T	O
cells	O
.	O

Similar	O
to	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
we	O
demonstrated	O
that	O
recombinant	O
vascular	B-PRGE
-	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
when	O
co	O
-	O
immobilized	O
with	O
anti	O
-	O
CD3	O
mAb	O
,	O
significantly	O
enhanced	O
the	O
induction	O
of	O
transcription	O
factors	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
as	O
determined	O
by	O
electromobility	O
shift	O
assays	O
.	O
alpha	B-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
ligation	O
alone	O
had	O
no	O
effect	O
on	O
transcription	O
factor	O
binding	O
.	O

The	O
requirements	O
for	O
induction	O
of	O
transcription	O
factors	O
reflected	O
the	O
requirements	O
for	O
the	O
secretion	O
of	O
multiple	O
cytokines	O
,	O
including	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
and	O
granulocyte	B-PRGE
macrophage	I-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

In	O
contrast	O
to	O
freshly	O
isolated	O
T	O
cells	O
,	O
in	O
vitro	O
-	O
cultured	O
T	O
cells	O
did	O
not	O
require	O
costimulation	O
for	O
cytokine	O
secretion	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
alone	O
.	O

Comparison	O
of	O
the	O
dose	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
demonstrated	O
that	O
half	O
-	O
maximal	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
achieved	O
using	O
the	O
same	O
dose	O
of	O
anti	O
-	O
CD3	O
for	O
both	O
freshly	O
isolated	O
and	O
cultured	O
T	O
cells	O
.	O

Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	O
required	O
to	O
achieve	O
half	O
-	O
maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
ligands	O
.	O

Therefore	O
,	O
costimulation	O
by	O
alpha	B-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
ligands	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
interaction	O
of	O
the	O
cells	O
with	O
its	O
substrate	O
.	O

We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	B-PRGE
4	I-PRGE
beta	I-PRGE
1	I-PRGE
in	O
freshly	O
isolated	O
T	O
cells	O
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR	O
/	O
CD3	O
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	O
factors	O
required	O
for	O
cytokine	O
gene	O
induction	O
.	O

Defective	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
FosB	B-PRGE
,	O
and	O
JunB	B-PRGE
in	O
anergic	O
T	O
helper	O
1	O
cells	O
.	O

Anergic	O
CD4	O
+	O
Th	O
cells	O
do	O
not	O
produce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
when	O
challenged	O
with	O
Ag	O
-	O
pulsed	O
accessory	O
cells	O
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	O
T	O
cells	O
are	O
defective	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
DNA	O
enhancer	O
elements	O
:	O
NF	O
-	O
AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	O
NFATp	B-PRGE
,	O
Fos	B-PRGE
,	O
and	O
Jun	B-PRGE
protein	O
complex	O
)	O
and	O
Activator	O
Protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
(	O
that	O
binds	O
Fos	B-PRGE
and	O
Jun	B-PRGE
heterodimers	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA	O
-	O
protein	O
interactions	O
in	O
anergic	O
T	O
cells	O
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP	O
-	O
1	O
family	O
members	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
FosB	B-PRGE
,	O
and	O
JunB	B-PRGE
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR	O
/	O
CD3	O
-	O
signaling	O
defect	O
because	O
CD3	O
cross	O
-	O
linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular	O
-	O
free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	B-PRGE
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	O
and	O
anergic	O
T	O
cells	O
.	O

Thus	O
,	O
defective	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP	O
-	O
1	O
Fos	B-PRGE
and	O
Jun	B-PRGE
family	O
members	O
in	O
anergic	O
T	O
cells	O
.	O

C	O
/	O
EBP	O
activators	O
are	O
required	O
for	O
HIV	O
-	O
1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	O
cell	O
lines	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
C	O
/	O
EBP	O
sites	O
and	O
C	O
/	O
EBP	O
transcriptional	O
activators	O
are	O
necessary	O
for	O
HIV	O
-	O
1	O
LTR	O
activity	O
in	O
monocytes	O
/	O
macrophages	O
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C	O
/	O
EBP	O
proteins	O
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C	O
/	O
EBP	O
protein	O
LIP	O
inhibited	O
HIV	O
-	O
1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	O
U1	O
cells	O
,	O
demonstrating	O
that	O
C	O
/	O
EBP	O
proteins	O
are	O
required	O
for	O
provirus	O
induction	O
.	O

U1	O
lines	O
overexpressing	O
C	O
/	O
EBP	O
activator	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
produced	O
more	O
viral	O
mRNA	O
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	O
lines	O
,	O
demonstrating	O
that	O
C	O
/	O
EBP	O
proteins	O
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

HIV	O
-	O
1	O
harboring	O
mutations	O
within	O
two	O
C	O
/	O
EBP	O
sites	O
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	O
promonocytic	O
cells	O
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O

These	O
data	O
identify	O
C	O
/	O
EBP	O
proteins	O
as	O
regulators	O
of	O
HIV	O
-	O
1	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Inhibition	O
of	O
transcription	O
factor	O
Stat1	B-PRGE
activity	O
in	O
mononuclear	O
cell	O
cultures	O
and	O
T	O
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
a	O
cascade	O
of	O
gene	O
activation	O
and	O
subsequent	O
proliferation	O
and	O
differentiation	O
into	O
effector	O
phenotypes	O
.	O

The	O
regulation	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
was	O
analyzed	O
in	O
PHA	B-PRGE
-	O
activated	O
mononuclear	O
cells	O
and	O
in	O
purified	O
T	O
cells	O
activated	O
by	O
cross	O
-	O
linking	O
cell	O
surface	O
CD3	O
.	O

Cell	O
activation	O
resulted	O
in	O
a	O
delayed	O
induction	O
of	O
STAT	O
DNA	O
-	O
binding	O
activity	O
,	O
which	O
was	O
sustained	O
for	O
several	O
days	O
,	O
was	O
composed	O
predominantly	O
of	O
Stat1	B-PRGE
and	O
Stat3	B-PRGE
,	O
and	O
was	O
blocked	O
by	O
cycloheximide	O
and	O
actinomycin	O
D	O
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	O
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	B-PRGE
activity	O
.	O

cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
components	O
,	O
but	O
did	O
not	O
inhibit	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
and	O
CD69	B-PRGE
expression	O
or	O
the	O
induction	O
of	O
activator	O
protein	O
1	O
transcription	O
factors	O
.	O

cAMP	O
signaling	O
inhibited	O
Stat1	B-PRGE
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down	O
-	O
regulation	O
of	O
Stat1	B-PRGE
protein	O
and	O
mRNA	O
levels	O
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	O
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	O
-	O
activated	O
Janus	O
kinase	O
-	O
STAT	O
signaling	O
pathway	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein	O
-	O
Barr	O
virus	O
gene	O
expression	O
in	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	O
cells	O
.	O

Although	O
case	O
-	O
oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	O
epithelial	O
cells	O
is	O
/	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV	O
-	O
positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	B-PRGE
nuclear	I-PRGE
antigen	I-PRGE
(	I-PRGE
EBNA	I-PRGE
)	I-PRGE
1	I-PRGE
mRNA	O
,	O
but	O
not	O
EBNA2	B-PRGE
mRNA	O
.	O

The	O
EBNA	O
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	O
promoters	O
,	O
Qp	O
:	O
by	O
contrast	O
,	O
both	O
Cp	O
and	O
Wp	O
were	O
silent	O
,	O
thus	O
resulting	O
in	O
the	O
lack	O
of	O
EBNA2	B-PRGE
mRNA	O
.	O

Latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
(	I-PRGE
LMP	I-PRGE
)	I-PRGE
2A	I-PRGE
mRNA	O
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	O
LMP1	B-PRGE
nor	O
LMP2B	B-PRGE
mRNA	O
was	O
detected	O
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O

Transcripts	O
from	O
the	O
BamHI	O
-	O
A	O
region	O
of	O
the	O
viral	O
genome	O
were	O
detectable	O
in	O
all	O
cases	O
.	O

BZLF1	B-PRGE
mRNA	O
and	O
the	O
product	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	O
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	O
cells	O
carried	O
EBV	O
genomes	O
in	O
a	O
tightly	O
latent	O
form	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	O
carcinoma	O
cells	O
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'	O
latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
'	O
s	O
lymphoma	O
than	O
'	O
latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

The	O
role	O
of	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
gene	I-PRGE
1	I-PRGE
(	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

The	O
induction	O
of	O
immediate	O
early	O
genes	O
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	O
factor	O
products	O
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function	O
-	O
related	O
genes	O
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	O
early	O
gene	O
,	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
the	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	O
cell	O
precursors	O
has	O
been	O
recently	O
elaborated	O
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc	O
-	O
finger	O
transcription	O
factor	O
encoded	O
by	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
include	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
CD44	B-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
genes	O
.	O

The	O
role	O
of	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O

Apoptosis	O
mediated	O
by	O
HIV	B-PRGE
protease	I-PRGE
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Expression	O
of	O
the	O
human	B-PRGE
immunodeficiency	I-PRGE
virus	I-PRGE
type	I-PRGE
1	I-PRGE
(	I-PRGE
HIV	I-PRGE
)	I-PRGE
protease	I-PRGE
in	O
cultured	O
cells	O
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	O
protease	O
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	O
lymphocytes	O
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	O
structural	O
proteins	O
,	O
infectivity	O
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
.	O

We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	O
protease	O
depletes	O
the	O
infected	O
cells	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
leading	O
to	O
oxidative	O
stress	O
-	O
dependent	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
cellular	O
factor	O
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O

Purified	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
cleaved	O
by	O
HIV	B-PRGE
protease	I-PRGE
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
muteins	O
that	O
have	O
noncleavable	O
alterations	O
surrounding	O
the	O
HIV	B-PRGE
protease	I-PRGE
cleavage	O
site	O
.	O

Activation	O
of	O
Stat	B-PRGE
5b	I-PRGE
in	O
erythroid	O
progenitors	O
correlates	O
with	O
the	O
ability	O
of	O
ErbB	O
to	O
induce	O
sustained	O
cell	O
proliferation	O
.	O

Self	O
renewal	O
of	O
normal	O
erythroid	O
progenitors	O
is	O
induced	O
by	O
the	O
receptor	O
tyrosine	O
kinase	O
c	O
-	O
ErbB	O
,	O
whereas	O
other	O
receptors	O
(	O
c	B-PRGE
-	I-PRGE
Kit	I-PRGE
/	O
Epo	B-PRGE
-	I-PRGE
R	I-PRGE
)	O
regulate	O
erythroid	O
differentiation	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c	O
-	O
ErbB	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	O
transcription	O
factor	O
family	O
.	O

Ligand	O
activation	O
of	O
c	O
-	O
ErbB	O
induced	O
the	O
tyrosine	O
phosphorylation	O
,	O
DNA	O
-	O
binding	O
,	O
and	O
reporter	O
gene	O
transcription	O
of	O
Stat	B-PRGE
5b	I-PRGE
in	O
erythroblasts	O
.	O

In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
Kit	I-PRGE
was	O
unable	O
to	O
induce	O
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Activation	O
of	O
the	O
erythropoietin	B-PRGE
receptor	I-PRGE
caused	O
specific	O
DNA	O
-	O
binding	O
of	O
Stat	B-PRGE
5b	I-PRGE
,	O
but	O
failed	O
to	O
induce	O
reporter	O
gene	O
transcription	O
.	O

These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c	O
-	O
ErbB	O
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	O
progenitors	O
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
activated	O
human	O
T	O
lymphocytes	O
during	O
aging	O
.	O

Transcription	O
factor	O
NF	O
kappa	O
B	O
(	O
nuclear	O
factor	O
kappa	O
B	O
)	O
is	O
induced	O
in	O
T	O
lymphocytes	O
from	O
young	O
individuals	O
following	O
activation	O
with	O
a	O
variety	O
of	O
stimuli	O
including	O
anti	O
-	O
CD3	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

In	O
contrast	O
,	O
activated	O
T	O
lymphocytes	O
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O

The	O
age	O
-	O
related	O
decline	O
in	O
induction	O
of	O
NF	O
kappa	O
B	O
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	B-PRGE
and	O
p65	B-PRGE
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	O
kappa	O
B	O
in	O
T	O
cells	O
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

Furthermore	O
,	O
similar	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	O
cells	O
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	O
kappa	O
B	O
remain	O
unaltered	O
during	O
aging	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age	O
-	O
associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
activated	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

Interaction	O
of	O
HTLV	O
-	O
I	O
Tax	B-PRGE
with	O
the	O
human	O
proteasome	O
:	O
implications	O
for	O
NF	O
-	O
kappa	O
B	O
induction	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
potent	O
transactivator	O
protein	O
termed	O
Tax	B-PRGE
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T	O
-	O
cell	O
immortalization	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	B-PRGE
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	B-PRGE
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O

Tax	B-PRGE
does	O
not	O
bind	O
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	O
transcription	O
factors	O
.	O

One	O
family	O
of	O
host	O
transcription	O
factors	O
whose	O
activity	O
is	O
altered	O
by	O
Tax	B-PRGE
includes	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
.	O

These	O
transcription	O
factors	O
are	O
post	O
-	O
transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	O
proteins	O
termed	O
I	O
kappa	O
B	O
that	O
serve	O
to	O
sequester	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
complexes	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	O
.	O

This	O
proteolytic	O
event	O
liberates	O
NF	O
-	O
kappa	O
B	O
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	O
enhancer	O
elements	O
.	O

Similarly	O
,	O
the	O
p105	B-PRGE
precursor	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
subunit	O
is	O
also	O
post	O
-	O
translationally	O
processed	O
in	O
the	O
proteasome	O
.	O

The	O
mechanisms	O
by	O
which	O
Tax	B-PRGE
activates	O
NF	O
-	O
kappa	O
B	O
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B-PRGE
and	O
the	O
HsN3	B-PRGE
subunit	O
of	O
the	O
human	O
proteasome	O
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	B-PRGE
proteasome	O
subunit	O
with	O
HTLV	O
-	O
I	O
Tax	B-PRGE
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	B-PRGE
with	O
either	O
p100	B-PRGE
or	O
p65	B-PRGE
-	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
targets	O
these	O
cytoplasmic	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
complexes	O
to	O
the	O
proteasome	O
for	O
processing	O
.	O

Epstein	O
-	O
Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate	O
-	O
early	O
BRLF1	B-PRGE
protein	O
through	O
a	O
cell	O
-	O
specific	O
mechanism	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
the	O
causative	O
agent	O
of	O
infectious	O
mononucleosis	O
,	O
is	O
a	O
human	O
herpesvirus	O
associated	O
with	O
epithelial	O
cell	O
malignancies	O
(	O
nasopharyngeal	O
carcinoma	O
)	O
as	O
well	O
as	O
B	O
-	O
cell	O
malignancies	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV	O
-	O
associated	O
nasopharyngeal	O
carcinomas	O
.	O

It	O
is	O
known	O
that	O
expression	O
of	O
a	O
single	O
viral	O
immediate	O
-	O
early	O
protein	O
,	O
BZLF1	B-PRGE
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	O
cells	O
.	O

Cellular	O
regulation	O
of	O
BZLF1	B-PRGE
transcription	O
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O

Here	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
expression	O
of	O
another	O
viral	O
immediate	O
-	O
early	O
protein	O
,	O
BRLF1	B-PRGE
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell	O
-	O
specific	O
fashion	O
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell	O
-	O
type	O
specific	O
.	O

Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
protein	O
,	O
Id	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
Id	O
family	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	O
kDa	O
variant	O
of	O
the	O
14	O
kDa	O
Id	B-PRGE
-	I-PRGE
3	I-PRGE
protein	O
termed	O
Id	O
-	O
3L	O
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	O
amino	O
acid	O
carboxy	O
-	O
terminus	O
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	O
intron	O
'	O
and	O
alternative	O
splicing	O
.	O

Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1	O
.	O
1	O
kb	O
Id	O
-	O
3L	O
transcript	O
together	O
with	O
the	O
predominant	O
0	O
.	O
95	O
kb	O
Id	B-PRGE
-	I-PRGE
3	I-PRGE
transcript	O
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O

The	O
variant	O
Id	O
-	O
3L	O
protein	O
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id	B-PRGE
-	I-PRGE
3	I-PRGE
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	O
binding	O
of	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
protein	O
,	O
E47	B-PRGE
,	O
to	O
an	O
E	O
box	O
recognition	O
sequence	O
.	O

Multifactor	O
cis	O
-	O
dominant	O
negative	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
in	O
anergized	O
T	O
cells	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcriptional	O
blockade	O
in	O
anergic	O
T	O
cell	O
clones	O
is	O
not	O
fully	O
understood	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	O
construct	O
containing	O
as	O
an	O
enhancer	O
four	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
site	O
and	O
one	O
copy	O
of	O
the	O
octamer	O
site	O
(	O
4X	O
NF	O
-	O
AT	O
-	O
Oct	O
)	O
.	O

This	O
construct	O
was	O
only	O
slightly	O
reduced	O
(	O
1	O
.	O
3	O
-	O
fold	O
)	O
in	O
its	O
expression	O
when	O
stimulated	O
under	O
anergic	O
conditions	O
,	O
while	O
a	O
whole	O
mouse	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
construct	O
showed	O
a	O
reduction	O
of	O
4	O
.	O
3	O
-	O
fold	O
.	O

Addition	O
of	O
the	O
-	O
176	O
to	O
-	O
96	O
sequence	O
to	O
the	O
4X	O
NF	O
-	O
AT	O
-	O
Oct	O
construct	O
did	O
not	O
impart	O
the	O
ability	O
to	O
be	O
affected	O
by	O
anergy	O
,	O
but	O
addition	O
of	O
the	O
-	O
236	O
to	O
-	O
96	O
sequence	O
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-	O
150	O
AP	O
-	O
1	O
binding	O
site	O
(	O
-	O
152	O
to	O
-	O
147	O
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O

Mutational	O
studies	O
of	O
the	O
-	O
236	O
to	O
-	O
96	O
sequence	O
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-	O
130	O
AP	O
-	O
1	O
-	O
like	O
site	O
(	O
-	O
187	O
to	O
-	O
181	O
)	O
and	O
the	O
-	O
150	O
proximal	O
AP	O
-	O
1	O
site	O
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

Because	O
the	O
-	O
180	O
site	O
is	O
not	O
required	O
for	O
trans	O
-	O
activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O

The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	O
factors	O
that	O
exert	O
a	O
cis	O
-	O
acting	O
dominant	O
negative	O
regulatory	O
effect	O
on	O
the	O
trans	O
-	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Characterization	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
gene	O
promoter	O
.	O

MNDA	B-PRGE
(	O
myeloid	B-PRGE
cell	I-PRGE
nuclear	I-PRGE
differentiation	I-PRGE
antigen	I-PRGE
)	O
is	O
an	O
interferon	O
alpha	O
regulated	O
nuclear	O
protein	O
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O

To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage	O
-	O
specific	O
and	O
interferon	O
-	O
regulated	O
expression	O
,	O
the	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Two	O
interferon	O
-	O
stimulated	O
response	O
elements	O
(	O
ISRE	O
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	B-PRGE
as	O
a	O
TATA	O
-	O
less	O
interferon	O
-	O
regulated	O
gene	O
.	O

Other	O
DNA	O
elements	O
present	O
include	O
a	O
cluster	O
of	O
Myb	O
sites	O
,	O
several	O
Ets	O
,	O
an	O
Ets	O
related	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
and	O
an	O
Sp1	B-PRGE
site	O
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	O
start	O
sites	O
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	B-PRGE
expression	O
.	O

The	O
5	O
'	O
flanking	O
sequence	O
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	O
alpha	O
.	O

The	O
findings	O
indicate	O
that	O
MNDA	B-PRGE
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	O
cell	O
specific	O
genes	O
and	O
genes	O
up	O
-	O
regulated	O
by	O
interferon	O
alpha	O
.	O

Regulation	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
transcription	O
by	O
core	O
-	O
binding	O
factor	O
.	O

GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
activation	O
in	O
T	O
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
Sp1	B-PRGE
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
and	O
enhancer	O
also	O
encompass	O
binding	O
sites	O
for	O
core	O
-	O
binding	O
factor	O
(	O
CBF	O
)	O
.	O

Significantly	O
,	O
the	O
CBF	O
sites	O
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	O
core	O
regions	O
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	O
linked	O
binding	O
sites	O
for	O
CBF	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFATp	B-PRGE
.	O

The	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
CBF	O
site	O
TGTGGTCA	O
is	O
located	O
51	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
and	O
also	O
overlaps	O
a	O
YY	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
site	O
.	O

A	O
2	O
-	O
bp	O
mutation	O
within	O
the	O
CBF	O
site	O
resulted	O
in	O
a	O
2	O
-	O
3	O
-	O
fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69	O
-	O
bp	O
proximal	O
promoter	O
fragment	O
and	O
a	O
627	O
-	O
bp	O
full	O
-	O
length	O
promoter	O
fragment	O
.	O

Stepwise	O
deletions	O
into	O
the	O
proximal	O
promoter	O
also	O
revealed	O
that	O
the	O
CBF	O
site	O
,	O
but	O
not	O
the	O
YY	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O

The	O
AML1	B-PRGE
and	O
CBF	B-PRGE
beta	I-PRGE
genes	O
that	O
encode	O
CBF	O
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto	O
-	O
oncogenes	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

This	O
study	O
adds	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
to	O
a	O
growing	O
list	O
of	O
cytokines	O
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	O
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	O
cells	O
.	O

The	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
locus	O
may	O
represent	O
one	O
of	O
several	O
target	O
genes	O
that	O
are	O
dysregulated	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Requirements	O
for	O
induction	O
of	O
vitamin	O
D	O
-	O
mediated	O
gene	O
regulation	O
in	O
normal	O
human	O
B	O
lymphocytes	O
.	O

Mature	O
human	O
lymphocytes	O
are	O
unique	O
targets	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
in	O
that	O
vitamin	B-PRGE
D	I-PRGE
receptors	I-PRGE
(	O
VDR	B-PRGE
)	O
are	O
not	O
constitutively	O
expressed	O
,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	O
for	O
both	O
the	O
up	O
-	O
regulation	O
of	O
VDR	B-PRGE
and	O
establishment	O
of	O
reactivity	O
to	O
the	O
lipophilic	O
ligand	O
.	O

Treatment	O
of	O
B	O
lymphocytes	O
with	O
the	O
cytokine	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up	O
-	O
regulation	O
of	O
VDR	B-PRGE
expression	O
but	O
fails	O
to	O
generate	O
vitamin	O
D	O
-	O
responsive	O
element	O
(	O
VDRE	O
)	O
-	O
reactive	O
nuclear	O
protein	O
complexes	O
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25	B-PRGE
-	I-PRGE
hydroxyvitamin	I-PRGE
D3	I-PRGE
24	I-PRGE
-	I-PRGE
hydroxylase	I-PRGE
.	O

Stimulation	O
of	O
B	O
lymphocytes	O
by	O
either	O
ligation	O
of	O
CD40	B-PRGE
Ag	I-PRGE
or	O
cross	O
-	O
linking	O
the	O
Ig	O
receptor	O
is	O
also	O
insufficient	O
to	O
render	O
B	O
lymphocytes	O
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	O
lymphocytes	O
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O

In	O
the	O
presence	O
of	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up	O
-	O
regulation	O
of	O
VDR	B-PRGE
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	O
binding	O
complexes	O
and	O
the	O
induction	O
of	O
24	B-PRGE
-	I-PRGE
hydroxylase	I-PRGE
message	O
.	O

Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	O
lymphocytes	O
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O

Regulation	O
of	O
sialoadhesin	B-PRGE
expression	O
on	O
rat	O
macrophages	O
.	O

Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
lipopolysaccharide	O
.	O

Sialoadhesin	B-PRGE
is	O
a	O
macrophage	O
-	O
restricted	O
member	O
of	O
the	O
Ig	O
superfamily	O
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e	O
.	O
g	O
.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	B-PRGE
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	B-PRGE
expression	O
on	O
freshly	O
isolated	O
rat	O
macrophages	O
and	O
the	O
rat	O
macrophage	O
cell	O
line	O
R2	O
.	O

The	O
cytokines	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	B-PRGE
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC	O
-	O
mediated	O
induction	O
of	O
sialoadhesin	B-PRGE
.	O

Sialoadhesin	B-PRGE
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	O
/	O
LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC	O
-	O
dependent	O
enhancement	O
of	O
sialoadhesin	B-PRGE
expression	O
,	O
with	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
being	O
more	O
potent	O
than	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
LPS	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

The	O
regulation	O
of	O
sialoadhesin	B-PRGE
expression	O
was	O
mediated	O
by	O
the	O
GC	B-PRGE
receptor	I-PRGE
,	O
and	O
not	O
by	O
mineralocorticoid	B-PRGE
receptor	I-PRGE
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	O
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	B-PRGE
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	B-PRGE
expression	O
on	O
rat	O
macrophages	O
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
T	O
cell	O
-	O
derived	O
cytokines	O
,	O
or	O
LPS	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	B-PRGE
and	O
ATF	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
JUN	O
.	O

The	O
human	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	O
its	O
antigen	O
receptor	O
or	O
via	O
the	O
CD	B-PRGE
-	I-PRGE
40	I-PRGE
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	O
family	O
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	B-PRGE
bind	O
to	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Jun	O
proteins	O
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O

Here	O
,	O
using	O
the	O
murine	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
A20	O
,	O
we	O
show	O
that	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
.	O

In	O
A20	O
B	O
cells	O
,	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
is	O
not	O
regulated	O
by	O
NFATp	B-PRGE
bound	O
to	O
the	O
kappa	O
3	O
element	O
.	O

Instead	O
,	O
ATF	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Jun	O
proteins	O
bind	O
to	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
and	O
NFATp	B-PRGE
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-	O
76	O
nucleotides	O
relative	O
to	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
transcription	O
start	O
site	O
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium	O
-	O
mediated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
both	O
A20	O
B	O
cells	O
and	O
Ar	O
-	O
5	O
cells	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	O
footprinting	O
of	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B-PRGE
demonstrated	O
that	O
the	O
-	O
76	O
site	O
binds	O
to	O
NFATp	B-PRGE
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp	B-PRGE
-	O
binding	O
sites	O
in	O
the	O
proximal	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
,	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Analysis	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
of	O
human	B-PRGE
retinoic	I-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
,	O
termed	O
RAR	B-PRGE
alpha	I-PRGE
,	O
RAR	B-PRGE
beta	I-PRGE
,	O
and	O
RAR	B-PRGE
gamma	I-PRGE
,	O
have	O
been	O
described	O
.	O

They	O
are	O
composed	O
of	O
different	O
structural	O
domains	O
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

RARs	O
specifically	O
bind	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9	O
-	O
cis	O
-	O
RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
of	O
hRAR	B-PRGE
alpha	I-PRGE
(	O
hRAR	B-PRGE
alpha	I-PRGE
-	O
LBD	O
,	O
amino	O
acids	O
154	O
to	O
462	O
)	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	O
proteins	O
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand	O
-	O
binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	O
mapping	O
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B-PRGE
alpha	I-PRGE
-	O
LBD	O
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all	O
-	O
trans	O
RA	O
or	O
9	O
-	O
cis	O
RA	O
.	O

Interestingly	O
,	O
residue	O
C	O
-	O
235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R	O
-	O
276	O
and	O
R	O
-	O
394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	B-PRGE
alpha	I-PRGE
-	O
LBD	O
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand	O
-	O
inducible	O
transactivation	O
function	O
of	O
RAR	B-PRGE
alpha	I-PRGE
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	O
subunit	O
of	O
human	O
proximal	O
sequence	O
element	O
-	O
binding	O
transcription	O
factor	O
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	B-PRGE
nuclear	I-PRGE
RNA	I-PRGE
genes	O
by	O
RNA	O
polymerases	O
II	O
and	O
III	O
.	O

The	O
proximal	O
sequence	O
element	O
(	O
PSE	O
)	O
-	O
binding	O
transcription	O
factor	O
(	O
PTF	O
)	O
,	O
which	O
binds	O
the	O
PSE	O
of	O
both	O
RNA	O
polymerase	O
II	O
-	O
and	O
RNA	O
polymerase	O
III	O
-	O
transcribed	O
mammalian	O
small	B-PRGE
nuclear	I-PRGE
RNA	I-PRGE
(	O
snRNA	B-PRGE
)	O
genes	O
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	O
PTF	O
,	O
a	O
complex	O
of	O
four	O
subunits	O
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	B-PRGE
gamma	I-PRGE
and	O
delta	B-PRGE
subunits	I-PRGE
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	O
encoding	O
PTF	B-PRGE
beta	I-PRGE
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti	O
-	O
PTF	B-PRGE
beta	I-PRGE
antibodies	O
.	O

Native	O
PTF	B-PRGE
beta	I-PRGE
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF	O
-	O
Oct	O
-	O
1	O
-	O
DNA	O
complex	O
,	O
can	O
be	O
recognized	O
by	O
polyclonal	O
antibodies	O
raised	O
against	O
recombinant	O
PTF	B-PRGE
beta	I-PRGE
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	B-PRGE
beta	I-PRGE
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	B-PRGE
genes	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
TBP	B-PRGE
)	O
and	O
TFIIIB90	B-PRGE
can	O
weakly	O
associate	O
with	O
PTF	O
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B-PRGE
gamma	I-PRGE
/	O
PTF	B-PRGE
delta	I-PRGE
and	O
TBP	B-PRGE
and	O
the	O
involvement	O
of	O
TFIIIB90	B-PRGE
in	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	B-PRGE
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP	B-PRGE
-	O
containing	O
complex	O
related	O
to	O
TFIIIB	O
is	O
required	O
for	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	B-PRGE
genes	O
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four	O
-	O
subunit	O
PTF	O
.	O

Induction	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B	O
-	O
cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
and	O
protein	O
increase	O
with	O
cross	O
-	O
linking	O
of	O
surface	O
immunoglobulin	O
.	O

We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
B	O
cells	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	O
and	O
a	O
downstream	O
regulatory	O
region	O
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	O
site	O
that	O
result	O
in	O
loss	O
of	O
CREB	O
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
transient	O
-	O
transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	O
site	O
in	O
the	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
implies	O
that	O
the	O
regulation	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	O
cells	O
.	O

Treatment	O
of	O
the	O
mature	O
B	O
-	O
cell	O
line	O
BAL	O
-	O
17	O
with	O
either	O
anti	O
-	O
immunoglobulin	O
M	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	O
site	O
.	O

Treatment	O
of	O
the	O
more	O
immature	O
B	O
-	O
cell	O
line	O
,	O
Ramos	O
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium	O
-	O
dependent	O
apoptosis	O
.	O

bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	O
site	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	O
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	O
kinase	O
C	O
rather	O
than	O
by	O
protein	O
kinase	O
A	O
.	O

Although	O
the	O
CRE	O
site	O
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
requires	O
participation	O
of	O
the	O
upstream	O
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	O
alters	O
its	O
interaction	O
with	O
the	O
upstream	O
regulatory	O
element	O
.	O

The	O
CRE	O
site	O
in	O
the	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
during	O
the	O
activation	O
of	O
mature	O
B	O
cells	O
and	O
during	O
the	O
rescue	O
of	O
immature	O
B	O
cells	O
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	O
site	O
is	O
responsible	O
for	O
induction	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	O
kinase	O
C	O
is	O
involved	O
.	O

E3	B-PRGE
,	O
a	O
hematopoietic	O
-	O
specific	O
transcript	O
directly	O
regulated	O
by	O
the	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
RAR	B-PRGE
alpha	I-PRGE
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	O
library	O
constructed	O
from	O
the	O
murine	O
RA	O
-	O
inducible	O
MPRO	O
promyelocyte	O
cell	O
line	O
to	O
identify	O
immediate	O
-	O
early	O
genes	O
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O

E3	B-PRGE
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate	O
-	O
early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	B-PRGE
transcripts	O
were	O
RA	O
-	O
inducible	O
in	O
HL60	O
cells	O
,	O
but	O
not	O
in	O
an	O
RA	O
-	O
resistant	O
subclone	O
,	O
HL60R	O
,	O
that	O
harbors	O
a	O
mutated	O
RAR	B-PRGE
alpha	I-PRGE
gene	O
.	O

However	O
,	O
when	O
HL60R	O
cells	O
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	B-PRGE
alpha	I-PRGE
gene	O
,	O
RA	O
induced	O
a	O
10	O
-	O
fold	O
increase	O
in	O
E3	B-PRGE
mRNA	O
levels	O
.	O

E3	B-PRGE
transcripts	O
are	O
present	O
in	O
the	O
myeloid	O
,	O
B	O
-	O
lymphoid	O
,	O
and	O
erythroid	O
lineages	O
,	O
absent	O
in	O
nonhematopoietic	O
cells	O
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	O
cells	O
.	O

The	O
murine	O
E3	B-PRGE
promoter	O
harbors	O
a	O
single	O
bipartite	O
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O

These	O
results	O
indicate	O
that	O
E3	B-PRGE
is	O
a	O
hematopoietic	O
-	O
specific	O
gene	O
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	B-PRGE
alpha	I-PRGE
during	O
myelopoiesis	O
.	O

Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O

Early	O
studies	O
in	O
murine	O
T	O
cell	O
lines	O
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
N	O
-	O
terminal	O
domain	O
are	O
required	O
for	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	O
T	O
cell	O
lines	O
have	O
suggested	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
is	O
not	O
necessary	O
for	O
steroid	O
-	O
regulated	O
apoptosis	O
and	O
that	O
GR	B-PRGE
-	O
mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	B-PRGE
N	O
-	O
terminal	O
transactivation	O
domain	O
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	B-PRGE
,	O
GR	B-PRGE
variants	O
,	O
and	O
the	O
androgen	B-PRGE
receptor	I-PRGE
(	O
AR	B-PRGE
)	O
into	O
receptor	O
-	O
negative	O
S49	O
murine	O
thymoma	O
cells	O
.	O

GR	B-PRGE
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate	O
-	O
limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	B-PRGE
-	O
mediated	O
induction	O
of	O
an	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
LTR	O
reporter	O
gene	O
was	O
observed	O
.	O

Analysis	O
of	O
GR	B-PRGE
chimeric	O
receptors	O
containing	O
the	O
potent	O
VP16	B-PRGE
and	O
E1A	B-PRGE
viral	O
transactivation	O
domains	O
in	O
place	O
of	O
the	O
GR	B-PRGE
N	O
terminus	O
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	B-PRGE
can	O
initiate	O
apoptosis	O
in	O
S49	O
cells	O
after	O
treatment	O
with	O
5	O
alpha	O
-	O
dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid	O
-	O
regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte	O
-	O
specific	O
gene	O
called	O
GIG18	B-PRGE
.	O

We	O
found	O
that	O
GIG18	B-PRGE
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	B-PRGE
and	O
GR	B-PRGE
,	O
demonstrating	O
that	O
AR	B-PRGE
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	O
cells	O
and	O
,	O
moreover	O
,	O
that	O
GIG18	B-PRGE
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid	O
-	O
treated	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	B-PRGE
-	O
mediated	O
transrepression	O
cannot	O
be	O
excluded	O
.	O

Selenium	O
-	O
mediated	O
inhibition	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
and	O
HIV	O
-	O
1	O
LTR	O
promoter	O
activity	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	O
genes	O
as	O
well	O
as	O
in	O
HIV	O
-	O
1	O
replication	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	O
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O

Various	O
antioxidants	O
inhibit	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
these	O
stimuli	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	B-PRGE
peroxidase	I-PRGE
(	O
GPX	B-PRGE
)	O
,	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
selenium	O
-	O
deprived	O
Jurkat	O
and	O
ESb	O
-	O
L	O
T	O
lymphocytes	O
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	B-PRGE
activity	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
TNF	O
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
showed	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF	O
-	O
kappa	O
B	O
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
was	O
not	O
suppressed	O
.	O

These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
target	O
genes	O
and	O
HIV	O
-	O
1	O
.	O

Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	O
gene	O
expression	O
in	O
anthracycline	O
-	O
induced	O
differentiation	O
of	O
human	O
erythroleukemic	O
cells	O
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	O
leukemic	O
cell	O
line	O
K562	O
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	O
encoding	O
gamma	O
-	O
globin	O
and	O
porphobilinogen	B-PRGE
deaminase	I-PRGE
(	O
PBGD	B-PRGE
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

By	O
using	O
run	O
-	O
on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	O
an	O
enhancement	O
of	O
the	O
transcription	O
of	O
erythroid	O
genes	O
,	O
including	O
gamma	O
-	O
globin	O
,	O
PBGD	B-PRGE
,	O
erythropoietin	B-PRGE
receptor	I-PRGE
,	O
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
factor	O
.	O

In	O
contrast	O
,	O
in	O
DOX	O
-	O
treated	O
cells	O
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	O
was	O
unchanged	O
in	O
comparison	O
with	O
control	O
cells	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	O
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
mRNAs	O
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half	O
-	O
lives	O
of	O
these	O
mRNAs	O
.	O

Because	O
the	O
increase	O
in	O
erythroid	O
mRNA	O
steady	O
-	O
state	O
level	O
in	O
anthracycline	O
-	O
treated	O
cells	O
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA	O
-	O
treated	O
cells	O
and	O
mRNA	O
stabilization	O
in	O
DOX	O
-	O
treated	O
cells	O
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Finally	O
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA	O
-	O
treated	O
but	O
not	O
in	O
DOX	O
-	O
treated	O
cells	O
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Indeed	O
,	O
erythroid	O
gene	O
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

Human	O
TAFII	B-PRGE
105	I-PRGE
is	O
a	O
cell	O
type	O
-	O
specific	O
TFIID	O
subunit	O
related	O
to	O
hTAFII130	B-PRGE
.	O

We	O
previously	O
characterized	O
Drosophila	O
and	O
human	O
TAF	O
subunits	O
that	O
make	O
up	O
the	O
core	O
TFIID	O
complex	O
found	O
in	O
all	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	O
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	O
isolated	O
from	O
other	O
cell	O
types	O
.	O

The	O
cDNA	O
encoding	O
hTAFII105	B-PRGE
reveals	O
a	O
highly	O
conserved	O
C	O
-	O
terminal	O
domain	O
shared	O
by	O
hTAFII130	B-PRGE
and	O
oTAFII110	B-PRGE
,	O
while	O
the	O
N	O
-	O
terminal	O
coactivator	O
domain	O
has	O
diverged	O
significantly	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	B-PRGE
mRNA	O
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	O
.	O

Transient	O
overexpression	O
of	O
hTAFII105	B-PRGE
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	O
cells	O
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	B-PRGE
is	O
a	O
cell	O
type	O
-	O
specific	O
subunit	O
of	O
TFIID	O
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	O
cells	O
.	O

IL	O
-	O
12	O
-	O
induced	O
activation	O
of	O
NK	O
and	O
T	O
cells	O
occurs	O
in	O
the	O
absence	O
of	O
immediate	O
-	O
early	O
activation	O
gene	O
expression	O
.	O

The	O
responses	O
of	O
lymphocytes	O
to	O
IL	O
-	O
2	O
and	O
IL	O
-	O
12	O
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	O
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	O
.	O

Using	O
reverse	O
-	O
transcription	O
PCR	O
differential	O
display	O
,	O
we	O
isolated	O
an	O
mRNA	O
species	O
expressed	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
but	O
not	O
IL	O
-	O
12	O
-	O
stimulated	O
NK	O
cells	O
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	O
encoding	O
the	O
transcription	O
factor	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	O
and	O
NK	O
cells	O
upon	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
but	O
not	O
IL	O
-	O
12	O
,	O
stimulation	O
.	O

Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA	O
-	O
encoding	O
members	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
family	O
demonstrated	O
that	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
junB	B-PRGE
are	O
also	O
expressed	O
upon	O
stimulation	O
of	O
NK	O
and	O
T	O
cells	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
but	O
not	O
IL	O
-	O
12	O
,	O
whereas	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
junD	B-PRGE
is	O
not	O
modified	O
by	O
either	O
cytokine	O
.	O

Accordingly	O
,	O
increased	O
AP	O
-	O
1	O
DNA	O
-	O
binding	O
activity	O
and	O
AP	O
-	O
1	O
-	O
dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
stimulated	O
cells	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
genes	O
reported	O
to	O
regulate	O
cytokine	O
-	O
induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
induce	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
accumulation	O
in	O
NK	O
and	O
T	O
cells	O
,	O
whereas	O
only	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL	O
-	O
12	O
-	O
mediated	O
activation	O
of	O
T	O
and	O
NK	O
cells	O
does	O
not	O
involve	O
expression	O
of	O
members	O
of	O
the	O
immediate	O
-	O
early	O
activation	O
genes	O
family	O
(	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
and	O
junB	B-PRGE
)	O
,	O
AP	O
-	O
1	O
transcriptional	O
activity	O
,	O
or	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
IL	O
-	O
12	O
-	O
stimulated	O
cells	O
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O

Induction	O
of	O
activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
CD28	B-PRGE
stimulation	O
involves	O
both	O
phosphatidylinositol	O
3	O
-	O
kinase	O
and	O
acidic	B-PRGE
sphingomyelinase	I-PRGE
signals	O
.	O

A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	B-PRGE
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	B-PRGE
acts	O
as	O
a	O
costimulus	O
to	O
TCR	O
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	B-PRGE
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	O
T	O
cell	O
blasts	O
can	O
be	O
stimulated	O
via	O
the	O
CD28	B-PRGE
surface	O
molecule	O
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	O
T	O
cells	O
to	O
CD28	B-PRGE
activation	O
in	O
isolation	O
.	O

Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	B-PRGE
stimulation	O
by	O
B7	B-PRGE
-	O
transfected	O
CHO	O
cells	O
induced	O
a	O
proliferative	O
response	O
in	O
T	O
cells	O
that	O
was	O
not	O
accompanied	O
by	O
measurable	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

However	O
,	O
subsequent	O
analysis	O
of	O
transcription	O
factor	O
generation	O
revealed	O
that	O
B7	B-PRGE
stimulation	O
induced	O
both	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
complexes	O
,	O
but	O
not	O
NF	O
-	O
AT	O
.	O

In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	O
by	O
class	O
II	O
MHC	O
/	O
superantigen	O
,	O
either	O
with	O
or	O
without	O
CD28	B-PRGE
ligation	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappaB	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28	B-PRGE
-	O
mediated	O
induction	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
.	O

This	O
revealed	O
that	O
NF	O
-	O
kappaB	O
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	B-PRGE
sphingomyelinase	I-PRGE
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
inhibitor	O
,	O
wortmannin	O
.	O

In	O
contrast	O
,	O
AP	O
-	O
1	O
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
CD28	B-PRGE
-	O
derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B-PRGE
sphingomyelinase	I-PRGE
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
linked	O
pathways	O
.	O

A	O
critical	O
role	O
of	O
Sp1	B-PRGE
-	O
and	O
Ets	O
-	O
related	O
transcription	O
factors	O
in	O
maintaining	O
CTL	O
-	O
specific	O
expression	O
of	O
the	O
mouse	O
perforin	B-PRGE
gene	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
potential	O
cis	O
-	O
elements	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
the	O
mouse	O
perforin	B-PRGE
gene	O
.	O

DNase	O
I	O
hypersensitive	O
site	O
(	O
DHS	O
)	O
mapping	O
revealed	O
that	O
the	O
perforin	B-PRGE
locus	O
contained	O
six	O
DHS	O
within	O
7	O
.	O
0	O
kb	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
(	O
-	O
7	O
.	O
0	O
kb	O
)	O
and	O
two	O
DHS	O
in	O
intron	O
2	O
.	O

The	O
six	O
5	O
'	O
upstream	O
and	O
one	O
intronic	O
DHS	O
were	O
detected	O
in	O
only	O
perforin	B-PRGE
-	O
expressing	O
lymphocytes	O
.	O

Chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
activities	O
directed	O
by	O
5	O
'	O
upstream	O
promoter	O
were	O
detected	O
preferentially	O
in	O
perforin	O
-	O
expressing	O
cell	O
lines	O
.	O

A	O
construct	O
termed	O
PFP5a	O
containing	O
-	O
795	O
bp	O
exhibited	O
the	O
highest	O
CAT	B-PRGE
activity	O
,	O
and	O
PFP9a20	O
containing	O
only	O
-	O
73	O
bp	O
also	O
produced	O
significantly	O
high	O
CAT	B-PRGE
activity	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

The	O
proximal	O
region	O
in	O
PFP9a20	O
contained	O
two	O
potential	O
Sp1	B-PRGE
binding	O
sites	O
(	O
GC	O
box	O
and	O
GT	O
box	O
)	O
and	O
one	O
Ets	O
binding	O
site	O
(	O
EBS	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis	O
-	O
elements	O
bound	O
specific	O
protein	O
factors	O
.	O

When	O
single	O
-	O
point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
in	O
PFP9a20	O
,	O
at	O
least	O
3	O
-	O
fold	O
less	O
CAT	B-PRGE
activity	O
was	O
observed	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O

To	O
confirm	O
the	O
importance	O
of	O
the	O
three	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
perforin	B-PRGE
gene	O
expression	O
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
of	O
PFP5a	O
.	O

The	O
point	O
mutations	O
resulted	O
in	O
a	O
2	O
.	O
5	O
-	O
to	O
3	O
-	O
fold	O
reduction	O
of	O
CAT	B-PRGE
activity	O
.	O

The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis	O
-	O
acting	O
elements	O
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL	O
-	O
specific	O
expression	O
of	O
perforin	B-PRGE
.	O

Soluble	O
factors	O
secreted	O
by	O
activated	O
T	O
-	O
lymphocytes	O
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	O
cytokine	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
in	O
glial	O
cells	O
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi	O
-	O
directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	O
factors	O
,	O
cytokines	O
,	O
and	O
neuropeptides	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	O
T	O
-	O
lymphocytes	O
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	O
,	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
in	O
glial	O
cells	O
.	O

The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O

Activation	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	O
kDA	O
glial	O
labile	O
repressor	O
protein	O
,	O
GLRP	B-PRGE
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
promoter	O
.	O

Although	O
GLRP	B-PRGE
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	O
factor	O
AP	O
-	O
1	O
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP	O
-	O
1	O
family	O
members	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T	O
-	O
lymphocytes	O
and	O
astrocytes	O
via	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
2	I-PRGE
to	O
regulate	O
the	O
immune	O
response	O
.	O

Regulation	O
of	O
cytokine	O
and	O
cytokine	O
receptor	O
expression	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	O
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	I-PRGE
expression	O
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	O
cells	O
where	O
they	O
bind	O
their	O
cytoplasmic	O
receptor	O
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	O
genes	O
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	O
response	O
elements	O
(	O
GRE	O
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	O
genes	O
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	O
factors	O
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	O
expression	O
,	O
GCS	O
up	O
-	O
regulate	O
cytokine	O
receptor	O
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	O
effects	O
on	O
target	O
cells	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid	O
-	O
induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O

The	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
factor	O
.	O

The	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
factor	O
is	O
a	O
member	O
of	O
the	O
POU	O
(	O
Pit	O
-	O
Oct	O
-	O
Unc	O
)	O
family	O
of	O
transcription	O
factors	O
and	O
is	O
expressed	O
only	O
in	O
B	O
lymphocytes	O
and	O
in	O
neuronal	O
cells	O
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

The	O
primary	O
RNA	O
transcript	O
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O

The	O
forms	O
produced	O
in	O
B	O
lymphocytes	O
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	O
cells	O
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	O
simplex	O
virus	O
immediate	O
-	O
early	O
genes	O
and	O
the	O
cellular	O
tyrosine	B-PRGE
hydroxylase	I-PRGE
gene	O
.	O

Thus	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	O
cells	O
and	O
neuronal	O
cells	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

Tissue	O
and	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
the	O
tuberous	O
sclerosis	O
gene	O
,	O
TSC2	B-PRGE
,	O
in	O
human	O
tissues	O
.	O

TSC2	B-PRGE
is	O
a	O
gene	O
on	O
chromosome	O
16p13	O
.	O
3	O
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	B-PRGE
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin	O
-	O
labeled	O
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	B-PRGE
gene	O
expression	O
in	O
autopsy	O
-	O
or	O
biopsy	O
-	O
derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	B-PRGE
messenger	O
RNA	O
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e	O
.	O
g	O
.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	O
cells	O
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	O
neurons	O
,	O
e	O
.	O
g	O
.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	B-PRGE
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	B-PRGE
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e	O
.	O
g	O
.	O
,	O
epithelia	O
and	O
lymphocytes	O
,	O
with	O
central	O
nervous	O
system	O
pyramidal	O
cells	O
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and	O
/	O
or	O
in	O
cells	O
with	O
important	O
secretory	O
/	O
transport	O
functions	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	B-PRGE
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor	O
/	O
growth	O
suppressor	O
.	O

Cell	O
specific	O
expression	O
of	O
human	O
Bruton	B-PRGE
'	I-PRGE
s	I-PRGE
agammaglobulinemia	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
gene	O
(	O
Btk	B-PRGE
)	O
is	O
regulated	O
by	O
Sp1	B-PRGE
-	O
and	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
-	O
family	O
members	O
.	O

Bruton	B-PRGE
'	I-PRGE
s	I-PRGE
agammaglobulinemia	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
(	O
Btk	B-PRGE
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
involved	O
in	O
the	O
human	O
disease	O
X	O
-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	O
cells	O
with	O
the	O
exception	O
of	O
T	O
-	O
cells	O
and	O
plasma	O
cells	O
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	O
bp	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
seems	O
to	O
be	O
sufficient	O
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	O
revealed	O
two	O
Sp1	B-PRGE
binding	O
sites	O
as	O
well	O
as	O
a	O
PU	O
-	O
box	O
.	O

The	O
transcription	O
factor	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
bound	O
to	O
the	O
PU	O
-	O
box	O
in	O
B	O
-	O
cells	O
.	O

In	O
the	O
erythroleukemia	O
cell	O
line	O
K562	O
,	O
due	O
to	O
the	O
absence	O
of	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
only	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
bound	O
to	O
the	O
Btk	B-PRGE
promoter	O
.	O

Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	O
box	O
had	O
no	O
effect	O
in	O
the	O
T	O
-	O
cell	O
line	O
Jurkat	O
,	O
where	O
none	O
of	O
the	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
family	O
members	O
is	O
expressed	O
.	O

In	O
addition	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
as	O
well	O
as	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
were	O
able	O
to	O
transactivate	O
Btk	B-PRGE
expression	O
.	O

In	O
fetal	O
liver	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
-	O
/	O
-	O
mice	O
,	O
which	O
lack	O
lymphoid	O
and	O
myeloid	O
cells	O
,	O
expression	O
of	O
Btk	B-PRGE
was	O
reduced	O
two	O
-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	B-PRGE
gene	O
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1	B-PRGE
-	O
and	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
-	O
family	O
members	O
.	O

Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Stat5	B-PRGE
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
stimulates	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high	O
-	O
affinity	O
receptor	O
.	O

IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	O
regulatory	O
regions	O
,	O
PRRI	O
and	O
PRRII	O
.	O

PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
276	O
and	O
-	O
244	O
,	O
which	O
contains	O
NF	O
-	O
kappaB	O
and	O
SRE	O
/	O
CArG	O
motifs	O
.	O

PRRII	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
,	O
which	O
binds	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Ets	O
protein	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
proteins	O
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
transcription	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
,	O
8	O
.	O
5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86	O
-	O
nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
responsive	O
element	O
(	O
mIL	O
-	O
2rE	O
)	O
.	O

This	O
putative	O
human	O
IL	O
-	O
2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd	O
/	O
EBSd	O
)	O
.	O

These	O
are	O
essential	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
inducibility	O
of	O
PRRIII	O
/	O
CAT	B-PRGE
reporter	O
constructs	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
induced	O
the	O
binding	O
of	O
Stat5a	O
and	O
b	O
proteins	O
to	O
the	O
human	O
GASd	O
element	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd	O
/	O
EBSd	O
element	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
regulation	O
and	O
suggest	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
factor	O
can	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
.	O

Sterol	O
dependent	O
LDL	B-PRGE
-	I-PRGE
receptor	I-PRGE
gene	O
transcription	O
in	O
lymphocytes	O
from	O
normal	O
and	O
CML	O
patients	O
.	O

Sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	O
coding	O
for	O
especially	O
low	B-PRGE
density	I-PRGE
lipoprotein	I-PRGE
(	I-PRGE
LDL	I-PRGE
)	I-PRGE
-	I-PRGE
receptor	I-PRGE
,	O
3	B-PRGE
-	I-PRGE
hydroxy	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
methylglutaryl	I-PRGE
coenzyme	I-PRGE
A	I-PRGE
(	I-PRGE
HMG	I-PRGE
-	I-PRGE
CoA	I-PRGE
)	I-PRGE
reductase	I-PRGE
and	O
HMG	B-PRGE
-	I-PRGE
CoA	I-PRGE
synthase	I-PRGE
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	B-PRGE
-	I-PRGE
interferon	I-PRGE
therapy	O
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL	B-PRGE
-	I-PRGE
receptor	I-PRGE
gene	O
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha	B-PRGE
-	I-PRGE
interferon	I-PRGE
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	O
kDa	O
sterol	O
regulatory	O
element	O
binding	O
factor	O
as	O
well	O
as	O
LDL	B-PRGE
-	I-PRGE
receptor	I-PRGE
gene	O
transcription	O
in	O
lymphocytes	O
from	O
CML	O
patients	O
.	O

Lymphocytes	O
from	O
CML	O
patients	O
lack	O
a	O
47	O
kDa	O
factor	O
having	O
affinity	O
for	O
a	O
genomic	O
sterol	O
regulatory	O
sequence	O
.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Since	O
the	O
human	O
genomic	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	O
-	O
interferon	O
therapy	O
.	O

Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	B-PRGE
receptor	I-PRGE
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
protein	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

A	O
novel	O
immunosuppressive	O
factor	O
in	O
bovine	O
colostrum	O
blocks	O
activation	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
gene	O
enhancer	O
at	O
the	O
NFAT	O
site	O
.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	O
inhibitory	O
factor	O
,	O
CIF	O
)	O
inhibits	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL2	B-PRGE
)	O
production	O
in	O
activated	O
T	O
helper	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	B-PRGE
mRNA	O
.	O

To	O
determine	O
whether	O
CIF	O
blocks	O
at	O
the	O
level	O
of	O
IL2	B-PRGE
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	O
T	O
leukemia	O
cell	O
line	O
Jurkat	O
by	O
transient	O
transfection	O
.	O

These	O
contained	O
the	O
luciferase	O
gene	O
under	O
the	O
control	O
of	O
either	O
the	O
human	O
IL2	B-PRGE
upstream	O
enhancer	O
region	O
(	O
segments	O
-	O
326	O
to	O
+	O
45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	O
element	O
contained	O
within	O
it	O
(	O
segments	O
-	O
255	O
to	O
-	O
285	O
)	O
.	O

Expression	O
of	O
luciferase	O
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O

CIF	O
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	O
element	O
.	O

CIF	O
failed	O
to	O
inhibit	O
several	O
other	O
enhancer	O
elements	O
.	O

The	O
NFAT	O
-	O
controlled	O
luciferase	O
gene	O
system	O
distinguishes	O
CIF	O
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-PRGE
beta	I-PRGE
1	I-PRGE
and	O
TGF	B-PRGE
beta	I-PRGE
2	I-PRGE
and	O
the	O
glucocorticoids	O
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	O
and	O
cyclosporine	O
.	O

The	O
NFAT	O
-	O
luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	O
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	O
immunoglobulin	O
germline	O
promoter	O
.	O

Previous	O
analyses	O
of	O
immunoglobulin	O
V	O
region	O
promoters	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	O
motif	O
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	O
genes	O
.	O

The	O
germline	O
promoters	O
(	O
Ko	O
)	O
located	O
upstream	O
of	O
the	O
J	O
region	O
gene	O
segments	O
of	O
the	O
kappa	O
locus	O
also	O
contain	O
an	O
octamer	O
motif	O
(	O
containing	O
a	O
single	O
base	O
pair	O
mutation	O
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
factors	O
in	O
vitro	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	O
motif	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
from	O
the	O
unrearranged	O
kappa	O
locus	O
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
for	O
the	O
variant	O
octamer	O
motif	O
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	O
motif	O
in	O
transcriptional	O
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	O
motif	O
binds	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
vitro	O
with	O
5	O
-	O
fold	O
lower	O
affinity	O
than	O
the	O
consensus	O
octamer	O
motif	O
,	O
mutation	O
of	O
the	O
variant	O
octamer	O
motif	O
to	O
either	O
a	O
consensus	O
octamer	O
or	O
non	O
-	O
octamer	O
motif	O
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	O
promoter	O
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	O
and	O
V	O
region	O
promoters	O
by	O
kappa	O
enhancers	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
germline	O
promoters	O
and	O
V	O
region	O
promoters	O
differ	O
in	O
their	O
dependence	O
on	O
octamer	O
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	O
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V	O
-	O
J	O
recombination	O
of	O
the	O
kappa	O
light	O
chain	O
locus	O
.	O

Characterization	O
of	O
the	O
murine	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
gene	O
p27Kip1	B-PRGE
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27Kip1	B-PRGE
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell	O
-	O
cycle	O
progression	O
.	O

p27Kip1	B-PRGE
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin	O
/	O
cdks	O
(	O
cyclin	O
-	O
dependent	O
kinase	O
)	O
complexes	O
and	O
/	O
or	O
interferes	O
physically	O
with	O
cyclin	O
/	O
cdks	O
activation	O
by	O
CAK	O
.	O

Interestingly	O
,	O
the	O
expression	O
level	O
of	O
p27Kip1	B-PRGE
mRNA	O
was	O
maximal	O
in	O
resting	O
Go	O
T	O
-	O
cells	O
and	O
rapidly	O
declined	O
following	O
anti	O
-	O
CD3	O
activation	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
p27Kip1	B-PRGE
gene	O
from	O
murine	O
genomic	O
DNA	O
and	O
the	O
functional	O
analysis	O
of	O
the	O
promoter	O
of	O
the	O
p27Kip1	B-PRGE
gene	O
.	O

The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5	O
.	O
6	O
kb	O
of	O
DNA	O
.	O

Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	O
initiation	O
sites	O
.	O

The	O
promoter	O
region	O
lacked	O
a	O
TATA	O
box	O
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	O
factors	O
including	O
two	O
Sp1	B-PRGE
,	O
CRE	O
,	O
Myb	B-PRGE
and	O
NFkB	O
located	O
at	O
positions	O
-	O
153	O
,	O
-	O
178	O
,	O
-	O
286	O
,	O
-	O
875	O
,	O
and	O
-	O
1011	O
,	O
respectively	O
.	O

To	O
analyze	O
the	O
regulatory	O
mechanisms	O
controlling	O
p27Kip1	B-PRGE
gene	O
expression	O
,	O
we	O
characterized	O
the	O
5	O
'	O
-	O
flanking	O
region	O
from	O
nt	O
-	O
1609	O
to	O
+	O
178	O
.	O

The	O
-	O
326	O
to	O
-	O
615	O
region	O
contained	O
positive	O
regulatory	O
elements	O
.	O

The	O
state	O
of	O
maturation	O
of	O
monocytes	O
into	O
macrophages	O
determines	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
on	O
HIV	O
replication	O
.	O

The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
on	O
HIV	O
infection	O
in	O
human	O
monocytes	O
as	O
they	O
matured	O
into	O
monocyte	O
-	O
derived	O
macrophages	O
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV	O
-	O
1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
up	O
-	O
regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	O
mRNA	O
in	O
monocytes	O
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	B-PRGE
Ag	I-PRGE
assay	O
.	O

Using	O
a	O
nuclear	O
run	O
-	O
on	O
assay	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two	O
-	O
to	O
threefold	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	O
RNA	O
expression	O
.	O

Conversely	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	O
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O

The	O
reversal	O
from	O
stimulation	O
to	O
inhibition	O
occurred	O
after	O
3	O
to	O
5	O
days	O
of	O
adherence	O
to	O
plastic	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O

The	O
effect	O
of	O
both	O
cytokines	O
on	O
the	O
monocyte	O
maturation	O
/	O
differentiation	O
(	O
CD11b	B-PRGE
,	O
CD13	B-PRGE
,	O
and	O
CD26	B-PRGE
)	O
and	O
other	O
macrophage	O
markers	O
(	O
CD14	B-PRGE
and	O
CD68	B-PRGE
)	O
was	O
examined	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
enhanced	O
CD11b	B-PRGE
,	O
but	O
inhibited	O
CD26	B-PRGE
expression	O
and	O
delayed	O
CD13	B-PRGE
loss	O
.	O

IL	B-PRGE
-	I-PRGE
13	I-PRGE
had	O
similar	O
effects	O
on	O
CD11b	B-PRGE
and	O
CD13	B-PRGE
,	O
but	O
no	O
effect	O
on	O
CD26	B-PRGE
.	O

Hence	O
,	O
these	O
cytokines	O
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
translocation	O
.	O

A	O
novel	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
in	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
promoter	O
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
in	O
non	O
-	O
monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
promoter	O
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43	O
-	O
mer	O
oligonucleotide	O
derived	O
from	O
the	O
functionally	O
identified	O
cis	O
-	O
acting	O
element	O
revealed	O
specific	O
complexes	O
.	O

By	O
competition	O
analysis	O
with	O
transcription	O
factor	O
consensus	O
sequence	O
oligonucleotides	O
and	O
by	O
immunosupershift	O
,	O
transcription	O
factor	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
this	O
regulatory	O
element	O
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
consensus	O
sequence	O
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	O
motif	O
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low	O
-	O
mobility	O
complexes	O
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
-	O
170	O
/	O
+	O
108	O
)	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
depended	O
on	O
the	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
so	O
-	O
far	O
-	O
unrecognized	O
SP	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
in	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
promoter	O
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	O
.	O

Engagement	O
of	O
the	O
Lewis	O
X	O
antigen	O
(	O
CD15	O
)	O
results	O
in	O
monocyte	O
activation	O
.	O

We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
-	O
treated	O
endothelial	O
cells	O
increased	O
expression	O
of	O
tissue	B-PRGE
factor	I-PRGE
and	O
CD36	B-PRGE
on	O
monocytes	O
.	O

Using	O
immunological	O
cross	O
-	O
linking	O
to	O
mimic	O
receptor	O
engagement	O
by	O
natural	O
ligands	O
,	O
we	O
now	O
show	O
that	O
CD15	O
(	O
Lewis	O
X	O
)	O
,	O
a	O
monocyte	O
counter	O
-	O
receptor	O
for	O
endothelial	B-PRGE
selectins	I-PRGE
may	O
participate	O
in	O
this	O
response	O
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross	O
-	O
linking	O
induced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
from	O
peripheral	O
blood	O
monocytes	O
and	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
MM6	O
.	O

Quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
showed	O
an	O
increase	O
in	O
steady	O
-	O
state	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
after	O
3	O
to	O
4	O
hours	O
of	O
cross	O
-	O
linking	O
.	O

CD15	O
cross	O
-	O
linking	O
also	O
concomitantly	O
increased	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
mRNA	O
,	O
while	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
levels	O
of	O
beta	B-PRGE
-	I-PRGE
actin	I-PRGE
mRNA	O
,	O
indicating	O
specificity	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	O
genes	O
by	O
CD15	O
engagement	O
,	O
a	O
CAT	B-PRGE
plasmid	O
reporter	O
construct	O
containing	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
promoter	O
/	O
enhancer	O
sequences	O
was	O
introduced	O
into	O
MM6	O
.	O

Subsequent	O
cross	O
-	O
linking	O
of	O
CD15	O
increased	O
CAT	B-PRGE
activity	O
.	O

CD15	O
engagement	O
by	O
monoclonal	O
antibody	O
also	O
attenuated	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
transcript	O
degradation	O
,	O
demonstrating	O
that	O
signaling	O
via	O
CD15	O
also	O
had	O
posttranscriptional	O
effects	O
.	O

Nuclear	O
extracts	O
of	O
anti	O
-	O
CD15	O
cross	O
-	O
linked	O
cells	O
demonstrated	O
enhanced	O
levels	O
of	O
the	O
transcriptional	O
factor	O
activator	O
protein	O
-	O
1	O
,	O
minimally	O
changed	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
and	O
did	O
not	O
affect	O
SV40	B-PRGE
promoter	I-PRGE
specific	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O

In	O
addition	O
to	O
its	O
well	O
-	O
recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	O
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O

Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	O
lymphocytes	O
of	O
the	O
human	O
FOSB	B-PRGE
gene	O
(	O
G0S3	B-PRGE
)	O
.	O

G0S3	B-PRGE
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0	O
/	O
G1	O
switch	O
regulatory	O
genes	O
(	O
G0S	O
genes	O
)	O
selected	O
by	O
screening	O
cDNA	O
libraries	O
prepared	O
from	O
human	O
blood	O
mononuclear	O
cells	O
cultured	O
for	O
2	O
hr	O
with	O
lectin	O
and	O
cycloheximide	O
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	O
FOSB	B-PRGE
gene	O
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	O
transcriptional	O
regulator	O
.	O

Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
reveals	O
a	O
4	O
-	O
exon	O
structure	O
characteristic	O
of	O
the	O
FOS	O
family	O
of	O
genes	O
.	O

Freshly	O
isolated	O
cells	O
show	O
high	O
levels	O
of	O
FOSB	B-PRGE
/	O
G0S3	B-PRGE
and	O
FOS	B-PRGE
/	O
G0S7	B-PRGE
mRNAs	O
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-PRGE
mRNA	O
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

Levels	O
of	O
FOSB	B-PRGE
mRNA	O
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	B-PRGE
and	O
FOSB	B-PRGE
mRNAs	O
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	B-PRGE
.	O

These	O
differences	O
in	O
expression	O
of	O
FOS	B-PRGE
and	O
FOSB	B-PRGE
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Regions	O
of	O
low	O
base	O
order	O
-	O
dependent	O
stem	O
-	O
loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem	O
-	O
loop	O
stability	O
(	O
e	O
.	O
g	O
.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O

Regions	O
of	O
low	O
potential	O
in	O
a	O
68	O
.	O
5	O
-	O
kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	B-PRGE
gene	O
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	O
DNA	O
sequences	O
.	O

V3	O
loop	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B-PRGE
2	I-PRGE
-	O
induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	O
region	O
of	O
the	O
HTLV	O
-	O
III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
driven	O
T	O
cell	O
proliferation	O
.	O

V3	O
-	O
BH10	O
,	O
which	O
consists	O
of	O
42	O
amino	O
acids	O
and	O
has	O
a	O
loop	O
structure	O
,	O
suppressed	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
driven	O
proliferation	O
of	O
all	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
cells	O
[	O
Kit225	O
,	O
ED	O
-	O
40515	O
(	O
+	O
)	O
,	O
KT	O
-	O
3	O
,	O
7	O
-	O
day	O
PHA	O
-	O
blasts	O
,	O
and	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
cell	O
lines	O
(	O
Hut102	O
,	O
Molt	O
-	O
4	O
,	O
and	O
Jurkat	O
)	O
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
driven	O
cell	O
growth	O
of	O
CD8	O
-	O
positive	O
lymphocytes	O
purified	O
from	O
7	O
-	O
day	O
PHA	O
-	O
blasts	O
,	O
indicating	O
that	O
CD4	B-PRGE
molecules	O
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

The	O
treatment	O
with	O
anti	O
-	O
V3	O
loop	O
monoclonal	O
antibody	O
(	O
902	O
antibody	O
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3	O
-	O
BH10	O
.	O

In	O
addition	O
,	O
V3	O
-	O
BH10	O
generated	O
the	O
arrest	O
of	O
Kit225	O
cells	O
and	O
also	O
purified	O
CD8	O
-	O
positive	O
lymphocytes	O
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Neither	O
chromatin	O
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	O
cells	O
cultured	O
with	O
V3	O
-	O
BH10	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

V3	O
-	O
BH10	O
neither	O
blocked	O
radiolabeled	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
to	O
IL	O
-	O
2	O
receptors	O
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	O
proteins	O
(	O
p120	B-PRGE
,	O
p98	B-PRGE
,	O
p96	B-PRGE
,	O
p54	B-PRGE
,	O
and	O
p38	B-PRGE
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
stimulation	O
.	O

However	O
,	O
V3	O
-	O
BH10	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
mRNA	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
but	O
not	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
or	O
junB	B-PRGE
.	O

Thus	O
,	O
the	O
binding	O
of	O
V3	O
loop	O
of	O
gp120	B-PRGE
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
T	O
cell	O
growth	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
activation	O
in	O
human	O
monocytes	O
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O

The	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
thought	O
to	O
be	O
crucially	O
involved	O
in	O
the	O
gene	O
activation	O
of	O
several	O
cytokines	O
,	O
including	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	B-PRGE
mRNA	O
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	O
blood	O
-	O
derived	O
human	O
monocytes	O
(	O
PBM	O
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
FCM	O
strongly	O
inhibits	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
PBM	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
effect	O
of	O
FCM	O
.	O

On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF	O
-	O
kappaB	O
activation	O
by	O
LPS	O
.	O

Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes	O
/	O
macrophages	O
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	O
structural	O
cells	O
such	O
as	O
fibroblasts	O
.	O

Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	B-PRGE
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

Prolonged	O
poor	O
glycemic	O
control	O
in	O
non	O
-	O
insulin	B-PRGE
-	O
dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	B-PRGE
secretion	O
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so	O
-	O
called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT	O
-	O
T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D	O
-	O
ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	B-PRGE
gene	O
transcription	O
.	O

The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	B-PRGE
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta	B-PRGE
-	I-PRGE
actin	I-PRGE
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	B-PRGE
gene	O
promoter	O
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D	O
-	O
ribose	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	B-PRGE
mRNA	O
and	O
insulin	B-PRGE
content	O
was	O
observed	O
in	O
the	O
glycation	O
-	O
induced	O
cells	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
an	O
insulin	B-PRGE
gene	I-PRGE
transcription	I-PRGE
factor	I-PRGE
,	O
PDX	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
IPF1	B-PRGE
/	O
STF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

These	O
effects	O
of	O
D	O
-	O
ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N	O
-	O
acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	B-PRGE
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE	O
-	O
I	O
enhancer	O
element	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
in	O
different	O
T	O
cell	O
subsets	O
.	O

The	O
immunomodulatory	O
cytokine	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
affects	O
cells	O
of	O
most	O
hemopoietic	O
lineages	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
is	O
secreted	O
by	O
activated	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	O
Th	O
cells	O
toward	O
the	O
Th2	O
phenotype	O
.	O

We	O
have	O
previously	O
identified	O
an	O
enhancer	O
element	O
,	O
PRE	O
-	O
I	O
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
,	O
we	O
analyzed	O
nuclear	O
factors	O
binding	O
to	O
the	O
PRE	O
-	O
I	O
site	O
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
of	O
Th1	O
and	O
Th2	O
cells	O
.	O

We	O
show	O
that	O
PRE	O
-	O
I	O
interacts	O
with	O
PMA	O
-	O
and	O
PMA	O
/	O
ionomycin	O
-	O
inducible	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	O
factors	O
.	O

Using	O
anti	O
-	O
C	B-PRGE
/	I-PRGE
EBPbeta	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
)	O
,	O
anti	O
-	O
C	B-PRGE
/	I-PRGE
EBPdelta	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL6beta	I-PRGE
)	O
,	O
anti	O
-	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
,	O
anti	O
-	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
,	O
anti	O
-	O
Fos	O
,	O
and	O
anti	O
-	O
Jun	O
Abs	O
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE	O
-	O
I	O
binding	O
factor	O
POS	O
-	O
1	O
is	O
composed	O
of	O
different	O
transcription	O
factors	O
in	O
different	O
Th	O
cell	O
subsets	O
.	O

In	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
producing	O
Th0	O
-	O
like	O
human	O
Jurkat	O
and	O
mouse	O
EL	O
-	O
4	O
cells	O
,	O
POS	O
-	O
1	O
(	O
designated	O
POS	O
-	O
1a	O
)	O
contains	O
NF	B-PRGE
-	I-PRGE
IL6beta	I-PRGE
and	O
Jun	O
.	O

In	O
the	O
mouse	O
Th2	O
D10	O
cells	O
and	O
in	O
the	O
human	O
Th2	O
clones	O
,	O
POS	O
-	O
1	O
(	O
designated	O
POS	O
-	O
1b	O
)	O
contains	O
NF	B-PRGE
-	I-PRGE
IL6beta	I-PRGE
,	O
Jun	O
,	O
and	O
NF	O
-	O
ATc	O
/	O
p	O
.	O

In	O
contrast	O
,	O
POS	O
-	O
1	O
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	O
Th1	O
clones	O
.	O

These	O
findings	O
suggest	O
that	O
PRE	O
-	O
I	O
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
levels	O
.	O

Inhibitory	O
effect	O
of	O
growth	O
hormone	O
on	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
translocation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytes	O
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP	O
-	O
1	O
promonocytic	O
cells	O
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O

The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti	O
-	O
hGH	O
mAb	O
.	O

The	O
GH	O
-	O
induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Inhibition	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
by	O
THP	O
-	O
1	O
-	O
hGH	O
-	O
transfected	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	O
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	O
inhibition	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
was	O
observed	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
PMA	O
.	O

Inhibition	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
by	O
LPS	O
-	O
stimulated	O
THP	O
-	O
1	O
-	O
hGH	O
cells	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

The	O
capacity	O
of	O
GH	O
to	O
inhibit	O
LPS	O
-	O
induced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
by	O
monocytes	O
without	O
altering	O
other	O
pathways	O
leading	O
to	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
may	O
be	O
of	O
potential	O
relevance	O
in	O
septic	O
shock	O
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O

Impaired	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
genes	O
and	O
of	O
transcriptional	O
regulatory	O
proteins	O
binding	O
distinct	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
promoter	O
elements	O
in	O
activated	O
human	O
T	O
cells	O
during	O
aging	O
.	O

The	O
activation	O
of	O
transcriptional	O
factor	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
AP	O
-	O
1	O
is	O
essential	O
for	O
normal	O
T	O
cell	O
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	O
cells	O
during	O
aging	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age	O
-	O
associated	O
impairments	O
of	O
AP	O
-	O
1	O
in	O
human	O
T	O
cells	O
.	O

Whereas	O
T	O
cells	O
from	O
young	O
subjects	O
stimulated	O
with	O
cross	O
-	O
linked	O
anti	O
-	O
CD3epsilon	B-PRGE
mAb	O
OKT3	O
plus	O
PMA	O
or	O
with	O
the	O
lectin	O
PHA	B-PRGE
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
protein	O
expression	O
,	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
but	O
not	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	O
cells	O
from	O
certain	O
elderly	O
subjects	O
.	O

In	O
addition	O
,	O
RNase	O
protection	O
assays	O
revealed	O
that	O
anti	O
-	O
CD3	O
/	O
PMA	O
-	O
stimulated	O
T	O
cells	O
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
/	O
or	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
compared	O
to	O
T	O
cells	O
from	O
young	O
subjects	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	O
of	O
nuclear	O
regulatory	O
proteins	O
recognizing	O
the	O
AP	O
-	O
1	O
consensus	O
TRE	O
motif	O
,	O
the	O
proximal	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
TRE	O
-	O
like	O
promoter	O
element	O
,	O
and	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
serum	O
response	O
element	O
(	O
SRE	O
)	O
were	O
determined	O
in	O
resting	O
and	O
stimulated	O
T	O
cells	O
.	O

Although	O
the	O
stimulation	O
of	O
T	O
cells	O
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	O
of	O
nuclear	O
protein	O
complexes	O
binding	O
the	O
AP	O
-	O
1	O
TRE	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
TRE	O
,	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
SRE	O
DNA	O
sequence	O
motifs	O
,	O
age	O
-	O
related	O
reductions	O
in	O
the	O
activation	O
of	O
AP	O
-	O
1	O
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
TRE	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
SRE	O
binding	O
complexes	O
.	O

Furthermore	O
,	O
the	O
nuclear	O
protein	O
complexes	O
binding	O
the	O
SRE	O
motif	O
induced	O
in	O
activated	O
T	O
cells	O
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
and	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
pointing	O
toward	O
age	O
-	O
related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	O
regulatory	O
proteins	O
distinct	O
from	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
/	O
AP	O
-	O
1	O
.	O

These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
as	O
well	O
as	O
their	O
nuclear	O
regulatory	O
proteins	O
may	O
contribute	O
to	O
the	O
age	O
-	O
related	O
impairments	O
of	O
AP	O
-	O
1	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Interaction	O
of	O
transcription	O
factors	O
RFX1	B-PRGE
and	O
MIBP1	B-PRGE
with	O
the	O
gamma	O
motif	O
of	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
hepatitis	O
B	O
virus	O
core	O
promoter	O
.	O

The	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
core	O
promoter	O
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	O
gamma	O
,	O
is	O
active	O
in	O
both	O
HeLa	O
cervical	O
carcinoma	O
cells	O
and	O
Huh7	O
hepatoma	O
cells	O
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	O
factor	O
RFX1	B-PRGE
can	O
bind	O
to	O
NRE	O
gamma	O
and	O
transactivate	O
the	O
core	O
promoter	O
through	O
this	O
site	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene	O
-	O
suppressive	O
activity	O
of	O
NRE	O
gamma	O
prevented	O
RFX1	B-PRGE
from	O
binding	O
to	O
NRE	O
gamma	O
.	O

In	O
addition	O
,	O
RFX1	B-PRGE
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	O
,	O
with	O
the	O
transcription	O
factor	O
MIBP1	B-PRGE
to	O
NRE	O
gamma	O
.	O

In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	B-PRGE
gene	O
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	B-PRGE
acts	O
with	O
MIBP1	B-PRGE
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	O
gamma	O
site	O
.	O

The	O
ability	O
of	O
RFX1	B-PRGE
to	O
transactivate	O
the	O
core	O
promoter	O
raises	O
the	O
possibility	O
that	O
RFX1	B-PRGE
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
.	O

Differentiation	O
-	O
dependent	O
expression	O
of	O
a	O
human	O
carboxylesterase	O
in	O
monocytic	O
cells	O
and	O
transcription	O
factor	O
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	O
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte	O
/	O
macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	O
carboxylesterase	O
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA	O
-	O
treated	O
THP	O
-	O
1	O
cells	O
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-	O
1	O
to	O
-	O
275	O
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
,	O
is	O
bound	O
by	O
nuclear	O
factors	O
Sp1	B-PRGE
and	O
IRBP	B-PRGE
but	O
not	O
by	O
C	O
/	O
EBPs	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B-PRGE
and	O
IRBP	B-PRGE
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation	O
-	O
dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Characterization	O
of	O
the	O
human	O
platelet	B-PRGE
/	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
:	O
identification	O
of	O
a	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
element	O
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O

Platelet	B-PRGE
/	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
130	O
-	O
kD	O
member	O
of	O
the	O
Ig	O
gene	O
superfamily	O
that	O
is	O
expressed	O
on	O
platelets	O
,	O
endothelial	O
cells	O
,	O
and	O
certain	O
leukocyte	O
subsets	O
.	O

To	O
examine	O
the	O
factors	O
controlling	O
vascular	O
-	O
specific	O
expression	O
of	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
we	O
cloned	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O

5	O
'	O
-	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
5	O
'	O
-	O
RACE	O
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	O
bp	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O

Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
(	O
TIS	O
)	O
showed	O
no	O
canonical	O
TATA	O
or	O
CAAT	O
elements	O
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA	O
-	O
less	O
promoters	O
encompassed	O
the	O
TIS	O
.	O

5	O
'	O
-	O
serially	O
truncated	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
segments	O
cloned	O
in	O
front	O
of	O
a	O
luciferase	O
reporter	O
drove	O
transcription	O
in	O
both	O
a	O
lineage	O
-	O
and	O
orientation	O
-	O
specific	O
manner	O
.	O

Putative	O
cis	O
-	O
acting	O
control	O
elements	O
present	O
within	O
a	O
300	O
-	O
bp	O
core	O
promoter	O
included	O
two	O
ets	B-PRGE
sites	O
,	O
an	O
Sp1	B-PRGE
site	O
,	O
tandem	O
E	O
-	O
box	O
domains	O
,	O
two	O
GATA	O
-	O
associated	O
sites	O
(	O
CACCC	O
)	O
,	O
an	O
AP	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
site	O
,	O
and	O
a	O
GATA	O
element	O
at	O
-	O
24	O
.	O

Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	O
sequence	O
at	O
position	O
-	O
24	O
,	O
and	O
gel	O
-	O
shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	O
factor	O
,	O
but	O
not	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

Understanding	O
the	O
cis	O
-	O
and	O
transacting	O
factors	O
that	O
regulate	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular	O
-	O
specific	O
gene	O
expression	O
is	O
achieved	O
.	O

Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
megakaryoblastic	O
disorders	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	O
cells	O
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML	O
-	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

These	O
blast	O
cells	O
express	O
lineage	O
-	O
specific	O
transcription	O
factors	O
such	O
as	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
common	O
to	O
these	O
lineages	O
and	O
frequently	O
express	O
erythroid	O
-	O
specific	O
mRNAs	O
such	O
as	O
gamma	O
-	O
globin	O
and	O
erythroid	B-PRGE
delta	I-PRGE
-	I-PRGE
aminolevulinate	I-PRGE
synthase	I-PRGE
(	O
ALAS	B-PRGE
-	I-PRGE
E	I-PRGE
)	O
,	O
indicating	O
that	O
most	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

These	O
results	O
suggest	O
that	O
blasts	O
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	O
of	O
both	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

Cloning	O
of	O
the	O
novel	O
human	O
myeloid	O
-	O
cell	O
-	O
specific	O
C	O
/	O
EBP	O
-	O
epsilon	O
transcription	O
factor	O
.	O

Chicken	O
NF	B-PRGE
-	I-PRGE
M	I-PRGE
transcription	O
factor	O
,	O
in	O
cooperation	O
with	O
either	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
or	O
v	O
-	O
Myb	O
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
in	O
heterologous	O
cell	O
types	O
,	O
such	O
as	O
embryonic	O
fibroblasts	O
.	O

In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
family	O
of	O
transcriptional	O
regulators	O
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	O
NF	B-PRGE
-	I-PRGE
M	I-PRGE
,	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
beta	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
)	O
.	O

However	O
,	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
gene	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	O
cells	O
.	O

By	O
using	O
a	O
reverse	O
transcription	O
-	O
PCR	O
-	O
based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
highly	O
homologous	O
members	O
of	O
the	O
C	O
/	O
EBP	O
family	O
of	O
transcriptional	O
regulators	O
,	O
we	O
have	O
cloned	O
a	O
novel	O
human	O
gene	O
encoding	O
a	O
member	O
of	O
the	O
C	O
/	O
EBP	O
gene	O
family	O
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	B-PRGE
,	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
.	O

A	O
1	O
.	O
2	O
-	O
kb	O
cDNA	O
encoding	O
full	O
-	O
length	O
human	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
was	O
cloned	O
from	O
a	O
promyelocyte	O
-	O
late	O
myeloblast	O
-	O
derived	O
lambda	O
gt11	O
library	O
.	O

Molecular	O
analysis	O
of	O
the	O
cDNA	O
and	O
genomic	O
clones	O
indicated	O
the	O
presence	O
of	O
two	O
exons	O
encoding	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
32	O
kDa	O
and	O
a	O
pI	O
of	O
9	O
.	O
5	O
.	O

Primer	O
extension	O
analysis	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
mRNA	O
detected	O
a	O
single	O
major	O
transcription	O
start	O
site	O
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
.	O

The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	O
box	O
but	O
has	O
a	O
number	O
of	O
purine	O
-	O
rich	O
stretches	O
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	O
family	O
of	O
transcriptional	O
regulators	O
.	O

Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	O
and	O
late	O
-	O
myeloblast	O
-	O
like	O
cell	O
lines	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	O
anti	O
-	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
antibodies	O
raised	O
against	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
(	O
amino	O
acids	O
1	O
to	O
115	O
)	O
showed	O
that	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
is	O
a	O
32	O
-	O
kDa	O
nuclear	O
phosphoprotein	O
.	O

The	O
human	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double	O
-	O
stranded	O
DNA	O
containing	O
consensus	O
C	O
/	O
EBP	O
sites	O
.	O

Cotransfection	O
of	O
the	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	O
acetyltransferase	O
reporter	O
vectors	O
containing	O
myeloid	O
-	O
cell	O
-	O
specific	O
c	O
-	O
mim	O
and	O
human	O
myeloperoxidase	O
promoters	O
suggested	O
a	O
role	O
for	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
.	O

Transient	O
tranfection	O
of	O
a	O
promyelocyte	O
cell	O
line	O
(	O
NB4	O
)	O
with	O
a	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
expression	O
plasmid	O
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
epsilon	I-PRGE
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
ferritin	O
heavy	O
-	O
chain	O
gene	O
:	O
the	O
activity	O
of	O
the	O
CCAAT	O
binding	O
factor	O
NF	O
-	O
Y	O
is	O
modulated	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O

The	O
ferritin	B-PRGE
H	I-PRGE
-	I-PRGE
chain	I-PRGE
gene	O
promoter	O
regulation	O
was	O
analyzed	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
(	O
FLCs	O
)	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O

In	O
the	O
majority	O
of	O
cell	O
lines	O
studied	O
,	O
the	O
regulation	O
of	O
ferritin	O
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O

However	O
,	O
in	O
differentiating	O
erythroid	O
cells	O
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	O
synthesis	O
,	O
and	O
in	O
macrophages	O
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O

We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	B-PRGE
H	I-PRGE
-	O
gene	O
promoter	O
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	O
to	O
a	O
reporter	O
gene	O
is	O
77	O
nucleotides	O
upstream	O
of	O
the	O
TATA	O
box	O
.	O

This	O
cis	O
element	O
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	O
(	O
heme	O
-	O
responsive	O
factor	O
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme	O
-	O
treated	O
FLCs	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O

The	O
CCAAT	O
element	O
present	O
in	O
reverse	O
orientation	O
in	O
this	O
promoter	O
region	O
of	O
the	O
ferritin	B-PRGE
H	I-PRGE
-	I-PRGE
chain	I-PRGE
gene	O
is	O
necessary	O
for	O
binding	O
and	O
for	O
gene	O
activity	O
,	O
since	O
a	O
single	O
point	O
mutation	O
is	O
able	O
to	O
abolish	O
the	O
binding	O
of	O
HRF	O
and	O
the	O
transcriptional	O
activity	O
in	O
transfected	O
cells	O
.	O

By	O
competition	O
experiments	O
and	O
supershift	O
assays	O
,	O
we	O
identified	O
the	O
induced	O
HRF	O
as	O
containing	O
at	O
least	O
the	O
ubiquitous	O
transcription	O
factor	O
NF	O
-	O
Y	O
.	O

NF	O
-	O
Y	O
is	O
formed	O
by	O
three	O
subunits	O
,	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
all	O
of	O
which	O
are	O
necessary	O
for	O
DNA	O
binding	O
.	O

Cotransfection	O
with	O
a	O
transdominant	O
negative	O
mutant	O
of	O
the	O
NF	O
-	O
YA	O
subunit	O
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	O
,	O
indicating	O
that	O
NF	O
-	O
Y	O
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O

We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF	O
-	O
YA	O
subunit	O
in	O
heme	O
-	O
treated	O
and	O
control	O
FLCs	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O

Characterization	O
of	O
a	O
mutant	O
cell	O
line	O
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
multiple	O
stimuli	O
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	O
kappaB	O
,	O
NF	O
-	O
kappaB	O
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	O
kappaB	O
is	O
proteolyzed	O
and	O
NF	O
-	O
kappaB	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	O
kappaB	O
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70	O
/	O
Z3	O
-	O
derived	O
1	O
.	O
3E2	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
,	O
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
several	O
stimuli	O
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin	O
-	O
1	O
,	O
or	O
double	O
-	O
stranded	O
RNA	O
,	O
I	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O

Neither	O
a	O
mutation	O
in	O
I	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
nor	O
a	O
mutation	O
in	O
p50	B-PRGE
or	O
relA	B-PRGE
,	O
the	O
two	O
major	O
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
this	O
cell	O
line	O
,	O
accounts	O
for	O
this	O
phosphorylation	O
defect	O
.	O

As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1	O
.	O
3E2	O
cells	O
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC	O
-	O
insensitive	O
pathways	O
,	O
induce	O
I	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
degradation	O
in	O
1	O
.	O
3E2	O
.	O

Analysis	O
of	O
the	O
redox	O
status	O
of	O
1	O
.	O
3E2	O
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild	O
-	O
type	O
70Z	O
/	O
3	O
.	O

We	O
also	O
report	O
that	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
derived	O
Tax	B-PRGE
trans	O
-	O
activator	O
induces	O
NF	O
-	O
kappaB	O
activity	O
in	O
1	O
.	O
3E2	O
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	O
kappaB	O
molecules	O
,	O
I	B-PRGE
kappaB	I-PRGE
beta	I-PRGE
and	O
the	O
recently	O
identified	O
I	B-PRGE
kappaB	I-PRGE
epsilon	I-PRGE
,	O
are	O
not	O
degraded	O
in	O
the	O
1	O
.	O
3E2	O
cell	O
line	O
following	O
stimulation	O
.	O

Our	O
results	O
demonstrate	O
that	O
1	O
.	O
3E2	O
is	O
a	O
cellular	O
transduction	O
mutant	O
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
,	O
I	B-PRGE
kappaB	I-PRGE
beta	I-PRGE
,	O
and	O
I	B-PRGE
kappaB	I-PRGE
epsilon	I-PRGE
degradation	O
.	O

Transcription	O
mediated	O
by	O
NFAT	O
is	O
highly	O
inducible	O
in	O
effector	O
CD4	B-PRGE
+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
but	O
not	O
in	O
Th1	O
cells	O
.	O

Transcriptional	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	O
genes	O
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
among	O
others	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4	B-PRGE
+	O
T	O
helper	O
(	O
pTh	O
)	O
cells	O
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	O
cells	O
(	O
eTh1	O
and	O
eTh2	O
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	O
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

eTh2	O
cells	O
are	O
the	O
major	O
source	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
while	O
gamma	B-PRGE
interferon	I-PRGE
is	O
produced	O
by	O
eTh1	O
cells	O
.	O

Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	O
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	O
cells	O
into	O
either	O
eTh1	O
or	O
eTh2	O
cells	O
to	O
mediate	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O

However	O
,	O
although	O
NFAT	O
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	O
complexes	O
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high	O
-	O
level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	O
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O

In	O
contrast	O
to	O
activated	O
pTh	O
cells	O
,	O
neither	O
eTh1	O
nor	O
eTh2	O
cells	O
produced	O
significant	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	O
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
activated	O
NFAT	O
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	O
cells	O
and	O
that	O
the	O
failure	O
of	O
eTh1	O
cells	O
to	O
produce	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high	O
-	O
level	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
by	O
NFAT	O
.	O

Regulation	O
of	O
NFAT	O
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	O
or	O
eTh2	O
.	O

Constitutive	O
expression	O
of	O
p50	B-PRGE
homodimer	O
in	O
freshly	O
isolated	O
human	O
monocytes	O
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	O
and	O
mature	O
macrophages	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O

We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF	O
-	O
kappaB	O
with	O
monocyte	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	O
inactive	O
p50	B-PRGE
homodimer	O
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50	B-PRGE
/	O
p65	B-PRGE
and	O
p50	B-PRGE
/	O
RelB	B-PRGE
heterodimers	O
.	O

As	O
in	O
MDMs	O
,	O
AMs	O
constitutively	O
expressed	O
p50	B-PRGE
/	O
p65	B-PRGE
and	O
p50	B-PRGE
/	O
RelB	B-PRGE
although	O
at	O
lower	O
levels	O
.	O

HIV	O
infection	O
of	O
fresh	O
monocytes	O
failed	O
to	O
induce	O
p50	B-PRGE
/	O
p65	B-PRGE
as	O
seen	O
in	O
MDMs	O
.	O

The	O
replacement	O
of	O
p50	B-PRGE
homodimers	O
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	O
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

The	O
change	O
in	O
NF	O
-	O
kappaB	O
components	O
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV	O
-	O
infected	O
individuals	O
.	O

Identification	O
of	O
nucleotide	O
sequences	O
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	O
terminal	O
repeat	O
in	O
activated	O
T	O
cells	O
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	O
(	O
DEN	O
)	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
mink	O
cell	O
focus	O
-	O
forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

Another	O
important	O
activity	O
of	O
DEN	O
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	O
T	O
cells	O
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF	O
-	O
kappaB	O
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O

Immune	O
hyperactivation	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
T	O
cells	O
mediated	O
by	O
Tat	O
and	O
the	O
CD28	B-PRGE
pathway	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

Infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	O
and	O
CD28	O
receptors	O
.	O

Expression	O
of	O
the	O
HIV	O
-	O
1	O
transactivator	O
Tat	O
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	O
plus	O
CD28	B-PRGE
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
superinduction	O
by	O
Tat	O
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28	B-PRGE
-	O
responsive	O
element	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	O
amino	O
acids	O
encoded	O
by	O
the	O
second	O
exon	O
of	O
Tat	O
.	O

c	B-PRGE
-	I-PRGE
Rel	I-PRGE
is	O
a	O
target	O
of	O
pentoxifylline	O
-	O
mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell	O
-	O
dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

We	O
found	O
that	O
in	O
T	O
cells	O
,	O
anti	O
-	O
CD3	O
-	O
induced	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF	O
-	O
kappaB	O
family	O
members	O
was	O
not	O
significantly	O
affected	O
.	O

However	O
,	O
induction	O
of	O
NF	O
-	O
AT	O
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	O
factors	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
chain	I-PRGE
mRNA	O
induction	O
was	O
not	O
affected	O
.	O

These	O
observations	O
implicated	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
as	O
an	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
factor	O
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O

In	O
contrast	O
with	O
the	O
observation	O
in	O
T	O
cells	O
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
induction	O
was	O
not	O
blocked	O
by	O
PF	O
in	O
B	O
cells	O
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

A	O
T	O
cell	O
-	O
specific	O
enhancer	O
in	O
the	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
locus	O
is	O
activated	O
cooperatively	O
by	O
Oct	O
and	O
NFAT	O
elements	O
within	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O

Interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
a	O
cytokine	O
that	O
is	O
expressed	O
primarily	O
in	O
activated	O
T	O
cells	O
.	O

Here	O
we	O
identified	O
an	O
inducible	O
T	O
cell	O
-	O
specific	O
enhancer	O
14	O
kb	O
upstream	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
that	O
responded	O
to	O
activation	O
of	O
T	O
cell	O
receptor	O
signaling	O
pathways	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	O
A	O
-	O
sensitive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
found	O
only	O
in	O
T	O
cells	O
.	O

Four	O
NFAT	O
-	O
like	O
elements	O
exist	O
within	O
the	O
enhancer	O
.	O

The	O
two	O
most	O
active	O
NFAT	O
-	O
like	O
elements	O
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O

One	O
of	O
these	O
NFAT	O
-	O
like	O
elements	O
encompassed	O
overlapping	O
Oct	O
-	O
and	O
NFATp	O
/	O
c	O
-	O
binding	O
sites	O
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	O
and	O
NFAT	O
family	O
proteins	O
.	O

A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	O
response	O
element	O
(	O
nGRE	O
)	O
in	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
.	O

Interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	O
mediators	O
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O

The	O
regulation	O
of	O
human	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	O
elements	O
have	O
been	O
discovered	O
in	O
the	O
promoter	O
region	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

We	O
have	O
identified	O
a	O
negative	O
regulatory	O
element	O
located	O
in	O
the	O
region	O
between	O
-	O
685	O
and	O
-	O
395	O
.	O

Within	O
this	O
region	O
,	O
a	O
19	O
-	O
bp	O
nuclear	O
factor	O
binding	O
site	O
(	O
-	O
570	O
to	O
-	O
552	O
)	O
was	O
characterized	O
by	O
DNase	O
I	O
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O

A	O
consensus	O
sequence	O
for	O
a	O
negative	O
glucocorticoid	O
response	O
element	O
(	O
nGRE	O
)	O
and	O
a	O
transcription	B-PRGE
activator	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
binding	O
site	O
were	O
noted	O
within	O
this	O
footprint	O
.	O

Functional	O
studies	O
showed	O
a	O
2	O
.	O
5	O
-	O
fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19	O
-	O
bp	O
binding	O
site	O
was	O
deleted	O
in	O
the	O
reporter	O
constructs	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
/	O
CAT	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
/	O
SV40	O
promoter	O
/	O
CAT	B-PRGE
.	O

Dexamethasone	O
(	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild	O
-	O
type	O
fragment	O
but	O
not	O
in	O
a	O
deletion	O
mutant	O
lacking	O
the	O
19	O
-	O
bp	O
site	O
.	O

A	O
protein	O
of	O
about	O
150	O
kD	O
that	O
bound	O
to	O
this	O
negative	O
regulatory	O
sequence	O
was	O
identified	O
by	O
UV	O
cross	O
-	O
linking	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	O
regulatory	O
region	O
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	O
gene	O
.	O

TRAMP	B-PRGE
,	O
a	O
novel	O
apoptosis	O
-	O
mediating	O
receptor	O
with	O
sequence	O
homology	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
1	I-PRGE
and	O
Fas	B-PRGE
(	O
Apo	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CD95	B-PRGE
)	O
.	O

A	O
novel	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
designated	O
TRAMP	B-PRGE
,	O
has	O
been	O
identified	O
.	O

The	O
structural	O
organization	O
of	O
the	O
393	O
amino	O
acid	O
long	O
human	O
TRAMP	B-PRGE
is	O
most	O
homologous	O
to	O
TNF	B-PRGE
receptor	I-PRGE
1	I-PRGE
.	O

TRAMP	B-PRGE
is	O
abundantly	O
expressed	O
on	O
thymocytes	O
and	O
lymphocytes	O
.	O

Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine	O
-	O
rich	O
domains	O
,	O
and	O
the	O
cytoplasmic	O
region	O
contains	O
a	O
death	O
domain	O
known	O
to	O
signal	O
apoptosis	O
.	O

Overexpression	O
of	O
TRAMP	B-PRGE
leads	O
to	O
two	O
major	O
responses	O
,	O
NF	O
-	O
kappaB	O
activation	O
and	O
apoptosis	O
.	O

TRAMP	B-PRGE
-	O
induced	O
cell	O
death	O
is	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
ICE	O
-	O
like	O
proteases	O
,	O
but	O
not	O
by	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
addition	O
,	O
TRAMP	B-PRGE
does	O
not	O
appear	O
to	O
interact	O
with	O
any	O
of	O
the	O
known	O
apoptosis	O
-	O
inducing	O
ligands	O
of	O
the	O
TNF	O
family	O
.	O

Involvement	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
RelA	B-PRGE
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
transcription	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
an	O
important	O
transcription	O
factor	O
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF	O
-	O
kappa	O
B1	O
gene	O
encodes	O
a	O
105	O
-	O
kD	O
protein	O
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	B-PRGE
component	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
regulates	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	O
cell	O
lines	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	B-PRGE
(	O
PHA	B-PRGE
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Characterization	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
promoter	O
identified	O
an	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA	O
/	O
PHA	B-PRGE
-	O
mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Furthermore	O
,	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
was	O
required	O
for	O
endogenous	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
gene	O
expression	O
,	O
since	O
PMA	O
/	O
PHA	B-PRGE
-	O
stimulated	O
T	O
cell	O
lines	O
expressing	O
antisense	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
RNA	O
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
transcription	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
gene	O
expression	O
.	O

Differentiation	O
of	O
U	O
-	O
937	O
promonocytic	O
cells	O
by	O
etoposide	O
and	O
ICRF	O
-	O
193	O
,	O
two	O
antitumour	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U	O
-	O
937	O
human	O
promonocytic	O
leukemia	O
cells	O
of	O
two	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF	O
-	O
193	O
.	O

One	O
hour	O
pulse	O
-	O
treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	O
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse	O
-	O
treatment	O
with	O
6	O
microM	O
ICRF	O
-	O
193	O
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0	O
.	O
15	O
microM	O
)	O
and	O
ICRF	O
-	O
193	O
(	O
0	O
.	O
3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane	O
-	O
bound	O
enzyme	O
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane	O
-	O
bound	O
and	O
cytosolic	O
enzyme	O
.	O

By	O
contrast	O
,	O
ICRF	O
-	O
193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation	O
-	O
inducing	O
concentrations	O
,	O
both	O
topoisomerase	O
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP	O
-	O
1	O
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide	O
-	O
treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF	O
-	O
193	O
-	O
treated	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF	O
-	O
kappa	O
(	O
B	O
)	O
and	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
factors	O
was	O
little	O
affected	O
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti	O
-	O
topoisomerase	O
drugs	O
.	O

Nuclear	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
protein	O
complexes	O
are	O
differentially	O
distributed	O
within	O
human	O
thymocytes	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/	O
Rel	O
proteins	O
are	O
inducible	O
transcriptional	O
regulators	O
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF	O
-	O
kappa	O
B	O
proteins	O
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50	B-PRGE
/	O
p65	B-PRGE
and	O
p50	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
complexes	O
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	O
Abs	O
allowed	O
visualization	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50	B-PRGE
/	O
p65	B-PRGE
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B-PRGE
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	B-PRGE
,	O
p50	B-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
activities	O
were	O
found	O
in	O
both	O
CD4	B-PRGE
-	O
and	O
CD8	O
-	O
positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
complexes	O
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	O
-	O
kappa	O
B	O
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	O
domain	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
ZEBRA	B-PRGE
protein	O
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O

The	O
ZEBRA	B-PRGE
protein	O
from	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O

ZEBRA	B-PRGE
,	O
a	O
member	O
of	O
the	O
bZIP	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	O
lytic	O
cycle	O
promoters	O
.	O

It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	B-PRGE
'	O
s	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O

We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	B-PRGE
,	O
Z	O
(	O
S186A	O
)	O
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O

The	O
mutant	O
,	O
containing	O
a	O
serine	O
-	O
to	O
-	O
alanine	O
substitution	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA	B-PRGE
-	O
binding	O
sites	O
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA	B-PRGE
-	O
responsive	O
promoters	O
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV	O
-	O
infected	O
cell	O
lines	O
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B-PRGE
protein	O
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
ZEBRA	B-PRGE
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B-PRGE
protein	O
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B-PRGE
protein	O
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	O
viral	O
promoters	O
in	O
a	O
chromatinized	O
viral	O
episome	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
U937	O
cells	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte	O
/	O
macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
cytokines	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	O
in	O
a	O
promonocytic	O
cell	O
line	O
(	O
U937	O
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
inhibitor	O
hydrolysis	O
.	O

No	O
degradation	O
of	O
p105	O
and	O
p100	O
inhibitors	O
was	O
observed	O
under	O
these	O
conditions	O
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	O
cells	O
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF	O
-	O
kappaB	O
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	O
A2	O
and	O
5	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
are	O
also	O
involved	O
.	O

However	O
,	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
involving	O
the	O
acidic	B-PRGE
sphingomyelinase	I-PRGE
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	O
cells	O
.	O

Possible	O
role	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF	O
-	O
kappa	O
B	O
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	O
C	O
epsilon	O
transcription	O
.	O

We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
or	O
anti	O
-	O
CD40	B-PRGE
monoclonal	O
antibody	O
(	O
mAb	O
)	O
participates	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
responsible	O
for	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O

Both	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
anti	O
-	O
CD40	B-PRGE
mAb	O
induced	O
activation	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3	O
-	O
kinase	O
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	O
kinase	O
C	O
,	O
and	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3	O
-	O
kinase	O
.	O

In	O
addition	O
,	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF	O
-	O
kappa	O
B	O
activation	O
caused	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
anti	O
-	O
CD40	B-PRGE
mAb	O
,	O
or	O
their	O
combination	O
.	O

NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	O
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
anti	O
-	O
CD40	B-PRGE
mAb	O
than	O
in	O
those	O
stimulated	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
alone	O
.	O

These	O
results	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
ligation	O
of	O
CD40	B-PRGE
induce	O
NF	O
-	O
kappa	O
B	O
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3	O
-	O
kinase	O
pathway	O
and	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	O
C	O
epsilon	O
transcription	O
.	O

T	O
-	O
lymphocytes	O
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O

The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	O
filarial	O
antigen	O
-	O
specific	O
T	O
-	O
cells	O
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O

Circulating	O
T	O
-	O
cells	O
from	O
individuals	O
with	O
filaria	O
-	O
induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	O
monolayers	O
than	O
did	O
T	O
-	O
cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

In	O
contrast	O
to	O
the	O
MF	O
individuals	O
where	O
no	O
effect	O
was	O
seen	O
,	O
transendothelial	O
migration	O
of	O
48	O
-	O
hr	O
filarial	O
antigen	O
stimulated	O
T	O
-	O
cells	O
from	O
LP	O
individuals	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
greater	O
than	O
migration	O
of	O
48	O
-	O
hr	O
media	O
-	O
stimulated	O
T	O
-	O
cells	O
.	O

In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA	B-PRGE
-	I-PRGE
4	I-PRGE
/	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T	O
-	O
cells	O
.	O

Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
involved	O
in	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
influence	O
of	O
the	O
anti	O
-	O
allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O

Azeptin	O
dose	O
-	O
dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HF	O
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

Generation	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
1	I-PRGE
-	I-PRGE
beta	I-PRGE
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
from	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
-	O
treated	O
PBL	O
and	O
human	O
monocytes	O
(	O
HM	O
)	O
was	O
decreased	O
to	O
approximately	O
1	O
/	O
3	O
to	O
2	O
/	O
3	O
of	O
the	O
control	O
levels	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	O
generation	O
,	O
each	O
cytokine	O
mRNA	O
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
-	O
mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	O
by	O
10	O
(	O
-	O
5	O
)	O
M	O
Azeptin	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
PBL	O
,	O
HM	O
and	O
HF	O
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	O
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
T	O
cell	O
activation	O
factor	O
NF	O
-	O
ATc	O
positively	O
regulates	O
HIV	O
-	O
1	O
replication	O
and	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV	O
-	O
1	O
replication	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
may	O
influence	O
HIV	O
-	O
1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV	O
-	O
1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

We	O
report	O
that	O
certain	O
NF	O
-	O
AT	O
(	O
Rel	O
)	O
family	O
members	O
productively	O
bind	O
the	O
kappaB	O
regulatory	O
elements	O
,	O
synergize	O
with	O
NF	O
-	O
kappaB	O
and	O
Tat	B-PRGE
in	O
transcriptional	O
activation	O
of	O
HIV	O
-	O
1	O
,	O
and	O
enhance	O
HIV	O
-	O
1	O
replication	O
in	O
T	O
cells	O
.	O

These	O
results	O
link	O
regulatory	O
factors	O
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV	O
-	O
1	O
replication	O
.	O

Differentiation	O
of	O
T	O
-	O
helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	O
family	O
of	O
transcription	O
factors	O
.	O

Interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
and	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
control	O
the	O
differentiation	O
of	O
T	O
-	O
helper	O
cells	O
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	O
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T	O
-	O
lymphocytes	O
.	O

Cytokine	O
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	O
domain	O
of	O
the	O
corresponding	O
cytokine	O
receptor	O
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	O
sites	O
for	O
latent	O
,	O
cytoplasmic	O
transcription	O
factors	O
known	O
as	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
proteins	O
.	O

Receptor	O
/	O
Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
of	O
the	O
corresponding	O
Stat	O
protein	O
.	O

Although	O
Stat	O
binding	O
to	O
the	O
intracellular	O
domain	O
of	O
the	O
cytokine	O
receptor	O
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	O
protein	O
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
phosphotyrosine	O
.	O

Specific	O
docking	O
sites	O
within	O
individual	O
cytokine	O
receptors	O
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	O
proteins	O
.	O

The	O
direct	O
coupling	O
between	O
cytokine	O
receptor	O
and	O
transcription	O
factor	O
helps	O
to	O
explain	O
how	O
different	O
cytokines	O
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Regulation	O
of	O
the	O
tissue	B-PRGE
factor	I-PRGE
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Role	O
of	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
,	O
and	O
Sp1	B-PRGE
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide	O
-	O
induced	O
expression	O
.	O

Tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
expression	O
by	O
peripheral	O
blood	O
monocytes	O
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	B-PRGE
gene	O
transcription	O
in	O
monocytes	O
.	O

The	O
human	O
TF	B-PRGE
promoter	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
,	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
Sp1	B-PRGE
.	O

NF	O
-	O
kappa	O
B	O
/	O
Rel	O
proteins	O
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP	O
-	O
1	O
and	O
Sp1	B-PRGE
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
uninduced	O
and	O
LPS	O
-	O
induced	O
TF	B-PRGE
gene	O
expression	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	B-PRGE
sites	O
mediated	O
basal	O
expression	O
in	O
uninduced	O
cells	O
.	O

The	O
two	O
AP	O
-	O
1	O
sites	O
bound	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
heterodimers	O
in	O
both	O
unstimulated	O
and	O
LPS	O
-	O
stimulated	O
cells	O
.	O

Maximal	O
LPS	O
induction	O
of	O
the	O
TF	B-PRGE
promoter	O
required	O
the	O
two	O
AP	O
-	O
1	O
sites	O
and	O
the	O
kappa	O
B	O
site	O
within	O
the	O
LPS	O
response	O
element	O
.	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
kappa	O
B	O
site	O
abolished	O
LPS	O
induction	O
.	O

Replacement	O
of	O
the	O
two	O
AP	O
-	O
1	O
sites	O
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	O
LPS	O
induction	O
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP	O
-	O
1	O
sites	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	O
response	O
element	O
in	O
Drosophila	O
Schneider	O
cells	O
by	O
coexpression	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
and	O
p65	B-PRGE
or	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
and	O
p65	B-PRGE
required	O
the	O
transactivation	O
domains	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
and	O
p65	B-PRGE
.	O

These	O
data	O
indicated	O
that	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
,	O
and	O
Sp1	B-PRGE
regulate	O
TF	B-PRGE
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
.	O

Physical	O
interactions	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
proteins	O
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
regulatory	O
elements	O
of	O
many	O
inducible	O
T	O
-	O
cell	O
genes	O
contain	O
adjacent	O
or	O
overlapping	O
binding	O
sites	O
for	O
the	O
Ets	O
and	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
families	O
of	O
transcription	O
factors	O
.	O

Similar	O
arrays	O
of	O
functionally	O
important	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
and	O
Ets	O
binding	O
sites	O
are	O
present	O
in	O
the	O
transcriptional	O
enhancers	O
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	O
protein	O
binding	O
sites	O
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
that	O
has	O
been	O
co	O
-	O
opted	O
during	O
HIV	O
evolution	O
.	O

Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	O
and	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
proteins	O
cooperatively	O
regulate	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
remained	O
unknown	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	O
and	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
proteins	O
both	O
in	O
vitro	O
and	O
in	O
activated	O
normal	O
human	O
T	O
cells	O
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	O
domain	O
of	O
Ets	O
proteins	O
and	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
Ets	O
-	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
interaction	O
requires	O
the	O
presence	O
of	O
DNA	O
binding	O
sites	O
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	O
sites	O
for	O
Ets	O
and	O
NF	O
-	O
kappaB	O
proteins	O
.	O

A	O
dominant	O
-	O
negative	O
mutant	O
of	O
NF	O
-	O
kappaB	O
p50	B-PRGE
that	O
binds	O
DNA	O
but	O
fails	O
to	O
interact	O
with	O
Ets	O
proteins	O
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
enhancers	O
by	O
NF	O
-	O
kappaB	O
(	O
p50	B-PRGE
+	O
p65	B-PRGE
)	O
and	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB	O
proteins	O
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
and	O
HIV	O
-	O
2	O
enhancers	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	O
and	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
proteins	O
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T	O
-	O
cell	O
genes	O
and	O
viruses	O
.	O

These	O
interactions	O
represent	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
novel	O
immunosuppressive	O
and	O
antiviral	O
therapies	O
.	O

Oxidant	O
-	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e	O
.	O
g	O
.	O
ulcerative	O
colitis	O
,	O
Crohn	O
'	O
s	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte	O
-	O
derived	O
oxidants	O
.	O

Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	O
factors	O
such	O
as	O
nuclear	O
transcription	O
factor	O
kappa	O
beta	O
.	O

Nuclear	O
transcription	O
factor	O
kB	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
and	O
pleiotropic	O
regulator	O
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

This	O
transcription	O
factor	O
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	O
protein	O
I	O
-	O
kB	O
thereby	O
allowing	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	O
molecules	O
(	O
e	O
.	O
g	O
.	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
cytokines	O
(	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
enzymes	O
(	O
iNOS	B-PRGE
)	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
post	O
-	O
translationally	O
modified	O
I	O
-	O
kappa	O
B	O
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	B-PRGE
proteasome	I-PRGE
complex	O
.	O

Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
adhesion	O
molecules	O
.	O

Expression	O
of	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC	O
-	O
derived	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O

Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
gene	O
in	O
B	O
cells	O
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O

Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non	O
-	O
B	O
NHL	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O

The	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
transcript	O
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O

In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non	O
-	O
B	O
lymphomas	O
.	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O

A	O
follicular	O
expression	O
pattern	O
was	O
also	O
found	O
in	O
all	O
non	O
-	O
malignant	O
reactive	O
lymph	O
nodes	O
.	O

Hence	O
,	O
the	O
expression	O
of	O
LAZ3	B-PRGE
/	O
BCL6	B-PRGE
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	O
cells	O
from	O
the	O
germinal	O
centers	O
.	O

Induction	O
of	O
relA	B-PRGE
(	O
p65	B-PRGE
)	O
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
subunit	O
expression	O
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
subunits	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	B-PRGE
homodimers	O
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50	B-PRGE
/	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
heterodimers	O
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7	O
-	O
day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	B-PRGE
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
subunit	O
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
mRNA	O
was	O
significantly	O
higher	O
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50	B-PRGE
/	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
heterodimers	O
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50	B-PRGE
/	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
complexes	O
that	O
are	O
readily	O
available	O
for	O
inducer	O
-	O
mediated	O
stimulation	O
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
in	O
allergen	O
-	O
specific	O
human	O
T	O
-	O
cell	O
clones	O
are	O
suppressed	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
)	O
,	O
a	O
selective	O
eosinophil	O
-	O
activating	O
factor	O
,	O
produced	O
by	O
helper	O
T	O
cells	O
.	O

To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
,	O
we	O
established	O
allergen	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
from	O
asthmatic	O
patients	O
.	O

GC	O
efficiently	O
suppressed	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
of	O
T	O
-	O
cell	O
clones	O
activated	O
via	O
either	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
or	O
IL	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
.	O

Induction	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
mRNA	O
upon	O
TCR	O
and	O
IL	O
-	O
2R	O
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O

Human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
/	O
enhancer	O
-	O
luciferase	O
gene	O
construct	O
transfected	O
to	O
T	O
-	O
cell	O
clones	O
was	O
transcribed	O
on	O
either	O
TCR	O
or	O
IL	O
-	O
2R	O
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500	O
-	O
bp	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
segment	O
located	O
5	O
'	O
upstream	O
of	O
the	O
coding	O
region	O
contains	O
activation	O
-	O
inducible	O
enhancer	O
elements	O
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR	O
-	O
stimulated	O
T	O
cells	O
.	O

NF	O
-	O
AT	O
and	O
NF	O
-	O
kappaB	O
were	O
not	O
significantly	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
stimulation	O
.	O

Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
production	O
by	O
human	O
CD4	B-PRGE
+	O
T	O
cells	O
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	O
and	O
IL	O
-	O
2R	O
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T	O
-	O
cell	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
.	O

Involvement	O
of	O
an	O
SAF	O
-	O
like	O
transcription	O
factor	O
in	O
the	O
activation	O
of	O
serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
gene	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
by	O
lipopolysaccharide	O
.	O

Serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
(	O
SAA	B-PRGE
)	O
has	O
been	O
linked	O
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high	O
-	O
density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	O
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	B-PRGE
gene	O
in	O
THP	O
-	O
1	O
monocyte	O
/	O
macrophage	O
cells	O
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B-PRGE
gene	O
is	O
induced	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	B-PRGE
promoter	O
sequence	O
between	O
-	O
280	O
and	O
-	O
226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O

Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA	O
-	O
binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

Characterization	O
of	O
the	O
DNA	O
-	O
binding	O
protein	O
by	O
UV	O
cross	O
-	O
linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation	O
/	O
supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	O
factor	O
designated	O
SAF	O
.	O

These	O
results	O
demonstrated	O
that	O
LPS	O
-	O
mediated	O
SAA	B-PRGE
gene	O
induction	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	O
activity	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	B-PRGE
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
or	O
nuclear	O
localization	O
sequences	O
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	B-PRGE
transmembrane	O
receptor	O
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	B-PRGE
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	B-PRGE
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	O
domain	O
(	O
DeltaE	O
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	O
domain	O
(	O
ICN	O
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	O
factor	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
-	O
binding	O
site	O
within	O
the	O
NOTCH1	B-PRGE
ankyrin	O
repeat	O
region	O
of	O
the	O
intracellular	O
domain	O
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
-	O
binding	O
site	O
,	O
which	O
lies	O
within	O
the	O
intracellular	O
domain	O
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	O
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	O
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	O
localization	O
sequences	O
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	O
-	O
bound	O
DeltaE	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	O
-	O
bound	O
DeltaE	O
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	O
ICN	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	B-PRGE
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP	B-PRGE
-	I-PRGE
Jkappa	I-PRGE
at	O
promoter	O
sites	O
.	O

Transcriptional	O
induction	O
of	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
differentiated	O
monocyte	O
-	O
like	O
(	O
U937	O
)	O
cells	O
is	O
regulated	O
by	O
AP	O
-	O
1	O
and	O
an	O
upstream	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
beta	I-PRGE
site	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP	O
-	O
1	O
site	O
and	O
a	O
distal	O
promoter	O
element	O
regulate	O
transcriptional	O
induction	O
of	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
during	O
monocytic	O
differentiation	O
.	O

Chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
expression	O
constructs	O
containing	O
regions	O
of	O
the	O
human	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	O
cells	O
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
mediated	O
differentiation	O
.	O

Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	O
AP	O
-	O
1	O
element	O
;	O
however	O
,	O
at	O
16	O
-	O
96	O
h	O
post	O
-	O
PMA	O
,	O
the	O
mutant	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
displayed	O
AP	O
-	O
1	O
independent	O
PMA	O
-	O
mediated	O
transactivation	O
.	O

The	O
AP	O
-	O
1	O
mutant	O
constructs	O
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA	O
-	O
treated	O
fibroblasts	O
.	O

Western	O
and	O
supershift	O
analyses	O
indicated	O
that	O
functional	O
Jun	O
and	O
Fos	O
proteins	O
were	O
present	O
in	O
nuclear	O
extracts	O
of	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	O
promoter	O
sequences	O
in	O
regulating	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT	B-PRGE
/	I-PRGE
enhancer	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
-	I-PRGE
beta	I-PRGE
(	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
beta	I-PRGE
)	O
binding	O
site	O
between	O
-	O
2010	O
and	O
-	O
1954	O
in	O
regulating	O
transcription	O
of	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
monocytic	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	O
expression	O
of	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
addition	O
,	O
our	O
data	O
suggests	O
that	O
the	O
rapid	O
PMA	O
-	O
mediated	O
induction	O
of	O
collagenase	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
is	O
controlled	O
by	O
a	O
mechanism	O
distinct	O
from	O
that	O
regulating	O
the	O
sustained	O
expression	O
of	O
this	O
proteinase	O
in	O
activated	O
macrophages	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	O
negative	O
effector	O
on	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	O
factors	O
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	O
cells	O
.	O

To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O

This	O
employs	O
an	O
Escherichia	O
coli	O
tester	O
strain	O
carrying	O
a	O
modified	O
lac	O
operon	O
as	O
a	O
reporter	O
gene	O
,	O
with	O
the	O
lac	O
operator	O
sequence	O
replaced	O
by	O
an	O
octamer	O
sequence	O
.	O

Oct	B-PRGE
-	I-PRGE
2	I-PRGE
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac	O
+	O
to	O
Lac	O
-	O
.	O

Introduction	O
of	O
a	O
cDNA	O
expression	O
library	O
prepared	O
from	O
a	O
human	O
T	O
-	O
cell	O
line	O
into	O
the	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
harboring	O
tester	O
strain	O
allowed	O
selection	O
of	O
three	O
Lac	O
+	O
clones	O
out	O
of	O
1	O
x	O
10	O
(	O
5	O
)	O
transformants	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	O
zinc	O
finger	O
protein	O
was	O
found	O
to	O
derepress	O
beta	B-PRGE
-	I-PRGE
galactosidase	I-PRGE
activity	O
in	O
the	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	O
probe	O
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
suggesting	O
a	O
dominant	O
negative	O
effect	O
on	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein	O
-	O
protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O

A	O
negative	O
role	O
for	O
phosphoinositide	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
in	O
T	O
-	O
cell	O
antigen	O
receptor	O
function	O
.	O

BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T	O
-	O
cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O

Phosphoinositide	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
(	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T	O
-	O
cell	O
function	O
,	O
including	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
the	O
costimulatory	O
receptor	O
CD28	B-PRGE
,	O
and	O
negative	O
regulators	O
of	O
T	O
-	O
cell	O
activation	O
such	O
as	O
CTLA	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T	O
-	O
cell	O
differentiation	O
and	O
lymphocyte	O
proliferation	O
.	O

PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
in	O
TCR	O
-	O
directed	O
T	O
-	O
cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
.	O

RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	O
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	O
and	O
serum	O
response	O
factor	O
were	O
not	O
affected	O
by	O
expression	O
of	O
the	O
mutant	O
forms	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
.	O

We	O
found	O
,	O
however	O
,	O
that	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
'	O
(	O
NF	O
-	O
AT	O
)	O
elicited	O
by	O
the	O
TCR	O
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
inhibited	O
TCR	O
-	O
mediated	O
NF	O
-	O
AT	O
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
potently	O
enhanced	O
TCR	O
-	O
controlled	O
NF	O
-	O
AT	O
induction	O
.	O

These	O
effects	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
were	O
not	O
mediated	O
by	O
previously	O
identified	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
effectors	O
,	O
such	O
as	O
protein	O
kinase	O
B	O
,	O
a	O
positive	O
regulator	O
of	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
,	O
or	O
the	O
GTPase	O
Rac	O
,	O
and	O
are	O
therefore	O
likely	O
to	O
involve	O
a	O
novel	O
,	O
as	O
yet	O
unknown	O
,	O
effector	O
molecule	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T	O
-	O
cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
in	O
T	O
cells	O
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	O
-	O
signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T	O
-	O
cell	O
homeostasis	O
.	O

NF	O
-	O
kappa	O
B	O
-	O
independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	O
infected	O
T	O
lymphocytic	O
cells	O
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	O
cytokine	O
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O

Pretreatment	O
of	O
ACH	O
-	O
2	O
T	O
cells	O
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF	O
-	O
kappa	O
B	O
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH	O
-	O
2	O
cell	O
line	O
.	O

Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
following	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
or	O
PMA	O
-	O
induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF	O
-	O
kappa	O
B	O
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

Lineage	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
runt	B-PRGE
box	O
polypeptides	O
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

Translocations	O
involving	O
the	O
human	O
CBFA2	B-PRGE
locus	O
have	O
been	O
associated	O
with	O
leukemia	O
.	O

This	O
gene	O
,	O
originally	O
named	O
AML1	B-PRGE
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
gene	O
runt	B-PRGE
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O

To	O
clarify	O
the	O
role	O
of	O
mammalian	O
runt	B-PRGE
products	O
in	O
normal	O
and	O
leukemic	O
hematopoiesis	O
,	O
we	O
have	O
studied	O
their	O
pattern	O
of	O
expression	O
in	O
mouse	O
hematopoietic	O
tissues	O
in	O
the	O
adult	O
and	O
during	O
ontogeny	O
using	O
an	O
anti	O
-	O
runt	O
box	O
antiserum	O
.	O

In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	O
myeloid	O
cells	O
and	O
in	O
B	O
lymphocytes	O
.	O

Within	O
the	O
erythroid	O
lineage	O
,	O
runt	B-PRGE
expression	O
is	O
biphasic	O
,	O
clearly	O
present	O
in	O
the	O
erythroblasts	O
of	O
early	O
blood	O
islands	O
and	O
of	O
the	O
fetal	O
liver	O
,	O
but	O
absent	O
in	O
the	O
adult	O
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	O
and	O
adult	O
hematopoietic	O
populations	O
shows	O
several	O
runt	O
isoforms	O
.	O

At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
activates	O
the	O
long	O
terminal	O
repeat	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	O
motif	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
between	O
peripheral	O
blood	O
lymphocytes	O
and	O
transfected	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
HT29	O
activates	O
transcription	O
of	O
the	O
long	O
terminal	O
repeats	O
(	O
LTR	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

HIV	O
-	O
1	O
LTR	O
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus	O
-	O
encoded	O
and	O
cellular	O
proteins	O
.	O

Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV	O
-	O
1	O
LTR	O
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	O
regulatory	O
elements	O
located	O
in	O
the	O
U3	O
region	O
are	O
involved	O
in	O
cell	O
-	O
to	O
-	O
cell	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimer	O
to	O
an	O
HIV	O
-	O
1	O
kappaB	O
oligonucleotide	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
contact	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	O
inhibitor	B-PRGE
kappaB	I-PRGE
alpha	I-PRGE
.	O

NF	O
-	O
kappaB	O
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O

HIV	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	B-PRGE
T	O
cells	O
stimulated	O
with	O
CD3	O
/	O
CD28	B-PRGE
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	B-PRGE
T	O
cells	O
stimulated	O
by	O
cross	O
-	O
linking	O
CD3	O
and	O
CD28	B-PRGE
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	O
CD4	B-PRGE
T	O
cells	O
stimulated	O
in	O
the	O
same	O
way	O
.	O

Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	B-PRGE
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	O
and	O
memory	O
T	O
cells	O
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS	O
-	O
isolated	O
)	O
subsets	O
of	O
CD4	B-PRGE
T	O
cells	O
identified	O
by	O
expression	O
of	O
both	O
CD45RA	B-PRGE
and	O
CD62L	B-PRGE
.	O

Remixing	O
of	O
purified	O
T	O
cells	O
showed	O
that	O
naive	O
T	O
cells	O
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	O
T	O
cells	O
and	O
that	O
memory	O
T	O
cells	O
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	O
T	O
cells	O
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	O
T	O
cells	O
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	O
coreceptors	O
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	O
factors	O
,	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
activator	O
protein	O
-	O
1	O
.	O

The	O
inherent	O
resistance	O
of	O
naive	O
T	O
cells	O
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	B-PRGE
T	O
cells	O
from	O
HIV	O
-	O
infected	O
adults	O
.	O

Control	O
of	O
NFATx1	B-PRGE
nuclear	O
translocation	O
by	O
a	O
calcineurin	O
-	O
regulated	O
inhibitory	O
domain	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
through	O
cis	O
-	O
acting	O
elements	O
located	O
in	O
the	O
promoters	O
of	O
several	O
cytokine	O
genes	O
.	O

NFATx1	B-PRGE
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	O
family	O
of	O
transcription	O
factors	O
.	O

We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	B-PRGE
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O

We	O
found	O
that	O
NFATx1	B-PRGE
DNA	O
binding	O
activity	O
and	O
interaction	O
with	O
AP	O
-	O
1	O
polypeptides	O
were	O
dependent	O
on	O
its	O
central	O
Rel	O
similarity	O
region	O
and	O
that	O
transcriptional	O
activation	O
was	O
reduced	O
by	O
deletions	O
of	O
either	O
its	O
N	O
-	O
terminal	O
domain	O
or	O
its	O
C	O
-	O
terminal	O
domain	O
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	O
transcriptional	O
activation	O
motifs	O
in	O
both	O
regions	O
.	O

We	O
also	O
identified	O
a	O
potent	O
inhibitory	O
sequence	O
within	O
its	O
N	O
-	O
terminal	O
domain	O
.	O

We	O
show	O
that	O
the	O
inactivation	O
of	O
the	O
inhibition	O
was	O
dependent	O
on	O
the	O
activity	O
of	O
calcineurin	O
,	O
a	O
calcium	O
-	O
calmodulin	O
-	O
dependent	O
phosphatase	O
.	O

We	O
also	O
show	O
that	O
calcineurin	O
associated	O
with	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NFATx1	B-PRGE
at	O
multiple	O
docking	O
sites	O
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	B-PRGE
.	O

We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	O
residues	O
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	O
proteins	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	B-PRGE
of	O
the	O
mapped	O
60	O
residues	O
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O

Our	O
results	O
support	O
the	O
model	O
proposing	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
confers	O
calcium	O
-	O
signaling	O
dependence	O
on	O
NFATx1	B-PRGE
transactivation	O
activity	O
by	O
regulating	O
its	O
intracellular	O
localization	O
through	O
a	O
protein	O
module	O
that	O
associates	O
with	O
calcineurin	O
and	O
is	O
a	O
target	O
of	O
its	O
phosphatase	O
activity	O
.	O

Neuronal	B-PRGE
(	I-PRGE
type	I-PRGE
I	I-PRGE
)	I-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
regulates	O
nuclear	O
factor	O
kappaB	O
activity	O
and	O
immunologic	B-PRGE
(	I-PRGE
type	I-PRGE
II	I-PRGE
)	I-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
expression	O
.	O

Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O

NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	O
synthase	O
(	O
NOS	O
)	O
isoforms	O
:	O
neuronal	B-PRGE
NOS	I-PRGE
(	O
nNOS	B-PRGE
)	O
,	O
endothelial	B-PRGE
NOS	I-PRGE
,	O
and	O
immunologic	B-PRGE
NOS	I-PRGE
(	O
iNOS	B-PRGE
)	O
.	O

We	O
show	O
that	O
nNOS	B-PRGE
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	O
in	O
glia	O
.	O

NO	O
derived	O
from	O
nNOS	B-PRGE
in	O
glia	O
inhibits	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
kappaB	O
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	O
kappaB	O
activation	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	O
kappaB	O
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O

In	O
Jurkat	O
cells	O
,	O
a	O
human	O
T	O
-	O
cell	O
lymphoma	O
cell	O
line	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
induces	O
NF	O
kappaB	O
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	O
cells	O
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
NF	O
kappaB	O
activation	O
in	O
astrocytes	O
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	O
kappaB	O
activation	O
in	O
astrocytes	O
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O

In	O
astrocytes	O
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	O
kappaB	O
-	O
dependent	O
enzyme	O
,	O
iNOS	B-PRGE
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	O
kappaB	O
.	O

NF	O
kappaB	O
activation	O
in	O
glia	O
from	O
mice	O
lacking	O
nNOS	B-PRGE
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	O
from	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
nNOS	B-PRGE
in	O
astrocytes	O
regulates	O
NF	O
kappaB	O
activity	O
and	O
iNOS	B-PRGE
expression	O
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	B-PRGE
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	O
kappaB	O
-	O
regulated	O
genes	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B	B-PRGE
-	I-PRGE
cell	I-PRGE
-	I-PRGE
specific	I-PRGE
activator	I-PRGE
protein	I-PRGE
.	O

Germline	O
transcripts	O
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	O
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B	B-PRGE
-	I-PRGE
cell	I-PRGE
-	I-PRGE
specific	I-PRGE
activator	I-PRGE
protein	I-PRGE
(	O
BSAP	B-PRGE
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	B-PRGE
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	B-PRGE
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	B-PRGE
plays	O
a	O
role	O
in	O
both	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
dependent	O
induction	O
and	O
CD40	B-PRGE
-	O
mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	B-PRGE
is	O
unique	O
among	O
the	O
transcription	O
factors	O
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	O
switching	O
.	O

Retinoic	O
acid	O
-	O
induced	O
modulation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
production	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
expression	O
on	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune	O
-	O
modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	O
(	O
Ig	O
)	O
response	O
.	O

Investigating	O
cytokines	O
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
is	O
augmented	O
by	O
RA	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
,	O
another	O
important	O
cytokine	O
for	O
B	O
cell	O
immunoglobulin	O
production	O
,	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptors	O
on	O
T	O
cells	O
,	O
and	O
the	O
RA	O
nuclear	O
receptors	O
.	O

METHODS	O
:	O
Purified	O
T	O
cells	O
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent	O
/	O
media	O
control	O
for	O
0	O
,	O
6	O
-	O
8	O
,	O
and	O
24	O
h	O
.	O

Total	O
mRNA	O
was	O
extracted	O
from	O
T	O
cells	O
,	O
and	O
using	O
RT	O
-	O
PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL	O
-	O
2	O
and	O
RA	B-PRGE
receptors	I-PRGE
(	I-PRGE
RAR	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
beta	B-PRGE
,	O
gamma	B-PRGE
mRNA	O
were	O
determined	O
.	O

The	O
effects	O
of	O
RA	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	I-PRGE
alpha	I-PRGE
receptor	I-PRGE
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
production	O
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
-	I-PRGE
alpha	I-PRGE
expression	O
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Thus	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
may	O
be	O
another	O
important	O
cytokine	O
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

Itk	B-PRGE
,	O
a	O
T	O
cell	O
-	O
specific	O
tyrosine	O
kinase	O
,	O
is	O
required	O
for	O
CD2	B-PRGE
-	O
mediated	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
in	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
.	O

We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	B-PRGE
,	O
a	O
member	O
of	O
the	O
cytoplasmic	O
tyrosine	O
kinase	O
Tec	O
family	O
,	O
in	O
T	O
cell	O
activation	O
.	O

Stimulation	O
of	O
either	O
CD2	B-PRGE
or	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
/	O
CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody	O
-	O
mediated	O
cross	O
-	O
linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Itk	B-PRGE
,	O
which	O
was	O
maximal	O
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O

The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti	O
-	O
Itk	B-PRGE
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
promoter	O
activity	O
stimulated	O
by	O
cross	O
-	O
linking	O
of	O
CD2	B-PRGE
,	O
TCR	O
/	O
CD3	O
,	O
and	O
CD28	B-PRGE
with	O
antibodies	O
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	B-PRGE
mutant	O
lacking	O
the	O
kinase	O
activity	O
.	O

The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	O
wild	O
-	O
type	O
Itk	B-PRGE
.	O

Stimulation	O
of	O
CD2	B-PRGE
or	O
TCR	O
/	O
CD3	O
induced	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
the	O
binding	O
site	O
of	O
which	O
is	O
included	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
promoter	O
.	O

The	O
activation	O
of	O
NFAT	O
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	B-PRGE
mutant	O
.	O

These	O
results	O
demonstrate	O
that	O
Itk	B-PRGE
plays	O
a	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	B-PRGE
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR	O
/	O
CD3	O
complex	O
,	O
CD2	B-PRGE
,	O
and	O
CD28	B-PRGE
.	O

Jak3	B-PRGE
is	O
associated	O
with	O
CD40	B-PRGE
and	O
is	O
critical	O
for	O
CD40	B-PRGE
induction	O
of	O
gene	O
expression	O
in	O
B	O
cells	O
.	O

CD40	B-PRGE
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	O
lymphocytes	O
.	O

Although	O
CD40	B-PRGE
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	B-PRGE
-	O
mediated	O
events	O
.	O

We	O
show	O
that	O
engagement	O
of	O
CD40	B-PRGE
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	B-PRGE
as	O
well	O
as	O
of	O
STAT3	B-PRGE
.	O

Jak3	B-PRGE
is	O
constitutively	O
associated	O
with	O
CD40	B-PRGE
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline	O
-	O
rich	O
sequence	O
in	O
the	O
membrane	O
-	O
proximal	O
region	O
of	O
CD40	B-PRGE
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	B-PRGE
to	O
induce	O
expression	O
of	O
CD23	B-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
lymphotoxin	B-PRGE
-	I-PRGE
alpha	I-PRGE
genes	O
in	O
B	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	B-PRGE
is	O
activated	O
by	O
CD40	B-PRGE
and	O
plays	O
an	O
important	O
role	O
in	O
CD40	B-PRGE
-	O
mediated	O
functions	O
.	O

The	O
tumour	O
associated	O
cell	O
surface	O
antigen	O
A6H	O
is	O
costimulatory	O
for	O
human	O
CD4	B-PRGE
+	O
but	O
not	O
CD8	O
+	O
T	O
cells	O
.	O

The	O
A6H	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
recognizes	O
a	O
120	O
,	O
000	O
-	O
140	O
,	O
000	O
MW	O
antigen	O
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85	O
-	O
90	O
%	O
of	O
human	O
CD4	B-PRGE
+	O
and	O
CD8	O
+	O
T	O
cells	O
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

The	O
binding	O
of	O
the	O
A6H	O
mAb	O
induced	O
a	O
costimulatory	O
signal	O
in	O
anti	O
-	O
CD3	O
activated	O
T	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	O
costimulated	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
in	O
purified	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

Unexpectedly	O
,	O
the	O
CD8	O
+	O
T	O
-	O
cell	O
subpopulation	O
failed	O
to	O
respond	O
.	O

CD4	B-PRGE
+	O
T	O
cells	O
costimulated	O
with	O
the	O
A6H	O
mAb	O
upregulated	O
CD80	B-PRGE
,	O
CD86	B-PRGE
,	O
CD71	B-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
)	I-PRGE
R	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
gamma	I-PRGE
,	O
while	O
no	O
corresponding	O
up	O
-	O
regulation	O
of	O
these	O
cell	O
surface	O
molecules	O
was	O
seen	O
in	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	O
mAb	O
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	O
factors	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
which	O
are	O
known	O
to	O
be	O
transcriptional	O
regulators	O
of	O
several	O
cytokine	O
and	O
cytokine	O
receptor	O
genes	O
,	O
including	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
2R	O
genes	O
.	O

Co	O
-	O
ligation	O
of	O
the	O
A6H	O
antigen	O
and	O
the	O
CD3	O
complex	O
induced	O
expression	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
,	O
whereas	O
no	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
and	O
octamer	O
-	O
binding	O
(	O
Oct	O
)	O
proteins	O
was	O
seen	O
compared	O
to	O
T	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
alone	O
.	O

Furthermore	O
,	O
no	O
induction	O
of	O
AP	O
-	O
1	O
was	O
seen	O
in	O
A6H	O
costimulated	O
CD8	O
+	O
T	O
cells	O
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8	O
+	O
T	O
-	O
cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	O
ligation	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	O
molecule	O
or	O
distinct	O
regulation	O
of	O
the	O
A6H	O
transduced	O
AP	O
-	O
1	O
activation	O
pathway	O
may	O
exist	O
in	O
CD4	B-PRGE
+	O
and	O
CD8	O
+	O
T	O
cell	O
subpopulations	O
.	O

Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	O
myeloid	B-PRGE
cell	I-PRGE
nuclear	I-PRGE
differentiation	I-PRGE
antigen	I-PRGE
promoter	O
:	O
evidence	O
for	O
the	O
role	O
of	O
Sp1	B-PRGE
and	O
not	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
or	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
in	O
myelomonocytic	O
lineage	O
-	O
specific	O
expression	O
.	O

The	O
human	O
myeloid	B-PRGE
nuclear	I-PRGE
differentiation	I-PRGE
antigen	I-PRGE
(	O
MNDA	B-PRGE
)	O
is	O
expressed	O
specifically	O
in	O
maturing	O
cells	O
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	O
and	O
granulocytes	O
.	O

Epitope	O
enhancement	O
was	O
used	O
to	O
confirm	O
the	O
strict	O
lineage	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
MNDA	B-PRGE
in	O
bone	O
marrow	O
as	O
well	O
as	O
in	O
other	O
paraffin	O
-	O
embedded	O
fixed	O
tissues	O
.	O

A	O
1	O
-	O
kb	O
region	O
of	O
the	O
gene	O
that	O
includes	O
5	O
'	O
flanking	O
sequence	O
was	O
reported	O
earlier	O
to	O
contain	O
functional	O
promoter	O
activity	O
and	O
was	O
specifically	O
demethylated	O
in	O
expressing	O
cells	O
in	O
contrast	O
to	O
null	O
cells	O
.	O

Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1	O
-	O
kb	O
fragment	O
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA	B-PRGE
-	O
expressing	O
cells	O
than	O
non	O
-	O
expressing	O
cells	O
,	O
indicating	O
cell	O
-	O
specific	O
differences	O
in	O
transactivation	O
.	O

This	O
sequence	O
contains	O
consensus	O
elements	O
consistent	O
with	O
myeloid	O
-	O
specific	O
gene	O
expression	O
,	O
including	O
a	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
consensus	O
site	O
near	O
the	O
major	O
transcription	O
start	O
site	O
and	O
a	O
cluster	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
sites	O
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O

However	O
,	O
analysis	O
of	O
deletion	O
mutants	O
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-	O
73	O
to	O
-	O
16	O
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
sites	O
.	O

A	O
4	O
-	O
bp	O
mutation	O
of	O
the	O
core	O
Sp1	B-PRGE
consensus	O
element	O
(	O
GC	O
box	O
)	O
(	O
-	O
20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1	O
-	O
kb	O
fragment	O
.	O

Mutation	O
of	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
did	O
not	O
significantly	O
affect	O
promoter	O
activity	O
.	O

Only	O
a	O
small	O
region	O
(	O
-	O
35	O
to	O
+	O
22	O
)	O
including	O
the	O
Sp1	B-PRGE
element	O
and	O
transcription	O
start	O
site	O
,	O
but	O
not	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
was	O
footprinted	O
.	O

The	O
4	O
-	O
bp	O
mutation	O
of	O
the	O
core	O
Sp1	B-PRGE
consensus	O
element	O
abolished	O
footprinting	O
at	O
the	O
site	O
and	O
an	O
antibody	O
super	O
-	O
shift	O
reaction	O
showed	O
that	O
Sp1	B-PRGE
is	O
one	O
of	O
the	O
factors	O
binding	O
the	O
consensus	O
site	O
.	O

The	O
Sp1	B-PRGE
site	O
also	O
co	O
-	O
localizes	O
with	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
.	O

The	O
results	O
indicate	O
that	O
DNA	O
methylation	O
,	O
chromatin	O
structure	O
,	O
and	O
transactivation	O
at	O
an	O
Sp1	B-PRGE
site	O
contribute	O
to	O
the	O
highly	O
restricted	O
expression	O
of	O
this	O
myelomonocytic	O
lineage	O
specific	O
gene	O
.	O

Inhibitor	O
(	O
IK	B-PRGE
)	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induced	O
HLA	O
class	O
II	O
antigens	O
expression	O
also	O
inhibits	O
HLA	O
class	O
II	O
constitutive	O
expression	O
in	O
the	O
human	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
antigens	O
is	O
constitutive	O
in	O
professional	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	O
APCs	O
(	O
e	O
.	O
g	O
.	O
fibroblasts	O
)	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B-PRGE
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
of	O
MHC	O
class	O
II	O
antigens	O
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	B-PRGE
in	O
MHC	O
class	O
II	O
expression	O
since	O
over	O
-	O
expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	O
class	O
II	O
mRNA	O
expression	O
.	O

The	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
(	O
CIITA	B-PRGE
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induced	O
MHC	O
class	O
II	O
expressions	O
.	O

Examination	O
of	O
CIITA	B-PRGE
mRNA	O
in	O
IK	B-PRGE
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	B-PRGE
mRNA	O
transcription	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	B-PRGE
protein	O
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	O
class	O
II	O
antigens	O
and	O
that	O
inhibition	O
induced	O
by	O
IK	B-PRGE
is	O
upstream	O
of	O
CIITA	B-PRGE
in	O
this	O
regulatory	O
pathway	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
between	O
alpha	O
and	O
delta	O
gene	O
segments	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
alpha	O
/	O
delta	O
locus	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
alpha	O
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
(	O
BEAD	O
-	O
1	O
,	O
for	O
blocking	O
element	O
alpha	O
/	O
delta	O
1	O
)	O
was	O
localized	O
to	O
a	O
2	O
.	O
0	O
-	O
kb	O
region	O
3	O
'	O
of	O
TCR	O
delta	O
gene	O
segments	O
and	O
5	O
'	O
of	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
within	O
this	O
locus	O
.	O

BEAD	O
-	O
1	O
blocked	O
the	O
ability	O
of	O
the	O
TCR	O
delta	O
enhancer	O
(	O
Edelta	O
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin	O
-	O
integrated	O
construct	O
.	O

We	O
propose	O
that	O
BEAD	O
-	O
1	O
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	O
alpha	O
/	O
delta	O
locus	O
into	O
distinct	O
regulatory	O
domains	O
controlled	O
by	O
Edelta	O
and	O
the	O
TCR	O
alpha	O
enhancer	O
,	O
and	O
that	O
it	O
prevents	O
Edelta	O
from	O
opening	O
the	O
chromatin	O
of	O
the	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O

Quantification	O
of	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
mRNA	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	O
:	O
lack	O
of	O
correspondence	O
with	O
common	O
allelic	O
variants	O
.	O

It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	B-PRGE
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
different	O
VDR	B-PRGE
genotypes	O
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	B-PRGE
cDNA	O
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	O
VDR	B-PRGE
CDNA	O
mutated	O
at	O
a	O
BglII	O
restriction	O
site	O
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O

To	O
validate	O
the	O
method	O
,	O
we	O
made	O
use	O
of	O
earlier	O
receptor	O
binding	O
studies	O
indicating	O
that	O
normal	O
human	O
monocytes	O
and	O
activated	O
,	O
but	O
not	O
resting	O
,	O
lymphocytes	O
expressed	O
the	O
VDR	B-PRGE
.	O

The	O
concentration	O
of	O
the	O
VDR	B-PRGE
mRNA	O
was	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
7	O
)	O
g	O
/	O
g	O
of	O
total	O
RNA	O
in	O
cell	O
-	O
sorted	O
monocytes	O
and	O
in	O
in	O
vitro	O
activated	O
lymphocytes	O
,	O
but	O
only	O
10	O
(	O
-	O
12	O
)	O
g	O
/	O
g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	O
,	O
establishing	O
that	O
the	O
VDR	B-PRGE
mRNA	O
determined	O
by	O
our	O
method	O
in	O
PBMCs	O
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	O
.	O

Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O

The	O
concentration	O
of	O
the	O
VDR	B-PRGE
mRNA	O
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	O
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	O
calcitriol	O
,	O
serum	B-PRGE
osteocalcin	I-PRGE
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O

We	O
conclude	O
that	O
VDR	B-PRGE
polymorphism	O
does	O
not	O
affect	O
the	O
abundance	O
of	O
the	O
VDR	B-PRGE
mRNA	O
.	O

Regulation	O
of	O
CD95	B-PRGE
(	I-PRGE
Fas	I-PRGE
)	I-PRGE
ligand	I-PRGE
expression	O
by	O
TCR	O
-	O
mediated	O
signaling	O
events	O
.	O

Stimulation	O
of	O
mature	O
peripheral	O
T	O
cells	O
by	O
TCR	O
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	O
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O

However	O
,	O
under	O
some	O
conditions	O
,	O
engagement	O
of	O
the	O
TCR	O
leads	O
instead	O
to	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
TCR	O
-	O
stimulated	O
apoptosis	O
requires	O
expression	O
of	O
CD95	B-PRGE
ligand	I-PRGE
on	O
activated	O
T	O
cells	O
followed	O
by	O
an	O
interaction	O
between	O
CD95	B-PRGE
ligand	I-PRGE
and	O
the	O
CD95	B-PRGE
receptor	O
also	O
expressed	O
on	O
this	O
population	O
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	O
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B-PRGE
ligand	I-PRGE
gene	O
expression	O
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	B-PRGE
reporter	O
construct	O
containing	O
elements	O
of	O
the	O
CD95	B-PRGE
ligand	I-PRGE
promoter	O
.	O

Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	O
T	O
cell	O
line	O
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	B-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
are	O
required	O
for	O
TCR	O
-	O
stimulated	O
CD95	B-PRGE
ligand	I-PRGE
expression	O
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	O
-	O
stimulated	O
activation	O
of	O
the	O
Ras	O
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	B-PRGE
ligand	I-PRGE
.	O

Next	O
,	O
in	O
an	O
effort	O
to	O
determine	O
critical	O
transcription	O
factors	O
that	O
regulate	O
CD95	B-PRGE
ligand	I-PRGE
expression	O
,	O
we	O
demonstrate	O
a	O
cyclosporin	B-PRGE
A	I-PRGE
-	O
sensitive	O
nuclear	O
factor	O
-	O
AT	O
response	O
element	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
that	O
is	O
critical	O
for	O
optimal	O
CD95	B-PRGE
ligand	I-PRGE
reporter	O
activity	O
in	O
stimulated	O
T	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B-PRGE
ligand	I-PRGE
,	O
a	O
required	O
step	O
for	O
TCR	O
-	O
induced	O
apoptosis	O
.	O

CD40	B-PRGE
is	O
a	O
functional	O
activation	O
antigen	O
and	O
B7	B-PRGE
-	O
independent	O
T	O
cell	O
costimulatory	O
molecule	O
on	O
normal	O
human	O
lung	O
fibroblasts	O
.	O

CD40	B-PRGE
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	O
marrow	O
-	O
derived	O
cells	O
.	O

Recently	O
,	O
CD40	B-PRGE
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	B-PRGE
in	O
fibroblasts	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B-PRGE
expressed	O
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O

Communication	O
between	O
resident	O
tissue	O
fibroblasts	O
and	O
T	O
cells	O
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O

Signaling	O
through	O
CD40	B-PRGE
with	O
soluble	O
CD40	B-PRGE
ligand	I-PRGE
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
primed	O
lung	O
fibroblasts	O
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	B-PRGE
,	O
but	O
not	O
the	O
well	O
-	O
studied	O
costimulatory	O
molecules	O
B7	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
B7	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	O
fibroblasts	O
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40	B-PRGE
/	O
CD40L	B-PRGE
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O

Tap	O
:	O
a	O
novel	O
cellular	O
protein	O
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	O
aggregation	O
.	O

Tip	O
of	O
herpesvirus	O
saimiri	O
associates	O
with	O
Lck	B-PRGE
and	O
down	O
-	O
regulates	O
Lck	B-PRGE
-	O
mediated	O
activation	O
.	O

We	O
identified	O
a	O
novel	O
cellular	O
Tip	O
-	O
associated	O
protein	O
(	O
Tap	O
)	O
by	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
.	O

Tap	O
associated	O
with	O
Tip	O
following	O
transient	O
expression	O
in	O
COS	O
-	O
1	O
cells	O
and	O
stable	O
expression	O
in	O
human	O
Jurkat	O
-	O
T	O
cells	O
.	O

Expression	O
of	O
Tip	O
and	O
Tap	O
in	O
Jurkat	O
-	O
T	O
cells	O
induced	O
dramatic	O
cell	O
aggregation	O
.	O

Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up	O
-	O
regulated	O
surface	O
expression	O
of	O
adhesion	O
molecules	O
including	O
integrin	O
alpha	O
,	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
H	B-PRGE
-	I-PRGE
CAM	I-PRGE
.	O

Furthermore	O
,	O
NF	O
-	O
kappaB	O
transcriptional	O
factor	O
of	O
aggregated	O
cells	O
had	O
approximately	O
40	O
-	O
fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	O
cells	O
.	O

Thus	O
,	O
Tap	O
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	O
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

Transactivation	O
by	O
CIITA	B-PRGE
,	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome	O
-	O
associated	O
factor	O
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	B-PRGE
box	I-PRGE
binding	I-PRGE
protein	I-PRGE
.	O

CIITA	B-PRGE
is	O
a	O
positive	O
regulator	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
-	O
negative	O
cell	O
lines	O
.	O

Its	O
N	O
-	O
terminal	O
region	O
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	O
binding	O
domain	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	B-PRGE
activation	O
domain	O
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Specifically	O
the	O
altered	O
specificity	O
TBP	B-PRGE
(	O
TATA	B-PRGE
box	I-PRGE
binding	I-PRGE
protein	I-PRGE
)	O
assay	O
has	O
been	O
used	O
to	O
analyze	O
the	O
response	O
of	O
the	O
CIITA	B-PRGE
activation	O
domain	O
to	O
mutations	O
in	O
TBP	B-PRGE
known	O
to	O
disrupt	O
its	O
interaction	O
with	O
its	O
associated	O
general	O
factors	O
.	O

Transactivation	O
by	O
CIITA	B-PRGE
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	B-PRGE
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16	B-PRGE
-	O
mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O

A	O
TBP	B-PRGE
mutant	O
defective	O
in	O
interaction	O
with	O
TBP	B-PRGE
-	O
associated	O
factor	O
TAFII250	B-PRGE
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B-PRGE
activation	O
domain	O
.	O

Certain	O
interactions	O
between	O
TBP	B-PRGE
and	O
general	O
factors	O
that	O
are	O
specifically	O
required	O
for	O
acidic	O
activation	O
domains	O
were	O
also	O
required	O
for	O
CIITA	B-PRGE
-	O
mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O

Finally	O
,	O
like	O
VP16	B-PRGE
,	O
CIITA	B-PRGE
was	O
able	O
to	O
stimulate	O
elongation	O
of	O
transcription	O
.	O

Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	O
B	O
-	O
cell	O
-	O
specific	O
CIITA	B-PRGE
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	O
virus	O
transactivator	O
VP16	B-PRGE
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O

Specific	O
complex	O
formation	O
between	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome	O
-	O
associated	O
transactivators	O
CIITA	B-PRGE
and	O
RFX5	B-PRGE
.	O

Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II	O
-	O
negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	B-PRGE
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	O
family	O
of	O
DNA	O
binding	O
proteins	O
.	O

The	O
other	O
,	O
CIITA	B-PRGE
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	O
transcriptional	O
activation	O
domain	O
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O

Expression	O
plasmids	O
encoding	O
regions	O
of	O
RFX5	B-PRGE
fused	O
to	O
the	O
GAL4	B-PRGE
DNA	O
binding	O
domain	O
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	B-PRGE
sites	O
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	O
human	O
B	O
cell	O
line	O
.	O

However	O
,	O
these	O
plasmids	O
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	B-PRGE
gamma	I-PRGE
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	B-PRGE
and	O
class	O
II	O
major	O
histocompatibility	O
complex	O
surface	O
proteins	O
are	O
induced	O
.	O

Furthermore	O
,	O
these	O
plasmids	O
were	O
not	O
active	O
in	O
RJ2	O
.	O
2	O
.	O
5	O
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	O
in	O
which	O
both	O
copies	O
of	O
CIITA	B-PRGE
are	O
defective	O
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	B-PRGE
fusion	O
protein	O
could	O
be	O
restored	O
in	O
RJ2	O
.	O
2	O
.	O
5	O
by	O
cotransfection	O
with	O
a	O
CIITA	B-PRGE
expression	O
plasmid	O
.	O

Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	B-PRGE
and	O
CIITA	B-PRGE
was	O
detected	O
with	O
the	O
yeast	O
two	O
-	O
hybrid	O
and	O
far	O
-	O
Western	O
blot	O
assays	O
.	O

Thus	O
,	O
RFX5	B-PRGE
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	B-PRGE
.	O

RFX5	B-PRGE
and	O
CIITA	B-PRGE
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
.	O

In	O
this	O
complex	O
,	O
promoter	O
specificity	O
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	B-PRGE
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	O
activation	O
domain	O
of	O
CIITA	B-PRGE
.	O

Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical	O
-	O
induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	O
-	O
induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
are	O
discussed	O
.	O

Emphasis	O
is	O
placed	O
on	O
cytokines	O
that	O
have	O
been	O
studied	O
in	O
periodontitis	O
,	O
principally	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	O
-	O
1	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
interferon	I-PRGE
.	O

The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF	O
-	O
kappa	O
B	O
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	O
protein	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
that	O
belongs	O
to	O
the	O
ETS	O
protein	O
family	O
.	O

It	O
can	O
bind	O
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	O
genes	O
.	O

We	O
demonstrate	O
that	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
which	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
amino	O
acids	O
86	O
-	O
265	O
.	O

Analysis	O
of	O
Gal4	B-PRGE
-	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
fusion	O
proteins	O
revealed	O
that	O
the	O
N	O
-	O
terminal	O
86	O
amino	O
acids	O
of	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
contain	O
a	O
transcriptional	O
activation	O
domain	O
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	O
repression	O
domain	O
.	O

Furthermore	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
interacts	O
specifically	O
with	O
the	O
E74	O
target	O
sequence	O
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	O
site	O
independent	O
of	O
mitogenic	O
signaling	O
.	O

Thus	O
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	O
.	O

Overexpression	O
of	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
inhibits	O
hemin	O
-	O
induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O

Acquisition	O
of	O
heat	B-PRGE
shock	I-PRGE
factor	I-PRGE
2	I-PRGE
(	O
HSF2	B-PRGE
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	O
shock	O
genes	O
in	O
hemin	O
-	O
treated	O
K562	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O

Previous	O
studies	O
revealed	O
that	O
HSF2	B-PRGE
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	B-PRGE
and	O
whether	O
the	O
HSF2	B-PRGE
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

We	O
show	O
that	O
in	O
parental	O
K562	O
cells	O
,	O
the	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
isoform	O
is	O
predominantly	O
expressed	O
and	O
HSF2	B-PRGE
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
the	O
hemin	O
-	O
induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	O
shock	O
genes	O
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2	B-PRGE
-	I-PRGE
alpha	I-PRGE
results	O
in	O
an	O
enhanced	O
hemin	O
response	O
.	O

Furthermore	O
,	O
the	O
hemin	O
-	O
induced	O
accumulation	O
of	O
globin	O
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	O
in	O
cells	O
overexpressing	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

We	O
suggest	O
that	O
HSF2	B-PRGE
-	I-PRGE
beta	I-PRGE
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	B-PRGE
activity	O
during	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

Glucocorticoid	O
-	O
mediated	O
repression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
arteritis	O
-	O
SCID	O
chimeras	O
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large	O
-	O
sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self	O
-	O
sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	O
artery	O
-	O
SCID	O
chimeras	O
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	O
synthase	O
.	O

In	O
contrast	O
,	O
synthesis	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	O
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
was	O
unaffected	O
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	B-PRGE
gene	O
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	O
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose	O
-	O
response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	O
-	O
mediated	O
cytokine	O
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	O
cell	O
products	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
whereas	O
the	O
activation	O
of	O
tissue	O
-	O
infiltrating	O
macrophages	O
was	O
only	O
partially	O
affected	O
.	O

IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
mRNA	O
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
persistence	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
-	O
transcribing	O
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Histamine	O
modulates	O
the	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	B-PRGE
receptor	I-PRGE
in	O
the	O
human	O
promonocytic	O
cell	O
line	O
U937	O
.	O

We	O
examined	O
the	O
effects	O
of	O
histamine	O
and	O
its	O
agonists	O
on	O
the	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
proto	O
-	O
oncogenes	O
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
in	O
the	O
human	O
promonocytic	O
U937	O
cell	O
line	O
.	O

Histamine	O
transiently	O
increased	O
cAMP	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
through	O
H2	B-PRGE
receptors	I-PRGE
.	O

Dibutyryl	O
cAMP	O
also	O
increased	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
and	O
protein	O
,	O
and	O
levels	O
remained	O
elevated	O
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O

Dose	O
-	O
dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
induction	O
via	O
H2	B-PRGE
receptors	I-PRGE
.	O

Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	O
,	O
a	O
protein	O
kinase	O
A	O
/	O
protein	O
kinase	O
C	O
inhibitor	O
,	O
blocked	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
induction	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	O
kinase	O
C	O
inhibitor	O
.	O

No	O
modification	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
expression	O
could	O
be	O
detected	O
on	O
treatment	O
with	O
histamine	O
or	O
its	O
analogues	O
.	O

Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	O
a	O
down	O
-	O
regulation	O
of	O
the	O
levels	O
of	O
this	O
proto	O
-	O
oncogene	O
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	O
cells	O
.	O

Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O

This	O
homologous	O
mechanism	O
of	O
H2	B-PRGE
receptor	I-PRGE
desensitization	O
was	O
time	O
dependent	O
.	O

These	O
results	O
indicate	O
that	O
histamine	O
activates	O
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
production	O
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	O
cells	O
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	O
of	O
H2	B-PRGE
receptors	I-PRGE
.	O

Human	O
cytomegalovirus	O
induces	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
production	O
by	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
through	O
acting	O
concurrently	O
on	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
gene	O
transcription	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
cells	O
,	O
leading	O
to	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
secretion	O
.	O

The	O
functional	O
analysis	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
revealed	O
that	O
both	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
kappaB	O
factor	O
-	O
binding	O
elements	O
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
complexes	O
.	O

These	O
results	O
suggest	O
that	O
CMV	O
activates	O
these	O
transcriptional	O
factors	O
,	O
resulting	O
in	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
gene	O
expression	O
.	O

Concomitant	O
downregulation	O
of	O
IgH	O
3	O
'	O
enhancer	O
activity	O
and	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
.	O

Regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
expression	O
is	O
controlled	O
by	O
a	O
B	O
cell	O
-	O
specific	O
promoter	O
,	O
intronic	O
enhancer	O
and	O
additional	O
B	O
cell	O
-	O
specific	O
enhancer	O
elements	O
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	O
locus	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell	O
-	O
specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
'	O
s	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
oncogene	O
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	O
locus	O
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	O
gene	O
class	O
switch	O
recombination	O
.	O

We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
.	O

When	O
mouse	O
MPC11	O
plasmacytoma	O
cells	O
,	O
in	O
which	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	O
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
transcriptionally	O
inactive	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
,	O
essential	O
for	O
IgH	O
3	O
'	O
enhancer	O
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
cannot	O
be	O
excluded	O
.	O

Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	O
cells	O
carrying	O
the	O
t	O
(	O
12	O
;	O
15	O
)	O
translocation	O
,	O
is	O
down	O
-	O
regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	O
.	O

Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	O
factors	O
that	O
control	O
the	O
cell	O
-	O
specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	O
.	O

ETS1	B-PRGE
,	O
NFkappaB	O
and	O
AP1	O
synergistically	O
transactivate	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
one	O
such	O
cytokine	O
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NFkappaB	O
,	O
AP1	O
and	O
ETS	O
-	O
like	O
binding	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

ETS1	B-PRGE
is	O
a	O
transcription	O
factor	O
of	O
the	O
ETS	O
family	O
that	O
is	O
expressed	O
in	O
T	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	B-PRGE
can	O
transactivate	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
Jurkat	O
T	O
cells	O
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	B-PRGE
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	O
cells	O
,	O
may	O
act	O
in	O
concert	O
with	O
PMA	O
/	O
ionomycin	O
inducible	O
factors	O
.	O

Here	O
we	O
show	O
that	O
ETS1	B-PRGE
can	O
transactivate	O
a	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
reporter	O
construct	O
in	O
unstimulated	O
Jurkat	O
cells	O
,	O
providing	O
that	O
either	O
NFkappaB	O
or	O
AP1	O
transcription	O
factors	O
are	O
supplied	O
by	O
co	O
-	O
transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	O
and	O
AP1	O
is	O
induced	O
following	O
PMA	O
/	O
ionomycin	O
treatment	O
of	O
T	O
cells	O
.	O

Transactivation	O
by	O
ETS1	B-PRGE
,	O
NFkappaB	O
and	O
AP1	O
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	B-PRGE
,	O
and	O
inducible	O
NFkappaB	O
and	O
AP1	O
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	O
complex	O
in	O
activated	O
T	O
cells	O
.	O

Relief	O
of	O
cyclin	B-PRGE
A	I-PRGE
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	O
primary	O
T	O
lymphocytes	O
via	O
CD2	B-PRGE
and	O
CD28	B-PRGE
adhesion	O
molecules	O
.	O

Cyclin	B-PRGE
A	I-PRGE
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
at	O
the	O
Cyclin	B-PRGE
A	I-PRGE
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	O
antibodies	O
directed	O
at	O
CD2	B-PRGE
and	O
CD28	B-PRGE
adhesion	O
molecules	O
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	O
cells	O
.	O

Cyclin	B-PRGE
A	I-PRGE
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	O
CD2	B-PRGE
+	O
CD28	B-PRGE
whereas	O
stimulation	O
by	O
anti	O
CD2	B-PRGE
or	O
anti	O
CD28	B-PRGE
alone	O
was	O
not	O
effective	O
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
sites	O
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	O
binding	O
sites	O
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	O
-	O
Y	O
proteins	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	O
CD2	B-PRGE
or	O
anti	O
CD28	B-PRGE
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	O
CD2	B-PRGE
+	O
anti	O
CD28	B-PRGE
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	O
CD2	B-PRGE
+	O
anti	O
CD28	B-PRGE
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

Biphasic	O
control	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
expressed	O
on	O
B	O
cells	O
.	O

The	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
following	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
by	O
mAb	O
L243	O
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

Using	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
activity	O
neutralizing	O
antibodies	O
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
upregulation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
found	O
to	O
depend	O
,	O
at	O
later	O
time	O
point	O
,	O
on	O
an	O
autocrine	O
effect	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secreted	O
following	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	O
of	O
HLA	O
-	O
DR	O
antigens	O
.	O

In	O
fact	O
,	O
mAb	O
L243	O
but	O
not	O
the	O
staphylococcal	O
superantigens	O
,	O
staphylococcal	O
exotoxin	O
toxic	B-PRGE
shock	I-PRGE
syndrome	I-PRGE
toxin	I-PRGE
-	I-PRGE
I	I-PRGE
or	O
staphylococcal	B-PRGE
enterotoxin	I-PRGE
B	I-PRGE
,	O
regulate	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
.	O

Comparison	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	B-PRGE
and	O
Stat6	B-PRGE
in	O
lymphoid	O
cells	O
and	O
mammary	O
epithelial	O
cells	O
.	O

Stat	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
and	O
Jak	O
(	O
Janus	O
kinases	O
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	O
and	O
epithelial	O
cells	O
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	O
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

Upon	O
ligand	O
binding	O
and	O
cytokine	O
receptor	O
dimerization	O
,	O
Stat	O
proteins	O
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	O
kinases	O
.	O

Activated	O
Stat	O
proteins	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O

Stat5	B-PRGE
and	O
Stat6	B-PRGE
are	O
transcription	O
factors	O
active	O
in	O
mammary	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O

Prolactin	B-PRGE
activates	O
Stat5	B-PRGE
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
activates	O
Stat6	B-PRGE
.	O

Both	O
cytokines	O
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

We	O
investigated	O
the	O
transactivation	O
potential	O
of	O
Stat6	B-PRGE
and	O
found	O
that	O
it	O
is	O
not	O
restricted	O
to	O
lymphocytes	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
dependent	O
activation	O
of	O
Stat6	B-PRGE
was	O
also	O
observed	O
in	O
HC11	O
mammary	O
epithelial	O
cells	O
.	O

In	O
these	O
cells	O
,	O
Stat6	B-PRGE
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
promoter	O
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	O
cells	O
.	O

The	O
glucocorticoid	B-PRGE
receptor	I-PRGE
was	O
able	O
to	O
further	O
enhance	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	B-PRGE
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
Stat6	B-PRGE
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-PRGE
.	O

The	O
potencies	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	B-PRGE
,	O
Stat6	B-PRGE
,	O
and	O
viral	O
protein	O
VP16	B-PRGE
were	O
compared	O
.	O

Stat6	B-PRGE
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10	O
-	O
fold	O
stronger	O
than	O
that	O
of	O
Stat5	B-PRGE
.	O

In	O
pre	O
-	O
B	O
cells	O
(	O
Ba	O
/	O
F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-PRGE
was	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

The	O
immediate	O
-	O
early	O
gene	O
product	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
regulates	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
promoter	O
through	O
noncanonical	O
Egr	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
.	O

Although	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	O
-	O
170	O
and	O
-	O
139	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
promoter	O
.	O

Both	O
Sp1	B-PRGE
and	O
Sp3	B-PRGE
bound	O
to	O
the	O
5	O
'	O
portion	O
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA	O
-	O
inducible	O
factor	O
(	O
PIF	O
)	O
mainly	O
bound	O
to	O
its	O
3	O
'	O
portion	O
and	O
bound	O
to	O
the	O
Sp	O
binding	O
motifs	O
as	O
well	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
induction	O
of	O
PIF	O
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	O
was	O
constitutively	O
activated	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
-	O
transformed	O
MT	O
-	O
2	O
cells	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	O
is	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
based	O
on	O
its	O
recognition	O
by	O
anti	O
-	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
DNA	O
binding	O
motif	O
differed	O
substantially	O
from	O
the	O
canonical	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
site	O
.	O

In	O
addition	O
,	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
bound	O
to	O
the	O
Sp	O
binding	O
site	O
.	O

In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	B-PRGE
and	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
Jurkat	O
cells	O
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	B-PRGE
and	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
promoter	O
activity	O
.	O

Anti	O
-	O
Ehrlichia	O
chaffeensis	O
antibody	O
complexed	O
with	O
E	O
.	O
chaffeensis	O
induces	O
potent	O
proinflammatory	O
cytokine	O
mRNA	O
expression	O
in	O
human	O
monocytes	O
through	O
sustained	O
reduction	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Ehrlichia	O
chaffeensis	O
is	O
an	O
obligatory	O
intracellular	O
bacterium	O
that	O
infects	O
monocytes	O
and	O
macrophages	O
and	O
is	O
the	O
etiologic	O
agent	O
of	O
human	O
ehrlichiosis	O
in	O
the	O
United	O
States	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
the	O
exposure	O
of	O
human	O
monocytes	O
to	O
E	O
.	O
chaffeensis	O
induces	O
the	O
expression	O
of	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
genes	O
in	O
vitro	O
but	O
not	O
the	O
expression	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNAs	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
anti	O
-	O
E	O
.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E	O
.	O
chaffeensis	O
on	O
the	O
expression	O
of	O
major	O
proinflammatory	O
cytokines	O
in	O
human	O
monocytes	O
was	O
examined	O
.	O

Human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
was	O
treated	O
with	O
E	O
.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti	O
-	O
E	O
.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	O
mRNAs	O
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Anti	O
-	O
E	O
.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E	O
.	O
chaffeensis	O
significantly	O
enhanced	O
mRNA	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
in	O
THP	O
-	O
1	O
cells	O
.	O

The	O
expression	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNAs	O
was	O
also	O
induced	O
.	O

The	O
levels	O
of	O
secreted	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg	O
/	O
ml	O
.	O

Fab	O
fragment	O
of	O
anti	O
-	O
E	O
.	O
chaffeensis	O
immunoglobulin	O
G	O
complexed	O
with	O
E	O
.	O
chaffeensis	O
did	O
not	O
induce	O
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
mRNA	O
expression	O
and	O
that	O
binding	O
of	O
the	O
immune	O
complex	O
to	O
the	O
Fc	B-PRGE
gamma	I-PRGE
receptor	I-PRGE
is	O
required	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
and	O
enhanced	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
mRNA	O
expression	O
.	O

Furthermore	O
,	O
prolonged	O
degradation	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
were	O
demonstrated	O
in	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
anti	O
-	O
E	O
.	O
chaffeensis	O
serum	O
and	O
E	O
.	O
chaffeensis	O
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti	O
-	O
E	O
.	O
chaffeensis	O
antibody	O
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	O
proinflammatory	O
cytokines	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

S	O
-	O
allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
T	O
cells	O
.	O

Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S	O
-	O
allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cells	O
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
H2O2	O
.	O

Activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P	O
-	O
labeled	O
probe	O
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
both	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
H2O2	O
.	O

Supershift	O
with	O
specific	O
antibodies	O
to	O
NF	O
-	O
kappa	O
B	O
subunits	O
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65	B-PRGE
-	O
p50	B-PRGE
heterodimer	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
.	O

Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood	O
-	O
derived	O
monocytes	O
and	O
macrophages	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
with	O
regard	O
to	O
expression	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O

No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	O
early	O
genes	O
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O

Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	O
levels	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
in	O
both	O
monocytes	O
and	O
in	O
macrophages	O
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

The	O
production	O
of	O
both	O
cytokines	O
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	O
.	O

In	O
macrophages	O
,	O
a	O
slight	O
enhancement	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
was	O
seen	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
was	O
not	O
detected	O
.	O

The	O
data	O
indicate	O
that	O
cellular	O
genes	O
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	O
gene	O
products	O
could	O
be	O
detected	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
beta	O
-	O
amyloid	O
peptides	O
and	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
murine	O
microglia	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid	O
-	O
beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	O
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
in	O
the	O
N9	O
murine	O
microglial	O
cell	O
line	O
.	O

Co	O
-	O
stimulation	O
of	O
microglia	O
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
and	O
100	O
U	O
/	O
ml	O
IFN	B-PRGE
gamma	I-PRGE
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
contains	O
both	O
RelA	B-PRGE
and	O
p50	B-PRGE
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
proteins	O
,	O
RelA	B-PRGE
and	O
p50	B-PRGE
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
plus	O
IFN	B-PRGE
gamma	I-PRGE
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
both	O
in	O
the	O
N9	O
microglial	O
cell	O
line	O
and	O
in	O
rat	O
primary	O
microglia	O
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF	O
-	O
kappa	O
B	O
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA	B-PRGE
/	O
p50	B-PRGE
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	O
B	O
-	O
dependent	O
genes	O
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B-PRGE
gamma	I-PRGE
,	O
or	O
by	O
LPS	O
.	O

AP	O
-	O
1	O
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV	O
-	O
I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	O
factors	O
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV	O
-	O
I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	O
lines	O
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	O
factors	O
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1	O
-	O
4	O
)	O
.	O

ATF	O
/	O
CREB	O
and	O
Sp	O
family	O
members	O
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA	O
-	O
protein	O
complexes	O
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA	O
-	O
protein	O
complex	O
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U	O
-	O
373	O
MG	O
glioblastoma	O
cell	O
line	O
or	O
the	O
THP	O
-	O
1	O
mature	O
monocytic	O
cell	O
line	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA	O
-	O
protein	O
complex	O
is	O
comprised	O
of	O
the	O
AP	O
-	O
1	O
components	O
,	O
Fos	O
and	O
Jun	O
.	O

Of	O
the	O
GATA	O
-	O
binding	O
proteins	O
,	O
only	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
selectively	O
regulates	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
promoter	O
in	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
producing	O
cells	O
which	O
express	O
multiple	O
GATA	O
-	O
binding	O
proteins	O
.	O

Interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
)	O
is	O
produced	O
by	O
T	O
lymphocytes	O
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	O
cells	O
.	O

Using	O
ATL	O
-	O
16T	O
cells	O
which	O
express	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
mRNA	O
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
promoter	O
,	O
that	O
regulates	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
transcription	O
.	O

This	O
cis	O
-	O
acting	O
sequence	O
contains	O
the	O
core	O
binding	O
motif	O
,	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
A	O
/	O
G	O
)	O
,	O
for	O
GATA	O
-	O
binding	O
family	O
proteins	O
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	B-PRGE
GATA	I-PRGE
-	I-PRGE
4	I-PRGE
(	O
hGATA	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
and	O
show	O
that	O
hGATA	B-PRGE
-	I-PRGE
4	I-PRGE
selectively	O
interacts	O
with	O
the	O
-	O
70	O
GATA	O
site	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
proximal	O
promoter	O
region	O
.	O

By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	O
regulatory	O
element	O
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
PMA	O
/	O
A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
activation	O
.	O

The	O
requirement	O
of	O
another	O
regulatory	O
element	O
called	O
CLE0	O
,	O
which	O
lies	O
downstream	O
of	O
the	O
-	O
70	O
GATA	O
site	O
,	O
was	O
also	O
demonstrated	O
.	O

ATL	O
-	O
16T	O
cells	O
express	O
mRNA	O
of	O
three	O
GATA	O
-	O
binding	O
proteins	O
,	O
hGATA	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
hGATA	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
hGATA	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	O
to	O
the	O
consensus	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
G	O
/	O
A	O
)	O
motif	O
.	O

However	O
,	O
using	O
ATL	O
-	O
16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
is	O
the	O
only	O
GATA	O
-	O
binding	O
protein	O
that	O
forms	O
specific	O
DNA	O
-	O
protein	O
complex	O
with	O
the	O
-	O
70	O
GATA	O
site	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA	O
-	O
binding	O
proteins	O
showed	O
that	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-	O
70	O
GATA	O
site	O
among	O
the	O
three	O
GATA	O
-	O
binding	O
proteins	O
.	O

When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
showed	O
the	O
highest	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA	O
-	O
binding	O
proteins	O
are	O
expressed	O
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O

BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
constitutively	O
expressed	O
in	O
B	O
cells	O
and	O
interacts	O
with	O
the	O
Oct1	B-PRGE
and	O
Oct2	B-PRGE
transcription	O
factors	O
.	O

Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
BOB	B-PRGE
.	I-PRGE
1	I-PRGE
/	O
OBF	B-PRGE
.	I-PRGE
1	I-PRGE
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O

Role	O
of	O
the	O
X2	O
box	O
in	O
activated	O
transcription	O
from	O
the	O
DRA	O
promoter	O
in	O
B	O
cells	O
.	O

We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	O
box	O
in	O
the	O
promoter	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
from	O
the	O
human	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
in	O
resting	O
and	O
activated	O
B	O
cells	O
.	O

NF	O
-	O
X2	O
,	O
which	O
contains	O
members	O
of	O
the	O
AP	O
-	O
1	O
/	O
ATF	O
/	O
CREB	O
families	O
of	O
transcription	O
factors	O
,	O
interacts	O
with	O
the	O
X2	O
box	O
(	O
5	O
'	O
-	O
TGCGTCA	O
-	O
3	O
'	O
)	O
from	O
positions	O
-	O
97	O
to	O
-	O
91	O
in	O
the	O
DRA	O
promoter	O
.	O

In	O
resting	O
Raji	O
cells	O
,	O
little	O
to	O
no	O
binding	O
to	O
the	O
X2	O
box	O
was	O
observed	O
.	O

In	O
sharp	O
contrast	O
,	O
in	O
B	O
cells	O
treated	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
containing	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
were	O
observed	O
.	O

As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild	O
-	O
type	O
DRA	O
promoter	O
but	O
not	O
from	O
a	O
DRA	O
promoter	O
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	O
box	O
.	O

Since	O
the	O
co	O
-	O
expression	O
with	O
a	O
dominant	O
negative	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	O
gene	O
depends	O
on	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
,	O
which	O
contains	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
.	O

Rescue	O
by	O
cytokines	O
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
of	O
human	O
antigen	O
-	O
specific	O
T	O
cell	O
clones	O
.	O

The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
-	O
induced	O
apoptosis	O
of	O
human	O
antigen	O
-	O
specific	O
T	O
helper	O
clones	O
with	O
different	O
cytokine	O
production	O
profiles	O
.	O

We	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
,	O
and	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
apoptosis	O
in	O
Th0	O
,	O
Th1	O
,	O
and	O
Th2	O
clones	O
.	O

We	O
also	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
protects	O
T	O
cell	O
clones	O
from	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	B-PRGE
,	O
Rb	B-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
proteins	O
.	O

In	O
contrast	O
,	O
IFN	O
-	O
alpha	O
/	O
beta	O
rescued	O
T	O
cell	O
clones	O
from	O
apoptosis	O
without	O
active	O
proliferation	O
,	O
and	O
expression	O
of	O
apoptosis	O
-	O
associated	O
proteins	O
tested	O
so	O
far	O
was	O
unaffected	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	O
cells	O
treated	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
contained	O
those	O
located	O
in	O
S	O
+	O
G2	O
/	O
M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	O
cells	O
treated	O
with	O
IFN	O
-	O
alpha	O
/	O
beta	O
were	O
located	O
in	O
G0	O
/	O
G1	O
phase	O
.	O

IFN	O
-	O
alpha	O
/	O
beta	O
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B-PRGE
transducers	I-PRGE
and	I-PRGE
activators	I-PRGE
of	I-PRGE
transcription	I-PRGE
(	I-PRGE
STAT	I-PRGE
)	I-PRGE
2	I-PRGE
protein	O
in	O
the	O
T	O
cell	O
clones	O
.	O

In	O
addition	O
,	O
over	O
-	O
expression	O
of	O
STAT2	B-PRGE
by	O
transfection	O
of	O
the	O
cDNA	O
prevented	O
apoptosis	O
of	O
the	O
T	O
cell	O
clones	O
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN	O
-	O
alpha	O
and	O
-	O
beta	O
mediate	O
anti	O
-	O
apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

Association	O
between	O
expression	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
integration	O
of	O
human	O
T	O
-	O
cell	O
-	O
leukemia	O
virus	O
type	O
1	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

It	O
is	O
known	O
that	O
the	O
expression	O
levels	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
in	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
cells	O
are	O
high	O
,	O
whereas	O
those	O
in	O
T	O
-	O
lymphoid	O
cells	O
are	O
not	O
.	O

In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNAs	O
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T	O
-	O
cell	O
-	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
provirus	O
were	O
done	O
.	O

The	O
levels	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
expression	O
of	O
ATL	O
cells	O
were	O
generally	O
higher	O
than	O
those	O
of	O
T	O
-	O
lymphoid	O
cells	O
.	O

However	O
,	O
ILT	O
-	O
mat	O
cells	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
although	O
they	O
were	O
ATL	O
cells	O
,	O
showed	O
rather	O
low	O
surface	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
expression	O
.	O

Southern	O
blot	O
hybridization	O
showed	O
that	O
only	O
two	O
and	O
four	O
bands	O
were	O
found	O
in	O
ILT	O
-	O
mat	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
respectively	O
,	O
whereas	O
>	O
10	O
bands	O
were	O
detected	O
in	O
other	O
ATL	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV	O
-	O
1	O
provirus	O
to	O
the	O
genome	O
of	O
T	O
cell	O
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
molecules	O
.	O

Transcription	O
factor	O
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
contains	O
a	O
nucleosome	O
-	O
free	O
region	O
encompassing	O
both	O
the	O
promoter	O
/	O
enhancer	O
region	O
and	O
a	O
large	O
region	O
(	O
255	O
nucleotides	O
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	O
factors	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
nt	O
465	O
to	O
720	O
)	O
:	O
three	O
AP	O
-	O
1	O
sites	O
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3	O
-	O
like	O
motif	O
(	O
AP3	O
-	O
L	O
)	O
,	O
a	O
downstream	O
binding	O
factor	O
(	O
DBF	O
)	O
site	O
,	O
and	O
juxtaposed	O
Sp1	B-PRGE
sites	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	O
site	O
is	O
an	O
interferon	O
-	O
responsive	O
factor	O
(	O
IRF	O
)	O
binding	O
site	O
and	O
that	O
the	O
AP3	O
-	O
L	O
motif	O
binds	O
the	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
NF	O
-	O
AT	O
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV	O
-	O
1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3	O
-	O
L	O
site	O
as	O
well	O
as	O
the	O
double	O
mutation	O
AP	O
-	O
1	O
(	O
III	O
)	O
/	O
AP3	O
-	O
L	O
did	O
not	O
affect	O
HIV	O
-	O
1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
virus	O
.	O

In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	B-PRGE
sites	O
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
(	O
III	O
)	O
,	O
AP3	O
-	O
L	O
,	O
and	O
DBF	O
sites	O
and	O
in	O
the	O
AP3	O
-	O
L	O
and	O
DBF	O
-	O
sites	O
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP	O
-	O
1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
and	O
AP3	O
-	O
L	O
sites	O
and	O
in	O
the	O
AP	O
-	O
1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3	O
-	O
L	O
,	O
and	O
DBF	O
sites	O
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

No	O
RNA	O
-	O
packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	O
genomic	O
RNA	O
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV	O
-	O
1	O
promoter	O
after	O
transient	O
transfection	O
of	O
the	O
HIV	O
-	O
1	O
provirus	O
DNA	O
or	O
of	O
long	O
terminal	O
repeat	O
-	O
luciferase	O
constructs	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

The	O
role	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
in	O
cytokine	O
gene	O
regulation	O
.	O

Transcription	O
factors	O
are	O
DNA	O
-	O
binding	O
proteins	O
that	O
regulate	O
gene	O
expression	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
critical	O
transcription	O
factor	O
for	O
maximal	O
expression	O
of	O
many	O
cytokines	O
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

Activation	O
and	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	O
proteins	O
(	O
I	O
kappa	O
B	O
)	O
that	O
sequester	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
of	O
immune	O
/	O
inflammatory	O
effector	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	O
kappa	O
B	O
.	O

Liberated	O
NF	O
-	O
kappa	O
B	O
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	O
promoter	O
sites	O
and	O
activates	O
gene	O
transcription	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Recently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
can	O
be	O
inhibited	O
in	O
vivo	O
by	O
treatment	O
with	O
antioxidants	O
,	O
corticosteroids	O
,	O
and	O
the	O
induction	O
of	O
endotoxin	O
tolerance	O
.	O

Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine	O
-	O
mediated	O
inflammatory	O
diseases	O
.	O

Role	O
of	O
ascorbate	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
T	O
-	O
cells	O
.	O

The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
Jurkat	O
T	O
-	O
cells	O
stimulated	O
by	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF	O
-	O
kappaB	O
to	O
DNA	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
Jurkat	O
cells	O
.	O

The	O
ability	O
of	O
ascorbate	O
to	O
enhance	O
cytoplasmic	O
inhibitory	O
IkBalpha	B-PRGE
protein	O
degradation	O
correlates	O
completely	O
with	O
its	O
capacity	O
to	O
induce	O
NF	O
-	O
kappaB	O
binding	O
to	O
DNA	O
and	O
to	O
potentiate	O
NF	O
-	O
kappaB	O
-	O
mediated	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
promoter	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
Jurkat	O
cells	O
but	O
not	O
in	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
ionomycin	O
.	O

AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	O
affect	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
provide	O
new	O
evidence	O
for	O
a	O
possible	O
relationship	O
between	O
the	O
activation	O
of	O
the	O
electron	O
-	O
transport	O
system	O
at	O
the	O
plasma	O
membrane	O
by	O
ascorbate	O
or	O
its	O
free	O
radical	O
and	O
redox	O
-	O
dependent	O
gene	O
transcription	O
in	O
T	O
-	O
cells	O
.	O

Pancreatic	O
islet	O
expression	O
studies	O
and	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
genes	O
encoding	O
hepatocyte	B-PRGE
nuclear	I-PRGE
factor	I-PRGE
-	I-PRGE
3alpha	I-PRGE
,	O
-	B-PRGE
3beta	I-PRGE
,	O
-	B-PRGE
3gamma	I-PRGE
,	O
-	B-PRGE
4gamma	I-PRGE
,	O
and	O
-	B-PRGE
6	I-PRGE
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	O
nuclear	O
factors	O
HNF	B-PRGE
-	I-PRGE
1alpha	I-PRGE
and	O
HNF	B-PRGE
-	I-PRGE
4alpha	I-PRGE
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta	O
-	O
cell	O
function	O
.	O

Mutations	O
in	O
these	O
liver	O
-	O
enriched	O
transcription	O
factors	O
result	O
in	O
two	O
forms	O
of	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
(	O
maturity	O
-	O
onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and	O
/	O
or	O
late	O
-	O
onset	O
type	O
2	O
diabetes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF	B-PRGE
-	I-PRGE
3alpha	I-PRGE
,	O
-	B-PRGE
3beta	I-PRGE
,	O
-	B-PRGE
3gamma	I-PRGE
,	O
-	B-PRGE
4gamma	I-PRGE
,	O
and	O
-	B-PRGE
6	I-PRGE
are	O
expressed	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	O
tandem	O
repeat	O
DNA	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
HNF	B-PRGE
-	I-PRGE
3alpha	I-PRGE
,	O
-	B-PRGE
3beta	I-PRGE
,	O
-	B-PRGE
3gamma	I-PRGE
,	O
-	B-PRGE
4gamma	I-PRGE
,	O
and	O
-	B-PRGE
6	I-PRGE
and	O
the	O
mapping	O
of	O
HNF	B-PRGE
-	I-PRGE
6	I-PRGE
to	O
chromosome	O
bands	O
15q21	O
.	O
1	O
-	O
21	O
.	O
2	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

RP1	B-PRGE
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
-	O
binding	O
EB1	O
-	O
like	O
gene	O
family	O
,	O
is	O
differentially	O
expressed	O
in	O
activated	O
T	O
cells	O
.	O

Cross	O
-	O
linking	O
of	O
the	O
CD3	O
and	O
CD28	B-PRGE
molecules	O
on	O
T	O
lymphocytes	O
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	O
lymphocyte	O
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	O
and	O
CD28	B-PRGE
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	B-PRGE
-	O
or	O
CD3	O
-	O
activated	O
or	O
resting	O
lymphocytes	O
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
of	O
the	O
cDNA	O
fragments	O
expressed	O
specifically	O
in	O
CD3	O
-	O
and	O
CD28	B-PRGE
-	O
activated	O
T	O
cells	O
was	O
designated	O
RP1	O
.	O

The	O
predictive	O
protein	O
-	O
coding	O
region	O
of	O
RP1	B-PRGE
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	B-PRGE
polyposis	I-PRGE
coli	I-PRGE
(	I-PRGE
APC	I-PRGE
)	I-PRGE
protein	I-PRGE
-	O
binding	O
EB1	B-PRGE
gene	O
family	O
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	O
RP1	B-PRGE
protein	O
revealed	O
specific	O
binding	O
to	O
wild	O
-	O
type	O
but	O
not	O
to	O
mutated	O
APC	B-PRGE
protein	O
.	O

The	O
rapid	O
up	O
-	O
regulation	O
of	O
RP1	B-PRGE
mRNA	O
in	O
properly	O
activated	O
T	O
cells	O
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate	O
/	O
early	O
gene	O
family	O
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	O
.	O

As	O
the	O
expression	O
level	O
of	O
the	O
RP1	B-PRGE
gene	O
in	O
activated	O
T	O
cells	O
and	O
a	O
spectrum	O
of	O
tumor	O
-	O
derived	O
cell	O
lines	O
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1	O
-	O
like	O
gene	O
family	O
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	O
cells	O
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	O
cells	O
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
was	O
examined	O
.	O

Stimulation	O
of	O
the	O
latently	O
HIV	O
-	O
infected	O
myelomonocytic	O
cell	O
line	O
OM	O
-	O
10	O
.	O
1	O
with	O
C	O
.	O
neoformans	O
and	O
C	O
.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio	O
-	O
dependent	O
increase	O
in	O
HIV	O
production	O
.	O

Induction	O
of	O
HIV	O
by	O
C	O
.	O
neoformans	O
was	O
enhanced	O
by	O
anti	O
-	O
capsular	O
antibody	O
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	O
.	O

In	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
HIV	O
plasmid	O
constructs	O
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
that	O
was	O
dependent	O
on	O
intact	O
NF	O
-	O
kappaB	O
binding	O
sequences	O
.	O

Thus	O
,	O
C	O
.	O
neoformans	O
and	O
C	O
.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
through	O
a	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
.	O

In	O
HIV	O
-	O
infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O

Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
protein	O
inhibits	O
bufalin	O
-	O
induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
in	O
human	O
leukemia	O
U937	O
cells	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan	O
'	O
su	O
,	O
caused	O
apoptosis	O
in	O
human	O
leukemia	O
U937	O
cells	O
by	O
anomalous	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	O
,	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
MAPK	B-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
U937	O
cells	O
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	O
cells	O
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
protein	O
.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	O
of	O
MAPK	B-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild	O
-	O
type	O
or	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
overexpressed	O
U937	O
cells	O
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	O
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Bufalin	O
treatment	O
activated	O
activator	O
protein	O
-	O
1	O
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
overexpressed	O
U937	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
acts	O
downstream	O
of	O
MAPK	B-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
but	O
upstream	O
of	O
MAPK	O
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	O
protein	O
-	O
1	O
may	O
be	O
down	O
-	O
regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	O
activity	O
by	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

A	O
shortened	O
life	O
span	O
of	O
EKLF	B-PRGE
-	O
/	O
-	O
adult	O
erythrocytes	O
,	O
due	O
to	O
a	O
deficiency	O
of	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
chains	O
,	O
is	O
ameliorated	O
by	O
human	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
chains	O
.	O

Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	B-PRGE
alleles	I-PRGE
in	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
were	O
inactivated	O
.	O

These	O
EKLF	B-PRGE
-	O
/	O
-	O
ES	O
cells	O
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

However	O
,	O
the	O
EKLF	B-PRGE
-	O
/	O
-	O
colonies	O
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	O
erythrocytes	O
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	O
globin	O
genes	O
were	O
appropriately	O
regulated	O
,	O
with	O
the	O
exception	O
of	O
beta	B-PRGE
h1	I-PRGE
-	I-PRGE
globin	I-PRGE
,	O
which	O
continued	O
to	O
be	O
expressed	O
at	O
a	O
very	O
low	O
level	O
.	O

The	O
ratio	O
of	O
adult	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
/	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
mRNA	O
in	O
the	O
mutant	O
ES	O
cells	O
was	O
1	O
/	O
15	O
of	O
that	O
in	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

When	O
the	O
EKLF	B-PRGE
-	O
/	O
-	O
cells	O
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	B-PRGE
phosphate	I-PRGE
isomerase	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
GPI	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
isozymes	O
and	O
hemoglobins	O
that	O
distinguish	O
ES	O
cell	O
-	O
derived	O
erythrocytes	O
from	O
host	O
blastocyst	O
-	O
derived	O
erythrocytes	O
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	O
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

This	O
indicated	O
that	O
the	O
EKLF	B-PRGE
-	O
/	O
-	O
erythrocytes	O
in	O
adult	O
animals	O
must	O
be	O
short	O
-	O
lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta	B-PRGE
-	I-PRGE
versus	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
chains	I-PRGE
,	O
leading	O
to	O
the	O
precipitation	O
of	O
excess	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
chains	O
to	O
form	O
Heinz	O
bodies	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF	B-PRGE
-	O
/	O
-	O
ES	O
cells	O
of	O
a	O
human	O
LCR	O
/	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
as	O
well	O
as	O
mature	O
erythrocytes	O
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

Induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
by	O
anti	O
-	O
HLA	O
class	O
I	O
monoclonal	O
antibodies	O
.	O

Monoclonal	O
antibodies	O
against	O
either	O
monomorphic	O
or	O
polymorphic	O
determinants	O
of	O
class	O
I	O
antigen	O
induced	O
in	O
PBMC	O
and	O
highly	O
purified	O
T	O
lymphocytes	O
the	O
nuclear	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
complexes	O
.	O

These	O
included	O
both	O
p50	B-PRGE
/	O
p50	B-PRGE
and	O
p50	B-PRGE
/	O
p65	B-PRGE
dimers	O
,	O
recognized	O
by	O
specific	O
antibodies	O
in	O
EMSA	O
.	O

The	O
induced	O
complexes	O
were	O
detectable	O
in	O
extracts	O
of	O
cells	O
incubated	O
with	O
anti	O
-	O
class	O
I	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
for	O
1	O
.	O
5	O
h	O
;	O
the	O
induction	O
was	O
maximal	O
at	O
5	O
h	O
,	O
persistent	O
at	O
16	O
h	O
and	O
no	O
longer	O
observed	O
at	O
40	O
h	O
.	O

The	O
mAb	O
failed	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
cells	O
incubated	O
in	O
the	O
presence	O
of	O
3	O
,	O
4	O
-	O
dichloroisocoumarin	O
,	O
an	O
inhibitor	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
degradation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	O
factors	O
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105	B-PRGE
/	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
in	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	O
promoters	O
during	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
controlled	O
cytokine	O
promoters	O
.	O

We	O
show	O
for	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
,	O
as	O
well	O
as	O
human	O
and	O
mouse	O
primary	O
T	O
lymphocytes	O
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	O
proteins	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
RelA	B-PRGE
/	O
p65	B-PRGE
and	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
/	O
p50	B-PRGE
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B-PRGE
remains	O
unaffected	O
.	O

CsA	O
does	O
not	O
interfere	O
with	O
the	O
synthesis	O
of	O
Rel	O
proteins	O
,	O
but	O
prevents	O
the	O
inducible	O
degradation	O
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
upon	O
T	O
cell	O
activation	O
.	O

CsA	O
neither	O
inhibits	O
the	O
processing	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
precursor	O
p105	B-PRGE
to	O
p50	B-PRGE
,	O
nor	O
does	O
it	O
"	O
stabilize	O
"	O
the	O
C	O
-	O
terminal	O
portion	O
of	O
p105	B-PRGE
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
gamma	I-PRGE
,	O
which	O
is	O
degraded	O
during	O
p105	B-PRGE
processing	O
to	O
mature	O
p50	B-PRGE
.	O

These	O
results	O
indicate	O
that	O
CsA	O
interferes	O
with	O
a	O
specific	O
event	O
in	O
the	O
signal	O
-	O
induced	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
,	O
but	O
does	O
not	O
affect	O
the	O
processing	O
of	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
/	O
p105	B-PRGE
to	O
p50	B-PRGE
.	O

EBF	B-PRGE
and	O
E47	B-PRGE
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
.	O

Early	B-PRGE
B	I-PRGE
cell	I-PRGE
factor	I-PRGE
(	O
EBF	B-PRGE
)	O
and	O
E47	B-PRGE
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	O
cDNAs	O
encoding	O
EBF	B-PRGE
or	O
a	O
covalent	O
homodimer	O
of	O
E47	B-PRGE
,	O
individually	O
or	O
together	O
,	O
into	O
immature	O
hematopoietic	O
Ba	O
/	O
F3	O
cells	O
,	O
which	O
lack	O
both	O
factors	O
.	O

In	O
combination	O
,	O
EBF	B-PRGE
and	O
E47	B-PRGE
induce	O
efficient	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
,	O
lambda5	B-PRGE
and	O
VpreB	B-PRGE
,	O
whereas	O
other	O
pre	O
-	O
B	O
cell	O
-	O
specific	O
genes	O
remain	O
silent	O
.	O

Multiple	O
functionally	O
important	O
EBF	B-PRGE
and	O
E47	B-PRGE
binding	O
sites	O
were	O
identified	O
in	O
the	O
lambda5	B-PRGE
promoter	O
/	O
enhancer	O
region	O
,	O
indicating	O
that	O
lambda5	B-PRGE
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	O
factors	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-PRGE
and	O
E47	B-PRGE
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	O
cell	O
lineage	O
.	O

Nuclear	O
levels	O
of	O
NF	O
-	O
kappaB	O
correlate	O
with	O
syncytium	O
-	O
forming	O
capacity	O
of	O
8e51	O
cells	O
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O

The	O
double	O
NF	O
-	O
kappaB	O
site	O
identified	O
in	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF	O
-	O
kappaB	O
subunits	O
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
8e51	O
T	O
-	O
cells	O
,	O
that	O
harbour	O
a	O
defective	O
HIV	O
-	O
1	O
.	O

At	O
least	O
four	O
different	O
specific	O
NF	O
-	O
kappaB	O
complexes	O
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	O
antibodies	O
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF	O
-	O
kappaB	O
family	O
members	O
,	O
with	O
the	O
transactivating	O
RelA	B-PRGE
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O

The	O
importance	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
complexes	O
with	O
syncytia	O
-	O
forming	O
activity	O
of	O
8e51	O
cells	O
.	O

In	O
fact	O
,	O
8e51	O
cells	O
that	O
had	O
almost	O
lost	O
their	O
syncytia	O
-	O
forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
complex	O
than	O
the	O
actively	O
fusing	O
cells	O
.	O

The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	O
factors	O
did	O
not	O
change	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
leukocyte	O
-	O
specific	O
pp52	B-PRGE
promoter	O
in	O
B	O
and	O
T	O
cells	O
.	O

The	O
leukocyte	O
-	O
specific	O
,	O
cytoskeleton	O
-	O
binding	O
pp52	B-PRGE
(	O
LSP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
WP	B-PRGE
-	I-PRGE
34	I-PRGE
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	O
and	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
macrophages	O
.	O

We	O
previously	O
detected	O
a	O
tissue	O
-	O
specific	O
promoter	O
preceding	O
the	O
exon	O
encoding	O
the	O
N	O
terminus	O
of	O
the	O
pp52	B-PRGE
leukocyte	I-PRGE
protein	I-PRGE
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	B-PRGE
promoter	O
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	O
'	O
terminus	O
of	O
pp52	B-PRGE
mRNA	O
,	O
tandem	O
pairs	O
of	O
Ets	O
and	O
SP1	O
motifs	O
,	O
and	O
a	O
lone	O
C	O
/	O
EBP	O
motif	O
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	O
with	O
these	O
motifs	O
in	O
B	O
cells	O
vs	O
T	O
cells	O
.	O

The	O
Ets	O
motifs	O
are	O
preferentially	O
bound	O
by	O
PU	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	O
family	O
member	O
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
C	O
/	O
EBP	O
motif	O
is	O
bound	O
by	O
Ig	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
1	I-PRGE
in	O
pre	O
-	O
B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6beta	I-PRGE
or	O
a	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6beta	I-PRGE
-	O
Ig	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
1	I-PRGE
heterodimer	O
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig	B-PRGE
/	I-PRGE
EBP	I-PRGE
-	I-PRGE
1	I-PRGE
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	O
.	O

These	O
findings	O
reveal	O
the	O
features	O
controlling	O
the	O
pp52	B-PRGE
promoter	O
in	O
B	O
and	O
T	O
cells	O
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	O
of	O
this	O
promoter	O
in	O
other	O
leukocyte	O
lineages	O
.	O

Transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
differentially	O
expressed	O
in	O
murine	O
Th1	O
and	O
Th2	O
cells	O
and	O
controls	O
Th2	O
-	O
specific	O
expression	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
.	O

Interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	B-PRGE
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	O
by	O
Th1	O
cells	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	B-PRGE
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1	O
-	O
and	O
Th2	O
-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
activation	O
in	O
EL	O
-	O
4	O
cells	O
,	O
which	O
express	O
both	O
Th1	O
-	O
and	O
Th2	O
-	O
type	O
cytokines	O
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
critical	O
for	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
site	O
abolished	O
antigen	O
-	O
or	O
cAMP	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
Th1	O
cells	O
or	O
in	O
a	O
non	O
-	O
lymphoid	O
,	O
non	O
-	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
producing	O
cell	O
line	O
activated	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	B-PRGE
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
Th1	O
cells	O
,	O
and	O
antigen	O
-	O
or	O
cAMP	O
-	O
activated	O
Th2	O
cells	O
(	O
but	O
not	O
Th1	O
cells	O
)	O
expressed	O
the	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
protein	O
.	O

Thus	O
,	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti	O
-	O
Tat	B-PRGE
single	O
-	O
chain	O
intrabodies	O
and	O
NF	O
-	O
kappa	O
B	O
antagonists	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	B-PRGE
,	O
an	O
early	O
regulatory	O
protein	O
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Tat	B-PRGE
also	O
superactivates	O
the	O
HIV	O
-	O
1	O
promoter	O
through	O
a	O
TAR	O
-	O
independent	O
mechanism	O
,	O
including	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
-	O
induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
inhibitors	O
of	O
Tat	B-PRGE
and	O
NF	O
-	O
kappa	O
B	O
cooperatively	O
down	O
-	O
regulate	O
this	O
Tat	B-PRGE
-	O
mediated	O
LTR	O
superactivation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go	O
-	O
6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti	O
-	O
Tat	B-PRGE
single	O
-	O
chain	O
intracellular	O
antibody	O
(	O
sFv	O
intrabody	O
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go	O
-	O
6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti	O
-	O
Tat	B-PRGE
sFv	O
intrabodies	O
and	O
the	O
two	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
alone	O
or	O
the	O
anti	O
-	O
Tat	B-PRGE
sFv	O
intrabodies	O
alone	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	O
cells	O
and	O
prolong	O
clinical	O
benefit	O
.	O

Transcription	O
factors	O
in	O
immune	O
-	O
mediated	O
disease	O
.	O

A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	O
proteins	O
regulating	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
has	O
emerged	O
recently	O
.	O

Several	O
small	O
molecules	O
,	O
an	O
antisense	O
oligonucleotide	O
,	O
and	O
gene	O
therapeutic	O
agents	O
that	O
inhibit	O
NF	O
-	O
kappa	O
b	O
activation	O
have	O
been	O
described	O
.	O

Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O

In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	O
factors	O
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4	B-PRGE
+	O
T	O
cell	O
subsets	O
is	O
at	O
a	O
very	O
early	O
stage	O
.	O

Three	O
interacting	O
proteins	O
have	O
recently	O
been	O
shown	O
to	O
contribute	O
to	O
subset	O
-	O
restricted	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
.	O

There	O
are	O
other	O
elements	O
regulating	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

CholecystokininB	B-PRGE
receptor	I-PRGE
from	O
human	O
Jurkat	O
lymphoblastic	O
T	O
cells	O
is	O
involved	O
in	O
activator	O
protein	O
-	O
1	O
-	O
responsive	O
gene	O
activation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	O
(	B-PRGE
CCK	I-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
)	I-PRGE
receptor	I-PRGE
in	O
human	O
lymphoblastic	O
Jurkat	O
T	O
cells	O
.	O

We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	O
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	O
gene	O
strategy	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
with	O
the	O
reporter	O
plasmid	O
p	O
[	O
(	O
TRE	O
)	O
3	O
-	O
tk	O
-	O
Luc	O
]	O
and	O
found	O
that	O
CCK	O
-	O
8	O
was	O
able	O
to	O
dose	O
-	O
dependently	O
induce	O
luciferase	B-PRGE
expression	O
related	O
to	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP	O
-	O
1	O
complex	O
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

The	O
involvement	O
of	O
the	O
CCK	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
receptor	I-PRGE
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
receptor	I-PRGE
antagonist	O
PD	O
-	O
135	O
,	O
158	O
.	O

This	O
effect	O
was	O
confirmed	O
in	O
COS	O
-	O
7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
receptor	I-PRGE
cloned	O
from	O
Jurkat	O
T	O
cells	O
.	O

To	O
better	O
understand	O
the	O
AP	O
-	O
1	O
-	O
dependent	O
luciferase	B-PRGE
expression	O
in	O
Jurkat	O
T	O
cells	O
,	O
we	O
tested	O
two	O
specific	O
inhibitors	O
of	O
serine	B-PRGE
/	I-PRGE
threonine	I-PRGE
phosphatases	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
-	B-PRGE
2A	I-PRGE
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O

These	O
compounds	O
strongly	O
increased	O
the	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
response	O
,	O
whereas	O
we	O
have	O
not	O
observed	O
a	O
contribution	O
of	O
phosphatase	O
inhibitors	O
on	O
a	O
CCK	O
-	O
8	O
-	O
induced	O
luciferase	B-PRGE
activity	O
.	O

To	O
confirm	O
that	O
CCK	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
receptors	I-PRGE
are	O
involved	O
in	O
AP	O
-	O
1	O
response	O
,	O
we	O
investigated	O
the	O
CCK	O
-	O
8	O
effect	O
on	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
,	O
a	O
natural	O
endogenous	O
gene	O
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP	O
-	O
1	O
.	O

In	O
Jurkat	O
T	O
cells	O
activated	O
by	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
and	O
phytohemagglutinin	B-PRGE
,	O
CCK	O
-	O
8	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

This	O
induction	O
was	O
abolished	O
by	O
PD	O
-	O
135	O
,	O
158	O
.	O

Our	O
results	O
indicate	O
that	O
CCK	O
-	O
8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	O
T	O
cells	O
through	O
stimulation	O
of	O
CCK	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
receptors	I-PRGE
by	O
modulation	O
of	O
expression	O
of	O
AP	O
-	O
1	O
-	O
regulated	O
genes	O
.	O

Epstein	O
-	O
Barr	O
virus	O
binding	O
to	O
CD21	B-PRGE
activates	O
the	O
initial	O
viral	O
promoter	O
via	O
NF	O
-	O
kappaB	O
induction	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	O
human	O
B	O
lymphocytes	O
via	O
CD21	B-PRGE
,	O
the	O
CR2	B-PRGE
complement	O
receptor	O
.	O

Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	O
B	O
cells	O
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	B-PRGE
on	O
purified	O
resting	O
human	O
B	O
cells	O
rapidly	O
activates	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	O
latent	O
gene	O
promoter	O
.	O

Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	O
neutrophils	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA	O
-	O
binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
p50	B-PRGE
/	O
RelA	B-PRGE
,	O
is	O
induced	O
in	O
phagocytosing	O
neutrophils	O
.	O

Under	O
these	O
conditions	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10	O
-	O
15	O
min	O
,	O
and	O
returning	O
to	O
near	O
-	O
basal	O
levels	O
by	O
30	O
min	O
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	O
B	O
-	O
responsive	O
genes	O
is	O
enhanced	O
in	O
phagocytosing	O
neutrophils	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
neutrophils	O
.	O

Surfactant	B-PRGE
protein	I-PRGE
A	I-PRGE
activates	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Because	O
surfactant	O
protein	O
(	O
SP	O
)	O
A	O
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
as	O
well	O
as	O
surface	O
proteins	O
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP	O
-	O
A	O
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP	O
-	O
A	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
THP	O
-	O
1	O
cells	O
by	O
SP	O
-	O
A	O
doses	O
as	O
low	O
as	O
1	O
microgram	O
/	O
ml	O
occurred	O
within	O
30	O
min	O
of	O
SP	O
-	O
A	O
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O

This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O

Moreover	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
blocked	O
SP	O
-	O
A	O
-	O
dependent	O
increases	O
in	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
levels	O
.	O

These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP	O
-	O
A	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP	O
-	O
A	O
induced	O
inflammation	O
in	O
the	O
lung	O
.	O

alpha	O
-	O
Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
B	O
mobilization	O
.	O

The	O
adherence	O
of	O
monocytes	O
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha	O
-	O
tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
.	O

Endothelial	O
cells	O
were	O
treated	O
with	O
TCP	O
,	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha	O
-	O
tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
or	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
.	O

Cytokine	O
-	O
stimulated	O
cell	O
surface	O
expression	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
CD106	B-PRGE
)	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
(	O
ELAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
CD62E	B-PRGE
)	O
,	O
but	O
not	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
CD54	B-PRGE
)	O
,	O
was	O
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
by	O
TCP	O
succinate	O
but	O
not	O
by	O
TCP	O
or	O
TCP	O
acetate	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF	O
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+	O
/	O
-	O
28	O
to	O
12	O
+	O
/	O
-	O
4	O
channels	O
and	O
from	O
225	O
+	O
/	O
-	O
38	O
to	O
79	O
+	O
/	O
-	O
21	O
channels	O
,	O
respectively	O
.	O

Succinate	O
alone	O
had	O
no	O
effect	O
.	O

Decreased	O
adhesion	O
molecule	O
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	O
TCP	O
(	O
200	O
microM	O
,	O
72	O
h	O
)	O
,	O
reduced	O
U	O
-	O
937	O
cell	O
adhesion	O
to	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
(	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
HUVEC	O
by	O
30	O
%	O
(	O
P	O
<	O
0	O
.	O
025	O
)	O
and	O
to	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
-	O
stimulated	O
HUVEC	O
by	O
56	O
%	O
(	O
P	O
<	O
0	O
.	O
010	O
)	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
of	O
HUVEC	O
nuclear	O
proteins	O
revealed	O
a	O
decrease	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
stimulated	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	O
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
endothelial	O
cells	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O

Distinct	O
mechanisms	O
for	O
N	O
-	O
acetylcysteine	O
inhibition	O
of	O
cytokine	O
-	O
induced	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
-	O
characterized	O
,	O
thiol	O
-	O
containing	O
antioxidant	O
,	O
on	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
(	O
EC	O
)	O
.	O

NAC	O
inhibited	O
interleukin	O
-	O
1	O
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
-	O
induced	O
,	O
but	O
not	O
basal	O
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O

Monocytic	O
cell	O
adhesion	O
to	O
EC	O
in	O
response	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha	B-PRGE
-	I-PRGE
thrombin	I-PRGE
,	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O

Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
NAC	O
inhibited	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
-	O
induced	O
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
both	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

NAC	O
had	O
no	O
effect	O
on	O
the	O
half	O
-	O
life	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
or	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
.	O

Although	O
NAC	O
reduced	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
in	O
EC	O
as	O
measured	O
by	O
gel	O
-	O
shift	O
assays	O
using	O
an	O
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
of	O
the	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
(	O
VCAM	O
-	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
site	O
of	O
the	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
gene	O
(	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
-	O
NF	O
-	O
kappa	O
B	O
)	O
was	O
used	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
has	O
been	O
reported	O
to	O
be	O
redox	O
sensitive	O
,	O
we	O
studied	O
the	O
effects	O
of	O
NAC	O
on	O
the	O
EC	O
redox	O
environment	O
.	O

NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
whereas	O
the	O
binding	O
affinity	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
VCAM	O
-	O
NF	O
-	O
kappa	O
B	O
oligomer	O
peaked	O
at	O
a	O
GSH	O
-	O
to	O
-	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
ratio	O
of	O
approximately	O
200	O
and	O
decreased	O
at	O
higher	O
ratios	O
,	O
the	O
binding	O
to	O
the	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
-	O
NF	O
-	O
kappa	O
B	O
oligomer	O
appeared	O
relatively	O
unaffected	O
even	O
at	O
ratios	O
>	O
400	O
,	O
i	O
.	O
e	O
.	O
,	O
those	O
achieved	O
in	O
EC	O
treated	O
with	O
40	O
mM	O
NAC	O
.	O

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
its	O
consensus	O
sequences	O
in	O
the	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
gene	O
exhibits	O
marked	O
differences	O
in	O
redox	O
sensitivity	O
,	O
allowing	O
for	O
differential	O
gene	O
expression	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
.	O

Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH	O
-	O
to	O
-	O
GSSG	O
ratio	O
within	O
the	O
EC	O
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist	O
-	O
induced	O
monocyte	O
adhesion	O
to	O
EC	O
.	O

Human	O
monocyte	O
binding	O
to	O
fibronectin	B-PRGE
enhances	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
early	O
signaling	O
events	O
.	O

Leukocyte	O
integrins	O
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O

This	O
integrin	O
-	O
mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O

Moreover	O
,	O
integrin	O
-	O
ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
intracellular	O
signaling	O
pathways	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
triggers	O
a	O
well	O
-	O
defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	B-PRGE
or	O
arginine	O
-	O
glycine	O
-	O
aspartate	O
(	O
RGD	O
)	O
-	O
coated	O
substrata	O
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix	O
-	O
adherent	O
cells	O
.	O

Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	B-PRGE
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	O
in	O
steady	O
state	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
mRNA	O
for	O
the	O
high	B-PRGE
affinity	I-PRGE
Fc	I-PRGE
gammaRI	I-PRGE
receptor	I-PRGE
.	O

By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	O
was	O
associated	O
with	O
a	O
5	O
-	O
to	O
10	O
-	O
fold	O
increase	O
in	O
the	O
STAT1	B-PRGE
-	O
containing	O
DNA	O
-	O
binding	O
complex	O
that	O
binds	O
to	O
Fc	O
gammaRI	O
promoter	O
elements	O
.	O

Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-PRGE
and	O
the	O
tyrosine	O
kinases	O
JAK1	B-PRGE
and	O
JAK2	B-PRGE
was	O
enhanced	O
significantly	O
in	O
RGD	O
-	O
adherent	O
monocytes	O
compared	O
with	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	O
-	O
mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	O
-	O
induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O

The	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
domain	O
of	O
CD36	B-PRGE
is	O
required	O
for	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
binding	O
of	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	O
-	O
macrophages	O
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

The	O
integral	O
membrane	O
glycoprotein	O
CD36	B-PRGE
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte	O
-	O
macrophages	O
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B-PRGE
-	O
Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O

To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	B-PRGE
transfected	O
Chinese	O
hampster	O
ovary	O
(	O
CHO	O
)	O
cells	O
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF	O
-	O
kappaB	O
sequence	O
following	O
activation	O
of	O
CD36	B-PRGE
-	O
producing	O
CHO	O
cells	O
with	O
the	O
proinflammatory	O
cytokine	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	B-PRGE
transfected	O
cells	O
with	O
the	O
human	O
CD36	B-PRGE
-	O
specific	O
antibody	O
OKM5	O
.	O

We	O
also	O
determined	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
required	O
an	O
intact	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
segment	O
on	O
CD36	B-PRGE
.	O

Our	O
results	O
support	O
the	O
idea	O
that	O
human	O
CD36	B-PRGE
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O

Transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

The	O
coordinated	O
production	O
of	O
all	O
blood	O
cells	O
from	O
a	O
common	O
stem	O
cell	O
is	O
a	O
highly	O
regulated	O
process	O
involving	O
successive	O
stages	O
of	O
commitment	O
and	O
differentiation	O
.	O

From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	O
factor	O
genes	O
and	O
from	O
the	O
characterizations	O
of	O
chromosome	O
breakpoints	O
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	O
factors	O
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O

During	O
myelopoiesis	O
,	O
which	O
includes	O
the	O
development	O
of	O
granulocytic	O
and	O
monocytic	O
lineages	O
,	O
transcription	O
factors	O
from	O
several	O
families	O
are	O
active	O
,	O
including	O
AML1	B-PRGE
/	O
CBF	B-PRGE
beta	I-PRGE
,	O
C	O
/	O
EBP	O
,	O
Ets	O
,	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
,	O
HOX	O
,	O
and	O
MZF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Few	O
of	O
these	O
factors	O
are	O
expressed	O
exclusively	O
in	O
myeloid	O
cells	O
;	O
instead	O
it	O
appears	O
that	O
they	O
cooperatively	O
regulate	O
transcription	O
of	O
myeloid	O
-	O
specific	O
genes	O
.	O

Here	O
we	O
discuss	O
recent	O
advances	O
in	O
transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
role	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Rel	O
/	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
consists	O
of	O
multiple	O
polypeptide	O
subunits	O
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein	O
-	O
protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	O
factor	O
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
role	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary	O
-	O
butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

1	O
.	O

In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O

2	O
.	O

Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene	O
-	O
contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O

For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	O
a	O
history	O
of	O
exposure	O
to	O
MTBE	O
or	O
benzene	O
.	O

3	O
.	O

Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O

4	O
.	O

When	O
apoptotic	O
lymphocytes	O
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	O
lymphocytes	O
from	O
the	O
control	O
group	O
,	O
statistically	O
-	O
significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
8	O
and	O
12	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80	O
.	O
5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
Test	O
)	O
.	O

MTBE	O
and	O
benzene	O
-	O
induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O

Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	O
from	O
chemically	O
-	O
exposed	O
individuals	O
,	O
between	O
20	O
-	O
50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S	O
-	O
G2	O
/	O
M	O
boundaries	O
.	O

5	O
.	O

One	O
of	O
the	O
signaling	O
molecules	O
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	O
factor	O
Kappa	O
-	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

NF	O
-	O
kappa	O
B	O
was	O
examined	O
as	O
one	O
of	O
the	O
many	O
molecular	O
mechanisms	O
for	O
mediating	O
cell	O
death	O
by	O
MTBE	O
and	O
benzene	O
.	O

Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	O
of	O
the	O
chemically	O
-	O
exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O

This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	O
molecule	O
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O

Activation	O
of	O
a	O
novel	O
gene	O
in	O
3q21	O
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
in	O
leukemia	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
,	O
GR6	B-PRGE
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	O
,	O
that	O
is	O
normally	O
expressed	O
in	O
early	O
fetal	O
development	O
but	O
not	O
in	O
adult	O
peripheral	O
blood	O
.	O

GR6	B-PRGE
is	O
activated	O
in	O
the	O
UCSD	O
-	O
AML1	O
cell	O
line	O
and	O
in	O
a	O
leukemic	O
sample	O
,	O
both	O
of	O
which	O
carry	O
a	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
.	O

In	O
UCSD	O
-	O
AML1	O
,	O
we	O
have	O
also	O
identified	O
fusion	O
transcripts	O
between	O
the	O
ecotropic	B-PRGE
viral	I-PRGE
insertion	I-PRGE
site	I-PRGE
I	I-PRGE
(	O
EVI1	B-PRGE
)	O
gene	O
in	O
3q26	O
and	O
GR6	B-PRGE
and	O
between	O
EVI1	B-PRGE
and	O
Ribophorin	B-PRGE
I	I-PRGE
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	B-PRGE
in	O
3q21	O
.	O

All	O
fusions	O
splice	O
the	O
5	O
'	O
ends	O
of	O
the	O
3q21	O
genes	O
into	O
exon	O
2	O
of	O
the	O
EVI1	B-PRGE
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1	B-PRGE
-	O
EVI1	B-PRGE
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	O
(	O
3	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
12	O
)	O
,	O
in	O
which	O
acute	B-PRGE
myelogenous	I-PRGE
leukemia	I-PRGE
1	I-PRGE
-	O
EVI1	B-PRGE
fusions	O
and	O
ETV6	B-PRGE
-	O
EVI1	B-PRGE
fusions	O
,	O
respectively	O
,	O
occur	O
.	O

The	O
Ribophorin	B-PRGE
I	I-PRGE
-	O
EVI1	B-PRGE
fusion	O
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	O
(	O
3	O
;	O
3	O
)	O
.	O

Alcohol	O
-	O
induced	O
regulation	O
of	O
nuclear	O
regulatory	O
factor	O
-	O
kappa	O
beta	O
in	O
human	O
monocytes	O
.	O

Acute	O
ethanol	O
exposure	O
has	O
the	O
capacity	O
to	O
modulate	O
immune	O
functions	O
,	O
particularly	O
,	O
to	O
down	O
regulate	O
monocyte	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O

Considering	O
that	O
nuclear	O
regulatory	O
factor	O
-	O
kappa	O
beta	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/	O
Rel	O
is	O
a	O
common	O
regulatory	O
element	O
of	O
the	O
promoter	O
region	O
of	O
the	O
inflammatory	O
cytokine	O
genes	O
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
monocytes	O
.	O

Adherence	O
-	O
isolated	O
monocytes	O
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
monocytes	O
with	O
a	O
preferential	O
induction	O
of	O
the	O
inhibitory	O
,	O
p50	B-PRGE
/	O
p50	B-PRGE
,	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
homodimer	O
,	O
and	O
resulted	O
in	O
no	O
induction	O
of	O
the	O
p65	B-PRGE
/	O
p50	B-PRGE
heterodimer	O
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65	B-PRGE
/	O
p50	B-PRGE
heterodimer	O
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

Thus	O
,	O
such	O
unique	O
activation	O
of	O
the	O
inhibitory	O
p50	B-PRGE
/	O
p50	B-PRGE
homodimer	O
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
inflammatory	O
cytokine	O
genes	O
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
by	O
disrupting	O
NF	O
-	O
kappa	O
B	O
signaling	O
in	O
monocytes	O
.	O

Four	O
P	O
-	O
like	O
elements	O
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein	O
-	O
1	O
family	O
proteins	O
.	O

We	O
previously	O
identified	O
the	O
P	O
sequence	O
as	O
a	O
critical	O
regulatory	O
element	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

In	O
the	O
mouse	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	O
sequence	O
designated	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
P	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P	O
-	O
like	O
elements	O
and	O
their	O
binding	O
factors	O
in	O
the	O
native	O
promoter	O
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Transfection	O
of	O
EL	O
-	O
4	O
cells	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
-	O
reporter	O
constructs	O
carrying	O
mutated	O
P	O
-	O
like	O
elements	O
showed	O
that	O
four	O
P	O
-	O
like	O
elements	O
,	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
but	O
not	O
P3	O
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	O
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	O
or	O
P2	O
proved	O
to	O
contain	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
proteins	O
as	O
major	O
components	O
.	O

Activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
family	O
proteins	O
interacted	O
with	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
.	O

NFAT	O
/	O
AP	O
-	O
1	O
complex	O
formed	O
only	O
with	O
P	O
and	O
P2	O
.	O

Cross	O
-	O
competition	O
assays	O
among	O
the	O
P	O
-	O
like	O
elements	O
revealed	O
element	O
-	O
specific	O
and	O
common	O
complexes	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	O
element	O
linked	O
to	O
the	O
SV40	O
promoter	O
responded	O
to	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O

It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P	O
-	O
like	O
element	O
-	O
binding	O
complexes	O
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

The	O
ability	O
of	O
BHRF1	B-PRGE
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus	O
-	O
infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	B-PRGE
,	O
an	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
early	O
-	O
lytic	O
-	O
cycle	O
protein	O
with	O
distant	O
homology	O
to	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
as	O
an	O
anti	O
-	O
apoptosis	O
protein	O
.	O

Expression	O
of	O
BHRF1	B-PRGE
in	O
MCF	O
-	O
Fas	O
cells	O
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti	O
-	O
Fas	B-PRGE
antibody	O
and	O
TNF	O
-	O
mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	B-PRGE
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
ability	O
of	O
BHRF1	B-PRGE
to	O
protect	O
MCF	O
-	O
Fas	O
cells	O
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-PRGE
resembled	O
that	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
as	O
it	O
inhibited	O
TNF	O
-	O
and	O
anti	O
-	O
Fas	B-PRGE
-	O
induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-PRGE
phospholipase	I-PRGE
A2	I-PRGE
and	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
/	O
CPP32	B-PRGE
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
like	O
transcription	O
factors	O
.	O

A	O
putative	O
function	O
of	O
BHRF1	B-PRGE
in	O
EBV	O
-	O
infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus	O
-	O
infected	O
cells	O
from	O
TNF	O
-	O
and	O
/	O
or	O
anti	O
-	O
Fas	B-PRGE
-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B-PRGE
nor	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
a	O
B	O
-	O
cell	O
line	O
,	O
BJAB	O
,	O
protected	O
the	O
cells	O
from	O
anti	O
-	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum	O
-	O
starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	B-PRGE
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

NF	O
-	O
AT	O
activation	O
induced	O
by	O
a	O
CAML	B-PRGE
-	O
interacting	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
.	O

Activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcription	O
factor	O
(	O
NF	O
-	O
AT	O
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O

The	O
CAML	B-PRGE
(	O
calcium	B-PRGE
-	I-PRGE
modulator	I-PRGE
and	I-PRGE
cyclophilin	I-PRGE
ligand	I-PRGE
)	O
protein	O
is	O
a	O
coinducer	O
of	O
NF	O
-	O
AT	O
activation	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B-PRGE
.	O

Cross	O
-	O
linking	O
of	O
this	O
lymphocyte	O
-	O
specific	O
protein	O
,	O
designated	O
TACI	B-PRGE
(	O
transmembrane	B-PRGE
activator	I-PRGE
and	I-PRGE
CAML	I-PRGE
-	I-PRGE
interactor	I-PRGE
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	O
Jurkat	O
cells	O
with	O
TACI	B-PRGE
-	O
specific	O
antibodies	O
led	O
to	O
activation	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
AT	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFkappaB	O
.	O

TACI	B-PRGE
-	O
induced	O
activation	O
of	O
NF	O
-	O
AT	O
was	O
specifically	O
blocked	O
by	O
a	O
dominant	O
-	O
negative	O
CAML	B-PRGE
mutant	O
,	O
thus	O
implicating	O
CAML	B-PRGE
as	O
a	O
signaling	O
intermediate	O
.	O

The	O
DNA	O
binding	O
domain	O
of	O
the	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
transcription	O
factor	O
is	O
responsible	O
for	O
its	O
B	O
cell	O
-	O
specific	O
activity	O
and	O
binds	O
to	O
a	O
B	O
cell	O
110	O
-	O
kDa	O
nuclear	O
protein	O
.	O

Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
transcription	O
factor	O
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	O
B	O
cell	O
proliferation	O
and	O
/	O
or	O
differentiation	O
.	O

Furthermore	O
,	O
it	O
is	O
highly	O
expressed	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
and	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
and	O
its	O
regulation	O
in	O
several	O
human	O
lymphoid	O
cell	O
lines	O
using	O
co	O
-	O
transfection	O
assays	O
and	O
show	O
that	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	O
cell	O
lines	O
studied	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

In	O
particular	O
the	O
best	O
responder	O
cell	O
line	O
was	O
the	O
Burkitt	O
'	O
s	O
cell	O
line	O
Namalwa	O
.	O

The	O
activity	O
of	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
in	O
B	O
and	O
not	O
T	O
cells	O
was	O
observed	O
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c	B-PRGE
-	I-PRGE
MYC	I-PRGE
promoter	O
was	O
used	O
as	O
a	O
reporter	O
.	O

Furthermore	O
,	O
the	O
functional	O
domains	O
responsible	O
for	O
DNA	O
binding	O
,	O
transactivation	O
,	O
and	O
negative	O
regulation	O
,	O
previously	O
characterized	O
in	O
a	O
fibroblast	O
context	O
,	O
were	O
found	O
to	O
have	O
similar	O
activity	O
in	O
B	O
cells	O
.	O

The	O
region	O
of	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
responsible	O
for	O
the	O
B	O
cell	O
specific	O
activity	O
was	O
defined	O
to	O
be	O
the	O
N	O
-	O
terminal	O
218	O
amino	O
acids	O
containing	O
the	O
DNA	O
binding	O
domain	O
.	O

Finally	O
,	O
a	O
110	O
-	O
kDa	O
protein	O
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	O
,	O
but	O
not	O
T	O
,	O
cell	O
lines	O
that	O
specifically	O
binds	O
to	O
this	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
N	O
-	O
terminal	O
domain	O
.	O

We	O
hypothesize	O
that	O
this	O
110	O
-	O
kDa	O
protein	O
may	O
be	O
a	O
functionally	O
important	O
B	O
cell	O
-	O
specific	O
co	O
-	O
activator	O
of	O
A	B-PRGE
-	I-PRGE
MYB	I-PRGE
.	O

Evidence	O
that	O
calcineurin	O
is	O
rate	O
-	O
limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O

Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O

In	O
vitro	O
,	O
CsA	O
inhibits	O
lymphocyte	O
gene	O
activation	O
by	O
inhibiting	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
(	O
CN	O
)	O
.	O

In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50	O
-	O
75	O
%	O
of	O
CN	O
activity	O
in	O
circulating	O
leukocytes	O
.	O

We	O
modeled	O
this	O
degree	O
of	O
CN	O
inhibition	O
in	O
primary	O
human	O
leukocytes	O
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	O
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O

In	O
CsA	O
-	O
treated	O
leukocytes	O
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	O
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
proteins	O
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	O
reporter	O
gene	O
construct	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
accumulation	O
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
CN	O
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
proliferation	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
in	O
the	O
allogeneic	O
mixed	O
lymphocyte	O
cultures	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	O
activity	O
is	O
rate	O
-	O
limiting	O
for	O
the	O
activation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Thus	O
,	O
the	O
reduction	O
of	O
CN	O
activity	O
observed	O
in	O
CsA	O
-	O
treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
gene	O
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O

Cooperation	O
of	O
binding	O
sites	O
for	O
STAT6	B-PRGE
and	O
NF	O
kappa	O
B	O
/	O
rel	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
up	O
-	O
regulation	O
of	O
the	O
human	O
IgE	B-PRGE
germline	O
promoter	O
.	O

Ig	O
heavy	O
chain	O
class	O
switching	O
is	O
directed	O
by	O
cytokines	O
inducing	O
transcription	O
from	O
unrearranged	O
CH	O
genes	O
.	O

Subsequently	O
,	O
such	O
primed	O
cells	O
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O

In	O
the	O
case	O
of	O
IgE	O
class	O
switching	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
activates	O
the	O
IgE	O
germline	O
promoter	O
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	O
factor	O
STAT6	B-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4STAT	I-PRGE
)	O
with	O
a	O
responsive	O
DNA	O
element	O
in	O
the	O
proximal	O
region	O
of	O
the	O
promoter	O
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis	O
-	O
acting	O
elements	O
that	O
interact	O
with	O
members	O
of	O
the	O
NF	O
kappa	O
B	O
/	O
rel	O
transcription	O
factor	O
family	O
in	O
an	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
independent	O
fashion	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	O
complex	O
formed	O
on	O
the	O
upstream	O
site	O
(	O
NF	B-PRGE
kappa	I-PRGE
B1	I-PRGE
)	O
contains	O
the	O
classical	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimer	O
.	O

The	O
complex	O
on	O
the	O
proximal	O
site	O
(	O
NF	B-PRGE
kappa	I-PRGE
B2	I-PRGE
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	B-PRGE
and	O
relB	B-PRGE
.	O

IgE	O
germline	O
promoter	O
reporter	O
gene	O
constructs	O
carrying	O
point	O
mutations	O
in	O
the	O
NF	B-PRGE
kappa	I-PRGE
B2	I-PRGE
site	O
were	O
largely	O
unresponsive	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	B-PRGE
kappa	I-PRGE
B1	I-PRGE
site	O
responded	O
to	O
cytokine	O
stimulation	O
better	O
than	O
the	O
wild	O
-	O
type	O
promoter	O
.	O

The	O
NF	B-PRGE
kappa	I-PRGE
B2	I-PRGE
effect	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
STAT6	B-PRGE
binding	O
site	O
,	O
demonstrating	O
that	O
the	O
NF	B-PRGE
kappa	I-PRGE
B2	I-PRGE
motif	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
mediating	O
cytokine	O
up	O
-	O
regulation	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	O
kappa	O
B	O
/	O
rel	O
binding	O
site	O
and	O
the	O
STAT6	B-PRGE
response	O
element	O
conferred	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inducibility	O
to	O
a	O
heterologous	O
minimal	O
promoter	O
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	O
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	B-PRGE
kappa	I-PRGE
B2	I-PRGE
nucleoprotein	O
complex	O
may	O
cooperate	O
with	O
DNA	O
-	O
bound	O
STAT6	B-PRGE
to	O
achieve	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
dependent	O
activation	O
of	O
the	O
human	O
IgE	O
germline	O
gene	O
.	O

Dual	O
effects	O
of	O
LPS	O
antibodies	O
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS	O
-	O
induced	O
proinflammatory	O
functions	O
.	O

Human	O
phagocytes	O
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	O
CD14	B-PRGE
(	O
mCD14	B-PRGE
)	O
,	O
a	O
proinflammatory	O
LPS	O
receptor	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti	O
-	O
LPS	O
Abs	O
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	B-PRGE
.	O

Ab	O
-	O
associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC	O
-	O
LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	O
CD14	B-PRGE
-	O
transfected	O
Chinese	O
hamster	O
ovary	O
fibroblasts	O
(	O
CHO	O
-	O
CD14	B-PRGE
cells	O
)	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

LPS	O
core	O
-	O
and	O
O	O
-	O
side	O
chain	O
-	O
specific	O
mAbs	O
inhibited	O
mCD14	B-PRGE
-	O
mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

O	O
-	O
side	O
chain	O
-	O
specific	O
mAb	O
concurrently	O
enhanced	O
complement	O
-	O
dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	B-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
CR1	B-PRGE
)	O
and	O
uptake	O
by	O
CHO	O
-	O
CD14	B-PRGE
cells	O
involving	O
another	O
heat	O
-	O
labile	O
serum	O
factor	O
(	O
s	O
)	O
and	O
cell	O
-	O
associated	O
recognition	O
molecule	O
(	O
s	O
)	O
.	O

Core	O
-	O
specific	O
mAb	O
inhibited	O
mCD14	B-PRGE
-	O
mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non	O
-	O
mCD14	B-PRGE
-	O
mediated	O
LPS	O
uptake	O
.	O

The	O
modulation	O
by	O
anti	O
-	O
LPS	O
mAbs	O
of	O
mCD14	B-PRGE
-	O
mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS	O
-	O
induced	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
translocation	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
in	O
CHO	O
-	O
CD14	B-PRGE
cells	O
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non	O
-	O
mCD14	B-PRGE
-	O
mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

LPS	O
-	O
specific	O
Abs	O
thus	O
mediate	O
anti	O
-	O
inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	B-PRGE
and	O
augmenting	O
uptake	O
through	O
CR1	B-PRGE
or	O
other	O
cell	O
receptors	O
.	O

Human	O
neutrophils	O
express	O
GH	B-PRGE
-	I-PRGE
N	I-PRGE
gene	O
transcripts	O
and	O
the	O
pituitary	O
transcription	O
factor	O
Pit	B-PRGE
-	I-PRGE
1b	I-PRGE
.	O

Since	O
GH	B-PRGE
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	B-PRGE
in	O
granulocyte	O
subsets	O
.	O

By	O
immunocytochemistry	O
,	O
25	O
+	O
/	O
-	O
7	O
%	O
of	O
the	O
human	O
neutrophils	O
were	O
shown	O
to	O
express	O
immunoreactive	O
GH	B-PRGE
,	O
whereas	O
eosinophils	O
were	O
negative	O
.	O

Reversed	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
analysis	O
demonstrated	O
GH	B-PRGE
mRNA	O
in	O
neutrophils	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	O
the	O
GH	B-PRGE
-	I-PRGE
N	I-PRGE
gene	O
but	O
not	O
the	O
GH	B-PRGE
-	I-PRGE
V	I-PRGE
gene	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	O
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	O
transcription	O
factor	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
designated	O
Pit	B-PRGE
-	I-PRGE
1b	I-PRGE
.	O

Interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
upregulates	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
gene	O
expression	O
in	O
activated	O
human	O
T	O
lymphocytes	O
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein	O
-	O
1	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
the	O
stromal	O
-	O
derived	O
cytokine	O
interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
)	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
gene	O
regulation	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Production	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
requires	O
the	O
formation	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
gene	O
regulation	O
.	O

T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
/	O
CD3	O
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
,	O
whereas	O
the	O
CD28	O
responsive	O
complex	O
(	O
CD28RC	O
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	B-PRGE
signal	O
.	O

Costimulation	O
of	O
phytohemagglutinin	B-PRGE
/	O
anti	O
-	O
CD28	B-PRGE
activated	O
T	O
lymphocytes	O
with	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
induces	O
a	O
fivefold	O
enhanced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mRNA	O
accumulation	O
and	O
a	O
2	O
.	O
5	O
-	O
fold	O
enhanced	O
protein	O
secretion	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
gene	O
transcription	O
rate	O
is	O
increased	O
3	O
.	O
4	O
-	O
fold	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
is	O
in	O
part	O
mediated	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	O
(	O
60	O
%	O
)	O
and	O
AP	O
-	O
1	O
(	O
120	O
%	O
)	O
,	O
without	O
affecting	O
the	O
activities	O
of	O
NFkappaB	O
and	O
CD28RC	O
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O

We	O
also	O
show	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
induced	O
enhancement	O
of	O
the	O
AP	O
-	O
1	O
-	O
DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A	O
-	O
sensitive	O
.	O

Since	O
AP	O
-	O
1	O
is	O
part	O
of	O
the	O
NFAT	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
signaling	O
pathway	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
fos	B-PRGE
and	O
jun	B-PRGE
proteins	O
of	O
which	O
AP	O
-	O
1	O
consists	O
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester	O
-	O
inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin	O
-	O
2	O
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	O
kinase	O
C	O
activity	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
PKC	O
-	O
mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	O
rat	O
peritoneal	O
neutrophils	O
and	O
human	O
Jurkat	O
T	O
cells	O
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30	O
-	O
50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	O
activator	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	O
-	O
independent	O
mechanism	O
.	O

The	O
NH2Cl	O
-	O
treated	O
neutrophils	O
showed	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
PMA	O
-	O
induced	O
phosphorylation	O
of	O
a	O
47	O
-	O
kDa	O
protein	O
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	O
factor	O
of	O
NADPH	O
oxidase	O
,	O
p47	B-PRGE
(	I-PRGE
phox	I-PRGE
)	I-PRGE
.	O

Jurkat	O
T	O
cells	O
pretreated	O
with	O
NH2Cl	O
(	O
20	O
-	O
70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
following	O
PMA	O
stimulation	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
nuclear	O
transcription	O
factor	O
-	O
kappaB	O
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	O
-	O
mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	O
activity	O
.	O

HIV	O
-	O
1	O
Vpr	B-PRGE
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
[	O
see	O
comments	O
]	O

The	O
HIV	O
-	O
1	O
accessory	O
gene	O
product	O
Vpr	B-PRGE
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	B-PRGE
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B-PRGE
modulates	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	O
-	O
mediated	O
activation	O
,	O
Vpr	B-PRGE
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B-PRGE
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	B-PRGE
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
via	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Further	O
,	O
Vpr	B-PRGE
suppresses	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	O
-	O
12	O
,	O
TNF	B-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
all	O
of	O
which	O
are	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
.	O

The	O
effects	O
of	O
Vpr	B-PRGE
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	B-PRGE
can	O
regulate	O
NF	O
-	O
kappa	O
B	O
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B-PRGE
.	O

The	O
tax	B-PRGE
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
platelet	B-PRGE
-	I-PRGE
derived	I-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
B	I-PRGE
promoter	O
through	O
interactions	O
with	O
the	O
zinc	O
finger	O
transcription	O
factors	O
Sp1	B-PRGE
and	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Transcriptional	O
up	O
-	O
regulation	O
of	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
platelet	B-PRGE
-	I-PRGE
derived	I-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
B	I-PRGE
(	O
PDGF	B-PRGE
-	I-PRGE
B	I-PRGE
)	O
proto	O
-	O
oncogene	O
by	O
the	O
Tax	B-PRGE
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
PDGF	B-PRGE
-	I-PRGE
B	I-PRGE
promoter	O
,	O
Tax	B-PRGE
-	O
responsive	O
element	O
1	O
(	O
TRE1	O
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	B-PRGE
.	O

We	O
also	O
identified	O
Sp1	B-PRGE
,	O
Sp3	B-PRGE
,	O
and	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
as	O
the	O
primary	O
nuclear	O
transcription	O
factors	O
binding	O
to	O
TRE1	O
which	O
mediate	O
Tax	B-PRGE
responsiveness	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	B-PRGE
transactivates	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
PDGF	B-PRGE
-	I-PRGE
B	I-PRGE
proto	O
-	O
oncogene	O
.	O

In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	B-PRGE
was	O
able	O
to	O
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
a	O
template	O
containing	O
the	O
-	O
257	O
to	O
+	O
74	O
region	O
of	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
PDGF	B-PRGE
-	I-PRGE
B	I-PRGE
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	B-PRGE
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	B-PRGE
and	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
using	O
a	O
TRE1	O
probe	O
.	O

Analysis	O
of	O
Tax	B-PRGE
mutants	O
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	O
and	O
IEXL320G	O
,	O
were	O
unable	O
to	O
significantly	O
transactivate	O
the	O
c	B-PRGE
-	I-PRGE
sis	I-PRGE
/	O
PDGF	B-PRGE
-	I-PRGE
B	I-PRGE
promoter	O
.	O

Finally	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	B-PRGE
is	O
able	O
to	O
stably	O
bind	O
to	O
both	O
Sp1	B-PRGE
and	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Interestingly	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B-PRGE
mutant	O
IEXC29S	O
is	O
unable	O
to	O
interact	O
with	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
whereas	O
Tax	B-PRGE
mutant	O
IEXL320G	O
is	O
able	O
to	O
interact	O
with	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Induction	O
of	O
endothelial	O
cell	O
surface	O
adhesion	O
molecules	O
by	O
tumor	O
necrosis	O
factor	O
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTPase	O
)	O
inhibitors	O
can	O
down	O
-	O
modulate	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
in	O
ML	O
-	O
1a	O
,	O
a	O
monocytic	O
cell	O
line	O
(	O
Singh	O
and	O
Aggarwal	O
,	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
1995	O
:	O
270	O
:	O
10631	O
)	O
.	O

Since	O
TNF	O
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	O
molecules	O
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
examined	O
the	O
effect	O
of	O
PTPase	O
inhibitors	O
on	O
the	O
TNF	O
-	O
mediated	O
induction	O
of	O
intracellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	I-PRGE
ICAM	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	I-PRGE
VCAM	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
endothelial	B-PRGE
leukocyte	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	I-PRGE
ELAM	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Like	O
ML	O
-	O
1a	O
,	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
MVEC	O
)	O
treated	O
with	O
TNF	O
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF	O
-	O
kappa	O
B	O
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co	O
-	O
treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	O
.	O

The	O
induction	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
ELAM	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
TNF	O
in	O
MVEC	O
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down	O
-	O
regulated	O
by	O
PAO	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

PAO	O
was	O
found	O
to	O
be	O
effective	O
even	O
when	O
added	O
3	O
h	O
after	O
TNF	O
,	O
suggesting	O
a	O
rapid	O
mode	O
of	O
action	O
of	O
this	O
inhibitor	O
.	O

Besides	O
PAO	O
,	O
other	O
inhibitors	O
of	O
PTPase	O
,	O
including	O
pervanadate	O
and	O
diamide	O
,	O
also	O
blocked	O
TNF	O
-	O
dependent	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
induction	O
of	O
all	O
the	O
three	O
adhesion	O
proteins	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	O
was	O
also	O
blocked	O
by	O
the	O
PTPase	O
inhibitors	O
.	O

Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	O
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
by	O
TNF	O
.	O

Because	O
of	O
their	O
role	O
in	O
cell	O
adhesion	O
,	O
PTPase	O
may	O
provide	O
a	O
novel	O
target	O
of	O
drug	O
development	O
for	O
treatment	O
of	O
inflammation	O
,	O
atherogenesis	O
,	O
and	O
tumor	O
metastasis	O
.	O

The	O
spatial	O
distribution	O
of	O
human	O
immunoglobulin	O
genes	O
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O

The	O
three	O
-	O
dimensional	O
positioning	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
within	O
the	O
nucleus	O
of	O
human	O
cells	O
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

The	O
visualization	O
of	O
heavy	O
and	O
light	O
chain	O
genes	O
in	O
B	O
-	O
lymphoid	O
cells	O
showed	O
that	O
the	O
three	O
Ig	O
genes	O
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	O
genes	O
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	O
and	O
lambda	O
genes	O
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	O
genes	O
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	O
genes	O
.	O

The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	O
cell	O
types	O
.	O

Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
cannot	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	O
.	O

Transcriptional	O
activation	O
of	O
the	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
T	O
lymphocytes	O
expressing	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-PRGE
protein	O
.	O

Recruitment	O
and	O
extravasation	O
of	O
T	O
cells	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
are	O
favored	O
by	O
adhesion	O
molecule	O
-	O
mediated	O
interactions	O
of	O
circulating	O
T	O
cells	O
with	O
endothelial	O
cells	O
.	O

Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV	O
-	O
1	O
-	O
infected	O
T	O
lymphocytes	O
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	O
molecules	O
expressed	O
by	O
HTLV	O
-	O
1	O
-	O
transformed	O
T	O
cells	O
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
[	O
CD106	B-PRGE
]	O
)	O
,	O
a	O
110	O
-	O
kDa	O
member	O
of	O
the	O
immunoglobulin	O
gene	O
superfamily	O
,	O
first	O
identified	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
inflammatory	O
cytokines	O
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	O
cells	O
obtained	O
from	O
one	O
patient	O
with	O
HTLV	O
-	O
1	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	O
T	O
cells	O
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O

The	O
role	O
of	O
the	O
viral	O
trans	O
-	O
activator	O
Tax	B-PRGE
protein	O
in	O
the	O
induction	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	O
molecule	O
on	O
Jurkat	O
T	O
-	O
cell	O
clones	O
stably	O
expressing	O
the	O
tax	B-PRGE
gene	O
.	O

The	O
effect	O
of	O
Tax	B-PRGE
on	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX	O
-	O
9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	B-PRGE
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
performed	O
with	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
constructs	O
revealed	O
that	O
Tax	B-PRGE
was	O
trans	O
activating	O
the	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
via	O
two	O
NF	O
-	O
kappaB	O
sites	O
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
promoter	O
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B-PRGE
-	O
induced	O
expression	O
of	O
this	O
adhesion	O
molecule	O
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF	O
-	O
kappaB	O
motifs	O
,	O
confirming	O
that	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
induced	O
on	O
Tax	B-PRGE
-	O
expressing	O
cells	O
in	O
a	O
kappaB	O
-	O
dependent	O
manner	O
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	B-PRGE
-	O
induced	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
on	O
T	O
cells	O
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV	O
-	O
1	O
-	O
associated	O
diseases	O
.	O

Blockade	O
of	O
T	O
-	O
cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF	O
-	O
kappaB	O
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	O
which	O
are	O
induced	O
during	O
T	O
-	O
cell	O
activation	O
.	O

This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
transactivating	O
functions	O
and	O
expression	O
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
-	O
driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF	O
-	O
kappaB	O
,	O
and	O
NFAT	O
DNA	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3	O
-	O
T	O
-	O
cell	O
receptor	O
complex	O
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP	O
-	O
1	O
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-PRGE
and	O
NFATc	O
family	O
members	O
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B-PRGE
and	O
mRNA	O
induction	O
of	O
NFATc	O
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B-PRGE
and	O
NFATc	O
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	O
T	O
cells	O
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	O
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	O
factor	O
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
NH2	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	B-PRGE
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	O
and	O
NF	O
-	O
KB	O
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Suppression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
CD18	B-PRGE
-	O
mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
is	O
mediated	O
by	O
the	O
CD18	B-PRGE
antigen	O
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
.	O

METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron	O
/	O
ml	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
.	O

Dexamethasone	O
was	O
added	O
1	O
hour	O
before	O
TNFalpha	B-PRGE
stimulation	O
in	O
the	O
dexamethasone	O
group	O
.	O

After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti	O
-	O
CD18	B-PRGE
antibody	O
.	O

The	O
culture	O
plate	O
was	O
settled	O
for	O
15	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
and	O
then	O
neutrophils	O
were	O
activated	O
by	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
for	O
5	O
minutes	O
.	O

Nonadherent	O
neutrophils	O
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

The	O
intracellular	O
localization	O
of	O
NFkappaB	O
after	O
TNFalpha	B-PRGE
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti	O
-	O
p65	B-PRGE
antibody	O
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	B-PRGE
(	O
451	O
.	O
4	O
+	O
/	O
-	O
45	O
.	O
4	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156	O
.	O
7	O
+	O
/	O
-	O
27	O
.	O
3	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti	O
-	O
CD18	B-PRGE
antibody	O
(	O
157	O
.	O
6	O
+	O
/	O
-	O
25	O
.	O
1	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-	O
7	O
)	O
M	O
dexamethasone	O
(	O
207	O
.	O
9	O
+	O
/	O
-	O
31	O
.	O
5	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	O
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	B-PRGE
caused	O
NFkappaB	O
to	O
translocate	O
into	O
the	O
nucleus	O
.	O

Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	O
translocation	O
into	O
the	O
nucleus	O
.	O

CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	B-PRGE
expressed	O
on	O
activated	O
leukocytes	O
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	O
entry	O
into	O
the	O
nucleus	O
.	O

Helenalin	O
,	O
an	O
anti	O
-	O
inflammatory	O
sesquiterpene	O
lactone	O
from	O
Arnica	O
,	O
selectively	O
inhibits	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
[	O
see	O
comments	O
]	O

Alcoholic	O
extracts	O
prepared	O
form	O
Arnicae	O
flos	O
,	O
the	O
collective	O
name	O
for	O
flowerheads	O
from	O
Arnica	O
montana	O
and	O
A	O
.	O
chamissonis	O
ssp	O
.	O
foliosa	O
,	O
are	O
used	O
therapeutically	O
as	O
anti	O
-	O
inflammatory	O
remedies	O
.	O

The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O

While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti	O
-	O
inflammatory	O
effect	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13	O
-	O
dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti	O
-	O
inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O

NF	O
-	O
kappaB	O
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	O
complex	O
in	O
unstimulated	O
cells	O
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	O
subunit	O
,	O
IkappaB	O
.	O

Helenalin	O
inhibits	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T	O
-	O
cells	O
,	O
B	O
-	O
cells	O
and	O
epithelial	O
cells	O
and	O
abrogates	O
kappaB	O
-	O
driven	O
gene	O
expression	O
.	O

This	O
inhibition	O
is	O
selective	O
,	O
as	O
the	O
activity	O
of	O
four	O
other	O
transcription	O
factors	O
,	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
TBP	B-PRGE
,	O
Sp1	B-PRGE
and	O
STAT	O
5	O
was	O
not	O
affected	O
.	O

We	O
show	O
that	O
inhibition	O
is	O
not	O
due	O
to	O
a	O
direct	O
modification	O
of	O
the	O
active	O
NF	O
-	O
kappaB	O
heterodimer	O
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF	O
-	O
kappaB	O
/	O
IkappaB	O
complex	O
,	O
preventing	O
the	O
release	O
of	O
IkappaB	O
.	O

These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	B-PRGE
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
group	O
of	O
transcription	O
factors	O
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	O
cells	O
.	O

NFAT	O
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

This	O
process	O
requires	O
calcium	O
-	O
dependent	O
dephosphorylation	O
of	O
NFAT	O
caused	O
by	O
the	O
phosphatase	O
calcineurin	O
.	O

The	O
c	O
-	O
Jun	O
amino	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
phosphorylates	O
NFAT4	B-PRGE
on	O
two	O
sites	O
.	O

Mutational	O
removal	O
of	O
the	O
JNK	O
phosphorylation	O
sites	O
caused	O
constitutive	O
nuclear	O
localization	O
of	O
NFAT4	B-PRGE
.	O

In	O
contrast	O
,	O
JNK	O
activation	O
in	O
calcineurin	O
-	O
stimulated	O
cells	O
caused	O
nuclear	O
exclusion	O
of	O
NFAT4	B-PRGE
.	O

These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	O
of	O
NFAT4	B-PRGE
promoted	O
by	O
calcineurin	O
is	O
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

Hypoxia	O
enhances	O
induction	O
of	O
endothelial	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	O
.	O

Intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O

Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	O
expression	O
of	O
endothelial	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Human	O
endothelial	O
cells	O
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	O
of	O
added	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
examined	O
for	O
expression	O
of	O
functional	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+	O
/	O
-	O
0	O
.	O
4	O
-	O
fold	O
over	O
normoxia	O
)	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti	O
-	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
antibodies	O
or	O
antisense	O
oligonucleotides	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10	O
-	O
fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	O
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	O
-	O
dependent	O
cytoplasmic	O
-	O
to	O
-	O
nuclear	O
localization	O
of	O
the	O
nuclear	O
transcription	O
factor	O
-	O
kappa	O
B	O
p65	B-PRGE
(	O
Rel	B-PRGE
A	I-PRGE
)	O
subunit	O
.	O

Such	O
proteasome	O
activation	O
correlated	O
with	O
hypoxia	O
-	O
evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome	O
-	O
dependent	O
stimulus	O
for	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
.	O

Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	O
human	O
myeloid	O
-	O
selective	O
CCAAT	B-PRGE
/	I-PRGE
enhancer	I-PRGE
binding	I-PRGE
protein	I-PRGE
gene	O
(	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
)	O
.	O

Human	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT	B-PRGE
/	I-PRGE
enhancer	I-PRGE
binding	I-PRGE
protein	I-PRGE
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

Our	O
studies	O
showed	O
that	O
levels	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
were	O
markedly	O
increased	O
in	O
NB4	O
cells	O
(	O
promyelocytic	O
leukemia	O
line	O
)	O
,	O
because	O
they	O
were	O
induced	O
by	O
9	O
-	O
cis	O
retinoic	O
acid	O
(	O
9	O
-	O
cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

Accumulation	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	O
cells	O
to	O
9	O
-	O
cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5	O
.	O
1	O
-	O
fold	O
.	O

Dose	O
-	O
response	O
studies	O
showed	O
that	O
10	O
(	O
-	O
7	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
9	O
-	O
cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
;	O
but	O
even	O
10	O
(	O
-	O
10	O
)	O
mol	O
/	O
L	O
9	O
-	O
cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

NB4	O
cells	O
pulse	O
-	O
exposed	O
(	O
30	O
minutes	O
)	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	O
effect	O
on	O
base	O
levels	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
and	O
did	O
not	O
induce	O
differentiation	O
.	O

Macrophage	O
-	O
differentiation	O
of	O
NB4	O
reduced	O
levels	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
.	O

Nuclear	O
run	O
-	O
off	O
assays	O
and	O
half	O
-	O
life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
by	O
9	O
-	O
cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O

Furthermore	O
,	O
this	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	O
factors	O
because	O
9	O
-	O
cis	O
RA	O
induced	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
protein	O
in	O
NB4	O
cells	O
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
in	O
9	O
-	O
cis	O
RA	O
-	O
mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO	O
-	O
induced	O
differentiation	O
of	O
HL	O
-	O
60	O
cells	O
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
levels	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	O
promyelocytes	O
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

This	O
induction	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
mRNA	O
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	O
factors	O
.	O

We	O
suspect	O
that	O
the	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
epsilon	I-PRGE
promoter	O
/	O
enhancer	O
contains	O
a	O
retinoic	O
acid	O
-	O
response	O
element	O
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

Regulation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
its	O
inhibitor	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
/	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
monocytes	O
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

Blood	O
monocytes	O
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
.	O

Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV	O
-	O
1	O
in	O
vitro	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	O
to	O
production	O
of	O
cytokines	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	O
during	O
active	O
tuberculosis	O
and	O
by	O
M	O
.	O
tuberculosis	O
.	O

We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
the	O
major	O
cytoplasmic	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
with	O
tuberculosis	O
.	O

In	O
contrast	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O

Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
activated	O
in	O
monocytes	O
from	O
tuberculous	O
patients	O
.	O

The	O
expression	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
was	O
up	O
-	O
regulated	O
in	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O

By	O
contrast	O
,	O
the	O
expression	O
of	O
other	O
adherence	O
-	O
associated	O
early	O
genes	O
,	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
PBMC	O
of	O
tuberculous	O
patients	O
.	O

Further	O
,	O
M	O
.	O
tuberculosis	O
and	O
its	O
tuberculin	B-PRGE
,	O
purified	O
protein	O
derivative	O
,	O
induced	O
the	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
the	O
expression	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
monocytes	O
.	O

Expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
correlates	O
with	O
IFN	O
-	O
alpha	O
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	O
and	O
p53	B-PRGE
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN	O
-	O
alpha	O
2c	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
p53	B-PRGE
and	O
the	O
hybrid	O
bcr	O
/	O
abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	O
-	O
fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	O
-	O
alpha	O
therapy	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0	O
.	O
6895	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-	O
0	O
.	O
568	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr	O
/	O
abl	O
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
and	O
p53	B-PRGE
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	O
-	O
alpha	O
is	O
accompanied	O
by	O
upregulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
downregulation	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	O
cDNA	O
encoding	O
transcription	O
factor	O
NFATc	B-PRGE
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
family	O
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	O
and	O
immunoregulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full	O
-	O
length	O
cDNA	O
encoding	O
murine	B-PRGE
(	I-PRGE
m	I-PRGE
)	I-PRGE
NFATc	I-PRGE
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	O
structural	O
motifs	O
of	O
NFAT	O
family	O
members	O
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	O
homology	O
domain	O
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

mNFATc	B-PRGE
complexed	O
with	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
bound	O
specifically	O
to	O
the	O
murine	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
NFAT	O
recognition	O
sequence	O
and	O
activated	O
transcription	O
from	O
the	O
co	O
-	O
transfected	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	O
probe	O
hybridized	O
with	O
a	O
4	O
.	O
5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	O
T	O
cells	O
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	B-PRGE
transcript	O
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	B-PRGE
transcript	O
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B-PRGE
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O

Phosphatidylinositol	O
3	O
-	O
kinase	O
couples	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
to	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
.	O

Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
in	O
T	O
cells	O
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O

Phosphatidyl	O
inositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
is	O
activated	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	O
are	O
not	O
known	O
.	O

Here	O
we	O
identify	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
as	O
an	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
target	O
in	O
T	O
lymphocytes	O
and	O
PI3K	O
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

We	O
eliminate	O
both	O
Stat5	B-PRGE
and	O
Raf	O
/	O
MEK	O
pathways	O
from	O
E2F	O
regulation	O
.	O

Protein	B-PRGE
kinase	I-PRGE
B	I-PRGE
(	O
PKB	B-PRGE
)	O
is	O
activated	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
via	O
PI3K	O
.	O

The	O
expression	O
of	O
an	O
active	O
PKB	B-PRGE
is	O
sufficient	O
to	O
induce	O
E2F	O
activity	O
.	O

Inhibition	O
of	O
PI3K	O
inhibits	O
phosphorylation	O
of	O
Rb	B-PRGE
,	O
induction	O
of	O
cyclin	O
D3	O
,	O
and	O
degradation	O
of	O
p27kip1	B-PRGE
.	O

These	O
results	O
establish	O
a	O
crucial	O
PI3K	O
/	O
PKB	B-PRGE
-	O
mediated	O
link	O
between	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
teceptor	O
and	O
the	O
cell	O
cycle	O
machinery	O
.	O

Thiol	O
modulation	O
inhibits	O
the	O
interleukin	O
(	O
IL	O
)	O
-	O
1	O
-	O
mediated	O
activation	O
of	O
an	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
-	O
associated	O
protein	O
kinase	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
type	I-PRGE
I	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
)	O
is	O
associated	O
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	O
system	O
by	O
which	O
IL	O
-	O
1	O
exerts	O
its	O
various	O
signals	O
.	O

The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor	O
-	O
associated	O
protein	O
kinase	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al	O
.	O
,	O
Eur	O
.	O
J	O
.	O
Immunol	O
.	O
1994	O
.	O
24	O
:	O
1566	O
)	O
.	O

IL	O
-	O
1	O
signaling	O
is	O
commonly	O
accompanied	O
by	O
oxidative	O
processes	O
and	O
is	O
thought	O
to	O
be	O
subject	O
to	O
redox	O
regulation	O
.	O

We	O
therefore	O
investigated	O
whether	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
-	O
associated	O
protein	O
kinase	O
could	O
be	O
a	O
target	O
for	O
redox	O
regulation	O
and	O
whether	O
an	O
altered	O
activity	O
of	O
the	O
kinase	O
could	O
influence	O
IL	O
-	O
1	O
-	O
mediated	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

A	O
murine	O
T	O
cell	O
line	O
,	O
EL4	O
,	O
was	O
stimulated	O
with	O
IL	O
-	O
1	O
with	O
and	O
without	O
pretreatment	O
with	O
different	O
compounds	O
known	O
to	O
influence	O
the	O
cellular	O
redox	O
status	O
.	O

Thiol	O
modifying	O
agents	O
like	O
diamide	O
,	O
menadione	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
diethyl	O
dithiocarbamate	O
or	O
phenylarsine	O
oxide	O
inhibited	O
the	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
-	O
associated	O
protein	O
kinase	O
.	O

N	O
-	O
Acetylcysteine	O
,	O
alpha	O
,	O
alpha	O
'	O
-	O
dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O

The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O

The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
-	O
associated	O
kinase	O
similarly	O
impaired	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
EL4	O
cells	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
complex	O
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1RI	I-PRGE
-	O
associated	O
protein	O
kinase	O
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL	O
-	O
1	O
signaling	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

ATF1	B-PRGE
and	O
CREB	O
trans	O
-	O
activate	O
a	O
cell	O
cycle	O
regulated	O
histone	B-PRGE
H4	I-PRGE
gene	O
at	O
a	O
distal	O
nuclear	O
matrix	O
associated	O
promoter	O
element	O
.	O

Proteins	O
of	O
the	O
ATF	O
/	O
CREB	O
class	O
of	O
transcription	O
factors	O
stimulate	O
gene	O
expression	O
of	O
several	O
cell	O
growth	O
-	O
related	O
genes	O
through	O
protein	O
kinase	O
A	O
-	O
related	O
cAMP	O
response	O
elements	O
.	O

The	O
promoter	O
activity	O
of	O
cell	O
cycle	O
regulated	O
histone	B-PRGE
H4	I-PRGE
genes	O
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	O
cis	O
-	O
acting	O
elements	O
which	O
mediate	O
G1	O
/	O
S	O
phase	O
control	O
and	O
/	O
or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O

Using	O
protein	O
-	O
DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	O
promoter	O
contains	O
two	O
ATF	O
/	O
CREB	O
recognition	O
motifs	O
which	O
interact	O
with	O
CREB	O
,	O
ATF1	B-PRGE
,	O
and	O
ATF2	B-PRGE
but	O
not	O
with	O
ATF4	B-PRGE
/	O
CREB2	B-PRGE
.	O

One	O
ATF	O
/	O
CRE	O
motif	O
is	O
located	O
in	O
the	O
distal	O
promoter	O
at	O
the	O
nuclear	O
matrix	O
-	O
associated	O
Site	O
IV	O
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	O
promoter	O
at	O
Site	O
I	O
.	O
Both	O
ATF	O
/	O
CRE	O
motifs	O
overlap	O
binding	O
sequences	O
for	O
the	O
multifunctional	O
YY1	O
transcription	O
factor	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

Subnuclear	O
fractionation	O
reveals	O
that	O
there	O
are	O
two	O
ATF1	B-PRGE
isoforms	O
which	O
appear	O
to	O
differ	O
with	O
respect	O
to	O
DNA	O
binding	O
activity	O
and	O
partition	O
selectively	O
between	O
nuclear	O
matrix	O
and	O
nonmatrix	O
compartments	O
,	O
consistent	O
with	O
the	O
role	O
of	O
the	O
nuclear	O
matrix	O
in	O
regulating	O
gene	O
expression	O
.	O

Site	O
-	O
directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	O
I	O
and	O
Site	O
IV	O
together	O
support	O
ATF1	B-PRGE
-	O
and	O
CREB	O
-	O
induced	O
trans	O
-	O
activation	O
of	O
the	O
H4	B-PRGE
promoter	O
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF	O
/	O
CREB	O
factors	O
functionally	O
modulate	O
histone	B-PRGE
H4	I-PRGE
gene	O
transcription	O
at	O
distal	O
and	O
proximal	O
promoter	O
elements	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
induce	O
heterodimerization	O
of	O
STAT5	O
isoforms	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
both	O
cytokines	O
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	O
,	O
STAT5A	B-PRGE
and	O
STAT5B	B-PRGE
,	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
induced	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Both	O
cytokines	O
induced	O
assembly	O
of	O
STAT5A	B-PRGE
and	O
STAT5B	B-PRGE
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
or	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
treated	O
cells	O
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
treated	O
as	O
compared	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
treated	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-PRGE
and	O
STAT5B	B-PRGE
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	O
to	O
an	O
immobilized	O
GAS	O
element	O
.	O

Both	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
induced	O
substantial	O
amounts	O
of	O
STAT5A	B-PRGE
/	O
STAT5B	B-PRGE
heterodimerization	O
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	O
with	O
each	O
STAT5	O
isomer	O
.	O

These	O
data	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
induce	O
assembly	O
of	O
STAT	O
heterodimers	O
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	O
.	O

Molecular	O
mechanisms	O
of	O
anoxia	O
/	O
reoxygenation	O
-	O
induced	O
neutrophil	O
adherence	O
to	O
cultured	O
endothelial	O
cells	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	O
HUVECs	O
to	O
human	O
neutrophils	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Oxypurinol	O
and	O
catalase	B-PRGE
inhibited	O
phase	O
-	O
1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	B-PRGE
oxidase	I-PRGE
and	O
H2O2	O
.	O

In	O
comparison	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O

Anti	O
-	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
anti	O
-	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
antibodies	O
(	O
monoclonal	O
antibodies	O
[	O
mAbs	O
]	O
)	O
attenuated	O
phase	O
-	O
1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	O
for	O
constitutively	O
expressed	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
enhanced	O
surface	O
expression	O
of	O
preformed	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Phase	O
-	O
2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti	O
-	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
mAb	O
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
containing	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
or	O
activator	B-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
phase	O
-	O
2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Surface	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
-	O
1	O
and	O
-	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A	O
/	O
R	O
elicits	O
a	O
two	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p65	B-PRGE
subunits	O
bind	O
to	O
an	O
upstream	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
granulocyte	B-PRGE
macrophage	I-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	O
cells	O
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF	O
-	O
kappaB	O
like	O
site	O
in	O
the	O
5637	O
non	O
-	O
lymphoid	O
cell	O
line	O
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	O
binding	O
complex	O
of	O
NF	O
-	O
kappaB	O
subunits	O
(	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p65	B-PRGE
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV	O
-	O
LTR	O
-	O
kappaB	O
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p50	B-PRGE
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	O
T	O
-	O
lymphoid	O
HTLV	O
-	O
II	O
infected	O
cells	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	B-PRGE
factor	I-PRGE
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	B-PRGE
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	B-PRGE
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	B-PRGE
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes	O
/	O
macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	B-PRGE
activity	O
generated	O
by	O
both	O
unstimulated	O
and	O
endotoxin	O
-	O
stimulated	O
cells	O
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Increased	O
monocyte	O
TF	B-PRGE
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	B-PRGE
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	B-PRGE
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	B-PRGE
mRNA	O
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	B-PRGE
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	B-PRGE
activation	O
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	B-PRGE
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	B-PRGE
expression	O
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Agonistic	O
activity	O
of	O
a	O
CD40	B-PRGE
-	O
specific	O
single	O
-	O
chain	O
Fv	O
constructed	O
from	O
the	O
variable	O
regions	O
of	O
mAb	O
G28	O
-	O
5	O
.	O

A	O
single	O
-	O
chain	O
Fv	O
(	O
sFv	O
)	O
was	O
expressed	O
from	O
the	O
variable	O
regions	O
of	O
the	O
CD40	B-PRGE
-	O
specific	O
mAb	O
G28	O
-	O
5	O
.	O

The	O
molecule	O
bound	O
CD40	B-PRGE
with	O
a	O
high	O
affinity	O
(	O
2	O
.	O
2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O

Surprisingly	O
,	O
G28	O
-	O
5	O
sFv	O
was	O
a	O
potent	O
CD40	B-PRGE
agonist	O
that	O
rapidly	O
crosslinked	O
CD40	B-PRGE
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40	B-PRGE
-	O
Ig	O
in	O
solution	O
.	O

G28	O
-	O
5	O
sFv	O
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28	O
-	O
5	O
IgG	O
and	O
was	O
able	O
to	O
stimulate	O
CD40	B-PRGE
responses	O
by	O
B	O
cells	O
and	O
monocytes	O
.	O

G28	O
-	O
5	O
IgG	B-PRGE
partially	O
blocked	O
,	O
whereas	O
G28	O
-	O
5	O
sFv	O
augmented	O
CD40	B-PRGE
responses	O
during	O
stimulation	O
with	O
natural	O
ligand	O
(	O
gp39	B-PRGE
-	O
CD8	O
fusion	O
protein	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	O
site	O
of	O
G28	O
-	O
5	O
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	O
polymerase	O
II	O
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	B-PRGE
through	O
XPG	B-PRGE
.	O

Of	O
these	O
,	O
the	O
XPB	B-PRGE
and	O
XPD	B-PRGE
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	O
transcription	O
factor	O
,	O
TFIIH	O
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	B-PRGE
or	O
XPD	B-PRGE
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper	O
-	O
sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
or	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
cells	O
contained	O
reduced	O
amounts	O
of	O
TFIIH	O
.	O

Extracts	O
prepared	O
from	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
lymphoblastoid	O
cells	O
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
lymphoblastoid	O
cells	O
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	O
for	O
the	O
clinical	O
symptoms	O
in	O
XP	B-PRGE
-	I-PRGE
B	I-PRGE
or	O
XP	B-PRGE
-	I-PRGE
D	I-PRGE
patients	O
,	O
and	O
discuss	O
a	O
'	O
conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0	B-PRGE
/	I-PRGE
G1	I-PRGE
switch	I-PRGE
gene	I-PRGE
2	I-PRGE
(	O
G0S2	B-PRGE
)	O
in	O
cultured	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium	O
-	O
and	O
calmodulin	O
-	O
dependent	O
phosphatase	O
calcineurin	O
which	O
is	O
required	O
for	O
activation	O
of	O
target	O
genes	O
by	O
members	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
transcription	O
factor	O
family	O
.	O

Among	O
these	O
target	O
genes	O
is	O
the	O
gene	O
encoding	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL2	B-PRGE
)	O
,	O
a	O
cytokine	O
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

However	O
,	O
IL2	B-PRGE
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT	O
-	O
sensitive	O
gene	O
may	O
be	O
involved	O
.	O

The	O
human	O
G0	B-PRGE
/	I-PRGE
G1	I-PRGE
switch	I-PRGE
gene	I-PRGE
,	O
G0S2	B-PRGE
,	O
has	O
potential	O
NFAT	O
-	O
binding	O
sites	O
in	O
the	O
5	O
'	O
flank	O
and	O
encodes	O
a	O
small	O
basic	O
potential	O
phosphoprotein	O
of	O
unknown	O
function	O
.	O

Using	O
a	O
sensitive	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
,	O
G0S2	B-PRGE
mRNA	O
levels	O
were	O
assayed	O
in	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Freshly	O
isolated	O
cells	O
contain	O
high	O
levels	O
of	O
G0S2	B-PRGE
mRNA	O
which	O
rapidly	O
decline	O
.	O

This	O
"	O
spontaneous	O
stimulation	O
"	O
is	O
also	O
noted	O
with	O
some	O
other	O
G0S	B-PRGE
genes	O
and	O
has	O
been	O
attributed	O
to	O
some	O
aspect	O
of	O
the	O
isolation	O
procedure	O
.	O

In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	B-PRGE
mRNA	O
,	O
peaking	O
between	O
1	O
-	O
2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin	O
-	O
A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O

Both	O
these	O
responses	O
are	O
inhibited	O
by	O
CsA	O
.	O

Our	O
results	O
suggest	O
that	O
G0S2	B-PRGE
expression	O
is	O
required	O
to	O
commit	O
cells	O
to	O
enter	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
that	O
,	O
while	O
not	O
excluding	O
other	O
possible	O
targets	O
,	O
early	O
inhibition	O
of	O
G0S2	B-PRGE
expression	O
by	O
CsA	O
may	O
be	O
important	O
in	O
achieving	O
immunosuppression	O
.	O

G0S2	B-PRGE
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	O
in	O
response	O
to	O
self	O
and	O
not	O
-	O
self	O
antigens	O
.	O

Estrogen	B-PRGE
receptor	I-PRGE
diminishes	O
DNA	O
-	O
binding	O
activities	O
of	O
chicken	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CACCC	O
-	O
binding	O
proteins	O
.	O

The	O
estrogen	B-PRGE
receptor	I-PRGE
(	O
ER	B-PRGE
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	B-PRGE
alpha	I-PRGE
(	O
referred	O
to	O
throughout	O
as	O
ER	B-PRGE
)	O
on	O
DNA	O
-	O
binding	O
activities	O
of	O
transcription	O
factors	O
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	B-PRGE
H5	I-PRGE
gene	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	O
ER	B-PRGE
reduced	O
the	O
binding	O
activities	O
of	O
chicken	O
immature	O
erythrocyte	O
nuclear	O
extracted	O
proteins	O
to	O
GATA	O
and	O
CACCC	O
sites	O
in	O
the	O
H5	O
promoter	O
and	O
enhancer	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
NF1	O
and	O
Sp1	B-PRGE
were	O
not	O
affected	O
by	O
ER	B-PRGE
.	O

Binding	O
of	O
ER	B-PRGE
to	O
an	O
estrogen	O
response	O
element	O
was	O
enhanced	O
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O

This	O
lysate	O
was	O
also	O
necessary	O
for	O
ER	B-PRGE
to	O
diminish	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	B-PRGE
function	O
.	O

Both	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CACCC	O
-	O
binding	O
proteins	O
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O

We	O
hypothesize	O
that	O
interference	O
in	O
DNA	O
-	O
binding	O
activities	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CACCC	O
-	O
binding	O
proteins	O
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	B-PRGE
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O

Constitutive	O
expression	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
and	O
NF	O
kappa	O
B	O
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up	O
-	O
regulation	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
with	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	O
production	O
when	O
stimulated	O
either	O
via	O
their	O
T	O
-	O
cell	O
antigen	O
receptors	O
or	O
lectins	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal	O
/	O
neonatal	O
T	O
-	O
cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	O
regulatory	O
elements	O
required	O
for	O
T	O
-	O
cell	O
activation	O
.	O

We	O
used	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	O
factors	O
implicated	O
in	O
T	O
-	O
cell	O
activation	O
:	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
and	O
NF	O
kappa	O
B	O
(	O
p50	B-PRGE
subunit	O
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti	O
-	O
CD3	O
monoclonal	O
antibodies	O
resulted	O
in	O
up	O
-	O
regulation	O
of	O
both	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
by	O
anti	O
-	O
CD3	O
-	O
stimulated	O
cord	O
blood	O
mononuclear	O
cells	O
was	O
still	O
blunted	O
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	O
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	O
blood	O
cells	O
.	O

Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
are	O
currently	O
under	O
investigation	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
in	O
primary	O
human	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	O
necrosis	O
factor	O
through	O
the	O
control	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
controls	O
T	O
-	O
cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV	O
-	O
infected	O
human	O
T	O
lymphocytes	O
by	O
using	O
neutralizing	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibodies	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Primary	O
resting	O
T	O
lymphocytes	O
produced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
supported	O
HIV	O
replication	O
after	O
T	O
-	O
cell	O
receptor	O
activation	O
.	O

Addition	O
of	O
neutralizing	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
antibodies	O
drastically	O
reduced	O
p24	B-PRGE
antigen	O
release	O
and	O
prevented	O
CD4	B-PRGE
+	O
cell	O
depletion	O
associated	O
with	O
infection	O
.	O

Anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
also	O
prevented	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O

Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
reverted	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	O
affect	O
the	O
inhibition	O
of	O
HIV	O
p24	B-PRGE
antigen	O
release	O
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
the	O
same	O
cultures	O
.	O

Moreover	O
,	O
anti	O
-	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
inhibited	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
transcription	O
of	O
a	O
reporter	O
gene	O
in	O
primary	O
T	O
cells	O
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV	O
-	O
1	O
Tat	B-PRGE
.	O

Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
in	O
controlling	O
HIV	O
replication	O
in	O
primary	O
T	O
cells	O
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF	O
-	O
kappa	O
B	O
elevated	O
in	O
the	O
nucleus	O
of	O
T	O
cells	O
.	O

A	O
thiol	O
antioxidant	O
regulates	O
IgE	O
isotype	O
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

The	O
binding	O
site	O
for	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
present	O
at	O
the	O
promoter	O
region	O
of	O
the	O
germline	O
Cepsilon	O
gene	O
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	O
synthesis	O
by	O
human	O
B	O
cells	O
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
germline	O
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	O
Burkitt	O
'	O
s	O
lymphoma	O
B	O
cell	O
lines	O
,	O
DND39	O
and	O
DG75	O
.	O

In	O
both	O
cell	O
lines	O
,	O
n	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
by	O
anti	O
-	O
CD40	B-PRGE
monoclonal	O
antibody	O
.	O

Although	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
activated	O
signal	B-PRGE
transducers	I-PRGE
and	I-PRGE
activators	I-PRGE
of	I-PRGE
transcription	I-PRGE
(	I-PRGE
STAT	I-PRGE
)	I-PRGE
6	I-PRGE
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF	O
-	O
kappaB	O
or	O
STAT6	B-PRGE
only	O
partly	O
blocked	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
germline	O
Cepsilon	O
transcription	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
germline	O
Cepsilon	O
transcription	O
.	O

Of	O
note	O
,	O
CD40	B-PRGE
-	O
mediated	O
enhancement	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
driven	O
germline	O
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF	O
-	O
kappaB	O
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	O
.	O

NAC	O
inhibited	O
the	O
generation	O
of	O
Smu	O
/	O
Sepsilon	O
switch	O
fragments	O
in	O
normal	O
human	O
B	O
cells	O
costimulated	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
anti	O
-	O
CD40	B-PRGE
monoclonal	O
antibody	O
.	O

It	O
also	O
abolished	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
upregulation	O
of	O
CD40	B-PRGE
but	O
promoted	O
upregulation	O
of	O
CD23	B-PRGE
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF	O
-	O
kappaB	O
and	O
STAT6	B-PRGE
may	O
be	O
required	O
for	O
induction	O
of	O
germline	O
Cepsilon	O
transcription	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
that	O
CD40	B-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	O
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen	O
-	O
specific	O
human	O
helper	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Cytokines	O
produced	O
by	O
helper	O
T	O
cells	O
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	O
,	O
by	O
CD4	O
+	O
T	O
lymphocytes	O
in	O
patients	O
with	O
asthma	O
.	O

METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
cell	O
clones	O
and	O
T	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
production	O
by	O
CD4	O
+	O
T	O
cells	O
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
after	O
incubation	O
with	O
mite	O
allergen	O
,	O
suggesting	O
that	O
mite	O
-	O
specific	O
helper	O
T	O
cells	O
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O

A	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
promoter	O
/	O
enhancer	O
luciferase	O
gene	O
construct	O
transfected	O
into	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
producing	O
T	O
cell	O
clones	O
was	O
clearly	O
transcribed	O
after	O
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
segment	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	O
to	O
respond	O
to	O
activating	O
signals	O
in	O
human	O
helper	O
T	O
cells	O
.	O

The	O
same	O
gene	O
segment	O
was	O
not	O
transcribed	O
in	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
nonproducing	O
T	O
cell	O
clones	O
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
synthesis	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
T	O
cell	O
hybridomas	O
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	O
transcription	O
factor	O
may	O
be	O
essential	O
for	O
human	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
gene	O
transcription	O
.	O

CONCLUSION	O
:	O
Enhanced	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
production	O
by	O
helper	O
T	O
cells	O
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O

Elucidation	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
stability	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
must	O
be	O
released	O
from	O
cytoplasmic	O
inhibitory	O
molecules	O
(	O
I	O
kappa	O
Bs	O
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	O
genes	O
.	O

Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
in	O
some	O
cell	O
-	O
types	O
and	O
of	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
after	O
stimulation	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
mature	O
B	O
cells	O
.	O

We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
in	O
mature	O
B	O
cells	O
and	O
HeLa	O
cells	O
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	O
cells	O
although	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
is	O
considerably	O
more	O
stable	O
than	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

The	O
half	O
-	O
life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	O
cells	O
.	O

In	O
contrast	O
,	O
all	O
other	O
NF	O
-	O
kappa	O
B	O
/	O
I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell	O
-	O
types	O
.	O

The	O
elevated	O
turnover	O
of	O
endogenous	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
in	O
Namalwa	O
cells	O
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non	O
-	O
B	O
cells	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
pools	O
.	O

I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
efficiently	O
resynthesized	O
whereas	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
levels	O
stay	O
low	O
for	O
a	O
prolonged	O
time	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	O
is	O
inhibited	O
and	O
new	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre	O
-	O
and	O
post	O
-	O
inductive	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

These	O
observations	O
suggest	O
that	O
resynthesis	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Control	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
inhibitor	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	O
kappa	O
B	O
inhibitors	O
.	O

In	O
mammalian	O
cells	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
proteins	O
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
through	O
their	O
association	O
with	O
the	O
p65	B-PRGE
or	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
subunits	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
epsilon	I-PRGE
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29	O
.	O
1	O
T	O
cell	O
hybridoma	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
are	O
equally	O
associated	O
with	O
p65	B-PRGE
and	O
that	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
is	O
degraded	O
in	O
response	O
to	O
TNF	B-PRGE
alpha	I-PRGE
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	O
form	O
.	O

The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
beta	I-PRGE
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal	O
-	O
induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O

NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
members	O
regulating	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
in	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

A	O
kappa	O
B	O
-	O
site	O
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
gene	O
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
by	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
glucocorticoids	O
.	O

We	O
now	O
report	O
on	O
the	O
transcription	O
factors	O
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	O
sequence	O
.	O

In	O
vitro	O
,	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
kappa	O
B	O
site	O
appeared	O
to	O
bind	O
RelA	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
,	O
but	O
weakly	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
homodimers	O
.	O

In	O
addition	O
,	O
both	O
RelA	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
but	O
not	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
kappa	O
B	O
-	O
reporter	O
construct	O
.	O

In	O
monocytic	O
THP	O
-	O
1	O
cells	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
induced	O
two	O
nuclear	O
complexes	O
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
kappa	O
B	O
site	O
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
and	O
RelA	B-PRGE
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	O
kappa	O
B	O
site	O
in	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

The	O
second	O
complex	O
contained	O
RelA	B-PRGE
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
kappa	O
B	O
than	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

The	O
glucocorticoid	B-PRGE
receptor	I-PRGE
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	B-PRGE
homodimer	O
and	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
/	O
RelA	B-PRGE
heterodimer	O
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	B-PRGE
homodimers	O
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
monocytic	O
cells	O
.	O

LPS	O
tolerance	O
in	O
monocytes	O
/	O
macrophages	O
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	O
binding	O
motif	O
for	O
detection	O
of	O
upregulated	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
homodimers	O
.	O

When	O
monocytes	O
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	O
of	O
the	O
TNF	B-PRGE
(	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
)	O
gene	O
is	O
only	O
very	O
low	O
,	O
i	O
.	O
e	O
.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O

Tolerant	O
cells	O
still	O
express	O
the	O
CD14	B-PRGE
receptor	I-PRGE
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF	O
-	O
kappa	O
B	O
into	O
nucleus	O
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-	O
605	O
motif	O
of	O
the	O
human	O
TNF	O
promoter	O
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
there	O
is	O
a	O
predominance	O
of	O
p50p50	B-PRGE
of	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
now	O
show	O
that	O
a	O
mutant	O
motif	O
that	O
exchanges	O
the	O
terminal	O
3	O
'	O
C	O
for	O
a	O
G	O
fails	O
to	O
bind	O
the	O
p50	B-PRGE
homodimer	O
that	O
is	O
upregulated	O
in	O
LPS	O
toler	O
ant	O
human	O
Mono	O
Mac	O
6	O
cells	O
.	O

The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	O
P388D1	O
macrophage	O
cell	O
line	O
when	O
tested	O
with	O
the	O
-	O
516	O
motif	O
of	O
the	O
murine	O
TNF	O
promoter	O
(	O
GGGGGCTTTCCC	O
)	O
.	O

Here	O
the	O
wild	O
type	O
motif	O
gives	O
efficient	O
binding	O
of	O
p50p50	B-PRGE
that	O
again	O
is	O
upregulated	O
in	O
tolerant	O
cells	O
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	O
of	O
p50p50	B-PRGE
.	O

Conversely	O
,	O
the	O
murine	O
kappa	B-PRGE
light	I-PRGE
chain	I-PRGE
enhancer	O
motif	O
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B-PRGE
from	O
tolerant	O
murine	O
P388	O
macrophages	O
.	O

Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	O
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O

These	O
data	O
show	O
that	O
the	O
detection	O
of	O
upregulated	O
p50	B-PRGE
homodimers	O
in	O
LPS	O
tolerant	O
cells	O
is	O
dependent	O
on	O
subtle	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
DNA	O
binding	O
motif	O
.	O

Temporal	O
control	O
of	O
IgH	B-PRGE
gene	O
expression	O
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	B-PRGE
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	B-PRGE
3	O
'	O
LCR	O
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	B-PRGE
gene	O
expression	O
and	O
compare	O
it	O
with	O
the	O
5	O
'	O
LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	O
cytokines	O
and	O
mononuclear	O
cell	O
attracting	O
chemokines	O
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	O
cytokine	O
genes	O
,	O
but	O
cannot	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	O
genes	O
lack	O
respective	O
binding	O
sites	O
in	O
their	O
promoter	O
regions	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	O
factors	O
of	O
possible	O
importance	O
such	O
as	O
CREB	O
,	O
CTF	B-PRGE
,	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

To	O
explore	O
long	O
-	O
term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	O
factors	O
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	O
transcription	O
factor	O
proteins	O
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell	O
-	O
type	O
-	O
specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	B-PRGE
,	O
OTF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
OFT	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
NF	O
-	O
kappa	O
B	O
genes	O
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	O
significant	O
changes	O
were	O
detected	O
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	O
,	O
CTF	B-PRGE
,	O
and	O
OTF	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	O
factor	O
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	O
factor	O
proteins	O
is	O
required	O
.	O

[	O
Molecular	O
-	O
biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O

The	O
problem	O
of	O
the	O
neuro	O
-	O
immuno	O
interactions	O
on	O
the	O
level	O
of	O
the	O
protein	O
trans	O
-	O
factors	O
,	O
stimulating	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
expression	O
was	O
discussed	O
.	O

The	O
physico	O
-	O
chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	O
molecular	O
nuclear	O
proteins	O
(	O
SP	O
and	O
BP	O
-	O
14	O
,	O
18	O
,	O
19	O
kDs	O
)	O
isolated	O
from	O
splenic	O
and	O
brain	O
cells	O
of	O
immunized	O
rats	O
were	O
studied	O
.	O

The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
vitro	O
and	O
stimulation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2mRNA	I-PRGE
synthesis	O
in	O
splenic	O
T	O
-	O
lymphocytes	O
culture	O
in	O
normal	O
conditions	O
were	O
shown	O
.	O

The	O
protective	O
effect	O
of	O
SP	O
and	O
BP	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2mRNA	I-PRGE
synthesis	O
in	O
stressful	O
conditions	O
and	O
by	O
the	O
T	O
-	O
cells	O
treatment	O
with	O
the	O
CsA	O
was	O
demonstrated	O
.	O

Induction	O
of	O
interleukin	O
-	O
12	O
p40	B-PRGE
transcript	O
by	O
CD40	B-PRGE
ligation	O
via	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
.	O

Interleukin	O
-	O
12	O
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes	O
/	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	O
T	O
cells	O
and	O
antigen	O
-	O
presenting	O
cells	O
via	O
CD40	B-PRGE
-	O
CD40	B-PRGE
ligand	I-PRGE
(	O
CD40L	B-PRGE
)	O
.	O

So	O
far	O
,	O
transcriptional	O
analyses	O
of	O
p40	B-PRGE
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	O
stimuli	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	B-PRGE
by	O
CD40	B-PRGE
ligation	O
in	O
a	O
human	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Daudi	O
,	O
and	O
a	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
,	O
THP	O
-	O
1	O
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B-PRGE
or	O
by	O
transfection	O
with	O
a	O
CD40L	B-PRGE
expression	O
vector	O
,	O
secreted	O
p40	B-PRGE
and	O
showed	O
enhanced	O
p40	B-PRGE
mRNA	O
expression	O
.	O

Sequence	O
analysis	O
of	O
the	O
p40	B-PRGE
promoter	O
region	O
identified	O
two	O
potential	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
binding	O
sites	O
conserved	O
between	O
mouse	O
and	O
human	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
which	O
is	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	B-PRGE
genes	O
formed	O
an	O
NF	O
-	O
kappaB	O
complex	O
with	O
nuclear	O
extract	O
from	O
Daudi	O
cells	O
stimulated	O
by	O
CD40	B-PRGE
ligation	O
.	O

Moreover	O
,	O
transfection	O
of	O
Daudi	O
cells	O
with	O
the	O
polymerized	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
ligated	O
to	O
a	O
thymidine	O
kinase	O
/	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
plasmid	O
greatly	O
induced	O
CAT	B-PRGE
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	O
mutated	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
did	O
not	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	B-PRGE
promoter	O
regions	O
could	O
be	O
important	O
for	O
the	O
p40	B-PRGE
induction	O
by	O
CD40	B-PRGE
ligation	O
via	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Oxidants	O
,	O
transcription	O
factors	O
,	O
and	O
intestinal	O
inflammation	O
.	O

It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O

Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

For	O
example	O
,	O
certain	O
oxidants	O
are	O
known	O
to	O
activate	O
the	O
nuclear	O
transcription	O
factor	O
kappa	O
B	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
different	O
adhesion	O
molecules	O
,	O
cytokines	O
,	O
and	O
enzymes	O
.	O

Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
.	O

This	O
transcription	O
factor	O
is	O
composed	O
of	O
products	O
from	O
the	O
fos	B-PRGE
and	O
jun	B-PRGE
proto	O
-	O
oncogene	O
family	O
and	O
is	O
believed	O
to	O
be	O
important	O
in	O
regulating	O
cell	O
growth	O
and	O
proliferation	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	O
epithelial	O
cell	O
apoptosis	O
,	O
and	O
the	O
B	B-PRGE
-	I-PRGE
cell	I-PRGE
lymphoma	I-PRGE
/	I-PRGE
leukemia	I-PRGE
-	I-PRGE
2	I-PRGE
gene	O
product	O
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant	O
-	O
dependent	O
manner	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
nontoxic	O
concentrations	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
in	O
modulating	O
apoptosis	O
.	O

Differential	O
induction	O
of	O
DNA	O
-	O
binding	O
activities	O
following	O
CD19	B-PRGE
cross	O
-	O
linking	O
in	O
human	O
B	O
lineage	O
cells	O
.	O

The	O
B	O
cell	O
-	O
specific	O
cell	O
surface	O
molecule	O
CD19	B-PRGE
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	O
effector	O
proteins	O
.	O

Cross	O
-	O
linking	O
CD19	B-PRGE
on	O
early	O
human	O
B	O
lineage	O
cells	O
induces	O
the	O
formation	O
of	O
a	O
CD19	B-PRGE
/	O
Vav	O
/	O
phosphatidylinositol	O
-	O
3	O
kinase	O
complex	O
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	B-PRGE
and	O
Vav	O
,	O
and	O
activation	O
of	O
the	O
Ras	O
pathway	O
.	O

To	O
further	O
explore	O
the	O
ramifications	O
of	O
CD19	B-PRGE
signaling	O
,	O
the	O
current	O
study	O
examined	O
whether	O
phosphorylation	O
of	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
activation	O
of	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
or	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
transcription	O
factors	O
occurred	O
following	O
CD19	B-PRGE
cross	O
-	O
linking	O
.	O

The	O
cells	O
used	O
were	O
the	O
BLIN	O
-	O
1	O
pre	O
-	O
B	O
cell	O
line	O
expressing	O
low	O
levels	O
of	O
cell	O
surface	O
mu	O
heavy	O
chain	O
associated	O
with	O
surrogate	O
light	O
chain	O
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	O
surface	O
mu	O
/	O
kappa	O
.	O

Lysates	O
from	O
CD19	B-PRGE
cross	O
-	O
linked	O
1E8	O
cells	O
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
fusion	O
protein	O
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
fusion	O
protein	O
occurred	O
using	O
lysates	O
from	O
CD19	B-PRGE
cross	O
-	O
linked	O
BLIN	O
-	O
1	O
cells	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
increased	O
,	O
while	O
constitutive	O
NF	O
-	O
kappaB	O
-	O
binding	O
activity	O
was	O
not	O
enhanced	O
,	O
following	O
2	O
h	O
of	O
CD19	B-PRGE
cross	O
-	O
linking	O
in	O
1E8	O
cells	O
.	O

Supershift	O
experiments	O
revealed	O
that	O
JunD	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
proteins	O
mediated	O
anti	O
-	O
CD19	B-PRGE
induced	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
in	O
1E8	O
cells	O
.	O

In	O
contrast	O
,	O
CD19	B-PRGE
cross	O
-	O
linking	O
in	O
BLIN	O
-	O
1	O
cells	O
resulted	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP	O
-	O
1	O
-	O
binding	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
CD19	B-PRGE
-	O
mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	O
factors	O
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	O
factor	O
recruitment	O
in	O
human	O
glial	O
cells	O
and	O
lymphocytes	O
.	O

The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV	O
-	O
1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
sequence	O
diversity	O
on	O
LTR	O
-	O
directed	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	O
from	O
proviral	O
DNA	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
peripheral	O
blood	O
.	O

Sequence	O
analysis	O
of	O
nineteen	O
LTRs	O
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	O
LTR	O
)	O
within	O
the	O
455	O
-	O
bp	O
U3	O
region	O
.	O

Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	O
LTR	O
in	O
U	O
-	O
373	O
MG	O
cells	O
(	O
an	O
astrocytoma	O
cell	O
line	O
)	O
as	O
well	O
as	O
in	O
Jurkat	O
cells	O
(	O
a	O
CD4	B-PRGE
-	O
positive	O
lymphocyte	O
cell	O
line	O
)	O
.	O

While	O
LTRs	O
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U	O
-	O
373	O
MG	O
cells	O
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	O
were	O
generally	O
more	O
active	O
in	O
Jurkat	O
cells	O
when	O
compared	O
to	O
the	O
LAI	O
LTR	O
.	O

Differences	O
in	O
LTR	O
sequence	O
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis	O
-	O
acting	O
sites	O
within	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	O
factor	O
binding	O
to	O
an	O
activating	O
transcription	O
factor	O
/	O
cAMP	O
response	O
element	O
binding	O
(	O
ATF	O
/	O
CREB	O
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
distal	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
sites	O
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	O
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	O
factor	O
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappaB	O
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	O
cells	O
.	O

Death	O
-	O
inducing	O
ligands	O
(	O
DILs	O
)	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
-	O
dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O

We	O
demonstrate	O
here	O
that	O
TRAIL	B-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
related	I-PRGE
apoptosis	I-PRGE
-	I-PRGE
inducing	I-PRGE
ligand	I-PRGE
)	O
,	O
a	O
recently	O
identified	O
DIL	O
,	O
also	O
activates	O
NFkappaB	O
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	B-PRGE
.	O

NFkappaB	O
activity	O
is	O
independent	O
from	O
FADD	B-PRGE
,	O
caspases	O
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	O
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B-PRGE
,	O
CD95	B-PRGE
,	O
TNFalpha	B-PRGE
,	O
or	O
doxorubicin	O
,	O
NFkappaB	O
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	O
inhibitor	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	O
IkappaBalpha	B-PRGE
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	O
lines	O
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	O
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	O
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	O
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

The	O
human	O
toll	O
signaling	O
pathway	O
:	O
divergence	O
of	O
nuclear	O
factor	O
kappaB	O
and	O
JNK	O
/	O
SAPK	O
activation	O
upstream	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
factor	I-PRGE
6	I-PRGE
(	O
TRAF6	B-PRGE
)	O
.	O

The	O
human	O
homologue	O
of	O
Drosophila	O
Toll	O
(	O
hToll	O
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	O
1	O
receptor	O
(	O
IL	O
-	O
1R	O
)	O
superfamily	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O

Signaling	O
by	O
hToll	O
is	O
shown	O
to	O
occur	O
through	O
sequential	O
recruitment	O
of	O
the	O
adapter	O
molecule	O
MyD88	B-PRGE
and	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
activated	I-PRGE
factor	I-PRGE
6	I-PRGE
(	O
TRAF6	B-PRGE
)	O
and	O
the	O
nuclear	B-PRGE
factor	I-PRGE
kappaB	I-PRGE
(	I-PRGE
NF	I-PRGE
-	I-PRGE
kappaB	I-PRGE
)	I-PRGE
-	I-PRGE
inducing	I-PRGE
kinase	I-PRGE
(	O
NIK	B-PRGE
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B-PRGE
failed	O
to	O
block	O
hToll	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
/	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinases	O
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O

Coactivation	O
by	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	O
promoters	O
through	O
interaction	O
with	O
octamer	O
-	O
bound	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	B-PRGE
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	B-PRGE
and	O
the	O
PC4	B-PRGE
-	O
depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	B-PRGE
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	O
-	O
derived	O
PC2	O
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	O
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	B-PRGE
in	O
the	O
reconstituted	O
system	O
,	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	B-PRGE
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	B-PRGE
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
/	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	O
coactivators	O
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	O
receptors	O
.	O

The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	O
receptors	O
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O

Ligand	O
binding	O
to	O
the	O
ligand	O
binding	O
domain	O
of	O
these	O
receptors	O
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	O
.	O

In	O
vitro	O
labeled	O
receptors	O
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	O
digestion	O
.	O

Proteolysis	O
products	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
quantified	O
.	O

The	O
amount	O
of	O
trypsin	O
-	O
resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Using	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
human	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	O
retinoic	B-PRGE
X	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
,	O
and	O
progesterone	O
receptor	O
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Mycobacterium	O
tuberculosis	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
can	O
induce	O
NF	O
-	O
kappaB	O
-	O
dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M	O
.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV	O
-	O
1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	B-PRGE
-	O
expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M	O
.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV	O
-	O
1	O
LTR	O
-	O
dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	O
tyrosine	O
kinase	O
(	O
s	O
)	O
,	O
protein	O
kinase	O
A	O
and	O
/	O
or	O
protein	O
kinase	O
C	O
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M	O
.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

M	O
.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild	O
-	O
type	O
,	O
but	O
not	O
the	O
kappaB	O
-	O
mutated	O
,	O
HIV	O
-	O
1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
results	O
suggest	O
that	O
M	O
.	O
tuberculosis	O
can	O
upregulate	O
HIV	O
-	O
1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	O
factor	O
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA	O
-	O
binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	O
factors	O
:	O
NFkappaB	O
,	O
AP	O
-	O
1	O
and	O
NFAT	O
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	O
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	O
activity	O
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	O
factor	O
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	O
lymphocytes	O
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	O
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	O
factor	O
DNA	O
-	O
binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Thrombopoietin	B-PRGE
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c	B-PRGE
-	I-PRGE
Mpl	I-PRGE
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O

Thrombopoietin	B-PRGE
(	O
TPO	B-PRGE
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT	O
-	O
7	O
/	O
GMT	O
,	O
from	O
the	O
human	O
leukemia	O
cell	O
line	O
UT	O
-	O
7	O
/	O
GM	O
(	O
N	O
.	O
Komatsu	O
,	O
et	O
al	O
.	O
,	O
Blood	O
,	O
89	O
:	O
4021	O
-	O
4033	O
,	O
1997	O
)	O
.	O

A	O
small	O
population	O
of	O
UT	O
-	O
7	O
/	O
GM	O
cells	O
positively	O
stained	O
for	O
hemoglobin	O
(	O
Hb	O
)	O
after	O
a	O
7	O
-	O
day	O
exposure	O
to	O
TPO	B-PRGE
.	O

More	O
than	O
50	O
%	O
of	O
TPO	B-PRGE
-	O
treated	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
positively	O
stained	O
for	O
Hb	O
.	O

Using	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
,	O
we	O
examined	O
how	O
TPO	B-PRGE
promotes	O
hemoglobinization	O
.	O

TPO	B-PRGE
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	B-PRGE
receptor	I-PRGE
but	O
not	O
the	O
erythropoietin	B-PRGE
(	I-PRGE
EPO	I-PRGE
)	I-PRGE
receptor	I-PRGE
.	O

There	O
was	O
no	O
competition	O
between	O
TPO	B-PRGE
and	O
EPO	B-PRGE
for	O
binding	O
to	O
EPO	B-PRGE
receptor	I-PRGE
.	O

These	O
findings	O
suggest	O
that	O
TPO	B-PRGE
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
.	O

Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	B-PRGE
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	B-PRGE
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	B-PRGE
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O

Redox	O
signals	O
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
several	O
T	O
cell	O
surface	O
receptors	O
.	O

Diminished	O
NF	O
-	O
kappaB	O
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF	O
-	O
kappaB	O
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF	O
-	O
kappaB	O
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	O
cell	O
lines	O
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF	O
-	O
kappaB	O
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF	O
-	O
kappaB	O
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF	O
-	O
kappaB	O
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF	O
-	O
kappaB	O
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF	O
-	O
kappaB	O
activation	O
may	O
be	O
relevant	O
to	O
immune	O
-	O
related	O
diseases	O
and	O
to	O
aging	O
.	O

Fibrinogen	O
activates	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
in	O
mononuclear	O
phagocytes	O
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

U937	O
cells	O
differentiated	O
with	O
PMA	O
in	O
nonadherent	O
culture	O
were	O
shown	O
to	O
express	O
two	O
fibrinogen	O
-	O
binding	O
integrins	O
,	O
predominately	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c	B-PRGE
/	O
CD18	B-PRGE
.	O

Cells	O
stimulated	O
with	O
fibrinogen	O
(	O
10	O
-	O
100	O
microg	O
/	O
ml	O
)	O
/	O
Mn2	O
+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up	O
-	O
regulated	O
by	O
fibrinogen	O
.	O

Fibrinogen	O
also	O
caused	O
activation	O
of	O
AP	O
-	O
1	O
,	O
but	O
not	O
SP1	B-PRGE
or	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
factors	O
.	O

Blocking	O
mAbs	O
against	O
CD18	B-PRGE
and	O
CD11b	B-PRGE
abrogated	O
fibrinogen	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV	O
-	O
1	O
enhancer	O
(	O
bearing	O
two	O
NF	O
-	O
kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
.	O

Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	B-PRGE
activity	O
by	O
2	O
.	O
6	O
-	O
fold	O
,	O
2	O
)	O
fibrinogen	O
/	O
Mn2	O
+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	B-PRGE
activity	O
by	O
3	O
.	O
2	O
-	O
fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	O
and	O
PMA	O
,	O
inducing	O
5	O
.	O
7	O
-	O
fold	O
the	O
CAT	B-PRGE
activity	O
induced	O
by	O
PMA	O
alone	O
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen	O
-	O
derived	O
proteins	O
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	O
regulatory	O
factors	O
,	O
including	O
NF	O
-	O
kappa	O
B	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	O
transduction	O
molecules	O
.	O

The	O
adoptive	O
transfer	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti	O
-	O
CD3	O
and	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	O
modified	O
variant	O
(	O
designated	O
D5G6	O
)	O
that	O
secretes	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
-	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
.	O

In	O
contrast	O
to	O
anti	O
-	O
CD3	O
/	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
activated	O
LN	O
cells	O
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
has	O
no	O
therapeutic	O
activity	O
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	B-PRGE
and	O
p59fyn	B-PRGE
and	O
proteins	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
were	O
analyzed	O
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	O
of	O
p56lck	B-PRGE
and	O
p59fyn	B-PRGE
were	O
lower	O
in	O
tumor	O
-	O
draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine	O
-	O
phosphorylated	O
substrates	O
was	O
markedly	O
depressed	O
following	O
anti	O
-	O
CD3	O
stimulation	O
.	O

After	O
5	O
-	O
day	O
anti	O
-	O
CD3	O
/	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
activation	O
,	O
levels	O
of	O
p56lck	B-PRGE
and	O
p59fyn	B-PRGE
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	B-PRGE
,	O
p59fyn	B-PRGE
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
Rel	B-PRGE
A	I-PRGE
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	B-PRGE
gene	O
results	O
in	O
loss	O
of	O
IL	O
-	O
1	O
-	O
and	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
-	O
mediated	O
function	O
.	O

MyD88	B-PRGE
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
and	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	B-PRGE
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	O
in	O
response	O
to	O
IL	O
-	O
1	O
.	O

Increases	O
in	O
interferon	O
-	O
gamma	O
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
blocked	O
in	O
MyD88	B-PRGE
-	O
/	O
-	O
Th1	O
-	O
developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B-PRGE
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL	O
-	O
1	O
receptor	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
receptor	O
.	O

Epstein	O
-	O
Barr	O
virus	O
-	O
transforming	O
protein	O
latent	B-PRGE
infection	I-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
activates	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
and	O
the	O
IkappaB	O
kinases	O
IKKalpha	B-PRGE
and	O
IKKbeta	B-PRGE
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	B-PRGE
infection	I-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
is	O
a	O
constitutively	O
aggregated	O
pseudo	O
-	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
that	O
activates	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
through	O
two	O
sites	O
in	O
its	O
C	O
-	O
terminal	O
cytoplasmic	O
domain	O
.	O

One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	B-PRGE
in	O
associating	O
with	O
TNFR	O
-	O
associated	O
factors	O
TRAF1	B-PRGE
and	O
TRAF2	B-PRGE
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	B-PRGE
in	O
associating	O
with	O
the	O
TNFRI	B-PRGE
death	O
domain	O
interacting	O
protein	O
TRADD	B-PRGE
.	O

TNFRI	B-PRGE
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF	O
-	O
kappaB	O
through	O
association	O
with	O
TRADD	B-PRGE
,	O
RIP	B-PRGE
,	O
and	O
TRAF2	B-PRGE
;	O
activation	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	I-PRGE
inducing	I-PRGE
kinase	I-PRGE
(	O
NIK	B-PRGE
)	O
;	O
activation	O
of	O
the	O
IkappaB	O
alpha	O
kinases	O
(	O
IKKalpha	B-PRGE
and	O
IKKbeta	B-PRGE
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
.	O

IkappaB	B-PRGE
alpha	I-PRGE
phosphorylation	O
on	O
Ser	O
-	O
32	O
and	O
Ser	O
-	O
36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF	O
-	O
kappaB	O
activation	O
by	O
LMP1	B-PRGE
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B-PRGE
,	O
IKKalpha	B-PRGE
,	O
and	O
IKKbeta	B-PRGE
.	O

Dominant	O
negative	O
mutants	O
of	O
NIK	B-PRGE
,	O
IKKalpha	B-PRGE
,	O
or	O
IKKbeta	B-PRGE
substantially	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
by	O
LMP1	B-PRGE
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
.	O

Dimethyldithiocarbamate	O
inhibits	O
in	O
vitro	O
activation	O
of	O
primary	O
human	O
CD4	B-PRGE
+	O
T	O
lymphocytes	O
.	O

Dithiocarbamates	O
(	O
DTC	O
)	O
,	O
a	O
diverse	O
group	O
of	O
industrial	O
and	O
therapeutic	O
chemicals	O
,	O
have	O
been	O
reported	O
to	O
inhibit	O
,	O
enhance	O
or	O
have	O
no	O
effect	O
on	O
the	O
immune	O
system	O
.	O

These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and	O
/	O
or	O
specific	O
compound	O
tested	O
.	O

The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O

We	O
demonstrate	O
that	O
0	O
.	O
1	O
-	O
0	O
.	O
5	O
microM	O
DMDTC	O
inhibits	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
human	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC	O
-	O
treated	O
T	O
cells	O
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O

The	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
is	O
apparently	O
permanent	O
as	O
DMDTC	O
-	O
treated	O
T	O
cells	O
did	O
not	O
regain	O
normal	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
activation	O
,	O
even	O
after	O
72	O
h	O
in	O
culture	O
.	O

DMDTC	O
does	O
not	O
appear	O
to	O
alter	O
NF	O
-	O
kappaB	O
directly	O
as	O
pre	O
-	O
incubation	O
of	O
nuclear	O
extracts	O
with	O
DMDTC	O
does	O
not	O
diminish	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

We	O
further	O
demonstrate	O
that	O
0	O
.	O
1	O
-	O
0	O
.	O
5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	B-PRGE
(	O
the	O
alpha	O
subunit	O
of	O
the	O
IL	O
-	O
2	O
receptor	O
)	O
in	O
T	O
cells	O
stimulated	O
with	O
phorbol	O
ester	O
.	O

These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Rho	O
potentiates	O
AP	O
-	O
1	O
transcription	O
in	O
T	O
cells	O
.	O

The	O
Rho	O
family	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	O
enhances	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
T	O
cells	O
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	O
(	O
V14Rho	O
)	O
has	O
little	O
or	O
no	O
effect	O
on	O
NFAT	O
,	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
enhancer	O
element	O
activities	O
under	O
similar	O
conditions	O
.	O

Overexpression	O
of	O
a	O
V14Rho	O
construct	O
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	O
deleted	O
)	O
abolishes	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O

The	O
effect	O
of	O
Rho	O
on	O
AP	O
-	O
1	O
is	O
independent	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathway	O
,	O
as	O
a	O
dominant	O
-	O
negative	O
MEK	O
and	O
a	O
MEK	O
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	O
-	O
induced	O
AP	O
-	O
1	O
activity	O
.	O

V14Rho	O
binds	O
strongly	O
to	O
protein	B-PRGE
kinase	I-PRGE
Calpha	I-PRGE
(	O
PKCalpha	B-PRGE
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	O
site	O
on	O
V14Rho	O
severely	O
diminished	O
this	O
association	O
.	O

Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	B-PRGE
as	O
an	O
effector	O
of	O
Rho	O
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
PKCalpha	B-PRGE
blocked	O
the	O
effects	O
of	O
activated	O
Rho	O
plus	O
PMA	O
on	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
Rho	O
potentiates	O
AP	O
-	O
1	O
transcription	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-PRGE
induction	O
of	O
NF	O
-	O
kappaB	O
involves	O
activation	O
of	O
the	O
IkappaB	B-PRGE
kinase	I-PRGE
alpha	I-PRGE
(	O
IKKalpha	B-PRGE
)	O
and	O
IKKbeta	B-PRGE
cellular	O
kinases	O
.	O

Tax	B-PRGE
corresponds	O
to	O
a	O
40	O
-	O
kDa	O
transforming	O
protein	O
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
by	O
an	O
unknown	O
mechanism	O
.	O

Tax	B-PRGE
expression	O
promotes	O
N	O
-	O
terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Our	O
studies	O
now	O
demonstrate	O
that	O
HTLV	O
-	O
1	O
Tax	B-PRGE
activates	O
the	O
recently	O
identified	O
cellular	O
kinases	O
IkappaB	B-PRGE
kinase	I-PRGE
alpha	I-PRGE
(	O
IKKalpha	B-PRGE
)	O
and	O
IKKbeta	B-PRGE
,	O
which	O
normally	O
phosphorylate	O
IkappaB	B-PRGE
alpha	I-PRGE
on	O
both	O
of	O
its	O
N	O
-	O
terminal	O
regulatory	O
serines	O
in	O
response	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
stimulation	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-PRGE
termed	O
M22	O
,	O
which	O
does	O
not	O
induce	O
NF	O
-	O
kappaB	O
,	O
fails	O
to	O
activate	O
either	O
IKKalpha	B-PRGE
or	O
IKKbeta	B-PRGE
.	O

Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV	O
-	O
1	O
-	O
infected	O
and	O
Tax	B-PRGE
-	O
expressing	O
T	O
-	O
cell	O
lines	O
.	O

Transfection	O
of	O
kinase	O
-	O
deficient	O
mutants	O
of	O
IKKalpha	B-PRGE
and	O
IKKbeta	B-PRGE
into	O
either	O
human	O
Jurkat	O
T	O
or	O
293	O
cells	O
also	O
inhibits	O
NF	O
-	O
kappaB	O
-	O
dependent	O
reporter	O
gene	O
expression	O
induced	O
by	O
Tax	B-PRGE
.	O

Similarly	O
,	O
a	O
kinase	O
-	O
deficient	O
mutant	O
of	O
NIK	B-PRGE
(	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	I-PRGE
inducing	I-PRGE
kinase	I-PRGE
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	O
-	O
1	O
signaling	O
pathways	O
leading	O
to	O
IKKalpha	B-PRGE
and	O
IKKbeta	B-PRGE
activation	O
,	O
blocks	O
Tax	B-PRGE
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

However	O
,	O
plasma	O
membrane	O
-	O
proximal	O
elements	O
in	O
these	O
proinflammatory	O
cytokine	O
pathways	O
are	O
apparently	O
not	O
involved	O
since	O
dominant	O
negative	O
mutants	O
of	O
the	O
TRAF2	B-PRGE
and	O
TRAF6	B-PRGE
adaptors	O
,	O
which	O
effectively	O
block	O
signaling	O
through	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
receptors	O
,	O
respectively	O
,	O
do	O
not	O
inhibit	O
Tax	B-PRGE
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV	O
-	O
1	O
Tax	B-PRGE
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	O
cytokine	O
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF	O
-	O
kappaB	O
activation	O
by	O
Tax	B-PRGE
may	O
play	O
a	O
central	O
role	O
in	O
HTLV	O
-	O
1	O
-	O
mediated	O
transformation	O
of	O
human	O
T	O
cells	O
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

A	O
CD28	B-PRGE
-	O
associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	O
gene	O
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	O
engagement	O
.	O

Stimulation	O
of	O
resting	O
human	O
T	O
cells	O
with	O
the	O
CD28	B-PRGE
-	O
specific	O
mAb	O
BW	O
828	O
induces	O
proliferation	O
and	O
cytokine	O
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	O
coengagement	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	O
signal	O
)	O
can	O
activate	O
T	O
cells	O
.	O

To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	B-PRGE
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	O
cells	O
by	O
the	O
stimulatory	O
mAb	O
BW	O
828	O
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	O
CD28	B-PRGE
mAb	O
9	O
.	O
3	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
BW	O
828	O
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2	O
+	O
,	O
but	O
did	O
not	O
lead	O
to	O
detectable	O
activation	O
of	O
the	O
protein	O
kinases	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	B-PRGE
response	O
element	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
mAb	O
9	O
.	O
3	O
increased	O
the	O
level	O
of	O
intracellular	O
Ca2	O
+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
was	O
unable	O
to	O
induce	O
the	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B-PRGE
828	I-PRGE
and	O
9	B-PRGE
.	I-PRGE
3	I-PRGE
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
activation	O
,	O
association	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
with	O
CD28	B-PRGE
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	B-PRGE
changes	O
with	O
activation	O
.	O

These	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
through	O
CD28	B-PRGE
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O
.	O

Cyclosporin	O
A	O
-	O
resistant	O
transactivation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
requires	O
activity	O
of	O
okadaic	O
acid	O
-	O
sensitive	O
serine	O
/	O
threonine	O
phosphatases	O
.	O

Expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
requires	O
activation	O
of	O
T	O
cells	O
through	O
stimulation	O
of	O
the	O
TCR	O
and	O
costimulation	O
through	O
accessory	O
receptors	O
.	O

We	O
have	O
found	O
recently	O
that	O
okadaic	O
acid	O
-	O
sensitive	O
Ser	O
/	O
Thr	O
phosphatases	O
are	O
involved	O
in	O
a	O
cyclosporin	O
A	O
-	O
insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

In	O
both	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
activated	O
tumorigenic	O
T	O
cell	O
lines	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O

The	O
transcription	O
factors	O
active	O
at	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
were	O
differentially	O
influenced	O
:	O
upon	O
down	O
-	O
modulation	O
of	O
okadaic	O
acid	O
-	O
sensitive	O
phosphatases	O
,	O
transactivation	O
by	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
NF	O
of	O
activated	O
T	O
cells	O
proteins	O
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP	O
-	O
1	O
proteins	O
was	O
even	O
enhanced	O
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	O
wall	O
cells	O
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O

We	O
find	O
that	O
iNO	O
produced	O
by	O
murine	O
macrophage	O
-	O
like	O
cells	O
,	O
RAW264	O
.	O
7	O
,	O
can	O
inhibit	O
cytokine	O
-	O
induced	O
endothelial	O
cell	O
activation	O
in	O
a	O
separated	O
and	O
mixed	O
endothelial	O
-	O
RAW264	O
.	O
7	O
coculture	O
system	O
.	O

Both	O
iNO	O
production	O
and	O
endothelial	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
were	O
induced	O
simultaneously	O
with	O
bacterial	O
LPS	O
and	O
murine	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Inhibition	O
of	O
iNO	B-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
activity	O
with	O
N	O
omega	O
-	O
monomethyl	O
-	O
L	O
-	O
arginine	O
in	O
endothelial	O
-	O
RAW264	O
.	O
7	O
cocultures	O
,	O
stimulated	O
with	O
murine	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
iNOS	B-PRGE
expression	O
in	O
endothelial	O
and	O
RAW264	O
.	O
7	O
cells	O
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O

Transient	O
transfection	O
studies	O
using	O
various	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
constructs	O
demonstrated	O
that	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
transcription	O
were	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	O
B	O
cis	O
-	O
acting	O
elements	O
.	O

Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
subunit	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B-PRGE
expression	O
in	O
macrophages	O
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Inhibition	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
with	O
AZT	O
.	O

The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O

S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3	O
'	O
-	O
azido	O
-	O
3	O
'	O
-	O
deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	O
reverse	O
transcriptase	O
.	O

Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV	O
-	O
1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	O
infected	O
CD4	B-PRGE
+	O
lymphocytes	O
(	O
SupT	O
)	O
in	O
culture	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
infected	O
with	O
a	O
primary	O
HIV	O
-	O
1	O
isolate	O
.	O

S9a	O
inhibited	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
-	O
driven	O
reporter	O
gene	O
activity	O
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
transcription	O
via	O
a	O
Tat	B-PRGE
-	O
induced	O
tar	O
-	O
independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF	O
-	O
kappaB	O
activation	O
of	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure	O
-	O
based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O

This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	O
genes	O
.	O

Retinoic	O
acid	O
inhibits	O
CD40	B-PRGE
+	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
mediated	O
IgE	O
production	O
in	O
vitro	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti	O
-	O
CD40	B-PRGE
+	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
-	O
mediated	O
B	O
-	O
cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-	O
12	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
RA	O
was	O
studied	O
in	O
anti	O
-	O
CD40	B-PRGE
(	O
1	O
microgram	O
/	O
mL	O
)	O
+	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
5	O
ng	O
/	O
mL	O
)	O
-	O
mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
B	O
cells	O
in	O
healthy	O
donors	O
.	O

Anti	O
-	O
CD40	B-PRGE
+	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+	O
/	O
-	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
+	O
/	O
-	O
4	O
.	O
4	O
%	O
in	O
B	O
cells	O
by	O
all	O
-	O
trans	O
RA	O
,	O
and	O
58	O
%	O
+	O
/	O
-	O
6	O
.	O
7	O
%	O
and	O
51	O
%	O
+	O
/	O
-	O
4	O
.	O
7	O
%	O
,	O
respectively	O
by	O
13	O
-	O
cis	O
RA	O
.	O

IgE	O
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-	O
14	O
)	O
mol	O
/	O
L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-	O
10	O
)	O
mol	O
/	O
L	O
for	O
PBMC	O
.	O

Maximal	O
inhibition	O
of	O
IgE	O
production	O
for	O
B	O
cells	O
was	O
at	O
10	O
(	O
-	O
8	O
)	O
mol	O
/	O
L	O
for	O
all	O
-	O
trans	O
RA	O
(	O
94	O
%	O
+	O
/	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
96	O
%	O
+	O
/	O
-	O
3	O
.	O
2	O
%	O
for	O
13	O
-	O
cis	O
RA	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	O
synthesis	O
(	O
10	O
(	O
-	O
10	O
)	O
mol	O
/	O
L	O
)	O
affected	O
neither	O
B	O
-	O
cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	O
,	O
IgG	O
,	O
and	O
IgM	O
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	O
production	O
shows	O
that	O
epsilon	O
germline	O
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O

To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	B-PRGE
receptors	I-PRGE
alpha	I-PRGE
,	O
beta	B-PRGE
,	O
and	O
gamma	B-PRGE
,	O
the	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
was	O
examined	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

The	O
data	O
show	O
that	O
unstimulated	O
human	O
peripheral	O
B	O
cells	O
express	O
mRNA	O
of	O
the	O
RA	B-PRGE
receptor	I-PRGE
alpha	I-PRGE
,	O
beta	B-PRGE
,	O
and	O
gamma	B-PRGE
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose	O
-	O
dependent	O
inhibition	O
of	O
IgE	O
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	O
receptor	O
with	O
high	O
specificity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	O
production	O
of	O
anti	O
-	O
CD40	B-PRGE
+	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
stimulated	O
B	O
cells	O
in	O
vitro	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
induction	O
in	O
CD45RO	B-PRGE
+	O
and	O
CD45RA	B-PRGE
+	O
T	O
cell	O
subsets	O
during	O
aging	O
.	O

An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	O
to	O
naive	O
T	O
cells	O
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O

Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
in	O
activated	O
memory	O
(	O
CD45RO	B-PRGE
+	O
)	O
and	O
naive	O
(	O
CD45RA	B-PRGE
+	O
)	O
T	O
cell	O
subsets	O
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	O
T	O
cells	O
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mediated	O
induction	O
of	O
NFkappaB	O
.	O

Although	O
treatment	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
induced	O
nuclear	O
localization	O
of	O
NFkappaB	O
in	O
both	O
memory	O
and	O
naive	O
T	O
cell	O
subsets	O
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	O
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	O
cells	O
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O

Examination	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
regulation	O
revealed	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mediated	O
degradation	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
in	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	O
.	O

In	O
addition	O
,	O
this	O
age	O
-	O
related	O
decrease	O
in	O
induction	O
of	O
nuclear	O
NFkappaB	O
correlated	O
with	O
decrease	O
in	O
intracellular	O
IL	O
-	O
2	O
receptor	O
expression	O
and	O
anti	O
-	O
CD3	O
-	O
induced	O
proliferation	O
of	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
subsets	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age	O
-	O
related	O
hyporesponsiveness	O
cannot	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O

Activation	O
of	O
E2F	O
-	O
mediated	O
transcription	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-PRGE
protein	O
in	O
a	O
p16	B-PRGE
(	O
INK4A	B-PRGE
)	O
-	O
negative	O
T	O
-	O
cell	O
line	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV	O
-	O
I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	B-PRGE
protein	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

This	O
40	O
-	O
kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	O
suppressor	O
p16	B-PRGE
(	O
INK4A	B-PRGE
)	O
.	O

Consequently	O
,	O
Tax	B-PRGE
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	O
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	B-PRGE
can	O
also	O
activate	O
E2F	O
-	O
mediated	O
transcription	O
independently	O
of	O
p16	B-PRGE
(	O
INK4A	B-PRGE
)	O
.	O

Indeed	O
,	O
when	O
Tax	B-PRGE
is	O
coexpressed	O
with	O
the	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
factor	O
in	O
CEM	O
T	O
-	O
cells	O
,	O
which	O
lack	O
expression	O
of	O
p16	B-PRGE
(	O
INK4A	B-PRGE
)	O
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F	O
-	O
binding	O
sites	O
.	O

In	O
addition	O
,	O
Tax	B-PRGE
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
itself	O
.	O

Using	O
Tax	B-PRGE
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	O
-	O
or	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoters	O
and	O
different	O
5	O
'	O
truncation	O
mutants	O
of	O
the	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
,	O
we	O
show	O
that	O
the	O
Tax	B-PRGE
-	O
dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	B-PRGE
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
and	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1	O
.	O
1	O
and	O
resistant	O
ICR27TK	O
.	O
3	O
human	O
leukemic	O
T	O
cells	O
.	O

Following	O
glucocorticoid	O
treatment	O
of	O
6TG1	O
.	O
1	O
cells	O
,	O
chromatin	O
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O

Fragmentation	O
was	O
not	O
observed	O
in	O
ICR27TK	O
.	O
3	O
cells	O
containing	O
mutant	O
glucocorticoid	O
receptors	O
(	O
L753F	O
)	O
that	O
are	O
activation	O
-	O
deficient	O
but	O
retain	O
the	O
ability	O
to	O
repress	O
AP	O
-	O
1	O
activity	O
.	O

Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP	O
-	O
1	O
activity	O
is	O
not	O
involved	O
.	O

As	O
described	O
in	O
other	O
systems	O
,	O
fragmentation	O
required	O
ongoing	O
protein	O
synthesis	O
.	O

However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O

Dexamethasone	O
treatment	O
completely	O
blocked	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activity	O
and	O
elicited	O
an	O
increase	O
in	O
the	O
amount	O
of	O
immunoreactive	O
IkappaB	B-PRGE
alpha	I-PRGE
in	O
sensitive	O
6TG1	O
.	O
1	O
cells	O
but	O
not	O
in	O
resistant	O
ICR27TK	O
.	O
3	O
cells	O
.	O

In	O
addition	O
,	O
mild	O
detergent	O
treatment	O
of	O
cell	O
extracts	O
indicated	O
that	O
a	O
substantial	O
amount	O
of	O
cytoplasmic	O
NF	O
-	O
kappaB	O
is	O
complexed	O
with	O
IkappaB	B-PRGE
alpha	I-PRGE
or	O
some	O
other	O
inhibitory	O
factor	O
.	O

These	O
results	O
suggest	O
that	O
induction	O
of	O
a	O
labile	O
inhibitory	O
factor	O
such	O
as	O
IkappaB	B-PRGE
alpha	I-PRGE
may	O
contribute	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O

Peripheral	O
T	O
lymphocytes	O
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	O
signaling	O
molecules	O
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

In	O
6	O
of	O
14	O
patients	O
,	O
T	O
lymphocytes	O
displayed	O
an	O
impaired	O
ability	O
to	O
translocate	O
NFeB	O
p65	B-PRGE
(	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
)	O
following	O
activation	O
by	O
anti	O
-	O
CD3	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
protein	O
.	O

We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	O
molecules	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
receptor	I-PRGE
(	I-PRGE
TCR	I-PRGE
)	I-PRGE
-	I-PRGE
zeta	I-PRGE
,	O
ZAP	B-PRGE
-	I-PRGE
70	I-PRGE
and	O
p56lck	B-PRGE
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i	O
.	O
e	O
.	O
,	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
molecules	O
.	O

T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	O
phosphatase	O
,	O
map	B-PRGE
kinase	I-PRGE
phosphatase	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MKP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
.	O

MKP	B-PRGE
-	I-PRGE
1	I-PRGE
inactivates	O
MAP	O
kinase	O
and	O
therefore	O
may	O
interfere	O
with	O
the	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
.	O

Abnormalities	O
of	O
I	O
or	O
more	O
signaling	O
molecules	O
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	O
cells	O
that	O
exhibited	O
all	O
5	O
defects	O
.	O

Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	O
molecule	O
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O

Finally	O
,	O
despite	O
impaired	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
translocation	O
,	O
T	O
cells	O
were	O
capable	O
of	O
transcribing	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Impairments	O
in	O
the	O
translocation	O
of	O
Rel	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
further	O
suggest	O
that	O
the	O
NFKB	O
family	O
members	O
Rel	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
Rel	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
the	O
peripheral	O
T	O
lymphocytes	O
of	O
patients	O
with	O
breast	O
cancer	O
.	O

Transcription	O
of	O
a	O
minimal	O
promoter	O
from	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
gene	O
is	O
regulated	O
by	O
CREB	O
/	O
ATF	O
and	O
SP1	B-PRGE
proteins	O
in	O
U937	O
promonocytic	O
cells	O
.	O

NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	O
monocytes	O
/	O
macrophages	O
,	O
and	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
is	O
the	O
only	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
family	O
member	O
whose	O
steady	O
-	O
state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	O
(	O
1	O
)	O
.	O

We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
gene	O
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
mRNA	O
following	O
activation	O
of	O
U937	O
promonocytic	O
cells	O
.	O

We	O
have	O
identified	O
a	O
104	O
-	O
bp	O
minimal	O
promoter	O
region	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
gene	O
that	O
is	O
sufficient	O
for	O
basal	O
and	O
activation	O
-	O
dependent	O
induction	O
of	O
transcription	O
in	O
U937	O
cells	O
.	O

This	O
region	O
contains	O
binding	O
sites	O
for	O
the	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
/	O
activation	O
transcription	O
factor	O
(	O
CREB	O
/	O
ATF	O
)	O
and	O
Sp1	B-PRGE
families	O
of	O
transcription	O
factors	O
.	O

Each	O
site	O
is	O
functionally	O
important	O
and	O
contributes	O
independently	O
to	O
transcription	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
gene	O
in	O
U937	O
cells	O
.	O

CD30	B-PRGE
is	O
a	O
CD40	B-PRGE
-	O
inducible	O
molecule	O
that	O
negatively	O
regulates	O
CD40	B-PRGE
-	O
mediated	O
immunoglobulin	O
class	O
switching	O
in	O
non	O
-	O
antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL	O
-	O
01	O
B	O
cells	O
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B-PRGE
in	O
human	O
B	O
cell	O
differentiation	O
.	O

CL	O
-	O
01	O
cells	O
are	O
IgM	O
+	O
IgD	O
+	O
CD30	B-PRGE
+	O
and	O
switch	O
to	O
IgG	O
,	O
IgA	O
,	O
and	O
IgE	O
when	O
exposed	O
to	O
CD40L	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

Switching	O
is	O
hampered	O
by	O
CD30	B-PRGE
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
of	O
downstream	O
C	O
(	O
H	O
)	O
genes	O
.	O

The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	B-PRGE
-	O
mediated	O
effects	O
in	O
naive	O
B	O
cells	O
.	O

Expression	O
of	O
CD30	B-PRGE
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B-PRGE
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and	O
/	O
or	O
exposure	O
to	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
12	O
.	O

Our	O
data	O
suggest	O
that	O
CD30	B-PRGE
critically	O
regulates	O
the	O
CD40	B-PRGE
-	O
mediated	O
differentiation	O
of	O
non	O
-	O
antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O

Induction	O
of	O
Mn	B-PRGE
SOD	I-PRGE
in	O
human	O
monocytes	O
without	O
inflammatory	O
cytokine	O
production	O
by	O
a	O
mutant	O
endotoxin	O
.	O

Endotoxin	O
selectively	O
induces	O
monocyte	O
Mn	B-PRGE
superoxide	I-PRGE
dismutase	I-PRGE
(	O
SOD	O
)	O
without	O
affecting	O
levels	O
of	O
Cu	B-PRGE
,	I-PRGE
Zn	I-PRGE
SOD	I-PRGE
,	O
catalase	B-PRGE
,	O
or	O
glutathione	O
peroxidase	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure	O
-	O
activity	O
relationship	O
and	O
the	O
mechanism	O
by	O
which	O
endotoxin	O
induces	O
Mn	B-PRGE
SOD	I-PRGE
.	O

In	O
this	O
study	O
we	O
demonstrated	O
that	O
a	O
mutant	O
Escherichia	O
coli	O
endotoxin	O
lacking	O
myristoyl	O
fatty	O
acid	O
at	O
the	O
3	O
'	O
R	O
-	O
3	O
-	O
hydroxymyristate	O
position	O
of	O
the	O
lipid	O
A	O
moiety	O
retained	O
its	O
full	O
capacity	O
to	O
coagulate	O
Limulus	O
amoebocyte	O
lysate	O
compared	O
with	O
the	O
wild	O
-	O
type	O
E	O
.	O
coli	O
endotoxin	O
and	O
markedly	O
stimulated	O
the	O
activation	O
of	O
human	O
monocyte	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
the	O
induction	O
of	O
Mn	B-PRGE
SOD	I-PRGE
mRNA	O
and	O
enzyme	O
activity	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
endotoxin	O
,	O
it	O
failed	O
to	O
induce	O
significant	O
production	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
1alpha	I-PRGE
by	O
monocytes	O
and	O
did	O
not	O
induce	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	O
cytokine	O
production	O
by	O
human	O
monocytes	O
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B-PRGE
SOD	I-PRGE
,	O
2	O
)	O
endotoxin	O
-	O
mediated	O
induction	O
of	O
Mn	B-PRGE
SOD	I-PRGE
and	O
inflammatory	O
cytokines	O
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	O
endotoxin	O
to	O
induce	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

An	O
allosteric	O
drug	O
,	O
o	O
,	O
o	O
'	O
-	O
bismyristoyl	O
thiamine	O
disulfide	O
,	O
suppresses	O
HIV	O
-	O
1	O
replication	O
through	O
prevention	O
of	O
nuclear	O
translocation	O
of	O
both	O
HIV	O
-	O
1	O
Tat	B-PRGE
and	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
efficacy	O
of	O
o	O
,	O
o	O
'	O
-	O
bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV	O
-	O
1	O
laboratory	O
isolates	O
(	O
HTLV	O
-	O
IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O

BMT	O
inhibited	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans	O
-	O
disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o	O
'	O
-	O
bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

BMT	O
inhibits	O
nuclear	O
translocation	O
of	O
both	O
HIV	O
-	O
1	O
transactivator	O
(	O
TAT	B-PRGE
)	O
and	O
the	O
cellular	O
transcriptional	O
nuclear	O
factor	O
-	O
KB	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Retinoid	O
X	O
receptor	O
and	O
c	O
-	O
cerbA	O
/	O
thyroid	O
hormone	O
receptor	O
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O

Nuclear	O
receptors	O
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O

Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
,	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
,	O
and	O
of	O
the	O
c	O
-	O
erbA	O
/	O
thyroid	O
hormone	O
(	O
T3	O
)	O
receptor	O
(	O
c	O
-	O
erbA	O
/	O
TR	O
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	O
cells	O
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	B-PRGE
cell	I-PRGE
factor	I-PRGE
-	O
dependent	O
erythroid	O
progenitors	O
.	O

RXR	O
,	O
RAR	O
,	O
and	O
c	O
-	O
erbA	O
/	O
TR	O
-	O
specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid	O
-	O
specific	O
gene	O
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O

Furthermore	O
,	O
while	O
ligand	O
-	O
activated	O
c	O
-	O
erbA	O
/	O
TR	O
accelerated	O
differentiation	O
,	O
unliganded	O
c	O
-	O
erbA	O
/	O
TR	O
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O

Thus	O
,	O
c	O
-	O
erbA	O
/	O
TR	O
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	O
cell	O
fate	O
:	O
unliganded	O
c	O
-	O
erbA	O
/	O
TR	O
supports	O
growth	O
while	O
ligand	O
-	O
activated	O
c	O
-	O
erbA	O
/	O
TR	O
induces	O
differentiation	O
.	O

Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	O
RXRs	O
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF	O
-	O
1	O
and	O
AF	O
-	O
2	O
,	O
or	O
AF	O
-	O
2	O
only	O
,	O
or	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
were	O
introduced	O
into	O
erythroid	O
progenitor	O
cells	O
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	O
-	O
specific	O
effects	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
wild	O
-	O
type	O
RXR	O
and	O
of	O
the	O
RXR	O
mutants	O
devoid	O
of	O
AF	O
-	O
1	O
and	O
/	O
or	O
AF	O
-	O
2	O
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	O
cells	O
.	O

In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	O
interfering	O
deltaDNA	O
-	O
binding	O
domain	O
RXR	O
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
.	O

Phosphatidylinositides	O
bind	O
to	O
plasma	O
membrane	O
CD14	B-PRGE
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B-PRGE
(	O
membrane	O
CD14	B-PRGE
)	O
,	O
a	O
cell	O
-	O
surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host	O
-	O
derived	O
mCD14	B-PRGE
ligands	O
are	O
poorly	O
defined	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol	O
-	O
4	O
-	O
phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	B-PRGE
.	O

Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	B-PRGE
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O

LPS	O
-	O
binding	O
protein	O
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	O
both	O
PS	O
-	O
and	O
PtdIns	O
-	O
mCD14	B-PRGE
binding	O
.	O

PtdIns	O
binding	O
to	O
mCD14	B-PRGE
can	O
be	O
blocked	O
by	O
anti	O
-	O
CD14	B-PRGE
monoclonal	O
antibodies	O
that	O
inhibit	O
LPS	O
-	O
mCD14	B-PRGE
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS	O
-	O
mCD14	B-PRGE
binding	O
and	O
LPS	O
-	O
induced	O
responses	O
in	O
monocytes	O
.	O

Serum	O
-	O
equilibrated	O
PtdIns	O
also	O
binds	O
to	O
mCD14	B-PRGE
-	O
expressing	O
cells	O
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	B-PRGE
ligands	O
in	O
vivo	O
.	O

Low	O
CD3	O
+	O
CD28	B-PRGE
-	O
induced	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	O
T	O
cells	O
.	O

The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O

We	O
analysed	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
purified	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor	O
-	O
mediated	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD3	O
+	O
anti	O
-	O
CD28	B-PRGE
stimulation	O
.	O

PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
by	O
neonatal	O
cells	O
was	O
undetectable	O
and	O
adult	O
cells	O
produced	O
low	O
amounts	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
mean	O
331	O
+	O
/	O
-	O
86	O
pg	O
/	O
ml	O
)	O
.	O

The	O
addition	O
of	O
anti	O
-	O
CD28	B-PRGE
mAb	O
to	O
anti	O
-	O
CD3	O
-	O
stimulated	O
cells	O
markedly	O
increased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
neonatal	O
T	O
cells	O
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	O
T	O
cells	O
(	O
respective	O
mean	O
values	O
:	O
385	O
+	O
/	O
-	O
109	O
pg	O
/	O
ml	O
and	O
4494	O
+	O
/	O
-	O
1199	O
pg	O
/	O
ml	O
)	O
.	O

As	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
critical	O
transcription	O
factor	O
in	O
the	O
control	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI	O
-	O
reactive	O
fluorochrome	O
DCFH	O
-	O
DA	O
and	O
flow	O
cytometry	O
.	O

In	O
neonatal	O
T	O
cells	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ROI	O
formation	O
after	O
anti	O
-	O
CD3	O
stimulation	O
were	O
low	O
compared	O
with	O
adult	O
T	O
cells	O
and	O
,	O
although	O
addition	O
of	O
anti	O
-	O
CD28	B-PRGE
mAb	O
increased	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
ROI	O
formation	O
,	O
levels	O
similar	O
to	O
those	O
of	O
adults	O
were	O
not	O
achieved	O
.	O

After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
.	O

Our	O
results	O
suggest	O
that	O
reduced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
by	O
neonatal	O
T	O
cells	O
is	O
specific	O
for	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD3	O
+	O
anti	O
-	O
CD28	B-PRGE
-	O
mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
cannot	O
effectively	O
activate	O
the	O
ROI	O
-	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O

Activated	O
platelets	O
induce	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
on	O
endothelial	O
cells	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Platelet	O
/	O
endothelium	O
interaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
inflammation	O
and	O
atherosclerosis	O
.	O

The	O
role	O
of	O
platelets	O
for	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
on	O
endothelial	O
cells	O
has	O
been	O
assessed	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
incubated	O
with	O
nonstimulated	O
or	O
ADP	O
-	O
activated	O
platelets	O
for	O
6	O
hours	O
,	O
and	O
secretion	O
of	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
surface	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
determined	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

In	O
the	O
presence	O
of	O
ADP	O
-	O
activated	O
platelets	O
,	O
both	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
secretion	O
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	O
platelets	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	O
-	O
dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	O
platelets	O
.	O

In	O
addition	O
,	O
ADP	O
-	O
activated	O
platelets	O
induced	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
-	O
dependent	O
transcription	O
.	O

Liposomal	O
transfection	O
of	O
a	O
double	O
-	O
stranded	O
kappaB	O
phosphorothioate	O
oligonucleotide	O
,	O
but	O
not	O
of	O
the	O
mutated	O
form	O
,	O
inhibited	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
secretion	O
and	O
surface	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
on	O
activated	O
endothelium	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
indicates	O
that	O
activated	O
platelets	O
modulate	O
chemotactic	O
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
adhesive	O
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
properties	O
of	O
endothelial	O
cells	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
.	O

Platelet	O
-	O
induced	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
system	O
might	O
contribute	O
to	O
early	O
inflammatory	O
events	O
in	O
atherogenesis	O
.	O

Altered	O
DNA	O
-	O
binding	O
specificity	O
mutants	O
of	O
EKLF	B-PRGE
and	O
Sp1	B-PRGE
show	O
that	O
EKLF	B-PRGE
is	O
an	O
activator	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
control	O
region	O
in	O
vivo	O
.	O

The	O
locus	O
control	O
region	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
cluster	O
contains	O
five	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
5	O
'	O
HS1	O
-	O
5	O
)	O
required	O
for	O
locus	O
activation	O
.	O

5	O
'	O
HS3	O
contains	O
six	O
G	O
-	O
rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	O
fingers	O
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	O
factor	O
Sp1	B-PRGE
,	O
interact	O
with	O
these	O
motifs	O
.	O

Because	O
point	O
mutagenesis	O
cannot	O
distinguish	O
between	O
family	O
members	O
,	O
it	O
is	O
not	O
known	O
which	O
protein	O
activates	O
5	O
'	O
HS3	O
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5	O
'	O
HS3	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	O
fingers	O
of	O
Sp1	B-PRGE
and	O
EKLF	B-PRGE
.	O

Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	B-PRGE
is	O
a	O
direct	O
activator	O
of	O
5	O
'	O
HS3	O
.	O

Activation	O
of	O
distinct	O
transcription	O
factors	O
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	O
proteases	O
.	O

Human	O
neutrophils	O
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early	O
-	O
response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	O
,	O
chemokines	O
,	O
and	O
the	O
high	O
-	O
affinity	O
surface	O
receptor	O
for	O
IgG	O
,	O
FcgammaRI	B-PRGE
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	O
factors	O
,	O
such	O
as	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
STAT	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	O
factors	O
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	O
-	O
kappaB	O
/	O
Rel	O
and	O
STAT	O
proteins	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	B-PRGE
induce	O
a	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50	B-PRGE
/	O
RelA	B-PRGE
dimers	O
,	O
and	O
that	O
IFNgamma	B-PRGE
promotes	O
the	O
binding	O
of	O
STAT1	B-PRGE
homodimers	O
to	O
the	O
IFNgamma	B-PRGE
response	O
region	O
of	O
the	O
FcgammaRI	B-PRGE
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	O
-	O
containing	O
DNA	O
-	O
binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	O
proteases	O
.	O

Transcription	O
factor	O
activation	O
in	O
lymphokine	O
activated	O
killer	O
cells	O
and	O
lymphocytes	O
from	O
patients	O
receiving	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
immunotherapy	O
.	O

Administration	O
of	O
the	O
cytokine	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP	O
-	O
1	O
,	O
Sp1	B-PRGE
,	O
NF	O
-	O
kappaB	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel	O
-	O
shift	O
assay	O
.	O

An	O
in	O
vitro	O
surrogate	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
healthy	O
individuals	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O

One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O

Prior	O
to	O
in	O
vivo	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	O
factors	O
in	O
PBMC	O
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	O
from	O
healthy	O
individuals	O
.	O

Over	O
a	O
3	O
-	O
week	O
course	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	O
patterns	O
of	O
AP	O
-	O
1	O
,	O
Sp1	B-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
proteins	O
changed	O
to	O
resemble	O
those	O
seen	O
in	O
PBMC	O
activated	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
vitro	O
.	O

However	O
,	O
the	O
cells	O
obtained	O
from	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
treated	O
patients	O
did	O
not	O
have	O
low	O
-	O
level	O
constitutive	O
expression	O
of	O
STAT	O
binding	O
factors	O
as	O
did	O
LAK	O
cells	O
.	O

When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	O
induction	O
patterns	O
were	O
noted	O
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	O
cells	O
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	O
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

A	O
critical	O
role	O
of	O
the	O
p75	B-PRGE
tumor	I-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
p75TNF	B-PRGE
-	I-PRGE
R	I-PRGE
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	O
,	O
lymphotoxin	B-PRGE
alpha	I-PRGE
,	O
or	O
the	O
p55TNF	B-PRGE
-	I-PRGE
R	I-PRGE
.	O

Despite	O
overwhelming	O
evidence	O
that	O
enhanced	O
production	O
of	O
the	O
p75	B-PRGE
tumor	I-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
p75TNF	B-PRGE
-	I-PRGE
R	I-PRGE
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi	O
-	O
organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O

We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	O
p75TNF	B-PRGE
-	I-PRGE
R	I-PRGE
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cell	O
compartment	O
.	O

This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	O
,	O
lymphotoxin	B-PRGE
alpha	I-PRGE
,	O
or	O
the	O
p55TNF	B-PRGE
-	I-PRGE
R	I-PRGE
,	O
although	O
coexpression	O
of	O
a	O
human	O
TNF	O
transgene	O
accelerated	O
pathology	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF	B-PRGE
-	I-PRGE
R	I-PRGE
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O

As	O
several	O
inflammatory	O
cytokines	O
and	O
oxidative	O
stresses	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
-	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Two	O
chronically	O
HIV	O
-	O
1	O
-	O
infected	O
cell	O
lines	O
,	O
U1	O
(	O
monocytic	O
)	O
and	O
ACH	O
-	O
2	O
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O

HIV	O
-	O
1	O
replication	O
was	O
determined	O
by	O
p24	B-PRGE
antigen	I-PRGE
level	O
.	O

The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
driven	O
gene	O
expression	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
were	O
also	O
examined	O
.	O

Cepharanthine	O
dose	O
dependently	O
inhibited	O
HIV	O
-	O
1	O
replication	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
and	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
but	O
not	O
in	O
ACH	O
-	O
2	O
cells	O
.	O

Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0	O
.	O
016	O
and	O
2	O
.	O
2	O
microg	O
/	O
ml	O
in	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
,	O
respectively	O
.	O

Cepharanthine	O
was	O
found	O
to	O
suppress	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
gene	O
expression	O
through	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
a	O
chronically	O
infected	O
monocytic	O
cell	O
line	O
.	O

Since	O
biscoclaurine	O
alkaloids	O
,	O
containing	O
cepharanthine	O
as	O
a	O
major	O
component	O
,	O
are	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
various	O
inflammatory	O
diseases	O
in	O
Japan	O
,	O
cepharanthine	O
should	O
be	O
further	O
pursued	O
for	O
its	O
chemotherapeutic	O
potential	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
.	O

Prostaglandin	O
E2	O
Up	O
-	O
regulates	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
-	O
driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-	O
independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	O
and	O
host	O
cellular	O
factors	O
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	O
immunomodulatory	O
molecule	O
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV	O
-	O
1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	O
,	O
a	O
Jurkat	O
-	O
derived	O
T	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV	O
-	O
1	O
LTR	O
-	O
mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	O
messengers	O
involved	O
in	O
this	O
PGE2	O
-	O
dependent	O
up	O
-	O
regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV	O
-	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
Ca2	O
+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV	O
-	O
1	O
LTR	O
-	O
based	O
vectors	O
suggested	O
that	O
PGE2	O
-	O
mediated	O
activation	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-	O
independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
PGE2	O
-	O
dependent	O
activating	O
effect	O
on	O
HIV	O
-	O
1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB	O
-	O
regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV	O
-	O
1	O
LTR	O
-	O
driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	B-PRGE
receptor	I-PRGE
subtype	I-PRGE
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV	O
-	O
1	O
.	O

Fcgamma	O
receptor	O
-	O
mediated	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
in	O
monocytes	O
is	O
independent	O
of	O
Ras	O
.	O

Receptors	O
for	O
the	O
Fc	O
portion	O
of	O
immunoglobulin	O
molecules	O
(	O
FcR	O
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	O
mediators	O
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

Cross	O
-	O
linking	O
of	O
FcR	O
with	O
immune	O
complexes	O
leads	O
,	O
first	O
to	O
activation	O
of	O
protein	O
-	O
tyrosine	O
kinases	O
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	O
receptors	O
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	O
in	O
monocytes	O
.	O

Cross	O
-	O
linking	O
of	O
FcR	O
,	O
on	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
,	O
by	O
immune	O
complexes	O
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
and	O
interleukin	O
1	O
production	O
.	O

These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
dominant	O
negative	O
mutants	O
of	O
Ras	O
and	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
in	O
these	O
cells	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
FcR	O
-	O
mediated	O
nuclear	O
factor	O
activation	O
,	O
suggesting	O
that	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
was	O
not	O
used	O
by	O
these	O
receptors	O
.	O

However	O
,	O
MAPK	O
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	O
cross	O
-	O
linking	O
with	O
immune	O
complexes	O
.	O

Using	O
the	O
specific	O
MAPK	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	O
activation	O
is	O
necessary	O
for	O
FcR	O
-	O
dependent	O
activation	O
of	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	O
receptors	O
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	O
kinases	O
and	O
requires	O
MAPK	O
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	O
kinase	O
receptors	O
,	O
FcR	O
-	O
mediated	O
MAPK	O
activation	O
does	O
not	O
involve	O
Ras	O
and	O
Raf	O
.	O

Differential	O
RNA	O
display	O
identifies	O
novel	O
genes	O
associated	O
with	O
decreased	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
expression	O
.	O

To	O
characterize	O
further	O
the	O
function	O
of	O
the	O
intracellular	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
,	O
we	O
have	O
developed	O
stable	O
transfectant	O
variants	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
cell	O
line	O
(	O
U937	O
)	O
which	O
express	O
either	O
decreased	O
or	O
increased	O
numbers	O
of	O
VDR	B-PRGE
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
changes	O
in	O
gene	O
expression	O
associated	O
with	O
this	O
variable	O
VDR	B-PRGE
expression	O
.	O

Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	B-PRGE
levels	O
was	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
mRNA	O
expression	O
.	O

Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O

Sequence	O
analysis	O
of	O
DD	O
products	O
revealed	O
two	O
cDNAs	O
with	O
identity	O
to	O
known	O
gene	O
products	O
:	O
the	O
catalytic	O
sub	O
-	O
unit	O
of	O
DNA	O
-	O
protein	O
kinase	O
(	O
DNA	B-PRGE
-	I-PRGE
PK	I-PRGE
(	I-PRGE
CS	I-PRGE
)	I-PRGE
)	O
,	O
and	O
the	O
peroxisomal	O
enzyme	O
17beta	B-PRGE
-	I-PRGE
hydroxysteroid	I-PRGE
dehydrogenase	I-PRGE
type	I-PRGE
IV	I-PRGE
(	O
17beta	B-PRGE
-	I-PRGE
HSD	I-PRGE
IV	I-PRGE
)	O
.	O

Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	O
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	B-PRGE
.	O

Down	O
-	O
regulation	O
of	O
17beta	B-PRGE
-	I-PRGE
HSD	I-PRGE
IV	I-PRGE
mRNA	O
expression	O
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	O
cells	O
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O

Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta	B-PRGE
-	I-PRGE
HSD	I-PRGE
IV	I-PRGE
or	O
DNA	B-PRGE
-	I-PRGE
PK	I-PRGE
(	I-PRGE
CS	I-PRGE
)	I-PRGE
mRNA	O
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone	O
-	O
dependent	O
trans	O
-	O
activator	O
,	O
VDR	B-PRGE
may	O
influence	O
gene	O
expression	O
by	O
ligand	O
-	O
independent	O
mechanisms	O
.	O

Downstream	O
activation	O
of	O
a	O
TATA	O
-	O
less	O
promoter	O
by	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
Bob1	B-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
directs	O
expression	O
of	O
the	O
homing	O
receptor	O
BLR1	B-PRGE
to	O
mature	O
B	O
cells	O
.	O

The	O
chemokine	O
receptor	O
,	O
BLR1	B-PRGE
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O

In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA	O
-	O
less	O
blr1	B-PRGE
core	O
promoter	O
that	O
confer	O
cell	O
type	O
-	O
and	O
differentiation	O
-	O
specific	O
expression	O
in	O
the	O
B	O
cells	O
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	O
promoter	O
region	O
(	O
-	O
36	O
with	O
respect	O
to	O
the	O
transcription	O
start	O
site	O
)	O
,	O
a	O
NF	O
-	O
kappaB	O
motif	O
(	O
+	O
44	O
)	O
,	O
and	O
a	O
noncanonical	O
octamer	O
motif	O
(	O
+	O
157	O
)	O
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene	O
-	O
targeted	O
mice	O
deficient	O
of	O
either	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
Bob1	B-PRGE
,	O
or	O
both	O
NF	O
-	O
kappaB	O
subunits	O
p50	B-PRGE
and	O
p52	B-PRGE
.	O

In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	O
of	O
BLR1	B-PRGE
was	O
reduced	O
or	O
absent	O
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52	B-PRGE
/	O
NF	O
-	O
kappaB	O
,	O
BLR1	B-PRGE
expression	O
was	O
unaffected	O
.	O

Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	B-PRGE
is	O
a	O
target	O
gene	O
for	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
Bob1	B-PRGE
,	O
and	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	O
for	O
these	O
factors	O
.	O

Interaction	O
of	O
sickle	O
erythrocytes	O
with	O
endothelial	O
cells	O
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

The	O
abnormal	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
to	O
endothelial	O
cells	O
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O

We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	O
RBC	O
with	O
cultured	O
endothelial	O
cells	O
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	O
adhesion	O
molecules	O
(	O
CAMs	O
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
and	O
the	O
adherence	O
of	O
SS	O
reticulocytes	O
.	O

We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	O
RBC	O
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
(	O
vWf	B-PRGE
)	O
,	O
derived	O
from	O
endothelial	O
cell	O
-	O
derived	O
conditioned	O
medium	O
(	O
E	O
-	O
CM	O
)	O
with	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O

Normal	O
RBC	O
show	O
none	O
of	O
these	O
phenomena	O
.	O

The	O
oxidant	O
stress	O
-	O
induced	O
signaling	O
resulted	O
in	O
an	O
increased	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	O
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
HUVEC	O
.	O

The	O
addition	O
of	O
oxygen	O
radical	O
scavenger	O
enzymes	O
(	O
catalase	B-PRGE
,	O
superoxide	B-PRGE
dismutase	I-PRGE
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	O
these	O
events	O
.	O

Additionally	O
,	O
preincubation	O
of	O
HUVEC	O
with	O
a	O
synthetic	O
peptide	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	B-PRGE
-	O
mediated	O
adhesion	O
of	O
SS	O
RBC	O
reduced	O
the	O
surface	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	O
-	O
kB	O
activation	O
.	O

Furthermore	O
,	O
SS	O
RBC	O
-	O
induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte	O
-	O
like	O
HL	O
-	O
60	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
approximately	O
a	O
sixfold	O
increase	O
in	O
platelet	B-PRGE
-	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
phosphorylation	O
,	O
each	O
of	O
which	O
was	O
blocked	O
by	O
protein	O
kinase	O
C	O
inhibitor	O
and	O
antioxidants	O
.	O

These	O
results	O
suggest	O
that	O
the	O
adherence	O
/	O
contact	O
of	O
SS	O
RBC	O
to	O
endothelial	O
cells	O
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	O
reticulocytes	O
,	O
indicating	O
that	O
injury	O
/	O
activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso	O
-	O
occlusion	O
in	O
SCD	O
.	O

Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	O
and	O
inhibition	O
of	O
NFkappaB	O
in	O
human	O
monocytes	O
:	O
effects	O
on	O
TNFalpha	B-PRGE
release	O
.	O

Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	O
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
.	O

TS	O
induces	O
the	O
synthesis	O
of	O
heat	O
shock	O
(	O
HS	O
)	O
/	O
stress	O
proteins	O
(	O
HSP	O
)	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
Hsp70	O
.	O

We	O
determined	O
whether	O
Hsp70	O
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	O
transcription	O
factor	O
,	O
HSF	O
.	O

HSF	O
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	O
.	O

Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	O
.	O

U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	O
factors	O
were	O
analyzed	O
,	O
and	O
Hsp70	O
expression	O
and	O
TNFalpha	B-PRGE
release	O
were	O
determined	O
in	O
parallel	O
.	O

TS	O
activated	O
HSF	O
,	O
which	O
was	O
associated	O
with	O
Hsp70	O
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	O
binding	O
activity	O
and	O
TNFalpha	B-PRGE
release	O
.	O

The	O
altered	O
cytokine	O
profile	O
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF	O
/	O
Hsp70	O
-	O
mediated	O
inhibition	O
of	O
NFkappaB	O
activity	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
gene	O
by	O
cytokines	O
:	O
cross	O
-	O
talk	O
between	O
STAT5	B-PRGE
and	O
other	O
signaling	O
molecules	O
.	O

The	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
promoter	O
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	B-PRGE
(	I-PRGE
signal	I-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
)	I-PRGE
5	I-PRGE
since	O
STAT5	B-PRGE
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL	B-PRGE
-	O
inducible	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
expression	O
.	O

However	O
,	O
not	O
only	O
is	O
expression	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
gene	O
regulated	O
by	O
STAT5	B-PRGE
but	O
it	O
is	O
also	O
affected	O
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	O
regulation	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
gene	O
by	O
cytokines	O
in	O
T	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
gene	O
is	O
expressed	O
in	O
a	O
cytotoxic	O
T	O
cell	O
line	O
,	O
CTLL	O
-	O
2	O
,	O
in	O
response	O
to	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
which	O
activates	O
STAT5	B-PRGE
.	O

While	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
does	O
not	O
activate	O
STAT5	B-PRGE
,	O
it	O
induces	O
expression	O
of	O
STAT5	B-PRGE
-	O
regulated	O
genes	O
in	O
CTLL	O
-	O
2	O
,	O
i	O
.	O
e	O
.	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
,	O
a	O
cytokine	B-PRGE
-	I-PRGE
inducible	I-PRGE
SH2	I-PRGE
-	I-PRGE
containing	I-PRGE
protein	I-PRGE
(	O
CIS	B-PRGE
)	O
,	O
and	O
oncostatin	B-PRGE
M	I-PRGE
(	O
OSM	B-PRGE
)	O
,	O
suggesting	O
that	O
STAT6	B-PRGE
activated	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
substitutes	O
for	O
the	O
function	O
of	O
STAT5	B-PRGE
in	O
T	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-	O
155	O
and	O
-	O
193	O
in	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
promoter	O
.	O

Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
expression	O
of	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
.	O

Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	O
,	O
Ras	B-PRGE
(	I-PRGE
G12V	I-PRGE
)	I-PRGE
,	O
suppressed	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
and	O
OSM	B-PRGE
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	O
is	O
mediated	O
by	O
the	O
region	O
between	O
-	O
105	O
and	O
-	O
193	O
in	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
promoter	O
.	O

In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	O
,	O
RasN17	B-PRGE
,	O
also	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
STAT5	B-PRGE
element	O
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	B-PRGE
and	O
OSM	B-PRGE
.	O

In	O
addition	O
,	O
Ras	B-PRGE
(	I-PRGE
G12V	I-PRGE
)	I-PRGE
complemented	O
signaling	O
by	O
an	O
erythropoietin	B-PRGE
receptor	I-PRGE
mutant	O
defective	O
in	O
Ras	O
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
casein	I-PRGE
promoter	O
by	O
the	O
mutant	O
erythropoietin	B-PRGE
receptor	I-PRGE
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	O
in	O
Stat5	B-PRGE
-	O
mediated	O
gene	O
expression	O
.	O

These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	B-PRGE
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O

The	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
family	O
of	O
transcription	O
factors	O
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

This	O
review	O
discusses	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
family	O
in	O
general	O
and	O
the	O
association	O
of	O
NF	O
-	O
kappaB	O
activation	O
with	O
cellular	O
/	O
molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O
.	O

TAL1	B-PRGE
and	O
LIM	O
-	O
only	O
proteins	O
synergistically	O
induce	O
retinaldehyde	B-PRGE
dehydrogenase	I-PRGE
2	I-PRGE
expression	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	B-PRGE
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	B-PRGE
and	O
the	O
LIM	O
-	O
only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	B-PRGE
and	O
LMO	O
are	O
highly	O
synergistic	O
in	O
T	O
-	O
cell	O
tumorigenesis	O
in	O
double	O
-	O
transgenic	O
mice	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	B-PRGE
and	O
LMO	O
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	B-PRGE
and	O
LMO	O
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B-PRGE
dehydrogenase	I-PRGE
2	I-PRGE
(	O
RALDH2	B-PRGE
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T	O
-	O
ALL	O
cell	O
lines	O
that	O
coexpressed	O
TAL1	B-PRGE
and	O
LMO	O
.	O

Exogenously	O
transfected	O
TAL1	B-PRGE
and	O
LMO	O
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	B-PRGE
expression	O
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
,	O
HPB	O
-	O
ALL	O
,	O
not	O
expressing	O
endogeneous	O
TAL1	B-PRGE
or	O
LMO	O
.	O

The	O
RALDH2	B-PRGE
transcripts	O
in	O
T	O
-	O
ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	O
intron	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1	B-PRGE
-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	B-PRGE
binds	O
to	O
this	O
site	O
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	B-PRGE
potentiated	O
the	O
induction	O
of	O
RALDH2	B-PRGE
by	O
TAL1	B-PRGE
and	O
LMO	O
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
TAL1	B-PRGE
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	B-PRGE
in	O
the	O
presence	O
of	O
LMO	O
and	O
GATA3	B-PRGE
.	O

Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	B-PRGE
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	O
by	O
TAL1	B-PRGE
and	O
LMO	O
in	O
T	O
-	O
ALL	O
.	O

In	O
this	O
case	O
,	O
TAL1	B-PRGE
and	O
LMO	O
act	O
as	O
cofactors	O
for	O
GATA3	B-PRGE
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	B-PRGE
.	O

Granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
activates	O
a	O
72	O
-	O
kDa	O
isoform	O
of	O
STAT3	B-PRGE
in	O
human	O
neutrophils	O
.	O

Granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
signaling	O
involves	O
activation	O
of	O
STATs	O
,	O
proteins	O
that	O
serve	O
the	O
dual	O
function	O
of	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
.	O

We	O
previously	O
demonstrated	O
that	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
activated	O
a	O
distinct	O
Stat3	B-PRGE
-	O
like	O
protein	O
in	O
immature	O
and	O
mature	O
normal	O
myeloid	O
cells	O
,	O
StatG	B-PRGE
.	O

StatG	B-PRGE
in	O
normal	O
immature	O
human	O
myeloid	O
cells	O
,	O
i	O
.	O
e	O
.	O
adult	O
CD34	B-PRGE
+	O
bone	O
marrow	O
cells	O
,	O
was	O
composed	O
of	O
Stat3beta	B-PRGE
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	B-PRGE
in	O
mature	O
normal	O
human	O
myeloid	O
cells	O
,	O
i	O
.	O
e	O
.	O
polymorphonuclear	O
neutrophilic	O
granulocytes	O
(	O
PMN	O
)	O
.	O

These	O
studies	O
revealed	O
that	O
the	O
major	O
protein	O
in	O
extracts	O
of	O
PMN	O
activated	O
by	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
to	O
bind	O
the	O
high	O
-	O
affinity	O
serum	O
-	O
inducible	O
element	O
(	O
hSIE	O
)	O
is	O
a	O
72	O
-	O
kDa	O
protein	O
that	O
cross	O
-	O
reacts	O
with	O
Stat3	B-PRGE
monoclonal	O
antibody	O
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	B-PRGE
.	O

Stat3gamma	B-PRGE
is	O
derived	O
from	O
Stat3alpha	B-PRGE
by	O
limited	O
proteolysis	O
and	O
lacks	O
the	O
carboxyl	O
-	O
terminal	O
portion	O
of	O
Stat3alpha	B-PRGE
.	O

Because	O
this	O
region	O
of	O
Stat3alpha	B-PRGE
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	B-PRGE
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	B-PRGE
for	O
Stat3	B-PRGE
binding	O
sites	O
in	O
these	O
terminally	O
differentiated	O
myeloid	O
cells	O
.	O

Differential	O
effects	O
of	O
protein	O
kinase	O
C	O
inhibitors	O
on	O
fibronectin	B-PRGE
-	O
induced	O
interleukin	B-PRGE
-	I-PRGE
beta	I-PRGE
gene	O
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
when	O
stimulated	O
with	O
the	O
extracellular	O
matrix	O
glycoprotein	O
,	O
fibronectin	B-PRGE
(	O
FN	B-PRGE
)	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	O
acts	O
upon	O
to	O
mediate	O
the	O
FN	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	O
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
response	O
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
protein	O
into	O
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	B-PRGE
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
under	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
protein	O
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full	O
-	O
length	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	B-PRGE
induction	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP	O
-	O
1	O
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
gene	O
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	O
,	O
we	O
conclude	O
that	O
PKC	O
is	O
necessary	O
for	O
FN	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
protein	O
production	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
by	O
unknown	O
mechanisms	O
.	O

Cloning	O
of	O
ARE	O
-	O
containing	O
genes	O
by	O
AU	O
-	O
motif	O
-	O
directed	O
display	O
.	O

A	O
procedure	O
suitable	O
for	O
cloning	O
labile	O
mRNAs	O
that	O
contain	O
AU	O
motifs	O
is	O
presented	O
(	O
AU	O
-	O
DD	O
)	O
.	O

These	O
motifs	O
are	O
regulatory	O
sequences	O
within	O
the	O
so	O
-	O
called	O
AU	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
often	O
found	O
in	O
3	O
'	O
untranslated	O
regions	O
of	O
genes	O
such	O
as	O
cytokines	O
,	O
proto	O
-	O
oncogenes	O
,	O
and	O
transcription	O
factors	O
.	O

AU	O
-	O
DD	O
is	O
an	O
AU	O
-	O
motif	O
-	O
directed	O
differential	O
display	O
that	O
permits	O
the	O
identification	O
of	O
ARE	O
-	O
containing	O
genes	O
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O

It	O
has	O
been	O
applied	O
to	O
peripheral	O
blood	O
monocytes	O
and	O
a	O
T	O
cell	O
clone	O
to	O
isolate	O
59	O
cDNA	O
fragments	O
associated	O
to	O
activation	O
.	O

Fourteen	O
percent	O
of	O
isolated	O
fragments	O
belong	O
to	O
already	O
known	O
genes	O
that	O
certainly	O
are	O
cytokines	O
and	O
transduction	O
/	O
transcription	O
factors	O
.	O

The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	O
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O

These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	O
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF	O
-	O
and	O
cytokine	O
-	O
receptor	O
families	O
target	O
a	O
common	O
cis	O
-	O
element	O
of	O
the	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
promoter	O
.	O

CD40	B-PRGE
activation	O
of	O
B	O
cells	O
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O

IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
transcription	O
factor	O
activated	O
by	O
either	O
CD40	B-PRGE
or	O
cytokines	O
.	O

We	O
have	O
found	O
that	O
these	O
different	O
sets	O
of	O
signals	O
target	O
a	O
common	O
cis	O
-	O
acting	O
element	O
in	O
the	O
promoter	O
of	O
this	O
gene	O
,	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gamma	O
-	O
activated	O
site	O
(	O
GAS	O
)	O
.	O

Targeting	O
of	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
GAS	O
is	O
not	O
confined	O
to	O
activation	O
via	O
CD40	B-PRGE
but	O
extends	O
to	O
other	O
stimuli	O
that	O
mimic	O
the	O
CD40	B-PRGE
signaling	O
cascade	O
,	O
like	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
EBV	O
.	O

In	O
contrast	O
to	O
induction	O
of	O
STATs	O
by	O
cytokines	O
,	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
GAS	O
-	O
binding	O
complex	O
activated	O
by	O
CD40	B-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
or	O
EBV	O
contains	O
Rel	O
proteins	O
,	O
specifically	O
p50	B-PRGE
and	O
p65	B-PRGE
.	O

In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	B-PRGE
together	O
with	O
either	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel	O
/	O
STAT	O
complexes	O
.	O

Given	O
the	O
importance	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
a	O
variety	O
of	O
biologic	O
functions	O
from	O
proliferation	O
to	O
apoptosis	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
modulation	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
may	O
be	O
a	O
critical	O
control	O
point	O
in	O
B	O
cell	O
activation	O
.	O

Regulation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	B-PRGE
nuclear	O
import	O
in	O
T	O
lymphocytes	O
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
.	O

Activation	O
of	O
T	O
lymphocytes	O
by	O
Ags	O
or	O
cytokines	O
results	O
in	O
translocation	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
.	O

The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	O
localization	O
sequence	O
(	O
NLS	O
)	O
within	O
the	O
karyophilic	O
protein	O
by	O
a	O
cytoplasmic	O
receptor	O
such	O
as	O
the	O
importin	O
(	O
karyopherin	O
)	O
-	O
alpha	O
subunit	O
.	O

The	O
NLSs	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFAT	O
differ	O
and	O
the	O
NLS	O
of	O
STAT1	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Herein	O
we	O
demonstrate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	B-PRGE
in	O
Jurkat	O
T	O
lymphocytes	O
is	O
significantly	O
inhibited	O
by	O
a	O
cell	O
-	O
permeable	O
peptide	O
carrying	O
the	O
NLS	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
subunit	O
.	O

NLS	O
peptide	O
-	O
mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	O
factors	O
results	O
in	O
inhibition	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF	O
-	O
kappa	O
B	O
or	O
the	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
and	O
NFAT	O
.	O

Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	O
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	O
NLS	O
receptor	O
complex	O
comprised	O
of	O
the	O
Rch1	B-PRGE
/	O
importin	O
(	O
karyopherin	O
)	O
-	O
beta	O
heterodimer	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
,	O
NFAT	O
,	O
and	O
STAT1	B-PRGE
in	O
Jurkat	O
T	O
cells	O
can	O
be	O
regulated	O
by	O
NLS	O
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	O
T	O
cells	O
to	O
target	O
members	O
of	O
the	O
importin	O
(	O
karyopherin	O
)	O
-	O
alpha	O
beta	O
NLS	O
receptor	O
complex	O
.	O

Epithelial	O
cell	O
-	O
initiated	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
early	O
tissue	O
damage	O
in	O
amebic	O
infection	O
of	O
human	O
intestine	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
role	O
of	O
the	O
host	O
inflammatory	O
response	O
in	O
the	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
and	O
the	O
role	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
in	O
initiating	O
that	O
response	O
.	O

METHODS	O
:	O
E	O
.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID	O
-	O
HU	O
-	O
INT	O
)	O
mice	O
.	O

Human	O
intestinal	O
epithelial	O
cell	O
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	O
p65	B-PRGE
subunit	O
of	O
nuclear	O
factor	O
kappaB	O
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	O
from	O
SCID	O
-	O
HU	O
-	O
INT	O
mice	O
.	O

RESULTS	O
:	O
Administration	O
of	O
the	O
antisense	O
oligonucleotide	O
blocked	O
the	O
production	O
of	O
human	O
interleukin	B-PRGE
1beta	I-PRGE
and	O
interleukin	B-PRGE
8	I-PRGE
by	O
intestinal	O
epithelial	O
cells	O
and	O
inhibited	O
neutrophil	O
influx	O
into	O
the	O
E	O
.	O
histolytica	O
-	O
infected	O
intestinal	O
xenografts	O
.	O

Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	O
from	O
SCID	O
-	O
HU	O
-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O

CONCLUSIONS	O
:	O
Intestinal	O
epithelial	O
cells	O
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil	O
-	O
mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E	O
.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
.	O

In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	O
cells	O
by	O
tissue	B-PRGE
inhibitor	I-PRGE
of	I-PRGE
metalloproteinases	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B-PRGE
inhibitor	I-PRGE
of	I-PRGE
metalloproteinases	I-PRGE
(	I-PRGE
TIMP	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Results	O
indicate	O
that	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
positive	O
BL	O
lines	O
show	O
resistance	O
to	O
cold	O
-	O
shock	O
-	O
induced	O
apoptosis	O
.	O

Furthermore	O
,	O
recombinant	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
not	O
TIMP	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB	O
-	O
94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95	B-PRGE
-	O
dependent	O
and	O
-	O
independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma	O
-	O
radiation	O
)	O
pathways	O
in	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
negative	O
BL	O
lines	O
.	O

TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
suppression	O
of	O
PCD	O
is	O
not	O
due	O
to	O
metalloproteinase	O
inhibition	O
,	O
as	O
reduction	O
and	O
alkylation	O
of	O
the	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
did	O
not	O
abolish	O
this	O
activity	O
.	O

Retroviral	O
induction	O
of	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O

This	O
resistance	O
to	O
apoptosis	O
is	O
reversed	O
by	O
anti	O
-	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
antibodies	O
,	O
demonstrating	O
that	O
secreted	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
active	O
in	O
blocking	O
apoptosis	O
.	O

Furthermore	O
,	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
upregulation	O
induced	O
expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
but	O
not	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
as	O
well	O
as	O
decreased	O
NF	O
-	O
kappaB	O
activity	O
as	O
compared	O
with	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
suppresses	O
apoptosis	O
in	O
B	O
cells	O
and	O
suggests	O
a	O
novel	O
activity	O
for	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
tissue	O
homeostasis	O
.	O

Interleukin	O
-	O
12	O
expression	O
in	O
B	O
cells	O
by	O
transformation	O
with	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Although	O
interleukin	O
(	O
IL	O
)	O
-	O
12	O
was	O
originally	O
purified	O
from	O
an	O
Epstein	O
-	O
Barr	O
(	O
EBV	O
)	O
-	O
transformed	O
B	O
cell	O
line	O
and	O
the	O
high	O
correlation	O
of	O
EBV	O
infection	O
and	O
IL	O
-	O
12	O
expression	O
has	O
been	O
suggested	O
,	O
no	O
study	O
has	O
reported	O
whether	O
EBV	O
infection	O
is	O
directly	O
linked	O
to	O
IL	O
-	O
12	O
expression	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL	O
-	O
12	O
expression	O
in	O
B	O
cells	O
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O

Human	O
peripheral	O
B	O
cells	O
became	O
capable	O
of	O
constitutively	O
producing	O
p40	B-PRGE
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	O
of	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
of	O
EBV	O
.	O

These	O
B	O
cells	O
expressed	O
p40	B-PRGE
and	O
p35	B-PRGE
mRNA	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
strongly	O
enhanced	O
p40	B-PRGE
and	O
p70	O
production	O
.	O

Furthermore	O
,	O
transfection	O
with	O
LMP1	B-PRGE
expression	O
vector	O
into	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
Daudi	O
,	O
led	O
to	O
p40	B-PRGE
production	O
with	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	O
B	O
cells	O
with	O
EBV	O
induces	O
IL	O
-	O
12	O
expression	O
potentially	O
through	O
LMP1	B-PRGE
expression	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Anaphylatoxins	O
C5a	B-PRGE
and	O
C3a	B-PRGE
induce	O
nuclear	O
factor	O
kappaB	O
activation	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

The	O
anaphylatoxins	O
C5a	B-PRGE
and	O
C3a	B-PRGE
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O

In	O
this	O
study	O
the	O
capability	O
of	O
C5a	B-PRGE
and	O
C3a	B-PRGE
to	O
induce	O
transcription	O
factor	O
activation	O
was	O
examined	O
.	O

C5a	B-PRGE
and	O
C3a	B-PRGE
stimulation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	O
sequence	O
.	O

The	O
p50	B-PRGE
and	O
p65	B-PRGE
proteins	O
,	O
constituents	O
of	O
the	O
prototypic	O
nuclear	O
factor	O
kappaB	O
,	O
were	O
identified	O
as	O
components	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
by	O
anti	O
-	O
peptide	O
antibodies	O
in	O
gel	O
supershift	O
assays	O
.	O

C5a	B-PRGE
induced	O
kappaB	O
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30	O
-	O
40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O

Binding	O
to	O
kappaB	O
sequence	O
was	O
accompanied	O
by	O
an	O
initial	O
decrease	O
and	O
subsequent	O
increase	O
in	O
the	O
cytoplasmic	O
IkappaBalpha	B-PRGE
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti	O
-	O
IkappaBalpha	B-PRGE
antibody	O
.	O

Pertussis	O
toxin	O
treatment	O
markedly	O
decreased	O
kappaB	O
binding	O
activities	O
induced	O
by	O
both	O
C5a	B-PRGE
and	O
C3a	B-PRGE
,	O
whereas	O
cholera	O
toxin	O
displayed	O
no	O
inhibitory	O
effect	O
.	O

Neither	O
of	O
the	O
two	O
toxins	O
affected	O
kappaB	O
binding	O
activity	O
induced	O
by	O
TNFalpha	B-PRGE
in	O
the	O
same	O
cells	O
.	O

These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	O
C5a	B-PRGE
and	O
C3a	B-PRGE
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein	O
-	O
coupled	O
transcription	O
factor	O
activation	O
.	O

Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
T	O
-	O
cell	O
lines	O
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
.	O

The	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
kinase	O
activates	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
and	O
induces	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
T	O
-	O
cell	O
lines	O
.	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
inhibited	O
by	O
mutant	O
signaling	O
molecules	O
that	O
inhibit	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
or	O
the	O
calcineurin	O
/	O
NFAT	O
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	O
molecules	O
that	O
activate	O
these	O
pathways	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	O
and	O
the	O
calcineurin	O
/	O
NFAT	O
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
activation	O
of	O
both	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	B-PRGE
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
whose	O
activation	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
MEK1S218	O
/	O
222A	O
and	O
the	O
MEK1	B-PRGE
/	O
MEK2	B-PRGE
inhibitor	O
PD098059	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	O
is	O
MAPK	O
-	O
dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-PRGE
and	O
MEK2	B-PRGE
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	O
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	O
-	O
dependent	O
.	O

Experiments	O
in	O
COS	O
-	O
1	O
and	O
EL	O
-	O
4	O
cells	O
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
NF	O
-	O
kappaB	O
.	O

While	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
by	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
NFAT	O
delta418	O
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	O
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
NFAT	O
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin	O
-	O
dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
Bcl	B-PRGE
-	I-PRGE
X	I-PRGE
(	I-PRGE
L	I-PRGE
)	I-PRGE
.	O

Activation	O
of	O
human	O
macrophages	O
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

Positive	O
-	O
pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	O
cells	O
can	O
be	O
submitted	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
strain	O
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O

The	O
lung	O
macrophage	O
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	O
mediators	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
the	O
chemokines	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
8	I-PRGE
and	O
-	B-PRGE
6	I-PRGE
,	O
and	O
matrix	B-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
9	I-PRGE
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O

These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	O
alveolar	O
macrophages	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
promonocytic	O
THP	O
-	O
1	O
cells	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O

Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	O
endotoxin	O
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O

Dexamethasone	O
prevented	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
in	O
ventilated	O
macrophages	O
.	O

Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
secretion	O
by	O
alveolar	O
type	O
II	O
-	O
like	O
cells	O
.	O

Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	O
cells	O
,	O
bronchial	O
cells	O
,	O
and	O
fibroblasts	O
failed	O
to	O
produce	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
load	O
.	O

This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress	O
-	O
induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O

Stat6	B-PRGE
inhibits	O
human	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activity	O
in	O
T	O
cells	O
.	O

The	O
differentiation	O
of	O
naive	O
T	O
-	O
helper	O
(	O
Th	O
)	O
cells	O
into	O
cytokine	O
-	O
secreting	O
effector	O
Th	O
cells	O
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	O
cytokines	O
.	O

Interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
secreting	O
Th2	O
cells	O
.	O

In	O
Th2	O
cells	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	O
factors	O
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
family	O
members	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
induces	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
are	O
not	O
known	O
,	O
although	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
activated	O
transcription	O
factor	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
6	I-PRGE
(	O
Stat6	B-PRGE
)	O
is	O
required	O
for	O
this	O
effect	O
.	O

We	O
report	O
here	O
that	O
Stat6	B-PRGE
interacts	O
with	O
three	O
binding	O
sites	O
in	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

These	O
sites	O
overlap	O
the	O
P1	O
,	O
P2	O
,	O
and	O
P4	O
NFAT	O
elements	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Stat6	B-PRGE
in	O
regulating	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
transcription	O
,	O
we	O
used	O
Stat6	B-PRGE
-	O
deficient	O
Jurkat	O
T	O
cells	O
with	O
different	O
intact	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
constructs	O
in	O
cotransfection	O
assays	O
.	O

We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	O
response	O
element	O
from	O
the	O
germline	O
IgE	O
promoter	O
was	O
highly	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
Stat6	B-PRGE
-	O
expressing	O
Jurkat	O
cells	O
,	O
the	O
intact	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
was	O
repressed	O
under	O
similar	O
conditions	O
.	O

We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	B-PRGE
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
promoter	O
polymorphisms	O
in	O
allergies	O
and	O
asthma	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	O
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O

These	O
cytokines	O
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TGF	O
-	O
beta	O
gene	O
promoters	O
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O

DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
gene	O
and	O
four	O
in	O
the	O
TGF	O
-	O
beta	O
gene	O
promoters	O
(	O
3	O
in	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
and	O
1	O
in	O
TGF	B-PRGE
-	I-PRGE
beta2	I-PRGE
)	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
gene	O
polymorphism	O
was	O
a	O
C	O
-	O
to	O
-	O
A	O
exchange	O
571	O
base	O
pairs	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
and	O
was	O
present	O
between	O
consensus	O
binding	O
sequences	O
for	O
Sp1	B-PRGE
and	O
elevated	O
total	O
serum	O
.	O

This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	O
serum	O
IgE	O
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0	O
.	O
009	O
)	O
.	O

The	O
base	O
exchange	O
at	O
-	O
509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF	O
-	O
beta	O
promoter	O
also	O
linked	O
to	O
elevated	O
total	O
IgE	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
polymorphism	O
represented	O
a	O
C	O
-	O
to	O
-	O
T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	O
consensus	O
sequence	O
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein	O
-	O
Barr	O
virus	O
in	O
B	O
lymphocytes	O
(	O
Review	O
)	O
.	O

Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O

Most	O
viruses	O
cannot	O
compete	O
with	O
the	O
various	O
immune	O
mechanisms	O
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O

Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O

A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O

This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation	O
-	O
dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O

Both	O
are	O
true	O
for	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

B	O
cells	O
and	O
epithelial	O
cells	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O

The	O
former	O
can	O
become	O
latently	O
infected	O
and	O
are	O
thought	O
to	O
be	O
the	O
virus	O
reservoir	O
in	O
vivo	O
,	O
whereas	O
the	O
latter	O
were	O
shown	O
to	O
be	O
permissive	O
for	O
lytic	O
replication	O
.	O

However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	O
permissive	O
for	O
viral	O
replication	O
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	O
factors	O
.	O

These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	O
immediate	O
-	O
early	O
genes	O
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	O
gene	O
regulatory	O
mechanisms	O
.	O

Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	O
gene	O
regulation	O
may	O
result	O
in	O
EBV	O
-	O
associated	O
disease	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
transcription	O
:	O
role	O
of	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
region	O
(	O
review	O
)	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transcription	O
is	O
dependent	O
on	O
the	O
interaction	O
of	O
host	O
-	O
cell	O
transcription	O
factors	O
with	O
cis	O
-	O
regulatory	O
DNA	O
elements	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	O
initiation	O
site	O
in	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
including	O
the	O
Sp1	B-PRGE
and	O
NF	O
-	O
kappaB	O
binding	O
sites	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5	O
'	O
-	O
untranslated	O
leader	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
also	O
contains	O
important	O
transcriptional	O
elements	O
.	O

These	O
regulatory	O
elements	O
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	O
factors	O
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV	O
-	O
1	O
transcription	O
and	O
replication	O
.	O

The	O
5	O
'	O
-	O
UTR	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappaB	O
,	O
NF	O
-	O
AT	O
,	O
IRF	O
,	O
and	O
Sp1	B-PRGE
.	O

Mutations	O
in	O
these	O
binding	O
sites	O
can	O
interfere	O
with	O
the	O
viral	O
response	O
to	O
cell	O
activation	O
signals	O
,	O
decrease	O
LTR	O
transcription	O
,	O
and	O
inhibit	O
viral	O
replication	O
.	O

The	O
5	O
'	O
-	O
UTR	O
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	O
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O

We	O
propose	O
that	O
the	O
inducible	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
5	O
'	O
-	O
UTR	O
comprise	O
a	O
downstream	O
enhancer	O
domain	O
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	O
promoter	O
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host	O
-	O
cell	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
5	O
'	O
-	O
UTR	O
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

Molecular	O
cloning	O
of	O
FKHRL1P2	B-PRGE
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	O
head	O
domain	O
transcription	O
factor	O
family	O
.	O

Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	O
head	O
domain	O
protein	O
in	O
human	O
T	O
helper	O
cells	O
.	O

We	O
cloned	O
and	O
characterized	O
a	O
fork	O
head	O
cDNA	O
from	O
human	O
T	O
helper	O
cell	O
mRNA	O
using	O
differential	O
display	O
RT	O
-	O
PCR	O
.	O

The	O
cDNA	O
contains	O
a	O
546	O
-	O
nucleotide	O
(	O
nt	O
)	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
that	O
codes	O
for	O
the	O
carboxyl	O
-	O
terminal	O
180	O
amino	O
acids	O
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	B-PRGE
gene	O
.	O

This	O
ORF	O
does	O
not	O
contain	O
the	O
characteristic	O
DNA	O
-	O
binding	O
domain	O
found	O
in	O
members	O
of	O
the	O
forkhead	O
protein	O
family	O
.	O

In	O
-	O
vitro	O
transcription	O
/	O
translation	O
of	O
this	O
cDNA	O
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O

We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in	O
-	O
vitro	O
-	O
translated	O
20	O
-	O
kDa	O
protein	O
.	O

This	O
antibody	O
also	O
recognizes	O
in	O
human	O
T	O
lymphocytes	O
a	O
70	O
-	O
kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	B-PRGE
gene	O
product	O
.	O

The	O
mRNA	O
levels	O
for	O
fkhrl1	B-PRGE
is	O
elevated	O
in	O
T	O
helper	O
-	O
induced	O
lymphocytes	O
in	O
comparison	O
to	O
PHA	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Further	O
characterization	O
of	O
FKHRL1	B-PRGE
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	O
head	O
gene	O
subfamily	O
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O

Activation	O
of	O
the	O
human	O
delta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
promoter	O
in	O
primary	O
adult	O
erythroid	O
cells	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
or	O
insertion	O
of	O
an	O
erythroid	B-PRGE
Kruppel	I-PRGE
-	I-PRGE
like	I-PRGE
factor	I-PRGE
(	O
EKLF	B-PRGE
)	O
binding	O
site	O
in	O
the	O
delta	O
promoter	O
activates	O
its	O
expression	O
in	O
several	O
erythroid	O
cell	O
lines	O
.	O

We	O
extended	O
these	O
studies	O
using	O
a	O
novel	O
primary	O
human	O
adult	O
erythroid	O
cell	O
(	O
hAEC	O
)	O
system	O
to	O
investigate	O
these	O
effects	O
at	O
the	O
late	O
erythroblast	O
stage	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
at	O
-	O
70	O
bp	O
,	O
or	O
insertion	O
of	O
an	O
EKLF	B-PRGE
binding	O
site	O
at	O
-	O
85	O
bp	O
or	O
-	O
95	O
bp	O
in	O
the	O
promoter	O
significantly	O
increased	O
delta	B-PRGE
globin	I-PRGE
gene	O
expression	O
in	O
hAEC	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	O
box	O
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	B-PRGE
binding	O
site	O
in	O
delta	B-PRGE
-	I-PRGE
globin	I-PRGE
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	O
model	O
as	O
well	O
.	O

Interactions	O
between	O
the	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
and	O
CREB	B-PRGE
binding	I-PRGE
protein	I-PRGE
increase	O
transcription	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
genes	O
.	O

Class	O
II	O
major	O
histocompatibility	O
(	O
class	O
II	O
)	O
genes	O
are	O
regulated	O
in	O
a	O
B	O
-	O
cell	O
-	O
specific	O
and	O
gamma	B-PRGE
interferon	I-PRGE
-	O
inducible	O
fashion	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
(	O
CIITA	B-PRGE
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
CIITA	B-PRGE
is	O
to	O
recruit	O
the	O
CREB	B-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CBP	B-PRGE
)	O
to	O
class	O
II	O
promoters	O
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	B-PRGE
and	O
CBP	B-PRGE
were	O
demonstrated	O
.	O

Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	B-PRGE
decreased	O
the	O
activity	O
of	O
class	O
II	O
promoters	O
and	O
levels	O
of	O
class	O
II	O
determinants	O
on	O
the	O
surface	O
of	O
cells	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	O
II	O
gene	O
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	B-PRGE
by	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

We	O
conclude	O
that	O
CBP	B-PRGE
,	O
a	O
histone	O
acetyltransferase	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP	O
-	O
1	O
are	O
insufficient	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
:	O
requirement	O
for	O
CD28	B-PRGE
up	O
-	O
regulation	O
of	O
RE	O
/	O
AP	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
in	O
T	O
cells	O
requires	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	O
B	O
cells	O
requires	O
CD28	B-PRGE
activation	O
.	O

The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	B-PRGE
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
by	O
>	O
80	O
%	O
.	O

Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
AP	O
-	O
1	O
reporters	O
.	O

Therefore	O
,	O
activation	O
of	O
NFAT	O
and	O
AP	O
-	O
1	O
is	O
insufficient	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
.	O

In	O
contrast	O
,	O
an	O
RE	O
/	O
AP	O
reporter	O
was	O
blocked	O
by	O
CTLA4Ig	O
by	O
>	O
90	O
%	O
.	O

Thus	O
,	O
the	O
requirement	O
for	O
CD28	B-PRGE
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
appears	O
to	O
be	O
due	O
to	O
RE	O
/	O
AP	O
and	O
not	O
the	O
NFAT	O
or	O
AP	O
-	O
1	O
sites	O
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE	O
/	O
AP	O
is	O
not	O
mediated	O
by	O
NFAT	O
,	O
because	O
activation	O
of	O
a	O
NFAT	O
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV	O
-	O
1	O
expression	O
.	O

Phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
which	O
is	O
described	O
as	O
an	O
inhibitor	O
of	O
tyrosine	O
phosphatase	O
activity	O
,	O
inhibits	O
H2O2	O
release	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
as	O
measured	O
by	O
electrochemistry	O
.	O

Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	O
,	O
primary	O
monocytes	O
or	O
a	O
latently	O
infected	O
promonocytic	O
U1	O
cell	O
line	O
show	O
that	O
HIV	O
-	O
1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	B-PRGE
antigen	I-PRGE
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
stabilizes	O
inhibitory	B-PRGE
kappaB	I-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
human	O
monocytes	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

This	O
beneficial	O
effect	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibition	O
of	O
inflammatory	O
cytokine	O
production	O
,	O
including	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

Evidence	O
suggests	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
may	O
inhibit	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
through	O
an	O
unknown	O
mechanism	O
.	O

NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	B-PRGE
kappaB	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

We	O
hypothesized	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
prevents	O
human	O
monocyte	O
NF	O
-	O
kappaB	O
activation	O
and	O
resultant	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
by	O
stabilization	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
human	O
monocyte	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
,	O
NF	O
-	O
kappaB	O
activation	O
,	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
degradation	O
.	O

Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O

Cells	O
were	O
stimulated	O
with	O
endotoxin	O
(	O
LPS	O
,	O
100	O
ng	O
/	O
mL	O
)	O
with	O
and	O
without	O
human	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

Following	O
stimulation	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF	O
-	O
kappaB	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
levels	O
by	O
Western	O
blot	O
.	O

We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	O
monocytes	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
increased	O
to	O
798	O
+	O
/	O
-	O
67	O
pg	O
/	O
mL	O
(	O
p	O
<	O
.	O
001	O
versus	O
control	O
)	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
attenuated	O
LPS	O
-	O
stimulated	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
(	O
297	O
+	O
/	O
-	O
54	O
;	O
p	O
<	O
.	O
001	O
versus	O
LPS	O
alone	O
)	O
.	O

After	O
LPS	O
stimulation	O
in	O
human	O
monocytes	O
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
levels	O
decreased	O
,	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
increased	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
pretreatment	O
prevented	O
LPS	O
-	O
induced	O
decreases	O
in	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
levels	O
and	O
attenuated	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
appears	O
to	O
prevent	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
preserving	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
.	O

Regulation	O
of	O
fas	B-PRGE
-	I-PRGE
ligand	I-PRGE
expression	O
during	O
activation	O
-	O
induced	O
cell	O
death	O
in	O
T	O
lymphocytes	O
via	O
nuclear	O
factor	O
kappaB	O
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	O
factors	O
important	O
for	O
cytokine	O
gene	O
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
lymphocytes	O
that	O
is	O
dependent	O
on	O
FasL	B-PRGE
transcription	O
and	O
expression	O
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	O
genes	O
expressed	O
in	O
activated	O
lymphocytes	O
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation	O
-	O
induced	O
FasL	B-PRGE
expression	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
a	O
T	O
cell	O
hybridoma	O
leads	O
to	O
decreased	O
FasL	B-PRGE
expression	O
and	O
apoptosis	O
upon	O
T	O
cell	O
receptor	O
stimulation	O
.	O

We	O
identified	O
the	O
NF	O
-	O
kappaB	O
site	O
in	O
the	O
FasL	B-PRGE
promoter	O
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Co	O
-	O
expression	O
of	O
p65	B-PRGE
(	O
Rel	B-PRGE
A	I-PRGE
)	O
with	O
the	O
FasL	B-PRGE
promoter	O
enhanced	O
its	O
activity	O
,	O
and	O
co	O
-	O
expression	O
of	O
IkappaB	O
dramatically	O
inhibited	O
the	O
inducible	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
is	O
not	O
required	O
for	O
activation	O
-	O
induced	O
FasL	B-PRGE
promoter	O
activity	O
.	O

These	O
results	O
define	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
mediating	O
FasL	B-PRGE
expression	O
during	O
T	O
cell	O
activation	O
.	O

X	O
-	O
rays	O
-	O
induced	O
secretion	O
of	O
cellular	O
factor	O
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV	O
-	O
1	O
promoter	O
transcription	O
in	O
various	O
non	O
-	O
irradiated	O
transfected	O
cell	O
lines	O
.	O

Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
or	O
reporter	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
extracellular	O
factor	O
(	O
s	O
)	O
released	O
by	O
X	O
-	O
ray	O
-	O
treated	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
(	O
HT29	O
)	O
might	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
in	O
non	O
-	O
irradiated	O
HT29	O
cells	O
.	O

In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
,	O
X	O
-	O
ray	O
irradiation	O
up	O
-	O
regulates	O
HIV	O
-	O
1	O
LTR	O
transcription	O
through	O
the	O
kappaB	O
regulatory	O
elements	O
.	O

A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non	O
-	O
irradiated	O
cells	O
of	O
either	O
X	O
-	O
ray	O
-	O
treated	O
cells	O
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	O
cultures	O
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

In	O
addition	O
,	O
X	O
-	O
ray	O
activation	O
of	O
HIV	O
-	O
1	O
LTR	O
in	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	O
factors	O
,	O
suramin	O
.	O

The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS	O
-	O
related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O

Reactivation	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B-PRGE
50	I-PRGE
transactivator	I-PRGE
,	O
a	O
homolog	O
of	O
the	O
EBV	B-PRGE
R	I-PRGE
protein	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS	O
-	O
related	O
neoplasms	O
.	O

The	O
primary	O
reservoir	O
of	O
infection	O
consists	O
of	O
latently	O
infected	O
B	O
lymphocytes	O
and	O
possibly	O
other	O
mononuclear	O
cells	O
.	O

Viral	O
reactivation	O
from	O
latency	O
and	O
spread	O
from	O
this	O
lymphoid	O
reservoir	O
is	O
presumably	O
required	O
for	O
development	O
of	O
nonlymphoid	O
tumors	O
like	O
KS	O
.	O

Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	O
gene	O
,	O
ORF	B-PRGE
50	I-PRGE
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed	O
-	O
early	O
viral	O
genes	O
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
tax	B-PRGE
protein	O
abrogates	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
dependence	O
in	O
a	O
mouse	O
T	O
-	O
cell	O
line	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Tax	B-PRGE
,	O
the	O
viral	O
protein	O
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	O
T	O
cells	O
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	B-PRGE
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
dependent	O
T	O
-	O
cell	O
line	O
CTLL	O
-	O
2	O
.	O

Stable	O
expression	O
of	O
Tax	B-PRGE
in	O
CTLL	O
-	O
2	O
transformed	O
cell	O
growth	O
from	O
being	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
dependent	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
independent	O
.	O

Tax	B-PRGE
stimulated	O
transcription	O
through	O
NF	O
-	O
kappaB	O
and	O
the	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
-	O
like	O
sequence	O
in	O
the	O
HTLV	O
-	O
1	O
promoter	O
.	O

The	O
finding	O
of	O
Tax	B-PRGE
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF	O
-	O
kappaB	O
pathway	O
was	O
essential	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
growth	O
of	O
CTLL	O
-	O
2	O
cells	O
while	O
the	O
CRE	O
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation	O
-	O
related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL	O
-	O
2	O
/	O
Tax	B-PRGE
.	O

Our	O
results	O
show	O
that	O
Tax	B-PRGE
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	B-PRGE
plays	O
a	O
crucial	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
T	O
-	O
cell	O
transformation	O
induced	O
by	O
HTLV	O
-	O
1	O
,	O
in	O
addition	O
to	O
its	O
well	O
-	O
known	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
cell	O
transformation	O
.	O

Regulation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
synthesis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
C3a	B-PRGE
and	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
.	O

The	O
anaphylatoxin	O
C3a	B-PRGE
has	O
been	O
reported	O
to	O
have	O
immunomodulatory	O
effects	O
on	O
a	O
number	O
of	O
different	O
cell	O
types	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B-PRGE
and	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
human	O
PBMCs	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

C3a	B-PRGE
or	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
alone	O
exhibited	O
no	O
effect	O
on	O
the	O
expression	O
or	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

However	O
,	O
when	O
PBMC	O
were	O
stimulated	O
with	O
LPS	O
or	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
both	O
C3a	B-PRGE
and	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
were	O
found	O
to	O
enhance	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
release	O
by	O
PBMC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Since	O
C3a	B-PRGE
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	O
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	B-PRGE
-	O
mediated	O
enhancement	O
of	O
LPS	O
-	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
.	O

Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	O
on	O
the	O
observed	O
effects	O
of	O
C3a	B-PRGE
,	O
suggesting	O
that	O
the	O
effects	O
of	O
C3a	B-PRGE
on	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
are	O
independent	O
of	O
PGE2	O
formation	O
by	O
monocytes	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	B-PRGE
as	O
well	O
as	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
enhanced	O
LPS	O
-	O
induced	O
mRNA	O
levels	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Pretreatment	O
of	O
PBMCs	O
with	O
pertussis	O
toxin	O
blocked	O
the	O
functions	O
of	O
C3a	B-PRGE
and	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	O
by	O
a	O
G	O
protein	O
-	O
coupled	O
pathway	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B-PRGE
and	O
C3a	B-PRGE
(	I-PRGE
desArg	I-PRGE
)	I-PRGE
on	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
activating	O
protein	O
-	O
1	O
binding	O
.	O

Both	O
molecules	O
enhanced	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
activating	O
protein	O
-	O
1	O
binding	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B-PRGE
and	O
its	O
circulating	O
des	O
-	O
Arg	O
form	O
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

We	O
compared	O
U	O
-	O
937	O
cell	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
human	O
umbilical	O
venous	O
(	O
HUVECs	O
)	O
and	O
arterial	O
(	O
HUAECs	O
)	O
endothelial	O
cells	O
exposed	O
to	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interleukin	O
-	O
1	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

TNF	O
and	O
LPS	O
stimulated	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	I-PRGE
VCAM	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
surface	O
expression	O
and	O
adhesion	O
of	O
U	O
-	O
937	O
monocyte	O
-	O
like	O
cells	O
to	O
HUVECs	O
but	O
not	O
to	O
HUAECs	O
.	O

Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	O
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mediated	O
.	O

Interleukin	O
-	O
1	O
stimulated	O
U	O
-	O
937	O
cell	O
adhesion	O
to	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
surface	O
expression	O
in	O
both	O
HUVECs	O
and	O
HUAECs	O
.	O

Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG	O
-	O
132	O
blocked	O
TNF	O
-	O
and	O
LPS	O
-	O
stimulated	O
U	O
-	O
937	O
cell	O
adhesion	O
to	O
HUVECs	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF	O
-	O
and	O
LPS	O
-	O
stimulated	O
increases	O
in	O
HUVEC	O
surface	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

TNF	O
increased	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
and	O
mRNA	O
in	O
HUVECs	O
that	O
was	O
blocked	O
by	O
pyrrolidinedithiocarbamate	O
.	O

However	O
,	O
neither	O
TNF	O
or	O
LPS	O
stimulated	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
HUAECs	O
.	O

TNF	O
stimulated	O
expression	O
of	O
both	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
was	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	O
-	O
stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
between	O
HUVECs	O
and	O
HUAECs	O
.	O

These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	O
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	O
to	O
upregulate	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Tissue	B-PRGE
factor	I-PRGE
expression	O
of	O
human	O
monocytes	O
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O

The	O
expression	O
of	O
tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
promoted	O
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol	O
/	O
L	O
)	O
dose	O
-	O
dependently	O
reduced	O
TF	B-PRGE
activity	O
in	O
human	O
monocytes	O
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
TF	B-PRGE
activity	O
of	O
human	O
monocytes	O
.	O

TF	B-PRGE
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	O
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

LysoPC	O
inhibited	O
the	O
TF	B-PRGE
activity	O
of	O
Mono	O
Mac	O
-	O
6	O
cells	O
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O

LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	O
were	O
not	O
affected	O
by	O
lysoPC	O
.	O

In	O
contrast	O
,	O
LPS	O
-	O
mediated	O
nuclear	O
binding	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
/	O
Rel	O
to	O
a	O
TF	B-PRGE
-	O
specific	O
kappaB	O
site	O
was	O
inhibited	O
by	O
lysoPC	O
.	O

Induction	O
of	O
TF	B-PRGE
mRNA	O
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Inhibition	O
of	O
adenylyl	O
cyclase	O
by	O
pretreatment	O
with	O
2	O
'	O
-	O
deoxy	O
-	O
3	O
'	O
-	O
adenosine	O
monophosphate	O
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	B-PRGE
activity	O
promoted	O
by	O
lysoPC	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS	O
-	O
mediated	O
TF	B-PRGE
expression	O
of	O
human	O
monocytes	O
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF	O
-	O
kappaB	O
by	O
70	O
kDa	O
heat	O
shock	O
protein	O
.	O

The	O
70	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp70	O
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	O
protein	O
involved	O
in	O
chaperoning	O
proteins	O
to	O
various	O
cellular	O
organelles	O
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	O
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

We	O
exploited	O
this	O
ability	O
of	O
Hsp70	O
to	O
deliver	O
NF	O
-	O
kappaB	O
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C	O
-	O
terminal	O
Hsp70	O
peptide	O
and	O
the	O
p50	B-PRGE
subunit	O
of	O
NF	O
-	O
kappaB	O
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	B-PRGE
expression	O
and	O
TNFalpha	B-PRGE
production	O
.	O

We	O
therefore	O
propose	O
that	O
Hsp70	O
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O

CD2	O
signalling	O
induces	O
phosphorylation	O
of	O
CREB	B-PRGE
in	O
primary	O
lymphocytes	O
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
,	O
and	O
bind	O
transcription	O
factors	O
of	O
the	O
cAMP	B-PRGE
response	I-PRGE
element	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CREB	B-PRGE
)	O
/	O
activating	B-PRGE
transcription	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
family	O
.	O

We	O
have	O
used	O
a	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
model	O
of	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	O
promoter	O
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV	O
-	O
1	O
transcription	O
following	O
CD2	B-PRGE
but	O
not	O
CD3	O
receptor	O
cross	O
-	O
linking	O
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	B-PRGE
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	B-PRGE
and	O
CD3	O
receptor	O
-	O
mediated	O
signalling	O
in	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

CD2	B-PRGE
,	O
but	O
not	O
CD3	O
,	O
cross	O
-	O
linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O

CD2	B-PRGE
cross	O
-	O
linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	B-PRGE
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

Consistent	O
with	O
post	O
-	O
translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	B-PRGE
protein	O
was	O
observed	O
.	O

Phosphorylation	O
of	O
CREB	B-PRGE
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp	O
-	O
cAMP	O
-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
and	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
CD2	B-PRGE
and	O
CD3	O
cross	O
-	O
linking	O
increased	O
binding	O
of	O
nuclear	O
proteins	O
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B-PRGE
at	O
serine	O
133	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB	B-PRGE
/	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
family	O
of	O
transcription	O
factors	O
by	O
the	O
CD2	B-PRGE
signalling	O
pathway	O
and	O
suggest	O
CD2	B-PRGE
receptor	I-PRGE
modulation	O
of	O
CRE	O
-	O
mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e	O
.	O
g	O
.	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
)	O
.	O

Anoxia	O
/	O
reoxygenation	O
-	O
induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	O
endothelial	O
cells	O
.	O

A	O
nuclear	O
factor	O
-	O
kappaB	O
-	O
mediated	O
phenomenon	O
.	O

Exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
to	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
adhesion	O
to	O
HUVECs	O
.	O

This	O
A	O
/	O
R	O
-	O
induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	O
to	O
A	O
/	O
R	O
.	O

This	O
phenomenon	O
has	O
been	O
termed	O
"	O
A	O
/	O
R	O
tolerance	O
.	O
"	O
Exposing	O
HUVECs	O
to	O
A	O
/	O
R	O
induces	O
an	O
increase	O
in	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O

Interfering	O
with	O
either	O
NF	O
-	O
kappaB	O
activation	O
(	O
proteasome	O
inhibitor	O
)	O
or	O
translocation	O
(	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
)	O
prevents	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
(	O
ie	O
,	O
the	O
increase	O
in	O
A	O
/	O
R	O
-	O
induced	O
PMN	O
adhesion	O
to	O
HUVECs	O
is	O
the	O
same	O
after	O
the	O
first	O
and	O
second	O
A	O
/	O
R	O
challenges	O
)	O
.	O

NO	O
production	O
by	O
HUVECs	O
is	O
increased	O
after	O
the	O
second	O
A	O
/	O
R	O
challenge	O
,	O
but	O
not	O
after	O
the	O
first	O
A	O
/	O
R	O
challenge	O
.	O

Inhibition	O
of	O
NO	B-PRGE
synthase	I-PRGE
(	O
NOS	B-PRGE
)	O
during	O
the	O
second	O
A	O
/	O
R	O
challenge	O
prevents	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

However	O
,	O
while	O
HUVECs	O
contained	O
endothelial	O
NOS	B-PRGE
protein	O
,	O
no	O
inducible	O
NOS	B-PRGE
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	O
cells	O
.	O

Further	O
studies	O
indicated	O
that	O
inhibition	O
of	O
GTP	B-PRGE
-	I-PRGE
cyclohydrolase	I-PRGE
I	I-PRGE
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	B-PRGE
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A	O
/	O
R	O
-	O
tolerant	O
cells	O
.	O

Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	O
effect	O
the	O
hyperadhesion	O
response	O
induced	O
by	O
the	O
initial	O
A	O
/	O
R	O
challenge	O
.	O

A	O
/	O
R	O
also	O
induced	O
an	O
oxidant	O
stress	O
in	O
naive	O
HUVECs	O
,	O
but	O
not	O
in	O
A	O
/	O
R	O
-	O
tolerant	O
HUVECs	O
.	O

Inhibition	O
of	O
NOS	B-PRGE
during	O
the	O
second	O
A	O
/	O
R	O
insult	O
results	O
in	O
the	O
generation	O
of	O
an	O
oxidant	O
stress	O
similar	O
to	O
that	O
observed	O
after	O
the	O
first	O
A	O
/	O
R	O
challenge	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	O
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP	B-PRGE
-	I-PRGE
cyclohydrolase	I-PRGE
.	O

The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A	O
/	O
R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A	O
/	O
R	O
.	O

Role	O
of	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
up	O
-	O
regulation	O
of	O
Fas	B-PRGE
ligand	I-PRGE
in	O
normal	O
T	O
cells	O
and	O
aberrant	O
double	O
-	O
negative	O
lpr	O
and	O
gld	O
T	O
cells	O
.	O

We	O
previously	O
identified	O
a	O
Fas	B-PRGE
ligand	I-PRGE
regulatory	O
element	O
(	O
FLRE	O
)	O
in	O
the	O
Fas	B-PRGE
ligand	I-PRGE
(	O
fasL	B-PRGE
)	O
promoter	O
that	O
binds	O
Egr	O
family	O
proteins	O
and	O
demonstrated	O
that	O
Egr	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
PILOT	B-PRGE
)	O
but	O
not	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
NGFI	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
Krox	B-PRGE
-	I-PRGE
24	I-PRGE
,	O
Tis	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
Zif	B-PRGE
-	I-PRGE
268	I-PRGE
)	O
induces	O
transcription	O
of	O
fasL	B-PRGE
.	O

The	O
aberrant	O
CD4	B-PRGE
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
from	O
lpr	O
/	O
lpr	O
and	O
gld	O
/	O
gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	B-PRGE
and	O
FasL	B-PRGE
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	B-PRGE
mRNA	O
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	O
and	O
Egr	O
family	O
proteins	O
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	B-PRGE
.	O

Unstimulated	O
MRL	O
-	O
lpr	O
/	O
lpr	O
and	O
C3H	O
-	O
gld	O
/	O
gld	O
CD4	B-PRGE
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	O
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
Krox	B-PRGE
-	I-PRGE
20	I-PRGE
)	O
;	O
Egr	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
not	O
detected	O
.	O

Activation	O
of	O
normal	O
lymph	O
node	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
-	B-PRGE
2	I-PRGE
,	O
and	O
-	B-PRGE
3	I-PRGE
.	O

As	O
with	O
egr	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
expression	O
of	O
egr	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

Although	O
overexpressed	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
ineffective	O
,	O
overexpressed	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
as	O
potent	O
as	O
Egr	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
inducing	O
fasL	B-PRGE
promoter	O
-	O
dependent	O
reporter	O
constructs	O
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up	O
-	O
regulated	O
endogenous	O
fasL	B-PRGE
mRNA	O
in	O
HeLa	O
cells	O
.	O

FasL	B-PRGE
-	O
dependent	O
reporter	O
constructs	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
and	O
C3H	O
-	O
gld	O
/	O
gld	O
CD4	B-PRGE
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	O
family	O
binding	O
element	O
.	O

Thus	O
,	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
in	O
addition	O
to	O
Egr	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
regulates	O
FasL	B-PRGE
expression	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
and	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
aberrant	O
fasL	B-PRGE
up	O
-	O
regulation	O
in	O
lpr	O
/	O
lpr	O
and	O
gld	O
/	O
gld	O
CD4	B-PRGE
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
.	O

Involvement	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
in	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
production	O
by	O
human	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	O
fermentans	O
membrane	O
lipoproteins	O
.	O

Interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
is	O
a	O
chemokine	O
that	O
belongs	O
to	O
the	O
alpha	O
-	O
chemokine	O
or	O
CXC	O
subfamily	O
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
(	O
PMN	O
)	O
.	O

IL	B-PRGE
-	I-PRGE
8	I-PRGE
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
induction	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	O
fermentans	O
lipid	O
-	O
associated	O
membrane	O
proteins	O
(	O
LAMPf	O
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
by	O
THP	O
-	O
1	O
(	O
human	O
monocyte	O
)	O
cells	O
and	O
PMN	O
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	O
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
and	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
cascades	O
.	O

By	O
using	O
PD	O
-	O
98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK1	B-PRGE
(	O
a	O
kinase	O
upstream	O
of	O
ERK1	O
/	O
2	O
)	O
and	O
p38	O
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1	O
/	O
2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
by	O
monocytes	O
and	O
PMN	O
stimulated	O
with	O
bacterial	O
fractions	O
.	O

T	O
cell	O
priming	O
enhances	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
by	O
increasing	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
repetitive	O
activation	O
of	O
T	O
cells	O
(	O
priming	O
)	O
enhances	O
the	O
expression	O
of	O
many	O
cytokines	O
,	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
but	O
not	O
others	O
,	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	O
by	O
T	O
cells	O
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	B-PRGE
T	O
cells	O
selectively	O
enhances	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
expression	O
relative	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
proteins	O
.	O

As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	O
the	O
activation	O
-	O
dependent	O
engagement	O
of	O
the	O
P0	O
and	O
P1	O
NFAT	O
-	O
binding	O
elements	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
.	O

Moreover	O
,	O
each	O
proximal	O
P	O
element	O
is	O
essential	O
for	O
optimal	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activity	O
.	O

Activated	O
primed	O
CD4	B-PRGE
T	O
cells	O
contain	O
more	O
NFAT1	B-PRGE
and	O
support	O
greater	O
NFAT	O
-	O
directed	O
transcription	O
than	O
unprimed	O
CD4	B-PRGE
T	O
cells	O
,	O
while	O
activator	O
protein	O
1	O
binding	O
and	O
activator	O
protein	O
1	O
-	O
mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O

Increased	O
expression	O
of	O
wild	O
-	O
type	O
NFAT1	B-PRGE
substantially	O
increases	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activity	O
in	O
unprimed	O
CD4	B-PRGE
T	O
cells	O
,	O
suggesting	O
NFAT1	B-PRGE
may	O
be	O
limiting	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
in	O
this	O
cell	O
type	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	B-PRGE
acts	O
as	O
a	O
dominant	O
-	O
negative	O
,	O
reducing	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
promoter	O
activity	O
in	O
primed	O
CD4	B-PRGE
T	O
cells	O
and	O
confirming	O
the	O
importance	O
of	O
endogenous	O
NFAT	O
to	O
increased	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O

NFAT1	B-PRGE
appears	O
to	O
be	O
the	O
major	O
NFAT	O
family	O
member	O
responsible	O
for	O
the	O
initial	O
increased	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
by	O
primed	O
CD4	B-PRGE
T	O
cells	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	O
proteasome	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
inflammatory	O
response	O
.	O

Data	O
obtained	O
from	O
studies	O
in	O
our	O
laboratories	O
demonstrate	O
that	O
the	O
proteasome	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
cascade	O
by	O
regulating	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF	O
-	O
kappa	O
B	O
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue	O
-	O
damaging	O
granulocytes	O
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non	O
-	O
phlogistic	O
manner	O
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	O
neutrophils	O
and	O
eosinophils	O
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O

This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD	O
-	O
fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF	O
-	O
kappaB	O
,	O
SN	O
-	O
50	O
;	O
other	O
NF	O
-	O
kappaB	O
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG	O
-	O
132	O
.	O

Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2	O
-	O
6	O
h	O
)	O
pro	O
-	O
apoptotic	O
effects	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
in	O
neutrophils	O
and	O
unmasked	O
the	O
ability	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
to	O
induce	O
eosinophil	O
apoptosis	O
.	O

In	O
neutrophils	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
caused	O
a	O
gliotoxin	O
-	O
inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12	O
-	O
24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro	O
-	O
apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF	O
-	O
kappaB	O
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	O
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	O
.	O

Lactobacilli	O
and	O
vaginal	O
host	O
defense	O
:	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
cytokine	O
production	O
,	O
and	O
NF	O
-	O
kappaB	O
.	O

Lactobacilli	O
,	O
a	O
component	O
of	O
the	O
normal	O
vaginal	O
flora	O
,	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
the	O
Jurkat	O
T	O
lymphocyte	O
and	O
THP	O
-	O
1	O
macrophage	O
cell	O
lines	O
.	O

Activation	O
of	O
the	O
LTR	O
in	O
Jurkat	O
cells	O
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	B-PRGE
,	O
implicating	O
H2O2	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
THP	O
-	O
1	O
cells	O
occurred	O
in	O
the	O
absence	O
of	O
vanadate	O
and	O
was	O
unaffected	O
by	O
catalase	B-PRGE
.	O

The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O

Lactobacilli	O
also	O
increased	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alphaand	I-PRGE
interleukin	B-PRGE
-	I-PRGE
1betaproduction	I-PRGE
and	O
activated	O
NF	O
-	O
kappaB	O
in	O
THP	O
-	O
1	O
cells	O
and	O
increased	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alphaproduction	I-PRGE
by	O
human	O
monocytes	O
.	O

Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
cytokine	O
production	O
,	O
and	O
NF	O
-	O
kappaB	O
in	O
cells	O
of	O
macrophage	O
lineage	O
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

High	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	O
requires	O
NF	O
-	O
kappaB	O
activation	O
through	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	O
with	O
autologous	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
thymocytes	O
(	O
M	O
.	O
Rothe	O
,	O
L	O
.	O
Chene	O
,	O
M	O
.	O
Nugeyre	O
,	O
F	O
.	O
Barre	O
-	O
Sinoussi	O
,	O
and	O
N	O
.	O
Israel	O
,	O
J	O
.	O
Virol	O
.	O
72	O
:	O
5852	O
-	O
5861	O
,	O
1998	O
)	O
.	O

We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O

We	O
first	O
demonstrate	O
that	O
an	O
HIV	O
-	O
1	O
provirus	O
(	O
SF	O
-	O
2	O
strain	O
)	O
very	O
effectively	O
replicates	O
in	O
thymocytes	O
cocultured	O
with	O
TEC	O
whereas	O
this	O
provirus	O
,	O
with	O
kappaB	O
sites	O
deleted	O
,	O
fails	O
to	O
replicate	O
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF	O
-	O
kappaB	O
complexes	O
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	O
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	O
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	O
p50	B-PRGE
-	O
p65	B-PRGE
.	O

NF	O
-	O
kappaB	O
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV	O
-	O
1	O
transfected	O
in	O
thymocytes	O
.	O

The	O
cotransfection	O
of	O
this	O
LTR	O
with	O
a	O
mutated	O
IkappaBalpha	B-PRGE
molecule	O
formally	O
demonstrates	O
that	O
LTR	O
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kappaB	O
family	O
in	O
thymocytes	O
.	O

We	O
also	O
showed	O
that	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF	O
-	O
kappaB	O
activity	O
and	O
a	O
correlative	O
LTR	O
transactivation	O
.	O

However	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	O
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF	O
-	O
kappaB	O
activation	O
elicited	O
by	O
TNF	O
or	O
IL	O
-	O
1	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	O
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	O
the	O
necessary	O
cytokines	O
:	O
TNF	O
,	O
IL	O
-	O
1	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
.	O

Cross	O
-	O
linking	O
of	O
CD44	B-PRGE
on	O
rheumatoid	O
synovial	O
cells	O
up	O
-	O
regulates	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

CD44	B-PRGE
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	B-PRGE
.	O

Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	B-PRGE
cross	O
-	O
linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
subsequently	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
cell	O
adhesion	O
.	O

Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	O
synovial	O
cells	O
highly	O
expressed	O
CD44	B-PRGE
;	O
2	O
)	O
cross	O
-	O
linking	O
of	O
CD44	B-PRGE
markedly	O
but	O
transiently	O
augmented	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
its	O
mRNA	O
transcription	O
much	O
more	O
than	O
did	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up	O
-	O
regulated	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
;	O
4	O
)	O
CD44	B-PRGE
activated	O
the	O
transcription	O
factor	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
;	O
and	O
5	O
)	O
the	O
integrin	O
-	O
dependent	O
adhesive	O
function	O
of	O
RA	O
synovial	O
cells	O
to	O
T	O
cells	O
was	O
also	O
amplified	O
by	O
CD44	B-PRGE
cross	O
-	O
linking	O
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	O
synovial	O
cells	O
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B-PRGE
could	O
up	O
-	O
regulate	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
adhesion	O
to	O
T	O
cells	O
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	O
cells	O
and	O
synovial	O
cells	O
in	O
RA	O
synovitis	O
.	O

We	O
therefore	O
propose	O
that	O
such	O
cross	O
-	O
talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O

Oleic	O
acid	O
inhibits	O
endothelial	O
activation	O
:	O
A	O
direct	O
vascular	O
antiatherogenic	O
mechanism	O
of	O
a	O
nutritional	O
component	O
in	O
the	O
mediterranean	O
diet	O
.	O

Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	O
products	O
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	O
recombinant	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
1alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

The	O
endothelial	O
expression	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
and	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady	O
-	O
state	O
levels	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

At	O
10	O
to	O
100	O
micromol	O
/	O
L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	O
molecules	O
tested	O
.	O

After	O
a	O
72	O
-	O
hour	O
incubation	O
with	O
oleate	O
and	O
a	O
further	O
16	O
-	O
hour	O
incubation	O
with	O
oleate	O
plus	O
1	O
microg	O
/	O
mL	O
LPS	O
,	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
was	O
reduced	O
by	O
>	O
40	O
%	O
compared	O
with	O
control	O
.	O

Adhesion	O
of	O
monocytoid	O
U937	O
cells	O
to	O
LPS	O
-	O
treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	O
natural	O
killer	O
cells	O
at	O
nutritionally	O
relevant	O
concentrations	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
(	O
DG	O
and	O
GG	O
)	O
,	O
major	O
isoflavone	O
metabolites	O
,	O
may	O
be	O
partly	O
responsible	O
for	O
biological	O
effects	O
of	O
isoflavones	O
,	O
such	O
as	O
estrogen	B-PRGE
receptor	I-PRGE
binding	O
and	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
activation	O
or	O
inhibition	O
.	O

DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3	O
-	O
methylcholanthrene	O
-	O
induced	O
rat	O
liver	O
microsomes	O
.	O

The	O
Km	O
and	O
Vmax	O
for	O
daidzein	O
and	O
genistein	O
were	O
9	O
.	O
0	O
and	O
7	O
.	O
7	O
micromol	O
/	O
L	O
,	O
and	O
0	O
.	O
7	O
and	O
1	O
.	O
6	O
micromol	O
/	O
(	O
mg	O
protein	O
.	O
min	O
)	O
,	O
respectively	O
.	O

The	O
absence	O
of	O
ultraviolet	O
absorbance	O
maxima	O
shifts	O
in	O
the	O
presence	O
of	O
sodium	O
acetate	O
confirmed	O
that	O
the	O
synthesized	O
products	O
were	O
7	O
-	O
O	O
-	O
glucuronides	O
.	O

DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH	O
-	O
20	O
column	O
.	O

DG	O
and	O
GG	O
competed	O
with	O
the	O
binding	O
of	O
17beta	O
-	O
(	O
3H	O
)	O
estradiol	O
to	O
estrogen	B-PRGE
receptors	I-PRGE
of	O
B6D2F1	O
mouse	O
uterine	O
cytosol	O
.	O

The	O
concentrations	O
required	O
for	O
50	O
%	O
displacement	O
of	O
17beta	O
-	O
(	O
3H	O
)	O
estradiol	O
(	O
CB50	O
)	O
were	O
:	O
17beta	O
-	O
estradiol	O
,	O
1	O
.	O
34	O
nmol	O
/	O
L	O
;	O
diethylstilbestrol	O
,	O
1	O
.	O
46	O
nmol	O
/	O
L	O
;	O
daidzein	O
,	O
1	O
.	O
6	O
micromol	O
/	O
L	O
;	O
DG	O
,	O
14	O
.	O
7	O
micromol	O
/	O
L	O
;	O
genistein	O
,	O
0	O
.	O
154	O
micromol	O
/	O
L	O
;	O
GG	O
,	O
7	O
.	O
27	O
micromol	O
/	O
L	O
.	O

In	O
human	O
peripheral	O
blood	O
NK	O
cells	O
,	O
genistein	O
at	O
<	O
0	O
.	O
5	O
micromol	O
/	O
L	O
and	O
DG	O
and	O
GG	O
at	O
0	O
.	O
1	O
-	O
10	O
micromol	O
/	O
L	O
enhanced	O
NK	O
cell	O
-	O
mediated	O
K562	O
cancer	O
cell	O
killing	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
>	O
0	O
.	O
5	O
micromol	O
/	O
L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
glucuronides	O
only	O
inhibited	O
NK	O
cytotoxicity	O
at	O
50	O
micromol	O
/	O
L	O
.	O

Isoflavones	O
,	O
and	O
especially	O
the	O
isoflavone	O
glucuronides	O
,	O
enhanced	O
activation	O
of	O
NK	O
cells	O
by	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
additively	O
.	O

At	O
physiological	O
concentrations	O
,	O
DG	O
and	O
GG	O
were	O
weakly	O
estrogenic	O
,	O
and	O
they	O
activated	O
human	O
NK	O
cells	O
in	O
nutritionally	O
relevant	O
concentrations	O
in	O
vitro	O
,	O
probably	O
at	O
a	O
site	O
different	O
from	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
action	O
.	O

Osteoclast	O
markers	O
accumulate	O
on	O
cells	O
developing	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
precursors	O
.	O

Recent	O
studies	O
show	O
that	O
human	O
osteoclasts	O
develop	O
in	O
vitro	O
from	O
hematopoietic	O
cells	O
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and	O
/	O
or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O

Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	O
markers	O
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	O
cells	O
,	O
growth	O
factors	O
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O

Three	O
days	O
after	O
establishing	O
high	O
-	O
density	O
PBMC	O
cultures	O
(	O
1	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
cm2	O
)	O
,	O
in	O
serum	O
-	O
containing	O
medium	O
,	O
small	O
adherent	O
colonies	O
of	O
tartrate	O
resistant	O
acid	O
phosphatase	O
positive	O
(	O
TRAP	B-PRGE
+	O
)	O
cells	O
emerge	O
,	O
amidst	O
massive	O
monocyte	O
cell	O
death	O
.	O

These	O
adherent	O
cells	O
have	O
an	O
eccentrically	O
placed	O
,	O
round	O
nucleus	O
,	O
and	O
express	O
low	O
levels	O
of	O
TRAP	B-PRGE
and	O
sodium	O
fluoride	O
-	O
resistant	O
-	O
alpha	O
-	O
naphthyl	O
-	O
acetate	O
-	O
esterase	O
(	O
NaF	O
-	O
R	O
-	O
NSE	O
)	O
.	O

Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	O
(	O
vitronectin	O
receptor	O
[	O
VR	O
]	O
,	O
calcitonin	O
receptor	O
,	O
TRAP	B-PRGE
,	O
cathepsin	B-PRGE
K	I-PRGE
protein	O
,	O
and	O
mRNA	O
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O

When	O
cultured	O
on	O
bone	O
,	O
VR	O
+	O
,	O
TRAP	B-PRGE
+	O
cells	O
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

Although	O
these	O
pits	O
are	O
not	O
nearly	O
as	O
numerous	O
as	O
the	O
cells	O
of	O
preosteoclast	O
phenotype	O
,	O
they	O
do	O
represent	O
the	O
activity	O
of	O
a	O
subset	O
of	O
osteoclast	O
-	O
like	O
cells	O
that	O
has	O
achieved	O
osteoclastic	O
maturity	O
under	O
these	O
culture	O
conditions	O
.	O

Transcripts	O
for	O
osteoprotegerin	B-PRGE
ligand	I-PRGE
(	O
OPGL	B-PRGE
)	O
,	O
an	O
osteoclast	O
differentiation	O
factor	O
(	O
also	O
known	O
as	O
RANKL	B-PRGE
and	O
TRANCE	B-PRGE
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	O
cells	O
.	O

Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast	O
/	O
osteoclast	O
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	O
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O

Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	O
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O

The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Significantly	O
increased	O
oestrogen	O
receptor	O
expression	O
,	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
and	O
numbers	O
of	O
CD8	O
+	O
leukocytes	O
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56	B-PRGE
+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Apoptotic	O
cells	O
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O

In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O

The	O
unusual	O
CD56	B-PRGE
+	O
CD16	B-PRGE
-	O
eGLs	O
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56	B-PRGE
+	O
CD16	B-PRGE
+	O
natural	O
killer	O
cells	O
.	O

eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U	O
/	O
ml	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
over	O
48	O
-	O
h	O
and	O
120	O
-	O
h	O
time	O
courses	O
.	O

eGLs	O
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD	O
+	O
8	O
T	O
-	O
cell	O
numbers	O
and	O
increased	O
oestrogen	O
receptor	O
and	O
bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O

Clonality	O
of	O
isolated	O
eosinophils	O
in	O
the	O
hypereosinophilic	O
syndrome	O
.	O

The	O
idiopathic	O
hypereosinophilic	O
syndrome	O
(	O
IHES	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
unexplained	O
,	O
persistent	O
eosinophilia	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
eosinophilic	O
tissue	O
infiltration	O
.	O

In	O
the	O
absence	O
of	O
karyotypic	O
abnormalities	O
,	O
there	O
is	O
no	O
specific	O
test	O
to	O
detect	O
clonal	O
eosinophilia	O
in	O
IHES	O
.	O

Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
patterns	O
can	O
be	O
used	O
to	O
determine	O
whether	O
proliferative	O
disorders	O
are	O
clonal	O
in	O
origin	O
.	O

Methylation	O
of	O
HpaII	O
and	O
Hha	O
I	O
sites	O
near	O
the	O
polymorphic	O
trinucleotide	O
repeat	O
of	O
the	O
human	B-PRGE
androgen	I-PRGE
receptor	I-PRGE
gene	O
(	O
HUMARA	B-PRGE
)	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
X	O
-	O
inactivation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
nested	O
primers	O
to	O
analyze	O
X	O
-	O
inactivation	O
patterns	O
of	O
the	O
HUMARA	B-PRGE
loci	O
in	O
purified	O
eosinophils	O
from	O
female	O
patients	O
with	O
eosinophilia	O
.	O

Peripheral	O
blood	O
eosinophils	O
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O

Eosinophils	O
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
.	O

Eosinophil	O
-	O
depleted	O
leukocytes	O
from	O
this	O
patient	O
were	O
polyclonal	O
by	O
HUMARA	B-PRGE
analysis	O
,	O
thus	O
excluding	O
skewedness	O
of	O
random	O
X	O
-	O
inactivation	O
.	O

After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	O
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	O
eosinophils	O
.	O

In	O
contrast	O
,	O
eosinophils	O
purified	O
from	O
a	O
patient	O
with	O
Churg	O
-	O
Strauss	O
syndrome	O
and	O
from	O
six	O
patients	O
with	O
reactive	O
eosinophilias	O
attributed	O
to	O
allergy	O
,	O
parasitic	O
infection	O
,	O
or	O
drug	O
reaction	O
showed	O
a	O
polyclonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
by	O
HUMARA	B-PRGE
analysis	O
.	O

The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low	O
-	O
grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	B-PRGE
analysis	O
.	O

Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O

Binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
to	O
STAT5	O
target	O
sequences	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
.	O

The	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	O
cells	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T	O
-	O
cell	O
malignancy	O
termed	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

A	O
characteristic	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	O
cells	O
.	O

Although	O
NF	O
-	O
kappaB	O
/	O
Rel	O
factors	O
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T	O
-	O
cell	O
growth	O
factor	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
growth	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF	O
-	O
kappaB	O
/	O
Rel	O
members	O
,	O
predominantly	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	O
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
to	O
the	O
STAT5	O
site	O
present	O
in	O
the	O
Fc	B-PRGE
gammaR1	I-PRGE
gene	O
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O

Binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
to	O
the	O
Fc	B-PRGE
gammaR1	I-PRGE
STAT	O
site	O
also	O
occurs	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
immortalized	O
with	O
HTLV	O
-	O
I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	O
and	O
certain	O
STAT	O
enhancers	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF	O
-	O
ATc	O
in	O
effector	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
ATc	O
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	O
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	O
'	O
polyA	O
site	O
to	O
a	O
more	O
proximal	O
polyA	O
site	O
,	O
NF	O
-	O
ATc	O
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	O
T	O
cells	O
to	O
that	O
of	O
short	O
isoform	O
A	O
in	O
T	O
effector	O
cells	O
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	O
stimulation	O
factor	O
CstF	B-PRGE
-	I-PRGE
64	I-PRGE
to	O
the	O
proximal	O
polyA	O
site	O
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	O
T	O
cells	O
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF	O
-	O
ATc	O
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF	O
-	O
ATc	O
for	O
gene	O
induction	O
in	O
effector	O
T	O
cells	O
.	O

A	O
direct	O
interaction	O
between	O
the	O
adaptor	O
protein	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
and	O
the	O
kinase	O
zap	B-PRGE
-	I-PRGE
70	I-PRGE
induces	O
a	O
positive	O
signal	O
in	O
T	O
cells	O
.	O

Engagement	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	O
complex	O
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src	O
-	O
family	O
and	O
Syk	B-PRGE
/	O
Zap	B-PRGE
-	I-PRGE
70	I-PRGE
-	O
family	O
kinases	O
[	O
1	O
]	O
[	O
2	O
]	O
.	O

These	O
activated	O
kinases	O
then	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
intracellular	O
proteins	O
,	O
eventually	O
leading	O
to	O
T	O
-	O
cell	O
activation	O
.	O

One	O
of	O
the	O
prominent	O
substrates	O
for	O
these	O
kinases	O
is	O
the	O
adaptor	O
protein	O
Cbl	O
[	O
3	O
]	O
and	O
recent	O
studies	O
suggest	O
that	O
Cbl	O
negatively	O
regulates	O
upstream	O
kinases	O
such	O
as	O
Syk	B-PRGE
and	O
Zap	B-PRGE
-	I-PRGE
70	I-PRGE
[	O
4	O
]	O
[	O
5	O
]	O
.	O

Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
,	O
a	O
homologue	O
of	O
Cbl	O
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	O
cells	O
[	O
6	O
]	O
[	O
7	O
]	O
.	O

Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
undergoes	O
rapid	O
tyrosine	O
phosphorylation	O
upon	O
stimulation	O
of	O
the	O
TCR	O
and	O
cytokine	O
receptors	O
[	O
8	O
]	O
[	O
9	O
]	O
.	O

The	O
role	O
of	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
is	O
unclear	O
,	O
however	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
in	O
T	O
cells	O
induced	O
the	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

A	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
disrupted	O
the	O
interaction	O
between	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
and	O
Zap	B-PRGE
-	I-PRGE
70	I-PRGE
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
-	O
mediated	O
activation	O
of	O
NFAT	O
.	O

Unlike	O
the	O
proposed	O
role	O
of	O
Cbl	O
as	O
a	O
negative	O
regulator	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Cbl	O
homologue	O
Cbl	B-PRGE
-	I-PRGE
b	I-PRGE
has	O
a	O
positive	O
role	O
in	O
T	O
-	O
cell	O
signaling	O
,	O
most	O
likely	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
upstream	O
kinase	O
Zap	B-PRGE
-	I-PRGE
70	I-PRGE
.	O

Detection	O
of	O
intracellular	O
phosphorylated	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
flow	O
cytometry	O
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
of	O
human	O
monocytes	O
.	O

This	O
approach	O
uses	O
monoclonal	O
antibodies	O
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

It	O
enables	O
rapid	O
and	O
quantitative	O
assessment	O
of	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
phosphorylation	O
on	O
a	O
discrete	O
cell	O
basis	O
and	O
is	O
both	O
more	O
sensitive	O
and	O
less	O
time	O
consuming	O
than	O
immunoblotting	O
.	O

Furthermore	O
,	O
it	O
allows	O
for	O
discrimination	O
between	O
a	O
mixture	O
of	O
cells	O
that	O
differ	O
in	O
their	O
response	O
to	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

This	O
approach	O
should	O
allow	O
for	O
the	O
evaluation	O
of	O
different	O
intracellular	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
monoclonal	O
reagents	O
that	O
are	O
specific	O
for	O
native	O
and	O
activation	O
modified	O
proteins	O
.	O

Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O

In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O

Glucocorticoid	O
hormone	O
suppression	O
of	O
human	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
effect	O
of	O
Dex	O
was	O
completely	O
reversed	O
by	O
a	O
glucocorticoid	B-PRGE
receptor	I-PRGE
antagonist	O
,	O
RU38486	O
.	O

To	O
clarify	O
the	O
underlying	O
mechanisms	O
,	O
we	O
examined	O
effects	O
of	O
Dex	O
on	O
the	O
binding	O
avidity	O
of	O
beta2	B-PRGE
integrin	I-PRGE
on	O
the	O
neutrophil	O
surface	O
and	O
how	O
these	O
might	O
in	O
turn	O
affect	O
neutrophil	O
-	O
to	O
-	O
tumor	O
cell	O
binding	O
.	O

Dex	O
was	O
found	O
to	O
inhibit	O
these	O
neutrophil	O
properties	O
,	O
and	O
RU38486	O
completely	O
suppressed	O
both	O
forms	O
of	O
Dex	O
inhibition	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
glucocorticoid	O
hormone	O
inhibition	O
of	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
is	O
at	O
least	O
partially	O
due	O
to	O
a	O
lowering	O
of	O
the	O
ligand	O
binding	O
avidity	O
of	O
beta2	B-PRGE
integrin	I-PRGE
on	O
the	O
neutrophil	O
surface	O
.	O

Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	O
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O

BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-	O
dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O

We	O
evaluated	O
the	O
immunoreactivity	O
of	O
the	O
regulatory	O
and	O
catalytic	O
subunits	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
protein	O
kinase	O
A	O
)	O
and	O
1	O
of	O
its	O
substrates	O
,	O
Rap1	B-PRGE
,	O
in	O
platelets	O
from	O
untreated	O
euthymic	O
,	O
manic	O
,	O
and	O
depressed	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Platelets	O
were	O
collected	O
from	O
112	O
drug	O
-	O
free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O

The	O
levels	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Rap1	B-PRGE
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer	O
-	O
assisted	O
imaging	O
.	O

RESULTS	O
:	O
The	O
immunolabeling	O
of	O
the	O
catalytic	O
subunit	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
was	O
significantly	O
different	O
among	O
groups	O
(	O
P	O
<	O
.	O
001	O
)	O
,	O
with	O
higher	O
values	O
in	O
untreated	O
depressed	O
and	O
manic	O
patients	O
with	O
bipolar	O
disorder	O
compared	O
with	O
untreated	O
euthymic	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
immunolabeling	O
of	O
the	O
regulatory	O
subunits	O
(	O
type	O
I	O
and	O
type	O
II	O
)	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O

The	O
immunolabeling	O
of	O
Rap1	B-PRGE
was	O
significantly	O
higher	O
(	O
P	O
<	O
.	O
001	O
)	O
in	O
untreated	O
euthymic	O
,	O
depressed	O
,	O
and	O
manic	O
patients	O
than	O
in	O
healthy	O
persons	O
.	O

CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B-PRGE
and	O
the	O
catalytic	O
subunit	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
are	O
altered	O
in	O
the	O
platelets	O
of	O
bipolar	O
patients	O
.	O

These	O
findings	O
may	O
provide	O
clues	O
toward	O
understanding	O
the	O
involvement	O
of	O
cAMP	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
bipolar	O
disorder	O
.	O

Lineage	O
-	O
specific	O
activation	O
of	O
STAT3	B-PRGE
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
human	O
neutrophils	O
.	O

Binding	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
to	O
its	O
heterodimeric	O
receptor	O
induces	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
JAK1	B-PRGE
and	O
JAK2	B-PRGE
followed	O
by	O
tyrosine	O
phosphorylation	O
of	O
STAT1alpha	B-PRGE
.	O

Selective	O
activation	O
of	O
STAT1alpha	B-PRGE
at	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
receptor	O
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	O
tyrosine	O
motif	O
including	O
Y440	O
in	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
and	O
the	O
SH2	O
domain	O
of	O
STAT1alpha	B-PRGE
.	O

We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	B-PRGE
,	O
STAT3	B-PRGE
is	O
also	O
activated	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
human	O
neutrophils	O
.	O

The	O
activation	O
of	O
STAT3	B-PRGE
was	O
not	O
found	O
in	O
human	O
eosinophils	O
,	O
monocytes	O
,	O
and	O
HL	O
-	O
60	O
cells	O
,	O
although	O
the	O
STAT3	B-PRGE
protein	O
was	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
cell	O
type	O
-	O
specific	O
activation	O
of	O
STAT3	B-PRGE
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
also	O
observed	O
in	O
neutrophils	O
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	O
CD34	B-PRGE
+	O
hematopoietic	O
stem	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
single	O
cytokine	O
receptor	O
can	O
activate	O
different	O
STAT	O
family	O
members	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
,	O
which	O
might	O
result	O
in	O
cell	O
-	O
specific	O
gene	O
transcription	O
.	O

Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O

Acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
is	O
still	O
associated	O
with	O
a	O
mortality	O
of	O
60	O
to	O
80	O
%	O
.	O

AML	O
is	O
characterized	O
by	O
a	O
block	O
in	O
myeloid	O
differentiation	O
.	O

The	O
transcription	O
factors	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
C	B-PRGE
/	I-PRGE
EBPalpha	I-PRGE
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	O
cells	O
to	O
monocytes	O
or	O
granulocytes	O
.	O

In	O
particular	O
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
induces	O
expression	O
of	O
the	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
receptor	O
and	O
the	O
development	O
of	O
monocytes	O
,	O
whereas	O
C	B-PRGE
/	I-PRGE
EBPalpha	I-PRGE
increases	O
the	O
expression	O
of	O
the	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	I-PRGE
G	I-PRGE
-	I-PRGE
CSF	I-PRGE
)	I-PRGE
receptor	I-PRGE
and	O
leads	O
to	O
mature	O
granulocytes	O
.	O

In	O
AML	O
,	O
chromosomal	O
aberrations	O
result	O
in	O
oncoproteins	O
such	O
as	O
AML1	B-PRGE
/	O
ETO	O
,	O
PML	B-PRGE
/	O
RARalpha	B-PRGE
,	O
or	O
activated	O
Ras	O
,	O
which	O
can	O
deregulate	O
genes	O
important	O
for	O
normal	O
myelopoiesis	O
.	O

Thus	O
,	O
AML1	B-PRGE
/	O
ETO	O
can	O
bind	O
to	O
the	O
transcription	O
factor	O
C	B-PRGE
/	I-PRGE
EBPalpha	I-PRGE
,	O
inhibit	O
C	B-PRGE
/	I-PRGE
EBPalpha	I-PRGE
-	O
dependent	O
transcription	O
,	O
and	O
block	O
granulocytic	O
differentiation	O
.	O

However	O
,	O
AML1	B-PRGE
/	O
ETO	O
can	O
also	O
synergize	O
with	O
the	O
transcription	O
factor	O
AML1	B-PRGE
to	O
enhance	O
the	O
activity	O
of	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	O
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
PML	B-PRGE
/	O
RARalpha	B-PRGE
fusion	O
protein	O
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	O
corepressor	O
(	O
N	O
-	O
CoR	O
)	O
histone	O
deacetylase	O
complex	O
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	O
acetylation	O
and	O
a	O
repressive	O
chromatin	O
organization	O
.	O

Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	O
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	O
factors	O
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Impaired	O
binding	O
of	O
a	O
DQ2	B-PRGE
and	O
DQ8	B-PRGE
-	O
binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1	O
*	O
0501	O
/	O
DQB1	O
*	O
0302	O
trans	O
class	O
II	O
heterodimer	O
.	O

DQalpha	B-PRGE
and	O
DQbeta	B-PRGE
trans	O
heterodimeric	O
HLA	O
-	O
DQ	O
molecules	O
form	O
in	O
individuals	O
heterozygous	O
for	O
the	O
DQ2	O
and	O
DQ8	O
specificities	O
.	O

Unique	O
functions	O
and	O
disease	O
associations	O
have	O
been	O
postulated	O
for	O
such	O
trans	O
-	O
dimers	O
,	O
which	O
may	O
be	O
different	O
from	O
cis	O
-	O
encoded	O
DQ	O
molecules	O
encoded	O
by	O
the	O
corresponding	O
haplotypes	O
.	O

We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans	O
-	O
dimer	O
encoded	O
by	O
HLA	O
-	O
DQA1	O
*	O
0501	O
/	O
DQB1	O
*	O
0302	O
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	O
molecules	O
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O

Markedly	O
impaired	O
binding	O
was	O
observed	O
,	O
consistent	O
with	O
both	O
the	O
use	O
of	O
different	O
anchor	O
residues	O
and	O
with	O
changes	O
in	O
levels	O
of	O
DQ	O
cis	O
-	O
dimer	O
availability	O
for	O
peptide	O
binding	O
interactions	O
.	O

MDS1	B-PRGE
/	O
EVI1	B-PRGE
enhances	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
signaling	O
and	O
strengthens	O
its	O
growth	O
-	O
inhibitory	O
effect	O
but	O
the	O
leukemia	O
-	O
associated	O
fusion	O
protein	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
,	O
product	O
of	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
,	O
abrogates	O
growth	O
-	O
inhibition	O
in	O
response	O
to	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
.	O

MDS1	B-PRGE
/	O
EVI1	B-PRGE
,	O
located	O
on	O
chromosome	O
3	O
band	O
q26	O
,	O
encodes	O
a	O
zinc	O
-	O
finger	O
DNA	O
-	O
binding	O
transcription	O
activator	O
not	O
detected	O
in	O
normal	O
hematopoietic	O
cells	O
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O

MDS1	B-PRGE
/	O
EVI1	B-PRGE
is	O
inappropriately	O
activated	O
in	O
myeloid	O
leukemias	O
following	O
chromosomal	O
rearrangements	O
involving	O
band	O
3q26	O
.	O

The	O
rearrangements	O
lead	O
either	O
to	O
gene	O
truncation	O
,	O
and	O
to	O
expression	O
of	O
the	O
transcription	O
repressor	O
EVI1	B-PRGE
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
and	O
inv	O
(	O
3	O
)	O
(	O
q21q26	O
)	O
,	O
or	O
to	O
gene	O
fusion	O
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
(	O
q26	O
;	O
q22	O
)	O
which	O
results	O
in	O
the	O
fusion	O
protein	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
.	O

This	O
fusion	O
protein	O
contains	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
transcription	O
factor	O
AML1	B-PRGE
fused	O
in	O
-	O
frame	O
to	O
the	O
entire	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
with	O
the	O
exclusion	O
of	O
its	O
first	O
12	O
amino	O
acids	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
hematopoietic	O
precursor	O
cell	O
line	O
32Dcl3	O
,	O
expressing	O
either	O
the	O
normal	O
protein	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
or	O
the	O
fusion	O
protein	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
,	O
to	O
factors	O
that	O
control	O
cell	O
differentiation	O
or	O
cell	O
replication	O
.	O

The	O
32Dcl3	O
cells	O
are	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
dependent	O
for	O
growth	O
and	O
they	O
differentiate	O
into	O
granulocytes	O
when	O
exposed	O
to	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

They	O
are	O
growth	O
-	O
inhibited	O
by	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
.	O

We	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
has	O
no	O
effect	O
on	O
granulocytic	O
differentiation	O
induced	O
by	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
expression	O
of	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
blocks	O
differentiation	O
resulting	O
in	O
cell	O
death	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
previously	O
described	O
by	O
others	O
for	O
32Dcl3	O
cells	O
that	O
express	O
transgenic	O
Evil	B-PRGE
.	O

Furthermore	O
,	O
we	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
the	O
fusion	O
protein	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
completely	O
abrogates	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
and	O
allows	O
32Dcl3	O
cells	O
to	O
proliferate	O
,	O
expression	O
of	O
the	O
normal	O
protein	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
has	O
the	O
opposite	O
effect	O
,	O
and	O
it	O
strengthens	O
the	O
response	O
of	O
cells	O
to	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
.	O

By	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	B-PRGE
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
and	O
AML1	B-PRGE
/	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
)	O
physically	O
interacts	O
with	O
SMAD3	B-PRGE
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
signaling	O
.	O

Finally	O
,	O
we	O
have	O
correlated	O
the	O
response	O
of	O
the	O
cells	O
to	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
or	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
with	O
the	O
ability	O
of	O
the	O
normal	O
and	O
fusion	O
proteins	O
to	O
activate	O
or	O
repress	O
promoters	O
which	O
they	O
can	O
directly	O
regulate	O
by	O
binding	O
to	O
the	O
promoter	O
site	O
.	O

We	O
propose	O
that	O
mutations	O
of	O
MDS1	B-PRGE
/	O
EVI1	B-PRGE
either	O
by	O
gene	O
truncation	O
resulting	O
in	O
the	O
transcription	O
repressor	O
EVI1	B-PRGE
or	O
by	O
gene	O
fusion	O
to	O
AML1	B-PRGE
lead	O
to	O
an	O
altered	O
cellular	O
response	O
to	O
growth	O
and	O
differentiation	O
factors	O
that	O
could	O
result	O
in	O
leukemic	O
transformation	O
.	O

The	O
different	O
response	O
of	O
myeloid	O
cells	O
ectopically	O
expressing	O
the	O
normal	O
or	O
the	O
fusion	O
protein	O
to	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
could	O
depend	O
on	O
the	O
different	O
transactivation	O
properties	O
of	O
these	O
proteins	O
resulting	O
in	O
divergent	O
expression	O
of	O
downstream	O
genes	O
regulated	O
by	O
the	O
two	O
proteins	O
.	O

Interferon	O
-	O
alpha	O
induction	O
of	O
STATs1	B-PRGE
,	O
-	B-PRGE
3	I-PRGE
DNA	O
binding	O
and	O
growth	O
arrest	O
is	O
independent	O
of	O
Lck	B-PRGE
and	O
active	O
mitogen	O
-	O
activated	O
kinase	O
in	O
T	O
cells	O
.	O

Type	O
I	O
interferons	O
(	O
IFNs	O
)	O
are	O
a	O
family	O
of	O
cytokines	O
that	O
have	O
antiviral	O
and	O
antiproliferative	O
effects	O
.	O

Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	O
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O

The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	O
-	O
STAT	O
signaling	O
.	O

Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src	O
-	O
family	O
kinase	O
Lck	B-PRGE
in	O
JAK	O
-	O
STAT	O
signaling	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B-PRGE
in	O
IFN	O
-	O
alpha	O
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck	B-PRGE
-	O
defective	O
cell	O
line	O
derived	O
from	O
Jurkat	O
)	O
,	O
and	O
JCam	O
/	O
Lck	B-PRGE
(	O
JCam	O
cells	O
with	O
Lck	B-PRGE
restored	O
)	O
.	O

The	O
results	O
show	O
that	O
IFN	O
-	O
alpha	O
can	O
induce	O
MAPK	O
activity	O
,	O
but	O
only	O
in	O
cells	O
containing	O
Lck	B-PRGE
.	O

Furthermore	O
,	O
STATs1	B-PRGE
and	O
-	B-PRGE
3	I-PRGE
are	O
effectively	O
phosphorylated	O
and	O
activated	O
to	O
bind	O
DNA	O
in	O
the	O
absence	O
of	O
Lck	B-PRGE
expression	O
in	O
IFN	O
-	O
alpha	O
-	O
treated	O
cells	O
.	O

Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN	O
-	O
alpha	O
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O

These	O
data	O
indicate	O
that	O
Lck	B-PRGE
and	O
active	O
MAPK	O
do	O
not	O
affect	O
IFN	O
-	O
alpha	O
-	O
induced	O
growth	O
arrest	O
or	O
induction	O
of	O
STAT1s1	O
and	O
-	O
3	O
DNA	O
binding	O
ability	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

T	O
helper	O
differentiation	O
proceeds	O
through	O
Stat1	B-PRGE
-	O
dependent	O
,	O
Stat4	B-PRGE
-	O
dependent	O
and	O
Stat4	B-PRGE
-	O
independent	O
phases	O
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1	O
/	O
Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

Because	O
extinction	O
of	O
IL	O
-	O
12	O
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	O
cells	O
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL	O
-	O
12	O
signaling	O
pathway	O
.	O

Whereas	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
appears	O
to	O
repress	O
functional	O
IL	O
-	O
12	O
signaling	O
through	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
12R	I-PRGE
beta	I-PRGE
2	I-PRGE
expression	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
the	O
mouse	O
,	O
and	O
IFN	O
-	O
alpha	O
in	O
the	O
human	O
appear	O
to	O
induce	O
IL	B-PRGE
-	I-PRGE
12R	I-PRGE
beta	I-PRGE
2	I-PRGE
expression	O
and	O
promote	O
IL	O
-	O
12	O
responsiveness	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
12R	I-PRGE
beta	I-PRGE
1	I-PRGE
and	O
beta	B-PRGE
2	I-PRGE
subunits	O
,	O
regulated	O
by	O
TCR	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IFNs	O
.	O

The	O
second	O
stage	O
,	O
development	O
,	O
we	O
propose	O
is	O
the	O
true	O
IL	O
-	O
12	O
induced	O
developmental	O
stage	O
,	O
involving	O
expression	O
of	O
Stat4	B-PRGE
inducible	O
proteins	O
.	O

In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN	O
-	O
alpha	O
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	B-PRGE
.	O

It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	B-PRGE
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	B-PRGE
at	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	O
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	B-PRGE
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non	O
-	O
cytokine	O
genes	O
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	O
cell	O
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
cell	O
line	O
(	O
UF	O
-	O
1	O
)	O
associated	O
with	O
expression	O
of	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all	O
-	O
trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	O
factors	O
:	O
RA	O
receptors	O
(	O
RARs	O
)	O
and	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
.	O

RXRs	O
heterodimerize	O
with	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
-	I-PRGE
dihydroxyvitamin	I-PRGE
D3	I-PRGE
[	I-PRGE
1	I-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
]	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
cdk	O
)	O
inhibitor	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
has	O
a	O
vitamin	O
D3	O
-	O
responsive	O
element	O
(	O
VDRE	O
)	O
in	O
its	O
promoter	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	O
leukemic	O
cell	O
lines	O
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	O
cell	O
line	O
(	O
UF	O
-	O
1	O
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF	O
-	O
1	O
cells	O
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all	O
-	O
trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-	O
10	O
)	O
to	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF	O
-	O
1	O
cells	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B-PRGE
antigen	O
in	O
myeloid	O
leukemic	O
cells	O
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF	O
-	O
1	O
cells	O
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	B-PRGE
(	O
WAF1	B-PRGE
/	O
CIP1	B-PRGE
)	O
and	O
p27	B-PRGE
(	O
KIP1	B-PRGE
)	O
transcript	O
and	O
protein	O
expression	O
in	O
RA	O
-	O
resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	O
inhibitors	O
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA	O
-	O
resistant	O
UF	O
-	O
1	O
cells	O
toward	O
mature	O
granulocytes	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
derives	O
from	O
post	O
-	O
germinal	O
center	O
B	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
(	O
HIV	O
-	O
HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O

These	O
include	O
overrepresentation	O
of	O
clinically	O
aggressive	O
histologic	O
types	O
and	O
frequent	O
infection	O
of	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
cells	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
HD	O
of	O
the	O
general	O
population	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
a	O
transcription	O
factor	O
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
,	O
and	O
of	O
CD138	B-PRGE
/	O
syndecan	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
syn	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post	O
-	O
GC	O
,	O
terminal	O
B	O
-	O
cell	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV	O
-	O
HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O

We	O
have	O
found	O
that	O
RS	O
cells	O
of	O
all	O
histologic	O
categories	O
of	O
HIV	O
-	O
HD	O
consistently	O
display	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
-	O
)	O
/	O
syn	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
+	O
)	O
phenotype	O
and	O
thus	O
reflect	O
post	O
-	O
GC	O
B	O
cells	O
.	O

Although	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
-	O
)	O
/	O
syn	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
+	O
)	O
RS	O
cells	O
of	O
HIV	O
-	O
HD	O
express	O
CD40	B-PRGE
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	B-PRGE
ligand	I-PRGE
-	O
positive	O
(	O
CD40L	B-PRGE
+	O
)	O
reactive	O
T	O
lymphocytes	O
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B-PRGE
/	O
CD40L	B-PRGE
interactions	O
.	O

Conversely	O
,	O
RS	O
cells	O
of	O
virtually	O
all	O
HIV	O
-	O
HD	O
express	O
the	O
EBV	O
-	O
encoded	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
,	O
which	O
,	O
being	O
functionally	O
homologous	O
to	O
CD40	B-PRGE
,	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
modulation	O
of	O
the	O
HIV	O
-	O
HD	O
phenotype	O
.	O

Interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	O
cells	O
from	O
apoptosis	O
.	O

The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	O
cells	O
.	O

However	O
,	O
to	O
generate	O
and	O
maintain	O
immunological	O
memory	O
,	O
some	O
antigen	O
-	O
specific	O
T	O
cells	O
must	O
survive	O
and	O
revert	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O

Cytokines	O
that	O
bind	O
to	O
the	O
common	O
gamma	O
chain	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
promote	O
the	O
survival	O
of	O
T	O
cell	O
blasts	O
,	O
but	O
also	O
induce	O
proliferation	O
.	O

In	O
contrast	O
,	O
soluble	O
factors	O
secreted	O
by	O
stromal	O
cells	O
induce	O
Tcell	O
survival	O
in	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O

We	O
now	O
report	O
that	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
is	O
the	O
principal	O
mediator	O
of	O
stromal	O
cell	O
-	O
mediated	O
Tcell	O
rescue	O
from	O
apoptosis	O
.	O

Interferon	O
-	O
alpha	O
and	O
-	O
beta	O
promote	O
the	O
reversion	O
of	O
blast	O
Tcells	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
configuration	O
with	O
all	O
the	O
characteristic	O
features	O
of	O
stromal	O
cell	O
rescue	O
;	O
such	O
as	O
high	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
expression	O
and	O
low	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Type	O
I	O
interferons	O
and	O
stromal	O
cells	O
stimulate	O
apparently	O
identical	O
signaling	O
pathways	O
,	O
leading	O
to	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
activation	O
.	O

We	O
also	O
show	O
that	O
this	O
mechanism	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
persistence	O
of	O
T	O
cells	O
at	O
sites	O
of	O
chronic	O
inflammation	O
;	O
suggesting	O
that	O
chronic	O
inflammation	O
is	O
an	O
aberrant	O
consequence	O
of	O
immunological	O
memory	O
.	O

Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	O
leukocytes	O
.	O

Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	O
and	O
other	O
leukocytes	O
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

This	O
study	O
assessed	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O

Pretreatment	O
of	O
"	O
semimature	O
"	O
5	O
-	O
day	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
M	O
phi	O
)	O
for	O
24	O
h	O
with	O
methylprednisolone	O
,	O
dexamethasone	O
,	O
and	O
hydrocortisone	O
,	O
but	O
not	O
the	O
nonglucocorticoid	O
steroids	O
aldosterone	O
,	O
estradiol	O
,	O
and	O
progesterone	O
,	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
.	O

These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5	O
-	O
day	O
M	O
phi	O
ingestion	O
of	O
opsonized	O
erythrocytes	O
.	O

Similar	O
glucocorticoid	O
-	O
mediated	O
potentiation	O
was	O
observed	O
with	O
5	O
-	O
day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
"	O
targets	O
"	O
(	O
eosinophils	O
and	O
Jurkat	O
T	O
cells	O
)	O
and	O
in	O
uptake	O
of	O
apoptotic	O
neutrophils	O
by	O
alternative	O
phagocytes	O
(	O
human	O
glomerular	O
mesangial	O
cells	O
and	O
murine	O
M	O
phi	O
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O

Importantly	O
,	O
methylprednisolone	O
-	O
mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	O
neutrophils	O
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Furthermore	O
,	O
longer	O
-	O
term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	O
human	O
monocyte	O
-	O
derived	O
M	O
phi	O
,	O
with	O
greater	O
increases	O
in	O
5	O
-	O
day	O
M	O
phi	O
uptake	O
of	O
apoptotic	O
cells	O
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	O
phi	O
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	O
leukocytes	O
by	O
phagocytes	O
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

Glucocorticoid	O
-	O
induced	O
cell	O
death	O
requires	O
autoinduction	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
expression	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B-PRGE
expression	O
is	O
positively	O
autoregulated	O
in	O
human	O
leukemic	O
T	O
cells	O
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
.	O

To	O
determine	O
whether	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
,	O
a	O
wild	O
-	O
type	O
GR	B-PRGE
gene	O
under	O
the	O
control	O
of	O
a	O
tetracycline	O
-	O
regulated	O
promoter	O
was	O
stably	O
transfected	O
into	O
glucocorticoid	O
-	O
resistant	O
cells	O
lacking	O
endogenous	O
functional	O
receptor	O
.	O

Transfectants	O
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors	O
/	O
cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B-PRGE
expression	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1	O
.	O
1	O
cells	O
before	O
steroid	O
treatment	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O

In	O
the	O
absence	O
of	O
tetracycline	O
,	O
GR	B-PRGE
mRNA	O
and	O
protein	O
expression	O
increased	O
2	O
-	O
3	O
-	O
fold	O
,	O
and	O
cells	O
expressed	O
48	O
,	O
000	O
receptors	O
,	O
a	O
level	O
nearly	O
equivalent	O
to	O
that	O
present	O
in	O
6TG1	O
.	O
1	O
cells	O
after	O
18	O
h	O
of	O
autoinduction	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
markedly	O
inhibited	O
cell	O
growth	O
,	O
caused	O
G1	O
arrest	O
,	O
and	O
induced	O
significant	O
internucleosomal	O
DNA	O
fragmentation	O
.	O

These	O
studies	O
therefore	O
suggest	O
that	O
basal	O
level	O
GR	B-PRGE
expression	O
is	O
inadequate	O
to	O
mediate	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
glucocorticoid	O
-	O
sensitive	O
T	O
cells	O
and	O
that	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
this	O
process	O
.	O

Jeg	O
-	O
3	O
human	O
choriocarcinoma	O
-	O
induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
,	O
and	O
its	O
Jak	O
/	O
Stat	O
signaling	O
pathway	O
.	O

PROBLEM	O
:	O
The	O
mechanisms	O
of	O
the	O
immunosuppressive	O
and	O
immunosuppression	O
-	O
inducing	O
capacities	O
of	O
Jeg	O
-	O
3	O
human	O
choriocarcinoma	O
cell	O
line	O
supernatants	O
(	O
HCSs	O
)	O
are	O
not	O
yet	O
completely	O
understood	O
.	O

The	O
influence	O
on	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
interferon	B-PRGE
(	I-PRGE
IFN	I-PRGE
)	I-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
;	O
IL	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
and	O
gamma	O
-	O
chain	O
;	O
and	O
the	O
signaling	O
pathway	O
molecules	O
Janus	B-PRGE
kinase	I-PRGE
(	I-PRGE
Jak	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
Jak3	B-PRGE
,	O
signal	B-PRGE
transducers	I-PRGE
and	I-PRGE
activators	I-PRGE
of	I-PRGE
transcription	I-PRGE
(	I-PRGE
Stat	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
Stat3	B-PRGE
,	O
and	O
Stat5	B-PRGE
should	O
be	O
investigated	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
.	O

Secretion	O
of	O
ILs	O
was	O
blocked	O
with	O
monensine	O
.	O

Intracellular	O
ILs	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

For	O
IL	O
-	O
2R	O
and	O
signaling	O
pathway	O
molecule	O
analysis	O
,	O
peripheral	O
blood	O
lymphocytes	O
were	O
stimulated	O
with	O
phytohemagglutinin	B-PRGE
(	O
PHA	B-PRGE
)	O
.	O

IL	O
-	O
2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks	O
/	O
Stats	O
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent	O
-	O
age	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
+	O
cells	O
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O

PHA	B-PRGE
stimulates	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
-	I-PRGE
,	O
beta	B-PRGE
-	I-PRGE
,	O
and	O
gamma	B-PRGE
-	I-PRGE
chain	I-PRGE
expression	O
and	O
their	O
signaling	O
pathway	O
molecules	O
Jak1	B-PRGE
,	O
Jak3	B-PRGE
,	O
Stat1	B-PRGE
,	O
Stat3	B-PRGE
,	O
and	O
Stat5	B-PRGE
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha	O
-	O
chain	O
and	O
slightly	O
upregulates	O
the	O
beta	O
-	O
chain	O
.	O

Jak1	B-PRGE
,	O
Jak3	B-PRGE
,	O
Stat1	B-PRGE
,	O
Stat3	B-PRGE
,	O
and	O
Stat5	B-PRGE
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
;	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
;	O
and	O
Jak1	B-PRGE
,	O
Jak3	B-PRGE
,	O
Stat1	B-PRGE
,	O
Stat3	B-PRGE
,	O
and	O
Stat5	B-PRGE
expression	O
.	O

The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL	O
-	O
2R	O
regulation	O
gene	O
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O

Vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
3	O
'	O
-	O
untranslated	O
region	O
polymorphisms	O
:	O
lack	O
of	O
effect	O
on	O
mRNA	O
stability	O
.	O

Allelic	O
variation	O
at	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
3	O
-	O
5	O
-	O
fold	O
increased	O
risk	O
of	O
developing	O
prostate	O
cancer	O
and	O
with	O
differences	O
in	O
bone	O
mineralization	O
.	O

This	O
genetic	O
diversity	O
does	O
not	O
alter	O
the	O
VDR	B-PRGE
protein	O
structurally	O
,	O
but	O
instead	O
may	O
be	O
a	O
marker	O
(	O
s	O
)	O
of	O
other	O
,	O
nearby	O
polymorphisms	O
that	O
influence	O
message	O
stability	O
or	O
translation	O
.	O

The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-PRGE
3	O
'	O
-	O
UTR	O
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O

Initially	O
,	O
four	O
novel	O
,	O
frequently	O
occurring	O
sequence	O
variants	O
were	O
identified	O
that	O
associated	O
with	O
two	O
common	O
haplotypes	O
that	O
were	O
described	O
previously	O
.	O

These	O
common	O
sequence	O
variants	O
were	O
not	O
found	O
within	O
three	O
message	O
-	O
destabilizing	O
elements	O
that	O
we	O
mapped	O
within	O
the	O
3	O
'	O
-	O
UTR	O
of	O
the	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
mRNA	O
.	O

Furthermore	O
,	O
the	O
two	O
VDR	B-PRGE
3	O
'	O
-	O
UTR	O
haplotypes	O
conferred	O
an	O
identical	O
half	O
-	O
life	O
on	O
a	O
heterologous	O
beta	O
-	O
globin	O
reporter	O
gene	O
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
polymorphisms	O
within	O
the	O
VDR	B-PRGE
3	O
'	O
-	O
UTR	O
do	O
not	O
influence	O
message	O
stability	O
.	O

[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O

Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti	O
-	O
inflammatory	O
,	O
immunosuppressive	O
or	O
anti	O
-	O
tumoral	O
agents	O
.	O

Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	O
lymphoid	O
cells	O
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O

In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	O
lymphoid	O
cells	O
.	O

Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	O
receptor	O
belonging	O
to	O
the	O
steroid	O
receptor	O
superfamily	O
:	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
.	O

Once	O
activated	O
,	O
the	O
GR	B-PRGE
,	O
can	O
mediate	O
his	O
effects	O
through	O
direct	O
binding	O
on	O
the	O
DNA	O
or	O
via	O
protein	O
/	O
protein	O
interactions	O
with	O
transcription	O
factors	O
.	O

Depending	O
on	O
the	O
type	O
of	O
lymphocytes	O
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
"	O
death	O
genes	O
"	O
by	O
the	O
activated	O
GR	B-PRGE
(	O
I	O
kappa	O
B	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
)	O
or	O
repression	O
of	O
survival	O
factors	O
(	O
AP	O
-	O
1	O
,	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
)	O
.	O

In	O
the	O
case	O
of	O
thymic	O
selection	O
the	O
mechanism	O
is	O
more	O
subtle	O
depending	O
on	O
the	O
mutual	O
repression	O
of	O
Nur77	B-PRGE
and	O
GR	B-PRGE
.	O

Cleavage	O
of	O
transcription	O
factor	O
SP1	B-PRGE
by	O
caspases	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O

Apoptosis	O
is	O
instrumental	O
in	O
the	O
processes	O
generating	O
the	O
diversity	O
of	O
the	O
B	O
-	O
cell	O
repertoire	O
.	O

Autoreactive	O
B	O
-	O
cells	O
are	O
eliminated	O
by	O
anti	O
-	O
IgM	O
crosslinking	O
after	O
encountering	O
self	O
-	O
antigens	O
,	O
but	O
precise	O
mechanisms	O
leading	O
to	O
B	O
-	O
cell	O
apoptosis	O
are	O
still	O
not	O
well	O
understood	O
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	O
factor	O
SP1	B-PRGE
in	O
the	O
human	O
Burkitt	O
lymphoma	O
cell	O
line	O
BL60	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
.	O

Western	O
blot	O
analysis	O
revealed	O
two	O
cleavage	O
products	O
of	O
approximately	O
68	O
kDa	O
and	O
45	O
kDa	O
after	O
induction	O
of	O
apoptosis	O
.	O

Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD	O
-	O
fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	O
3	O
-	O
like	O
proteases	O
.	O

In	O
-	O
vitro	O
cleavage	O
of	O
recombinant	O
SP1	B-PRGE
by	O
recombinant	O
caspase	B-PRGE
3	I-PRGE
(	O
CPP32	B-PRGE
)	O
or	O
caspase	B-PRGE
7	I-PRGE
(	O
Mch	B-PRGE
3	I-PRGE
)	O
results	O
in	O
similar	O
cleavage	O
products	O
as	O
those	O
observed	O
in	O
vivo	O
.	O

Recombinant	O
caspase	B-PRGE
6	I-PRGE
(	O
Mch	B-PRGE
2	I-PRGE
)	O
primarily	O
generates	O
a	O
68	O
-	O
kDa	O
cleavage	O
product	O
,	O
as	O
observed	O
after	O
calcium	O
ionophore	O
(	O
CaI	O
)	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O

In	O
contrast	O
,	O
caspase	B-PRGE
1	I-PRGE
(	O
ICE	B-PRGE
)	O
did	O
not	O
cleave	O
SP1	B-PRGE
in	O
vitro	O
.	O

The	O
time	O
course	O
of	O
SP1	B-PRGE
cleavage	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
is	O
paralleled	O
by	O
an	O
increase	O
of	O
caspase	O
activity	O
measured	O
by	O
DEVD	O
-	O
p	O
-	O
nitroanilide	O
(	O
DEVD	O
-	O
pNA	O
)	O
cleavage	O
.	O

DNA	O
band	O
-	O
shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B-PRGE
/	O
DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B-PRGE
cleavage	O
product	O
.	O

By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	B-PRGE
3	I-PRGE
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22	O
-	O
kDa	O
C	O
-	O
terminal	O
SP1	B-PRGE
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O

Our	O
results	O
show	O
the	O
cleavage	O
of	O
the	O
human	O
transcription	O
factor	O
SP1	B-PRGE
in	O
vivo	O
and	O
in	O
vitro	O
,	O
underlining	O
the	O
central	O
role	O
of	O
caspase	B-PRGE
3	I-PRGE
-	O
like	O
proteases	O
during	O
the	O
process	O
of	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
.	O

Spi	B-PRGE
-	I-PRGE
C	I-PRGE
,	O
a	O
novel	O
Ets	O
protein	O
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O

A	O
novel	O
Ets	O
protein	O
was	O
isolated	O
by	O
yeast	O
one	O
-	O
hybrid	O
screening	O
of	O
a	O
cDNA	O
library	O
made	O
from	O
lipopolysaccharide	O
-	O
stimulated	O
mouse	O
splenic	O
B	O
cells	O
,	O
using	O
the	O
SP6	O
kappa	O
promoter	O
kappaY	O
element	O
as	O
a	O
bait	O
.	O

The	O
novel	O
Ets	O
protein	O
was	O
most	O
closely	O
related	O
to	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
and	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
within	O
the	O
DNA	O
binding	O
Ets	O
domain	O
and	O
was	O
therefore	O
named	O
Spi	B-PRGE
-	I-PRGE
C	I-PRGE
.	O

However	O
,	O
Spi	B-PRGE
-	I-PRGE
C	I-PRGE
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	O
protein	O
family	O
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
within	O
helix	O
1	O
of	O
the	O
Ets	O
domain	O
.	O

Spi	B-PRGE
-	I-PRGE
C	I-PRGE
was	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
gene	O
that	O
was	O
mapped	O
to	O
chromosome	O
10	O
,	O
region	O
C	O
.	O

Spi	B-PRGE
-	I-PRGE
C	I-PRGE
interacted	O
with	O
DNA	O
similarly	O
to	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band	O
-	O
shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	O
element	O
reporter	O
gene	O
upon	O
co	O
-	O
transfection	O
of	O
HeLa	O
cells	O
.	O

Spi	B-PRGE
-	I-PRGE
C	I-PRGE
RNA	O
was	O
expressed	O
in	O
mature	O
B	O
lymphocytes	O
and	O
at	O
lower	O
levels	O
in	O
macrophages	O
.	O

Furthermore	O
,	O
pre	O
-	O
B	O
cell	O
and	O
plasma	O
cell	O
lines	O
were	O
Spi	B-PRGE
-	I-PRGE
C	I-PRGE
-	O
negative	O
,	O
suggesting	O
that	O
Spi	B-PRGE
-	I-PRGE
C	I-PRGE
might	O
be	O
a	O
regulatory	O
molecule	O
during	O
a	O
specific	O
phase	O
of	O
B	O
lymphoid	O
development	O
.	O

Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O

X	O
chromosome	O
inactivation	O
patterns	O
at	O
the	O
androgen	B-PRGE
receptor	I-PRGE
locus	O
were	O
evaluated	O
to	O
determine	O
clonality	O
in	O
microdissected	O
lesional	O
tissue	O
and	O
in	O
leukocytes	O
from	O
2	O
women	O
with	O
Dupuytren	O
'	O
s	O
disease	O
.	O

The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
of	O
the	O
human	O
androgen	B-PRGE
receptor	I-PRGE
gene	O
.	O

This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	O
aldosterone	B-PRGE
receptors	I-PRGE
outside	O
the	O
acute	O
phase	O
.	O

Pseudo	O
-	O
hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i	O
.	O
e	O
.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80	O
/	O
60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol	O
/	O
l	O
)	O
;	O
hyperkalemia	O
(	O
7	O
.	O
6	O
mmol	O
/	O
l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg	O
/	O
dl	O
)	O
and	O
creatininemia	O
(	O
2	O
.	O
5	O
mg	O
/	O
dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3	O
-	O
:	O
16	O
mmol	O
/	O
l	O
;	O
N	O
:	O
27	O
-	O
30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg	O
/	O
100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8	O
-	O
15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg	O
/	O
ml	O
,	O
N	O
:	O
10	O
-	O
60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	B-PRGE
activity	O
(	O
>	O
37	O
ng	O
/	O
ml	O
/	O
h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	B-PRGE
(	O
869	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
:	O
1	O
.	O
120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol	O
/	O
l	O
;	O
N	O
:	O
0	O
.	O
5	O
-	O
2	O
.	O
5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol	O
/	O
l	O
(	O
N	O
supine	O
:	O
5	O
-	O
25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13	O
.	O
3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3	O
.	O
16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0	O
.	O
24	O
;	O
N	O
:	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0	O
.	O
35	O
;	O
N	O
:	O
0	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	B-PRGE
receptors	I-PRGE
in	O
mononuclear	O
leukocytes	O
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
was	O
reduced	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE	O
/	O
THF	O
and	O
alpha	O
THF	O
/	O
THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	O
mineralocorticoid	B-PRGE
receptors	I-PRGE
outside	O
the	O
acute	O
episode	O
.	O

In	O
vivo	O
modulation	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
mRNA	O
by	O
inhaled	O
fluticasone	O
propionate	O
in	O
bronchial	O
mucosa	O
and	O
blood	O
lymphocytes	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	B-PRGE
mRNA	O
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	B-PRGE
mRNA	O
levels	O
.	O

A	O
solution	O
hybridization	O
assay	O
was	O
used	O
for	O
quantitative	O
analysis	O
of	O
GR	B-PRGE
mRNA	O
.	O

In	O
addition	O
,	O
a	O
24	O
-	O
hour	O
urinary	O
cortisol	O
excretion	O
and	O
an	O
adrenocorticotropic	B-PRGE
hormone	I-PRGE
test	O
before	O
and	O
after	O
treatment	O
with	O
FP	O
were	O
performed	O
.	O

RESULTS	O
:	O
A	O
high	O
interindividual	O
variation	O
in	O
GR	B-PRGE
mRNA	O
expression	O
was	O
seen	O
.	O

However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-PRGE
mRNA	O
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36	O
.	O
6	O
+	O
/	O
-	O
23	O
.	O
1	O
and	O
25	O
.	O
0	O
+	O
/	O
-	O
10	O
.	O
9	O
amol	O
GR	B-PRGE
mRNA	O
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

In	O
the	O
peripheral	O
blood	O
lymphocytes	O
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	B-PRGE
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30	O
.	O
3	O
+	O
/	O
-	O
26	O
.	O
5	O
and	O
8	O
.	O
8	O
+	O
/	O
-	O
5	O
amol	O
GR	B-PRGE
mRNA	O
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O

A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24	O
-	O
hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+	O
/	O
-	O
109	O
and	O
157	O
+	O
/	O
-	O
66	O
nmol	O
/	O
L	O
,	O
respectively	O
;	O
P	O
<	O
.	O
01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	B-PRGE
hormone	I-PRGE
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O

CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue	O
-	O
specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B-PRGE
.	O

p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
mediates	O
signal	O
integration	O
of	O
TCR	O
/	O
CD28	B-PRGE
costimulation	O
in	O
primary	O
murine	O
T	O
cells	O
.	O

Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	O
and	O
another	O
by	O
the	O
CD28	B-PRGE
costimulatory	I-PRGE
receptor	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
costimulation	O
-	O
induced	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
in	O
primary	O
mouse	O
T	O
cells	O
.	O

In	O
contrast	O
to	O
that	O
reported	O
for	O
human	O
Jurkat	O
T	O
cells	O
,	O
we	O
found	O
that	O
p38	O
MAPK	O
,	O
but	O
not	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
is	O
weakly	O
activated	O
upon	O
stimulation	O
with	O
either	O
anti	O
-	O
CD3	O
or	O
anti	O
-	O
CD28	B-PRGE
in	O
murine	O
thymocytes	O
and	O
splenic	O
T	O
cells	O
.	O

However	O
,	O
p38	O
MAPK	O
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3	O
/	O
CD28	B-PRGE
coligation	O
or	O
PMA	O
/	O
Ca2	O
+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	O
-	O
CD3	O
/	O
CD28	B-PRGE
-	O
mediated	O
signaling	O
.	O

Activation	O
of	O
p38	O
MAPK	O
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O

In	O
contrast	O
,	O
PMA	O
-	O
induced	O
JNK	O
activation	O
is	O
inhibited	O
by	O
Ca2	O
+	O
ionophore	O
.	O

T	O
cell	O
proliferation	O
and	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induced	O
by	O
both	O
CD3	O
and	O
CD3	O
/	O
CD28	B-PRGE
ligation	O
and	O
the	O
nuclear	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
and	O
ATF	B-PRGE
-	I-PRGE
2	I-PRGE
proteins	O
are	O
each	O
blocked	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB203580	O
.	O

Our	O
findings	O
demonstrate	O
that	O
p38	O
MAPK	O
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
primary	O
mouse	O
T	O
cells	O
,	O
2	O
)	O
may	O
be	O
involved	O
in	O
the	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
activation	O
and	O
augmentation	O
of	O
AP	O
-	O
1	O
transcriptional	O
activity	O
,	O
and	O
3	O
)	O
regulates	O
whether	O
T	O
cells	O
enter	O
a	O
state	O
of	O
functional	O
unresponsiveness	O
.	O

The	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
involves	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O

IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
can	O
stimulate	O
mitogen	O
-	O
or	O
CD3	O
-	O
activated	O
T	O
cells	O
to	O
proliferate	O
,	O
produce	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
and	O
kill	O
tumor	O
cells	O
.	O

The	O
magnitude	O
of	O
these	O
functional	O
responses	O
is	O
greatly	O
augmented	O
when	O
T	O
cells	O
are	O
activated	O
by	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Although	O
peripheral	O
blood	O
T	O
cells	O
are	O
largely	O
unresponsive	O
to	O
these	O
cytokines	O
without	O
prior	O
activation	O
,	O
a	O
small	O
subset	O
of	O
CD8	B-PRGE
+	O
T	O
cells	O
(	O
CD8	B-PRGE
+	O
CD18bright	O
)	O
is	O
strongly	O
activated	O
by	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
this	O
report	O
we	O
show	O
that	O
the	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
CD8	B-PRGE
+	O
CD18bright	O
T	O
cells	O
correlates	O
with	O
the	O
activation	O
of	O
the	O
stress	O
kinases	O
,	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
and	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
/	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
but	O
not	O
with	O
the	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
.	O

The	O
functional	O
synergy	O
between	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B-PRGE
and	O
STAT3	B-PRGE
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL	O
-	O
12	O
or	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
alone	O
.	O

By	O
contrast	O
,	O
STAT	O
tyrosine	O
phosphorylation	O
is	O
not	O
augmented	O
over	O
that	O
seen	O
with	O
either	O
cytokine	O
alone	O
.	O

A	O
specific	O
inhibitor	O
of	O
p38	O
MAP	O
kinase	O
completely	O
inhibits	O
the	O
serine	O
phosphorylation	O
of	O
STAT1	B-PRGE
and	O
STAT3	B-PRGE
induced	O
by	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
abrogates	O
the	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
without	O
affecting	O
STAT	O
tyrosine	O
phosphorylation	O
.	O

This	O
suggests	O
that	O
p38	O
MAP	O
kinase	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
STAT	O
serine	O
phosphorylation	O
in	O
response	O
to	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Furthermore	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
optimal	O
activation	O
of	O
T	O
cells	O
by	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
may	O
depend	O
on	O
an	O
interaction	O
between	O
the	O
p38	O
MAP	O
kinase	O
and	O
Janus	O
kinase	O
/	O
STAT	O
signaling	O
pathways	O
.	O

Modulation	O
of	O
E2F	O
complexes	O
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
.	O

The	O
pocket	O
protein	O
-	O
E2F	O
complexes	O
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	O
protein	O
-	O
E2F	O
complexes	O
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
after	O
activation	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Consistent	O
with	O
previous	O
data	O
from	O
human	O
and	O
mouse	O
fibroblasts	O
and	O
T	O
-	O
lymphocytes	O
,	O
E2F4	B-PRGE
and	O
DP1	B-PRGE
form	O
the	O
predominant	O
E2F	O
heterodimers	O
both	O
in	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
human	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
,	O
whereas	O
E2F1	B-PRGE
and	O
-	B-PRGE
3	I-PRGE
are	O
first	O
detected	O
in	O
late	O
G1	O
,	O
and	O
their	O
expression	O
levels	O
increase	O
towards	O
S	O
phase	O
.	O

Intriguingly	O
,	O
the	O
major	O
E2F	O
complex	O
that	O
we	O
detected	O
in	O
quiescent	O
human	O
B	O
-	O
lymphocytes	O
is	O
consisted	O
of	O
pRB	B-PRGE
,	O
E2F4	B-PRGE
,	O
and	O
DP1	B-PRGE
.	O

Though	O
the	O
levels	O
of	O
DP1	B-PRGE
and	O
-	B-PRGE
2	I-PRGE
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B-PRGE
to	O
DP2	B-PRGE
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	O
components	O
,	O
DP1	B-PRGE
and	O
E2F4	B-PRGE
,	O
as	O
B	O
-	O
lymphocytes	O
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	O
migrating	O
forms	O
into	O
the	O
corresponding	O
faster	O
mobility	O
forms	O
.	O

We	O
further	O
demonstrated	O
that	O
this	O
change	O
in	O
phosphorylation	O
status	O
correlates	O
with	O
a	O
decrease	O
in	O
DNA	O
binding	O
activity	O
.	O

This	O
modulation	O
of	O
DNA	O
binding	O
activity	O
mediated	O
through	O
the	O
dephosphorylation	O
of	O
DP1	B-PRGE
and	O
E2F4	B-PRGE
could	O
help	O
to	O
explain	O
the	O
lack	O
of	O
in	O
vivo	O
DNA	O
footprinting	O
in	O
late	O
G1	O
and	O
S	O
phases	O
of	O
gene	O
promoters	O
negatively	O
regulated	O
through	O
E2F	O
sites	O
and	O
suggests	O
a	O
novel	O
mechanism	O
for	O
controlling	O
E2F	O
transcriptional	O
activity	O
during	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferation	O
.	O

Retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
agonist	O
-	O
induced	O
activation	O
of	O
dominant	O
-	O
negative	O
RXR	O
-	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha403	I-PRGE
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	O
and	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
nuclear	O
receptors	O
that	O
interact	O
with	O
specific	O
DNA	O
target	O
sequences	O
as	O
heterodimers	O
(	O
RXR	O
-	O
RAR	O
)	O
or	O
homodimers	O
(	O
RXR	O
-	O
RXR	O
)	O
.	O

RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH	O
-	O
terminally	O
truncated	O
RARalpha	B-PRGE
exhibiting	O
dominant	O
-	O
negative	O
activity	O
(	O
RARalpha403	B-PRGE
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	O
promyelocytes	O
while	O
potentiating	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
-	O
induced	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
/	O
monocyte	O
lineage	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	O
-	O
and	O
RAR	O
-	O
specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant	O
-	O
negative	O
activity	O
of	O
the	O
truncated	O
RARalpha	B-PRGE
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	O
-	O
specific	O
,	O
rather	O
than	O
an	O
RAR	O
-	O
specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	O
promyelocytes	O
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	O
response	O
elements	O
corresponding	O
to	O
RAR	O
-	O
RXR	O
heterodimers	O
rather	O
than	O
RXR	O
-	O
RXR	O
homodimers	O
.	O

This	O
RXR	O
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	O
-	O
specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross	O
-	O
talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	O
-	O
RARalpha403	B-PRGE
heterodimer	O
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	O
cells	O
we	O
observed	O
that	O
this	O
RXR	O
-	O
specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
mediated	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
lineage	O
or	O
in	O
transactivating	O
RAR	O
-	O
RXR	O
response	O
elements	O
.	O

RA	O
-	O
triggered	O
GALdbd	O
-	O
RARalpha	B-PRGE
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	O
cells	O
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	O
activity	O
.	O

However	O
,	O
the	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR	O
-	O
RAR	O
reporter	O
construct	O
in	O
the	O
multipotent	O
EML	O
cells	O
but	O
not	O
in	O
the	O
committed	O
MPRO	O
promyelocytes	O
,	O
indicating	O
that	O
differences	O
in	O
HDAC	O
-	O
containing	O
repressor	O
complexes	O
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	O
lineages	O
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR	O
-	O
RARalpha403	B-PRGE
heterodimers	O
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	O
T	O
-	O
cells	O
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
product	O
,	O
a	O
nuclear	O
phosphoprotein	O
,	O
is	O
expressed	O
independently	O
of	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
rearrangement	O
.	O

In	O
lymph	O
nodes	O
,	O
expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
is	O
restricted	O
to	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
-	O
cells	O
and	O
10	O
%	O
to	O
15	O
%	O
of	O
CD3	O
/	O
CD4	B-PRGE
+	O
intrafollicular	O
T	O
cells	O
.	O

Interfollicular	O
cells	O
are	O
negative	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
,	O
except	O
for	O
rare	O
CD3	O
+	O
/	O
CD4	B-PRGE
+	O
T	O
cells	O
.	O

Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL	O
/	O
GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	O
cells	O
to	O
surrounding	O
interfollicular	O
zones	O
.	O

This	O
prompted	O
a	O
study	O
of	O
follicular	O
borders	O
with	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
staining	O
in	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
to	O
compare	O
with	O
AITL	O
/	O
GC	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Formalin	O
-	O
fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Six	O
cases	O
of	O
AITL	O
/	O
GC	O
,	O
12	O
nonspecific	O
reactive	O
follicular	O
hyperplasia	O
(	O
FH	O
)	O
,	O
7	O
HIV	O
adenopathy	O
,	O
10	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
,	O
and	O
8	O
typical	O
AITL	O
(	O
ie	O
,	O
AITL	O
without	O
GC	O
)	O
were	O
studied	O
.	O

Double	O
staining	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
/	O
CD20	B-PRGE
,	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
/	O
CD3	O
,	O
and	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
/	O
CD57	B-PRGE
was	O
performed	O
in	O
selected	O
cases	O
.	O

RESULTS	O
:	O
In	O
FH	O
and	O
HIV	O
adenopathy	O
,	O
staining	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
revealed	O
densely	O
populated	O
GCs	O
with	O
well	O
-	O
defined	O
and	O
regular	O
GC	O
borders	O
,	O
whereas	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
cells	O
were	O
rare	O
in	O
the	O
interfollicular	O
areas	O
.	O

An	O
occasional	O
GC	O
with	O
an	O
ill	O
-	O
defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well	O
-	O
defined	O
,	O
regular	O
borders	O
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
cells	O
in	O
the	O
interfollicular	O
zones	O
.	O

In	O
AITL	O
/	O
GC	O
,	O
GCs	O
were	O
less	O
dense	O
,	O
GC	O
borders	O
were	O
ill	O
defined	O
and	O
irregular	O
,	O
and	O
the	O
number	O
of	O
interfollicular	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
cells	O
was	O
markedly	O
increased	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
Bcl6	B-PRGE
+	O
/	O
CD3	O
+	O
/	O
CD20	B-PRGE
-	O
/	O
CD57	B-PRGE
-	O
T	O
cells	O
.	O

Moreover	O
,	O
CD3	O
+	O
intrafollicular	O
T	O
cells	O
were	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
whereas	O
they	O
were	O
abundant	O
in	O
FH	O
.	O

Intrafollicular	O
CD57	B-PRGE
+	O
cells	O
did	O
not	O
stain	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL	O
/	O
GC	O
.	O

In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O

CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL	O
/	O
GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
was	O
useful	O
to	O
discern	O
them	O
.	O

(	O
2	O
)	O
Intrafollicular	O
CD3	O
+	O
T	O
cells	O
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
were	O
markedly	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
/	O
CD3	O
+	O
cells	O
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	O
T	O
cells	O
in	O
this	O
condition	O
.	O

(	O
3	O
)	O
Interfollicular	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
+	O
/	O
CD3	O
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
too	O
numerous	O
to	O
be	O
accounted	O
for	O
by	O
migration	O
alone	O
,	O
suggesting	O
local	O
proliferation	O
.	O

(	O
4	O
)	O
Intrafollicular	O
CD57	B-PRGE
+	O
cells	O
were	O
negative	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
indicating	O
heterogeneity	O
of	O
the	O
intrafollicular	O
T	O
-	O
cell	O
population	O
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
suggesting	O
up	O
-	O
regulation	O
of	O
Bcl	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
this	O
tumor	O
.	O

Differential	O
inhibition	O
of	O
Smad6	B-PRGE
and	O
Smad7	B-PRGE
on	O
bone	O
morphogenetic	O
protein	O
-	O
and	O
activin	O
-	O
mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
cells	O
.	O

Smad6	B-PRGE
and	O
Smad7	B-PRGE
prevent	O
ligand	O
-	O
induced	O
activation	O
of	O
signal	O
-	O
transducing	O
Smad	O
proteins	O
in	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B-PRGE
and	O
Smad7	B-PRGE
are	O
human	B-PRGE
bone	I-PRGE
morphogenetic	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
hBMP	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
inducible	O
antagonists	O
of	O
hBMP	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	O
B	O
cell	O
hybridoma	O
HS	O
-	O
72	O
cells	O
.	O

Moreover	O
,	O
we	O
confirmed	O
that	O
the	O
ectopic	O
expressions	O
of	O
Smad6	B-PRGE
and	O
Smad7	B-PRGE
inhibited	O
the	O
hBMP	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
Smad1	B-PRGE
/	O
Smad5	B-PRGE
phosphorylation	O
.	O

We	O
previously	O
reported	O
that	O
Smad7	B-PRGE
is	O
an	O
activin	B-PRGE
A	I-PRGE
-	O
inducible	O
antagonist	O
of	O
activin	B-PRGE
A	I-PRGE
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS	O
-	O
72	O
cells	O
.	O

Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	B-PRGE
was	O
induced	O
by	O
activin	B-PRGE
A	I-PRGE
in	O
HS	O
-	O
72	O
cells	O
,	O
Smad6	B-PRGE
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	B-PRGE
A	I-PRGE
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
Smad7	B-PRGE
,	O
but	O
not	O
Smad6	B-PRGE
,	O
inhibited	O
the	O
activin	B-PRGE
A	I-PRGE
-	O
induced	O
Smad2	B-PRGE
phosphorylation	O
in	O
HS	O
-	O
72	O
cells	O
.	O

Thus	O
,	O
Smad6	B-PRGE
and	O
Smad7	B-PRGE
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	B-PRGE
morphogenetic	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
activin	B-PRGE
A	I-PRGE
-	O
mediated	O
signaling	O
in	O
B	O
lineage	O
cells	O
.	O

Transcription	O
factors	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
mediate	O
induction	O
of	O
acid	O
sphingomyelinase	O
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25	O
-	O
dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	O
enzyme	O
acid	O
sphingomyelinase	O
(	O
ASM	O
;	O
E	O
.	O
C	O
.	O
3	O
.	O
1	O
.	O
4	O
.	O
12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP	O
-	O
1	O
cells	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	O
mononuclear	O
phagocytes	O
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	O
protection	O
assay	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell	O
-	O
type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	O
'	O
deletion	O
derivatives	O
of	O
the	O
upstream	O
regulatory	O
region	O
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	O
elements	O
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-	O
319	O
and	O
-	O
219	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	O
factor	O
expression	O
plasmids	O
for	O
AP	O
-	O
2	O
and	O
Sp1	B-PRGE
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	O
sites	O
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP	O
-	O
1	O
cells	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
2	O
and	O
Sp1	B-PRGE
is	O
essential	O
for	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
apoptosis	O
.	O

Induction	O
of	O
apoptosis	O
of	O
mononucleated	O
cells	O
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O

The	O
female	O
steroid	O
hormones	O
estrogen	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
Prog	O
)	O
are	O
known	O
to	O
modulate	O
the	O
reactivity	O
of	O
the	O
immune	O
system	O
;	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
they	O
can	O
regulate	O
induction	O
of	O
apoptosis	O
of	O
endothelial	O
cells	O
and	O
osteoblasts	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
mediated	O
induction	O
of	O
apoptosis	O
has	O
been	O
well	O
characterized	O
in	O
myeloid	O
cells	O
.	O

We	O
investigated	O
whether	O
E2	O
and	O
Prog	O
could	O
interfere	O
with	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
apoptosis	O
of	O
the	O
monoblastoid	O
U937	O
cell	O
line	O
.	O

Treatment	O
with	O
E2	O
or	O
Prog	O
increased	O
survival	O
and	O
prevented	O
apoptosis	O
induced	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
both	O
undifferentiated	O
and	O
macrophage	O
-	O
like	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
,	O
as	O
assessed	O
by	O
trypan	O
blue	O
exclusion	O
cell	O
counting	O
,	O
thymidine	O
incorporation	O
,	O
AnnexinV	O
labeling	O
,	O
followed	O
by	O
flow	O
cytometry	O
and	O
DNA	O
fragmentation	O
studies	O
.	O

This	O
effect	O
can	O
be	O
associated	O
with	O
the	O
activation	O
of	O
specific	O
hormone	O
receptors	O
,	O
since	O
we	O
observed	O
the	O
expression	O
of	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ER	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
ER	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
and	O
progesterone	B-PRGE
receptor	I-PRGE
(	O
PR	B-PRGE
)	O
mRNAs	O
;	O
the	O
ER	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
expression	O
was	O
confirmed	O
by	O
immunocytochemical	O
analysis	O
.	O

In	O
addition	O
,	O
hormone	O
-	O
mediated	O
survival	O
against	O
apoptosis	O
was	O
concentration	O
dependent	O
,	O
reaching	O
the	O
half	O
-	O
maximal	O
effect	O
at	O
10	O
nM	O
and	O
blocked	O
by	O
the	O
ER	O
antagonist	O
ICI	O
182	O
,	O
780	O
in	O
undifferentiated	O
cells	O
,	O
further	O
supporting	O
a	O
receptor	O
-	O
mediated	O
mechanism	O
of	O
cell	O
survival	O
.	O

Other	O
steroid	O
receptor	O
drugs	O
such	O
as	O
Raloxifene	O
,	O
RU486	O
,	O
or	O
the	O
ICI	O
182	O
,	O
780	O
in	O
PMA	O
-	O
differentiated	O
cells	O
displayed	O
agonist	O
activity	O
by	O
preventing	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
apoptosis	O
as	O
efficiently	O
as	O
the	O
hormones	O
alone	O
,	O
providing	O
further	O
evidence	O
to	O
the	O
notion	O
that	O
steroid	O
receptor	O
drugs	O
may	O
manifest	O
agonist	O
or	O
antagonist	O
activities	O
depending	O
on	O
the	O
cellular	O
context	O
in	O
which	O
they	O
are	O
studied	O
.	O

Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	O
Nip	O
-	O
2	O
protein	O
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	O
cells	O
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
ER	O
and	O
PR	B-PRGE
can	O
be	O
activated	O
by	O
endogenous	O
or	O
exogenous	O
ligands	O
to	O
induce	O
a	O
genetic	O
response	O
that	O
impairs	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
apoptosis	O
in	O
U937	O
cells	O
.	O

The	O
data	O
presented	O
here	O
suggest	O
that	O
the	O
female	O
steroid	O
receptors	O
play	O
a	O
role	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
by	O
preventing	O
apoptosis	O
of	O
monoblastoid	O
cells	O
;	O
this	O
effect	O
might	O
have	O
important	O
consequences	O
in	O
the	O
clinical	O
use	O
of	O
steroid	O
receptor	O
drugs	O
.	O

-	O
-	O
Vegeto	O
,	O
E	O
.	O
,	O
Pollio	O
,	O
G	O
.	O
,	O
Pellicciari	O
,	O
C	O
.	O
,	O
Maggi	O
,	O
A	O
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
inuced	O
apoptosis	O
.	O

Grf40	B-PRGE
,	O
A	O
novel	O
Grb2	O
family	O
member	O
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
LAT	B-PRGE
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	O
family	O
member	O
,	O
named	O
Grf40	B-PRGE
,	O
containing	O
the	O
common	O
SH3	O
-	O
SH2	O
-	O
SH3	O
motif	O
.	O

Expression	O
of	O
Grf40	B-PRGE
is	O
predominant	O
in	O
hematopoietic	O
cells	O
,	O
particularly	O
T	O
cells	O
.	O

Grf40	B-PRGE
binds	O
to	O
the	O
SH2	B-PRGE
domain	I-PRGE
-	I-PRGE
containing	I-PRGE
leukocyte	I-PRGE
protein	I-PRGE
of	I-PRGE
76	I-PRGE
kD	I-PRGE
(	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B-PRGE
.	O

Incidentally	O
,	O
Grf40	B-PRGE
binds	O
to	O
linker	B-PRGE
for	I-PRGE
activation	I-PRGE
of	I-PRGE
T	I-PRGE
cells	I-PRGE
(	O
LAT	B-PRGE
)	O
possibly	O
via	O
its	O
SH2	O
domain	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
Grf40	B-PRGE
in	O
Jurkat	O
cells	O
induced	O
a	O
significant	O
increase	O
of	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
-	O
dependent	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
activation	O
upon	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
stimulation	O
,	O
whereas	O
the	O
COOH	O
-	O
terminal	O
SH3	O
-	O
deleted	O
Grf40	B-PRGE
mutant	O
lacked	O
any	O
recognizable	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

Furthermore	O
,	O
the	O
SH2	O
-	O
deleted	O
Grf40	B-PRGE
mutant	O
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2	O
-	O
deleted	O
Grb2	B-PRGE
mutant	O
.	O

Our	O
data	O
suggest	O
that	O
Grf40	B-PRGE
is	O
an	O
adaptor	O
molecule	O
involved	O
in	O
TCR	O
-	O
mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	B-PRGE
with	O
SLP	B-PRGE
-	I-PRGE
76	I-PRGE
and	O
LAT	B-PRGE
.	O

Signal	O
transduction	O
through	O
interferon	O
-	O
gamma	O
receptor	O
on	O
human	O
eosinophils	O
.	O

BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon	O
-	O
gamma	O
receptor	O
(	O
IFN	O
-	O
gammaR	O
)	O
expression	O
on	O
eosinophils	O
.	O

But	O
signal	O
transduction	O
through	O
IFN	O
-	O
gammaR	O
on	O
eosinophils	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
the	O
Jak	O
/	O
Stat	O
pathway	O
in	O
the	O
signaling	O
of	O
eosinophils	O
after	O
IFN	O
-	O
gammaR	O
conjugation	O
by	O
the	O
ligand	O
binding	O
.	O

METHODS	O
:	O
Purified	O
peripheral	O
eosinophils	O
were	O
stimulated	O
with	O
IFN	O
-	O
gamma	O
at	O
37	O
degrees	O
C	O
for	O
1	O
-	O
60	O
min	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN	O
-	O
gammaR	O
,	O
Jak1	B-PRGE
,	O
Jak2	B-PRGE
,	O
and	O
Stat1alpha	B-PRGE
was	O
examined	O
by	O
immunoblotting	O
.	O

Gel	O
-	O
shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha	B-PRGE
-	O
DNA	O
complexes	O
.	O

RESULTS	O
:	O
We	O
show	O
that	O
binding	O
of	O
IFN	O
-	O
gamma	O
to	O
human	O
eosinophils	O
initiated	O
a	O
series	O
of	O
events	O
that	O
resulted	O
in	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
not	O
only	O
the	O
IFN	B-PRGE
-	I-PRGE
gammaRalpha	I-PRGE
chain	I-PRGE
but	O
also	O
Jak1	B-PRGE
,	O
Jak2	B-PRGE
,	O
and	O
Stat1alpha	B-PRGE
.	O

In	O
addition	O
,	O
IFN	O
-	O
gamma	O
enhanced	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Stat1alpha	B-PRGE
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
IFN	O
-	O
gamma	O
affects	O
eosinophils	O
through	O
its	O
specific	O
receptor	O
and	O
utilizes	O
the	O
Jak	O
/	O
Stat	O
pathway	O
as	O
its	O
mode	O
of	O
signaling	O
.	O

Constitutive	O
activation	O
of	O
an	O
epithelial	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
pathway	O
in	O
asthma	O
.	O

Cytokine	O
effects	O
on	O
immunity	O
and	O
inflammation	O
often	O
depend	O
on	O
the	O
transcription	O
factors	O
termed	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
,	O
so	O
STAT	O
signaling	O
pathways	O
are	O
candidates	O
for	O
influencing	O
inflammatory	O
disease	O
.	O

We	O
reasoned	O
that	O
selective	O
IFN	O
responsiveness	O
of	O
the	O
first	O
STAT	O
family	O
member	O
(	O
Stat1	B-PRGE
)	O
and	O
Stat1	B-PRGE
-	O
dependent	O
immune	O
-	O
response	O
genes	O
such	O
as	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
and	O
Stat1	B-PRGE
itself	O
in	O
airway	O
epithelial	O
cells	O
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	O
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O

On	O
the	O
basis	O
of	O
nuclear	O
localization	O
and	O
phosphorylation	O
,	O
we	O
found	O
that	O
epithelial	O
Stat1	B-PRGE
(	O
but	O
not	O
other	O
control	O
transcription	O
factors	O
)	O
was	O
invariably	O
activated	O
in	O
asthmatic	O
compared	O
with	O
normal	O
control	O
or	O
chronic	O
bronchitis	O
subjects	O
.	O

Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	B-PRGE
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
Stat1	B-PRGE
,	O
and	O
in	O
turn	O
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
correlated	O
with	O
T	O
-	O
cell	O
accumulation	O
in	O
tissue	O
.	O

However	O
,	O
only	O
low	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
producing	O
cells	O
were	O
detected	O
in	O
airway	O
tissue	O
in	O
all	O
subjects	O
.	O

The	O
results	O
therefore	O
provide	O
initial	O
evidence	O
linking	O
abnormal	O
behavior	O
of	O
STAT	O
pathways	O
for	O
cytokine	O
signaling	O
to	O
the	O
development	O
of	O
an	O
inflammatory	O
disease	O
.	O

In	O
that	O
context	O
,	O
the	O
results	O
also	O
change	O
the	O
current	O
scheme	O
for	O
asthma	O
pathogenesis	O
to	O
one	O
that	O
must	O
include	O
a	O
localized	O
gain	O
in	O
transcriptional	O
signal	O
ordinarily	O
used	O
for	O
a	O
T	O
helper	O
1	O
-	O
type	O
cytokine	O
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
in	O
combination	O
with	O
allergy	O
-	O
driven	O
overproduction	O
of	O
T	O
helper	O
2	O
-	O
type	O
cytokines	O
.	O

HLA	O
class	O
I	O
-	O
mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	O
E	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-PRGE
function	O
and	O
induction	O
of	O
E2F	O
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	O
class	O
I	O
Ags	O
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	O
class	O
I	O
molecules	O
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	O
class	O
I	O
-	O
mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B-PRGE
protein	O
in	O
the	O
T	O
cell	O
line	O
Jurkat	O
as	O
well	O
as	O
human	O
aortic	O
endothelial	O
cells	O
.	O

HLA	O
class	O
I	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-PRGE
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	O
Abs	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	O
receptors	O
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	O
class	O
I	O
molecules	O
induced	O
cyclin	O
E	O
-	O
associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	O
endothelial	O
cells	O
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B-PRGE
.	O

A	O
cdk2	B-PRGE
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	O
-	O
negative	O
cdk2	B-PRGE
construct	O
prevented	O
HLA	O
class	O
I	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-PRGE
;	O
in	O
contrast	O
,	O
dominant	O
-	O
negative	O
cdk4	B-PRGE
and	O
cdk6	B-PRGE
constructs	O
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	O
D	O
-	O
associated	O
kinase	O
activity	O
upon	O
HLA	O
class	O
I	O
ligation	O
,	O
suggesting	O
that	O
cyclin	O
E	O
-	O
dependent	O
kinase	O
activity	O
mediates	O
Rb	B-PRGE
inactivation	O
,	O
leading	O
to	O
E2F	O
activation	O
and	O
cell	O
proliferation	O
.	O

Increased	O
glucocorticoid	B-PRGE
receptor	I-PRGE
beta	I-PRGE
in	O
airway	O
cells	O
of	O
glucocorticoid	O
-	O
insensitive	O
asthma	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
-	O
insensitive	O
asthma	O
is	O
a	O
challenging	O
clinical	O
problem	O
that	O
can	O
be	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-PRGE
receptor	I-PRGE
(	O
GCR	B-PRGE
)	O
pre	O
-	O
mRNA	O
generates	O
a	O
second	O
GCR	O
,	O
termed	O
GCRbeta	B-PRGE
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-PRGE
.	O

Thus	O
increased	O
expression	O
of	O
GCRbeta	B-PRGE
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
examined	O
for	O
GCRbeta	B-PRGE
immunoreactivity	O
using	O
a	O
GCRbeta	B-PRGE
-	O
specific	O
antibody	O
by	O
immunohistochemical	O
staining	O
.	O

Cell	O
localization	O
of	O
GCRbeta	B-PRGE
expression	O
was	O
performed	O
using	O
a	O
double	O
immunostaining	O
technique	O
.	O

Patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta	B-PRGE
-	O
immunoreactive	O
cells	O
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

Furthermore	O
,	O
GCRbeta	B-PRGE
expression	O
in	O
GC	O
-	O
insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	O
cells	O
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B-PRGE
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O

In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta	B-PRGE
-	O
positive	O
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O

We	O
conclude	O
that	O
GC	O
-	O
insensitive	O
asthma	O
is	O
associated	O
with	O
increased	O
expression	O
of	O
GCRbeta	B-PRGE
in	O
airway	O
T	O
cells	O
.	O

Differences	O
in	O
phosphorylation	O
of	O
the	O
IL	O
-	O
2R	O
associated	O
JAK	O
/	O
STAT	O
proteins	O
between	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
cell	O
lines	O
and	O
uncultured	O
leukemic	O
cells	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
.	O

To	O
determine	O
activation	O
status	O
of	O
the	O
IL	O
-	O
2R	O
-	O
associated	O
(	O
Jak	O
/	O
STAT	O
)	O
pathway	O
in	O
the	O
HTLV	O
-	O
I	O
infected	O
cells	O
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-PRGE
,	O
STAT3	B-PRGE
,	O
and	O
STAT5	O
in	O
several	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
and	O
in	O
uncultured	O
leukemic	O
T	O
cells	O
isolated	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
(	O
ATLL	O
)	O
.	O

Constitutive	O
basal	O
phosphorylation	O
of	O
Jak3	B-PRGE
and	O
,	O
usually	O
,	O
STAT3	B-PRGE
and	O
STAT5	O
was	O
detected	O
in	O
all	O
four	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
cell	O
lines	O
tested	O
,	O
but	O
in	O
none	O
of	O
the	O
three	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
cell	O
lines	O
.	O

Similarly	O
,	O
there	O
was	O
no	O
detectable	O
basal	O
phosphorylation	O
of	O
Jak3	B-PRGE
and	O
STAT5	O
in	O
the	O
leukemic	O
cells	O
from	O
ATLL	O
patients	O
(	O
0	O
/	O
8	O
and	O
0	O
/	O
3	O
,	O
respectively	O
)	O
.	O

However	O
,	O
stimulation	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
resulted	O
in	O
Jak3	B-PRGE
and	O
STAT5	O
phosphorylation	O
in	O
both	O
leukemic	O
ATLL	O
cells	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
lines	O
.	O

Furthermore	O
,	O
expression	O
of	O
SHP	B-PRGE
-	I-PRGE
1	I-PRGE
phosphatase	I-PRGE
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	O
receptor	O
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
independent	O
cell	O
lines	O
(	O
3	O
/	O
4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	O
cells	O
(	O
0	O
/	O
3	O
)	O
.	O

Finally	O
,	O
the	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
(	O
313	O
)	O
but	O
not	O
the	O
control	O
,	O
HTLV	O
-	O
I	O
(	O
-	O
)	O
T	O
-	O
cell	O
lines	O
were	O
resistant	O
to	O
rapamycin	O
and	O
its	O
novel	O
analog	O
RAD	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
HTLV	O
-	O
I	O
infection	O
per	O
se	O
does	O
not	O
result	O
in	O
a	O
constitutive	O
phosphorylation	O
of	O
the	O
Jak3	B-PRGE
,	O
STAT3	B-PRGE
,	O
and	O
STAT5	O
proteins	O
;	O
(	O
2	O
)	O
malignant	O
transformation	O
in	O
at	O
least	O
some	O
cases	O
of	O
ATLL	O
does	O
not	O
require	O
the	O
constitutive	O
,	O
but	O
may	O
require	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
,	O
activation	O
of	O
the	O
IL	O
-	O
2R	O
Jak	O
/	O
STAT	O
pathway	O
;	O
and	O
(	O
3	O
)	O
there	O
are	O
major	O
differences	O
in	O
T	O
-	O
cell	O
immortalization	O
mechanism	O
(	O
s	O
)	O
which	O
appear	O
to	O
involve	O
SHP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
target	O
molecules	O
for	O
rapamycin	O
and	O
RAD	O
.	O

USF	O
/	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
enhances	O
,	O
while	O
Yin	B-PRGE
-	I-PRGE
Yang	I-PRGE
1	I-PRGE
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-PRGE
,	O
a	O
coreceptor	O
for	O
HIV	O
-	O
1	O
entry	O
.	O

Transcription	O
factors	O
USF1	B-PRGE
and	O
USF2	B-PRGE
up	O
-	O
regulate	O
gene	O
expression	O
(	O
i	O
.	O
e	O
.	O
,	O
HIV	O
-	O
1	O
long	O
terminal	O
repeats	O
)	O
via	O
interaction	O
with	O
an	O
E	O
box	O
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	O
site	O
for	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
.	O

The	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
oncoprotein	O
is	O
important	O
in	O
control	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
,	O
while	O
Yin	B-PRGE
-	I-PRGE
Yang	I-PRGE
1	I-PRGE
(	O
YY1	B-PRGE
)	O
has	O
been	O
shown	O
to	O
control	O
the	O
expression	O
of	O
a	O
number	O
of	O
cellular	O
and	O
viral	O
genes	O
.	O

These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
USF	O
/	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
up	O
-	O
regulates	O
,	O
while	O
YY1	B-PRGE
down	O
-	O
regulates	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-PRGE
,	O
a	O
coreceptor	O
for	O
T	O
cell	O
-	O
tropic	O
HIV	O
-	O
1	O
entry	O
.	O

We	O
have	O
identified	O
an	O
E	O
box	O
around	O
-	O
260	O
and	O
a	O
YY1	B-PRGE
binding	O
site	O
around	O
-	O
300	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Mutation	O
of	O
the	O
E	O
box	O
abolished	O
USF	O
/	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
-	O
mediated	O
up	O
-	O
regulation	O
of	O
CXCR4	B-PRGE
promoter	O
activity	O
,	O
and	O
mutation	O
of	O
the	O
YY1	B-PRGE
binding	O
site	O
was	O
associated	O
with	O
unresponsiveness	O
to	O
YY1	B-PRGE
-	O
mediated	O
inhibition	O
.	O

These	O
data	O
suggest	O
that	O
USF	O
/	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
and	O
YY1	B-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV	O
-	O
1	O
-	O
replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion	O
/	O
entry	O
process	O
and	O
viral	O
expression	O
.	O

Glucocorticoid	B-PRGE
receptors	I-PRGE
are	O
down	O
-	O
regulated	O
in	O
inflamed	O
colonic	O
mucosa	O
but	O
not	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
the	O
immune	O
system	O
and	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
are	O
linked	O
by	O
several	O
mechanisms	O
,	O
for	O
example	O
intracellular	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
hGR	B-PRGE
)	O
.	O

Glucocorticoids	O
are	O
the	O
standard	O
treatment	O
of	O
acute	O
attacks	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Binding	O
of	O
glucocorticoids	O
to	O
hGR	B-PRGE
down	O
-	O
regulates	O
the	O
transcription	O
of	O
inflammatory	O
genes	O
that	O
can	O
propagate	O
IBD	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
IBD	O
patients	O
were	O
either	O
treated	O
with	O
5	O
-	O
60	O
mg	O
of	O
prednisolone	O
for	O
more	O
than	O
1	O
week	O
or	O
were	O
without	O
glucocorticoid	O
treatment	O
for	O
more	O
than	O
4	O
weeks	O
.	O

hGR	B-PRGE
levels	O
were	O
determined	O
from	O
isolated	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
or	O
mucosal	O
biopsies	O
using	O
a	O
radioassay	O
with	O
[	O
3H	O
]	O
-	O
dexamethasone	O
.	O

Interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
6	I-PRGE
levels	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

RESULTS	O
:	O
The	O
systemic	O
(	O
PBMC	O
)	O
hGR	B-PRGE
levels	O
of	O
corticosteroid	O
-	O
treated	O
IBD	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
subjects	O
(	O
59	O
.	O
6	O
+	O
/	O
-	O
57	O
.	O
1	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
vs	O
.	O
227	O
.	O
0	O
+	O
/	O
-	O
90	O
.	O
8	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
IBD	O
patients	O
not	O
receiving	O
glucocorticoid	O
treatment	O
(	O
179	O
.	O
7	O
+	O
/	O
-	O
171	O
.	O
3	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Systemic	O
hGR	B-PRGE
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O

In	O
patients	O
with	O
connective	O
tissue	O
diseases	O
,	O
systemic	O
hGR	B-PRGE
levels	O
were	O
also	O
found	O
to	O
be	O
decreased	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
treatment	O
.	O

Systemic	O
hGR	B-PRGE
levels	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66	O
.	O
6	O
+	O
/	O
-	O
61	O
.	O
0	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56	O
.	O
1	O
+	O
/	O
-	O
51	O
.	O
6	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
)	O
.	O

In	O
contrast	O
to	O
these	O
findings	O
,	O
mucosal	O
hGR	B-PRGE
levels	O
were	O
significantly	O
decreased	O
in	O
both	O
steroid	O
-	O
treated	O
(	O
18	O
.	O
0	O
+	O
/	O
-	O
15	O
.	O
5	O
)	O
and	O
not	O
steroid	O
-	O
treated	O
(	O
37	O
.	O
8	O
+	O
/	O
-	O
30	O
.	O
5	O
)	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
125	O
.	O
6	O
+	O
/	O
-	O
97	O
.	O
1	O
;	O
P	O
=	O
0	O
.	O
00009	O
and	O
P	O
=	O
0	O
.	O
0008	O
respectively	O
)	O
.	O

IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O

CONCLUSION	O
:	O
In	O
IBD	O
there	O
is	O
no	O
difference	O
in	O
systemic	O
hGR	B-PRGE
levels	O
between	O
not	O
steroid	O
-	O
treated	O
patients	O
and	O
control	O
subjects	O
,	O
in	O
spite	O
of	O
inflammatory	O
activity	O
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
.	O

Mucosal	O
hGR	B-PRGE
levels	O
were	O
decreased	O
independently	O
of	O
treatment	O
,	O
probably	O
leading	O
to	O
a	O
decreased	O
protection	O
against	O
NF	O
-	O
kappaB	O
action	O
in	O
the	O
intestinal	O
mucosa	O
.	O

Bacterial	O
peptidoglycan	O
induces	O
CD14	B-PRGE
-	O
dependent	O
activation	O
of	O
transcription	O
factors	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	O
in	O
macrophages	O
through	O
CD14	B-PRGE
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

To	O
begin	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
transcription	O
of	O
cytokine	O
genes	O
,	O
we	O
wanted	O
to	O
determine	O
which	O
transcription	O
factors	O
are	O
activated	O
by	O
PGN	O
in	O
mouse	O
RAW264	O
.	O
7	O
and	O
human	O
THP	O
-	O
1	O
macrophage	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	O
factors	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CREB	B-PRGE
;	O
(	O
ii	O
)	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CREB	B-PRGE
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B-PRGE
and	O
ATF	B-PRGE
-	I-PRGE
1	I-PRGE
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
protein	O
synthesis	O
of	O
JunB	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP	O
-	O
1	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
;	O
and	O
(	O
iv	O
)	O
PGN	O
-	O
induced	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
was	O
mediated	O
through	O
CD14	B-PRGE
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
90	I-PRGE
of	I-PRGE
activated	I-PRGE
T	I-PRGE
-	I-PRGE
cells	I-PRGE
:	O
A	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
and	O
substrate	O
for	O
the	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
,	O
PKR	B-PRGE
.	O

NFAT	O
transcription	O
factors	O
play	O
a	O
central	O
role	O
in	O
initiating	O
T	O
-	O
cell	O
activation	O
through	O
the	O
induction	O
of	O
immediate	O
-	O
early	O
T	O
-	O
cell	O
specific	O
genes	O
including	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
.	O

NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
known	O
as	O
the	O
antigen	O
receptor	O
response	O
element	O
2	O
(	O
ARRE	O
-	O
2	O
)	O
.	O

Multiple	O
proteins	O
exhibiting	O
ARRE	O
-	O
2	O
binding	O
activity	O
have	O
been	O
isolated	O
,	O
including	O
a	O
heterodimer	O
from	O
stimulated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
consisting	O
of	O
Mr	O
=	O
90	O
000	O
(	O
NF90	B-PRGE
)	O
and	O
Mr	O
=	O
45	O
000	O
(	O
NF45	B-PRGE
)	O
subunits	O
.	O

The	O
subunits	O
of	O
this	O
heterodimer	O
have	O
been	O
cloned	O
,	O
and	O
NF90	B-PRGE
was	O
found	O
to	O
encode	O
a	O
protein	O
containing	O
two	O
domains	O
that	O
are	O
predicted	O
to	O
form	O
motifs	O
capable	O
of	O
binding	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O

Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B-PRGE
specifically	O
binds	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O

Furthermore	O
,	O
NF90	B-PRGE
was	O
phosphorylated	O
in	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
manner	O
likely	O
by	O
the	O
interferon	B-PRGE
-	I-PRGE
induced	I-PRGE
,	I-PRGE
double	I-PRGE
-	I-PRGE
stranded	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
kinase	I-PRGE
,	O
PKR	B-PRGE
.	O

The	O
NF90	B-PRGE
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T	O
-	O
cells	O
,	O
but	O
also	O
in	O
nonimmune	O
HeLa	O
cells	O
.	O

In	O
HeLa	O
cells	O
,	O
the	O
protein	O
was	O
almost	O
exclusively	O
localized	O
to	O
the	O
ribosome	O
salt	O
wash	O
fraction	O
of	O
cell	O
lysates	O
.	O

c	B-PRGE
-	I-PRGE
Myc	I-PRGE
and	O
E1A	B-PRGE
induced	O
cellular	O
sensitivity	O
to	O
activated	O
NK	O
cells	O
involves	O
cytotoxic	O
granules	O
as	O
death	O
effectors	O
.	O

The	O
contact	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
with	O
foreign	O
cells	O
and	O
with	O
certain	O
virus	O
-	O
infected	O
or	O
tumor	O
cells	O
triggers	O
the	O
cytolytic	O
machinery	O
of	O
NK	O
cells	O
.	O

This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	O
NK	O
cell	O
granules	O
.	O

The	O
oncoproteins	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
and	O
E1A	B-PRGE
render	O
cells	O
vulnerable	O
to	O
NK	O
cell	O
mediated	O
cytolysis	O
yet	O
the	O
mechanisms	O
of	O
sensitization	O
are	O
not	O
well	O
understood	O
.	O

In	O
a	O
model	O
where	O
foreign	O
cells	O
(	O
rat	O
fibroblasts	O
)	O
were	O
cocultured	O
with	O
human	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
activated	O
NK	O
cells	O
,	O
we	O
observed	O
that	O
NK	O
cells	O
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
or	O
E1A	B-PRGE
.	O

Both	O
the	O
parental	O
and	O
the	O
oncogene	O
expressing	O
fibroblasts	O
similarly	O
triggered	O
phosphoinositide	O
hydrolysis	O
in	O
the	O
bound	O
NK	O
cells	O
,	O
demonstrating	O
that	O
NK	O
cells	O
were	O
cytolytically	O
activated	O
in	O
contact	O
with	O
both	O
resistant	O
parental	O
and	O
oncogene	O
expressing	O
sensitive	O
target	O
fibroblasts	O
.	O

The	O
cell	O
death	O
was	O
independent	O
of	O
wild	O
-	O
type	O
p53	B-PRGE
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti	O
-	O
apoptotic	O
protein	O
EIB19K	B-PRGE
.	O

These	O
results	O
provided	O
evidence	O
that	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
and	O
E1A	B-PRGE
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post	O
-	O
triggering	O
stage	O
of	O
NK	O
cell	O
-	O
target	O
cell	O
interaction	O
.	O

In	O
consistence	O
,	O
the	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
and	O
E1A	B-PRGE
overexpressing	O
fibroblasts	O
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell	O
-	O
derived	O
granules	O
than	O
parental	O
cells	O
.	O

The	O
data	O
indicate	O
that	O
oncogenes	O
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O

This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	O
cells	O
towards	O
the	O
virus	O
-	O
infected	O
and	O
cancer	O
cells	O
.	O

Apoptosis	O
and	O
growth	O
inhibition	O
in	O
malignant	O
lymphocytes	O
after	O
treatment	O
with	O
arsenic	O
trioxide	O
at	O
clinically	O
achievable	O
concentrations	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
can	O
induce	O
clinical	O
remission	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
via	O
induction	O
of	O
differentiation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
As2O3	O
on	O
a	O
panel	O
of	O
malignant	O
lymphocytes	O
to	O
determine	O
whether	O
growth	O
-	O
inhibitory	O
and	O
apoptotic	O
effects	O
of	O
As2O3	O
can	O
be	O
observed	O
in	O
these	O
cells	O
at	O
clinically	O
achievable	O
concentrations	O
.	O

METHODS	O
:	O
Eight	O
malignant	O
lymphocytic	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
lymphocytic	O
leukemia	O
and	O
lymphoma	O
cells	O
were	O
treated	O
with	O
As2O3	O
,	O
with	O
or	O
without	O
dithiothreitol	O
(	O
DTT	O
)	O
or	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
an	O
inhibitor	O
of	O
glutathione	O
synthesis	O
)	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
cell	O
morphology	O
,	O
flow	O
cytometry	O
,	O
annexin	B-PRGE
V	I-PRGE
protein	O
level	O
,	O
and	O
terminal	B-PRGE
deoxynucleotidyl	I-PRGE
transferase	I-PRGE
labeling	O
of	O
DNA	O
fragments	O
.	O

Cellular	O
proliferation	O
was	O
determined	O
by	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxyuridine	O
incorporation	O
into	O
DNA	O
and	O
flow	O
cytometry	O
and	O
by	O
use	O
of	O
a	O
mitotic	O
arrest	O
assay	O
.	O

Mitochondrial	O
transmembrane	O
potential	O
(	O
delta	O
psi	O
(	O
m	O
)	O
)	O
was	O
measured	O
by	O
means	O
of	O
rhodamine	O
123	O
staining	O
and	O
flow	O
cytometry	O
.	O

Protein	O
expression	O
was	O
assessed	O
by	O
western	O
blot	O
analysis	O
or	O
immunofluorescence	O
.	O

RESULTS	O
:	O
Therapeutic	O
concentrations	O
of	O
As2O3	O
(	O
1	O
-	O
2	O
microM	O
)	O
had	O
dual	O
effects	O
on	O
malignant	O
lymphocytes	O
:	O
1	O
)	O
inhibition	O
of	O
growth	O
through	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
depletion	O
and	O
prolongation	O
of	O
cell	O
cycle	O
time	O
and	O
2	O
)	O
induction	O
of	O
apoptosis	O
.	O

As2O3	O
-	O
induced	O
apoptosis	O
was	O
preceded	O
by	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
.	O

DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3	O
-	O
induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O

Caspase	B-PRGE
-	I-PRGE
3	I-PRGE
activation	O
,	O
usually	O
resulting	O
from	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
was	O
not	O
always	O
associated	O
with	O
As2O3	O
-	O
induced	O
apoptosis	O
.	O

As2O3	O
induced	O
PML	B-PRGE
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	O
cycle	O
-	O
related	O
proteins	O
,	O
including	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
,	O
retinoblastoma	B-PRGE
protein	I-PRGE
,	O
cyclin	B-PRGE
-	I-PRGE
dependent	I-PRGE
kinase	I-PRGE
4	I-PRGE
,	O
cyclin	B-PRGE
D1	I-PRGE
,	O
and	O
p53	B-PRGE
,	O
or	O
expression	O
of	O
differentiation	O
-	O
related	O
antigens	O
.	O

CONCLUSIONS	O
:	O
Substantial	O
growth	O
inhibition	O
and	O
apoptosis	O
without	O
evidence	O
of	O
differentiation	O
were	O
induced	O
in	O
most	O
malignant	O
lymphocytic	O
cells	O
treated	O
with	O
1	O
-	O
2	O
microM	O
As2O3	O
.	O

As2O3	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
lymphoproliferative	O
disorders	O
.	O

A	O
role	O
for	O
RanBP1	B-PRGE
in	O
the	O
release	O
of	O
CRM1	B-PRGE
from	O
the	O
nuclear	O
pore	O
complex	O
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O

We	O
recently	O
developed	O
an	O
assay	O
in	O
which	O
nuclear	O
export	O
of	O
the	O
shuttling	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
can	O
be	O
reconstituted	O
in	O
permeabilized	O
cells	O
with	O
the	O
GTPase	O
Ran	B-PRGE
and	O
the	O
nuclear	O
export	O
receptor	O
CRM1	B-PRGE
.	O

We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O

After	O
preincubation	O
of	O
permeabilized	O
cells	O
with	O
a	O
Ran	B-PRGE
mutant	O
that	O
cannot	O
hydrolyze	O
GTP	O
(	O
RanQ69L	O
)	O
,	O
cytosol	O
supports	O
NFAT	O
export	O
,	O
but	O
CRM1	B-PRGE
and	O
Ran	B-PRGE
alone	O
do	O
not	O
.	O

The	O
RanQ69L	O
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B-PRGE
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
in	O
association	O
with	O
the	O
p62	B-PRGE
complex	O
and	O
Can	B-PRGE
/	O
Nup214	B-PRGE
.	O

RanGTP	O
-	O
dependent	O
association	O
of	O
CRM1	B-PRGE
with	O
these	O
nucleoporins	O
was	O
reconstituted	O
in	O
vitro	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B-PRGE
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	O
preincubation	O
.	O

It	O
also	O
stimulates	O
nuclear	O
export	O
in	O
cells	O
that	O
have	O
not	O
been	O
preincubated	O
with	O
RanQ69L	O
.	O

RanBP1	B-PRGE
as	O
well	O
as	O
Ran	B-PRGE
-	O
binding	O
domains	O
of	O
the	O
cytoplasmic	O
nucleoporin	O
RanBP2	B-PRGE
promote	O
the	O
release	O
of	O
CRM1	B-PRGE
from	O
the	O
NPC	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
RanGTP	O
is	O
important	O
for	O
the	O
targeting	O
of	O
export	O
complexes	O
to	O
the	O
cytoplasmic	O
side	O
of	O
the	O
NPC	O
and	O
that	O
RanBP1	B-PRGE
and	O
probably	O
RanBP2	B-PRGE
are	O
involved	O
in	O
the	O
dissociation	O
of	O
nuclear	O
export	O
complexes	O
from	O
the	O
NPC	O
in	O
a	O
terminal	O
step	O
of	O
transport	O
.	O

Expression	O
of	O
Th1	O
and	O
Th2	O
type	O
cytokines	O
responding	O
to	O
HBsAg	B-PRGE
and	O
HBxAg	B-PRGE
in	O
chronic	O
hepatitis	O
B	O
patients	O
.	O

The	O
cytokine	O
pattern	O
on	O
viral	O
antigen	O
recognition	O
is	O
believed	O
to	O
exert	O
a	O
profound	O
influence	O
on	O
the	O
resolution	O
of	O
viral	O
infections	O
and	O
viral	O
clearance	O
.	O

This	O
study	O
was	O
initiated	O
to	O
investigate	O
whether	O
a	O
cytokine	O
imbalance	O
oriented	O
toward	O
Th2	O
type	O
response	O
plays	O
a	O
role	O
in	O
chronic	O
hepatitis	O
B	O
.	O

Cytokine	O
profiles	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
associated	O
with	O
chronic	O
hepatitis	O
B	O
were	O
analysed	O
by	O
RT	O
-	O
PCR	O
.	O

Upon	O
HBsAg	B-PRGE
stimulation	O
,	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Among	O
these	O
cytokines	O
,	O
the	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	O
AST	O
/	O
ALT	O
.	O

However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	O
type	O
cytokines	O
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	O
.	O

Upon	O
HBxAg	B-PRGE
stimulation	O
,	O
there	O
was	O
no	O
recognizable	O
association	O
of	O
cytokine	O
patterns	O
with	O
AST	O
/	O
ALT	O
levels	O
.	O

In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	O
cytokine	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
by	O
HBsAg	B-PRGE
-	O
reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	O
cytokines	O
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O

Protein	B-PRGE
kinase	I-PRGE
B	I-PRGE
(	O
c	B-PRGE
-	I-PRGE
Akt	I-PRGE
)	O
,	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
and	O
STAT5	B-PRGE
are	O
activated	O
by	O
erythropoietin	B-PRGE
(	O
EPO	B-PRGE
)	O
in	O
HCD57	O
erythroid	O
cells	O
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO	B-PRGE
-	O
independent	O
,	O
apoptosis	O
-	O
resistant	O
subclone	O
(	O
HCD57	O
-	O
SREI	O
cells	O
)	O
.	O

We	O
found	O
that	O
erythropoietin	B-PRGE
(	O
EPO	B-PRGE
)	O
and	O
stem	B-PRGE
cell	I-PRGE
factor	I-PRGE
(	O
SCF	B-PRGE
)	O
activated	O
protein	B-PRGE
kinase	I-PRGE
B	I-PRGE
(	O
PKB	B-PRGE
/	O
Akt	B-PRGE
)	O
in	O
EPO	B-PRGE
-	O
dependent	O
HCD57	O
erythroid	O
cells	O
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B-PRGE
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57	O
-	O
SREI	O
cells	O
)	O
.	O

Constitutive	O
activations	O
of	O
PKB	B-PRGE
/	O
Akt	B-PRGE
,	O
STAT5a	B-PRGE
,	O
and	O
STAT5b	B-PRGE
were	O
noted	O
in	O
these	O
EPO	B-PRGE
-	O
independent	O
cells	O
.	O

PI3	O
-	O
kinase	O
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB	B-PRGE
/	O
Akt	B-PRGE
because	O
the	O
PI3	O
-	O
kinase	O
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB	B-PRGE
/	O
Akt	B-PRGE
and	O
factor	O
-	O
dependent	O
PKB	B-PRGE
/	O
Akt	B-PRGE
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57	O
-	O
SREI	O
and	O
HCD57	O
cells	O
correlated	O
with	O
the	O
activity	O
of	O
PKB	B-PRGE
/	O
Akt	B-PRGE
;	O
however	O
,	O
PKB	B-PRGE
/	O
Akt	B-PRGE
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	O
cells	O
with	O
SCF	B-PRGE
also	O
activated	O
PKB	B-PRGE
/	O
Akt	B-PRGE
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB	B-PRGE
/	O
PI3	O
-	O
kinase	O
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and	O
/	O
or	O
proliferation	O
.	O

Constitutive	O
STAT5	B-PRGE
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B-PRGE
or	O
EPOR	B-PRGE
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3	O
-	O
kinase	O
/	O
PKB	B-PRGE
/	O
Akt	B-PRGE
pathway	O
to	O
protect	O
the	O
EPO	B-PRGE
-	O
independent	O
HCD57	O
-	O
SREI	O
cells	O
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-PRGE
protein	O
induces	O
the	O
expression	O
of	O
STAT1	B-PRGE
and	O
STAT5	B-PRGE
genes	O
in	O
T	O
-	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-PRGE
transforms	O
normal	O
T	O
-	O
cells	O
in	O
the	O
presence	O
of	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
vitro	O
.	O

STAT	O
is	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine	O
-	O
induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
STATs	O
in	O
the	O
transformation	O
of	O
T	O
-	O
cells	O
by	O
HTLV	O
-	O
1	O
.	O

HTLV	O
-	O
1	O
-	O
transformed	O
T	O
-	O
cell	O
lines	O
expressed	O
higher	O
amounts	O
of	O
STAT1	B-PRGE
,	O
STAT3	B-PRGE
and	O
STAT5	B-PRGE
RNA	O
and	O
proteins	O
than	O
virus	O
-	O
negative	O
T	O
cells	O
.	O

The	O
expression	O
of	O
STAT1	B-PRGE
and	O
STAT5	B-PRGE
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
was	O
induced	O
by	O
Tax	B-PRGE
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-PRGE
and	O
STAT5	B-PRGE
of	O
a	O
HTLV	O
-	O
1	O
-	O
transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O

In	O
contrast	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
did	O
neither	O
in	O
a	O
cell	O
line	O
lacking	O
STAT3	B-PRGE
and	O
STAT5	B-PRGE
.	O

The	O
expression	O
of	O
STAT1	B-PRGE
,	O
STAT3	B-PRGE
and	O
STAT5	B-PRGE
mRNAs	O
were	O
also	O
induced	O
by	O
a	O
T	O
-	O
cell	O
mitogen	O
in	O
normal	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
STAT1	B-PRGE
and	O
STAT5	B-PRGE
by	O
Tax	B-PRGE
enhances	O
cytokine	O
-	O
induced	O
functions	O
of	O
virus	O
-	O
infected	O
T	O
-	O
cells	O
,	O
hence	O
the	O
induction	O
may	O
play	O
a	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
transformation	O
steps	O
of	O
T	O
-	O
cells	O
by	O
HTLV	O
-	O
1	O
.	O

Modulation	O
of	O
CD28	B-PRGE
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	O
molecule	O
CD28	B-PRGE
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

Although	O
CD28	B-PRGE
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down	O
-	O
regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	B-PRGE
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein	O
-	O
binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	O
alpha	O
and	O
beta	O
,	O
within	O
the	O
CD28	B-PRGE
minimal	O
promoter	O
.	O

Both	O
alpha	O
-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	B-PRGE
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	O
B	O
cells	O
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down	O
-	O
modulation	O
of	O
site	O
beta	O
-	O
but	O
not	O
site	O
alpha	O
-	O
binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha	O
-	O
and	O
beta	O
-	O
binding	O
activities	O
.	O

CD4	B-PRGE
+	O
and	O
CD8	O
+	O
T	O
cells	O
differ	O
in	O
their	O
beta	O
-	O
binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down	O
-	O
regulation	O
of	O
CD28	B-PRGE
in	O
senescent	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
vivo	O
expanded	O
CD4	B-PRGE
+	O
CD28null	B-PRGE
and	O
CD8	O
+	O
CD28null	B-PRGE
T	O
cells	O
uniformly	O
lack	O
alpha	O
-	O
and	O
beta	O
-	O
bound	O
complexes	O
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	O
activated	O
cells	O
and	O
not	O
of	O
senescent	O
cells	O
.	O

Glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
'	O
s	O
disease	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
anorexia	O
nervosa	O
do	O
not	O
display	O
cushingoid	O
features	O
in	O
spite	O
of	O
elevated	O
cortisol	O
plasma	O
levels	O
.	O

Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O

METHODS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
severe	O
restrictive	O
anorexia	O
nervosa	O
,	O
10	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
24	O
healthy	O
volunteers	O
without	O
psychiatric	O
disorders	O
or	O
mood	O
alterations	O
were	O
investigated	O
.	O

Glucocorticoid	B-PRGE
receptor	I-PRGE
characteristics	O
were	O
examined	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
represents	O
an	O
index	O
of	O
DNA	O
synthesis	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
on	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
was	O
comparable	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
normal	O
subjects	O
(	O
binding	O
capacity	O
3	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
23	O
vs	O
.	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
30	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
20	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
.	O

Conversely	O
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
affinity	O
was	O
significantly	O
decreased	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
'	O
s	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
dissociation	O
constant	O
4	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
31	O
and	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
34	O
vs	O
.	O
2	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
29	O
nmol	O
/	O
L	O
,	O
p	O
<	O
.	O
001	O
)	O
and	O
inversely	O
correlated	O
with	O
the	O
levels	O
of	O
urinary	O
free	O
cortisol	O
in	O
both	O
groups	O
of	O
patients	O
.	O

Basal	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
MNL	O
was	O
significantly	O
reduced	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
'	O
s	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
p	O
<	O
.	O
001	O
)	O
and	O
was	O
diminished	O
by	O
dexamethasone	O
to	O
an	O
extent	O
similar	O
to	O
control	O
subjects	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
but	O
significantly	O
(	O
p	O
<	O
.	O
001	O
)	O
less	O
in	O
those	O
with	O
Cushing	O
'	O
s	O
disease	O
.	O

In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	O
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
lack	O
of	O
cushingoid	O
features	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
is	O
not	O
ascribable	O
to	O
a	O
reduced	O
sensitivity	O
to	O
glucocorticoids	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
paucity	O
of	O
metabolic	O
substrates	O
.	O

Latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
of	O
Epstein	O
-	O
Barr	O
virus	O
interacts	O
with	O
JAK3	B-PRGE
and	O
activates	O
STAT	O
proteins	O
.	O

Latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
acts	O
like	O
a	O
permanently	O
activated	O
receptor	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
receptor	O
superfamily	O
and	O
is	O
absolutely	O
required	O
for	O
B	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	B-PRGE
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
via	O
two	O
C	O
-	O
terminal	O
activating	O
regions	O
.	O

We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	O
rich	O
sequence	O
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	B-PRGE
'	O
s	O
C	O
-	O
terminus	O
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
(	O
JAK3	B-PRGE
)	O
.	O

The	O
interaction	O
of	O
LMP1	B-PRGE
and	O
JAK3	B-PRGE
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto	O
/	O
transphosphorylation	O
of	O
JAK3	B-PRGE
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF	B-PRGE
-	I-PRGE
R	I-PRGE
:	O
LMP1	B-PRGE
chimera	O
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	O
transcription	O
factors	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
activating	O
region	O
in	O
the	O
LMP1	B-PRGE
C	O
-	O
terminus	O
and	O
identify	O
the	O
JAK	O
/	O
STAT	O
pathway	O
as	O
a	O
target	O
of	O
this	O
viral	O
integral	O
membrane	O
protein	O
in	O
B	O
cells	O
.	O

20	O
-	O
Epi	O
analogues	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	O
coactivator	O
complex	O
binding	O
to	O
the	O
vitamin	B-PRGE
D3	I-PRGE
receptor	I-PRGE
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20	O
-	O
epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
.	O

We	O
report	O
that	O
two	O
20	O
-	O
epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-PRGE
(	O
Waf1	B-PRGE
,	O
Cip1	B-PRGE
)	O
,	O
a	O
key	O
VDR	B-PRGE
target	O
gene	O
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100	O
-	O
fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B-PRGE
interacting	O
proteins	O
:	O
RXR	O
,	O
GRIP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
DRIP205	B-PRGE
,	O
a	O
subunit	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B-PRGE
with	O
RXR	O
or	O
GRIP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
differentiation	O
dose	O
-	O
response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand	O
-	O
dependent	O
recruitment	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
to	O
VDR	B-PRGE
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20	O
-	O
epi	O
analogue	O
in	O
inducing	O
VDR	B-PRGE
/	O
DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

Multiple	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
isoforms	O
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	O
lymphocytes	O
.	O

The	O
transcription	O
factor	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
that	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
embryonic	O
cardiac	O
cells	O
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

This	O
is	O
due	O
to	O
alternative	O
splice	O
/	O
polyadenylation	O
events	O
that	O
lead	O
to	O
the	O
predominant	O
synthesis	O
of	O
two	O
long	O
isoforms	O
in	O
naive	O
T	O
cells	O
and	O
a	O
shorter	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
isoform	O
in	O
effector	O
T	O
cells	O
.	O

Whereas	O
the	O
previously	O
described	O
isoform	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
/	O
A	O
contains	O
a	O
relatively	O
short	O
C	O
terminus	O
,	O
the	O
longer	O
isoforms	O
,	O
B	O
and	O
C	O
,	O
span	O
extra	O
C	O
-	O
terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	O
N	O
-	O
terminal	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
A	O
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
isoforms	O
,	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
/	O
C	O
contains	O
a	O
second	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
B	O
,	O
in	O
its	O
C	O
-	O
terminal	O
peptide	O
.	O

Various	O
stimuli	O
of	O
T	O
cells	O
that	O
induce	O
the	O
activity	O
of	O
TAD	O
-	O
A	O
also	O
enhance	O
the	O
activity	O
of	O
TAD	O
-	O
B	O
,	O
but	O
,	O
unlike	O
TAD	O
-	O
A	O
,	O
TAD	O
-	O
B	O
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
12	O
-	O
phorbol	O
13	O
-	O
acetate	O
-	O
stimulated	O
T	O
cells	O
.	O

The	O
shorter	O
C	O
-	O
terminal	O
peptide	O
of	O
isoform	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
/	O
B	O
exerts	O
a	O
suppressive	O
transcriptional	O
effect	O
.	O

These	O
properties	O
of	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
/	O
B	O
and	O
-	O
C	O
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	O
T	O
lymphocytes	O
in	O
which	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
/	O
B	O
and	O
-	O
C	O
are	O
predominantly	O
synthesized	O
.	O

Phorbol	O
ester	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
is	O
blocked	O
by	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
PD98059	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
contributes	O
to	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	O
myeloblastic	O
leukemia	O
ML	O
-	O
1	O
cells	O
.	O

Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	B-PRGE
and	O
ERK2	B-PRGE
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	B-PRGE
protein	O
levels	O
remained	O
constant	O
.	O

The	O
activity	O
of	O
JNK1	B-PRGE
was	O
also	O
significantly	O
induced	O
,	O
with	O
JNK1	B-PRGE
protein	O
levels	O
increasing	O
moderately	O
during	O
exposure	O
to	O
TPA	O
.	O

Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
(	O
MEK	O
)	O
,	O
inhibited	O
TPA	O
-	O
induced	O
ERK2	B-PRGE
activity	O
.	O

Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA	O
-	O
induced	O
differentiation	O
of	O
ML	O
-	O
1	O
cells	O
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	O
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	O
oxidase	O
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
inducibility	O
.	O

We	O
conclude	O
that	O
activation	O
of	O
the	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
is	O
necessary	O
for	O
TPA	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
.	O

Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

A	O
possible	O
correlation	O
between	O
immune	O
and	O
clinical	O
parameters	O
was	O
analysed	O
in	O
50	O
breast	O
cancer	O
patients	O
.	O

Immune	O
parameters	O
,	O
natural	O
killer	O
cell	O
and	O
T	O
lymphocyte	O
functions	O
and	O
the	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
were	O
analysed	O
against	O
the	O
clinical	O
parameters	O
comprising	O
the	O
tumour	O
burden	O
,	O
the	O
stage	O
of	O
the	O
disease	O
and	O
the	O
expression	O
of	O
hormone	O
receptors	O
on	O
the	O
tumour	O
.	O

In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut	O
-	O
off	O
values	O
.	O

Considerably	O
higher	O
proportions	O
of	O
low	O
responders	O
were	O
found	O
among	O
the	O
patient	O
population	O
.	O

Elevated	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
and	O
CD3	O
-	O
directed	O
cytolysis	O
correlated	O
with	O
the	O
expression	O
of	O
oestrogen	B-PRGE
receptors	I-PRGE
independently	O
of	O
the	O
clinical	O
/	O
histological	O
parameters	O
.	O

UV	O
-	O
induced	O
CYP1A1	B-PRGE
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	B-PRGE
P	I-PRGE
-	I-PRGE
4501A1	I-PRGE
(	O
CYP1A1	B-PRGE
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah	B-PRGE
-	I-PRGE
receptor	I-PRGE
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B-PRGE
P4501A1	I-PRGE
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	B-PRGE
mRNA	O
by	O
UV	O
irradiation	O
of	O
cultured	O
human	O
keratinocytes	O
(	O
HaCaT	O
cell	O
line	O
)	O
,	O
primary	O
human	O
blood	O
lymphocytes	O
and	O
mouse	O
Hepa	O
-	O
1	O
cells	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20	O
/	O
12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
linked	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	B-PRGE
mRNA	O
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	O
cells	O
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	B-PRGE
receptor	I-PRGE
ligand	O
,	O
Hepa	O
-	O
1	O
wild	O
-	O
type	O
and	O
Ah	B-PRGE
receptor	I-PRGE
deficient	O
c12	O
cell	O
lines	O
were	O
applied	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
cells	O
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6	O
-	O
formylindolo	O
[	O
3	O
,	O
2	O
-	O
b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B-PRGE
receptor	I-PRGE
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV	O
-	O
induced	O
CYP1A1	B-PRGE
gene	O
expression	O
in	O
mammalian	O
cells	O
is	O
mediated	O
by	O
an	O
Ah	B-PRGE
receptor	I-PRGE
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B-PRGE
receptor	I-PRGE
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Effects	O
of	O
diesel	O
organic	O
extracts	O
on	O
chemokine	O
production	O
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O

Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	O
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

Chemokines	O
are	O
a	O
group	O
of	O
chemotactic	O
cytokines	O
involved	O
in	O
the	O
recruitment	O
of	O
inflammatory	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP	O
-	O
PAHs	O
on	O
the	O
release	O
and	O
mRNA	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
RANTES	B-PRGE
by	O
PBMCs	O
obtained	O
from	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	O
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Secretion	O
of	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
RANTES	B-PRGE
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
increasing	O
concentrations	O
of	O
DEP	O
-	O
PAHs	O
(	O
range	O
,	O
0	O
.	O
5	O
ng	O
to	O
50	O
ng	O
/	O
mL	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Messenger	O
RNA	O
production	O
coding	O
for	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
RANTES	B-PRGE
,	O
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	O
proteins	O
.	O

Effects	O
of	O
DEP	O
-	O
PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
RANTES	B-PRGE
.	O

Moreover	O
,	O
supernatants	O
from	O
DEP	O
-	O
PAH	O
-	O
activated	O
cells	O
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	O
and	O
eosinophils	O
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti	O
-	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
anti	O
-	O
RANTES	B-PRGE
neutralizing	O
antibodies	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	O
pathways	O
are	O
modulated	O
by	O
DEP	O
-	O
PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O

Oxidative	O
stress	O
triggers	O
STAT3	B-PRGE
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
human	O
lymphocytes	O
.	O

Oxidizing	O
agents	O
are	O
powerful	O
activators	O
of	O
factors	O
responsible	O
for	O
the	O
transcriptional	O
activation	O
of	O
cytokine	O
-	O
encoding	O
genes	O
involved	O
in	O
tissue	O
injury	O
.	O

In	O
this	O
study	O
we	O
show	O
evidence	O
that	O
STAT3	B-PRGE
is	O
a	O
transcription	O
factor	O
whose	O
activity	O
is	O
modulated	O
by	O
H2O2	O
in	O
human	O
lymphocytes	O
,	O
in	O
which	O
endogenous	O
catalase	O
had	O
previously	O
been	O
inhibited	O
.	O

H2O2	O
-	O
induced	O
nuclear	O
translocation	O
of	O
STAT3	B-PRGE
to	O
form	O
sequence	O
-	O
specific	O
DNA	O
-	O
bound	O
complexes	O
was	O
evidenced	O
by	O
immunoblotting	O
of	O
nuclear	O
fractions	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
vanadate	O
was	O
found	O
to	O
strongly	O
synergize	O
with	O
H2O2	O
.	O

Moreover	O
,	O
anti	O
-	O
STAT3	B-PRGE
antibodies	O
specifically	O
precipitated	O
a	O
protein	O
of	O
92	O
kDa	O
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Phenylarsine	O
oxide	O
,	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
,	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
cooperated	O
and	O
cancelled	O
,	O
respectively	O
,	O
the	O
H2O2	O
-	O
promoted	O
STAT3	B-PRGE
nuclear	O
translocation	O
.	O

Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2	O
+	O
/	O
Cu2	O
+	O
ions	O
,	O
that	O
.	O
OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B-PRGE
.	O

Present	O
data	O
suggest	O
that	O
H2O2	O
and	O
vanadate	O
are	O
likely	O
to	O
inhibit	O
the	O
activity	O
of	O
intracellular	O
tyrosine	O
phosphatase	O
(	O
s	O
)	O
,	O
leading	O
to	O
enhanced	O
STAT3	B-PRGE
tyrosine	O
phosphorylation	O
and	O
hence	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-PRGE
can	O
be	O
modulated	O
by	O
oxidizing	O
agents	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
JAK	O
-	O
STAT	O
signaling	O
pathway	O
.	O

Binding	O
characteristics	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
peripheral	O
blood	O
lymphocytes	O
in	O
multiple	O
sclerosis	O
.	O

Although	O
the	O
exact	O
etiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
remains	O
unresolved	O
,	O
immune	O
reactions	O
are	O
believed	O
to	O
be	O
the	O
central	O
pathogenic	O
mechanisms	O
.	O

Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune	O
-	O
endocrine	O
interplay	O
.	O

Function	O
tests	O
in	O
MS	O
have	O
revealed	O
dysregulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O

We	O
characterized	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
binding	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
39	O
MS	O
patients	O
and	O
14	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
with	O
respect	O
to	O
dissociation	O
constant	O
and	O
binding	O
capacity	O
,	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
.	O

GR	B-PRGE
binding	O
parameters	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
(	O
Kd	O
8	O
.	O
98	O
+	O
/	O
-	O
1	O
.	O
07	O
nM	O
,	O
Bmax	O
183	O
+	O
/	O
-	O
29	O
.	O
8	O
fmol	O
/	O
mg	O
)	O
and	O
controls	O
(	O
Kd	O
9	O
.	O
36	O
+	O
/	O
-	O
1	O
.	O
17	O
nM	O
,	O
Bmax	O
158	O
+	O
/	O
-	O
16	O
fmol	O
/	O
mg	O
)	O
.	O

No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O

GR	B-PRGE
binding	O
parameters	O
were	O
analyzed	O
in	O
relation	O
to	O
the	O
results	O
of	O
the	O
combined	O
dexamethasone	O
-	O
CRH	B-PRGE
test	O
,	O
which	O
reflects	O
corticosteroid	O
receptor	O
function	O
at	O
the	O
hypothalamus	O
,	O
in	O
30	O
patients	O
and	O
9	O
controls	O
.	O

While	O
controls	O
showed	O
a	O
moderate	O
correlation	O
between	O
binding	O
affinity	O
of	O
the	O
GR	B-PRGE
in	O
lymphocytes	O
and	O
regulatory	O
function	O
at	O
the	O
hypothalamic	O
level	O
,	O
the	O
patients	O
did	O
not	O
.	O

These	O
data	O
suggest	O
that	O
the	O
physiological	O
relationship	O
between	O
binding	O
and	O
function	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
is	O
disturbed	O
in	O
MS	O
.	O

CBP	B-PRGE
/	O
p300	B-PRGE
integrates	O
Raf	O
/	O
Rac	O
-	O
signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
during	O
T	O
cell	O
activation	O
.	O

NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
,	O
an	O
inducibly	O
expressed	O
transcription	O
factor	O
,	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
cardiomyocytes	O
.	O

We	O
show	O
here	O
that	O
the	O
transcriptional	O
co	O
-	O
activators	O
CBP	B-PRGE
/	O
p300	B-PRGE
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	O
N	O
-	O
terminal	O
transactivation	O
domain	O
of	O
NF	B-PRGE
-	I-PRGE
ATc	I-PRGE
,	O
TAD	O
-	O
A	O
.	O

Similar	O
to	O
the	O
N	O
terminal	O
transactivation	O
domain	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
TAD	O
-	O
A	O
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP	B-PRGE
/	O
p300	B-PRGE
.	O

Constitutive	O
active	O
versions	O
of	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
and	O
Rac	O
synergistically	O
enhance	O
the	O
CBP	B-PRGE
/	O
p300	B-PRGE
-	O
mediated	O
increase	O
of	O
TAD	O
-	O
A	O
activity	O
,	O
indicating	O
the	O
important	O
role	O
CBP	B-PRGE
/	O
p300	B-PRGE
plays	O
in	O
the	O
integration	O
of	O
T	O
cell	O
activation	O
signals	O
.	O

Since	O
a	O
mutation	O
of	O
CBP	B-PRGE
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild	O
-	O
type	O
CBP	B-PRGE
in	O
T	O
cells	O
,	O
functions	O
of	O
CBP	B-PRGE
/	O
p300	B-PRGE
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF	O
-	O
AT	O
-	O
dependent	O
transcription	O
in	O
T	O
cells	O
.	O

Association	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
with	O
p47phox	B-PRGE
,	O
an	O
activator	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
in	O
B	O
cells	O
.	O

Interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
4	I-PRGE
plays	O
an	O
important	O
role	O
in	O
IgE	O
synthesis	O
in	O
B	O
cells	O
and	O
in	O
Th2	O
differentiation	O
in	O
T	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
on	O
the	O
surface	O
of	O
target	O
cells	O
.	O

IL	O
-	O
4R	O
are	O
thought	O
to	O
be	O
composed	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
)	O
and	O
either	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
gamma	I-PRGE
chain	I-PRGE
or	O
the	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha	I-PRGE
chain	I-PRGE
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
membrane	O
-	O
proximal	O
portion	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
(	O
hIL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B-PRGE
,	O
based	O
on	O
analyses	O
of	O
truncated	O
hIL	B-PRGE
-	I-PRGE
4R	I-PRGE
alphas	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	B-PRGE
,	O
an	O
activator	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two	O
-	O
hybrid	O
system	O
.	O

Furthermore	O
,	O
we	O
observed	O
the	O
association	O
of	O
p47phox	B-PRGE
with	O
the	O
hIL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
in	O
B	O
cells	O
derived	O
from	O
a	O
normal	O
donor	O
.	O

These	O
results	O
suggest	O
that	O
p47phox	B-PRGE
is	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
B	O
cells	O
.	O

However	O
,	O
activation	O
of	O
STAT6	B-PRGE
,	O
CD23	B-PRGE
expression	O
,	O
and	O
IgE	O
synthesis	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
were	O
not	O
affected	O
in	O
p47phox	B-PRGE
-	O
deficient	O
patients	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
p47phox	B-PRGE
may	O
be	O
important	O
in	O
other	O
signaling	O
activities	O
as	O
well	O
in	O
B	O
cells	O
.	O

Aiolos	B-PRGE
transcription	O
factor	O
controls	O
cell	O
death	O
in	O
T	O
cells	O
by	O
regulating	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
and	O
its	O
cellular	O
localization	O
.	O

We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	O
in	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
-	O
stimulated	O
or	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
deprived	O
cells	O
,	O
and	O
found	O
that	O
the	O
transcription	O
factor	O
Aiolos	B-PRGE
interacts	O
with	O
Ras	O
.	O

The	O
Ras	O
-	O
Aiolos	B-PRGE
interaction	O
was	O
confirmed	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Indirect	O
immunofluorescence	O
shows	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B-PRGE
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	O
.	O

We	O
also	O
identified	O
functional	O
Aiolos	B-PRGE
-	O
binding	O
sites	O
in	O
the	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
,	O
which	O
are	O
able	O
to	O
activate	O
the	O
luciferase	B-PRGE
reporter	O
gene	O
.	O

Mutation	O
of	O
Aiolos	B-PRGE
-	O
binding	O
sites	O
within	O
the	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
inhibits	O
transactivation	O
of	O
the	O
reporter	O
gene	O
luciferase	B-PRGE
,	O
suggesting	O
direct	O
control	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
by	O
Aiolos	B-PRGE
.	O

Co	O
-	O
transfection	O
experiments	O
confirm	O
that	O
Aiolos	B-PRGE
induces	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
deprived	O
cells	O
.	O

We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
via	O
Aiolos	B-PRGE
.	O

C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
in	O
rheumatoid	O
arthritis	O
:	O
correlation	O
with	O
inflammation	O
,	O
not	O
disease	O
specificity	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
tissue	O
was	O
examined	O
and	O
compared	O
with	O
osteoarthritis	O
tissue	O
for	O
the	O
presence	O
of	O
the	O
nuclear	O
transcription	O
factor	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
)	O
.	O

The	O
region	O
(	O
lining	O
or	O
sublining	O
)	O
,	O
cell	O
type	O
,	O
and	O
subcellular	O
distribution	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
of	O
the	O
expression	O
of	O
C	O
/	O
EBP	O
beta	O
was	O
characterized	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
fluid	O
and	O
blood	O
and	O
normal	O
peripheral	O
blood	O
were	O
also	O
examined	O
.	O

C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
was	O
detected	O
in	O
the	O
synovial	O
lining	O
and	O
in	O
sublining	O
cells	O
of	O
synovial	O
tissue	O
from	O
patients	O
with	O
both	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

A	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
nuclear	O
staining	O
was	O
seen	O
in	O
the	O
lining	O
layer	O
,	O
compared	O
to	O
cells	O
in	O
the	O
sublining	O
region	O
,	O
in	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

In	O
both	O
diseases	O
a	O
strong	O
correlation	O
(	O
r	O
=	O
0	O
.	O
79	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
synovial	O
lining	O
that	O
were	O
positive	O
for	O
nuclear	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
and	O
lining	O
cell	O
depth	O
.	O

Two	O
-	O
color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	O
and	O
fibroblast	O
-	O
like	O
synoviocytes	O
were	O
positive	O
for	O
nuclear	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
.	O

The	O
presence	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
was	O
confirmed	O
by	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
with	O
isolated	O
synovial	O
fibroblasts	O
.	O

Nuclear	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
was	O
also	O
detected	O
in	O
rheumatoid	O
synovial	O
fluid	O
monocytes	O
/	O
macrophages	O
,	O
but	O
not	O
in	O
lymphocytes	O
or	O
neutrophils	O
.	O

Western	O
blot	O
analysis	O
confirmed	O
the	O
presence	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
in	O
these	O
cells	O
.	O

The	O
intensity	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
staining	O
was	O
greater	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
synovial	O
fluid	O
monocytes	O
than	O
in	O
those	O
from	O
normal	O
or	O
rheumatoid	O
peripheral	O
blood	O
.	O

In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
,	O
suggest	O
a	O
potential	O
role	O
for	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
in	O
chronic	O
inflammation	O
.	O

The	O
regulation	O
of	O
the	O
production	O
or	O
activity	O
of	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
beta	I-PRGE
,	O
to	O
inhibit	O
inflammatory	O
mediator	O
expression	O
by	O
synovial	O
macrophages	O
and	O
fibroblasts	O
,	O
offers	O
a	O
novel	O
approach	O
to	O
therapeutic	O
intervention	O
.	O

p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
integrates	O
phosphatidylinositol	O
3	O
-	O
kinase	O
and	O
rapamycin	O
-	O
regulated	O
signals	O
for	O
E2F	O
regulation	O
in	O
T	O
lymphocytes	O
.	O

In	O
T	O
lymphocytes	O
,	O
the	O
hematopoietic	O
cytokine	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
uses	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
-	O
induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	O
3	O
-	O
kinase	O
also	O
regulates	O
the	O
activity	O
of	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
,	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
kinase	O
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T	O
-	O
cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T	O
-	O
cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
in	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
PI	O
3	O
-	O
kinase	O
activation	O
of	O
E2Fs	O
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
PI	O
3	O
-	O
kinase	O
-	O
induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	O
transcriptional	O
activity	O
include	O
both	O
rapamycin	O
-	O
resistant	O
and	O
rapamycin	O
-	O
sensitive	O
components	O
.	O

Expression	O
of	O
a	O
rapamycin	O
-	O
resistant	O
mutant	O
of	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
in	O
T	O
cells	O
could	O
restore	O
rapamycin	O
-	O
suppressed	O
E2F	O
responses	O
.	O

Thus	O
,	O
the	O
rapamycin	O
-	O
controlled	O
processes	O
involved	O
in	O
E2F	O
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
.	O

However	O
,	O
the	O
rapamycin	O
-	O
resistant	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T	O
-	O
cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin	O
-	O
sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T	O
-	O
cell	O
cycle	O
progression	O
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
is	O
able	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptors	O
,	O
PI	O
3	O
-	O
kinase	O
,	O
and	O
p70	B-PRGE
(	I-PRGE
s6k	I-PRGE
)	I-PRGE
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	O
lymphocytes	O
.	O

SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
suppresses	O
STAT5	B-PRGE
phosphorylation	O
and	O
lymphocyte	O
proliferation	O
.	O

Members	O
of	O
the	O
recently	O
discovered	O
SOCS	O
/	O
CIS	O
/	O
SSI	O
family	O
have	O
been	O
proposed	O
as	O
regulators	O
of	O
cytokine	O
signaling	O
,	O
and	O
while	O
targets	O
and	O
mechanisms	O
have	O
been	O
suggested	O
for	O
some	O
family	O
members	O
,	O
the	O
precise	O
role	O
of	O
these	O
proteins	O
remains	O
to	O
be	O
defined	O
.	O

To	O
date	O
no	O
SOCS	O
proteins	O
have	O
been	O
specifically	O
implicated	O
in	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
signaling	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
expression	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
both	O
T	O
-	O
cell	O
lines	O
and	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
stimulation	O
,	O
while	O
CIS	B-PRGE
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O

Unlike	O
CIS	B-PRGE
,	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
rapidly	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Tyrosine	O
phosphorylation	O
of	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
observed	O
upon	O
coexpression	O
with	O
Jak1	B-PRGE
and	O
Jak2	B-PRGE
but	O
only	O
weakly	O
with	O
Jak3	B-PRGE
.	O

In	O
these	O
experiments	O
,	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
associated	O
with	O
Jak1	B-PRGE
and	O
inhibited	O
Jak1	B-PRGE
phosphorylation	O
,	O
and	O
this	O
inhibition	O
was	O
markedly	O
enhanced	O
by	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
beta	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
)	O
.	O

Moreover	O
,	O
following	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
stimulation	O
of	O
T	O
cells	O
,	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
able	O
to	O
interact	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	O
complex	O
,	O
and	O
in	O
particular	O
tyrosine	O
phosphorylated	O
Jak1	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
.	O

Additionally	O
,	O
in	O
lymphocytes	O
expressing	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
but	O
not	O
CIS	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	B-PRGE
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
mediated	O
STAT5b	B-PRGE
tyrosine	O
phosphorylation	O
.	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

The	O
findings	O
suggest	O
that	O
when	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
rapidly	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
T	O
cells	O
,	O
it	O
acts	O
to	O
inhibit	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O

The	O
role	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
positive	O
cells	O
in	O
pregnancy	O
.	O

PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	O
HLA	O
antigens	O
on	O
the	O
trophoblast	O
,	O
fetal	O
antigens	O
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
restricted	O
way	O
.	O

Decidual	O
gammadelta	O
T	O
cells	O
,	O
which	O
significantly	O
increase	O
in	O
number	O
during	O
pregnancy	O
,	O
might	O
play	O
a	O
role	O
in	O
recognition	O
of	O
fetal	O
antigens	O
and	O
also	O
in	O
determining	O
the	O
quality	O
of	O
the	O
response	O
to	O
these	O
antigens	O
.	O

Our	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
this	O
cell	O
population	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
Peripheral	O
lymphocytes	O
from	O
healthy	O
pregnant	O
women	O
and	O
from	O
habitual	O
aborters	O
were	O
tested	O
by	O
immunocytochemistry	O
for	O
the	O
presence	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
and	O
progesterone	B-PRGE
receptor	I-PRGE
.	O

To	O
investigate	O
the	O
effect	O
of	O
treatment	O
with	O
a	O
pan	O
anti	O
gamma	O
/	O
delta	O
antibody	O
,	O
lymphocytes	O
were	O
incubated	O
for	O
3	O
hr	O
with	O
the	O
antibody	O
,	O
and	O
then	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	O
-	O
12	O
and	O
progesterone	B-PRGE
-	I-PRGE
induced	I-PRGE
blocking	I-PRGE
factor	I-PRGE
(	O
PIBF	B-PRGE
)	O
expression	O
(	O
by	O
immuno	O
-	O
cytochemistry	O
)	O
as	O
well	O
as	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
were	O
determined	O
.	O

RESULTS	O
:	O
In	O
peripheral	O
blood	O
of	O
healthy	O
pregnant	O
women	O
the	O
percentage	O
of	O
gamma	O
/	O
delta	O
TCR	O
+	O
cells	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
in	O
that	O
of	O
recurrent	O
aborters	O
or	O
of	O
non	O
-	O
pregnant	O
individuals	O
.	O

Ninety	O
-	O
seven	O
percent	O
of	O
gamma	O
/	O
delta	O
TCR	O
+	O
pregnancy	O
lymphocytes	O
expressed	O
progesterone	B-PRGE
receptor	I-PRGE
.	O

Binding	O
of	O
a	O
specific	O
antibody	O
to	O
the	O
gamma	O
/	O
delta	O
TCR	O
inhibited	O
PIBF	B-PRGE
-	O
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
,	O
whereas	O
it	O
increased	O
NK	O
activity	O
and	O
IL	O
-	O
12	O
expression	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
the	O
role	O
of	O
gamma	O
/	O
delta	O
TCR	O
-	O
bearing	O
lymphocytes	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O

Expression	O
and	O
role	O
of	O
PML	B-PRGE
gene	O
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-PRGE
and	O
Rb	B-PRGE
proteins	O
in	O
erythropoiesis	O
.	O

The	O
expression	O
of	O
the	O
PML	B-PRGE
gene	O
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

PML	B-PRGE
mRNA	O
and	O
protein	O
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	O
,	O
are	O
consistently	O
induced	O
by	O
growth	O
factor	O
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

Thereafter	O
,	O
PML	B-PRGE
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

In	O
functional	O
studies	O
,	O
PML	B-PRGE
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	B-PRGE
mRNA	O
(	O
alpha	O
-	O
PML	O
)	O
.	O

Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	O
)	O
with	O
alpha	O
-	O
PML	O
reduced	O
the	O
number	O
of	O
both	O
erythroid	O
and	O
granulocytic	O
colonies	O
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O

These	O
findings	O
suggest	O
that	O
PML	B-PRGE
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
pattern	O
of	O
PML	B-PRGE
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	O
pRb	B-PRGE
105	I-PRGE
.	O

Combined	O
treatment	O
of	O
HPCs	O
with	O
alpha	O
-	O
PML	O
and	O
alpha	O
-	O
Rb	O
oligomers	O
inhibited	O
both	O
PML	B-PRGE
and	O
Rb	B-PRGE
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Furthermore	O
,	O
PML	B-PRGE
and	O
pRb	B-PRGE
105	I-PRGE
were	O
co	O
-	O
immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	O
precursors	O
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B-PRGE
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B-PRGE
with	O
pRb	B-PRGE
105	I-PRGE
.	O

Signal	O
transduction	O
pathways	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
cytokines	O
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	O
human	O
neutrophils	O
or	O
transformed	O
cells	O
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
and	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
3	I-PRGE
induced	O
tyrosine	O
phosphorylation	O
of	O
92	O
-	O
kDa	O
protein	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
identified	O
this	O
92	O
-	O
kDa	O
protein	O
as	O
STAT5	B-PRGE
,	O
but	O
not	O
as	O
STATs1	B-PRGE
,	O
3	B-PRGE
,	O
and	O
6	B-PRGE
nor	O
c	B-PRGE
-	I-PRGE
fes	I-PRGE
and	O
vav	B-PRGE
protooncogene	O
products	O
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42	O
-	O
and	O
44	O
-	O
kDa	O
proteins	O
,	O
which	O
were	O
identified	O
as	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
,	O
in	O
human	O
monocytes	O
.	O

In	O
marked	O
contrast	O
to	O
neutrophils	O
and	O
MO7e	O
cells	O
,	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	O
in	O
monocytes	O
.	O

Among	O
upstream	O
signaling	O
molecules	O
of	O
ERK	O
,	O
Shc	B-PRGE
was	O
constitutively	O
associated	O
with	O
Grb2	B-PRGE
and	O
was	O
not	O
tyrosine	O
-	O
phosphorylated	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
FMLP	O
,	O
and	O
Sos1	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	I-PRGE
1	I-PRGE
were	O
not	O
phosphorylated	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
TNF	B-PRGE
,	O
and	O
FMLP	O
in	O
monocytes	O
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and	O
/	O
or	O
utilized	O
by	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
MO7e	O
cells	O
.	O

In	O
contrast	O
to	O
neutrophils	O
,	O
p38	O
was	O
constitutively	O
phosphorylated	O
and	O
agonist	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	O
monocytes	O
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA	O
-	O
induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	O
.	O

PD98059	O
inhibited	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
dependent	O
proliferation	O
of	O
MO7e	O
cells	O
.	O

Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	B-PRGE
and	O
functional	O
roles	O
of	O
ERK	O
and	O
/	O
or	O
p38	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
physiological	O
receptor	O
-	O
mediated	O
agonists	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
FMLP	O
.	O

Possible	O
roles	O
of	O
ERK	O
in	O
proliferation	O
of	O
transformed	O
cells	O
were	O
also	O
suggested	O
.	O

Tyrphostin	O
AG	O
-	O
490	O
inhibits	O
cytokine	O
-	O
mediated	O
JAK3	B-PRGE
/	O
STAT5a	B-PRGE
/	O
b	B-PRGE
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen	O
-	O
activated	O
human	O
T	O
cells	O
.	O

Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
(	O
JAK3	B-PRGE
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
required	O
for	O
T	O
cell	O
development	O
and	O
activated	O
by	O
cytokines	O
that	O
utilize	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
)	I-PRGE
receptor	I-PRGE
common	I-PRGE
gamma	I-PRGE
chain	I-PRGE
(	O
gamma	B-PRGE
(	I-PRGE
c	I-PRGE
)	I-PRGE
)	O
.	O

Genetic	O
inactivation	O
of	O
JAK3	B-PRGE
is	O
manifested	O
as	O
severe	O
combined	O
immunodeficiency	O
disease	O
(	O
SCID	O
)	O
in	O
humans	O
and	O
mice	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
JAK3	B-PRGE
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid	O
-	O
derived	O
diseases	O
.	O

Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG	O
-	O
490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B-PRGE
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
5a	I-PRGE
and	O
5b	B-PRGE
(	O
STAT5a	B-PRGE
/	O
b	B-PRGE
)	O
.	O

Similar	O
inhibitory	O
effects	O
were	O
observed	O
with	O
other	O
cytokines	O
that	O
use	O
gamma	B-PRGE
(	I-PRGE
c	I-PRGE
)	I-PRGE
.	O

AG	O
-	O
490	O
also	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
proliferative	O
growth	O
in	O
human	O
T	O
cells	O
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inhibitor	O
prevented	O
tetanus	O
toxoid	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
and	O
expansion	O
but	O
failed	O
to	O
block	O
activation	O
of	O
Zap70	B-PRGE
or	O
p56Lck	B-PRGE
after	O
anti	O
-	O
CD3	O
stimulation	O
of	O
human	O
T	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG	O
-	O
490	O
inhibits	O
the	O
JAK3	B-PRGE
-	O
mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	O
cell	O
receptor	O
-	O
derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	O
cell	O
-	O
derived	O
pathologies	O
such	O
as	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B-PRGE
-	O
induced	O
signal	O
transduction	O
.	O

Erythropoietin	B-PRGE
(	O
EPO	B-PRGE
)	O
and	O
its	O
receptor	O
(	O
EPOR	B-PRGE
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	B-PRGE
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O

Although	O
erythroid	O
progenitors	O
appear	O
to	O
be	O
the	O
principal	O
EPO	B-PRGE
-	O
responsive	O
cell	O
type	O
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B-PRGE
,	O
many	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
expressing	O
the	O
EPOR	B-PRGE
can	O
respond	O
to	O
EPO	B-PRGE
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
[	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
]	O
-	O
dependent	O
HT	O
-	O
2	O
line	O
)	O
in	O
which	O
the	O
EPO	B-PRGE
stimulation	O
of	O
the	O
EPOR	B-PRGE
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT	B-PRGE
-	I-PRGE
5	I-PRGE
induction	O
,	O
or	O
MAPK	O
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B-PRGE
and	O
JAK2	B-PRGE
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT	O
-	O
2	O
cells	O
expressing	O
the	O
EPOR	B-PRGE
with	O
Ba	O
/	O
F3	O
cells	O
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	O
proliferated	O
and	O
potently	O
activated	O
STAT	B-PRGE
-	I-PRGE
5	I-PRGE
and	O
MAPK	O
in	O
response	O
to	O
EPO	B-PRGE
.	O

These	O
data	O
indicate	O
that	O
an	O
unidentified	O
cellular	O
factor	O
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	B-PRGE
.	O

Moreover	O
,	O
Ba	O
/	O
F3	O
cells	O
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B-PRGE
-	O
responsiveness	O
to	O
HT	O
-	O
2	O
cells	O
that	O
lack	O
this	O
factor	O
.	O

Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	O
of	O
activated	O
T	O
cells	O
in	O
eosinophils	O
:	O
regulation	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

We	O
report	O
that	O
NF	B-PRGE
-	I-PRGE
AT1	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
AT4	I-PRGE
are	O
expressed	O
cytoplasmically	O
in	O
resting	O
eosinophils	O
,	O
whereas	O
NF	B-PRGE
-	I-PRGE
AT2	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
AT3	I-PRGE
have	O
not	O
been	O
seen	O
.	O

Likewise	O
,	O
NF	B-PRGE
-	I-PRGE
AT1	I-PRGE
mRNA	O
and	O
NF	B-PRGE
-	I-PRGE
AT4	I-PRGE
mRNA	O
have	O
been	O
detected	O
in	O
resting	O
eosinophils	O
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up	O
-	O
regulated	O
by	O
the	O
Th2	O
-	O
associated	O
cytokines	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

There	O
is	O
no	O
detectable	O
NF	O
-	O
AT	O
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	O
eosinophils	O
.	O

However	O
NF	O
-	O
ATs	O
appear	O
in	O
the	O
nuclei	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
,	O
or	O
ionomycin	O
-	O
stimulated	O
eosinophils	O
.	O

Only	O
NF	B-PRGE
-	I-PRGE
AT1	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
AT4	I-PRGE
,	O
but	O
not	O
NF	B-PRGE
-	I-PRGE
AT2	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
AT3	I-PRGE
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
or	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
stimulated	O
eosinophils	O
.	O

These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	O
lymphocytes	O
"	O
control	O
"	O
eosinophils	O
via	O
the	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
and	O
activation	O
of	O
NF	O
-	O
AT	O
in	O
eosinophils	O
.	O

The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
"	O
talking	O
"	O
may	O
exist	O
between	O
eosinophils	O
and	O
Th2	O
lymphocytes	O
.	O

Altered	O
memory	O
T	O
cell	O
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

The	O
chronic	O
immune	O
response	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
might	O
be	O
driven	O
by	O
activated	O
Th1	O
cells	O
without	O
sufficient	O
Th2	O
cell	O
differentiation	O
to	O
down	O
-	O
modulate	O
inflammation	O
.	O

To	O
test	O
whether	O
disordered	O
memory	O
T	O
cell	O
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1	O
-	O
dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	O
CD4	O
+	O
memory	O
T	O
cells	O
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

No	O
difference	O
in	O
cytokine	O
secretion	O
profiles	O
of	O
freshly	O
isolated	O
memory	O
T	O
cells	O
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O

A	O
cell	O
culture	O
system	O
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	O
effectors	O
from	O
resting	O
memory	O
T	O
cells	O
by	O
short	O
term	O
priming	O
.	O

Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O

Th2	O
cells	O
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti	O
-	O
CD28	B-PRGE
in	O
the	O
absence	O
of	O
TCR	O
ligation	O
.	O

By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O

Exogenous	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
producing	O
cells	O
and	O
a	O
significant	O
increase	O
in	O
well	O
-	O
differentiated	O
Th1	O
cells	O
that	O
produced	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
but	O
not	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
evident	O
after	O
priming	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-PRGE
.	O

The	O
data	O
suggest	O
that	O
CD4	B-PRGE
+	O
memory	O
T	O
cells	O
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine	O
-	O
producing	O
effector	O
cells	O
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1	O
-	O
dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O

ICSAT	B-PRGE
overexpression	O
is	O
not	O
sufficient	O
to	O
cause	O
adult	O
T	O
-	O
cell	O
leukemia	O
or	O
multiple	O
myeloma	O
.	O

ICSAT	B-PRGE
(	O
Interferon	B-PRGE
Consensus	I-PRGE
Sequence	I-PRGE
binding	I-PRGE
protein	I-PRGE
for	I-PRGE
Activated	I-PRGE
T	I-PRGE
cells	I-PRGE
)	O
is	O
a	O
lymphocyte	O
-	O
specific	O
member	O
of	O
the	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	O
(	O
Adult	O
T	O
-	O
cell	O
leukemia	O
)	O
-	O
16T	O
expression	O
library	O
.	O

In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-PRGE
in	O
lymphocytes	O
.	O

Although	O
spontaneous	O
tumorigenesis	O
was	O
not	O
observed	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
with	O
Concanavalin	O
A	O
stimulation	O
was	O
significantly	O
increased	O
in	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-PRGE
.	O

ICSAT	B-PRGE
overexpression	O
in	O
lymphocytes	O
seems	O
insufficient	O
for	O
the	O
leukemogenesis	O
of	O
ATL	O
or	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
however	O
,	O
it	O
may	O
regulate	O
T	O
cell	O
activation	O
and	O
its	O
overexpression	O
may	O
lead	O
to	O
leukemogenesis	O
via	O
controlling	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
ERK	B-PRGE
)	O
-	O
dependent	O
and	O
ERK	B-PRGE
-	O
independent	O
pathways	O
target	O
STAT3	B-PRGE
on	O
serine	O
-	O
727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	O
factors	O
and	O
cytokines	O
.	O

STAT3	B-PRGE
(	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
3	I-PRGE
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr	O
-	O
705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	O
or	O
growth	O
factors	O
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	O
serine	O
kinases	O
also	O
phosphorylate	O
STAT3	B-PRGE
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site	O
-	O
specific	O
antibody	O
,	O
that	O
STAT3	B-PRGE
is	O
phosphorylated	O
on	O
Ser	O
-	O
727	O
in	O
human	O
neutrophils	O
stimulated	O
with	O
chemotactic	O
factors	O
(	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	O
[	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
and	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
]	O
,	O
or	O
a	O
protein	O
kinase	O
C	O
activator	O
(	O
PMA	O
)	O
.	O

(	O
2	O
-	O
Amino	O
-	O
3	O
'	O
-	O
methoxyphenyl	O
)	O
oxanaphthalen	O
-	O
4	O
-	O
one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
ERK	B-PRGE
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-PRGE
induced	O
by	O
chemotactic	O
factors	O
or	O
PMA	O
.	O

The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	O
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15	O
-	O
30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
regardless	O
of	O
incubation	O
time	O
.	O

1	O
-	O
(	O
5	O
-	O
Isoquinolinylsulphonyl	O
)	O
-	O
2	O
-	O
methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B-PRGE
serine	O
kinase	O
,	O
and	O
4	O
-	O
(	O
4	O
-	O
fluorophenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
methylsulphinylphenyl	O
)	O
-	O
5	O
-	O
(	O
4	O
-	O
pyridyl	O
)	O
1H	O
-	O
imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

We	O
propose	O
that	O
neutrophils	O
use	O
both	O
ERK	B-PRGE
-	O
dependent	O
and	O
ERK	B-PRGE
-	O
independent	O
pathways	O
to	O
phosphorylate	O
Ser	O
-	O
727	O
on	O
STAT3	B-PRGE
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B-PRGE
-	O
activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	O
kinase	O
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	O
.	O

Activation	O
of	O
STAT5	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
relies	O
on	O
Janus	O
kinase	O
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	O
activation	O
through	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
receptor	O
(	O
IL	O
-	O
4R	O
)	O
.	O

By	O
functionally	O
expressing	O
receptor	O
mutants	O
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
chain	I-PRGE
are	O
dispensable	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
STAT5	O
activity	O
.	O

However	O
,	O
disruption	O
of	O
a	O
membrane	O
-	O
proximal	O
proline	O
-	O
rich	O
sequence	O
motif	O
(	O
'	O
box1	O
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	O
IL	O
-	O
4R	O
abolished	O
not	O
only	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	O
kinases	O
JAK1	B-PRGE
and	O
JAK3	B-PRGE
,	O
but	O
also	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
triggered	O
activation	O
of	O
STAT5	O
and	O
concomitant	O
cell	O
proliferation	O
.	O

A	O
dominant	O
-	O
negative	O
version	O
of	O
STAT5b	B-PRGE
,	O
but	O
not	O
of	O
STAT5a	B-PRGE
,	O
interfered	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
induced	O
DNA	O
synthesis	O
in	O
Ba	O
/	O
F3	O
cells	O
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	B-PRGE
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL	O
-	O
4R	O
.	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	O
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
that	O
both	O
STAT5a	B-PRGE
and	O
STAT5b	B-PRGE
can	O
contribute	O
to	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
triggered	O
transcriptional	O
control	O
.	O

Diminished	O
responses	O
to	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
by	O
human	O
monocytes	O
differentiated	O
in	O
vitro	O
:	O
role	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
13Ralpha1	I-PRGE
chain	I-PRGE
and	O
STAT6	B-PRGE
.	O

The	O
primary	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
receptor	O
complex	O
on	O
human	O
monocytes	O
is	O
believed	O
to	O
be	O
a	O
heterodimer	O
comprised	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
chain	I-PRGE
and	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
gamma	I-PRGE
chain	I-PRGE
(	O
gamma	O
(	O
c	O
)	O
)	O
-	O
like	O
molecule	O
,	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
.	O

mRNA	O
levels	O
for	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
,	O
were	O
markedly	O
decreased	O
in	O
in	O
vitro	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMac	O
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	O
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
regulation	O
of	O
lipopolysaccharide	O
-	O
induced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
.	O

Analysis	O
of	O
cell	O
lines	O
Daudi	O
and	O
THP	O
-	O
1	O
that	O
differentially	O
express	O
gamma	O
(	O
c	O
)	O
and	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
showed	O
that	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
can	O
activate	O
STAT6	B-PRGE
in	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
-	O
positive	O
THP	O
-	O
1	O
cells	O
but	O
not	O
in	O
gamma	O
(	O
c	O
)	O
-	O
positive	O
,	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
-	O
negative	O
Daudi	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
13	I-PRGE
activation	O
of	O
STAT6	B-PRGE
was	O
reduced	O
in	O
MDMac	O
which	O
was	O
associated	O
with	O
diminished	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
induced	O
expression	O
of	O
CD23	B-PRGE
and	O
MHC	O
class	O
II	O
.	O

However	O
,	O
with	O
reduced	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
expression	O
and	O
low	O
nuclear	O
STAT6	B-PRGE
activity	O
,	O
some	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
-	O
induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	O
.	O

In	O
the	O
absence	O
of	O
functional	O
IL	B-PRGE
-	I-PRGE
13R	I-PRGE
alpha1	I-PRGE
and	O
gamma	O
(	O
c	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
must	O
signal	O
through	O
an	O
alternative	O
receptor	O
complex	O
on	O
MDMac	O
.	O

Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
alpha	I-PRGE
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
receptor	O
complex	O
on	O
MDMac	O
.	O

Monoallelic	O
expression	O
of	O
Pax5	B-PRGE
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
?	O

It	O
is	O
generally	O
assumed	O
that	O
most	O
mammalian	O
genes	O
are	O
transcribed	O
from	O
both	O
alleles	O
.	O

Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
one	O
allele	O
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
of	O
the	O
same	O
gene	O
.	O

Indeed	O
,	O
the	O
vast	O
majority	O
of	O
human	O
disease	O
syndromes	O
and	O
engineered	O
mutations	O
in	O
the	O
mouse	O
genome	O
are	O
recessive	O
,	O
indicating	O
that	O
recessiveness	O
is	O
the	O
'	O
default	O
'	O
state	O
.	O

However	O
,	O
a	O
minority	O
of	O
genes	O
are	O
semi	O
-	O
dominant	O
,	O
as	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
these	O
genes	O
leads	O
to	O
phenotypic	O
abnormalities	O
.	O

This	O
condition	O
,	O
known	O
as	O
haploinsufficiency	O
,	O
has	O
been	O
described	O
for	O
five	O
of	O
the	O
nine	O
mammalian	O
Pax	O
genes	O
,	O
which	O
are	O
associated	O
with	O
mouse	O
developmental	O
mutants	O
and	O
human	O
disease	O
syndromes	O
.	O

Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-PRGE
gene	O
is	O
subject	O
to	O
allele	O
-	O
specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O

Pax5	B-PRGE
is	O
predominantly	O
transcribed	O
from	O
only	O
one	O
of	O
its	O
two	O
alleles	O
in	O
early	O
B	O
-	O
lymphoid	O
progenitors	O
and	O
mature	O
B	O
cells	O
,	O
while	O
it	O
transiently	O
switches	O
to	O
a	O
biallelic	O
mode	O
of	O
transcription	O
in	O
pre	O
-	O
B	O
and	O
immature	O
B	O
cells	O
.	O

As	O
a	O
consequence	O
,	O
B	O
-	O
lymphoid	O
tissues	O
are	O
mosaic	O
with	O
regard	O
to	O
the	O
transcribed	O
allele	O
,	O
and	O
heterozygous	O
mutation	O
of	O
Pax5	B-PRGE
therefore	O
results	O
in	O
deletion	O
of	O
B	O
lymphocytes	O
expressing	O
only	O
the	O
mutant	O
allele	O
.	O

The	O
allele	O
-	O
specific	O
regulation	O
of	O
Pax5	B-PRGE
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	O
genes	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
different	O
models	O
accounting	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
,	O
provide	O
further	O
evidence	O
in	O
support	O
of	O
the	O
allele	O
-	O
specific	O
regulation	O
of	O
Pax5	B-PRGE
and	O
discuss	O
the	O
implication	O
of	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
recent	O
literature	O
describing	O
the	O
stochastic	O
and	O
monoallelic	O
activation	O
of	O
other	O
hematopoietic	O
genes	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
BamHI	O
-	O
Q	O
promoter	O
is	O
positively	O
regulated	O
by	O
STATs	O
and	O
Zta	B-PRGE
interference	O
with	O
JAK	O
/	O
STAT	O
activation	O
leads	O
to	O
loss	O
of	O
BamHI	O
-	O
Q	O
promoter	O
activity	O
.	O

In	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
associated	O
tumors	O
in	O
nonimmunocompromised	O
patients	O
,	O
EBV	O
gene	O
expression	O
is	O
highly	O
restricted	O
.	O

EBV	B-PRGE
-	I-PRGE
encoded	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
(	I-PRGE
EBNA	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	O
are	O
not	O
.	O

This	O
pattern	O
of	O
EBNA	O
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI	O
-	O
Q	O
promoter	O
(	O
Qp	O
)	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	O
/	O
STAT	O
pathway	O
positively	O
regulates	O
Qp	O
activity	O
.	O

In	O
transient	O
-	O
transfection	O
assays	O
,	O
a	O
Qp	O
-	O
CAT	O
reporter	O
was	O
activated	O
by	O
cotransfected	O
JAK	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

The	O
ability	O
of	O
Qp	O
to	O
bind	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT	O
-	O
binding	O
sites	O
reduced	O
Qp	O
responsiveness	O
to	O
Janus	B-PRGE
kinase	I-PRGE
(	I-PRGE
JAK	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Consistent	O
with	O
a	O
role	O
for	O
STATs	O
in	O
Qp	O
function	O
,	O
Qp	O
using	O
Burkitt	O
'	O
s	O
lymphoma	O
Rael	O
cells	O
and	O
cultured	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
cells	O
contained	O
nuclear	O
STAT	O
protein	O
.	O

We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV	O
-	O
positive	O
NPC	O
cell	O
lines	O
in	O
culture	O
was	O
related	O
to	O
Qp	O
activity	O
.	O

Passaging	O
of	O
the	O
NPC	O
cell	O
line	O
HK666	O
led	O
to	O
activation	O
of	O
expression	O
of	O
BZLF1	B-PRGE
,	O
which	O
encodes	O
Zta	B-PRGE
and	O
loss	O
of	O
Qp	O
function	O
.	O

Transient	O
expression	O
assays	O
linked	O
Zta	B-PRGE
expression	O
to	O
the	O
down	O
-	O
regulation	O
of	O
Qp	O
.	O

Cotransfection	O
of	O
Zta	B-PRGE
reduced	O
Qp	O
activity	O
in	O
reporter	O
assays	O
.	O

This	O
negative	O
regulation	O
required	O
Zta	B-PRGE
DNA	O
-	O
binding	O
activity	O
.	O

We	O
provide	O
evidence	O
that	O
Zta	B-PRGE
up	O
-	O
regulation	O
of	O
p53	B-PRGE
leads	O
to	O
p53	B-PRGE
-	O
mediated	O
interference	O
with	O
JAK	O
/	O
STAT	O
activation	O
of	O
Qp	O
.	O

The	O
data	O
imply	O
that	O
JAK	O
/	O
STAT	O
signaling	O
has	O
a	O
role	O
in	O
EBV	O
-	O
associated	O
malignancies	O
.	O

Selective	O
DNA	O
-	O
binding	O
activity	O
of	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
stimulated	O
STAT	O
molecules	O
in	O
human	O
monocytes	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
activated	O
STAT	O
molecules	O
to	O
two	O
kinds	O
of	O
GAS	O
-	O
motif	O
sequences	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
activated	O
STAT1	B-PRGE
could	O
bind	O
to	O
the	O
GAS	O
-	O
motif	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	O
receptor	O
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	O
region	O
of	O
the	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
whereas	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
activated	O
STAT1	B-PRGE
and	O
STAT5	B-PRGE
could	O
bind	O
to	O
both	O
sequences	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibited	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
STAT	O
activation	O
without	O
newly	O
synthesized	O
protein	O
.	O

We	O
further	O
demonstrated	O
that	O
aspirin	O
,	O
but	O
not	O
dexamethasone	O
,	O
suppressed	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
induced	O
STAT	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
activated	O
STAT1	B-PRGE
has	O
a	O
specificity	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
,	O
whereas	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
activated	O
STAT1	B-PRGE
and	O
STAT5	B-PRGE
have	O
a	O
broader	O
spectrum	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activities	O
.	O

Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	O
cells	O
by	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
but	O
not	O
by	O
highly	O
expressed	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
chimeric	O
gene	O
,	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
,	O
generated	O
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

To	O
evaluate	O
whether	O
this	O
enhancement	O
is	O
the	O
primary	O
role	O
of	O
AML1	O
/	O
ETO	O
in	O
leukemogenesis	O
,	O
effects	O
of	O
over	O
-	O
expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
the	O
murine	O
myeloid	O
precursor	O
cell	O
line	O
,	O
32Dcl3	O
,	O
were	O
examined	O
.	O

When	O
32Dcl3	O
cells	O
expressing	O
exogenous	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	O
cells	O
stably	O
expressing	O
AML1	O
/	O
ETO	O
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1	O
/	O
ETO	O
.	O

The	O
Legionella	O
pneumophila	O
rpoS	B-PRGE
gene	O
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O

To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	O
coli	O
stress	O
and	O
stationary	O
-	O
phase	O
sigma	O
factor	O
RpoS	B-PRGE
was	O
identified	O
by	O
complementation	O
of	O
an	O
E	O
.	O
coli	O
rpoS	B-PRGE
mutation	O
.	O

An	O
open	O
reading	O
frame	O
that	O
is	O
approximately	O
60	O
%	O
identical	O
to	O
the	O
E	O
.	O
coli	O
rpoS	B-PRGE
gene	O
was	O
identified	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L	O
.	O
pneumophila	O
RpoS	B-PRGE
increased	O
in	O
stationary	O
phase	O
.	O

An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	B-PRGE
gene	O
on	O
the	O
chromosome	O
of	O
L	O
.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Both	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
strains	O
were	O
more	O
resistant	O
to	O
stress	O
when	O
in	O
stationary	O
phase	O
than	O
when	O
in	O
the	O
logarithmic	O
phase	O
of	O
growth	O
.	O

This	O
finding	O
indicates	O
that	O
L	O
.	O
pneumophila	O
RpoS	B-PRGE
is	O
not	O
required	O
for	O
a	O
stationary	O
-	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
.	O

Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL	O
-	O
60	O
-	O
and	O
THP	O
-	O
1	O
-	O
derived	O
macrophages	O
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O

These	O
data	O
suggest	O
that	O
L	O
.	O
pneumophila	O
possesses	O
a	O
growth	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B-PRGE
control	O
and	O
that	O
RpoS	B-PRGE
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
role	O
of	O
rpoS	B-PRGE
in	O
L	O
.	O
pneumophila	O
is	O
very	O
different	O
from	O
what	O
has	O
previously	O
been	O
reported	O
for	O
E	O
.	O
coli	O
rpoS	B-PRGE
.	O

Cutting	O
edge	O
:	O
TCR	O
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B-PRGE
activation	O
in	O
human	O
T	O
cells	O
.	O

Recent	O
data	O
show	O
that	O
TCR	O
/	O
CD3	O
stimulation	O
induces	O
activation	O
of	O
Stat5	B-PRGE
in	O
murine	O
T	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long	O
-	O
lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-PRGE
(	O
but	O
not	O
Stat5	B-PRGE
)	O
in	O
allogen	O
-	O
specific	O
human	O
CD4	O
+	O
T	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-PRGE
.	O

Compared	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
CD3	B-PRGE
ligation	O
induces	O
a	O
delayed	O
Stat3	B-PRGE
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
.	O

CD3	B-PRGE
-	O
mediated	O
activation	O
of	O
Stat3	B-PRGE
is	O
almost	O
completely	O
inhibited	O
by	O
a	O
Src	O
kinase	O
inhibitor	O
(	O
PP1	O
)	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
Stat3	B-PRGE
activation	O
is	O
unaffected	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B-PRGE
ligation	O
by	O
mAb	O
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	O
-	O
sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-PRGE
in	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
TCR	O
/	O
CD3	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induce	O
Stat3	B-PRGE
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O

[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood	O
-	O
glucose	O
,	O
cholesterol	O
,	O
HDL	O
-	O
cholesterol	O
,	O
triglyceride	O
,	O
beta	O
-	O
lipoproteins	O
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B-PRGE
,	O
T3	O
,	O
T4	O
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	B-PRGE
and	O
progesterone	B-PRGE
receptor	I-PRGE
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O

A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2	O
.	O
5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O

Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
decreases	O
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
increases	O
,	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
to	O
dexamethasone	O
:	O
potential	O
regulation	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune	O
/	O
inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
,	O
a	O
proinflammatory	O
cytokine	O
)	O
and	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
10	I-PRGE
(	O
an	O
anti	O
-	O
inflammatory	O
cytokine	O
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
/	O
macrophages	O
to	O
glucocorticoids	O
.	O

To	O
accomplish	O
this	O
,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibition	O
by	O
dexamethasone	O
in	O
LPS	O
-	O
stimulated	O
whole	O
-	O
blood	O
cell	O
cultures	O
.	O

Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-PRGE
or	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
measurement	O
of	O
LPS	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
secretion	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
dexamethasone	O
on	O
phorbolmyristate	O
-	O
acetate	O
-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
secretion	O
by	O
the	O
human	O
monocytic	O
cell	O
line	O
U937	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha	B-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
pretreated	O
U937	O
cells	O
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
concentration	O
and	O
affinity	O
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS	O
-	O
induced	O
TNFalpha	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B-PRGE
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O

The	O
concentration	O
of	O
LPS	O
employed	O
influenced	O
the	O
effect	O
of	O
dexamethasone	O
on	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
secretion	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Pretreatment	O
with	O
TNFalpha	B-PRGE
diminished	O
,	O
and	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
secretion	O
in	O
whole	O
-	O
blood	O
cell	O
cultures	O
(	O
P	O
<	O
0	O
.	O
01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
both	O
)	O
.	O

TNFalpha	B-PRGE
decreased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
secretion	O
by	O
human	O
monocytes	O
in	O
a	O
LPS	O
dose	O
-	O
dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B-PRGE
or	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
pretreatment	O
;	O
TNFalpha	B-PRGE
blocks	O
their	O
effects	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B-PRGE
receptor	I-PRGE
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O

This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro	O
-	O
/	O
antiinflammatory	O
cytokine	O
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	O
acid	O
receptors	O
:	O
a	O
possible	O
target	O
for	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
oncogene	O
action	O
.	O

The	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
oncogene	O
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B-PRGE
hormone	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
/	O
TR	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto	O
-	O
oncogene	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
in	O
erythropoiesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	B-PRGE
hormone	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
/	O
TR	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
the	O
closely	O
related	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
RAR	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	O
kinase	O
oncogene	O
.	O

When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O

Expression	O
of	O
the	O
human	O
RAR	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
receptor	O
-	O
negative	O
erythroblasts	O
conferred	O
RA	O
-	O
induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR	B-PRGE
-	I-PRGE
alpha	I-PRGE
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
/	O
TR	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O

Glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Glucocorticoid	B-PRGE
receptor	I-PRGE
concentrations	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

In	O
summary	O
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O

A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-PRGE
receptors	I-PRGE
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O

A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-PRGE
receptors	I-PRGE
which	O
is	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-	O
dexamethasone	O
as	O
radioligand	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12	O
-	O
day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-PRGE
receptor	I-PRGE
binding	O
is	O
altered	O
in	O
this	O
'	O
stressful	O
'	O
disease	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B-PRGE
receptor	I-PRGE
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor	O
-	O
ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
immune	O
responses	O
.	O

Single	O
point	O
estimation	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
lymphocytes	O
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
GR	B-PRGE
)	O
in	O
human	O
lymphocytes	O
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi	O
-	O
point	O
Scatchard	O
analysis	O
.	O

The	O
assay	O
conditions	O
-	O
concentration	O
of	O
the	O
ligand	O
20	O
nmol	O
/	O
l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2	O
-	O
6	O
mil	O
.	O

cells	O
/	O
tube	O
in	O
the	O
assay	O
volume	O
0	O
.	O
25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole	O
-	O
cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non	O
-	O
applicable	O
for	O
receptor	O
quantitation	O
.	O

The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	B-PRGE
concentration	O
7131	O
+	O
/	O
-	O
1256	O
sites	O
/	O
cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O

The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O

The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
found	O
in	O
these	O
children	O
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O

A	O
novel	O
B	O
cell	O
-	O
derived	O
coactivator	O
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer	O
-	O
binding	O
transcription	O
factors	O
.	O

A	O
novel	O
B	O
cell	O
-	O
restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	O
/	O
Oct	O
-	O
dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	O
cell	O
-	O
derived	O
extracts	O
complemented	O
with	O
fractionated	O
B	O
cell	O
nuclear	O
proteins	O
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
)	O
.	O

OCA	B-PRGE
-	I-PRGE
B	I-PRGE
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	O
/	O
Oct	O
-	O
dependent	O
transcription	O
of	O
the	O
ubiquitously	O
expressed	O
histone	O
H2B	O
promoter	O
and	O
the	O
transcription	O
of	O
USF	B-PRGE
-	O
and	O
Sp1	B-PRGE
-	O
regulated	O
promoters	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
is	O
a	O
tissue	O
-	O
,	O
promoter	O
-	O
,	O
and	O
factor	O
-	O
specific	O
coactivator	O
and	O
that	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell	O
-	O
specific	O
activation	O
of	O
immunoglobulin	O
promoters	O
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	O
factors	O
and	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
discuss	O
the	O
implications	O
of	O
OCA	B-PRGE
-	I-PRGE
B	I-PRGE
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue	O
-	O
specific	O
promoters	O
.	O

Expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
jun	B-PRGE
B	I-PRGE
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

The	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
jun	B-PRGE
B	I-PRGE
proto	O
-	O
oncogenes	O
was	O
studied	O
in	O
phytohemagglutinin	B-PRGE
(	O
PHA	B-PRGE
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

Specific	O
mRNAs	O
for	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O

Both	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
jun	B-PRGE
B	I-PRGE
mRNAs	O
decreased	O
to	O
pre	O
-	O
activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
remained	O
elevated	O
.	O

In	O
PHA	B-PRGE
-	O
activated	O
PBL	O
,	O
no	O
age	O
-	O
related	O
differences	O
were	O
observed	O
in	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
or	O
jun	B-PRGE
B	I-PRGE
mRNA	O
expression	O
.	O

However	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
levels	O
decreased	O
significantly	O
(	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
1	O
.	O
16	O
+	O
/	O
-	O
0	O
.	O
09	O
arbitrary	O
units	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
young	O
vs	O
.	O
old	O
)	O
in	O
PBL	O
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B-PRGE
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti	O
-	O
CD2	B-PRGE
pathway	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
jun	B-PRGE
B	I-PRGE
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti	O
-	O
CD2	B-PRGE
-	O
activated	O
purified	O
T	O
cells	O
.	O

No	O
age	O
-	O
related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto	O
-	O
oncogenes	O
by	O
anti	O
-	O
CD2	B-PRGE
activated	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA	B-PRGE
-	O
activated	O
PBL	O
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age	O
-	O
related	O
changes	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
expression	O
and	O
in	O
the	O
ratio	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
to	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
.	O

SCL	B-PRGE
and	O
related	O
hemopoietic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factors	O
.	O

The	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
proteins	O
are	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	O
,	O
SCL	B-PRGE
,	O
TAL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
LYL	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E2A	B-PRGE
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B-PRGE
and	O
LYL	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
low	O
or	O
undetectable	O
in	O
normal	O
T	O
cell	O
populations	O
.	O

SCL	B-PRGE
is	O
expressed	O
in	O
erythroid	O
,	O
megakaryocyte	O
and	O
mast	O
cell	O
populations	O
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
)	O
.	O

In	O
addition	O
,	O
both	O
SCL	B-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	O
erythroleukemia	O
cells	O
and	O
are	O
down	O
-	O
modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
K562	O
cells	O
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	B-PRGE
in	O
erythroid	O
differentiation	O
events	O
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
SCL	B-PRGE
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Studies	O
of	O
the	O
function	O
of	O
SCL	B-PRGE
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self	O
-	O
renewal	O
events	O
in	O
erythroid	O
cells	O
.	O

Mutations	O
in	O
the	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
pituitary	O
-	O
specific	O
transcription	O
factor	O
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU	O
-	O
specific	O
domain	O
,	O
and	O
POU	O
-	O
homeodomain	O
,	O
respectively	O
.	O

Cell	O
cycle	O
-	O
dependent	O
initiation	O
and	O
lineage	O
-	O
dependent	O
abrogation	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O

The	O
programmed	O
activation	O
/	O
repression	O
of	O
transcription	O
factors	O
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O

The	O
DNA	O
-	O
binding	O
protein	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid	O
-	O
expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O

We	O
analyzed	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
"	O
pure	O
"	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte	O
-	O
macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
.	O

These	O
results	O
suggest	O
a	O
microenvironment	O
-	O
directed	O
,	O
two	O
-	O
step	O
model	O
for	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
differentiating	O
hematopoietic	O
progenitors	O
that	O
involves	O
(	O
i	O
)	O
cycle	O
-	O
dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage	O
-	O
dependent	O
maintenance	O
or	O
suppression	O
.	O

Hypothetically	O
,	O
on	O
/	O
off	O
switches	O
of	O
lineage	O
-	O
restricted	O
transactivators	O
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	O
progenitors	O
.	O

Activation	O
of	O
human	O
CD4	B-PRGE
T	O
lymphocytes	O
.	O

Interaction	O
of	O
fibronectin	B-PRGE
with	O
VLA	B-PRGE
-	I-PRGE
5	I-PRGE
receptor	I-PRGE
on	O
CD4	B-PRGE
cells	O
induces	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
.	O

Fibronectin	B-PRGE
synergized	O
with	O
anti	O
-	O
CD3	O
antibody	O
to	O
promote	O
CD4	B-PRGE
cell	O
proliferation	O
in	O
a	O
serum	O
-	O
free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-PRGE
cells	O
were	O
cultured	O
with	O
anti	O
-	O
CD3	O
alone	O
or	O
fibronectin	B-PRGE
alone	O
.	O

In	O
addition	O
,	O
anti	O
-	O
CD29	B-PRGE
(	O
integrin	B-PRGE
beta	I-PRGE
1	I-PRGE
)	O
as	O
well	O
as	O
anti	O
-	O
VLA	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
human	O
fibronectin	O
receptor	O
)	O
antibodies	O
blocked	O
this	O
CD4	B-PRGE
cell	O
activation	O
in	O
this	O
system	O
.	O

Although	O
anti	O
-	O
CD3	O
alone	O
or	O
fibronectin	B-PRGE
alone	O
cannot	O
induce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
message	O
by	O
CD4	B-PRGE
cells	O
,	O
the	O
combination	O
of	O
anti	O
-	O
CD3	O
plus	O
fibronectin	B-PRGE
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
message	O
by	O
CD4	O
cells	O
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-PRGE
-	O
VLA	B-PRGE
-	I-PRGE
5	I-PRGE
fibronectin	B-PRGE
receptor	O
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	O
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP	O
-	O
1	O
transcriptional	O
factor	O
.	O

Thus	O
the	O
VLA	B-PRGE
-	I-PRGE
5	I-PRGE
fibronectin	I-PRGE
receptor	I-PRGE
on	O
CD4	B-PRGE
cells	O
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	O
-	O
TCR	O
-	O
mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-PRGE
.	O

1	B-PRGE
,	I-PRGE
25	I-PRGE
-	I-PRGE
Dihydroxyvitamin	I-PRGE
D3	I-PRGE
receptor	I-PRGE
RNA	O
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
in	O
hematopoietic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O

Constitutive	O
expression	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG	O
-	O
1	O
(	O
myeloblasts	O
)	O
,	O
HL	O
-	O
60	O
(	O
promyelocytes	O
)	O
,	O
ML	O
-	O
3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP	O
-	O
1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S	O
-	O
LB1	O
(	O
HTLV	O
-	O
1	O
-	O
transfected	O
T	O
lymphocytes	O
)	O
.	O

Receptor	O
transcripts	O
were	O
4	O
.	O
6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptors	I-PRGE
.	O

Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid	O
/	O
myeloid	O
somatic	O
hybrid	O
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
in	O
B	O
lymphocytes	O
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

HL	O
-	O
60	O
cells	O
were	O
cultured	O
with	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	O
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O

Levels	O
of	O
occupied	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
protein	O
increased	O
in	O
these	O
HL	O
-	O
60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptors	I-PRGE
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady	O
-	O
state	O
levels	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL	O
-	O
60	O
toward	O
either	O
granulocytes	O
or	O
macrophages	O
.	O

Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
.	O

In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
increased	O
markedly	O
.	O

Half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Consistent	O
with	O
this	O
short	O
t1	O
/	O
2	O
,	O
accumulation	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
RNA	O
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptors	I-PRGE
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O

Charybdotoxin	O
-	O
sensitive	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	O
binding	O
.	O

Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
stimulated	O
K	O
+	O
channels	O
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
K	O
+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand	O
-	O
induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2	O
+	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
+	O
channel	O
is	O
not	O
associated	O
with	O
changes	O
in	O
cell	O
-	O
cycle	O
gene	O
activation	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
IL	O
-	O
2R	O
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand	O
-	O
dependent	O
opening	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
+	O
channels	O
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

Cloning	O
of	O
murine	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
T	O
cell	O
-	O
specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3	O
-	O
epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O

CD3	B-PRGE
-	I-PRGE
epsilon	I-PRGE
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte	O
-	O
specific	O
enhancer	O
of	O
CD3	B-PRGE
-	I-PRGE
epsilon	I-PRGE
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF	B-PRGE
-	I-PRGE
1	I-PRGE
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-	O
called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Murine	O
and	O
human	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
displayed	O
a	O
95	O
.	O
5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3	O
-	O
epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence	O
-	O
specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell	O
-	O
specific	O
element	O
in	O
the	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
TCR	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
enhancer	O
.	O

The	O
T	O
lineage	O
-	O
specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
CD3	B-PRGE
-	I-PRGE
epsilon	I-PRGE
enhancers	O
imply	O
an	O
important	O
role	O
for	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

HTLV	O
-	O
1	O
Tax	B-PRGE
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
T	O
-	O
cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP	O
-	O
1	O
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP	O
-	O
1	O
proteins	O
,	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
Fra	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
JunB	B-PRGE
,	O
and	O
JunD	B-PRGE
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	B-PRGE
.	O

By	O
using	O
the	O
human	O
T	O
-	O
cell	O
line	O
(	O
JPX	O
-	O
9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-PRGE
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
and	O
JunD	B-PRGE
was	O
also	O
transactivated	O
by	O
Tax1	B-PRGE
.	O

Moreover	O
,	O
Tax1	B-PRGE
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	O
finger	O
motifs	O
,	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Egr	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1	B-PRGE
-	O
inducible	O
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B-PRGE
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	O
TNF	B-PRGE
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-PRGE
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	O
stimulation	O
.	O

The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-PRGE
mRNA	O
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-PRGE
mRNA	O
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	O
TNF	B-PRGE
gene	O
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	B-PRGE
promoter	O
between	O
-	O
200	O
to	O
-	O
100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O

The	O
PMA	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
correlated	O
well	O
with	O
TNF	B-PRGE
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP	O
-	O
1	O
complex	O
(	O
junB	B-PRGE
and	O
junD	B-PRGE
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML	O
-	O
1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP	O
-	O
1	O
,	O
AP	O
-	O
2	O
,	O
and	O
NF	O
kappa	O
B	O
sequence	O
located	O
within	O
the	O
TNF	B-PRGE
promoter	O
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	O
binding	O
complexes	O
relative	O
to	O
the	O
resting	O
cells	O
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	O
TNF	B-PRGE
genes	O
are	O
discussed	O
.	O

The	O
rhombotin	O
family	O
of	O
cysteine	O
-	O
rich	O
LIM	O
-	O
domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T	O
-	O
cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T	O
-	O
cell	O
leukemia	O
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	B-PRGE
gene	O
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine	O
-	O
rich	O
regions	O
called	O
LIM	O
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc	O
-	O
binding	O
proteins	O
and	O
to	O
iron	O
-	O
sulfur	O
centers	O
of	O
ferredoxins	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-PRGE
gene	O
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T	O
-	O
cell	O
leukemia	O
-	O
specific	O
translocations	O
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Human	O
and	O
mouse	O
Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-PRGE
,	O
encode	O
two	O
tandem	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O

Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	B-PRGE
.	O

Since	O
the	O
Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T	O
-	O
cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B-PRGE
gene	O
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-PRGE
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	B-PRGE
)	O
and	O
11p13	O
(	O
Rhom	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T	O
-	O
cell	O
leukemia	O
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	O
gene	O
family	O
as	O
a	O
class	O
of	O
T	O
-	O
cell	O
oncogenes	O
with	O
duplicated	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O

Two	O
distinct	O
forms	O
of	O
active	O
transcription	O
factor	O
CREB	B-PRGE
(	O
cAMP	B-PRGE
response	I-PRGE
element	I-PRGE
binding	I-PRGE
protein	I-PRGE
)	O
.	O

Mammalian	O
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	O
factor	O
CREB	B-PRGE
(	O
cAMP	B-PRGE
response	I-PRGE
element	I-PRGE
binding	I-PRGE
protein	I-PRGE
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-PRGE
gene	O
transcript	O
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14	O
-	O
amino	O
acid	O
serine	O
-	O
rich	O
insertion	O
present	O
in	O
one	O
of	O
the	O
CREB	B-PRGE
isoforms	O
.	O

We	O
show	O
that	O
both	O
CREB	B-PRGE
isoforms	O
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	O
response	O
element	O
in	O
vitro	O
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-PRGE
proteins	O
bind	O
DNA	O
as	O
dimers	O
.	O

Both	O
proteins	O
impart	O
cAMP	O
-	O
regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-PRGE
.	O

The	O
presence	O
of	O
multiple	O
CREB	B-PRGE
isoforms	O
with	O
identical	O
DNA	O
-	O
binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	O
domain	O
raises	O
the	O
possibility	O
that	O
CREB	B-PRGE
proteins	O
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Constitutive	O
expression	O
of	O
HIV	O
-	O
1	O
tat	B-PRGE
protein	O
in	O
human	O
Jurkat	O
T	O
cells	O
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	O
cell	O
lines	O
that	O
constitutively	O
express	O
functional	O
human	O
immune	O
deficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
tat	B-PRGE
protein	O
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV	O
-	O
1	O
tat	B-PRGE
cDNA	O
,	O
is	O
described	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat	O
-	O
tat	B-PRGE
cell	O
lines	O
as	O
compared	O
with	O
control	O
cell	O
lines	O
was	O
observed	O
.	O

Effects	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
on	O
the	O
human	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
RWLeu	O
-	O
4	O
.	O

The	O
effects	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
,	O
RWLeu	O
-	O
4	O
,	O
were	O
investigated	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000	O
-	O
3000	O
sites	O
/	O
cell	O
,	O
and	O
half	O
-	O
maximal	O
binding	O
occurring	O
at	O
0	O
.	O
21	O
-	O
0	O
.	O
33	O
nM	O
.	O

Treatment	O
of	O
RWLeu	O
-	O
4	O
cells	O
with	O
VD3	O
induced	O
24R	O
-	O
hydroxylase	O
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O

Exposure	O
of	O
RWLeu	O
-	O
4	O
cells	O
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3	O
.	O
5	O
-	O
10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

Exposure	O
of	O
RWLeu	O
-	O
4	O
cells	O
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage	O
/	O
monocyte	O
type	O
cells	O
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O

Progressive	O
expression	O
of	O
cell	O
surface	O
maturation	O
-	O
specific	O
antigens	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
was	O
induced	O
by	O
treatment	O
of	O
RWLeu	O
-	O
4	O
cells	O
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c	B-PRGE
-	I-PRGE
myc	I-PRGE
RNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu	O
-	O
4	O
cells	O
,	O
increased	O
after	O
0	O
.	O
5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr	B-PRGE
-	I-PRGE
abl	I-PRGE
oncogene	I-PRGE
product	O
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor	O
-	O
effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Lymphocyte	O
cell	O
lines	O
from	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-PRGE
alpha	I-PRGE
,	I-PRGE
25	I-PRGE
-	I-PRGE
dihydroxyvitamin	I-PRGE
D3	I-PRGE
receptor	I-PRGE
.	O

Lymphocyte	O
cell	O
lines	O
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR	O
-	O
II	O
)	O
.	O

These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T	O
-	O
lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
S	O
-	O
LB1	O
)	O
from	O
a	O
normal	O
individual	O
.	O

The	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
of	O
S	O
-	O
LB1	O
was	O
comparable	O
to	O
the	O
well	O
-	O
characterized	O
chick	O
intestinal	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5	O
-	O
20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA	O
-	O
cellulose	O
.	O

Three	O
cell	O
lines	O
established	O
from	O
patients	O
with	O
VDDR	O
-	O
II	O
(	O
Rh	O
-	O
VDR	O
,	O
Sh	O
-	O
VDR	O
,	O
and	O
Ab	O
-	O
VDR	O
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	O
and	O
treatment	O
of	O
the	O
cultured	O
cells	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25	O
-	O
dihydroxy	O
-	O
vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
.	O

In	O
a	O
fourth	O
cell	O
line	O
,	O
A1	O
-	O
VDR	O
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
D3	I-PRGE
-	I-PRGE
24	I-PRGE
-	I-PRGE
hydroxylase	I-PRGE
activity	O
was	O
not	O
detectable	O
.	O

Induction	O
of	O
24	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	O
line	O
,	O
designated	O
Ro	O
-	O
VDR	O
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	O
cell	O
line	O
from	O
a	O
normal	O
donor	O
.	O

The	O
capacity	O
of	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro	O
-	O
VDR	O
.	O

In	O
all	O
cell	O
lines	O
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	O
was	O
detectable	O
,	O
the	O
receptor	O
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3	O
.	O
7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA	O
-	O
cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro	O
-	O
VDR	O
and	O
A1	O
-	O
VDR	O
cells	O
where	O
elution	O
from	O
DNA	O
-	O
cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
.	O

While	O
Ro	O
-	O
VDR	O
cells	O
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	O
from	O
A1	O
-	O
VDR	O
cells	O
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	O
coding	O
for	O
both	O
the	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
oncogene	O
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte	O
-	O
monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
(	I-PRGE
OH	I-PRGE
)	I-PRGE
2D3	I-PRGE
receptor	I-PRGE
status	O
of	O
these	O
cells	O
.	O

Use	O
of	O
these	O
cell	O
lines	O
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O

Heterogeneity	O
of	O
antigen	O
molecules	O
recognized	O
by	O
anti	O
-	O
tax1	B-PRGE
monoclonal	O
antibody	O
Lt	O
-	O
4	O
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
,	O
Lt	O
-	O
4	O
,	O
directed	O
against	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
trans	O
-	O
activator	O
(	O
tax1	B-PRGE
)	O
antigen	O
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-PRGE
and	O
related	O
antigens	O
in	O
a	O
variety	O
of	O
T	O
cell	O
lines	O
bearing	O
HTLV	O
-	O
I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV	O
-	O
I	O
)	O
and	O
HTLV	O
-	O
II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O

Lt	O
-	O
4	O
reacted	O
with	O
all	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	O
cell	O
lines	O
bearing	O
STLV	O
-	O
I	O
,	O
but	O
not	O
with	O
an	O
HTLV	O
-	O
II	O
-	O
bearing	O
cell	O
line	O
.	O

Lt	O
-	O
4	O
detected	O
40	O
kd	O
tax1	B-PRGE
antigen	O
molecules	O
in	O
most	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	O
kd	O
tax1	B-PRGE
antigen	O
.	O

In	O
the	O
STLV	O
-	O
I	O
-	O
bearing	O
T	O
cell	O
lines	O
,	O
tax1	B-PRGE
-	O
related	O
antigen	O
molecules	O
detected	O
by	O
Lt	O
-	O
4	O
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36	O
-	O
41	O
kd	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
BMRF1	B-PRGE
promoter	O
for	O
early	O
antigen	O
(	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
)	O
is	O
regulated	O
by	O
the	O
EBV	O
transactivators	O
,	O
BRLF1	B-PRGE
and	O
BZLF1	B-PRGE
,	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
early	O
antigen	O
diffuse	O
component	O
(	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
)	O
is	O
essential	O
for	O
Epstein	O
-	O
Barr	O
virus	O
DNA	O
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	O
(	O
BMRF1	B-PRGE
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate	O
-	O
early	O
viral	O
transactivators	O
,	O
BZLF1	B-PRGE
(	O
Z	O
)	O
and	O
BRLF1	B-PRGE
(	O
R	O
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	O
cells	O
and	O
epithelial	O
cells	O
.	O

In	O
lymphoid	O
cells	O
,	O
Z	O
or	O
R	O
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
promoter	O
activity	O
,	O
whereas	O
both	O
transactivators	O
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
epithelial	O
cells	O
,	O
the	O
Z	O
transactivator	O
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
promoter	O
;	O
the	O
effect	O
of	O
R	O
and	O
Z	O
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	O
alone	O
.	O

Deletional	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
promoter	O
demonstrated	O
that	O
in	O
epithelial	O
cells	O
the	O
potential	O
AP	O
-	O
1	O
binding	O
site	O
plays	O
an	O
essential	O
role	O
in	O
Z	O
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

In	O
lymphoid	O
cells	O
,	O
only	O
the	O
upstream	O
sequences	O
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z	O
/	O
R	O
combination	O
,	O
and	O
the	O
AP	O
-	O
1	O
site	O
is	O
dispensable	O
.	O

These	O
data	O
suggest	O
that	O
EA	B-PRGE
-	I-PRGE
D	I-PRGE
(	O
BMRF1	B-PRGE
)	O
promoter	O
regulation	O
by	O
Z	O
and	O
R	O
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

Decreased	O
concentration	O
of	O
1	B-PRGE
,	I-PRGE
25	I-PRGE
-	I-PRGE
dihydroxyvitamin	I-PRGE
D3	I-PRGE
receptors	I-PRGE
in	O
peripheral	O
mononuclear	O
cells	O
of	O
patients	O
with	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O

However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
cannot	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-PRGE
)	O
,	O
abnormalities	O
of	O
VDR	B-PRGE
have	O
been	O
postulated	O
in	O
XLH	O
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-PRGE
in	O
PHA	O
-	O
activated	O
peripheral	O
mononuclear	O
cells	O
from	O
10	O
XLH	O
patients	O
.	O

Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
1	O
fmol	O
/	O
mg	O
protein	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
0	O
)	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate	O
-	O
supplemented	O
patients	O
(	O
58	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
and	O
controls	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-PRGE
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
two	O
patients	O
,	O
VDR	B-PRGE
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-PRGE
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

Two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
glucocorticoid	O
receptor	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	O
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
.	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B-PRGE
with	O
one	O
-	O
site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A	O
-	O
ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	O
C7	O
cells	O
(	O
a	O
human	O
acute	O
lymphoblastic	O
T	O
-	O
cell	O
line	O
)	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20	O
-	O
to	O
50	O
-	O
fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
'	O
s	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	O
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	O
C7	O
cells	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	O
affinity	O
CVZ	O
binding	O
site	O
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B	O
-	O
cell	O
line	O
,	O
IM	O
-	O
9	O
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
'	O
s	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	O
'	O
s	O
binding	O
sites	O
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B-PRGE
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	O
-	O
resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
GR	B-PRGE
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

[	O
The	O
role	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
and	O
HLA	O
antigens	O
in	O
the	O
pathogenesis	O
of	O
Cushing	O
'	O
s	O
syndrome	O
]	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko	O
-	O
Cushing	O
'	O
s	O
syndrome	O
.	O

Incidence	O
of	O
HLA	O
antigens	O
was	O
determined	O
in	O
94	O
of	O
them	O
.	O

A	O
significant	O
rise	O
of	O
A10	B-PRGE
and	O
B27	B-PRGE
antigen	I-PRGE
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko	O
-	O
Cushing	O
'	O
s	O
syndrome	O
.	O

The	O
levels	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
lymphocytes	O
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

The	O
patients	O
carrying	O
B27	B-PRGE
antigen	I-PRGE
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O

Antigen	B-PRGE
B27	I-PRGE
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
blood	O
lymphocytes	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
human	O
peripheral	O
leukocytes	O
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B-PRGE
in	O
human	O
leukocytes	O
,	O
PMN	O
,	O
and	O
monocytes	O
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O

2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	O
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-PRGE
.	O

This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B-PRGE
may	O
be	O
of	O
functional	O
significance	O
.	O

3	O
)	O
In	O
Cushing	O
'	O
s	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-PRGE
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B-PRGE
from	O
that	O
of	O
cortisol	O
.	O

4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B-PRGE
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
"	O
circadian	O
pacemaker	O
"	O
of	O
GR	B-PRGE
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O

Progesterone	O
suppression	O
of	O
pregnancy	O
lymphocytes	O
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	O
lymphocytes	O
is	O
mediated	O
by	O
specific	O
progesterone	O
receptors	O
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B-PRGE
receptor	I-PRGE
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	O
factor	O
by	O
progesterone	O
-	O
treated	O
pregnancy	O
lymphocytes	O
.	O

RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	O
factor	O
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	O
receptors	O
and	O
glucocorticoid	O
binding	O
sites	O
are	O
not	O
involved	O
.	O

[	O
The	O
effect	O
of	O
24	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O

Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2	O
+	O
and	O
of	O
25	O
-	O
OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	B-PRGE
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T	O
-	O
and	O
0	O
-	O
lymphocytes	O
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	O
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O

Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O

Disruption	O
of	O
the	O
human	O
SCL	B-PRGE
locus	O
by	O
"	O
illegitimate	O
"	O
V	O
-	O
(	O
D	O
)	O
-	O
J	O
recombinase	O
activity	O
.	O

A	O
fusion	O
complementary	O
DNA	O
in	O
the	O
T	O
cell	O
line	O
HSB	O
-	O
2	O
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	O
transcription	O
factor	O
SCL	B-PRGE
.	O

The	O
fusion	O
cDNA	O
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	O
locus	O
,	O
SIL	O
(	O
SCL	B-PRGE
interrupting	O
locus	O
)	O
,	O
and	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
SCL	B-PRGE
.	O

Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-PRGE
5	O
'	O
regulatory	O
region	O
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V	O
-	O
(	O
D	O
)	O
-	O
J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	O
or	O
a	O
T	O
cell	O
receptor	O
.	O

Two	O
other	O
T	O
cell	O
lines	O
,	O
CEM	O
and	O
RPMI	O
8402	O
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Thus	O
,	O
in	O
lymphocytes	O
,	O
growth	O
-	O
affecting	O
genes	O
other	O
than	O
immune	O
receptors	O
risk	O
rearrangements	O
.	O

[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney	O
-	O
tonifying	O
and	O
qi	O
-	O
invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
]	O

The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GCR	B-PRGE
)	O
in	O
the	O
peripheral	O
lymphocytes	O
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O

In	O
animal	O
experiment	O
,	O
GCR	B-PRGE
of	O
spleen	O
lymphocytic	O
cell	O
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O

The	O
results	O
showed	O
that	O
GCR	B-PRGE
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
didn	O
'	O
t	O
change	O
with	O
aging	O
.	O

So	O
we	O
think	O
that	O
GCR	B-PRGE
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney	O
-	O
tonifying	O
and	O
Qi	O
-	O
invigorating	O
,	O
the	O
GCR	B-PRGE
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O

Thyroid	O
hormone	O
receptors	O
form	O
distinct	O
nuclear	O
protein	O
-	O
dependent	O
and	O
independent	O
complexes	O
with	O
a	O
thyroid	O
hormone	O
response	O
element	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	O
proteins	O
and	O
recombinant	O
thyroid	O
hormone	O
receptors	O
(	O
TRs	O
)	O
to	O
the	O
palindromic	O
thyroid	O
hormone	O
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	O
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein	O
-	O
DNA	O
complexes	O
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3	O
-	O
responsive	O
pituitary	O
(	O
GH3	O
)	O
cells	O
with	O
a	O
TREp	O
-	O
containing	O
DNA	O
fragment	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	O
binding	O
of	O
reticulocyte	O
lysate	O
-	O
synthesized	O
TRs	O
.	O

TR	B-PRGE
alpha	I-PRGE
1	I-PRGE
and	O
TR	B-PRGE
beta	I-PRGE
2	I-PRGE
each	O
formed	O
a	O
single	O
major	O
TR	O
:	O
TREp	O
complex	O
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-PRGE
beta	I-PRGE
1	I-PRGE
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	O
as	O
an	O
oligomer	O
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S	O
-	O
TR	B-PRGE
alpha	I-PRGE
1	I-PRGE
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	O
resulted	O
in	O
not	O
only	O
the	O
35S	O
-	O
TR	O
:	O
TREp	O
complex	O
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S	O
-	O
TR	B-PRGE
alpha	I-PRGE
1	I-PRGE
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	O
with	O
NE	O
from	O
COS	O
-	O
7	O
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	O
to	O
mediate	O
T3	O
-	O
responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	O
shifted	O
complex	O
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	O
:	O
TRE	O
complex	O
was	O
also	O
present	O
in	O
NE	O
from	O
T3	O
-	O
unresponsive	O
JEG	O
-	O
3	O
cells	O
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	O
bound	O
to	O
TREp	O
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Truncation	O
of	O
TR	B-PRGE
alpha	I-PRGE
1	I-PRGE
at	O
amino	O
acid	O
210	O
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl	O
-	O
terminus	O
of	O
the	O
TRs	O
is	O
essential	O
for	O
interaction	O
with	O
nuclear	O
proteins	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

[	O
Glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Quantitation	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
GCR	B-PRGE
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B-PRGE
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O

It	O
is	O
stated	O
that	O
GCR	B-PRGE
of	O
healthy	O
controls	O
and	O
GCS	O
-	O
untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol	O
-	O
dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B-PRGE
count	O
in	O
cortisol	O
-	O
dependent	O
BA	O
tends	O
to	O
rise	O
.	O

Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B-PRGE
level	O
estimated	O
by	O
3H	O
-	O
triamcinolone	O
acetonide	O
.	O

Megakaryocytic	O
and	O
erythrocytic	O
lineages	O
share	O
specific	O
transcription	O
factors	O
.	O

Erythroid	O
-	O
specific	O
genes	O
contain	O
binding	O
sites	O
for	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
(	O
also	O
called	O
GF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Eryf	B-PRGE
-	I-PRGE
1	I-PRGE
;	O
refs	O
1	O
-	O
3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA	O
-	O
binding	O
protein	O
of	O
the	O
erythrocytic	O
lineage	O
.	O

NF	B-PRGE
-	I-PRGE
E1	I-PRGE
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	O
lineage	O
.	O

A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	O
megakaryocytic	O
cell	O
line	O
and	O
purified	O
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	O
regions	O
of	O
two	O
megakaryocytic	O
-	O
specific	O
genes	O
.	O

The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	O
protein	O
;	O
also	O
,	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
messenger	O
RNA	O
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	O
and	O
erythroid	O
cell	O
lines	O
.	O

Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF	B-PRGE
-	I-PRGE
E1	I-PRGE
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic	O
-	O
specific	O
promoter	O
.	O

We	O
also	O
find	O
that	O
NF	O
-	O
E2	O
,	O
another	O
trans	O
-	O
acting	O
factor	O
of	O
the	O
erythrocytic	O
lineage	O
,	O
is	O
present	O
in	O
megakaryocytes	O
.	O

Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans	O
-	O
acting	O
factors	O
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	O
and	O
the	O
megakaryocytic	O
lineages	O
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	O
and	O
megakaryocytic	O
lineages	O
in	O
most	O
erythroblastic	O
and	O
megakaryoblastic	O
permanent	O
cell	O
lines	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	O
zipper	O
class	O
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-PRGE
DR	I-PRGE
alpha	I-PRGE
promoter	O
.	O

Several	O
mutants	O
derived	O
from	O
transformed	O
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O

The	O
failure	O
to	O
express	O
a	O
class	O
II	O
gene	O
in	O
at	O
least	O
one	O
such	O
mutant	O
line	O
has	O
been	O
mapped	O
to	O
the	O
MHC	O
class	O
II	O
X	O
box	O
,	O
a	O
conserved	O
transcriptional	O
element	O
in	O
the	O
promoter	O
region	O
.	O

A	O
complementary	O
DNA	O
encoding	O
a	O
DNA	O
-	O
binding	O
protein	O
(	O
human	B-PRGE
X	I-PRGE
box	I-PRGE
binding	I-PRGE
protein	I-PRGE
,	O
hXBP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
whose	O
target	O
is	O
the	O
human	O
DR	B-PRGE
alpha	I-PRGE
X	O
box	O
and	O
the	O
3	O
'	O
flanking	O
region	O
has	O
now	O
been	O
cloned	O
.	O

This	O
complementary	O
DNA	O
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
proto	O
-	O
oncogene	O
product	O
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	O
target	O
sequence	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
.	O

Mutation	O
of	O
the	O
hXBP	B-PRGE
-	I-PRGE
1	I-PRGE
DNA	O
target	O
sequence	O
decreased	O
DR	B-PRGE
alpha	I-PRGE
promoter	O
activity	O
in	O
vivo	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
acts	O
as	O
a	O
transcription	O
factor	O
in	O
B	O
cells	O
.	O

Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
transactivates	O
latent	O
membrane	O
protein	O
LMP1	B-PRGE
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
(	I-PRGE
EBV	I-PRGE
)	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
(	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
or	O
leader	O
protein	O
(	O
EBNA	B-PRGE
-	I-PRGE
LP	I-PRGE
)	O
affects	O
expression	O
of	O
the	O
EBV	O
latent	O
infection	O
membrane	O
protein	O
LMP1	B-PRGE
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
under	O
control	O
of	O
simian	O
virus	O
40	O
or	O
Moloney	O
murine	O
leukemia	O
virus	O
promoters	O
resulted	O
in	O
increased	O
LMP1	B-PRGE
expression	O
in	O
P3HR	O
-	O
1	O
-	O
infected	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
and	O
the	O
P3HR	O
-	O
1	O
or	O
Daudi	O
cell	O
line	O
.	O

(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA	B-PRGE
-	I-PRGE
LP	I-PRGE
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-PRGE
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
affect	O
LMP1	B-PRGE
expression	O
.	O

(	O
iii	O
)	O
LMP1	B-PRGE
expression	O
in	O
Daudi	O
and	O
P3HR	O
-	O
1	O
-	O
infected	O
cells	O
was	O
controlled	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
Daudi	O
cells	O
increased	O
LMP1	B-PRGE
mRNA	O
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	O
genes	O
were	O
required	O
for	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
transactivation	O
of	O
LMP1	B-PRGE
since	O
cotransfection	O
of	O
recombinant	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
vectors	O
and	O
genomic	O
LMP1	B-PRGE
DNA	O
fragments	O
enhanced	O
LMP1	B-PRGE
expression	O
in	O
the	O
EBV	O
-	O
negative	O
B	O
-	O
lymphoma	O
cell	O
lines	O
BJAB	O
,	O
Louckes	O
,	O
and	O
BL30	O
.	O

(	O
v	O
)	O
An	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
responsive	O
element	O
was	O
found	O
within	O
the	O
-	O
512	O
to	O
+	O
40	O
LMP1	B-PRGE
DNA	O
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
reporter	O
gene	O
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
vector	O
.	O

(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
transactivated	O
LMP1	B-PRGE
as	O
well	O
as	O
the	O
EBV	O
type	O
1	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-PRGE
,	O
whereas	O
a	O
transformation	O
-	O
competent	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
deletion	O
mutant	O
did	O
transactivate	O
LMP1	B-PRGE
.	O

LMP1	B-PRGE
is	O
a	O
potent	O
effector	O
of	O
B	O
-	O
lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
induce	O
cellular	O
CD23	B-PRGE
gene	O
expression	O
.	O

Thus	O
,	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
transactivation	O
of	O
LMP1	B-PRGE
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV	O
-	O
induced	O
growth	O
transformation	O
.	O

Protein	O
kinase	O
inhibitor	O
H	O
-	O
7	O
blocks	O
accumulation	O
of	O
unspliced	O
mRNA	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O

Rex	B-PRGE
,	O
the	O
post	O
-	O
transcriptional	O
regulator	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	O
viral	O
gag	B-PRGE
-	O
pol	B-PRGE
mRNA	O
.	O

Rex	B-PRGE
is	O
a	O
phosphoprotein	O
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-PRGE
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H	O
-	O
7	O
[	O
1	O
-	O
(	O
5	O
-	O
isoquinolinyl	O
-	O
sulfonyl	O
)	O
-	O
2	O
-	O
methylpiperazine	O
]	O
.	O

Treatment	O
of	O
an	O
HTLV	O
-	O
I	O
infected	O
human	O
T	O
-	O
cell	O
line	O
with	O
H	O
-	O
7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	O
gag	B-PRGE
-	O
pol	B-PRGE
mRNA	O
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-PRGE
protein	O
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-PRGE
.	O

In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H	O
-	O
7	O
used	O
.	O

Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B-PRGE
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV	O
-	O
I	O
.	O

Mononuclear	O
leukocyte	O
glucocorticoid	B-PRGE
receptor	I-PRGE
binding	O
characteristics	O
and	O
down	O
-	O
regulation	O
in	O
major	O
depression	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-	O
DEX	O
-	O
binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	O
receptor	O
affinity	O
(	O
1	O
/	O
Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	O
leukocytes	O
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	O
(	O
1	O
.	O
0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	O
GC	O
receptor	O
down	O
-	O
regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down	O
-	O
regulated	O
Bmax	O
after	O
DEX	O
.	O

By	O
paired	O
t	O
-	O
test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down	O
-	O
regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor	O
-	O
binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-	O
mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

The	O
56	O
-	O
59	O
-	O
kilodalton	O
protein	O
identified	O
in	O
untransformed	O
steroid	O
receptor	O
complexes	O
is	O
a	O
unique	O
protein	O
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70	B-PRGE
-	I-PRGE
and	O
90	B-PRGE
-	I-PRGE
kilodalton	I-PRGE
heat	I-PRGE
shock	I-PRGE
proteins	I-PRGE
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	O
,	O
untransformed	O
progestin	O
,	O
estrogen	O
,	O
androgen	O
,	O
and	O
glucocorticoid	O
receptor	O
complexes	O
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59	O
-	O
kDa	O
protein	O
[	O
Tai	O
,	O
P	O
.	O
K	O
.	O
,	O
Maeda	O
,	O
Y	O
.	O
,	O
Nakao	O
,	O
K	O
.	O
,	O
Wakim	O
,	O
N	O
.	O
G	O
.	O
,	O
Duhring	O
,	O
J	O
.	O
L	O
.	O
,	O
&	O
Faber	O
,	O
L	O
.	O
E	O
.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269	O
-	O
5275	O
]	O
.	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	O
antibody	O
KN	O
382	O
/	O
EC1	O
raised	O
against	O
the	O
rabbit	O
59	O
-	O
kDa	O
protein	O
reacts	O
with	O
9S	O
,	O
untransformed	O
glucocorticoid	O
receptor	O
complexes	O
in	O
cytosol	O
prepared	O
from	O
human	O
IM	O
-	O
9	O
lymphocytes	O
but	O
not	O
with	O
4S	O
salt	O
-	O
transformed	O
receptors	O
.	O

The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	O
antibody	O
is	O
a	O
56	O
-	O
kDa	O
protein	O
(	O
p56	O
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

There	O
are	O
at	O
least	O
six	O
isomorphs	O
of	O
p56	O
by	O
two	O
-	O
dimensional	O
gel	O
analysis	O
.	O

N	O
-	O
Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	O
is	O
a	O
unique	O
human	O
protein	O
.	O

When	O
p56	O
is	O
immunoadsorbed	O
from	O
IM	O
-	O
9	O
cell	O
cytosol	O
,	O
both	O
the	O
70	B-PRGE
-	I-PRGE
and	O
90	B-PRGE
-	I-PRGE
kDa	I-PRGE
heat	I-PRGE
shock	I-PRGE
proteins	I-PRGE
are	O
coadsorbed	O
in	O
an	O
immune	O
-	O
specific	O
manner	O
.	O

Neither	O
heat	O
shock	O
protein	O
reacts	O
directly	O
with	O
the	O
EC1	O
antibody	O
.	O

We	O
conclude	O
that	O
p56	O
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-PRGE
and	O
hsp90	B-PRGE
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	O
steroid	O
receptors	O
.	O

Detection	O
in	O
non	O
-	O
erythroid	O
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	O
cell	O
transcription	O
factor	O
EF1	B-PRGE
.	O

The	O
erythroid	O
transcription	O
factor	O
erythroid	B-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
EF1	B-PRGE
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
characteristics	O
of	O
EF1	B-PRGE
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
types	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-PRGE
-	O
like	O
activity	O
in	O
non	O
-	O
erythroid	O
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
II	O
rex	B-PRGE
gene	O
are	O
not	O
required	O
for	O
p24rex	B-PRGE
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-	O
acting	O
regulatory	O
genes	O
,	O
tax	B-PRGE
and	O
rex	B-PRGE
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	B-PRGE
gene	O
product	O
(	O
HTLV	O
-	O
I	O
p40tax	B-PRGE
and	O
HTLV	O
-	O
II	O
p37tax	B-PRGE
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	B-PRGE
gene	O
encodes	O
two	O
protein	O
products	O
,	O
p27rex	B-PRGE
/	O
p21rex	B-PRGE
and	O
p26rex	B-PRGE
/	O
p24rex	B-PRGE
in	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
,	O
respectively	O
.	O

Rex	B-PRGE
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	B-PRGE
/	O
pol	B-PRGE
and	O
singly	O
spliced	O
env	B-PRGE
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-PRGE
gene	O
is	O
critical	O
for	O
Rex	B-PRGE
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-PRGE
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV	O
-	O
I	O
rex	B-PRGE
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-PRGE
,	O
and	O
by	O
analogy	O
HTLV	O
-	O
II	O
p24rex	B-PRGE
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	B-PRGE
/	I-PRGE
rex	I-PRGE
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-PRGE
gene	O
on	O
Rex	B-PRGE
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B-PRGE
of	O
HTLV	O
-	O
II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-PRGE
gene	O
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

[	O
Glucocorticoid	B-PRGE
receptors	I-PRGE
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang	O
-	O
deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
GCR	B-PRGE
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang	O
-	O
deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	B-PRGE
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	B-PRGE
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/	O
-	O
413	O
and	O
4433	O
+	O
/	O
-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/	O
-	O
962	O
and	O
5622	O
+	O
/	O
-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

GCR	B-PRGE
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/	O
-	O
370	O
,	O
4986	O
+	O
/	O
-	O
419	O
and	O
4524	O
+	O
/	O
-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B-PRGE
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

The	O
murine	O
BCL6	B-PRGE
gene	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

The	O
chromosomal	O
translocation	O
involving	O
3q27	O
is	O
often	O
detected	O
in	O
human	O
B	O
-	O
cell	O
lymphomas	O
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large	O
-	O
cell	O
component	O
.	O

The	O
BCL6	B-PRGE
gene	O
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Here	O
we	O
cloned	O
the	O
murine	O
BCL6	B-PRGE
(	O
mBCL6	B-PRGE
)	O
cDNA	O
from	O
the	O
muscle	O
cDNA	O
library	O
using	O
the	O
human	O
BCL6	B-PRGE
(	O
hBCL6	B-PRGE
)	O
cDNA	O
as	O
a	O
probe	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	B-PRGE
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel	O
-	O
like	O
zinc	O
-	O
finger	O
motif	O
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B-PRGE
,	O
indicating	O
that	O
the	O
BCL6	B-PRGE
gene	O
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

Expression	O
of	O
the	O
mBCL6	B-PRGE
gene	O
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	O
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2	O
+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

These	O
results	O
suggest	O
that	O
BCL6	B-PRGE
plays	O
a	O
role	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

Bik	B-PRGE
,	O
a	O
novel	O
death	O
-	O
inducing	O
protein	O
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl	O
-	O
2	O
family	O
proteins	O
and	O
interacts	O
with	O
viral	O
and	O
cellular	O
survival	O
-	O
promoting	O
proteins	O
.	O

The	O
survival	O
-	O
promoting	O
activity	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	O
proteins	O
.	O

We	O
have	O
identified	O
a	O
novel	O
cellular	O
protein	O
,	O
Bik	B-PRGE
,	O
that	O
interacts	O
with	O
the	O
cellular	O
survival	O
-	O
promoting	O
proteins	O
,	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
,	O
as	O
well	O
as	O
the	O
viral	O
survival	O
-	O
promoting	O
proteins	O
,	O
Epstein	O
Barr	O
virus	O
-	O
BHRF1	B-PRGE
and	O
adenovirus	O
E1B	B-PRGE
-	I-PRGE
19	I-PRGE
kDa	I-PRGE
.	O

In	O
transient	O
transfection	O
assays	O
,	O
Bik	B-PRGE
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death	O
-	O
promoting	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
,	O
Bax	B-PRGE
and	O
Bak	B-PRGE
.	O

This	O
death	O
-	O
promoting	O
activity	O
of	O
Bik	B-PRGE
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
,	O
EBV	B-PRGE
-	I-PRGE
BHRF1	I-PRGE
and	O
E1B	O
-	O
19	O
kDa	O
proteins	O
suggesting	O
that	O
Bik	B-PRGE
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	O
and	O
viral	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

While	O
Bik	B-PRGE
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B-PRGE
and	O
BH2	B-PRGE
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
,	O
it	O
does	O
share	O
a	O
9	O
amino	O
acid	O
domain	O
(	O
BH3	B-PRGE
)	O
with	O
Bax	B-PRGE
and	O
Bak	B-PRGE
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death	O
-	O
promoting	O
activity	O
of	O
these	O
proteins	O
.	O

Staphylococcal	O
enterotoxins	O
modulate	O
interleukin	O
2	O
receptor	O
expression	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-PRGE
protein	I-PRGE
-	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
3	I-PRGE
(	O
Jak3	B-PRGE
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
proteins	O
)	O
.	O

Staphylococcal	O
enterotoxins	O
(	O
SE	O
)	O
stimulate	O
T	O
cells	O
expressing	O
the	O
appropriate	O
variable	O
region	O
beta	O
chain	O
of	O
(	O
V	O
beta	O
)	O
T	O
-	O
cell	O
receptors	O
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	O
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	O
cells	O
.	O

In	O
addition	O
,	O
SE	O
can	O
induce	O
an	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here	O
,	O
we	O
show	O
that	O
SE	O
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2R	I-PRGE
)	I-PRGE
beta	I-PRGE
and	O
gamma	B-PRGE
chains	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
gamma	I-PRGE
)	O
in	O
human	O
antigen	O
-	O
specific	O
CD4	B-PRGE
+	O
T	O
-	O
cell	O
lines	O
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-PRGE
and	O
SEB	B-PRGE
,	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
was	O
down	O
-	O
regulated	O
,	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
gamma	I-PRGE
was	O
slightly	O
up	O
-	O
regulated	O
,	O
while	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
remained	O
largely	O
unaffected	O
.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL	O
-	O
2Rs	O
were	O
accompanied	O
by	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-PRGE
protein	I-PRGE
-	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
3	I-PRGE
(	O
Jak3	B-PRGE
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
called	O
Stat3	B-PRGE
and	O
Stat5	B-PRGE
.	O

In	O
parallel	O
experiments	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	O
,	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-PRGE
alpha	I-PRGE
and	O
IL2R	B-PRGE
gamma	I-PRGE
was	O
further	O
up	O
-	O
regulated	O
,	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-PRGE
and	O
Stat	O
proteins	O
was	O
partly	O
normalized	O
.	O

Yet	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-PRGE
/	O
Stat	O
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	O
stimulation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	O
can	O
modulate	O
IL	O
-	O
2R	O
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak	O
/	O
Stat	O
pathway	O
in	O
CD4	B-PRGE
+	O
T	O
-	O
cell	O
lines	O
.	O

Mutation	O
of	O
Jak3	B-PRGE
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B-PRGE
in	O
lymphoid	O
development	O
.	O

Males	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-PRGE
receptor	I-PRGE
gamma	I-PRGE
chain	I-PRGE
(	O
gamma	B-PRGE
c	I-PRGE
)	O
gene	O
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
.	O

The	O
Janus	O
family	O
tyrosine	O
kinase	O
Jak3	B-PRGE
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-PRGE
c	I-PRGE
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B-PRGE
might	O
cause	O
an	O
XSCID	O
-	O
like	O
phenotype	O
.	O

A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O

An	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
transformed	O
cell	O
line	O
derived	O
from	O
her	O
lymphocytes	O
had	O
normal	O
gamma	B-PRGE
c	I-PRGE
expression	O
but	O
lacked	O
Jak3	B-PRGE
protein	O
and	O
had	O
greatly	O
diminished	O
Jak3	B-PRGE
messenger	O
RNA	O
.	O

Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-PRGE
JH4	O
domain	O
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B-PRGE
JH2	O
domain	O
.	O

The	O
lack	O
of	O
Jak3	B-PRGE
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
to	O
activate	O
Stat6	B-PRGE
in	O
the	O
EBV	O
-	O
transformed	O
cell	O
line	O
from	O
the	O
patient	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-PRGE
c	I-PRGE
are	O
dependent	O
on	O
Jak3	B-PRGE
and	O
that	O
Jak3	B-PRGE
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	O
glucocorticoid	B-PRGE
receptor	I-PRGE
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95	O
-	O
8	O
lymphoid	O
cells	O
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95	O
-	O
8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	O
lymphoid	O
cell	O
line	O
(	O
HL	O
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	O
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150	O
-	O
200	O
kd	O
fractions	O
after	O
Sephacryl	O
G	O
-	O
200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B-PRGE
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95	O
-	O
8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95	O
-	O
8	O
cells	O
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	O
receptor	O
.	O

Expression	O
of	O
the	O
chemokine	O
receptor	O
BLR2	B-PRGE
/	O
EBI1	B-PRGE
is	O
specifically	O
transactivated	O
by	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	O
receptors	O
that	O
are	O
related	O
to	O
Burkitt	B-PRGE
'	I-PRGE
s	I-PRGE
lymphoma	I-PRGE
receptor	I-PRGE
1	I-PRGE
(	O
BLR1	B-PRGE
)	O
and	O
are	O
expressed	O
in	O
activated	O
lymphocytes	O
we	O
used	O
RT	O
-	O
PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	O
transmembrane	O
receptor	O
termed	O
BLR2	B-PRGE
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G	O
-	O
protein	O
coupled	O
chemokine	O
receptors	O
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	O
EBI1	B-PRGE
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-PRGE
mRNA	O
could	O
be	O
highly	O
stimulated	O
in	O
mitogen	O
-	O
and	O
anti	O
-	O
CD3	O
-	O
treated	O
peripheral	O
blood	O
lymphocytes	O
.	O

BLR2	B-PRGE
-	O
specific	O
mRNA	O
could	O
be	O
detected	O
in	O
all	O
Epstein	O
-	O
Barr	O
virus	O
positive	O
B	O
cell	O
lines	O
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-PRGE
gene	O
could	O
be	O
specifically	O
induced	O
in	O
Epstein	O
-	O
Barr	O
virus	O
negative	O
BL	O
41	O
cells	O
via	O
estrogen	O
-	O
mediated	O
activation	O
of	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
nuclear	I-PRGE
antigen	I-PRGE
2	I-PRGE
,	O
a	O
key	O
regulator	O
of	O
viral	O
and	O
cellular	O
genes	O
in	O
immortalized	O
B	O
cells	O
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B-PRGE
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	O
lymphocytes	O
and	O
in	O
viral	O
pathogenesis	O
.	O

Interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
can	O
induce	O
the	O
activation	O
of	O
Jak	B-PRGE
1	I-PRGE
,	O
Jak	B-PRGE
3	I-PRGE
and	O
STAT	B-PRGE
5	I-PRGE
proteins	O
in	O
murine	O
T	O
cells	O
.	O

The	O
activation	O
of	O
Janus	O
protein	O
tyrosine	O
kinases	O
(	O
Jak	O
)	O
and	O
STAT	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
proteins	O
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	O
.	O

IL	B-PRGE
-	I-PRGE
7	I-PRGE
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-PRGE
1	I-PRGE
and	O
Jak	B-PRGE
3	I-PRGE
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	O
proteins	O
.	O

The	O
STAT	O
proteins	O
utilized	O
by	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
were	O
identical	O
to	O
those	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	O
5	O
isoforms	O
.	O

Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B-PRGE
1	I-PRGE
and	O
3	B-PRGE
,	O
and	O
STAT	B-PRGE
5	I-PRGE
activity	O
strongly	O
correlated	O
with	O
the	O
growth	O
-	O
promoting	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
-	O
induced	O
proliferation	O
.	O

Lymphocyte	O
glucocorticoid	B-PRGE
receptor	I-PRGE
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic	O
-	O
hippocampal	O
glucocorticoid	B-PRGE
type	I-PRGE
II	I-PRGE
receptor	I-PRGE
(	O
GCII	B-PRGE
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	O
GCII	B-PRGE
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

In	O
an	O
open	O
-	O
label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM	O
-	O
III	O
-	O
R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	O
GCII	B-PRGE
sites	O
per	O
cell	O
(	O
sites	O
/	O
cell	O
)	O
values	O
of	O
793	O
+	O
/	O
-	O
106	O
versus	O
2	O
,	O
563	O
+	O
/	O
-	O
499	O
(	O
+	O
/	O
-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3	O
.	O
5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.	O
001	O
)	O
.	O

GCII	B-PRGE
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3	O
.	O
9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.	O
001	O
)	O
.	O

GCII	B-PRGE
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

Only	O
SRI	O
responders	O
showed	O
GCII	B-PRGE
sites	O
/	O
cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2	O
.	O
1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.	O
05	O
)	O
.	O

Oncogenicity	O
of	O
human	O
papillomavirus	O
-	O
or	O
adenovirus	O
-	O
transformed	O
cells	O
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	O
killer	O
cells	O
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-PRGE
and	O
E7	B-PRGE
proteins	O
to	O
target	O
cells	O
for	O
rejection	O
by	O
the	O
host	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
response	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-PRGE
-	O
and	O
E7	B-PRGE
-	O
expressing	O
human	O
fibroblastic	O
or	O
keratinocyte	O
-	O
derived	O
human	O
cells	O
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	O
or	O
interferon	O
(	O
IFN	O
)	O
-	O
activated	O
NK	O
cells	O
.	O

Cells	O
expressing	O
the	O
E1A	B-PRGE
oncoprotein	O
were	O
selectively	O
killed	O
by	O
unstimulated	O
NK	O
cells	O
,	O
while	O
the	O
same	O
parental	O
cells	O
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
or	O
HPV	O
-	O
18	O
E7	B-PRGE
oncoprotein	O
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

The	O
ability	O
of	O
IFN	O
-	O
activated	O
NK	O
cells	O
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	O
'	O
s	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i	O
.	O
e	O
.	O
,	O
non	O
-	O
viral	O
oncogene	O
-	O
expressing	O
)	O
but	O
not	O
virally	O
transformed	O
cells	O
.	O

E1A	B-PRGE
blocked	O
IFN	O
'	O
s	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O

The	O
extent	O
of	O
IFN	O
-	O
induced	O
NK	O
cell	O
killing	O
of	O
E1A	B-PRGE
-	O
expressing	O
cells	O
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B-PRGE
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B-PRGE
to	O
block	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
in	O
target	O
cells	O
.	O

In	O
contrast	O
,	O
E7	B-PRGE
blocked	O
neither	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
nor	O
IFN	O
'	O
s	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O

In	O
conclusion	O
,	O
E1A	B-PRGE
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	O
cell	O
response	O
,	O
whereas	O
the	O
E7	B-PRGE
oncoprotein	O
lacks	O
this	O
activity	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	O
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	O
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	O
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	O
activate	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factors	O
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	O
cell	O
priming	O
cultures	O
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	O
production	O
and	O
STAT	O
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-PRGE
(	I-PRGE
IFN	I-PRGE
)	I-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
but	O
not	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
4	I-PRGE
,	O
production	O
by	O
effector	O
cells	O
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
inhibition	O
of	O
IL	O
-	O
12	O
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL	O
-	O
12	O
.	O

SFs	O
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	O
factor	O
Stat1	B-PRGE
,	O
but	O
not	O
Stat3	B-PRGE
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B-PRGE
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	O
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
.	O

Active	O
Stat3	B-PRGE
,	O
but	O
not	O
Stat1	B-PRGE
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	B-PRGE
and	O
Stat3	B-PRGE
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

Anti	O
-	O
immunoglobulin	O
M	O
activates	O
nuclear	O
calcium	B-PRGE
/	I-PRGE
calmodulin	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
kinase	I-PRGE
II	I-PRGE
in	O
human	O
B	O
lymphocytes	O
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	O
protein	O
,	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
is	O
phosphorylated	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	O
lymphocytes	O
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
(	O
CaM	O
kinase	O
)	O
might	O
phosphorylate	O
the	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

The	O
dephosphorylated	O
form	O
of	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	O
kinase	O
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	O
B	O
cell	O
lines	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
.	O

Activity	O
of	O
the	O
CaM	O
kinases	O
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	O
kinase	O
family	O
,	O
KN	O
-	O
62	O
.	O

Stimulation	O
of	O
cells	O
with	O
anti	O
-	O
IgM	O
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	O
kinase	O
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN	O
-	O
62	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	O
specific	O
for	O
CaM	B-PRGE
kinase	I-PRGE
II	I-PRGE
.	O

Two	O
-	O
dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti	O
-	O
IgM	O
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O

Incubation	O
of	O
isolated	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
with	O
purified	O
CaM	B-PRGE
kinase	I-PRGE
II	I-PRGE
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti	O
-	O
IgM	O
or	O
ionomycin	O
.	O

These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	O
receptor	O
on	O
B	O
lymphocytes	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	O
CaM	B-PRGE
kinase	I-PRGE
II	I-PRGE
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA	O
-	O
binding	O
proteins	O
.	O

rel	B-PRGE
Is	O
rapidly	O
tyrosine	O
-	O
phosphorylated	O
following	O
granulocyte	B-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
treatment	O
of	O
human	O
neutrophils	O
.	O

Stimulation	O
of	O
neutrophils	O
with	O
granulocyte	B-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O

The	O
effects	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	O
receptors	O
.	O

G	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptors	O
lack	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	O
show	O
that	O
the	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O

Using	O
monospecific	O
antibodies	O
,	O
the	O
80	O
-	O
kDa	O
tyrosine	O
-	O
phosphorylated	O
protein	O
has	O
been	O
shown	O
to	O
be	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
a	O
proto	O
-	O
oncogene	O
belonging	O
to	O
a	O
family	O
of	O
transcriptional	O
regulators	O
which	O
include	O
NF	O
-	O
kB	O
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
was	O
unique	O
to	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
that	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
which	O
also	O
stimulates	O
neutrophils	O
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
.	O

The	O
consequences	O
of	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine	O
-	O
phosphorylated	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
which	O
binds	O
to	O
DNA	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	O
following	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	O
kinase	O
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-PRGE
-	I-PRGE
rel	I-PRGE
.	O

Thus	O
,	O
the	O
tyrosine	O
kinase	O
activated	O
by	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	O
regulator	O
.	O

Retinoic	O
acid	O
-	O
induced	O
expression	O
of	O
CD38	B-PRGE
antigen	O
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

CD38	B-PRGE
is	O
a	O
leukocyte	O
differentiation	O
antigen	O
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T	O
-	O
and	O
B	O
-	O
lymphocytes	O
.	O

In	O
myeloid	O
cells	O
,	O
CD38	B-PRGE
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-PRGE
.	O

Recently	O
we	O
reported	O
that	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-PRGE
expression	O
in	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O

Here	O
we	O
report	O
that	O
ATRA	O
-	O
induced	O
expression	O
of	O
CD38	B-PRGE
antigen	O
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B-PRGE
acid	I-PRGE
-	I-PRGE
alpha	I-PRGE
receptor	I-PRGE
(	O
RAR	B-PRGE
alpha	I-PRGE
)	O
.	O

ATRA	O
failed	O
to	O
induce	O
CD38	B-PRGE
expression	O
in	O
a	O
mutant	O
subclone	O
of	O
the	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cell	O
line	O
(	O
designated	O
HL	O
-	O
60R	O
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA	O
-	O
induced	O
granulocytic	O
differentiation	O
.	O

Retroviral	O
vector	O
-	O
mediated	O
transduction	O
of	O
RA	O
receptor	O
(	O
RAR	B-PRGE
alpha	I-PRGE
)	O
into	O
this	O
HL	O
-	O
60R	O
subclone	O
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B-PRGE
.	O

In	O
contrast	O
,	O
CD38	B-PRGE
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL	O
-	O
60R	O
cells	O
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-PRGE
beta	I-PRGE
,	O
RAR	B-PRGE
gamma	I-PRGE
,	O
or	O
RXR	B-PRGE
alpha	I-PRGE
receptor	O
.	O

Induction	O
of	O
CD38	B-PRGE
in	O
acute	O
promyelocytic	O
and	O
acute	O
myeloblastic	O
leukemia	O
cells	O
was	O
independent	O
of	O
ATRA	O
-	O
induced	O
cytodifferentiation	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-PRGE
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
,	O
but	O
not	O
on	O
normal	O
circulating	O
granulocytes	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-PRGE
is	O
ATRA	O
inducible	O
in	O
myeloid	O
leukemia	O
cells	O
and	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-PRGE
alpha	I-PRGE
in	O
HL	O
-	O
60	O
cells	O
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-PRGE
alpha	I-PRGE
in	O
CD38	B-PRGE
expression	O
in	O
other	O
hematopoietic	O
cells	O
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Several	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cells	O
by	O
treatment	O
with	O
protein	O
kinase	O
C	O
-	O
activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O

In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP	O
-	O
1	O
myeloid	O
leukemia	O
cell	O
line	O
acquire	O
macrophage	O
-	O
like	O
characteristics	O
after	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O

To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O

Both	O
RA	O
and	O
PMA	O
effectively	O
down	O
-	O
regulated	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
expression	O
,	O
while	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
decreased	O
only	O
after	O
PMA	O
treatment	O
.	O

Expression	O
of	O
the	O
beta	O
2	O
-	O
integrin	O
genes	O
,	O
CD11a	B-PRGE
and	O
CD11b	B-PRGE
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

Their	O
effects	O
on	O
the	O
src	O
-	O
family	O
tyrosine	O
kinase	O
genes	O
were	O
different	O
:	O
hck	B-PRGE
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	B-PRGE
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O

RA	O
also	O
enhanced	O
lyn	B-PRGE
mRNA	O
production	O
rapidly	O
in	O
HL	O
-	O
60	O
,	O
indicating	O
that	O
the	O
activation	O
of	O
lyn	B-PRGE
gene	O
expression	O
is	O
common	O
in	O
monocytic	O
and	O
granulocytic	O
maturation	O
of	O
myeloid	O
leukemia	O
cells	O
.	O

To	O
examine	O
whether	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
is	O
involved	O
in	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
,	O
THP	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
-	O
reporter	O
gene	O
containing	O
5	O
copies	O
of	O
the	O
AP	O
-	O
1	O
binding	O
sites	O
.	O

In	O
contrast	O
to	O
PMA	O
,	O
RA	O
did	O
not	O
induce	O
any	O
CAT	B-PRGE
activity	O
in	O
these	O
cells	O
,	O
thus	O
suggesting	O
that	O
the	O
RA	O
-	O
induced	O
changes	O
in	O
the	O
expression	O
of	O
those	O
genes	O
described	O
above	O
were	O
not	O
dependent	O
on	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	O
matrix	O
protein	O
tenascin	O
.	O

Tenascin	O
(	O
TN	O
)	O
is	O
an	O
extracellular	O
matrix	O
protein	O
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	O
inhibits	O
proliferation	O
of	O
human	O
T	O
cells	O
in	O
response	O
to	O
alpha	O
CD3	O
Ab	O
co	O
-	O
immobilized	O
with	O
the	O
extracellular	O
matrix	O
protein	O
fibronectin	B-PRGE
(	O
FN	B-PRGE
)	O
.	O

TN	O
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	O
CD3	O
/	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
by	O
phorbol	O
ester	O
/	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL	O
-	O
2R	O
.	O

The	O
presence	O
of	O
TN	O
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	O
CD3	O
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF	O
-	O
AT1	O
transcription	O
factor	O
complexes	O
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	O
as	O
a	O
natural	O
antagonist	O
to	O
FN	B-PRGE
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	O
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O

HLA	O
-	O
DR	O
-	O
,	O
CD33	B-PRGE
+	O
,	O
CD56	B-PRGE
+	O
,	O
CD16	B-PRGE
-	O
myeloid	O
/	O
natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French	O
-	O
American	O
-	O
British	O
acute	O
myeloid	O
leukemia	O
-	O
M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	B-PRGE
+	O
,	O
CD56	B-PRGE
+	O
,	O
CD11a	B-PRGE
+	O
,	O
CD13lo	B-PRGE
,	O
CD15lo	B-PRGE
,	O
CD34	B-PRGE
+	O
/	O
-	O
,	O
HLA	O
-	O
DR	O
-	O
,	O
CD16	B-PRGE
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	O
(	O
CD33	B-PRGE
,	O
CD13	B-PRGE
,	O
CD15	B-PRGE
)	O
and	O
NK	O
cell	O
-	O
associated	O
(	O
CD56	B-PRGE
)	O
antigens	O
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B-PRGE
(	O
neural	O
cell	O
adhesion	O
molecule	O
)	O
in	O
leukemic	O
blasts	O
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B-PRGE
,	O
no	O
case	O
expressed	O
CD2	B-PRGE
,	O
CD3	O
,	O
or	O
CD8	B-PRGE
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	B-PRGE
beta	I-PRGE
,	O
gamma	B-PRGE
,	O
delta	B-PRGE
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-PRGE
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	O
variant	O
(	O
FAB	O
AML	O
-	O
M3v	O
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic	B-PRGE
/	I-PRGE
retinoic	I-PRGE
acid	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
RAR	B-PRGE
alpha	I-PRGE
)	O
fusion	O
transcript	O
in	O
RT	O
-	O
PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	O
17q	O
:	O
1	O
with	O
del	O
(	O
17	O
)	O
(	O
q25	O
)	O
and	O
the	O
other	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q23	O
;	O
q21	O
)	O
and	O
the	O
promyelocytic	B-PRGE
leukemia	I-PRGE
zinc	I-PRGE
finger	I-PRGE
/	O
RAR	B-PRGE
alpha	I-PRGE
fusion	O
transcript	O
.	O

All	O
cases	O
tested	O
(	O
6	O
/	O
20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33	B-PRGE
+	O
,	O
CD56	B-PRGE
+	O
,	O
CD16	B-PRGE
-	O
acute	O
leukemias	O
and	O
normal	O
CD56	B-PRGE
+	O
,	O
CD16	B-PRGE
-	O
NK	O
precursor	O
cells	O
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	O
CD56	B-PRGE
+	O
,	O
CD33	B-PRGE
+	O
,	O
CD16	B-PRGE
-	O
counterpart	O
cell	O
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	O
and	O
NK	O
cell	O
lineages	O
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid	O
/	O
NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA	O
-	O
nonresponsive	O
cases	O
from	O
ATRA	O
-	O
responsive	O
true	O
APL	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	O
myeloid	O
cell	O
lines	O
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	O
myeloid	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
KG	O
-	O
1	O
.	O

The	O
glutathione	O
-	O
depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	B-PRGE
and	O
CD34	B-PRGE
genes	O
.	O

Moreover	O
,	O
DEM	O
abolished	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
induced	O
activation	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
suggesting	O
that	O
inhibition	O
of	O
differentiation	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
redox	O
modifications	O
of	O
these	O
proteins	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B-PRGE
in	O
human	O
T	O
lymphocytes	O
.	O

An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL	O
-	O
2R	O
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-PRGE
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
of	O
proteins	O
.	O

In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
ligation	O
,	O
whereas	O
tyrosine	O
-	O
phosphorylated	O
stat1	O
proteins	O
(	O
91	O
and	O
84	O
kDa	O
proteins	O
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
treatment	O
of	O
HeLa	O
cells	O
.	O

Apart	O
from	O
stat3	B-PRGE
,	O
another	O
cytoplasmic	O
protein	O
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B-PRGE
or	O
stat1	O
mAb	O
or	O
antisera	O
.	O

Since	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induced	O
nuclear	O
translocation	O
of	O
the	O
84	O
kDa	O
protein	O
and	O
stat3	B-PRGE
followed	O
identical	O
kinetics	O
,	O
p84	O
is	O
a	O
candidate	O
for	O
a	O
new	O
,	O
yet	O
undefined	O
,	O
member	O
of	O
the	O
STAT	O
family	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-PRGE
and	O
an	O
as	O
yet	O
undefined	O
84	O
-	O
kDa	O
protein	O
in	O
antigen	O
-	O
specific	O
human	O
T	O
cell	O
lines	O
.	O

Induction	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
by	O
Tax1	B-PRGE
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
and	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
LFA	O
-	O
1	O
in	O
adult	O
-	O
T	O
-	O
cell	O
-	O
leukemia	O
cell	O
lines	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV	O
-	O
I	O
TaxI	B-PRGE
in	O
the	O
up	O
-	O
regulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
human	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
and	O
the	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
LFA	O
-	O
I	O
in	O
ATL	O
-	O
derived	O
cell	O
lines	O
.	O

Induction	O
of	O
TaxI	B-PRGE
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
carrying	O
the	O
TaxI	B-PRGE
gene	O
under	O
the	O
metallothionein	O
promoter	O
led	O
to	O
increases	O
in	O
mRNA	O
and	O
surface	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

The	O
response	O
of	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
to	O
TaxI	B-PRGE
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O

Transactivation	O
of	O
the	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
promoter	O
by	O
TaxI	B-PRGE
was	O
further	O
shown	O
by	O
co	O
-	O
transfection	O
of	O
a	O
CAT	B-PRGE
reporter	O
construct	O
with	O
the	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
promoter	O
and	O
a	O
plasmid	O
expressing	O
TaxI	B-PRGE
.	O

The	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
or	O
LFA	O
-	O
I	O
in	O
4	O
ATL	O
cell	O
lines	O
was	O
next	O
examined	O
.	O

ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
mRNA	O
was	O
quite	O
low	O
in	O
MT	O
-	O
I	O
,	O
but	O
no	O
genomic	O
changes	O
were	O
found	O
.	O

The	O
CAT	B-PRGE
reporter	O
with	O
the	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
promoter	O
was	O
inactive	O
in	O
MT	O
-	O
I	O
.	O

Finally	O
,	O
combined	O
treatment	O
of	O
MT	O
-	O
I	O
with	O
5	O
-	O
azacytidine	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induced	O
re	O
-	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

Collectively	O
,	O
(	O
a	O
)	O
transcriptional	O
factor	O
(	O
s	O
)	O
necessary	O
for	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
I	I-PRGE
gene	O
may	O
be	O
repressed	O
in	O
MT	O
-	O
I	O
through	O
DNA	O
methylation	O
.	O

Three	O
other	O
ATL	O
cell	O
lines	O
(	O
TL	O
-	O
OmI	O
,	O
H582	O
,	O
HuT102	O
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	O
for	O
the	O
LFA	B-PRGE
-	I-PRGE
I	I-PRGE
beta	I-PRGE
chain	I-PRGE
(	O
CD18	B-PRGE
)	O
.	O

H582	O
and	O
HuT102	O
were	O
also	O
negative	O
for	O
the	O
LFA	B-PRGE
-	I-PRGE
I	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
CDIIa	B-PRGE
)	O
mRNA	O
.	O

No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	B-PRGE
reporter	O
gene	O
with	O
the	O
CD18	B-PRGE
promoter	O
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	O
factor	O
(	O
s	O
)	O
necessary	O
for	O
CD18	B-PRGE
expression	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	O
prostatic	O
cancer	O
LNCaP	O
cells	O
as	O
induced	O
by	O
T	O
lymphocyte	O
-	O
conditioned	O
medium	O
.	O

Human	O
prostatic	O
epithelial	O
cells	O
from	O
an	O
androgen	O
-	O
dependent	O
LNCaP	O
cell	O
line	O
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B-PRGE
(	O
PHA	B-PRGE
)	O
-	O
stimulated	O
lymphocytes	O
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth	O
-	O
modulating	O
effect	O
was	O
dose	O
-	O
dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	O
receptor	O
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate	B-PRGE
-	I-PRGE
specific	I-PRGE
antigen	I-PRGE
(	O
PSA	B-PRGE
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	O
cell	O
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	O
and	O
intracellular	O
proteins	O
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	B-PRGE
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	O
8	O
and	O
18	O
,	O
associated	O
with	O
differentiated	O
cell	O
types	O
of	O
prostate	O
epithelia	O
,	O
and	O
neuron	B-PRGE
-	I-PRGE
specific	I-PRGE
enolase	I-PRGE
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	O
cells	O
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	O
cells	O
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	O
modulator	O
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	O
,	O
TNF	O
,	O
and	O
some	O
commonly	O
known	O
lymphokines	O
.	O

The	O
interaction	O
between	O
lymphoid	O
and	O
prostatic	O
cells	O
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

The	O
Ah	B-PRGE
receptor	I-PRGE
recognizes	O
DNA	O
binding	O
sites	O
for	O
the	O
B	B-PRGE
cell	I-PRGE
transcription	I-PRGE
factor	I-PRGE
,	O
BSAP	B-PRGE
:	O
a	O
possible	O
mechanism	O
for	O
dioxin	O
-	O
mediated	O
alteration	O
of	O
CD19	B-PRGE
gene	O
expression	O
in	O
human	O
B	O
lymphocytes	O
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	B-PRGE
gene	O
in	O
a	O
human	O
B	O
lymphocyte	O
cell	O
line	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-PRGE
mRNA	O
by	O
67	O
%	O
in	O
the	O
IM	O
-	O
9	O
cell	O
line	O
.	O

Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA	O
-	O
binding	O
complex	O
in	O
IM	O
-	O
9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-PRGE
receptor	I-PRGE
.	O

In	O
addition	O
,	O
the	O
Ah	B-PRGE
receptor	I-PRGE
complex	O
recognized	O
a	O
DNA	O
binding	O
site	O
for	O
B	B-PRGE
cell	I-PRGE
lineage	I-PRGE
-	I-PRGE
specific	I-PRGE
activator	I-PRGE
protein	I-PRGE
(	O
BSAP	B-PRGE
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
CD19	B-PRGE
gene	O
which	O
is	O
similar	O
to	O
the	O
consensus	O
Ah	B-PRGE
receptor	I-PRGE
DNA	O
binding	O
site	O
.	O

These	O
results	O
suggest	O
that	O
the	O
AhR	B-PRGE
could	O
interfere	O
with	O
BSAP	B-PRGE
-	O
stimulated	O
CD19	B-PRGE
gene	O
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	O
binding	O
site	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-PRGE
and	O
Jak1	B-PRGE
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-PRGE
alpha	I-PRGE
and	O
STAT3	B-PRGE
complexes	O
in	O
human	O
T	O
cells	O
and	O
monocytes	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
affects	O
monocytes	O
and	O
T	O
cells	O
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte	O
-	O
mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	O
and	O
T	O
cells	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
,	O
STAT1	B-PRGE
alpha	I-PRGE
and	O
STAT3	B-PRGE
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo	O
-	O
and	O
heterodimers	O
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	O
express	O
a	O
novel	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
stimulated	O
STAT	O
protein	O
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	O
kDa	O
that	O
is	O
recognized	O
by	O
the	O
anti	O
-	O
STAT3	B-PRGE
Ab	O
but	O
is	O
not	O
observed	O
in	O
T	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
treatment	O
of	O
both	O
T	O
cells	O
and	O
monocytes	O
results	O
in	O
the	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-PRGE
and	O
Jak1	B-PRGE
,	O
but	O
not	O
Jak2	B-PRGE
or	O
Jak3	B-PRGE
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
in	O
cells	O
such	O
as	O
monocytes	O
and	O
T	O
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	O
protein	O
pairs	O
.	O

Interleukin	B-PRGE
2	I-PRGE
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	O
proteins	O
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	O
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

While	O
the	O
binding	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	O
,	O
Jak	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Jak	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

Since	O
many	O
cytokines	O
that	O
activate	O
Jak	O
kinases	O
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	O
family	O
of	O
transcription	O
factors	O
,	O
the	O
ability	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O

Exposure	O
of	O
activated	O
human	O
T	O
lymphocytes	O
or	O
of	O
a	O
natural	O
killer	O
cell	O
line	O
(	O
NKL	O
)	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-PRGE
alpha	I-PRGE
,	O
Stat1	B-PRGE
beta	I-PRGE
,	O
and	O
Stat3	B-PRGE
,	O
as	O
well	O
as	O
of	O
two	O
Stat	O
-	O
related	O
proteins	O
,	O
p94	B-PRGE
and	O
p95	B-PRGE
.	O

p94	B-PRGE
and	O
p95	B-PRGE
share	O
homology	O
with	O
Stat1	B-PRGE
at	O
the	O
phosphorylation	O
site	O
and	O
in	O
the	O
Src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-PRGE
.	O

These	O
Stat	O
proteins	O
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	O
DNA	O
sequence	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	O
genes	O
involved	O
in	O
immune	O
cell	O
function	O
.	O

Direct	O
demonstration	O
of	O
NFATp	B-PRGE
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	O
HT	O
-	O
2	O
cells	O
using	O
a	O
specific	O
NFATp	B-PRGE
polyclonal	O
antibody	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
genes	O
,	O
and	O
NFAT	O
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	O
is	O
a	O
substrate	O
for	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	O
phosphatase	O
.	O

Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	O
NFATp	B-PRGE
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110	O
-	O
130	O
-	O
kDa	O
NFATp	B-PRGE
protein	O
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	B-PRGE
from	O
untreated	O
HT	O
-	O
2	O
cells	O
with	O
calcineurin	O
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B-PRGE
,	O
demonstrating	O
that	O
NFATp	B-PRGE
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	O
.	O

NFATp	B-PRGE
immunoprecipitated	O
from	O
32P	O
-	O
labeled	O
HT	O
-	O
2	O
cells	O
migrated	O
as	O
an	O
approximately	O
120	O
-	O
kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-PRGE
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-PRGE
dephosphorylation	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	B-PRGE
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	O
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-PRGE
is	O
a	O
calcineurin	O
substrate	O
in	O
cells	O
.	O

Temperature	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
peripheral	O
blood	O
mononuclear	O
leucocyte	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25	O
-	O
79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-PRGE
receptors	I-PRGE
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B-PRGE
receptor	I-PRGE
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-PRGE
receptors	I-PRGE
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-PRGE
receptor	I-PRGE
number	O
and	O
affinity	O
.	O

Evidence	O
for	O
normal	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
messenger	O
ribonucleic	O
acid	O
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

Absorptive	O
hypercalciuria	O
(	O
a	O
stone	O
-	O
forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
gene	O
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-PRGE
gene	O
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race	O
-	O
and	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B-PRGE
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O

The	O
coding	O
region	O
of	O
VDR	B-PRGE
messenger	O
RNA	O
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	O
sequence	O
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B-PRGE
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B-PRGE
genotype	O
.	O

The	O
DNA	O
-	O
binding	O
properties	O
of	O
two	O
heat	O
shock	O
factors	O
,	O
HSF1	B-PRGE
and	O
HSF3	B-PRGE
,	O
are	O
induced	O
in	O
the	O
avian	O
erythroblast	O
cell	O
line	O
HD6	O
.	O

Avian	O
cells	O
express	O
three	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF	O
)	O
genes	O
corresponding	O
to	O
a	O
novel	O
factor	O
,	O
HSF3	B-PRGE
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B-PRGE
and	O
HSF2	B-PRGE
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	O
reveals	O
that	O
HSF3	B-PRGE
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-PRGE
and	O
HSF2	B-PRGE
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

HSF3	B-PRGE
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	O
cell	O
line	O
HD6	O
,	O
the	O
lymphoblast	O
cell	O
line	O
MSB	O
,	O
and	O
embryo	O
fibroblasts	O
,	O
and	O
yet	O
its	O
DNA	O
-	O
binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O

Acquisition	O
of	O
HSF3	B-PRGE
DNA	O
-	O
binding	O
activity	O
in	O
HD6	O
cells	O
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non	O
-	O
DNA	O
-	O
binding	O
dimer	O
to	O
a	O
DNA	O
-	O
binding	O
trimer	O
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-PRGE
is	O
oligomerization	O
of	O
an	O
inert	O
monomer	O
to	O
a	O
DNA	O
-	O
binding	O
trimer	O
.	O

Induction	O
of	O
HSF3	B-PRGE
DNA	O
-	O
binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B-PRGE
.	O

As	O
occurs	O
for	O
HSF1	B-PRGE
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-PRGE
to	O
the	O
nucleus	O
.	O

HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	O
activator	O
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	O
overexpressed	O
HSF3	B-PRGE
measured	O
by	O
using	O
a	O
heat	O
shock	O
element	O
-	O
containing	O
reporter	O
construct	O
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	O
GAL4	B-PRGE
-	O
HSF3	B-PRGE
protein	O
on	O
a	O
GAL4	B-PRGE
reporter	O
construct	O
.	O

These	O
results	O
reveal	O
that	O
HSF3	B-PRGE
is	O
negatively	O
regulated	O
in	O
avian	O
cells	O
and	O
acquires	O
DNA	O
-	O
binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O

A	O
central	O
role	O
for	O
a	O
single	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
binding	O
site	O
in	O
a	O
thymic	O
locus	O
control	O
region	O
.	O

Locus	O
control	O
regions	O
(	O
LCRs	O
)	O
are	O
powerful	O
assemblies	O
of	O
cis	O
elements	O
that	O
organize	O
the	O
actions	O
of	O
cell	O
-	O
type	O
-	O
specific	O
trans	O
-	O
acting	O
factors	O
.	O

A	O
2	O
.	O
3	O
-	O
kb	O
LCR	O
in	O
the	O
human	O
adenosine	B-PRGE
deaminase	I-PRGE
(	O
ADA	B-PRGE
)	O
gene	O
first	O
intron	O
,	O
which	O
controls	O
expression	O
in	O
thymocytes	O
,	O
is	O
composed	O
of	O
a	O
200	O
-	O
bp	O
enhancer	O
domain	O
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	O
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	O
contains	O
a	O
28	O
-	O
bp	O
core	O
region	O
and	O
local	O
adjacent	O
augmentative	O
cis	O
elements	O
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
binding	O
site	O
.	O

In	O
both	O
transiently	O
cotransfected	O
human	O
cells	O
and	O
stable	O
chromatin	O
-	O
integrated	O
yeast	O
cells	O
,	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
strongly	O
transactivated	O
reporter	O
constructs	O
that	O
contained	O
polymerized	O
core	O
sequences	O
.	O

c	B-PRGE
-	I-PRGE
Myb	I-PRGE
protein	O
was	O
strongly	O
evident	O
in	O
T	O
lymphoblasts	O
in	O
which	O
the	O
enhancer	O
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c	B-PRGE
-	I-PRGE
myb	I-PRGE
expression	O
with	O
that	O
of	O
mouse	O
ADA	B-PRGE
and	O
human	O
ADA	B-PRGE
LCR	O
-	O
directed	O
transgene	O
expression	O
.	O

Point	O
mutation	O
of	O
the	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
site	O
within	O
the	O
intact	O
2	O
.	O
3	O
-	O
kb	O
LCR	O
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	O
activity	O
in	O
transgenic	O
thymocytes	O
.	O

Within	O
the	O
context	O
of	O
a	O
complex	O
enhancer	O
and	O
LCR	O
,	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte	O
-	O
specific	O
gene	O
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
(	O
Spi	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
regulate	O
expression	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
gene	O
.	O

Growth	O
factor	O
receptors	O
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	O
factors	O
activating	O
the	O
expression	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	I-PRGE
GM	I-PRGE
-	I-PRGE
CSF	I-PRGE
)	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
gene	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
in	O
myelomonocytic	O
cells	O
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-	O
53	O
and	O
-	O
41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	O
constructs	O
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	O
cell	O
transcription	O
factor	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
binds	O
specifically	O
to	O
this	O
site	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	O
site	O
located	O
upstream	O
of	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
between	O
positions	O
-	O
70	O
and	O
-	O
54	O
is	O
involved	O
in	O
positive	O
-	O
negative	O
regulation	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
activity	O
.	O

C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
is	O
the	O
major	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	O
cells	O
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
or	O
the	O
C	O
/	O
EBP	O
site	O
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
activity	O
in	O
myelomonocytic	O
cells	O
only	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU	O
-	O
SF	O
)	O
when	O
binding	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
on	O
a	O
myeloid	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
binding	O
site	O
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	O
cell	O
enhancer	O
sites	O
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
to	O
extracts	O
from	O
certain	O
nonmyeloid	O
cell	O
types	O
which	O
do	O
not	O
express	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
,	O
including	O
T	O
cells	O
and	O
epithelial	O
cells	O
,	O
but	O
not	O
from	O
erythroid	O
cells	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU	O
-	O
SF	O
complex	O
binds	O
to	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	O
promoters	O
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
site	O
adjacent	O
to	O
a	O
single	O
-	O
stranded	O
region	O
.	O

Expression	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
in	O
nonmyeloid	O
cells	O
can	O
activate	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
.	O

Deletion	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU	O
-	O
SF	O
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU	O
-	O
SF	O
complex	O
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
can	O
also	O
active	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
promoter	O
in	O
nonmyeloid	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Expression	O
of	O
the	O
nucleoside	B-PRGE
diphosphate	I-PRGE
kinase	I-PRGE
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O

Expression	O
of	O
nucleoside	B-PRGE
diphosphate	I-PRGE
(	I-PRGE
NDP	I-PRGE
)	I-PRGE
kinase	I-PRGE
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-PRGE
gene	O
product	O
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	O
cell	O
types	O
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

In	O
order	O
to	O
determine	O
whether	O
NDP	B-PRGE
kinase	I-PRGE
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-PRGE
kinase	I-PRGE
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
NDP	B-PRGE
kinase	I-PRGE
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

However	O
,	O
the	O
difference	O
of	O
NDP	B-PRGE
kinase	I-PRGE
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-PRGE
kinase	I-PRGE
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-PRGE
gene	O
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O

The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	O
cell	O
types	O
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O

Cloning	O
a	O
cDNA	O
from	O
human	O
NK	O
/	O
T	O
cells	O
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

A	O
cDNA	O
clone	O
,	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
was	O
isolated	O
from	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
minus	O
T	O
cell	O
subtractive	O
library	O
.	O

The	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
clone	O
coded	O
for	O
an	O
mRNA	O
of	O
2061	O
bp	O
in	O
length	O
.	O

It	O
encodes	O
a	O
deduced	O
327	O
aa	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35	O
.	O
2	O
kDa	O
.	O

Searching	O
of	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
DNA	O
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O

However	O
,	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O
,	O
contains	O
a	O
putative	O
nuclear	O
targeting	O
sequence	O
,	O
and	O
has	O
several	O
SPXX	O
motifs	O
which	O
are	O
frequently	O
found	O
in	O
gene	O
regulatory	O
proteins	O
.	O

One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	O
domains	O
.	O

Northern	O
hybridization	O
data	O
showed	O
that	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
not	O
a	O
lymphoid	O
specific	O
gene	O
and	O
is	O
expressed	O
in	O
a	O
hepatoma	O
cell	O
line	O
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O

A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	O
B4	B-PRGE
-	I-PRGE
2	I-PRGE
recognizes	O
a	O
32	O
-	O
34	O
kDa	O
protein	O
in	O
lymphocytes	O
.	O

The	O
human	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
encodes	O
a	O
nuclear	O
DNA	O
-	O
binding	O
protein	O
uniquely	O
expressed	O
in	O
normal	O
and	O
neoplastic	O
T	O
-	O
lineage	O
lymphocytes	O
.	O

The	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T	O
-	O
cell	O
enhancers	O
.	O

TCF	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
fashion	O
within	O
a	O
set	O
of	O
human	O
and	O
mouse	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	O
antibody	O
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
.	O

As	O
expected	O
,	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
was	O
detectable	O
only	O
in	O
cell	O
lines	O
of	O
T	O
lineage	O
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3	O
+	O
T	O
cells	O
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O

The	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T	O
-	O
cell	O
malignancies	O
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	O
neoplasms	O
.	O

These	O
observations	O
imply	O
a	O
T	O
cell	O
-	O
specific	O
function	O
for	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf	B-PRGE
-	I-PRGE
1	I-PRGE
knock	O
-	O
out	O
mice	O
.	O

In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
can	O
serve	O
as	O
a	O
pan	O
-	O
T	O
-	O
lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O

Constitutive	O
overexpression	O
of	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
gene	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	B-PRGE
.	O

L	B-PRGE
-	I-PRGE
selectin	I-PRGE
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
gene	O
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	O
cell	O
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
mRNA	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
promoter	O
to	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-PRGE
,	O
which	O
is	O
a	O
viral	O
transcriptional	O
transactivator	O
.	O

Flow	O
cytometry	O
showed	O
that	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
was	O
expressed	O
on	O
fresh	O
ATL	O
cells	O
along	O
with	O
other	O
activation	O
antigens	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	O
cells	O
overexpressed	O
that	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
mRNA	O
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
mRNA	O
in	O
the	O
infiltrating	O
leukemic	O
cells	O
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O

Intravenous	O
injection	O
of	O
a	O
rat	O
T	O
-	O
cell	O
line	O
that	O
overexpresses	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
showed	O
increased	O
organ	O
infiltration	O
.	O

The	O
induction	O
of	O
Tax	B-PRGE
expression	O
in	O
JPX9	O
cells	O
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	O
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
promoter	O
by	O
Tax	B-PRGE
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
4	O
,	O
215	O
.	O
4	O
+	O
/	O
-	O
4	O
,	O
111	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
1	O
,	O
148	O
.	O
0	O
+	O
/	O
-	O
269	O
.	O
0	O
ng	O
/	O
mL	O
and	O
991	O
.	O
9	O
+	O
/	O
-	O
224	O
ng	O
/	O
mL	O
,	O
respectively	O
)	O
.	O

These	O
results	O
indicated	O
that	O
ATL	O
cells	O
constitutively	O
overexpress	O
the	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
gene	O
that	O
can	O
be	O
transactivated	O
by	O
HTLV	O
-	O
1	O
Tax	B-PRGE
.	O

The	O
overexpression	O
of	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
as	O
well	O
as	O
of	O
inflammatory	O
cytokines	O
,	O
by	O
ATL	O
cells	O
may	O
provide	O
a	O
basis	O
for	O
ATL	O
cells	O
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O

The	O
DNA	O
and	O
steroid	O
binding	O
domains	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
are	O
not	O
altered	O
in	O
mononuclear	O
cells	O
of	O
treated	O
CLL	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O

The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor	O
-	O
cDNA	O
.	O

The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA	O
-	O
and	O
the	O
steroid	O
-	O
binding	O
region	O
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

In	O
one	O
individual	O
who	O
had	O
not	O
been	O
treated	O
before	O
analysis	O
a	O
silent	O
mutation	O
was	O
found	O
in	O
one	O
receptor	O
allele	O
.	O

The	O
results	O
suggest	O
that	O
mechanisms	O
other	O
than	O
altered	O
ligand	O
or	O
DNA	O
binding	O
of	O
the	O
receptor	O
may	O
be	O
responsible	O
for	O
the	O
lack	O
of	O
response	O
to	O
chemotherapy	O
.	O

This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	O
and	O
human	O
lymphoma	O
cells	O
in	O
culture	O
.	O

BCL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
the	O
molecular	O
pathogenesis	O
of	O
B	O
-	O
cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
product	O
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
normal	O
and	O
neoplastic	O
B	O
-	O
cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
under	O
heterologous	O
promoters	O
or	O
lacking	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
function	O
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
(	O
Schneider	O
et	O
al	O
.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL	B-PRGE
-	I-PRGE
6	I-PRGE
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	O
clone	O
with	O
sensitive	O
PCR	O
-	O
based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al	O
.	O
1993	O
)	O
.	O

Prolactin	B-PRGE
and	O
interleukin	O
-	O
2	O
receptors	O
in	O
T	O
lymphocytes	O
signal	O
through	O
a	O
MGF	O
-	O
STAT5	O
-	O
like	O
transcription	O
factor	O
.	O

The	O
cell	O
surface	O
receptors	O
for	O
PRL	B-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	O
lymphocytes	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over	O
-	O
lapping	O
sets	O
of	O
genes	O
of	O
T	O
cells	O
.	O

PRL	O
and	O
IL	O
-	O
2	O
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak	O
/	O
Stat	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
pathway	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
activate	O
Stat	O
proteins	O
in	O
different	O
T	O
cell	O
lines	O
.	O

The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat	O
-	O
specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
PRL	B-PRGE
-	O
induced	O
DNA	O
-	O
binding	O
proteins	O
in	O
Nb2	O
and	O
C196	O
T	O
cell	O
lines	O
were	O
investigated	O
.	O

A	O
comparison	O
with	O
the	O
Stat	O
proteins	O
induced	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
PRL	B-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
T47D	O
mammary	O
tumor	O
cells	O
was	O
made	O
.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL	B-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
factors	O
.	O

A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
PRL	B-PRGE
with	O
their	O
respective	O
receptors	O
.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	O
was	O
also	O
observed	O
.	O

Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B-PRGE
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	O
factors	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
and	O
Stat1	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O

Attenuation	O
of	O
gamma	B-PRGE
interferon	I-PRGE
-	O
induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	O
kinases	O
and	O
Stat1	O
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-PRGE
interferon	I-PRGE
is	O
impaired	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-PRGE
interferon	I-PRGE
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	O
protein	O
tyrosine	O
kinases	O
,	O
including	O
the	O
Janus	O
kinases	O
Jak1	B-PRGE
and	O
Jak2	B-PRGE
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
Stat1	O
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-PRGE
interferon	I-PRGE
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B-PRGE
and	O
Jak2	B-PRGE
and	O
phosphorylation	O
of	O
Stat1	O
was	O
developed	O
in	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
differentiated	O
U	O
-	O
937	O
cells	O
.	O

Analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-PRGE
interferon	I-PRGE
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	O
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L	O
.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	B-PRGE
,	O
Jak2	B-PRGE
,	O
and	O
Stat1	O
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon	O
-	O
treated	O
cells	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B-PRGE
,	O
Jak2	B-PRGE
,	O
and	O
Stat1	O
increased	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
U	O
-	O
937	O
cells	O
incubated	O
with	O
gamma	B-PRGE
interferon	I-PRGE
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L	O
.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-PRGE
,	O
Jak2	B-PRGE
,	O
and	O
Stat1	O
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L	O
.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U	O
-	O
937	O
cells	O
were	O
also	O
obtained	O
with	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	O
mononuclear	O
phagocytes	O
with	O
L	O
.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B-PRGE
interferon	I-PRGE
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak	O
-	O
Stat1	O
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B-PRGE
interferon	I-PRGE
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	O
and	O
polymorphonuclear	O
leukocytes	O
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P	O
.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B-PRGE
sigma	I-PRGE
factor	I-PRGE
were	O
undertaken	O
.	O

The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	O
adhesins	O
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	O
and	O
neutrophils	O
.	O

Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P	O
.	O
aeruginosa	O
.	O

The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P	O
.	O
aeruginosa	O
to	O
macrophages	O
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O

Identification	O
of	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
within	O
the	O
promoter	O
of	O
the	O
platelet	B-PRGE
glycoprotein	I-PRGE
Ib	I-PRGE
alpha	I-PRGE
gene	O
.	O

Platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
-	O
IX	O
-	O
V	O
is	O
a	O
multisubunit	O
adhesion	O
receptor	O
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
"	O
giant	O
"	O
platelets	O
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	O
Ib	O
-	O
IX	O
-	O
V	O
complex	O
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	O
elements	O
supporting	O
the	O
expression	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
complex	O
(	O
GP	B-PRGE
Ib	I-PRGE
alpha	I-PRGE
)	O
.	O

GP	B-PRGE
Ib	I-PRGE
alpha	I-PRGE
promoter	O
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	O
erythroleukemia	O
cells	O
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	O
,	O
luciferase	O
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	O
start	O
site	O
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	O
erythroleukemia	O
cells	O
.	O

In	O
cells	O
of	O
nonhematopoietic	O
lineage	O
,	O
human	O
endothelial	O
and	O
HeLa	O
cells	O
,	O
the	O
GP	B-PRGE
Ib	I-PRGE
alpha	I-PRGE
promoter	O
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	O
constructs	O
.	O

Gel	O
shift	O
assays	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
93	O
and	O
150	O
nucleotides	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O

The	O
results	O
define	O
essential	O
cis	O
-	O
acting	O
elements	O
responsible	O
for	O
the	O
expression	O
of	O
GP	B-PRGE
Ib	I-PRGE
alpha	I-PRGE
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	O
platelets	O
into	O
the	O
bloodstream	O
.	O

Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	O
inhibitory	O
protein	O
repressor	O
element	O
in	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
.	O

T	O
cell	O
expression	O
of	O
interleukin	B-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
directed	O
by	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
DNA	O
elements	O
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

A	O
strong	O
repressor	O
element	O
,	O
termed	O
nuclear	O
inhibitory	O
protein	O
(	O
NIP	O
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
between	O
nucleotides	O
-	O
271	O
and	O
-	O
250	O
.	O

Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	O
promoter	O
.	O

DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	O
region	O
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Complex	O
1	O
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	O
'	O
portion	O
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O

Complex	O
2	O
corresponds	O
to	O
binding	O
of	O
transcription	O
factor	O
(	O
upstream	O
stimulatory	O
factor	O
)	O
to	O
an	O
E	O
-	O
box	O
motif	O
in	O
the	O
5	O
'	O
portion	O
of	O
the	O
NIP	O
region	O
.	O

DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	O
stimulatory	O
factor	O
but	O
is	O
clearly	O
distinct	O
.	O

To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	O
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	O
site	O
of	O
an	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
-	O
linked	O
reporter	O
construct	O
and	O
examined	O
their	O
effects	O
on	O
NIP	O
-	O
mediated	O
repression	O
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
;	O
both	O
repressor	O
activity	O
and	O
complex	O
3	O
binding	O
require	O
the	O
consensus	O
sequence	O
CTCACNTNC	O
.	O

The	O
activation	O
of	O
the	O
Jak	O
-	O
STAT	B-PRGE
1	I-PRGE
signaling	O
pathway	O
by	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
in	O
eosinophils	O
.	O

The	O
intracellular	O
signal	O
transduction	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
in	O
eosinophils	O
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	O
-	O
STAT	O
pathway	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
signal	O
transduction	O
mechanism	O
.	O

Eosinophils	O
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

The	O
involvement	O
of	O
Jak	B-PRGE
2	I-PRGE
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

The	O
activation	O
of	O
Jak	B-PRGE
2	I-PRGE
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	O
kinase	O
.	O

Jak	B-PRGE
2	I-PRGE
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	O
with	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

Further	O
,	O
the	O
immunoprecipitated	O
Jak	B-PRGE
2	I-PRGE
obtained	O
from	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
stimulated	O
cells	O
underwent	O
autophosphorylation	O
.	O

Jak	B-PRGE
2	I-PRGE
coprecipitated	O
with	O
the	O
beta	O
-	O
subunit	O
of	O
the	O
IL	O
-	O
5	O
receptor	O
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	O
with	O
the	O
receptor	O
.	O

The	O
nuclear	O
factor	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
p91	B-PRGE
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

STAT	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
stimulation	O
.	O

The	O
presence	O
of	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

IL	B-PRGE
-	I-PRGE
5	I-PRGE
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma	O
-	O
activating	O
sequence	O
.	O

In	O
the	O
presence	O
of	O
an	O
anti	O
-	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
Ab	O
,	O
the	O
band	O
was	O
supershifted	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
activated	O
the	O
Jak	B-PRGE
2	I-PRGE
-	O
STAT	B-PRGE
1	I-PRGE
signaling	O
pathway	O
in	O
eosinophils	O
.	O

We	O
speculate	O
that	O
the	O
Jak	B-PRGE
2	I-PRGE
-	O
STAT	B-PRGE
1	I-PRGE
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
-	O
inducible	O
genes	O
in	O
eosinophils	O
.	O

Constitutively	O
activated	O
Jak	O
-	O
STAT	O
pathway	O
in	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
)	O
.	O

HTLV	O
-	O
I	O
-	O
infected	O
peripheral	O
blood	O
T	O
cells	O
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
.	O

Whereas	O
the	O
Jak	O
kinases	O
Jak1	B-PRGE
and	O
Jak3	B-PRGE
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
proteins	O
Stat3	B-PRGE
and	O
Stat5	B-PRGE
are	O
activated	O
in	O
normal	O
T	O
cells	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O

In	O
HTLV	O
-	O
I	O
-	O
infected	O
cord	O
blood	O
lymphocytes	O
,	O
the	O
transition	O
from	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	O
-	O
STAT	O
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV	O
-	O
I	O
-	O
mediated	O
T	O
cell	O
transformation	O
.	O

Heterogeneous	O
expression	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
proteins	O
in	O
endemic	O
Burkitt	O
'	O
s	O
lymphoma	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
infected	O
cells	O
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
six	O
EBV	O
-	O
encoded	O
nuclear	O
antigens	O
(	O
EBNA1	B-PRGE
,	O
2	B-PRGE
,	O
3A	B-PRGE
,	O
3B	B-PRGE
,	O
3C	B-PRGE
,	O
-	B-PRGE
LP	I-PRGE
)	O
,	O
three	O
latent	O
membrane	O
proteins	O
(	O
LMP1	B-PRGE
,	O
2A	B-PRGE
,	O
2B	B-PRGE
)	O
,	O
and	O
two	O
nuclear	O
RNAs	O
(	O
EBERs	O
)	O
are	O
expressed	O
.	O

This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O

In	O
EBV	O
-	O
positive	O
cases	O
of	O
Hodgkin	O
'	O
s	O
disease	O
,	O
the	O
EBERs	O
,	O
EBNA1	B-PRGE
,	O
and	O
the	O
LMPs	O
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	O
and	O
EBNA1	B-PRGE
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	O
proteins	O
in	O
17	O
cases	O
of	O
EBV	O
-	O
positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O

Expression	O
of	O
LMP1	B-PRGE
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	O
cells	O
in	O
two	O
cases	O
and	O
EBNA2	B-PRGE
was	O
detected	O
in	O
some	O
tumor	O
cells	O
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B-PRGE
trans	I-PRGE
-	I-PRGE
activator	I-PRGE
protein	I-PRGE
was	O
expressed	O
in	O
a	O
few	O
tumor	O
cells	O
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	O
cell	O
lines	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B-PRGE
gene	O
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O

A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
have	O
tumor	O
-	O
specific	O
rearrangements	O
of	O
the	O
TAL1	B-PRGE
gene	O
.	O

Although	O
TAL1	B-PRGE
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	O
lymphocytes	O
,	O
TAL1	B-PRGE
gene	O
products	O
are	O
readily	O
detected	O
in	O
leukemic	O
cells	O
that	O
harbor	O
a	O
rearranged	O
TAL1	B-PRGE
allele	O
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-PRGE
promotes	O
the	O
development	O
of	O
T	O
-	O
ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-PRGE
is	O
expressed	O
in	O
the	O
leukemic	O
cells	O
of	O
most	O
patients	O
with	O
T	O
-	O
ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-PRGE
gene	O
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B-PRGE
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B-PRGE
transcription	O
in	O
primary	O
T	O
-	O
ALL	O
cells	O
.	O

Monoallelic	O
expression	O
of	O
TAL1	B-PRGE
was	O
observed	O
in	O
the	O
leukemic	O
cells	O
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B-PRGE
gene	O
rearrangement	O
.	O

In	O
the	O
leukemic	O
cells	O
of	O
patients	O
without	O
detectable	O
TAL1	B-PRGE
rearrangements	O
,	O
TAL1	B-PRGE
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	B-PRGE
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
(	O
affecting	O
expression	O
of	O
a	O
single	O
TAL1	B-PRGE
allele	O
)	O
or	O
changes	O
in	O
trans	O
-	O
acting	O
factors	O
that	O
control	O
TAL1	B-PRGE
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-PRGE
alleles	O
)	O
.	O

A	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
cytokines	O
expressed	O
by	O
human	O
Th2	O
-	O
type	O
lymphocytes	O
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
T	O
-	O
cell	O
-	O
expressed	O
cytokines	O
[	O
human	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
-	B-PRGE
4	I-PRGE
,	O
-	B-PRGE
5	I-PRGE
and	O
-	B-PRGE
13	I-PRGE
and	O
human	O
and	O
mouse	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
]	O
.	O

It	O
contains	O
a	O
core	O
sequence	O
CTTGG	O
.	O
.	O
.	O

CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	O
sequences	O
in	O
each	O
gene	O
.	O

This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans	O
-	O
acting	O
factors	O
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
element	O
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	O
gene	O
by	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
J6	O
upon	O
stimulation	O
.	O

In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O

In	O
different	O
genes	O
,	O
the	O
core	O
sequences	O
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	O
and	O
its	O
presence	O
in	O
several	O
T	O
-	O
cell	O
-	O
expressed	O
cytokine	O
genes	O
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	O
in	O
T	O
helper	O
cells	O
.	O

The	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
/	O
receptor	O
interaction	O
activates	O
Lyn	B-PRGE
and	O
Jak2	B-PRGE
tyrosine	I-PRGE
kinases	I-PRGE
and	O
propagates	O
signals	O
via	O
the	O
Ras	O
-	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
MAP	O
kinase	O
and	O
the	O
Jak	O
-	O
STAT	O
pathways	O
in	O
eosinophils	O
.	O

We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
5	I-PRGE
with	O
the	O
receptor	O
activates	O
Lyn	B-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
within	O
1	O
min	O
and	O
Jak2	B-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
within	O
1	O
-	O
3	O
min	O
.	O

IL	B-PRGE
-	I-PRGE
5	I-PRGE
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-PRGE
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
MEK	O
,	O
and	O
MAP	O
kinases	O
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

Jak2	B-PRGE
kinase	I-PRGE
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	O
nuclear	O
proteins	O
.	O

The	O
activation	O
of	O
STAT	O
nuclear	O
factors	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	O
activation	O
site	O
(	O
GAS	O
)	O
probe	O
.	O

We	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
induces	O
two	O
GAS	O
-	O
binding	O
proteins	O
in	O
eosinophils	O
,	O
one	O
of	O
which	O
is	O
STAT1	O
.	O

We	O
conclude	O
that	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B-PRGE
-	O
-	O
>	O
Ras	O
-	O
-	O
>	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
-	O
>	O
MEK	O
-	O
-	O
>	O
MAP	O
kinase	O
and	O
(	O
2	O
)	O
Jak2	B-PRGE
-	O
-	O
>	O
STAT1	O
.	O

E1A	B-PRGE
gene	O
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	O
cells	O
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	O
cells	O
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-PRGE
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-PRGE
expression	O
in	O
human	O
cells	O
.	O

Only	O
stably	O
transfected	O
target	O
cells	O
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-PRGE
proteins	O
in	O
Ad	O
-	O
infected	O
targets	O
.	O

The	O
inability	O
of	O
E1A	B-PRGE
gene	O
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	O
cells	O
or	O
by	O
viral	O
gene	O
effects	O
on	O
class	O
I	O
MHC	O
antigen	O
expression	O
on	O
target	O
cells	O
.	O

This	O
differential	O
effect	O
of	O
E1A	B-PRGE
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	O
cells	O
suggests	O
that	O
human	O
NK	O
cells	O
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A	B-PRGE
-	O
immortalized	O
cells	O
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	O
infected	O
cells	O
in	O
the	O
human	O
host	O
.	O

RB	B-PRGE
and	O
a	O
novel	O
E2F	B-PRGE
-	I-PRGE
1	I-PRGE
binding	O
protein	O
in	O
MHC	O
class	O
II	O
deficient	O
B	O
-	O
cell	O
lines	O
and	O
normal	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
of	O
the	O
class	O
IL	O
transactivator	O
CIITA	B-PRGE
in	O
class	O
II	O
non	O
-	O
inducible	O
RB	B-PRGE
-	O
defective	O
tumor	O
lines	O
.	O

The	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
encode	O
cell	O
surface	O
proteins	O
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T	O
-	O
cells	O
.	O

The	O
class	O
II	O
proteins	O
are	O
expressed	O
constitutively	O
on	O
B	O
-	O
cells	O
and	O
EBV	O
-	O
transformed	O
B	O
-	O
cells	O
,	O
and	O
are	O
inducible	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
on	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Retinoblastoma	B-PRGE
protein	I-PRGE
(	O
RB	B-PRGE
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	O
repressor	O
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	O
E2F	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

RB	B-PRGE
-	O
defective	O
tumor	O
lines	O
are	O
non	O
-	O
inducible	O
for	O
MHC	O
class	O
II	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-PRGE
expression	O
vectors	O
re	O
-	O
establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-PRGE
status	O
of	O
a	O
series	O
of	O
B	O
-	O
cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Nuclear	O
matrix	O
-	O
bound	O
RB	B-PRGE
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-PRGE
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O

A	O
second	O
E2F	B-PRGE
-	I-PRGE
I	I-PRGE
binding	O
protein	O
,	O
most	O
likely	O
DP	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-	O
negative	O
B	O
-	O
cell	O
lines	O
.	O

We	O
also	O
examined	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
induction	O
of	O
CIITA	B-PRGE
in	O
RB	B-PRGE
-	O
defective	O
lines	O
.	O

CIITA	B-PRGE
is	O
a	O
class	O
II	O
gene	O
transactivator	O
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	O
class	O
II	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

CIITA	B-PRGE
mRNA	O
is	O
normally	O
inducible	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
class	O
II	O
non	O
-	O
inducible	O
,	O
RB	B-PRGE
-	O
defective	O
lines	O
,	O
and	O
in	O
one	O
line	O
,	O
re	O
-	O
expression	O
of	O
RB	B-PRGE
has	O
no	O
effect	O
on	O
CIITA	B-PRGE
mRNA	O
induction	O
levels	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB	B-PRGE
-	O
defective	O
cells	O
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-PRGE
inducibility	O
.	O

Latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
induces	O
cyclin	B-PRGE
D2	I-PRGE
expression	O
,	O
pRb	B-PRGE
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
-	O
mediated	O
growth	O
inhibition	O
in	O
EBV	O
-	O
positive	O
B	O
cells	O
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor	O
-	O
suppressor	O
protein	O
pRb	B-PRGE
,	O
the	O
G1	O
cyclins	O
,	O
the	O
cyclin	O
-	O
dependent	O
kinases	O
,	O
and	O
their	O
inhibitors	O
.	O

These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF	O
-	O
beta	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild	O
-	O
type	O
EBV	O
or	O
its	O
transforming	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
results	O
in	O
the	O
loss	O
of	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
-	O
mediated	O
growth	O
inhibition	O
in	O
human	O
B	O
cells	O
.	O

Chemical	O
cross	O
-	O
linking	O
with	O
125I	O
-	O
labeled	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
showed	O
an	O
essentially	O
normal	O
TGF	O
-	O
beta	O
receptor	O
profile	O
in	O
EBV	O
-	O
positive	O
and	O
EBV	O
-	O
negative	O
Burkitt	O
'	O
s	O
lymphoma	O
cell	O
lines	O
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
-	O
mediated	O
modulation	O
of	O
junB	B-PRGE
gene	O
expression	O
.	O

However	O
,	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B-PRGE
in	O
EBV	O
(	O
or	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
-	O
positive	O
cells	O
as	O
opposed	O
to	O
EBV	O
-	O
negative	O
cells	O
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Furthermore	O
,	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-PRGE
D2	I-PRGE
;	O
normal	O
B	O
cells	O
or	O
EBV	O
-	O
negative	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
do	O
not	O
express	O
D	O
-	O
type	O
cyclins	O
.	O

Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	O
cell	O
cycle	O
regulators	O
by	O
LMP	B-PRGE
-	I-PRGE
1	I-PRGE
can	O
lead	O
to	O
pRb	B-PRGE
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

C	O
/	O
EBP	O
proteins	O
activate	O
transcription	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
macrophages	O
/	O
monocytes	O
.	O

Three	O
binding	O
sites	O
for	O
C	O
/	O
EBP	O
proteins	O
are	O
found	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
(	O
V	O
.	O
M	O
.	O
Tesmer	O
,	O
A	O
.	O
Rajadhyaksha	O
,	O
J	O
.	O
Babin	O
,	O
and	O
M	O
.	O
Bina	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
90	O
:	O
7298	O
-	O
7302	O
,	O
1993	O
)	O
.	O

We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C	O
/	O
EBP	O
proteins	O
and	O
C	O
/	O
EBP	O
sites	O
in	O
regulating	O
transcription	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Inhibition	O
of	O
endogenous	O
C	O
/	O
EBP	O
proteins	O
,	O
using	O
either	O
an	O
excess	O
of	O
C	O
/	O
EBP	O
binding	O
sites	O
or	O
a	O
trans	O
-	O
dominant	O
negative	O
inhibitor	O
,	O
demonstrated	O
that	O
C	O
/	O
EBP	O
proteins	O
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV	O
-	O
1	O
LTR	O
transcription	O
in	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
is	O
the	O
only	O
known	O
C	O
/	O
EBP	O
family	O
member	O
which	O
is	O
increased	O
when	O
U937	O
cells	O
are	O
activated	O
.	O

Mutational	O
analyses	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
showed	O
that	O
one	O
C	O
/	O
EBP	O
site	O
is	O
required	O
for	O
normal	O
LTR	O
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C	O
/	O
EBP	O
sites	O
are	O
functionally	O
equivalent	O
.	O

However	O
,	O
transcription	O
from	O
crippled	O
HIV	O
-	O
1	O
LTRs	O
lacking	O
C	O
/	O
EBP	O
sites	O
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	O
cells	O
.	O

Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	O
expression	O
,	O
and	O
HIV	O
replication	O
.	O

Sp1	B-PRGE
functions	O
in	O
a	O
chromatin	O
-	O
dependent	O
manner	O
to	O
augment	O
human	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
.	O

The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	O
sequence	O
for	O
the	O
Sp1	B-PRGE
binding	O
site	O
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
in	O
augmenting	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
the	O
presence	O
of	O
the	O
far	O
-	O
upstream	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
enhancer	O
,	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
.	O

We	O
show	O
that	O
in	O
transiently	O
transfected	O
erythroid	O
cells	O
,	O
deletion	O
of	O
the	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
has	O
no	O
effect	O
on	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	O
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
retaining	O
this	O
region	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
augments	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
a	O
chromatin	O
-	O
dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
is	O
required	O
for	O
the	O
activation	O
of	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	O
+	O
C	O
-	O
rich	O
region	O
to	O
increase	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
from	O
a	O
stably	O
integrated	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
is	O
mediated	O
by	O
its	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
Sp1	B-PRGE
.	O

Interleukin	O
12	O
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-PRGE
in	O
human	O
lymphocytes	O
.	O

Interleukin	O
12	O
(	O
IL	O
-	O
12	O
)	O
is	O
an	O
important	O
immunoregulatory	O
cytokine	O
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	O
receptor	O
superfamily	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL	O
-	O
12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	O
family	O
tyrosine	O
kinase	O
JAK2	B-PRGE
and	O
Tyk2	B-PRGE
,	O
implicating	O
these	O
kinases	O
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL	O
-	O
12	O
.	O

Recently	O
,	O
transcription	O
factors	O
known	O
as	O
STATs	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	O
that	O
bind	O
hematopoietin	O
receptors	O
and	O
activate	O
JAK	O
kinases	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL	O
-	O
12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	O
family	O
member	O
,	O
STAT4	B-PRGE
,	O
and	O
show	O
that	O
STAT4	B-PRGE
expression	O
is	O
regulated	O
by	O
T	O
-	O
cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL	O
-	O
12	O
stimulates	O
formation	O
of	O
a	O
DNA	O
-	O
binding	O
complex	O
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	O
proteins	O
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-PRGE
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	O
phosphorylation	O
by	O
IL	O
-	O
12	O
,	O
identify	O
a	O
rapid	O
signal	O
-	O
transduction	O
pathway	O
likely	O
to	O
mediate	O
IL	O
-	O
12	O
-	O
induced	O
gene	O
expression	O
.	O

Overexpression	O
of	O
DR	B-PRGE
-	I-PRGE
nm23	I-PRGE
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	O
gene	O
family	O
,	O
inhibits	O
granulocyte	O
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	O
myeloid	O
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	O
clone	O
,	O
DR	B-PRGE
-	I-PRGE
nm23	I-PRGE
,	O
differentially	O
expressed	O
in	O
a	O
blast	O
-	O
crisis	O
cDNA	O
library	O
,	O
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	O
metastatic	O
suppressor	O
genes	O
,	O
nm23	B-PRGE
-	I-PRGE
H1	I-PRGE
and	O
nm23	B-PRGE
-	I-PRGE
H2	I-PRGE
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	O
zipper	O
-	O
like	O
and	O
the	O
RGD	O
domain	O
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2	O
-	O
and	O
in	O
the	O
COOH	O
-	O
terminal	O
portion	O
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	O
function	O
.	O

DR	B-PRGE
-	I-PRGE
nm23	I-PRGE
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	O
purified	O
CD34	B-PRGE
+	O
cells	O
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	O
precursor	O
32Dc13	O
cell	O
line	O
,	O
which	O
is	O
growth	O
-	O
factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR	B-PRGE
-	I-PRGE
nm23	I-PRGE
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Transcription	O
factors	O
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	O
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time	O
-	O
frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
and	O
Oct1	B-PRGE
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
and	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	O
factor	O
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
extracted	O
from	O
mitogen	O
-	O
stimulated	O
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	B-PRGE
and	O
NF	O
-	O
AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	O
proteins	O
,	O
such	O
as	O
transcription	O
factors	O
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	O
lymphocytes	O
.	O

Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long	O
-	O
term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B-PRGE
receptor	I-PRGE
behavior	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long	O
-	O
term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-PRGE
receptor	I-PRGE
status	O
,	O
in	O
hirsute	O
women	O
.	O

DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O

Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O

Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman	O
-	O
Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4	O
-	O
month	O
intervals	O
during	O
treatment	O
.	O

Gonadotropin	O
-	O
releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-PRGE
receptors	I-PRGE
in	O
mononuclear	O
leukocytes	O
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O

RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	O
transaminase	O
after	O
8	O
months	O
of	O
therapy	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman	O
-	O
Gallwey	O
score	O
after	O
1	O
year	O
:	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
14	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
)	O
.	O

A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH	O
-	O
stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha	O
-	O
hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O

Cycles	O
remained	O
ovulatory	O
.	O

Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B-PRGE
receptors	I-PRGE
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O

This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Androgen	B-PRGE
receptor	I-PRGE
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O

Flutamide	O
affects	O
androgen	B-PRGE
receptor	I-PRGE
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O

HIV	O
-	O
1	O
envelope	O
glycoproteins	O
induce	O
activation	O
of	O
activated	O
protein	O
-	O
1	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	B-PRGE
positive	O
T	O
cells	O
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-PRGE
positive	O
T	O
cell	O
lines	O
and	O
purified	O
T	O
cells	O
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
,	O
gp	B-PRGE
160	I-PRGE
,	O
can	O
induce	O
activation	O
of	O
transcription	O
factor	O
,	O
activated	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-PRGE
are	O
mediated	O
through	O
the	O
CD4	B-PRGE
molecule	O
,	O
since	O
treatment	O
of	O
gp160	B-PRGE
with	O
soluble	O
CD4	B-PRGE
-	O
IgG	O
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-PRGE
negative	O
T	O
cell	O
lines	O
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-PRGE
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-PRGE
160	I-PRGE
-	O
induced	O
nuclear	O
extracts	O
with	O
polyclonal	O
antibodies	O
to	O
Fos	O
and	O
Jun	O
proteins	O
indicates	O
that	O
AP	O
-	O
1	O
complex	O
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160	B-PRGE
-	O
induced	O
AP	O
-	O
1	O
complex	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis	O
-	O
independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	B-PRGE
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	O
cells	O
:	O
pre	O
-	O
treatment	O
of	O
CD4	B-PRGE
+	O
T	O
cells	O
with	O
gp160	B-PRGE
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti	O
-	O
CD3	O
-	O
induced	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	B-PRGE
were	O
seen	O
with	O
anti	O
-	O
CD4	B-PRGE
mAb	O
.	O

The	O
aberrant	O
activation	O
of	O
AP	O
-	O
1	O
by	O
gp160	B-PRGE
in	O
CD4	B-PRGE
positive	O
T	O
cells	O
could	O
result	O
in	O
up	O
-	O
regulation	O
of	O
cytokines	O
containing	O
AP	O
-	O
1	O
sites	O
,	O
e	O
.	O
g	O
.	O
interleukin	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
granulocyte	B-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
,	O
and	O
concurrently	O
lead	O
to	O
T	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
in	O
a	O
human	O
NK	O
cell	O
line	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
is	O
an	O
important	O
immunoregulatory	O
protein	O
produced	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
(	O
LGL	O
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	O
(	O
ILs	O
)	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	O
expression	O
in	O
both	O
T	O
cells	O
and	O
LGL	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	O
cell	O
lines	O
that	O
produce	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
line	O
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	O
line	O
NK3	O
.	O
3	O
derived	O
from	O
human	O
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
synergized	O
in	O
the	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
mRNAs	O
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta	I-PRGE
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
on	O
NK3	O
.	O
3	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
cytoplasmic	O
mRNA	O
.	O

In	O
contrast	O
,	O
IL	O
-	O
12	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Furthermore	O
,	O
both	O
transforming	O
growth	O
factor	O
-	O
beta	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	O
gene	O
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
but	O
not	O
IL	O
-	O
12	O
induced	O
nuclear	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP1	O
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	O
binding	O
protein	O
complexes	O
is	O
correlated	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	O
-	O
12	O
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3	O
.	O
3	O
cell	O
line	O
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	O
cells	O
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	O
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid	O
-	O
specific	O
mRNAs	O
encoding	O
gamma	O
-	O
globin	O
and	O
erythroid	O
delta	B-PRGE
-	I-PRGE
aminolevulinate	I-PRGE
synthase	I-PRGE
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	O
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	O
encoding	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	O
blasts	O
and	O
TMD	O
blasts	O
correspond	O
to	O
the	O
erythroid	O
/	O
megakaryocytic	O
bipotential	O
progenitor	O
cells	O
.	O

Activation	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
by	O
the	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
HMG	O
protein	O
on	O
nucleosome	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O

Lymphoid	B-PRGE
enhancer	I-PRGE
-	I-PRGE
binding	I-PRGE
factor	I-PRGE
1	I-PRGE
(	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
regulatory	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
that	O
activates	O
the	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	O
TCR	B-PRGE
alpha	I-PRGE
)	O
enhancer	O
in	O
a	O
context	O
-	O
restricted	O
manner	O
in	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
enhancer	O
,	O
which	O
contains	O
DNA	O
-	O
binding	O
sites	O
for	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
binding	O
site	O
inhibit	O
the	O
activity	O
of	O
multimerized	O
copies	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
in	O
Jurkat	O
T	O
cells	O
,	O
and	O
that	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
GAL4	B-PRGE
can	O
activate	O
a	O
GAL4	B-PRGE
-	O
substituted	O
HIV	O
-	O
1	O
enhancer	O
80	O
-	O
to	O
100	O
-	O
fold	O
in	O
vivo	O
.	O

Second	O
,	O
recombinant	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
shown	O
to	O
activate	O
HIV	O
-	O
1	O
transcription	O
on	O
chromatin	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O

By	O
using	O
a	O
nucleosome	O
-	O
assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	O
in	O
vitro	O
strongly	O
represses	O
HIV	O
-	O
1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
or	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter	O
-	O
binding	O
protein	O
,	O
Sp1	B-PRGE
.	O

Addition	O
of	O
TFE	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
which	O
binds	O
to	O
an	O
E	O
-	O
box	O
motif	O
upstream	O
of	O
the	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
sites	O
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O

Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer	O
-	O
binding	O
proteins	O
(	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Ets	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
TFE	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B-PRGE
.	O

A	O
truncation	O
mutant	O
of	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
HMG	O
-	O
88	O
)	O
,	O
which	O
contains	O
the	O
HMG	O
box	O
but	O
lacks	O
the	O
trans	O
-	O
activation	O
domain	O
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	O
DNA	O
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	O
domain	O
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
vitro	O
is	O
a	O
chromatin	O
-	O
dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans	O
-	O
activation	O
domain	O
in	O
addition	O
to	O
the	O
HMG	O
domain	O
.	O

Phosphorylation	O
of	O
the	O
transcription	O
factor	O
NFATp	B-PRGE
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	O
A	O
-	O
treated	O
human	O
B	O
and	O
T	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	O
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	O
component	O
to	O
the	O
nucleus	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	O
B	O
and	O
Jurkat	O
T	O
cell	O
lines	O
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-PRGE
that	O
is	O
inhibited	O
in	O
DNA	O
-	O
binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	O
complex	O
with	O
Fos	O
and	O
Jun	O
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-PRGE
migration	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	O
or	O
alkaline	B-PRGE
phosphatase	I-PRGE
restores	O
NFATp	B-PRGE
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	O
complex	O
with	O
Fos	O
and	O
Jun	O
proteins	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA	O
-	O
sensitive	O
regulation	O
of	O
NFATp	B-PRGE
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Disruption	O
of	O
a	O
GATA	O
motif	O
in	O
the	O
Duffy	B-PRGE
gene	O
promoter	O
abolishes	O
erythroid	O
gene	O
expression	O
in	O
Duffy	B-PRGE
-	O
negative	O
individuals	O
.	O

The	O
mRNA	O
for	O
the	O
Duffy	B-PRGE
blood	O
group	O
antigen	O
,	O
the	O
erythrocyte	O
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	O
receptor	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-PRGE
antigen	I-PRGE
/	I-PRGE
chemokine	I-PRGE
receptor	I-PRGE
gene	O
(	O
DARC	B-PRGE
)	O
is	O
composed	O
of	O
a	O
single	O
exon	O
and	O
that	O
most	O
Duffy	B-PRGE
-	O
negative	O
blacks	O
carry	O
a	O
silent	O
FY	B-PRGE
*	I-PRGE
B	I-PRGE
allele	O
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-	O
46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	O
cells	O
by	O
disrupting	O
a	O
binding	O
site	O
for	O
the	O
GATA1	B-PRGE
erythroid	O
transcription	O
factor	O
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY	B-PRGE
*	I-PRGE
A	I-PRGE
and	O
FY	B-PRGE
*	I-PRGE
B	I-PRGE
alleles	O
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	B-PRGE
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid	O
-	O
specific	O
repression	O
of	O
the	O
DARC	B-PRGE
gene	O
in	O
Duffy	B-PRGE
-	O
negative	O
individuals	O
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-PRGE
receptor	I-PRGE
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	O
cells	O
(	O
U937	O
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	O
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin	O
-	O
and	O
fluorescein	O
-	O
labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double	O
-	O
labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-PRGE
receptor	I-PRGE
expression	O
in	O
U937	O
cells	O
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up	O
-	O
regulation	O
of	O
GR	B-PRGE
mRNA	O
while	O
no	O
enhanced	O
GR	B-PRGE
expression	O
was	O
perceived	O
with	O
RA	O
/	O
VD	O
treatment	O
.	O

Microtubules	O
mediate	O
cellular	O
25	O
-	O
hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
monocytes	O
.	O

The	O
genomic	O
actions	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
.	O

Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol	O
-	O
VDR	B-PRGE
complex	O
,	O
the	O
role	O
of	O
microtubules	O
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	O
cells	O
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	O
monocytes	O
.	O

Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24	O
-	O
hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24	O
-	O
hydroxylase	O
mRNA	O
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
VDR	B-PRGE
binding	O
.	O

Thus	O
,	O
intact	O
microtubules	O
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

Interestingly	O
,	O
microtubule	O
disruption	O
also	O
decreased	O
monocyte	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	O
mitochondrial	O
1	O
alpha	O
-	O
hydroxylase	O
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O

Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O

Thus	O
,	O
microtubules	O
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL	O
-	O
60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

The	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL	O
-	O
60	O
cells	O
,	O
but	O
active	O
in	O
U	O
-	O
937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr	B-PRGE
-	I-PRGE
1	I-PRGE
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL	O
-	O
60	O
cells	O
constitutively	O
expressing	O
an	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
transgene	O
(	O
HL	O
-	O
60Egr	O
-	O
1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Expression	O
of	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
GATA	O
-	O
binding	O
proteins	O
during	O
human	O
hematopoiesis	O
.	O

Tal	B-PRGE
-	I-PRGE
1	I-PRGE
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
domain	O
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
1A	O
promoter	O
,	O
which	O
contains	O
two	O
consensus	O
GATA	O
-	O
binding	O
sites	O
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O

Because	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

In	O
immature	O
hematopoietic	O
cells	O
,	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
are	O
coexpressed	O
in	O
committed	O
progenitors	O
cells	O
(	O
CD34	B-PRGE
+	O
/	O
CD38	B-PRGE
(	O
2	O
+	O
)	O
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	O
cells	O
(	O
CD34	B-PRGE
(	O
2	O
+	O
)	O
/	O
CD38	B-PRGE
-	O
)	O
.	O

In	O
contrast	O
,	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
strongly	O
expressed	O
in	O
both	O
most	O
primitive	O
and	O
committed	O
progenitors	O
cells	O
,	O
whereas	O
GATA	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
modulates	O
the	O
transcription	O
of	O
tal	B-PRGE
-	I-PRGE
1	I-PRGE
during	O
the	O
differentiation	O
of	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
basosophilic	O
lineages	O
.	O

Cell	O
type	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
CD20	B-PRGE
/	O
B1	B-PRGE
antigen	O
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	B-PRGE
(	O
B1	B-PRGE
)	O
gene	O
encodes	O
a	O
B	O
cell	O
-	O
specific	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	B-PRGE
promoter	O
-	O
CAT	B-PRGE
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-	O
186	O
and	O
-	O
280	O
and	O
between	O
bases	O
-	O
280	O
and	O
-	O
454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-	O
214	O
and	O
-	O
201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B-PRGE
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B-PRGE
in	O
pre	O
-	O
B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	B-PRGE
promoter	O
-	O
CAT	B-PRGE
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	B-PRGE
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	O
proteins	O
suggesting	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
confirmed	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
affinity	O
of	O
the	O
BAT	O
box	O
binding	O
proteins	O
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25	O
-	O
fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	O
box	O
binding	O
proteins	O
dissociated	O
from	O
the	O
BAT	O
box	O
10	O
-	O
fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	O
cells	O
.	O

The	O
BAT	O
box	O
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B-PRGE
in	O
the	O
pre	O
-	O
B	O
cell	O
line	O
,	O
PB	O
-	O
697	O
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	B-PRGE
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
and	O
a	O
BAT	O
box	O
-	O
deleted	O
CD20	B-PRGE
-	O
CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B-PRGE
and	O
perhaps	O
CD21	B-PRGE
.	O

A	O
mutation	O
of	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
in	O
primary	O
cortisol	O
resistance	O
.	O

The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O

In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	B-PRGE
receptors	I-PRGE
(	O
hGR	B-PRGE
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O

We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	B-PRGE
glucocorticoid	O
-	O
binding	O
domain	O
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
'	O
s	O
mononuclear	O
leukocytes	O
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-PRGE
cDNAs	O
,	O
and	O
the	O
entire	O
hGR	B-PRGE
cDNA	O
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O

When	O
the	O
wild	O
-	O
type	O
hGR	B-PRGE
and	O
hGR	B-PRGE
-	O
Ile	O
729	O
were	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
and	O
assayed	O
for	O
[	O
3H	O
]	O
-	O
Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0	O
.	O
799	O
+	O
/	O
-	O
0	O
.	O
068	O
and	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
06	O
nM	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
respectively	O
.	O

When	O
the	O
wild	O
-	O
type	O
hGR	B-PRGE
and	O
hGR	B-PRGE
-	O
Ile	O
729	O
were	O
expressed	O
in	O
CV	O
-	O
1	O
cells	O
that	O
were	O
cotransfected	O
with	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
long	O
terminal	O
repeat	O
fused	O
to	O
the	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
,	O
the	O
hGR	B-PRGE
-	O
Ile	O
729	O
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B-PRGE
activity	O
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-PRGE
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
signal	O
-	O
transduction	O
pathway	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second	O
-	O
messenger	O
Ca2	O
+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
among	O
which	O
are	O
calmodulin	B-PRGE
,	O
calcineurin	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
.	O

Hence	O
,	O
Ca2	O
+	O
binds	O
to	O
calmodulin	B-PRGE
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	B-PRGE
to	O
calcineurin	O
;	O
the	O
activated	O
calcineurin	O
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	O
subunit	O
of	O
NF	O
-	O
AT	O
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	O
transcriptional	O
activator	O
.	O

As	O
described	O
by	O
Jun	O
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	O
receptors	O
called	O
immunophilins	O
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin	O
-	O
drug	O
complexes	O
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
.	O

Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O

Their	O
mechanisms	O
of	O
action	O
are	O
multiple	O
and	O
complex	O
and	O
a	O
number	O
of	O
reports	O
describe	O
significant	O
systemic	O
effects	O
of	O
locally	O
administered	O
glucocorticoids	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
short	O
-	O
term	O
systemic	O
effects	O
of	O
intranasally	O
administered	O
glucocorticoids	O
,	O
14	O
normal	O
healthy	O
subjects	O
were	O
treated	O
with	O
two	O
doses	O
of	O
either	O
budesonide	O
(	O
BUD	O
)	O
or	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
for	O
2	O
weeks	O
.	O

Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
and	O
methallothionein	B-PRGE
(	O
MTIIa	B-PRGE
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	O
lymphocytes	O
using	O
a	O
solution	O
hybridization	O
assay	O
.	O

Serum	O
cortisol	O
,	O
osteocalcin	B-PRGE
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O

An	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
treatment	O
and	O
at	O
the	O
end	O
of	O
the	O
6	O
-	O
week	O
washout	O
period	O
with	O
no	O
statistically	O
significant	O
change	O
in	O
cortisol	O
response	O
.	O

In	O
peripheral	O
lymphocytes	O
,	O
GR	B-PRGE
mRNA	O
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

MTIIa	B-PRGE
mRNA	O
levels	O
increased	O
significantly	O
.	O

Serum	O
osteocalcin	B-PRGE
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O

Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O

In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	O
lymphocytes	O
.	O

These	O
effects	O
are	O
receptor	O
-	O
dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
function	O
intact	O
.	O

Finally	O
,	O
these	O
short	O
-	O
term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side	O
-	O
effects	O
usually	O
observed	O
during	O
long	O
-	O
term	O
treatment	O
with	O
glucocorticoids	O
.	O

Transcriptional	O
activity	O
of	O
core	O
binding	O
factor	O
-	O
alpha	O
(	O
AML1	B-PRGE
)	O
and	O
beta	O
subunits	O
on	O
murine	O
leukemia	O
virus	O
enhancer	O
cores	O
.	O

Core	O
binding	O
factor	O
(	O
CBF	O
)	O
,	O
also	O
known	O
as	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2	O
and	O
SL3	O
enhancer	O
factor	O
1	O
,	O
is	O
a	O
mammalian	O
transcription	O
factor	O
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	O
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
core	O
elements	O
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T	O
-	O
cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

CBF	O
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	O
binding	O
subunit	O
,	O
CBF	B-PRGE
alpha	I-PRGE
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B-PRGE
beta	I-PRGE
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B-PRGE
alpha	I-PRGE
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-PRGE
alpha	I-PRGE
subunit	O
is	O
AML1	B-PRGE
,	O
also	O
called	O
Cbf	B-PRGE
alpha	I-PRGE
2	I-PRGE
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

An	O
exogenously	O
expressed	O
Cbf	B-PRGE
alpha	I-PRGE
2	I-PRGE
-	O
encoded	O
subunit	O
(	O
CBF	B-PRGE
alpha	I-PRGE
2	O
-	O
451	O
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	O
enhancer	O
in	O
P19	O
and	O
HeLa	O
cells	O
.	O

Activity	O
was	O
mediated	O
through	O
the	O
core	O
elements	O
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B-PRGE
beta	I-PRGE
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	O
enhancer	O
.	O

The	O
longest	O
form	O
,	O
CBF	B-PRGE
beta	I-PRGE
-	O
187	O
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B-PRGE
alpha	I-PRGE
2	O
-	O
451	O
twofold	O
in	O
HeLa	O
cells	O
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	O
cells	O
.	O

Transcriptional	O
activation	O
by	O
CBF	B-PRGE
beta	I-PRGE
required	O
binding	O
to	O
the	O
CBF	B-PRGE
alpha	I-PRGE
subunit	O
,	O
as	O
a	O
form	O
of	O
CBF	B-PRGE
beta	I-PRGE
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B-PRGE
beta	I-PRGE
-	O
148	O
,	O
failed	O
to	O
increase	O
activity	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	O
required	O
both	O
subunits	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	O
is	O
a	O
factor	O
in	O
T	O
lymphocytes	O
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	O
cores	O
.	O

We	O
also	O
examined	O
whether	O
CBF	O
could	O
distinguish	O
a	O
1	O
-	O
bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	O
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B-PRGE
alpha	I-PRGE
and	O
CBF	B-PRGE
beta	I-PRGE
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1	O
-	O
bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	O
cells	O
recognize	O
the	O
SL3	O
core	O
remains	O
to	O
be	O
elucidated	O
.	O

A	O
newly	O
established	O
megakaryoblastic	O
/	O
erythroid	O
cell	O
line	O
that	O
differentiates	O
to	O
red	O
cells	O
in	O
the	O
presence	O
of	O
erythropoietin	B-PRGE
and	O
produces	O
platelet	O
-	O
like	O
particles	O
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	O
cell	O
line	O
(	O
NS	O
-	O
Meg	O
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myeloid	O
leukemia	O
.	O

The	O
NS	O
-	O
Meg	O
cells	O
were	O
positive	O
for	O
alpha	O
-	O
naphthyl	O
acetate	O
esterase	O
and	O
periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B-PRGE
,	O
CD7	B-PRGE
,	O
CD13	B-PRGE
,	O
CD34	B-PRGE
,	O
CD41a	B-PRGE
,	O
and	O
glycophorin	B-PRGE
A	I-PRGE
antigens	O
.	O

Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha	O
-	O
granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	O
peroxidase	O
activity	O
.	O

The	O
NS	O
-	O
Meg	O
cells	O
spontaneously	O
produced	O
platelet	O
-	O
like	O
particles	O
which	O
contained	O
alpha	O
-	O
granules	O
,	O
mitochondria	O
and	O
dense	O
bodies	O
,	O
strongly	O
suggesting	O
platelet	O
production	O
.	O

Erythropoietin	B-PRGE
(	O
Epo	B-PRGE
)	O
,	O
granulocyte	B-PRGE
/	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
and	O
interleukin	B-PRGE
3	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
promoted	O
the	O
growth	O
of	O
NS	O
-	O
Meg	O
cells	O
.	O

Phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
increased	O
the	O
expression	O
of	O
both	O
CD41a	B-PRGE
and	O
CD61	B-PRGE
antigens	O
.	O

Ten	O
-	O
day	O
exposure	O
to	O
Epo	B-PRGE
induced	O
mature	O
erythroblasts	O
and	O
red	O
cells	O
.	O

These	O
benzidine	O
-	O
positive	O
cells	O
were	O
positive	O
for	O
hemoglobin	O
F	O
staining	O
.	O

Untreated	O
NS	O
-	O
Meg	O
cells	O
expressed	O
mRNA	O
for	O
the	O
Epo	B-PRGE
receptor	I-PRGE
(	O
EpoR	B-PRGE
)	O
,	O
for	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
for	O
alpha	O
1	O
,	O
alpha	O
2	O
and	O
gamma	O
globin	O
genes	O
.	O

These	O
results	O
indicate	O
that	O
NS	O
-	O
Meg	O
cells	O
undergo	O
terminal	O
differentiation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
lineages	O
.	O

This	O
cell	O
line	O
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O

Identification	O
and	O
purification	O
of	O
human	O
Stat	O
proteins	O
activated	O
in	O
response	O
to	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

A	O
key	O
cytokine	O
induced	O
during	O
the	O
immune	O
response	O
is	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	O
lymphocytes	O
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	O
factors	O
induced	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Human	O
peripheral	O
blood	O
lymphocytes	O
were	O
observed	O
to	O
contain	O
several	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	O
human	O
lymphocyte	O
line	O
,	O
termed	O
YT	O
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
inducible	O
component	O
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin	B-PRGE
-	O
induced	O
transcription	O
factor	O
first	O
identified	O
in	O
sheep	O
mammary	O
gland	O
tissue	O
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-PRGE
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
during	O
the	O
immune	O
response	O
.	O

The	O
role	O
of	O
shared	O
receptor	O
motifs	O
and	O
common	O
Stat	O
proteins	O
in	O
the	O
generation	O
of	O
cytokine	O
pleiotropy	O
and	O
redundancy	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	O
proteins	O
activated	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
by	O
cytokines	O
with	O
shared	O
and	O
distinct	O
actions	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
rapidly	O
activated	O
Stat5	B-PRGE
in	O
fresh	O
PBL	O
,	O
and	O
Stat3	B-PRGE
and	O
Stat5	B-PRGE
in	O
preactivated	O
PBL	O
.	O

IL	B-PRGE
-	I-PRGE
7	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
induced	O
the	O
same	O
complexes	O
as	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine	O
-	O
phosphorylated	O
motifs	O
in	O
the	O
cytoplasmic	O
domains	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7R	I-PRGE
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	O
proteins	O
.	O

IL	B-PRGE
-	I-PRGE
13	I-PRGE
Induced	O
the	O
same	O
complexes	O
as	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL	B-PRGE
-	I-PRGE
4R	I-PRGE
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	O
.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	O
can	O
activate	O
different	O
combinations	O
of	O
Stat	O
proteins	O
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	O
can	O
activate	O
the	O
same	O
Stat	O
protein	O
.	O

Functional	O
roles	O
of	O
in	O
vivo	O
footprinted	O
DNA	O
motifs	O
within	O
an	O
alpha	B-PRGE
-	I-PRGE
globin	I-PRGE
enhancer	O
.	O

Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	O
alpha	O
-	O
like	O
globin	O
genes	O
,	O
embryonic	O
zeta	O
2	O
and	O
adult	O
alpha	O
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	O
enhancer	O
,	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
.	O

Previous	O
protein	O
-	O
DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
consists	O
of	O
multiple	O
nuclear	O
factor	O
binding	O
motifs	O
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
manner	O
.	O

We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	O
binding	O
motifs	O
of	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	O
cell	O
cultures	O
.	O

Three	O
of	O
these	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
enhancer	O
motifs	O
,	O
5	O
'	O
NF	O
-	O
E2	O
/	O
AP1	O
,	O
GT	O
II	O
,	O
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
c	O
)	O
,	O
positively	O
regulate	O
the	O
zeta	B-PRGE
2	I-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
embryonic	O
/	O
fetal	O
erythroid	O
K562	O
cells	O
and	O
the	O
adult	B-PRGE
alpha	I-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
adult	O
erythroid	O
MEL	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3	O
'	O
NF	O
-	O
E2	O
/	O
AP1	O
motif	O
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-PRGE
2	I-PRGE
-	I-PRGE
globin	I-PRGE
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	O
AP1	O
factors	O
and	O
the	O
erythroid	O
-	O
enriched	O
NF	O
-	O
E2	O
factor	O
.	O

Mutation	O
in	O
the	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
d	O
)	O
motif	O
,	O
which	O
exhibits	O
an	O
adult	O
erythroid	O
-	O
specific	O
genomic	O
footprint	O
,	O
decreases	O
the	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
enhancer	O
function	O
in	O
dimethyl	O
sulfoxide	O
-	O
induced	O
MEL	O
cells	O
but	O
not	O
in	O
K562	O
cells	O
.	O

These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS	B-PRGE
-	I-PRGE
40	I-PRGE
motifs	O
.	O

The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
of	O
human	O
alpha	O
-	O
like	O
globin	O
promoters	O
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	O
nuclear	O
factors	O
in	O
vivo	O
.	O

Erythropoietin	B-PRGE
stimulates	O
transcription	O
of	O
the	O
TAL1	B-PRGE
/	O
SCL	B-PRGE
gene	O
and	O
phosphorylation	O
of	O
its	O
protein	O
products	O
.	O

Activation	O
of	O
the	O
TAL1	B-PRGE
(	O
or	O
SCL	B-PRGE
)	O
gene	O
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	O
products	O
of	O
this	O
gene	O
contain	O
the	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
motif	O
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
canonical	O
DNA	O
sequence	O
CANNTG	O
as	O
protein	O
heterodimers	O
.	O

TAL1	B-PRGE
expression	O
by	O
erythroid	O
cells	O
in	O
vivo	O
and	O
in	O
chemical	O
-	O
induced	O
erythroleukemia	O
cell	O
lines	O
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	O
hormone	O
erythropoietin	B-PRGE
(	O
Epo	B-PRGE
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-PRGE
gene	O
and	O
its	O
protein	O
products	O
were	O
affected	O
by	O
Epo	B-PRGE
in	O
splenic	O
erythroblasts	O
from	O
mice	O
infected	O
with	O
an	O
anemia	O
-	O
inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	B-PRGE
elicited	O
a	O
rapid	O
,	O
dose	O
-	O
related	O
increase	O
in	O
TAL1	B-PRGE
mRNA	O
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	O
.	O

An	O
Epo	B-PRGE
-	O
inducible	O
TAL1	B-PRGE
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	O
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B-PRGE
-	O
induced	O
phosphorylation	O
of	O
nuclear	O
TAL1	B-PRGE
protein	O
.	O

These	O
results	O
indicate	O
that	O
Epo	B-PRGE
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-PRGE
locus	O
in	O
Friend	O
virus	O
-	O
induced	O
erythroblasts	O
and	O
establish	O
a	O
link	O
between	O
Epo	B-PRGE
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
differentiation	O
of	O
diverse	O
cell	O
lineages	O
.	O

Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-PRGE
metalloproteinase	I-PRGE
9	I-PRGE
and	O
transcription	O
factor	O
AP	O
-	O
1	O
in	O
bovine	O
leucocytes	O
.	O

Theileria	O
annulata	O
infects	O
bovine	O
leucocytes	O
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O

The	O
present	O
study	O
describes	O
parasite	O
-	O
induced	O
changes	O
in	O
host	O
cell	O
gene	O
expression	O
which	O
have	O
a	O
direct	O
bearing	O
on	O
this	O
transformation	O
process	O
.	O

T	O
.	O
annulata	O
-	O
infected	O
leucocytes	O
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	O
activities	O
.	O

One	O
of	O
these	O
,	O
previously	O
called	O
B1	O
,	O
is	O
a	O
97	O
-	O
kDa	O
protein	O
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein	O
-	O
free	O
,	O
conditioned	O
medium	O
.	O

An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	O
clone	O
.	O

The	O
predicted	O
protein	O
sequence	O
of	O
B1	O
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B-PRGE
metalloproteinase	I-PRGE
9	I-PRGE
(	O
MMP9	B-PRGE
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O

RNAase	O
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B-PRGE
activity	O
,	O
unique	O
to	O
infected	O
cells	O
,	O
is	O
due	O
to	O
increased	O
MMP9	B-PRGE
mRNA	O
levels	O
.	O

We	O
also	O
assayed	O
the	O
levels	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
demonstrated	O
that	O
it	O
was	O
constitutively	O
present	O
in	O
increased	O
amounts	O
in	O
Theileria	O
-	O
infected	O
cells	O
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	O
encoding	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
a	O
common	O
component	O
of	O
AP	O
-	O
1	O
and	O
observed	O
that	O
it	O
was	O
indeed	O
up	O
-	O
regulated	O
in	O
infected	O
cells	O
.	O

Since	O
AP	O
-	O
1	O
is	O
implicated	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
MMP9	B-PRGE
can	O
confer	O
metastatic	O
properties	O
,	O
these	O
results	O
are	O
of	O
considerable	O
significance	O
with	O
respect	O
to	O
the	O
transformed	O
phenotype	O
induced	O
by	O
Theileria	O
infection	O
.	O

The	O
role	O
of	O
NFATp	B-PRGE
in	O
cyclosporin	O
A	O
-	O
sensitive	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
.	O

The	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
alpha	I-PRGE
)	O
gene	O
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	O
cells	O
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O

Maximal	O
induction	O
of	O
TNF	B-PRGE
alpha	I-PRGE
mRNA	O
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	O
cells	O
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	O
-	O
dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

We	O
have	O
previously	O
identified	O
a	O
promoter	O
element	O
,	O
kappa	O
3	O
,	O
that	O
is	O
required	O
for	O
calcium	O
-	O
stimulated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
the	O
TNF	B-PRGE
alpha	I-PRGE
gene	O
in	O
activated	O
T	O
cells	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	O
3	O
binding	O
factor	O
contains	O
NFATp	B-PRGE
,	O
a	O
cyclosporin	O
-	O
sensitive	O
DNA	O
-	O
binding	O
protein	O
required	O
for	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
.	O

NFATp	B-PRGE
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	O
3	O
element	O
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-PRGE
alpha	I-PRGE
gene	O
induction	O
.	O

Thus	O
,	O
although	O
the	O
kappa	O
3	O
element	O
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp	B-PRGE
-	O
binding	O
sites	O
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin	O
-	O
sensitive	O
promoter	O
element	O
in	O
T	O
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-PRGE
.	O

The	O
involvement	O
of	O
NFATp	B-PRGE
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
TNF	B-PRGE
alpha	I-PRGE
genes	O
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	O
genes	O
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
beta	I-PRGE
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-	O
mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	O
cell	O
proliferation	O
and	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
generation	O
were	O
studied	O
.	O

Dexamethasone	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
T	O
cell	O
proliferation	O
by	O
30	O
%	O
-	O
88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
(	O
Tac	B-PRGE
,	O
p55	B-PRGE
,	O
CD25	B-PRGE
)	O
and	O
beta	B-PRGE
(	O
p75	B-PRGE
)	O
genes	O
in	O
activated	O
T	O
cells	O
was	O
examined	O
next	O
.	O

In	O
T	O
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	B-PRGE
(	O
PHA	B-PRGE
-	I-PRGE
p	I-PRGE
)	O
and	O
4	O
beta	O
-	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
a	O
30	O
%	O
reduction	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
membrane	O
expression	O
compared	O
to	O
T	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Inhibition	O
of	O
membrane	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
expression	O
by	O
10	O
(	O
-	O
6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	O
human	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
rhIL	O
-	O
2	O
)	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
in	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen	O
-	O
stimulated	O
T	O
cells	O
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
gene	O
was	O
unaffected	O
by	O
DM	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	B-PRGE
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
stimulates	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
expression	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-	O
6	O
)	O
M	O
DM	O
increased	O
T	O
cell	O
p50	B-PRGE
NF	O
-	O
kappa	O
B	O
mRNA	O
levels	O
by	O
four	O
-	O
fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

Further	O
,	O
the	O
level	O
of	O
nuclear	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
sites	O
in	O
activated	O
T	O
cells	O
increased	O
in	O
response	O
to	O
DM	O
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	O
cell	O
membrane	O
expression	O
of	O
IL	O
-	O
2R	O
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Visualization	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
subunit	O
in	O
the	O
nucleus	O
of	O
follicular	O
dendritic	O
cells	O
in	O
germinal	O
centers	O
.	O

NF	O
-	O
kappa	O
B	O
,	O
a	O
50	O
kDa	O
/	O
65	O
kDa	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
heterodimer	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NF	O
-	O
kappa	O
B	O
is	O
related	O
to	O
a	O
particular	O
cell	O
type	O
and	O
/	O
or	O
differentiation	O
step	O
during	O
immunopoiesis	O
.	O

Using	O
in	O
situ	O
hybridization	O
on	O
sections	O
from	O
non	O
HIV	O
hyperplastic	O
lymph	O
nodes	O
,	O
we	O
found	O
that	O
the	O
gene	O
of	O
the	O
105	O
kDa	O
precursor	O
of	O
p50	B-PRGE
was	O
overexpressed	O
in	O
the	O
light	O
zone	O
of	O
germinal	O
centers	O
,	O
with	O
a	O
network	O
aspect	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

By	O
immunohistochemistry	O
,	O
p50	B-PRGE
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
,	O
confirming	O
the	O
involvement	O
of	O
FDC	O
.	O

Furthermore	O
,	O
p50	B-PRGE
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	O
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	O
clusters	O
from	O
normal	O
tonsils	O
.	O

As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	B-PRGE
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
.	O

Nuclei	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
were	O
negative	O
.	O

We	O
next	O
studied	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
protein	O
expression	O
in	O
FDC	O
clusters	O
.	O

p65	B-PRGE
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
FDC	O
,	O
whereas	O
nuclei	O
were	O
negative	O
.	O

Furthermore	O
,	O
p65	B-PRGE
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	O
.	O

c	B-PRGE
-	I-PRGE
Rel	I-PRGE
protein	O
was	O
detected	O
only	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
and	O
not	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
of	O
FDC	O
.	O

Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell	O
-	O
dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	O
clusters	O
,	O
p50	B-PRGE
is	O
mainly	O
related	O
to	O
FDC	O
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	B-PRGE
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
.	O

These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
protein	O
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O

Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

A	O
mAb	O
,	O
R24	O
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	O
cells	O
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	O
mAb	O
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	O
mAb	O
stimulates	O
GD3	O
+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
-	O
chain	O
,	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
beta	I-PRGE
-	O
chain	O
,	O
HLA	O
-	O
DR	O
,	O
CD11a	B-PRGE
,	O
and	O
CD11c	B-PRGE
.	O

Additionally	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activity	O
but	O
not	O
IL	O
-	O
1	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	O
stimulation	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
activity	O
also	O
was	O
detected	O
after	O
R24	O
treatment	O
.	O

Furthermore	O
,	O
R24	O
treatment	O
resulted	O
in	O
translocation	O
of	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
,	O
but	O
little	O
or	O
no	O
NF	O
kappa	O
B	O
p50	B-PRGE
or	O
p65	B-PRGE
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	O
kappa	O
B	O
binding	O
complexes	O
containing	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
and	O
p50	B-PRGE
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

R24	O
-	O
stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin	O
/	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
may	O
be	O
involved	O
in	O
the	O
R24	O
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
blocked	O
the	O
R24	O
-	O
stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	O
kinases	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
by	O
R24	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-PRGE
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B2	I-PRGE
p100	B-PRGE
gene	O
product	O
:	O
implications	O
for	O
viral	O
latency	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	O
human	O
CD4	B-PRGE
T	O
cells	O
.	O

HTLV	O
-	O
I	O
encodes	O
an	O
essential	O
40	O
-	O
kDa	O
protein	O
termed	O
Tax	B-PRGE
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	O
genes	O
.	O

Tax	B-PRGE
-	O
mediated	O
transformation	O
of	O
T	O
cells	O
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	O
genes	O
that	O
normally	O
regulate	O
lymphocyte	O
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	O
factors	O
.	O

In	O
particular	O
,	O
Tax	B-PRGE
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
CREB	O
/	O
ATF	O
families	O
,	O
as	O
well	O
as	O
the	O
cellular	O
factors	O
HEB	O
-	O
1	O
and	O
p67SRF	B-PRGE
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV	O
-	O
I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV	O
-	O
I	O
Tax	B-PRGE
can	O
physically	O
associate	O
with	O
p100	B-PRGE
,	O
the	O
product	O
of	O
the	O
Rel	O
-	O
related	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B2	I-PRGE
gene	O
,	O
both	O
in	O
transfected	O
cells	O
and	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
leukemic	O
T	O
-	O
cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-PRGE
with	O
p100	B-PRGE
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-PRGE
-	O
induced	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeats	O
,	O
reflecting	O
p100	B-PRGE
-	O
mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-PRGE
protein	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-PRGE
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
does	O
not	O
associate	O
with	O
p100	B-PRGE
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
human	O
monocytes	O
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	O
cytokine	O
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	O
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N	O
-	O
acetylglucosaminyl	O
-	O
1	O
,	O
6	O
-	O
anhydro	O
-	O
N	O
-	O
acetylmuramyl	O
-	O
L	O
-	O
alanyl	O
-	O
D	O
-	O
isoglutamyl	O
-	O
m	O
-	O
diaminopimelyl	O
-	O
D	O
-	O
alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	O
transglycosylase	O
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	O
expression	O
in	O
human	O
monocytes	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
after	O
2	O
h	O
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	O
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
activator	O
protein	O
-	O
1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
tyrosine	O
kinase	O
-	O
dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
involves	O
activation	O
of	O
an	O
H7	O
-	O
inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
expression	O
could	O
be	O
enhanced	O
by	O
co	O
-	O
stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and	O
/	O
or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
human	O
monocytes	O
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	O
during	O
sepsis	O
.	O

The	O
p65	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
regulates	O
I	O
kappa	O
B	O
by	O
two	O
distinct	O
mechanisms	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
is	O
generally	O
localized	O
to	O
the	O
cytoplasm	O
by	O
its	O
inhibitor	O
I	O
kappa	O
B	O
.	O

Overproduced	O
I	O
kappa	O
B	O
,	O
free	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
is	O
rapidly	O
degraded	O
.	O

Overexpression	O
of	O
p65	B-PRGE
increases	O
endogenous	O
I	O
kappa	O
B	O
protein	O
in	O
both	O
carcinoma	O
and	O
lymphoid	O
cells	O
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	O
kappa	O
B	O
mRNA	O
.	O

In	O
contrast	O
,	O
p65	B-PRGE
delta	I-PRGE
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	O
kappa	O
B	O
protein	O
levels	O
.	O

Both	O
overexpressed	O
p65	B-PRGE
and	O
coexpressed	O
p50	B-PRGE
are	O
cytoplasmic	O
,	O
whereas	O
p65	B-PRGE
delta	I-PRGE
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	O
kappa	O
B	O
induced	O
by	O
p65	B-PRGE
can	O
maintain	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
.	O

Thus	O
,	O
p65	B-PRGE
and	O
I	O
kappa	O
B	O
are	O
linked	O
in	O
an	O
autoregulatory	O
loop	O
,	O
ensuring	O
that	O
NF	O
-	O
kappa	O
B	O
is	O
held	O
in	O
the	O
cytoplasm	O
until	O
cells	O
are	O
specifically	O
induced	O
to	O
translocate	O
it	O
to	O
the	O
nucleus	O
.	O

A	O
chimeric	O
type	O
II	O
/	O
type	O
I	O
interleukin	O
-	O
1	O
receptor	O
can	O
mediate	O
interleukin	O
-	O
1	O
induction	O
of	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

The	O
type	B-PRGE
I	I-PRGE
interleukin	I-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
(	O
IL	O
-	O
1R	O
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	O
cells	O
.	O

This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	O
domain	O
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O

In	O
contrast	O
to	O
the	O
type	O
I	O
receptor	O
,	O
the	O
type	B-PRGE
II	I-PRGE
IL	I-PRGE
-	I-PRGE
1R	I-PRGE
has	O
a	O
small	O
cytoplasmic	O
tail	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal	O
-	O
transducing	O
or	O
a	O
regulatory	O
molecule	O
.	O

Here	O
we	O
report	O
that	O
the	O
type	B-PRGE
II	I-PRGE
IL	I-PRGE
-	I-PRGE
1R	I-PRGE
does	O
not	O
mediate	O
gene	O
activation	O
in	O
Jurkat	O
cells	O
.	O

However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
regions	O
of	O
the	O
human	O
type	B-PRGE
II	I-PRGE
interleukin	I-PRGE
-	I-PRGE
1	I-PRGE
fused	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
type	B-PRGE
I	I-PRGE
IL	I-PRGE
-	I-PRGE
1R	I-PRGE
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	O
I	O
IL	O
-	O
1R	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
extracellular	O
domain	O
of	O
the	O
type	B-PRGE
II	I-PRGE
IL	I-PRGE
-	I-PRGE
1R	I-PRGE
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin	O
-	O
1	O
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	O
cytoplasmic	O
domain	O
.	O

Mice	O
deficient	O
for	O
the	O
55	B-PRGE
kd	I-PRGE
tumor	I-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L	O
.	O
monocytogenes	O
infection	O
.	O

The	O
multiple	O
biological	O
activities	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	O
surface	O
receptors	O
of	O
55	O
kd	O
(	O
TNFRp55	B-PRGE
)	O
and	O
75	O
kd	O
(	O
TNFRp75	B-PRGE
)	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-PRGE
-	O
deficient	O
mouse	O
strain	O
.	O

Cells	O
from	O
TNFRp55	B-PRGE
-	O
/	O
-	O
mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-PRGE
but	O
display	O
normal	O
numbers	O
of	O
high	O
affinity	O
TNFRp75	B-PRGE
molecules	O
.	O

Thymocyte	O
development	O
and	O
lymphocyte	O
populations	O
are	O
unaltered	O
,	O
and	O
clonal	O
deletion	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
cells	O
is	O
not	O
impaired	O
.	O

However	O
,	O
TNF	O
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
lymphocytes	O
from	O
TNFRp55	B-PRGE
-	O
deficient	O
mice	O
.	O

The	O
loss	O
of	O
TNFRp55	B-PRGE
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S	O
.	O
aureus	O
enterotoxin	B-PRGE
B	I-PRGE
.	O

In	O
contrast	O
,	O
TNFRp55	B-PRGE
-	O
deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L	O
.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O

Thus	O
,	O
the	O
55	B-PRGE
kd	I-PRGE
TNFR	I-PRGE
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
'	O
s	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O

Minimally	O
modified	O
low	O
density	O
lipoprotein	O
-	O
induced	O
inflammatory	O
responses	O
in	O
endothelial	O
cells	O
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
minimally	O
oxidized	O
LDL	O
(	O
MM	O
-	O
LDL	O
)	O
activated	O
endothelial	O
cells	O
to	O
increase	O
their	O
interaction	O
with	O
monocytes	O
but	O
not	O
neutrophils	O
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
monocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte	O
-	O
specific	O
response	O
is	O
induced	O
.	O

Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
by	O
MM	O
-	O
LDL	O
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C	O
-	O
depleted	O
endothelial	O
cells	O
.	O

A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM	O
-	O
LDL	O
cited	O
above	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
MM	O
-	O
LDL	O
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM	O
-	O
LDL	O
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	O
kappa	O
B	O
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte	O
-	O
endothelial	O
interactions	O
.	O

Although	O
endothelial	B-PRGE
leukocyte	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	O
ELAM	B-PRGE
)	O
mRNA	O
synthesis	O
can	O
be	O
regulated	O
by	O
NF	O
kappa	O
B	O
,	O
ELAM	B-PRGE
was	O
not	O
expressed	O
and	O
ELAM	B-PRGE
mRNA	O
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM	O
-	O
LDL	O
.	O

We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	O
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O

Tumor	O
necrosis	O
factor	O
receptor	O
expression	O
and	O
signal	O
transduction	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter	O
-	O
relationship	O
between	O
HIV	O
-	O
1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	I-PRGE
TNF	I-PRGE
)	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV	O
-	O
1	O
replication	O
.	O

DESIGN	O
:	O
Infected	O
promyelocytic	O
and	O
promonocytic	O
cells	O
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	O
receptors	O
.	O

METHODS	O
:	O
TNF	O
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	O
antibody	O
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O

HIV	O
-	O
1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
assay	O
.	O

RESULTS	O
:	O
In	O
the	O
OM	O
-	O
10	O
.	O
1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
HIV	O
-	O
1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B-PRGE
kd	I-PRGE
TNF	I-PRGE
receptor	I-PRGE
(	O
TR75	B-PRGE
)	O
expression	O
although	O
55	B-PRGE
kD	I-PRGE
TNF	I-PRGE
receptor	I-PRGE
(	O
TR55	B-PRGE
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O

A	O
series	O
of	O
uninfected	O
parental	O
HL	O
-	O
60	O
subclones	O
all	O
reduced	O
TR75	B-PRGE
surface	O
expression	O
in	O
response	O
to	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
treatment	O
.	O

Enhanced	O
TR75	B-PRGE
expression	O
on	O
OM	O
-	O
10	O
.	O
1	O
cells	O
followed	O
the	O
same	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV	O
-	O
1	O
production	O
.	O

An	O
increase	O
in	O
TR75	B-PRGE
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV	O
-	O
1	O
infection	O
of	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Although	O
TR55	B-PRGE
expression	O
was	O
unaltered	O
during	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O

Antibody	O
cross	O
-	O
linking	O
of	O
TR55	B-PRGE
,	O
in	O
the	O
absence	O
of	O
exogenous	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
induced	O
maximal	O
HIV	O
-	O
1	O
expression	O
,	O
an	O
up	O
-	O
modulation	O
of	O
surface	O
TR75	B-PRGE
,	O
and	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
OM	O
-	O
10	O
.	O
1	O
cultures	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	O
anti	O
-	O
TR55	B-PRGE
antibody	O
was	O
used	O
.	O

Anti	O
-	O
TR55	B-PRGE
antibody	O
cross	O
-	O
linking	O
in	O
chronically	O
infected	O
U1	O
promonocytic	O
cultures	O
could	O
only	O
partially	O
substitute	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
HIV	O
-	O
1	O
expression	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV	O
-	O
1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	O
receptors	O
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	O
signal	O
transduction	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer	O
/	O
promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	B-PRGE
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
inserted	O
into	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
place	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
binding	O
sites	O
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	O
cells	O
and	O
on	O
HIV	O
infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
or	O
continuous	O
T	O
-	O
leukemia	O
cell	O
lines	O
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Sp1	B-PRGE
enhancer	O
plus	O
the	O
downstream	O
TATA	O
element	O
were	O
replaced	O
with	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	O
cytomegalovirus	O
immediate	O
-	O
early	O
enhancer	O
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
heterologous	O
enhancer	O
elements	O
are	O
capable	O
of	O
restoring	O
Tat	B-PRGE
responsiveness	O
to	O
the	O
HIV	O
LTR	O
in	O
the	O
context	O
of	O
directing	O
reporter	O
gene	O
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O

Ras	O
oncogene	O
transformation	O
of	O
human	O
B	O
lymphoblasts	O
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

The	O
p21ras	B-PRGE
small	O
GTP	O
binding	O
proteins	O
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	O
Ha	O
-	O
ras	O
oncogene	O
in	O
EBV	O
-	O
immortalized	O
B	O
lymphoblasts	O
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
subunit	O
,	O
with	O
an	O
impaired	O
immunoglobulin	O
gene	O
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Since	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
subunit	O
is	O
a	O
hallmark	O
of	O
lymphocyte	O
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B-PRGE
naturally	O
triggers	O
B	O
cell	O
activation	O
.	O

The	O
ras	O
-	O
transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL	O
-	O
2r	O
,	O
as	O
assessed	O
by	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
induction	O
following	O
treatment	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	O
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	O
genes	O
indicates	O
that	O
the	O
ras	O
oncogene	O
blocks	O
terminal	O
differentiation	O
to	O
plasma	O
cells	O
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte	O
-	O
specific	O
transcription	O
factors	O
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B-PRGE
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	O
factors	O
PEA1	O
(	O
AP1	O
)	O
,	O
PEA3	B-PRGE
,	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
NF	O
-	O
kB	O
.	O

The	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
protooncogene	O
product	O
represses	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
and	O
the	O
5	O
'	O
regulatory	O
region	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
subunit	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
share	O
functional	O
kappa	O
B	O
enhancer	O
elements	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T	O
-	O
cell	O
activation	O
.	O

These	O
kappa	O
B	O
enhancer	O
elements	O
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B-PRGE
,	O
p65	B-PRGE
,	O
and	O
the	O
product	O
of	O
the	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
protooncogene	O
(	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
)	O
.	O

Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B-PRGE
and	O
p50	B-PRGE
form	O
the	O
prototypical	O
NF	O
-	O
kappa	O
B	O
complex	O
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T	O
-	O
cell	O
activation	O
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B	O
-	O
directed	O
transcription	O
from	O
either	O
the	O
HIV	O
-	O
1	O
LTR	O
or	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B-PRGE
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B-PRGE
,	O
markedly	O
represses	O
p65	B-PRGE
-	O
mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

These	O
inhibitory	O
effects	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
correlate	O
with	O
its	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-PRGE
,	O
suggesting	O
that	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
inhibition	O
involves	O
competition	O
with	O
p50	B-PRGE
/	O
p65	B-PRGE
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-PRGE
.	O

Dimerization	O
of	O
NF	B-PRGE
-	I-PRGE
KB2	I-PRGE
with	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
.	O

Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	B-PRGE
(	O
p105	B-PRGE
)	O
,	O
NFKB2	B-PRGE
(	O
p100	B-PRGE
)	O
,	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
,	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
and	O
relB	B-PRGE
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	O
B	O
DNA	O
elements	O
have	O
been	O
isolated	O
.	O

We	O
have	O
previously	O
found	O
that	O
NFKB2	B-PRGE
(	O
p49	B-PRGE
/	O
p52	B-PRGE
)	O
acts	O
in	O
concert	O
with	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
to	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	B-PRGE
.	O

Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	O
p49	B-PRGE
and	O
heterodimeric	O
p49	B-PRGE
/	O
p65	B-PRGE
for	O
binding	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

p49	B-PRGE
has	O
a	O
approximately	O
18	O
-	O
fold	O
-	O
lower	O
affinity	O
for	O
the	O
HIV	O
kappa	O
B	O
site	O
(	O
KD	O
=	O
69	O
.	O
1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50	O
-	O
kDa	O
protein	O
NFKB1	B-PRGE
(	O
p50	B-PRGE
)	O
derived	O
from	O
p105	B-PRGE
(	O
KD	O
=	O
3	O
.	O
9	O
pM	O
)	O
.	O

In	O
contrast	O
,	O
the	O
affinity	O
of	O
heterodimeric	O
NFKB2	B-PRGE
(	O
p49	B-PRGE
)	O
/	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
for	O
this	O
site	O
is	O
approximately	O
6	O
-	O
fold	O
higher	O
(	O
KD	O
=	O
11	O
.	O
8	O
pM	O
)	O
than	O
that	O
of	O
p49	B-PRGE
alone	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
in	O
vitro	O
transcription	O
was	O
stimulated	O
18	O
-	O
fold	O
by	O
the	O
addition	O
of	O
preformed	O
,	O
heterodimeric	O
NFKB2	B-PRGE
(	O
p49	B-PRGE
)	O
/	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
protein	O
.	O

Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
.	O

Recombinant	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-PRGE
,	O
p49	B-PRGE
/	O
p65	B-PRGE
,	O
and	O
p50	B-PRGE
/	O
p65	B-PRGE
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B-PRGE
(	O
p49	B-PRGE
)	O
or	O
NFKB1	B-PRGE
(	O
p50	B-PRGE
)	O
.	O

Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49	B-PRGE
/	O
p65	B-PRGE
in	O
transiently	O
transfected	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
transcriptionally	O
active	O
factors	O
mediating	O
the	O
effect	O
of	O
the	O
HTLV	O
-	O
I	O
Tax	B-PRGE
transactivator	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
kappa	O
B	O
enhancer	O
include	O
the	O
product	O
of	O
the	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
proto	O
-	O
oncogene	O
.	O

The	O
transactivator	O
HTLV	O
-	O
I	O
Tax	B-PRGE
activates	O
the	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B-PRGE
2	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
receptor	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
via	O
a	O
kappa	O
B	O
site	O
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	O
family	O
.	O

Tax1	B-PRGE
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	O
HeLa	O
and	O
lymphoid	O
Jurkat	O
cells	O
.	O

This	O
activation	O
was	O
not	O
observed	O
in	O
undifferentiated	O
embryocarcinoma	O
F9	O
cells	O
.	O

Overexpression	O
of	O
the	O
p50	B-PRGE
,	O
p65	B-PRGE
and	O
Rel	O
proteins	O
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
kappa	O
B	O
site	O
was	O
observed	O
only	O
with	O
Rel	O
and	O
Rel	O
plus	O
p65	B-PRGE
.	O

Moreover	O
,	O
whereas	O
both	O
Tax	B-PRGE
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
kappa	O
B	O
site	O
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O

Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B-PRGE
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O

This	O
established	O
a	O
clear	O
difference	O
between	O
both	O
stimuli	O
,	O
indicating	O
that	O
Rel	O
is	O
the	O
functionally	O
active	O
factor	O
.	O

We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	O
family	O
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	O
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	O
B	O
sites	O
.	O

p105	B-PRGE
and	O
p98	B-PRGE
precursor	O
proteins	O
play	O
an	O
active	O
role	O
in	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
signal	O
transduction	O
.	O

The	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
is	O
composed	O
of	O
two	O
distinct	O
subgroups	O
,	O
proteins	O
that	O
undergo	O
proteolytic	O
processing	O
and	O
contain	O
SWI6	O
/	O
ankyrin	O
repeats	O
in	O
their	O
carboxyl	O
termini	O
(	O
p105	B-PRGE
,	O
p98	B-PRGE
)	O
,	O
and	O
those	O
without	O
such	O
repeats	O
that	O
do	O
not	O
require	O
processing	O
(	O
p65	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
RelB	B-PRGE
,	O
and	O
Dorsal	B-PRGE
)	O
.	O

We	O
demonstrate	O
that	O
the	O
p105	B-PRGE
and	O
p98	B-PRGE
precursors	O
share	O
functional	O
properties	O
with	O
the	O
I	O
kappa	O
B	O
proteins	O
,	O
which	O
also	O
contain	O
SWI6	O
/	O
ankyrin	O
repeats	O
.	O

Both	O
p105	B-PRGE
and	O
p98	B-PRGE
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
members	O
,	O
including	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
.	O

Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B-PRGE
or	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O

These	O
complexes	O
undergo	O
stimulus	O
-	O
responsive	O
processing	O
to	O
produce	O
active	O
p50	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
p55	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
complexes	O
.	O

These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
plays	O
a	O
major	O
role	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	O
activator	O
NF	O
-	O
kappa	O
B	O
and	O
its	O
inhibitor	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
NK	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
MAD	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	O
T	O
lymphocytes	O
and	O
monocytes	O
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
with	O
concomitant	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
and	O
protein	O
synthesis	O
.	O

Transfection	O
studies	O
reveal	O
that	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
and	O
by	O
homodimers	O
of	O
p65	B-PRGE
and	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
NF	O
-	O
kappa	O
B	O
and	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Subsequently	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
resurgence	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF	O
-	O
kappa	O
B	O
is	O
again	O
inhibited	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	B-PRGE
and	O
activation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
related	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA	O
-	O
binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
transcription	O
factor	O
family	O
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS	O
-	O
generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p50	B-PRGE
heterodimers	O
as	O
well	O
as	O
p50	B-PRGE
/	O
p65	B-PRGE
(	O
NF	O
-	O
kappa	O
B	O
)	O
kappa	O
B	O
DNA	O
-	O
binding	O
complexes	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	O
ester	O
-	O
sensitive	O
protein	O
kinase	O
C	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
p105	B-PRGE
,	O
and	O
p50	B-PRGE
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
.	O

LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B-PRGE
(	O
an	O
I	O
kappa	O
B	O
-	O
like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	B-PRGE
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	B-PRGE
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p50	B-PRGE
and	O
p50	B-PRGE
/	O
p65	B-PRGE
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B-PRGE
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
protein	O
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
(	O
Mo	O
)	O
constitutively	O
display	O
the	O
beta	O
-	O
chain	O
of	O
the	O
receptor	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
whereas	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
-	O
chain	O
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Here	O
we	O
report	O
that	O
binding	O
of	O
human	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	B-PRGE
CSF	I-PRGE
(	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
gene	O
in	O
Mo	O
resulting	O
in	O
accumulation	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
mRNA	O
and	O
subsequent	O
release	O
of	O
bioactive	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
protein	O
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induced	O
release	O
of	O
an	O
activity	O
-	O
stimulating	O
growth	O
of	O
monocyte	O
-	O
type	O
colonies	O
by	O
a	O
neutralizing	O
anti	O
-	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
antibody	O
.	O

Transcriptional	O
activation	O
of	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
.	O

Moreover	O
,	O
using	O
a	O
heterologous	O
promoter	O
(	O
herpes	O
thymidine	O
kinase	O
)	O
construct	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
,	O
it	O
is	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
binding	O
by	O
an	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
monocyte	O
-	O
derived	O
nuclear	O
protein	O
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induces	O
gene	O
expression	O
of	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
human	O
blood	O
-	O
derived	O
Mo	O
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O

Age	O
-	O
related	O
decreases	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
by	O
human	O
T	O
cells	O
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	O
transcriptional	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

Although	O
transcriptional	O
factors	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
it	O
is	O
unknown	O
if	O
the	O
age	O
-	O
related	O
decline	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
by	O
activated	O
human	O
T	O
cells	O
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	O
regulatory	O
proteins	O
.	O

In	O
the	O
current	O
studies	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
by	O
T	O
cells	O
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B-PRGE
,	O
PHA	B-PRGE
plus	O
PMA	O
,	O
crosslinked	O
anti	O
-	O
CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

Substantial	O
decreases	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
produced	O
by	O
stimulated	O
T	O
cells	O
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

Analyses	O
of	O
nuclear	O
extracts	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
showed	O
that	O
decreased	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
by	O
stimulated	O
T	O
cells	O
of	O
elderly	O
individuals	O
was	O
closely	O
associated	O
with	O
impairments	O
in	O
the	O
activation	O
of	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

By	O
contrast	O
,	O
T	O
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
exhibited	O
normal	O
activation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF	O
-	O
AT	O
showed	O
that	O
the	O
age	O
-	O
related	O
reductions	O
in	O
stimulus	O
-	O
dependent	O
NF	O
-	O
AT	O
complexes	O
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
AP	O
-	O
1	O
.	O

The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
reduced	O
in	O
T	O
cells	O
from	O
certain	O
elderly	O
individuals	O
;	O
however	O
,	O
alterations	O
of	O
NF	O
kappa	O
B	O
did	O
not	O
correlate	O
with	O
changes	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
age	O
-	O
related	O
impairments	O
in	O
the	O
activation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
AP	O
-	O
1	O
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF	O
-	O
AT	O
.	O

Effects	O
of	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
responses	O
to	O
Cryptococcus	O
neoformans	O
,	O
Candida	O
albicans	O
,	O
and	O
lipopolysaccharide	O
.	O

Deactivation	O
of	O
mononuclear	O
phagocytes	O
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	O
cytokine	O
interleukin	B-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
effected	O
dose	O
-	O
dependent	O
inhibition	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
release	O
in	O
PBMC	O
stimulated	O
by	O
LPS	O
and	O
C	O
.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0	O
.	O
1	O
U	O
/	O
ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U	O
/	O
ml	O
.	O

In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U	O
/	O
ml	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibited	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
response	O
to	O
C	O
.	O
albicans	O
by	O
only	O
50	O
%	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
profoundly	O
inhibited	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
from	O
PBMC	O
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
mRNA	O
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibited	O
translocation	O
of	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O

All	O
three	O
stimuli	O
induced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
in	O
PBMC	O
,	O
although	O
over	O
10	O
-	O
fold	O
less	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
released	O
in	O
response	O
to	O
C	O
.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C	O
.	O
albicans	O
.	O

Thus	O
,	O
while	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
has	O
deactivating	O
effects	O
on	O
PBMC	O
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus	O
-	O
and	O
response	O
-	O
specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O

Inhibition	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
of	O
proinflammatory	O
cytokine	O
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

Epstein	O
-	O
Barr	O
virus	O
nuclear	B-PRGE
antigen	I-PRGE
2	I-PRGE
and	O
latent	O
membrane	O
protein	O
independently	O
transactivate	O
p53	B-PRGE
through	O
induction	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

B	O
-	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B-PRGE
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	O
latent	O
genes	O
and	O
p53	B-PRGE
,	O
p53	B-PRGE
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10	O
-	O
fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	O
human	O
B	O
cells	O
;	O
the	O
induced	O
p53	B-PRGE
was	O
transcriptionally	O
active	O
.	O

Latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	O
nuclear	B-PRGE
antigen	I-PRGE
2	I-PRGE
mediated	O
the	O
increase	O
in	O
p53	B-PRGE
levels	O
via	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

Protein	O
-	O
tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-PRGE
1beta	I-PRGE
and	O
NFkappaB	O
activation	O
,	O
but	O
not	O
NFkappaB	O
nuclear	O
translocation	O
.	O

In	O
human	O
monocytes	O
,	O
interleukin	B-PRGE
1beta	I-PRGE
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	B-PRGE
1beta	I-PRGE
gene	O
.	O

Expression	O
of	O
interleukin	B-PRGE
1beta	I-PRGE
and	O
other	O
cytokines	O
,	O
such	O
as	O
interleukin	B-PRGE
6	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NFkappaB	O
.	O

Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide	O
-	O
induced	O
tyrosine	O
kinase	O
activation	O
is	O
not	O
required	O
for	O
NFkappaB	O
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	O
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro	O
-	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
interleukin	B-PRGE
1beta	I-PRGE
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activation	O
.	O

Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	O
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	O
;	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
AP	O
-	O
1	O
-	O
dependent	O
transcription	O
is	O
enhanced	O
.	O

These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
inflammatory	O
mediators	O
requires	O
tyrosine	O
kinase	O
activity	O
,	O
tyrosine	O
kinase	O
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF	O
-	O
kappaB	O
-	O
mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

The	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
,	O
tissue	B-PRGE
factor	I-PRGE
,	O
endothelial	B-PRGE
leukocyte	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
genes	O
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B-PRGE
and	O
tissue	B-PRGE
factor	I-PRGE
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Induction	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50	B-PRGE
/	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-PRGE
,	O
or	O
significantly	O
modify	O
TNFalpha	B-PRGE
-	O
induced	O
phosphorylation	O
of	O
p65	B-PRGE
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	O
containing	O
multimerized	O
kappaB	O
sites	O
by	O
p65	B-PRGE
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	O
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
monocytes	O
and	O
endothelial	O
cells	O
by	O
inhibiting	O
NF	O
-	O
kappaB	O
-	O
mediated	O
transcription	O
.	O

Retinoic	O
acid	O
activates	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
in	O
myeloid	O
cells	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	O
cells	O
into	O
mature	O
granulocytes	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA	O
-	O
dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O

The	O
NB4	O
cell	O
line	O
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	O
cells	O
.	O

Because	O
interferon	O
(	O
IFN	O
)	O
regulatory	O
factors	O
(	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
other	O
IFN	O
-	O
inducible	O
gene	O
products	O
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O

We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
2	O
'	O
-	O
5	O
'	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
in	O
HL	O
-	O
60	O
,	O
U937	O
,	O
and	O
THP	O
-	O
1	O
cells	O
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
NB4	O
cells	O
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
activation	O
.	O

The	O
ATRA	O
-	O
induced	O
expression	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA	O
-	O
induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	O
in	O
myeloid	O
leukemia	O
cells	O
.	O

Effects	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
on	O
LPS	O
-	O
induced	O
transcription	O
factors	O
(	O
AP	O
-	O
1	O
,	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
)	O
which	O
are	O
involved	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
regulation	O
.	O

Interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
,	O
like	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
is	O
known	O
to	O
inhibit	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

We	O
showed	O
that	O
both	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inhibit	O
LPS	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
.	O

The	O
strong	O
inhibition	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
on	O
the	O
expression	O
of	O
transcription	O
factors	O
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
affected	O
the	O
expression	O
of	O
transcription	O
factors	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
transcription	O
rate	O
,	O
namely	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
nuclear	B-PRGE
factor	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
)	O
,	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inhibited	O
LPS	O
-	O
induced	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

The	O
inhibiting	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

Downregulation	O
of	O
LPS	O
-	O
induced	O
AP	O
-	O
1	O
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	O
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP	O
-	O
1	O
complex	O
,	O
namely	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Binding	O
activity	O
of	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
was	O
also	O
strongly	O
inhibited	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
whereas	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
showed	O
no	O
effect	O
.	O

NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
suggesting	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
affects	O
binding	O
activity	O
of	O
preexisting	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
.	O

Neither	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
nor	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
inhibited	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	B-PRGE
and	O
p105	B-PRGE
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
.	O

Furthermore	O
,	O
neither	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
nor	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
showed	O
any	O
effect	O
on	O
I	O
-	O
kappa	O
B	O
mRNA	O
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Thus	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
similarly	O
affect	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
.	O

However	O
,	O
for	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP	O
-	O
1	O
and	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
binding	O
activity	O
whereas	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
only	O
inhibited	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

Activation	O
of	O
human	O
monocytic	O
cells	O
by	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
lipoproteins	O
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF	O
-	O
kappa	O
B	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	O
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein	O
-	O
lipopeptide	O
-	O
induced	O
immune	O
cell	O
signaling	O
events	O
.	O

Like	O
LPS	O
,	O
purified	O
native	O
B	O
.	O
burgdorferi	O
OspA	B-PRGE
and	O
synthetic	O
analogs	O
of	O
OspA	B-PRGE
,	O
OspB	O
,	O
and	O
two	O
T	O
.	O
pallidum	O
lipoproteins	O
(	O
Tpp47	B-PRGE
and	O
Tpp17	B-PRGE
)	O
all	O
induced	O
NF	O
-	O
kappa	O
B	O
translocation	O
in	O
THP	O
-	O
1	O
human	O
monocytoid	O
cells	O
.	O

Acylation	O
of	O
OspA	B-PRGE
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

By	O
using	O
70Z	O
/	O
3	O
-	O
derived	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
either	O
lacking	O
or	O
expressing	O
human	O
CD14	B-PRGE
(	O
the	O
LPS	O
receptor	O
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	O
CD14	B-PRGE
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-PRGE
or	O
spirochetal	O
lipopeptides	O
(	O
assessed	O
by	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
expression	O
of	O
surface	O
immunoglobulin	O
M	O
)	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T	O
.	O
pallidum	O
lipoproteins	O
-	O
lipopeptides	O
induce	O
both	O
NF	O
-	O
kappa	O
B	O
and	O
cytokine	O
production	O
in	O
monocytes	O
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	O
lipoproteins	O
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	O
cells	O
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
pathway	O
via	O
enhanced	O
IkappaBalpha	B-PRGE
degradation	O
.	O

Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
causes	O
sustained	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
myelomonoblastic	O
PLB	O
-	O
985	O
cells	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
HIV1	O
-	O
infected	O
cells	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B-PRGE
protein	O
,	O
the	O
activity	O
of	O
the	O
double	B-PRGE
-	I-PRGE
stranded	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
PKR	B-PRGE
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF	O
-	O
kappaB	O
subunits	O
in	O
the	O
PLB	O
-	O
985	O
and	O
U937	O
myeloid	O
cell	O
models	O
.	O

HIV	O
-	O
1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low	O
-	O
level	O
expression	O
of	O
type	O
1	O
interferon	O
(	O
IFN	O
)	O
at	O
the	O
mRNA	O
level	O
.	O

Constitutive	O
PKR	B-PRGE
activity	O
was	O
also	O
detected	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
as	O
a	O
result	O
of	O
low	O
-	O
level	O
IFN	O
production	O
,	O
since	O
the	O
addition	O
of	O
anti	O
-	O
IFN	O
-	O
alpha	O
/	O
beta	O
antibody	O
to	O
the	O
cells	O
decreased	O
PKR	B-PRGE
expression	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
IkappaBalpha	B-PRGE
turnover	O
demonstrated	O
an	O
increased	O
degradation	O
of	O
IkappaBalpha	B-PRGE
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
that	O
may	O
account	O
for	O
the	O
constitutive	O
DNA	O
binding	O
activity	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF	O
-	O
kappaB	O
subunits	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
kappaB2	I-PRGE
p100	I-PRGE
and	O
a	O
moderate	O
increase	O
in	O
NF	B-PRGE
-	I-PRGE
kappaB2	I-PRGE
p52	I-PRGE
and	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
were	O
detected	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
,	O
whereas	O
NF	B-PRGE
-	I-PRGE
kappaB1	I-PRGE
p105	I-PRGE
/	O
p50	B-PRGE
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	O
cells	O
.	O

We	O
suggest	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myeloid	O
cells	O
induces	O
IFN	O
production	O
and	O
PKR	B-PRGE
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B-PRGE
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
subunits	O
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF	O
-	O
kappaB	O
/	O
IkappaBalpha	B-PRGE
by	O
an	O
autoregulatory	O
mechanism	O
.	O

Enhanced	O
turnover	O
of	O
IkappaBalpha	B-PRGE
and	O
the	O
accumulation	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
proteins	O
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
.	O

Differential	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
transcription	O
and	O
expression	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibit	O
the	O
cytokine	O
production	O
and	O
mRNA	O
expression	O
by	O
monocytes	O
/	O
macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
we	O
studied	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
,	O
expression	O
level	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP	O
-	O
1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
or	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

Both	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
were	O
seen	O
to	O
inhibit	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
and	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
in	O
both	O
monocytic	O
cell	O
lines	O
studied	O
.	O

In	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
reporter	O
plasmid	O
containing	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
promoter	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
inhibited	O
nuclear	O
NF	O
-	O
kappaB	O
activity	O
,	O
and	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
did	O
not	O
affect	O
NF	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
enhanced	O
the	O
degradation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
by	O
affecting	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
while	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
may	O
inhibit	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibit	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
by	O
different	O
mechanisms	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

Tyloxapol	O
inhibits	O
NF	O
-	O
kappa	O
B	O
and	O
cytokine	O
release	O
,	O
scavenges	O
HOCI	O
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine	O
-	O
mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease	O
-	O
and	O
oxidant	O
-	O
rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NK	O
-	O
kappa	O
B	O
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
in	O
cultured	O
human	O
monocytes	O
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
release	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

Tyloxapol	O
(	O
0	O
.	O
05	O
to	O
0	O
.	O
1	O
%	O
wt	O
/	O
vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7	O
.	O
5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl	O
-	O
mediated	O
lung	O
injury	O
in	O
rats	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+	O
/	O
-	O
133	O
to	O
128	O
+	O
/	O
-	O
52	O
centipoise	O
)	O
.	O

We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O

Cytomegalovirus	O
modulates	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
.	O

Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection	O
,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Several	O
recent	O
studies	O
have	O
suggested	O
that	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
6	I-PRGE
may	O
be	O
used	O
to	O
detect	O
both	O
infection	O
and	O
rejection	O
after	O
lung	O
transplantation	O
.	O

In	O
addition	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
.	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
and	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
CMV	O
immediate	B-PRGE
early	I-PRGE
1	I-PRGE
gene	O
product	O
increased	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
.	O

This	O
effect	O
of	O
the	O
CMV	O
immediate	B-PRGE
early	I-PRGE
1	I-PRGE
gene	O
product	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
.	O

These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross	O
-	O
talk	O
between	O
glucocorticoids	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
as	O
adhesion	O
molecules	O
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
.	O

We	O
observed	O
that	O
in	O
a	O
monocytic	O
(	O
U937	O
)	O
and	O
a	O
bronchial	O
epithelial	O
(	O
H292	O
)	O
cell	O
-	O
line	O
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Subsequent	O
analysis	O
of	O
the	O
human	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
has	O
revealed	O
that	O
both	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
and	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
upregulate	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	O
factor	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
target	O
sequence	O
(	O
TGGAAATTCC	O
)	O
.	O

No	O
glucocorticoid	O
recognition	O
sequences	O
are	O
present	O
in	O
this	O
promoter	O
region	O
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	O
NF	O
-	O
kappa	O
B	O
sequence	O
is	O
transactivated	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
upon	O
transfection	O
in	O
293	O
cells	O
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B-PRGE
receptor	I-PRGE
and	O
nuclear	O
factor	O
-	O
kappa	O
B	O
factors	O
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O

The	O
suppression	O
of	O
T	O
cell	O
function	O
and	O
NF	O
(	O
kappa	O
)	O
B	O
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N	O
-	O
acetylcysteine	O
.	O

Direct	O
evidence	O
that	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	O
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
is	O
presented	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	O
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N	O
-	O
tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	O
CD4	B-PRGE
+	O
or	O
CD8	O
+	O
T	O
cells	O
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti	O
-	O
CD28	O
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	O
.	O

Cytokine	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
INF	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
production	O
is	O
inhibited	O
95	O
-	O
100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4	B-PRGE
+	O
or	O
CD8	O
+	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
(	O
but	O
not	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O

Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	O
cells	O
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O

NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	O
production	O
(	O
>	O
2	O
.	O
5	O
-	O
fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	O
T	O
cells	O
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	O
(	O
kappa	O
)	O
B	O
and	O
I	O
(	O
kappa	O
)	O
B	O
proteases	O
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

Signal	O
transduction	O
by	O
DR3	B-PRGE
,	O
a	O
death	O
domain	O
-	O
containing	O
receptor	O
related	O
to	O
TNFR	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CD95	B-PRGE
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
TNFR	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
CD95	B-PRGE
(	O
also	O
called	O
Fas	B-PRGE
or	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
are	O
cytokine	O
receptors	O
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
"	O
death	O
domain	O
.	O
"	O
Another	O
death	O
domain	O
-	O
containing	O
member	O
of	O
the	O
TNFR	O
family	O
,	O
death	B-PRGE
receptor	I-PRGE
3	I-PRGE
(	O
DR3	B-PRGE
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	O
factor	O
kappaB	O
.	O

Expression	O
of	O
DR3	B-PRGE
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	O
.	O

DR3	B-PRGE
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	O
signaling	O
molecules	O
including	O
TRADD	B-PRGE
,	O
TRAF2	B-PRGE
,	O
FADD	B-PRGE
,	O
and	O
FLICE	B-PRGE
.	O

Thus	O
,	O
DR3	B-PRGE
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O

Regulation	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	O
expression	O
.	O

Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
,	O
also	O
known	O
as	O
type	B-PRGE
II	I-PRGE
interferon	I-PRGE
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	O
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
.	O

The	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	O
is	O
induced	O
/	O
inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O

In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	O
binding	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

CD14	B-PRGE
-	O
mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
monocytes	O
/	O
macrophages	O
via	O
CD14	B-PRGE
,	O
one	O
of	O
the	O
LPS	O
receptors	O
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P	O
-	O
LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	O
cytokines	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-PRGE
is	O
expressed	O
in	O
gingival	O
fibroblasts	O
and	O
to	O
define	O
the	O
P	O
-	O
LPS	O
-	O
mediated	O
signal	O
-	O
transducing	O
mechanism	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B-PRGE
is	O
expressed	O
at	O
high	O
density	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
gene	O
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti	O
-	O
human	O
CD14	B-PRGE
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
production	O
by	O
the	O
cells	O
.	O

Furthermore	O
,	O
P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	O
factors	O
,	O
i	O
.	O
e	O
.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP	O
-	O
1	O
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O

Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
contents	O
in	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B-PRGE
in	O
human	O
gingival	O
fibroblasts	O
and	O
to	O
show	O
that	O
the	O
signal	O
-	O
transducing	O
pathway	O
of	O
P	O
-	O
LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B-PRGE
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
factor	I-PRGE
3	I-PRGE
binding	O
sites	O
in	O
the	O
human	O
and	O
simian	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
LMP1	B-PRGE
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B	O
-	O
lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus	O
-	O
induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation	O
-	O
associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
homologs	O
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy	O
-	O
terminal	O
cytoplasmic	O
domain	O
essential	O
for	O
B	O
-	O
cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	O
EBV	O
LMP1s	B-PRGE
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-PRGE
,	O
including	O
the	O
ability	O
to	O
induce	O
NF	O
-	O
(	O
kappa	O
)	O
B	O
activity	O
in	O
human	O
cells	O
,	O
to	O
bind	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
associated	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
TRAF3	B-PRGE
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
genes	O
,	O
such	O
as	O
ICAM1	B-PRGE
,	O
in	O
human	O
B	O
lymphocytes	O
.	O

Multiple	O
TRAF3	B-PRGE
binding	O
sites	O
containing	O
a	O
PXQXT	O
/	O
S	O
core	O
sequence	O
can	O
be	O
identified	O
in	O
the	O
simian	O
EBV	O
LMP1s	B-PRGE
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT	O
/	O
S	O
-	O
containing	O
sequence	O
is	O
also	O
present	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
Hodgkin	O
'	O
s	O
disease	O
marker	O
,	O
CD30	B-PRGE
,	O
and	O
binds	O
TRAF3	B-PRGE
in	O
vitro	O
.	O

The	O
last	O
13	O
amino	O
acids	O
containing	O
a	O
PXQXT	O
/	O
S	O
sequence	O
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	B-PRGE
but	O
do	O
not	O
bind	O
TRAF3	B-PRGE
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	B-PRGE
.	O

The	O
conserved	O
TRAF3	B-PRGE
binding	O
sites	O
in	O
LMP1	B-PRGE
and	O
the	O
CD30	B-PRGE
Hodgkin	O
'	O
s	O
disease	O
marker	O
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B-PRGE
-	O
mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Tyrosine	O
kinase	O
and	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activities	O
in	O
CD40	B-PRGE
-	O
activated	O
human	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
,	O
human	O
B	O
lymphocytes	O
undergo	O
long	O
-	O
term	O
proliferation	O
when	O
activated	O
through	O
CD40	B-PRGE
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

The	O
nature	O
of	O
CD40	B-PRGE
-	O
dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	O
Epstein	O
-	O
Barr	O
virus	O
-	O
negative	O
B	O
lymphocytes	O
is	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
a	O
CD40	B-PRGE
-	O
dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	O
transduction	O
elements	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
depletion	O
generated	O
by	O
a	O
long	O
-	O
term	O
phorbol	O
12	O
myristate	O
13	O
-	O
acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40	B-PRGE
-	O
dependent	O
signals	O
.	O

The	O
use	O
of	O
the	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
-	O
specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
HIV	O
-	O
1	O
LTR	O
)	O
,	O
a	O
promoter	O
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
specific	O
inhibitor	O
H	O
-	O
89	O
totally	O
inhibited	O
HIV	O
-	O
1	O
LTR	O
activity	O
at	O
a	O
concentration	O
as	O
low	O
as	O
100	O
nM	O
without	O
affecting	O
cellular	O
proliferation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF	O
-	O
kappa	O
B	O
binding	O
sequence	O
from	O
the	O
kappa	O
light	O
chain	O
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	B-PRGE
(	O
RelA	B-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
were	O
present	O
in	O
CD40	B-PRGE
-	O
stimulated	O
B	O
cells	O
.	O

While	O
PKC	O
depletion	O
did	O
not	O
alter	O
the	O
NF	O
-	O
kappa	O
B	O
level	O
,	O
treatment	O
of	O
B	O
lymphocytes	O
with	O
H	O
-	O
89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
level	O
.	O

These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	B-PRGE
activation	O
of	O
B	O
lymphocytes	O
.	O

Characterization	O
of	O
a	O
CD43	B-PRGE
/	O
leukosialin	B-PRGE
-	O
mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
J393	O
induces	O
apoptosis	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140	O
-	O
kDa	O
surface	O
antigen	O
for	O
mAb	O
J393	O
as	O
CD43	B-PRGE
/	O
leukosialin	B-PRGE
,	O
the	O
major	O
sialoglycoprotein	O
of	O
leukocytes	O
.	O

While	O
Jurkat	O
cells	O
co	O
-	O
expressed	O
two	O
discrete	O
cell	O
-	O
surface	O
isoforms	O
of	O
CD43	B-PRGE
,	O
recognized	O
by	O
mAb	O
J393	O
and	O
mAb	O
G10	O
-	O
2	O
,	O
respectively	O
,	O
only	O
J393	O
/	O
CD43	B-PRGE
signaled	O
apoptosis	O
.	O

J393	O
/	O
CD43	B-PRGE
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O	O
-	O
linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10	O
-	O
2	O
/	O
CD43	B-PRGE
bore	O
complex	O
sialylated	O
tetra	O
-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	O
J393	O
killed	O
25	O
-	O
50	O
%	O
of	O
the	O
cell	O
population	O
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3	O
.	O
TcR	O
complex	O
or	O
the	O
integrins	O
CD18	B-PRGE
and	O
CD29	B-PRGE
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	O
cells	O
with	O
mAb	O
J393	O
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	O
receptor	O
costimulation	O
.	O

Tyrosine	O
kinase	O
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393	O
/	O
CD43	B-PRGE
-	O
mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	O
phosphatase	O
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium	O
-	O
IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393	O
/	O
CD43	B-PRGE
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	O
regulatory	O
protein	O
NF	O
-	O
kappaB	O
and	O
proteins	O
binding	O
the	O
interferon	O
-	O
inducible	O
regulatory	O
element	O
.	O

Since	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
express	O
cryptic	O
epitopes	O
for	O
mAb	O
J393	O
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-PRGE
-	O
mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
cell	O
lineages	O
.	O

Naive	O
(	O
CD45RA	B-PRGE
+	O
)	O
T	O
lymphocytes	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
-	O
induced	O
signals	O
than	O
memory	O
(	O
CD45RO	B-PRGE
+	O
)	O
cells	O
.	O

Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	O
lymphocytes	O
,	O
e	O
.	O
g	O
.	O
,	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
its	O
receptor	O
are	O
induced	O
.	O

These	O
ROI	O
-	O
induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

Now	O
we	O
have	O
examined	O
whether	O
naive	O
and	O
memory	O
T	O
lymphocytes	O
differ	O
in	O
their	O
sensitivity	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O

When	O
CD45RA	B-PRGE
+	O
(	O
naive	O
)	O
and	O
CD45RO	B-PRGE
+	O
(	O
memory	O
)	O
T	O
lymphocytes	O
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	O
cells	O
than	O
in	O
memory	O
cells	O
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O

The	O
composition	O
of	O
the	O
induced	O
nuclear	O
NF	O
-	O
kappaB	O
(	O
levels	O
of	O
p50	B-PRGE
and	O
RelA	B-PRGE
proteins	O
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O

The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI	O
-	O
forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	O
inhibitor	O
:	O
in	O
CD45RA	B-PRGE
+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
.	O

These	O
findings	O
indicate	O
that	O
T	O
cells	O
representing	O
different	O
activation	O
and	O
/	O
or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
and	O
RelB	B-PRGE
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
,	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
p65	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
and	O
RelB	B-PRGE
,	O
constitute	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B-PRGE
knockout	O
mice	O
have	O
no	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

An	O
overexpression	O
of	O
p50	B-PRGE
has	O
been	O
described	O
in	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

A	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
reported	O
in	O
mature	O
macrophages	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
were	O
key	O
nuclear	O
factors	O
in	O
functions	O
of	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	O
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
and	O
RelB	B-PRGE
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	O
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68	B-PRGE
+	O
cells	O
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-PRGE
,	O
p52	B-PRGE
,	O
and	O
RelB	B-PRGE
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA	B-PRGE
-	I-PRGE
DR	I-PRGE
+	O
cells	O
with	O
an	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	B-PRGE
and	O
RelB	B-PRGE
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a	B-PRGE
+	O
and	O
CD68	B-PRGE
+	O
cells	O
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B-PRGE
was	O
found	O
only	O
in	O
CD68	B-PRGE
-	O
and	O
CD1a	B-PRGE
-	O
cells	O
.	O

Cells	O
with	O
nuclear	O
p50	B-PRGE
were	O
negative	O
for	O
the	O
CD38	B-PRGE
,	O
CD20	B-PRGE
and	O
CD2	B-PRGE
markers	O
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B-PRGE
,	O
p52	B-PRGE
and	O
RelB	B-PRGE
are	O
restricted	O
to	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	O
in	O
GC	O
,	O
and	O
DC	O
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	O
macrophages	O
from	O
GC	O
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B-PRGE
and	O
RelB	B-PRGE
,	O
whereas	O
macrophages	O
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	O
cells	O
,	O
do	O
have	O
both	O
nuclear	O
p52	B-PRGE
and	O
RelB	B-PRGE
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B-PRGE
and	O
RelB	B-PRGE
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a	B-PRGE
+	O
,	O
CD68	B-PRGE
+	O
or	O
both	O
,	O
cells	O
APC	O
,	O
whereas	O
p50	B-PRGE
is	O
restricted	O
to	O
CD1a	B-PRGE
-	O
and	O
CD68	B-PRGE
-	O
APC	O
.	O

The	O
different	O
patterns	O
of	O
p50	B-PRGE
,	O
p52	B-PRGE
and	O
RelB	B-PRGE
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

CD40	B-PRGE
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti	O
-	O
IgM	B-PRGE
stimulation	O
of	O
primary	O
B	O
lymphocytes	O
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-PRGE
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-PRGE
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel	O
/	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
factors	O
in	O
primary	O
murine	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	B-PRGE
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-PRGE
ligands	O
expressed	O
on	O
L	O
cells	O
led	O
to	O
strong	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
controlled	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
reporter	O
gene	O
in	O
primary	O
B	O
lymphocytes	O
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	O
proteins	O
after	O
CD40	B-PRGE
induction	O
of	O
primary	O
B	O
cells	O
showed	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
accumulation	O
of	O
RelB	B-PRGE
and	O
,	O
less	O
pronounced	O
,	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
whereas	O
nuclear	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
but	O
not	O
RelB	B-PRGE
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	B-PRGE
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	B-PRGE
RNA	O
and	O
protein	O
.	O

S107	O
plasmacytoma	O
cells	O
,	O
which	O
express	O
CD40	B-PRGE
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50	B-PRGE
/	O
p65	B-PRGE
-	O
NF	O
-	O
kappaB	O
,	O
do	O
not	O
express	O
RelB	B-PRGE
after	O
CD40	B-PRGE
stimulation	O
.	O

In	O
S107	O
cells	O
stably	O
transfected	O
with	O
relB	B-PRGE
genes	O
,	O
stimulation	O
of	O
nuclear	O
RelB	B-PRGE
translocation	O
by	O
CD40	B-PRGE
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B-PRGE
signaling	O
pathways	O
exerts	O
a	O
long	O
-	O
lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B-PRGE
.	O

Since	O
LPS	O
and	O
anti	O
-	O
IgM	B-PRGE
were	O
unable	O
to	O
activate	O
RelB	B-PRGE
,	O
CD40	B-PRGE
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and	O
/	O
or	O
differentiation	O
of	O
B	O
lymphocytes	O
.	O

HIV	O
-	O
1	O
LTR	O
activity	O
in	O
human	O
CD40	B-PRGE
-	O
activated	O
B	O
lymphocytes	O
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
.	O

CD40	B-PRGE
-	O
stimulated	O
human	O
B	O
lymphocytes	O
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	O
factors	O
involved	O
in	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
which	O
contains	O
the	O
transcriptional	O
control	O
elements	O
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	O
region	O
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
was	O
essential	O
for	O
HIV	O
-	O
1	O
LTR	O
activity	O
in	O
CD40	B-PRGE
-	O
stimulated	O
B	O
lymphocytes	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF	O
-	O
kappaB	O
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B-PRGE
,	O
p65	B-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
NF	O
-	O
kappaB	O
subunits	O
was	O
present	O
in	O
nuclei	O
of	O
CD40	B-PRGE
-	O
stimulated	O
B	O
cells	O
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
B	O
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF	O
-	O
kappaB	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
via	O
T	O
cell	O
receptor	O
requires	O
a	O
Raf	O
kinase	O
and	O
Ca2	O
+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	O
and	O
calcineurin	O
.	O

Signals	O
transduced	O
via	O
the	O
TCR	O
activate	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	O
kinase	O
C	O
activator	O
PMA	O
in	O
combination	O
with	O
Ca2	O
+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	O
stimulation	O
,	O
bypassing	O
the	O
TCR	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	O
-	O
kappaB	O
following	O
TCR	O
stimulation	O
.	O

TCR	O
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	O
T	O
cells	O
with	O
PHA	B-PRGE
or	O
anti	O
-	O
CD3	B-PRGE
Abs	O
,	O
and	O
NF	O
-	O
kappaB	O
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
/	O
or	O
by	O
kappaB	O
-	O
dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	O
kinase	O
C	O
is	O
involved	O
in	O
TCR	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
PHA	B-PRGE
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B-PRGE
-	O
induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	O
kinase	O
.	O

The	O
TCR	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
also	O
dependent	O
on	O
a	O
Ca2	O
+	O
influx	O
,	O
because	O
the	O
Ca2	O
+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2	O
+	O
influx	O
,	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
largely	O
substituted	O
for	O
the	O
Ca2	O
+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
calcineurin	O
synergistically	O
induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	O
and	O
the	O
phosphatase	O
.	O

Synergistic	O
interactions	O
between	O
overlapping	O
binding	O
sites	O
for	O
the	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
and	O
ELK	B-PRGE
-	I-PRGE
1	I-PRGE
proteins	O
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	O
cytomegalovirus	O
major	O
immediate	O
-	O
early	O
promoters	O
in	O
monocyte	O
and	O
T	O
-	O
lymphocyte	O
cell	O
types	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	O
and	O
myeloid	O
cell	O
types	O
but	O
can	O
be	O
activated	O
in	O
differentiated	O
macrophages	O
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	O
immediate	O
-	O
early	O
gene	O
(	O
MIE	O
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte	O
-	O
like	O
U	O
-	O
937	O
cell	O
cultures	O
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Two	O
multicopy	O
basal	O
enhancer	O
motifs	O
within	O
the	O
SCMV	O
MIE	O
enhancer	O
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16	O
-	O
bp	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
3	O
copies	O
of	O
novel	O
17	O
-	O
bp	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
(	O
SRF	B-PRGE
)	O
binding	O
sites	O
referred	O
to	O
as	O
the	O
SNE	O
(	O
SRF	B-PRGE
/	O
NFkappaB	O
-	O
like	O
element	O
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	O
sites	O
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	O
and	O
T	O
-	O
cell	O
types	O
.	O

The	O
SCMV	O
SNE	O
sites	O
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B-PRGE
,	O
Rel	O
/	O
NFkappaB	O
,	O
ETS	O
,	O
and	O
YY1	O
class	O
transcription	O
factors	O
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	O
or	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	O
motifs	O
and	O
of	O
a	O
related	O
16	O
-	O
bp	O
SEE	O
(	O
SRF	B-PRGE
/	O
ETS	O
element	O
)	O
motif	O
found	O
in	O
the	O
HCMV	O
and	O
chimpanzee	O
CMV	O
MIE	O
enhancers	O
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	O
wild	O
-	O
type	O
and	O
mutant	O
elements	O
added	O
upstream	O
to	O
the	O
SCMV	O
MIE	O
or	O
simian	O
virus	O
40	O
minimal	O
promoter	O
regions	O
in	O
the	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
HL	O
-	O
60	O
,	O
THP	O
-	O
1	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

Unlike	O
classical	O
NFkappaB	O
sites	O
,	O
neither	O
the	O
SNE	O
nor	O
the	O
SEE	O
motif	O
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	O
elements	O
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-PRGE
binding	O
site	O
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	O
binding	O
motifs	O
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	O
complex	O
containing	O
both	O
the	O
cellular	O
SRF	B-PRGE
and	O
ELK	B-PRGE
-	I-PRGE
1	I-PRGE
proteins	O
.	O

This	O
protein	O
complex	O
was	O
more	O
abundant	O
in	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	O
,	O
HF	O
,	O
BALB	O
/	O
c	O
3T3	O
,	O
or	O
HL	O
-	O
60	O
cells	O
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O

A	O
40	O
-	O
fold	O
stimulation	O
of	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
activity	O
mediated	O
by	O
four	O
tandem	O
repeats	O
of	O
the	O
SNE	O
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250	O
-	O
fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA	O
-	O
transfected	O
U	O
-	O
937	O
cells	O
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	O
kinase	O
C	O
-	O
mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	O
SRF	B-PRGE
binding	O
site	O
compared	O
with	O
that	O
of	O
the	O
classical	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
promoter	O
serum	O
response	O
element	O
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	B-PRGE
and	O
ETS	O
motifs	O
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	O
SNEs	O
to	O
respond	O
to	O
serum	O
induction	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B-PRGE
factor	I-PRGE
(	O
TF	B-PRGE
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alfa	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS	O
-	O
induced	O
synthesis	O
of	O
the	O
pro	O
-	O
coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro	O
-	O
inflammatory	O
protein	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	O
PGE2	O
in	O
human	O
monocytes	O
.	O

Both	O
drugs	O
dose	O
-	O
dependently	O
inhibited	O
LPS	O
-	O
induced	O
TF	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
synthesis	O
at	O
the	O
mRNA	O
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	O
production	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
prototypic	O
probe	O
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
proteins	O
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti	O
-	O
thrombotic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	O
occurs	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	O
adhesion	O
molecules	O
CD62E	B-PRGE
,	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
and	O
CD106	B-PRGE
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	O
and	O
5	O
-	O
lipoxygenase	O
has	O
been	O
shown	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
CD54	B-PRGE
)	O
/	O
MAC	O
-	O
1	O
(	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	O
cells	O
to	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	O
molecules	O
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65	B-PRGE
/	O
p50	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
on	O
monocytic	O
HL60	O
cells	O
,	O
and	O
endothelial	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
CD62E	B-PRGE
)	O
and	O
vascular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
CD106	B-PRGE
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Expression	O
of	O
other	O
adhesion	O
molecules	O
such	O
as	O
lymphocyte	O
function	O
associated	O
-	O
antigen	O
-	O
1	O
(	O
CD11a	B-PRGE
/	O
CD18	B-PRGE
)	O
and	O
CD54	B-PRGE
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
regulated	O
chemokine	O
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
a	O
known	O
inducer	O
of	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	O
molecules	O
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Nuclear	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
is	O
a	O
hallmark	O
of	O
unstimulated	O
B	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O

B	O
lymphocytes	O
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	O
factors	O
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	O
cells	O
.	O

The	O
following	O
transcription	O
factors	O
were	O
studied	O
:	O
the	O
Octamer	O
factors	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
members	O
of	O
the	O
AP	O
-	O
1	O
factor	O
family	O
,	O
NF	O
-	O
AT	O
factors	O
,	O
in	O
particular	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
,	O
and	O
members	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kB	O
family	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
nuclear	O
translocation	O
of	O
NF	B-PRGE
-	I-PRGE
ATp	I-PRGE
,	O
a	O
member	O
of	O
the	O
growing	O
family	O
of	O
NF	O
-	O
AT	O
factors	O
,	O
is	O
a	O
hallmark	O
of	O
nonstimulated	O
B	O
cells	O
from	O
CLL	O
patients	O
that	O
distinguishes	O
B	O
-	O
CLL	O
cells	O
from	O
'	O
normal	O
'	O
B	O
lymphocytes	O
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF	O
-	O
kB2	O
/	O
p52	B-PRGE
.	O

Constitutive	O
binding	O
of	O
further	O
factor	O
proteins	O
to	O
DNA	O
,	O
such	O
as	O
JunD	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
FosB	B-PRGE
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
RelA	B-PRGE
/	O
p65	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
was	O
unaltered	O
.	O

It	O
is	O
remarkable	O
that	O
in	O
B	O
-	O
CLL	O
cells	O
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	O
factors	O
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	O
family	O
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O

It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'	O
pre	O
-	O
activation	O
'	O
,	O
i	O
.	O
e	O
.	O
constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF	O
-	O
AT	O
,	O
NF	O
-	O
kB	O
and	O
AP	O
-	O
1	O
factor	O
families	O
.	O

Induction	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
by	O
low	O
-	O
density	O
lipoprotein	O
.	O

Low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
is	O
a	O
well	O
-	O
established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	O
is	O
increased	O
recruitment	O
of	O
monocytes	O
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O

The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	O
lipoprotein	O
,	O
LDL	O
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	O
induces	O
the	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	O
promoter	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti	O
-	O
VCAM	O
antibodies	O
.	O

After	O
a	O
2	O
-	O
day	O
incubation	O
in	O
LDL	O
,	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative	O
-	O
stress	O
sensor	O
for	O
VCAM	O
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP	O
-	O
1	O
and	O
GATA	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	O
.	O

Thus	O
,	O
a	O
component	O
of	O
LDL	O
-	O
enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	O
is	O
attributed	O
to	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP	O
-	O
1	O
and	O
GATA	O
.	O

These	O
data	O
identify	O
LDL	O
as	O
a	O
VCAM	O
-	O
inducer	O
possibly	O
distinct	O
from	O
cytokines	O
and	O
endotoxin	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
subunit	O
p65	B-PRGE
mRNA	O
accumulation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
treated	O
with	O
sodium	O
salicylate	O
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	O
genes	O
is	O
still	O
unknown	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
;	O
heterodimer	O
of	O
p50	B-PRGE
and	O
p65	B-PRGE
)	O
proteins	O
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	O
mediators	O
when	O
monocytes	O
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
"	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
"	O
,	O
blocking	O
the	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
into	O
the	O
nuclear	O
compartment	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	O
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
kappa	O
B	O
mRNA	O
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
was	O
assessed	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF	O
-	O
kappa	O
B	O
p65	B-PRGE
mRNA	O
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF	O
-	O
kappa	O
B	O
,	O
p50	B-PRGE
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
p65	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	O
mediators	O
.	O

Genes	O
that	O
regulate	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
expression	O
in	O
T	O
cells	O
.	O

Interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
is	O
an	O
immunomodulatory	O
cytokine	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	O
factors	O
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	O
helper	O
cell	O
cytokine	O
gene	O
expression	O
.	O

Regulation	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
by	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
are	O
largely	O
due	O
to	O
transcriptional	O
inhibition	O
of	O
immunologically	O
relevant	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
.	O

In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	O
precursor	O
mRNA	O
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	B-PRGE
and	O
GRbeta	B-PRGE
.	O

We	O
previously	O
demonstrated	O
that	O
GRbeta	B-PRGE
could	O
antagonize	O
GRalpha	B-PRGE
-	O
mediated	O
transactivation	O
of	O
a	O
glucocorticoid	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
-	O
driven	O
reporter	O
gene	O
in	O
COS	O
-	O
7	O
cells	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	O
isoforms	O
on	O
glucocorticoid	B-PRGE
-	O
mediated	O
transrepression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	O
human	O
lymphocytes	O
,	O
stimulation	O
of	O
a	O
548	O
bp	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
luciferase	O
reporter	O
construct	O
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	B-PRGE
expression	O
vector	O
.	O

Transfection	O
of	O
a	O
GRbeta	B-PRGE
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Furthermore	O
,	O
GRbeta	B-PRGE
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	B-PRGE
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B-PRGE
in	O
Jurkat	O
cells	O
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B-PRGE
-	O
induced	O
transactivation	O
of	O
a	O
GRE	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
either	O
.	O

We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B-PRGE
.	O

GRbeta	B-PRGE
can	O
neither	O
antagonize	O
GRalpha	B-PRGE
-	O
mediated	O
transactivation	O
nor	O
transrepression	O
in	O
Jurkat	O
cells	O
,	O
indicating	O
a	O
cell	O
type	O
-	O
specific	O
pattern	O
of	O
GRbeta	B-PRGE
-	O
mediated	O
antiglucocorticoid	O
activity	O
.	O

Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O

Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	O
and	O
recruitment	O
of	O
neutrophils	O
(	O
PMN	O
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
activation	O
of	O
Stat3	B-PRGE
.	O

Using	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Increased	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
expression	O
was	O
localized	O
to	O
bronchial	O
and	O
alveolar	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B-PRGE
activation	O
with	O
kinetics	O
similar	O
to	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B-PRGE
activation	O
predominantly	O
within	O
alveoli	O
.	O

Intratracheal	O
instillation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
.	O

These	O
findings	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
and	O
Stat3	B-PRGE
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN	O
-	O
mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

Involvement	O
of	O
adenylate	O
cyclase	O
and	O
p70	B-PRGE
(	I-PRGE
S6	I-PRGE
)	I-PRGE
-	I-PRGE
kinase	I-PRGE
activation	O
in	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
up	O
-	O
regulation	O
in	O
human	O
monocytes	O
by	O
gp41	B-PRGE
envelope	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	O
gp41	B-PRGE
(	O
aa565	O
-	O
647	O
)	O
,	O
the	O
extracellular	O
domain	O
of	O
HIV	O
-	O
1	O
transmembrane	O
glycoprotein	O
,	O
stimulates	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
production	O
in	O
human	O
monocytes	O
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
up	O
-	O
regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	O
-	O
kappaB	O
pathways	O
.	O

gp41	B-PRGE
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
and	O
the	O
adenylate	O
cyclase	O
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
in	O
monocytes	O
.	O

In	O
contrast	O
,	O
gp41	B-PRGE
failed	O
to	O
stimulate	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
main	O
NF	O
-	O
kappaB	O
-	O
binding	O
site	O
2	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
promoter	O
after	O
addition	O
of	O
gp41	B-PRGE
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

Specific	O
inhibitors	O
of	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
(	O
rapamycin	O
)	O
,	O
and	O
Gi	O
protein	O
(	O
pertussis	O
toxin	O
)	O
,	O
prevented	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
by	O
gp41	B-PRGE
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
(	O
wortmannin	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Thus	O
HIV	O
-	O
1	O
gp41	B-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
up	O
-	O
regulation	O
in	O
monocytes	O
may	O
not	O
involve	O
NF	O
-	O
kappaB	O
,	O
MAPK	O
,	O
or	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	O
cyclase	O
and	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
Gi	O
/	O
Go	O
protein	O
to	O
effect	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
activation	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	O
protein	O
Tax	B-PRGE
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	B-PRGE
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B-PRGE
(	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
)	O
.	O

Whereas	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Tax	B-PRGE
-	O
expressing	O
T	O
-	O
cell	O
lines	O
consisted	O
mostly	O
of	O
p50	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
fresh	O
ATL	O
samples	O
contained	O
p50	B-PRGE
/	O
p50	B-PRGE
and	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	B-PRGE
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	B-PRGE
expression	O
.	O

Interestingly	O
,	O
the	O
NF	O
-	O
kappaB	O
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	B-PRGE
/	O
p50	B-PRGE
and	O
p50	B-PRGE
/	O
p65	B-PRGE
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
a	O
Tax	B-PRGE
-	O
independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	O
-	O
kappaB	O
subunit	O
activation	O
.	O

Apoptosis	O
-	O
resistant	O
T	O
cells	O
have	O
a	O
deficiency	O
in	O
NF	O
-	O
kappaB	O
-	O
mediated	O
induction	O
of	O
Fas	B-PRGE
ligand	I-PRGE
transcription	O
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4	B-PRGE
+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B-PRGE
ligand	I-PRGE
(	O
FasL	B-PRGE
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	B-PRGE
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
production	O
is	O
normal	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL	B-PRGE
-	O
and	O
a	O
consensus	O
NF	O
-	O
kappaB	O
-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	B-PRGE
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	O
-	O
kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FasL	B-PRGE
expression	O
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	B-PRGE
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF	O
-	O
kappaB	O
deprivation	O
.	O

NF	O
-	O
kappaB	O
regulates	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CD95	B-PRGE
-	O
and	O
TCR	O
-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF	O
-	O
kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B-PRGE
/	O
APO	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CD95	B-PRGE
-	O
mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF	O
-	O
kappaB	O
subunits	O
p50	B-PRGE
and	O
p65	B-PRGE
confers	O
resistance	O
against	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	B-PRGE
and	O
p65	B-PRGE
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	B-PRGE
-	O
mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O

Concanavalin	O
A	O
-	O
activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	O
-	O
kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti	O
-	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	O
-	O
kappaB	O
protects	O
against	O
Fas	B-PRGE
-	O
mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34	B-PRGE
+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34	B-PRGE
+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O

We	O
now	O
find	O
that	O
cytokine	O
-	O
driven	O
(	O
granulocyte	O
-	O
macrophage	O
CSF	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
CD34	B-PRGE
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	O
activation	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34	B-PRGE
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
CD34	B-PRGE
+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
CSF	I-PRGE
plus	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic	O
-	O
like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	O
I	O
+	O
/	O
MHC	O
IIbright	O
/	O
CD83	B-PRGE
+	O
/	O
CD86	B-PRGE
+	O
/	O
CD14	B-PRGE
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	B-PRGE
and	O
DC	B-PRGE
-	I-PRGE
CK1	I-PRGE
gene	O
expression	O
.	O

Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC	O
-	O
dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O

Comparison	O
of	O
KG1	O
to	O
the	O
PMA	O
-	O
unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-PRGE
receptors	I-PRGE
1	I-PRGE
and	O
2	B-PRGE
;	O
PKC	B-PRGE
isoforms	I-PRGE
alpha	I-PRGE
,	O
beta	B-PRGE
I	I-PRGE
,	O
beta	B-PRGE
II	I-PRGE
,	O
and	O
mu	B-PRGE
;	O
and	O
RelB	B-PRGE
,	O
suggesting	O
that	O
these	O
components	O
/	O
pathways	O
are	O
important	O
for	O
DC	O
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34	B-PRGE
+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	O
-	O
kappa	O
B	O
or	O
activating	O
protein	O
-	O
1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
/	O
or	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
does	O
not	O
induce	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
degradation	O
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
neither	O
activates	O
JNK	O
nor	O
increases	O
AP	O
-	O
1	O
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	O
the	O
activation	O
of	O
STAT3	B-PRGE
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	O
-	O
kappa	O
B	O
nor	O
AP	O
-	O
1	O
activation	O
is	O
required	O
for	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
(	O
mut	B-PRGE
-	I-PRGE
I	I-PRGE
kappa	I-PRGE
B	I-PRGE
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B-PRGE
-	O
CD25	B-PRGE
+	O
,	O
CD4	B-PRGE
-	O
CD8	O
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-PRGE
beta	I-PRGE
-	I-PRGE
chain	I-PRGE
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Differential	O
regulation	O
of	O
4E	B-PRGE
-	I-PRGE
BP1	I-PRGE
and	O
4E	B-PRGE
-	I-PRGE
BP2	I-PRGE
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL	O
-	O
60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U	O
-	O
937	O
monoblastic	O
cell	O
line	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	B-PRGE
-	I-PRGE
BP1	I-PRGE
and	O
4E	B-PRGE
-	I-PRGE
BP2	I-PRGE
.	O

Induction	O
of	O
HL	O
-	O
60	O
and	O
U	O
-	O
937	O
cell	O
differentiation	O
into	O
monocytes	O
/	O
macrophages	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E	B-PRGE
-	I-PRGE
BP1	I-PRGE
.	O

Dephosphorylation	O
of	O
4E	B-PRGE
-	I-PRGE
BP1	I-PRGE
was	O
also	O
observed	O
when	O
U	O
-	O
937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
/	O
macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	B-PRGE
-	I-PRGE
BP1	I-PRGE
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	B-PRGE
-	I-PRGE
BP2	I-PRGE
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Stimulation	O
of	O
CD40	B-PRGE
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-	O
mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B-PRGE
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B-PRGE
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O

CD40	B-PRGE
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	B-PRGE
negative	O
.	O

CD40	B-PRGE
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B-PRGE
-	O
positive	O
MM	O
by	O
stimulation	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
but	O
not	O
by	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
1beta	I-PRGE
or	O
CD40	B-PRGE
triggering	O
.	O

CD40	B-PRGE
ligation	O
on	O
MM	O
by	O
CD40L	B-PRGE
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	B-PRGE
fusion	O
protein	O
up	O
-	O
regulated	O
their	O
expression	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
MHC	O
class	O
I	O
and	O
class	O
II	O
molecules	O
and	O
their	O
secretion	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
a	I-PRGE
,	O
and	O
granulocyte	B-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
.	O

Furthermore	O
,	O
CD40	B-PRGE
ligation	O
of	O
a	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
+	O
,	O
MelanA	B-PRGE
/	O
MART1	B-PRGE
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
,	O
MelanA	B-PRGE
/	O
MART	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
specific	O
CTL	O
clone	O
.	O

Finally	O
,	O
CD40	B-PRGE
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	B-PRGE
-	O
CD40L	B-PRGE
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B-PRGE
-	O
positive	O
immunogenic	O
human	O
MMs	O
.	O

Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	O
G	O
immune	O
complexes	O
requires	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome	O
-	O
encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	O
NF	O
-	O
kappaB	O
in	O
the	O
inflammatory	O
model	O
.	O

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
the	O
CXC	O
chemokine	O
,	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
were	O
substantially	O
reduced	O
.	O

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	O
vascular	O
adhesion	O
molecule	O
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate	O
-	O
containing	O
liposomes	O
.	O

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O

Lung	O
instillation	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
alveolar	O
macrophage	O
-	O
depleted	O
rats	O
restored	O
the	O
NF	O
-	O
kappaB	O
activation	O
response	O
in	O
whole	O
lung	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
may	O
propagate	O
NF	O
-	O
kappaB	O
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
factor	I-PRGE
(	I-PRGE
TRAF	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
2	B-PRGE
,	O
or	O
3	B-PRGE
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT	O
/	O
S	O
in	O
STP	B-PRGE
-	I-PRGE
A11	I-PRGE
as	O
critical	O
for	O
TRAF	O
association	O
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	B-PRGE
-	I-PRGE
C488	I-PRGE
is	O
critical	O
for	O
TRAF	O
association	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	B-PRGE
-	I-PRGE
C488	I-PRGE
induced	O
NF	O
-	O
kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	O
.	O

The	O
HVS	O
STP	B-PRGE
-	I-PRGE
C488	I-PRGE
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP	B-PRGE
-	I-PRGE
C488	I-PRGE
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat	O
-	O
1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	B-PRGE
dominant	O
-	O
negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	O
in	O
STP	B-PRGE
-	I-PRGE
C488	I-PRGE
-	O
mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Regulation	O
of	O
Fas	B-PRGE
ligand	I-PRGE
expression	O
and	O
cell	O
death	O
by	O
apoptosis	B-PRGE
-	I-PRGE
linked	I-PRGE
gene	I-PRGE
4	I-PRGE
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	B-PRGE
/	O
Fas	B-PRGE
ligand	I-PRGE
(	O
FasL	B-PRGE
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG	O
-	O
4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	O
cell	O
-	O
receptor	O
-	O
induced	O
FasL	B-PRGE
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
ALG	B-PRGE
-	I-PRGE
4	I-PRGE
induced	O
transcription	O
of	O
FasL	B-PRGE
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG	B-PRGE
-	I-PRGE
4	I-PRGE
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B-PRGE
expression	O
.	O

Fas	B-PRGE
/	O
FasL	B-PRGE
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	B-PRGE
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T	O
-	O
cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	B-PRGE
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7	B-PRGE
.	I-PRGE
1	I-PRGE
molecules	O
.	O

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase	O
-	O
1	O
and	O
-	O
3	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
and	O
partially	O
blocked	O
by	O
Ac	O
-	O
DEVD	O
-	O
fmk	O
,	O
suggesting	O
that	O
SN50	O
-	O
mediated	O
apoptosis	O
is	O
caspase	O
-	O
dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N	O
'	O
-	O
tetrakis	O
[	O
2	O
-	O
pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	B-PRGE
ligand	I-PRGE
(	O
CD95	B-PRGE
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	O
death	O
effector	O
proteases	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
like	O
(	O
IL	O
-	O
1	O
converting	O
enzyme	O
)	O
,	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
like	O
(	O
CPP32	B-PRGE
/	O
Yama	B-PRGE
/	O
apopain	B-PRGE
)	O
,	O
and	O
caspase	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
like	O
and	O
without	O
cleavage	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
substrates	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
DNA	B-PRGE
fragmentation	I-PRGE
factor	I-PRGE
-	I-PRGE
45	I-PRGE
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50	O
-	O
induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	O
toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
.	O

Human	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
TLR2	B-PRGE
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	O
-	O
kappaB	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B-PRGE
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	B-PRGE
associates	O
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	B-PRGE
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B-PRGE
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	B-PRGE
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B-PRGE
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	O
-	O
type	O
TLR2	B-PRGE
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	B-PRGE
-	O
mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	B-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
factor	I-PRGE
6	I-PRGE
,	O
and	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	I-PRGE
inducing	I-PRGE
kinase	I-PRGE
,	O
when	O
coexpressed	O
with	O
TLR2	B-PRGE
,	O
abrogate	O
TLR2	B-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B-PRGE
and	O
IL	O
-	O
1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B-PRGE
by	O
DN	O
variants	O
.	O

Activation	O
of	O
the	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
-	O
STAT5a	B-PRGE
pathway	O
after	O
CD40	B-PRGE
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O

CD40	B-PRGE
/	O
CD40	B-PRGE
ligand	I-PRGE
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	B-PRGE
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	B-PRGE
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	B-PRGE
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O

After	O
CD40	B-PRGE
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
(	O
but	O
not	O
of	O
the	O
AP	O
-	O
1	O
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	B-PRGE
is	O
part	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
induced	O
by	O
CD40	B-PRGE
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	B-PRGE
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
tyrosine	O
kinase	O
was	O
associated	O
with	O
CD40	B-PRGE
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	B-PRGE
kinase	I-PRGE
3	I-PRGE
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40	B-PRGE
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B-PRGE
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	B-PRGE
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B-PRGE
-	O
induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B-PRGE
ligand	O
+	O
hyper	O
IgM	O
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B-PRGE
-	O
induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA	B-PRGE
/	O
NFkappaB1	B-PRGE
-	O
binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	O
-	O
binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	B-PRGE
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B-PRGE
and	O
NF	B-PRGE
-	I-PRGE
kappaB1	I-PRGE
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	B-PRGE
/	O
NF	B-PRGE
-	I-PRGE
kappaB1	I-PRGE
binding	O
complexes	O
.	O

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF	O
-	O
kappaB	O
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

Monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG	B-PRGE
-	O
AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
(	O
vWF	B-PRGE
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
,	O
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF	O
-	O
kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
mAECA	O
,	O
but	O
not	O
normal	O
human	O
IgG	B-PRGE
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	O
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
vWF	B-PRGE
secretion	O
.	O

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF	O
-	O
kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	B-PRGE
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	B-PRGE
that	O
constitutively	O
associates	O
with	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
1	I-PRGE
(	I-PRGE
TNFR1	I-PRGE
)	I-PRGE
-	I-PRGE
associated	I-PRGE
death	I-PRGE
domain	I-PRGE
protein	I-PRGE
TRADD	B-PRGE
to	O
mediate	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	B-PRGE
signaling	O
through	O
TRADD	B-PRGE
differs	O
from	O
TNFR1	B-PRGE
signaling	O
through	O
TRADD	B-PRGE
.	O

LMP1	B-PRGE
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	O
-	O
kappaB	O
or	O
synergize	O
with	O
TRADD	B-PRGE
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	B-PRGE
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	B-PRGE
does	O
not	O
require	O
TRADD	B-PRGE
residues	O
294	O
to	O
312	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	B-PRGE
requires	O
TRADD	B-PRGE
residues	O
296	O
to	O
302	O
.	O

LMP1	B-PRGE
is	O
partially	O
blocked	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
TRADD	B-PRGE
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	B-PRGE
,	O
LMP1	B-PRGE
can	O
interact	O
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
LMP1	B-PRGE
does	O
not	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	B-PRGE
or	O
RIP	O
,	O
LMP1	B-PRGE
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	B-PRGE
,	O
TRADD	B-PRGE
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Regulatory	O
effects	O
of	O
interleukin	B-PRGE
-	I-PRGE
11	I-PRGE
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin	B-PRGE
-	I-PRGE
11	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL	B-PRGE
-	I-PRGE
11	I-PRGE
mRNA	O
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
were	O
associated	O
with	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

It	O
is	O
interesting	O
that	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	O
chemokines	O
,	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
cytokine	O
-	O
inducible	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
;	O
the	O
presence	O
of	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
did	O
not	O
affect	O
these	O
chemokines	O
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
.	O

These	O
data	O
indicate	O
that	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
diminished	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
reduced	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

ETS	O
transcription	O
factors	O
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	O
necrosis	B-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
.	O

A	O
reporter	O
construct	O
containing	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
mouse	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264	O
.	O
7	O
macrophage	O
-	O
like	O
cells	O
.	O

The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	B-PRGE
protein	O
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	O
20	O
-	O
bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant	O
-	O
negative	O
ets	O
-	O
binding	O
factor	O
was	O
co	O
-	O
transfected	O
with	O
the	O
reporter	O
gene	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	B-PRGE
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264	O
.	O
7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
inducible	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	O
transcription	O
factors	O
in	O
the	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Abnormal	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65	B-PRGE
-	O
RelA	B-PRGE
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	O
receptor	O
-	O
initiated	O
signaling	O
events	O
and	O
lymphokine	O
production	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
protein	O
complex	O
in	O
lupus	O
T	O
cells	O
.	O

Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-PRGE
Abs	O
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane	O
-	O
mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	O
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
p65	B-PRGE
complexes	O
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-PRGE
protein	O
levels	O
.	O

As	O
p65	B-PRGE
complexes	O
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	B-PRGE
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	O
cytokine	O
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	O
-	O
kB	O
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kB	O
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O

The	O
p53	B-PRGE
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	B-PRGE
molecule	O
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	O
p53	B-PRGE
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	O
type	O
p53	B-PRGE
that	O
inhibits	O
tumor	O
progression	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	O
type	O
p53	B-PRGE
in	O
concert	O
with	O
the	O
nuclear	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Both	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	O
type	O
p53	B-PRGE
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation	O
/	O
proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IKK	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	I-PRGE
inducing	I-PRGE
kinase	I-PRGE
(	O
NIK	B-PRGE
)	O
,	O
IKK	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	B-PRGE
complex	I-PRGE
-	I-PRGE
associated	I-PRGE
protein	I-PRGE
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3	O
-	O
fold	O
greater	O
effect	O
on	O
IKK	B-PRGE
-	I-PRGE
alpha	I-PRGE
than	O
on	O
IKK	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK	B-PRGE
-	I-PRGE
beta	I-PRGE
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
beta	I-PRGE
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	O
-	O
alpha	O
/	O
beta	O
heterodimer	O
with	O
NIK	B-PRGE
,	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
epsilon	I-PRGE
in	O
unstimulated	O
cells	O
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	O
to	O
differential	O
patterns	O
of	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IkappaB	B-PRGE
-	I-PRGE
epsilon	I-PRGE
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IKK	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
and	O
NIK	B-PRGE
remained	O
complex	O
-	O
associated	O
.	O

NIK	B-PRGE
cannot	O
phosphorylate	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	B-PRGE
inhibited	O
stimulus	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
-	B-PRGE
beta	I-PRGE
.	O

Overexpression	O
of	O
IKK	O
complex	O
-	O
associated	O
protein	O
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS	O
-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
which	O
stimulates	O
PKC	B-PRGE
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5	O
'	O
-	O
(	O
N	O
-	O
ethyl	O
)	O
-	O
carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
Jun	B-PRGE
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
both	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
Jun	B-PRGE
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
)	O
or	O
decrease	O
(	O
Jun	B-PRGE
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP	O
-	O
1	O
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	B-PRGE
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B-PRGE
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP	O
-	O
1	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
oncoprotein	O
.	O

The	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
.	O

The	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA	O
-	O
binding	O
domain	O
relative	O
to	O
that	O
of	O
c	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
protein	O
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D	O
-	O
box	O
of	O
the	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
protein	O
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor	O
-	O
receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	O
61	O
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v	B-PRGE
-	I-PRGE
erb	I-PRGE
A	I-PRGE
function	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	B-PRGE
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H	B-PRGE
-	I-PRGE
2Kb	I-PRGE
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-PRGE
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	B-PRGE
/	O
p50	B-PRGE
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
and	O
v	B-PRGE
-	I-PRGE
rel	I-PRGE
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	B-PRGE
/	O
p50	B-PRGE
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1	B-PRGE
/	O
p50	B-PRGE
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild	O
-	O
type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	B-PRGE
/	O
p50	B-PRGE
,	O
c	B-PRGE
-	I-PRGE
and	O
v	B-PRGE
-	I-PRGE
rel	I-PRGE
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	B-PRGE
+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1	O
-	O
induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H	B-PRGE
-	I-PRGE
2Kb	I-PRGE
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
.	O

NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	B-PRGE
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-PRGE
expression	O
on	O
the	O
interaction	O
of	O
NF	O
-	O
kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-PRGE
expression	O
vector	O
.	O

Tax	B-PRGE
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-	O
linking	O
using	O
a	O
palindromic	O
NF	O
-	O
kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	B-PRGE
beta	I-PRGE
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2	O
.	O
10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	B-PRGE
expressing	O
cells	O
the	O
85	O
-	O
kDa	O
protein	O
and	O
a	O
92	O
-	O
kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	B-PRGE
protein	O
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	B-PRGE
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
and	O
thus	O
change	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Anti	O
-	O
CD2	B-PRGE
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	B-PRGE
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	O
-	O
CD2	B-PRGE
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	O
-	O
CD2	B-PRGE
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	O
-	O
CD2	B-PRGE
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	B-PRGE
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	B-PRGE
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-PRGE
with	O
its	O
natural	O
ligand	O
,	O
LFA	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

v	B-PRGE
-	I-PRGE
erbA	I-PRGE
overexpression	O
is	O
required	O
to	O
extinguish	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	B-PRGE
.	O

The	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
oncoprotein	O
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3	O
/	O
T4	O
)	O
receptor	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	O
-	O
specific	O
carbonic	B-PRGE
anhydrase	I-PRGE
II	I-PRGE
(	O
CAII	B-PRGE
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
.	O

This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	B-PRGE
transcription	O
by	O
the	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
oncoprotein	O
and	O
the	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
/	O
T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
activity	O
is	O
dominant	O
over	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
-	O
mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	B-PRGE
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	O
-	O
responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	B-PRGE
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O

The	O
c	B-PRGE
-	I-PRGE
erbA	I-PRGE
-	O
dependent	O
activation	O
of	O
this	O
CAII	B-PRGE
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v	B-PRGE
-	I-PRGE
erbA	I-PRGE
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

NF	O
-	O
X2	O
that	O
binds	O
to	O
the	O
DRA	O
X2	O
-	O
box	O
is	O
activator	O
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

Human	O
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2	O
-	O
box	O
to	O
which	O
nuclear	O
factor	O
X2	O
(	O
NF	O
-	O
X2	O
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	O
-	O
X2	O
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
protein	O
,	O
which	O
together	O
with	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
forms	O
the	O
heterodimeric	O
activator	O
protein	O
-	O
1	O
transcription	O
complex	O
.	O

Whereas	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
heterodimers	O
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2	O
-	O
box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-PRGE
gene	O
expression	O
.	O

Regulation	O
of	O
jun	B-PRGE
and	O
fos	B-PRGE
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M	O
-	O
CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-PRGE
and	O
fos	B-PRGE
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	O
recombinant	O
M	O
-	O
CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
mRNA	O
levels	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	O
-	O
CSF	O
regulates	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
.	O

M	O
-	O
CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun	B-PRGE
-	I-PRGE
B	I-PRGE
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
.	O

We	O
further	O
demonstrate	O
that	O
M	O
-	O
CSF	O
increases	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	B-PRGE
-	I-PRGE
B	I-PRGE
gene	O
.	O

Moreover	O
,	O
M	O
-	O
CSF	O
-	O
induced	O
expression	O
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
fos	B-PRGE
-	I-PRGE
B	I-PRGE
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	O
-	O
CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	O
/	O
fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

cAMP	O
-	O
dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-PRGE
and	O
JunB	B-PRGE
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP	O
-	O
1	O
proteins	O
.	O

We	O
demonstrate	O
that	O
JunD	B-PRGE
,	O
a	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-PRGE
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	O
-	O
,	O
phorbol	O
ester	O
-	O
,	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
inducible	O
enhancer	O
,	O
and	O
JunD	B-PRGE
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
complex	O
,	O
JunB	B-PRGE
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-PRGE
.	O

As	O
a	O
homodimer	O
JunB	B-PRGE
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
,	O
high	O
-	O
affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	B-PRGE
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A	O
-	O
dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP	O
-	O
1	O
-	O
related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP	O
-	O
dependent	O
second	O
-	O
messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-PRGE
and	O
other	O
AP	O
-	O
1	O
-	O
related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB	O
-	O
985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-PRGE
on	O
the	O
cell	O
surface	O
,	O
PLB	O
-	O
985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
strain	O
IIIB	O
.	O

PLB	O
-	O
IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid	O
-	O
specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fms	I-PRGE
proto	O
-	O
oncogene	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB	O
-	O
985	O
.	O

However	O
,	O
in	O
PLB	O
-	O
IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	O
-	O
kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	B-PRGE
beta	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
proteins	O
.	O

Inducibility	O
of	O
endogenous	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
RNA	O
was	O
also	O
increased	O
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

The	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
,	O
but	O
not	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	O
kinase	O
C	O
in	O
the	O
interleukin	B-PRGE
2	I-PRGE
promoter	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-	O
related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	O
in	O
induction	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar	O
-	O
5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
activity	O
in	O
Ar	O
-	O
5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Oct	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	O
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
site	O
located	O
at	O
-	O
150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
differentiation	O
,	O
with	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP	O
-	O
1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP	O
-	O
1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP	O
-	O
1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP	O
-	O
1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
,	O
the	O
generation	O
of	O
AP	O
-	O
1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	B-PRGE
nuclear	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
(	O
HNF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	B-PRGE
cofactor	I-PRGE
of	I-PRGE
HNF	I-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
(	O
DCoH	B-PRGE
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH	B-PRGE
-	O
HNF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	B-PRGE
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	B-PRGE
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	B-PRGE
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-PRGE
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	B-PRGE
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-PRGE
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	B-PRGE
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	B-PRGE
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	B-PRGE
plus	O
two	O
p50s	B-PRGE
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	B-PRGE
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

However	O
,	O
as	O
NF	O
-	O
kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	O
-	O
kappa	O
B	O
should	O
be	O
considered	O
.	O

ETS1	B-PRGE
transactivates	O
the	O
human	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	B-PRGE
and	O
ELF1	B-PRGE
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-	O
47	O
to	O
-	O
40	O
upstream	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	B-PRGE
,	O
but	O
not	O
ELF1	B-PRGE
,	O
can	O
transactivate	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-	O
GGAA	O
-	O
to	O
-	O
GGAT	O
-	O
prevents	O
the	O
binding	O
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	O
of	O
ETS1	B-PRGE
.	O

The	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-PRGE
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-PRGE
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-PRGE
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
rabbit	O
15	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O

The	O
15	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
(	O
lox	B-PRGE
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15	B-PRGE
-	I-PRGE
lox	I-PRGE
gene	O
contains	O
sequences	O
which	O
down	O
-	O
regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	O
cell	O
lines	O
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'	O
silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non	O
-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	B-PRGE
promoter	O
fragment	O
.	O

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
Sp1	B-PRGE
transcription	O
factors	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
-	O
induced	O
,	O
dendritic	O
cell	O
-	O
T	O
-	O
cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	O
factor	O
Sp1	B-PRGE
to	O
drive	O
the	O
HIV	O
-	O
1	O
promoter	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV	O
-	O
1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O

These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki	O
-	O
67	O
cell	O
cycle	O
antigen	O
.	O

The	O
expression	O
and	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	O
cells	O
lack	O
active	O
NF	O
-	O
kappa	O
B	O
but	O
express	O
Sp1	B-PRGE
as	O
expected	O
.	O

DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B-PRGE
,	O
p50	B-PRGE
,	O
and	O
p65	B-PRGE
.	O

However	O
,	O
DCs	O
lack	O
Sp1	B-PRGE
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
purified	O
DCs	O
.	O

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-PRGE
occurs	O
in	O
the	O
heterologous	O
DC	O
-	O
T	O
-	O
cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV	O
-	O
1	O
.	O

Therefore	O
,	O
HIV	O
-	O
1	O
-	O
induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV	O
-	O
1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Costimulation	O
requirement	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
requires	O
T	O
-	O
cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	O
and	O
the	O
auxiliary	O
receptor	O
CD28	B-PRGE
.	O

Several	O
transcription	O
factors	O
participate	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP	O
-	O
1	O
-	O
like	O
factors	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP	O
-	O
1	O
protein	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O

Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	O
,	O
the	O
MAP	O
kinase	O
-	O
related	O
kinase	O
that	O
phosphorylates	O
the	O
transactivation	O
domain	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	O
and	O
CD28	B-PRGE
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	O
kappa	O
B	O
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	O
activation	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP	O
-	O
1	O
/	O
NF	O
-	O
kappa	O
B	O
pathway	O
.	O

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-PRGE
protein	I-PRGE
I	I-PRGE
kappa	I-PRGE
B	I-PRGE
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
to	O
release	O
NF	O
kappa	O
B	O
.	O

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B	O
-	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
complex	O
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
was	O
observed	O
upon	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	O
Factor	B-PRGE
VII	I-PRGE
/	I-PRGE
VIIa	I-PRGE
to	O
the	O
tissue	B-PRGE
factor	I-PRGE
(	I-PRGE
TF	I-PRGE
)	I-PRGE
receptor	I-PRGE
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	B-PRGE
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	B-PRGE
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	B-PRGE
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-PRGE
activity	O
and	O
TF	B-PRGE
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-PRGE
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-PRGE
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

CIITA	B-PRGE
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	O
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	O
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	B-PRGE
class	I-PRGE
II	I-PRGE
transactivator	I-PRGE
(	O
CIITA	B-PRGE
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	B-PRGE
transcripts	O
while	O
MHC	O
class	O
II	O
-	O
negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	O
.	O

The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	O
CIITA	B-PRGE
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B-PRGE
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O

Identification	O
of	O
an	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
associated	O
protein	O
kinase	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	O
sites	O
on	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	O
kappa	O
B	O
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
phosphorylation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS	O
-	O
stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
-	O
bound	O
kinase	O
activity	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Mutational	O
analyses	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	O
sites	O
by	O
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
blocked	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
in	O
a	O
cell	O
-	O
free	O
system	O
using	O
THP	O
-	O
1	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
subsequent	O
dissociation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
.	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
complex	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
NF	O
kappa	O
B	O
,	O
and	O
Sp1	B-PRGE
transcription	O
factors	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
/	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
of	O
human	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
gene	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Functional	O
studies	O
with	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
/	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-	O
73	O
and	O
-	O
36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-	O
181	O
and	O
-	O
73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-	O
224	O
,	O
which	O
was	O
inducible	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
alone	O
.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	O
kappa	O
B	O
activation	O
by	O
the	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimers	O
.	O

Synergistic	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
in	O
monocytic	O
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	O
kappa	O
B	O
p65	B-PRGE
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
.	O

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	O
Sp1	B-PRGE
factor	O
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	O
-	O
I	O
tax	B-PRGE
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
T	O
-	O
cell	O
lines	O
.	O

The	O
HTLV	O
-	O
I	O
transcriptional	O
activator	O
tax	B-PRGE
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
gene	O
induction	O
.	O

Tax	O
-	O
expressing	O
cell	O
lines	O
produce	O
LT	O
biologic	O
activity	O
.	O

An	O
LT	O
promoter	O
(	O
LT	O
-	O
293	O
)	O
CAT	B-PRGE
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	O
-	O
producing	O
C81	O
-	O
66	O
-	O
45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	O
tax	B-PRGE
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1	O
-	O
CAT	B-PRGE
)	O
was	O
inactive	O
in	O
C81	O
-	O
66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
LT	O
gene	O
expression	O
.	O

Tax	B-PRGE
was	O
transfected	O
into	O
HTLV	O
-	O
I	O
-	O
negative	O
human	O
T	O
-	O
cell	O
lines	O
.	O

Jurkat	O
T	O
cells	O
stably	O
expressing	O
tax	B-PRGE
contained	O
elevated	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O

Tax	B-PRGE
co	O
-	O
transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV	O
-	O
I	O
-	O
LTR	O
-	O
CAT	B-PRGE
and	O
kappa	O
B	O
-	O
fos	B-PRGE
-	O
CAT	B-PRGE
and	O
also	O
activated	O
LT	O
-	O
293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	B-PRGE
induced	O
LT	O
-	O
293	O
activity	O
by	O
two	O
-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1	O
-	O
CAT	B-PRGE
.	O

The	O
increase	O
in	O
LT	O
-	O
293	O
CAT	B-PRGE
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	O
-	O
I	O
tax	B-PRGE
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T	O
-	O
cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T	O
-	O
lymphocytes	O
.	O

The	O
regulatory	O
role	O
of	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	O
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T	O
-	O
cells	O
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
lck	B-PRGE
and	O
fyn	B-PRGE
(	O
4	O
-	O
and	O
3	O
-	O
fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
,	O
notably	O
phospholipase	B-PRGE
C	I-PRGE
gamma	I-PRGE
1	I-PRGE
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2	O
+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-PRGE
PTPase	O
and	O
was	O
not	O
observed	O
in	O
CD45	B-PRGE
-	O
deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O

In	O
the	O
CD45	B-PRGE
-	O
negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
gene	O
and	O
accumulation	O
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T	O
-	O
lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	B-PRGE
antigen	O
and	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
-	I-PRGE
chain	I-PRGE
(	O
CD25	B-PRGE
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T	O
-	O
cell	O
antigen	O
receptor	O
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	B-PRGE
2	I-PRGE
production	O
.	O

Pervanadate	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	O
factor	O
.	O

We	O
thus	O
conclude	O
that	O
PTPases	O
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T	O
-	O
lymphocyte	O
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

The	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
promoters	O
,	O
the	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP	O
-	O
1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-	O
mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP	O
-	O
1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	O
-	O
JunD	B-PRGE
or	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
antibody	O
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B	O
-	O
like	O
site	O
binding	O
complexes	O
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	O
against	O
the	O
human	O
Rel	O
family	O
proteins	O
(	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
p65	B-PRGE
,	O
p50	B-PRGE
,	O
and	O
p49	B-PRGE
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	O
-	O
kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	B-PRGE
kappa	I-PRGE
B	I-PRGE
site	O
are	O
FK506	O
-	O
sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
NF	B-PRGE
-	I-PRGE
AT	I-PRGE
and	O
NFIL	B-PRGE
-	I-PRGE
2A	I-PRGE
sites	O
and	O
Ig	B-PRGE
kappa	I-PRGE
B	I-PRGE
site	O
,	O
but	O
also	O
the	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O

Monocyte	O
tethering	O
by	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
regulates	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
secretion	O
.	O

Signal	O
integration	O
and	O
NF	O
-	O
kappa	O
B	O
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	O
monocytes	O
to	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	O
tethering	O
factor	O
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet	O
-	O
activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti	O
-	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
mAb	O
that	O
prevents	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
from	O
binding	O
to	O
its	O
ligand	O
(	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
glycoprotein	I-PRGE
ligand	I-PRGE
-	I-PRGE
1	I-PRGE
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O

These	O
results	O
demonstrate	O
that	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

HMG	B-PRGE
-	I-PRGE
I	I-PRGE
binds	O
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	O
protein	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
to	O
the	O
human	O
gamma	O
-	O
globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma	O
-	O
globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-	O
175	O
T	O
-	O
C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
results	O
in	O
overexpression	O
of	O
gamma	O
-	O
globin	O
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up	O
-	O
regulation	O
of	O
the	O
gamma	O
-	O
globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
does	O
not	O
bind	O
to	O
this	O
mutant	O
sequence	O
.	O

A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis	O
-	O
elements	O
demonstrates	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
binding	O
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	O
complexes	O
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
promoter	O
activity	O
by	O
AML1	O
-	O
related	O
transcription	O
factor	O
,	O
PEBP2	O
.	O

The	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	O
enhancer	O
binding	O
-	O
protein	O
2	O
(	O
PEBP2	O
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O
alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	B-PRGE
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-PRGE
A1	I-PRGE
(	O
an	O
alpha	O
A	O
-	O
gene	O
product	O
)	O
and	O
alpha	B-PRGE
B1	I-PRGE
and	O
alpha	B-PRGE
B2	I-PRGE
(	O
two	O
alpha	O
B	O
-	O
encoded	O
isomers	O
)	O
for	O
their	O
effects	O
on	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

PEBP2	B-PRGE
alpha	I-PRGE
A1	I-PRGE
,	O
alpha	B-PRGE
B1	I-PRGE
,	O
and	O
alpha	B-PRGE
B2	I-PRGE
proteins	O
bound	O
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

PEBP2	B-PRGE
alpha	I-PRGE
A1	I-PRGE
and	O
alpha	B-PRGE
B1	I-PRGE
enhanced	O
the	O
expression	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
/	O
phytohemagglutinin	B-PRGE
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-PRGE
B2	I-PRGE
.	O

Coexpression	O
of	O
alpha	B-PRGE
B1	I-PRGE
and	O
alpha	B-PRGE
B2	I-PRGE
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-PRGE
B1	I-PRGE
/	O
alpha	B-PRGE
B2	I-PRGE
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	O
site	O
-	O
binding	O
protein	O
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	O
alpha	B-PRGE
A1	I-PRGE
antibodies	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	O
alpha	O
A	O
,	O
alpha	O
B	O
(	B-PRGE
AML1	I-PRGE
)	I-PRGE
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	O
in	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	O
isoforms	O
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

Differential	O
induction	O
of	O
the	O
NF	O
-	O
AT	O
complex	O
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O

Stimulation	O
of	O
human	O
CD4	B-PRGE
+	O
T	O
-	O
cell	O
clones	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	O
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	O
and	O
CD25	O
receptors	O
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	O
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O

The	O
inducible	O
factors	O
NK	O
-	O
kappa	O
B	O
,	O
beta	O
E2	O
,	O
CD28RC	B-PRGE
,	O
and	O
AP	O
-	O
1	O
are	O
not	O
expressed	O
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	O
-	O
AT	O
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	O
factors	O
that	O
regulates	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	B-PRGE
protein	O
.	O

The	O
IE2	B-PRGE
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	B-PRGE
)	O
dramatically	O
suppressed	O
this	O
IE2	B-PRGE
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	B-PRGE
,	O
Rb	B-PRGE
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-PRGE
specifically	O
interacts	O
with	O
IE2	B-PRGE
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	B-PRGE
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B-PRGE
.	O

Our	O
results	O
suggest	O
that	O
Rb	B-PRGE
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
its	O
repressor	O
RAZ	B-PRGE
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-PRGE
ZLF	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
product	O
,	O
ZEBRA	B-PRGE
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	B-PRGE
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF	B-PRGE
-	I-PRGE
1	I-PRGE
locus	O
and	O
the	O
adjacent	O
BRLF	B-PRGE
-	I-PRGE
1	I-PRGE
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ZEBRA	B-PRGE
protein	O
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp	O
/	O
Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

Transcripts	O
encoding	O
gp350	B-PRGE
/	I-PRGE
220	I-PRGE
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP	B-PRGE
-	I-PRGE
2A	I-PRGE
or	O
EBER	B-PRGE
-	I-PRGE
1	I-PRGE
loci	O
in	O
infected	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	O
of	O
Sp1	B-PRGE
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	B-PRGE
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-PRGE
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-PRGE
and	O
interleukin	B-PRGE
2	I-PRGE
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	B-PRGE
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	B-PRGE
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	B-PRGE
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	B-PRGE
,	O
and	O
Sp1	B-PRGE
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	O
terminus	O
of	O
CIITA	B-PRGE
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	O
combined	O
immune	O
deficiency	O
.	O

Type	O
II	O
major	O
histocompatibility	O
complex	O
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	O
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	O
class	O
II	O
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	O
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-PRGE
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-PRGE
is	O
an	O
MHC	O
class	O
II	O
gene	O
-	O
specific	O
transcription	O
activator	O
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	O
-	O
terminal	O
acidic	O
domain	O
(	O
amino	O
acids	O
26	O
-	O
137	O
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	O
viral	O
transcription	O
-	O
activating	O
domain	O
.	O

The	O
specificity	O
of	O
CIITA	B-PRGE
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C	O
-	O
terminal	O
residues	O
(	O
amino	O
acids	O
317	O
-	O
1130	O
)	O
.	O

The	O
transactivation	O
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	B-PRGE
alpha	I-PRGE
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	B-PRGE
dependent	O
.	O

Since	O
CIITA	B-PRGE
overexpression	O
in	O
normal	O
cells	O
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-PRGE
expression	O
serves	O
as	O
the	O
on	O
-	O
off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
in	O
lpr	O
CD4	B-PRGE
-	O
CD8	O
-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
binding	O
factor	O
.	O

The	O
inert	O
quality	O
of	O
MRL	O
-	O
Ipr	O
/	O
Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4	B-PRGE
-	O
CD8	O
-	O
(	O
CD4	O
-	O
8	O
-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
response	O
to	O
TCR	O
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	O
-	O
mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-PRGE
and	O
CD3	B-PRGE
zeta	I-PRGE
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
-	O
p65	B-PRGE
heterodimer	O
)	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
factors	O
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF	O
-	O
AT	O
complex	O
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF	O
-	O
AT	O
-	O
binding	O
factor	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF	O
-	O
AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O

GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	O
-	O
like	O
signals	O
.	O

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
gene	O
transcription	O
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-PRGE
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK	O
-	O
1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV	O
-	O
1	O
transactivator	O
protein	O
,	O
tax	B-PRGE
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	B-PRGE
activates	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
through	O
the	O
CK	O
-	O
1	O
/	O
CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
for	O
tax	B-PRGE
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK	O
-	O
1	O
/	O
CD28RE	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
CD28RE	O
and	O
the	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
respond	O
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
gene	O
.	O

Murine	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
1	I-PRGE
alpha	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	B-PRGE
,	O
LD78	B-PRGE
,	O
or	O
AT464	B-PRGE
)	O
are	O
members	O
of	O
the	O
-	O
C	O
-	O
C	O
family	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
chemokines	O
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	O
-	O
derived	O
MIP	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
/	O
GOS19	B-PRGE
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP	B-PRGE
-	I-PRGE
1	I-PRGE
alpha	I-PRGE
/	O
GOS19	B-PRGE
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK	O
-	O
1	O
family	O
)	O
affect	O
the	O
GOS19	B-PRGE
promoter	O
.	O

One	O
member	O
,	O
ICK	B-PRGE
-	I-PRGE
1A	I-PRGE
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK	O
-	O
1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP	O
-	O
1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK	O
-	O
1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	O
-	O
migrating	O
protein	O
-	O
DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK	O
-	O
1	O
binding	O
inactivates	O
the	O
GOS19	O
.	O
1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

Ligand	O
-	O
dependent	O
repression	O
of	O
the	O
erythroid	O
transcription	O
factor	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
the	O
estrogen	B-PRGE
receptor	I-PRGE
.	O

High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha	B-PRGE
-	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
,	O
band	O
3	O
,	O
band	O
4	O
.	O
1	O
,	O
and	O
the	O
erythroid	O
cell	O
-	O
specific	O
histone	O
H5	B-PRGE
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
an	O
erythroid	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-PRGE
receptor	I-PRGE
(	O
ER	B-PRGE
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4	O
-	O
hydroxytamoxifen	O
.	O

ER	B-PRGE
-	O
mediated	O
repression	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ER	B-PRGE
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
ER	B-PRGE
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
ER	B-PRGE
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
of	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
ER	B-PRGE
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
pp90rsk	O
and	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
by	O
pokeweed	O
mitogen	O
in	O
human	O
B	O
cells	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
on	O
the	O
induction	O
of	O
early	B-PRGE
growth	I-PRGE
response	I-PRGE
-	I-PRGE
1	I-PRGE
gene	O
(	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O

PWM	O
regulates	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
gene	O
demonstrated	O
that	O
PWM	O
induced	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
is	O
conferred	O
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	O
kinase	O
(	O
pp90rsk	O
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	O
and	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
(	O
SRF	B-PRGE
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	O
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
in	O
normal	O
human	O
B	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
controls	O
expression	O
of	O
inhibitor	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

Phorbol	O
ester	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
induction	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
and	O
the	O
activation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65	O
-	O
kilodalton	O
transactivating	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
with	O
p65	B-PRGE
restores	O
intracellular	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
expression	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	B-PRGE
plus	O
CD28	B-PRGE
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	B-PRGE
and	O
CD28	B-PRGE
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
-	O
dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O

Long	O
-	O
lasting	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	O
of	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	B-PRGE
+	O
CD28	B-PRGE
activation	O
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	B-PRGE
/	O
p50	B-PRGE
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B	O
-	O
specific	O
complexes	O
were	O
identified	O
as	O
NF	O
-	O
kappa	O
B	O
p50	B-PRGE
-	O
p65	B-PRGE
heterodimer	O
and	O
putative	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
homodimer	O
or	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
-	O
p65	B-PRGE
heterodimer	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	B-PRGE
+	O
CD28	B-PRGE
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
secretion	O
,	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	B-PRGE
+	O
CD28	B-PRGE
.	O

Synergism	O
between	O
the	O
CD3	O
antigen	O
-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	O
/	O
TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and	O
/	O
or	O
CD2	O
proteins	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and	O
/	O
or	O
sn	O
-	O
1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen	O
-	O
derived	O
signals	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	O
-	O
binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	B-PRGE
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
block	O
CD11b	B-PRGE
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL	O
-	O
60	O
granulocytes	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B-PRGE
and	O
p65	B-PRGE
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B-PRGE
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide	O
-	O
differentiated	O
HL	O
-	O
60	O
leukemia	O
cells	O
stimulated	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B-PRGE
integrin	O
expression	O
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O

Furthermore	O
,	O
the	O
p65	B-PRGE
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	B-PRGE
that	O
was	O
produced	O
by	O
formyl	O
-	O
met	O
-	O
leu	O
-	O
phe	O
and	O
TPA	O
.	O

However	O
,	O
the	O
p65	B-PRGE
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	B-PRGE
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Human	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
2	I-PRGE
gene	O
.	O

Intron	O
-	O
exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5	O
'	O
-	O
flanking	O
region	O
.	O

Interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
2	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
is	O
a	O
transcriptional	O
regulatory	O
protein	O
that	O
terminates	O
interferon	B-PRGE
beta	I-PRGE
expression	O
initiated	O
by	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
determined	O
the	O
intron	O
-	O
exon	O
structure	O
of	O
the	O
human	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
on	O
human	O
chromosome	O
4	O
.	O

The	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	O
TATA	O
box	O
.	O

When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	O
by	O
both	O
interferons	O
(	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
gamma	I-PRGE
)	O
and	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
,	O
interferon	B-PRGE
beta	I-PRGE
,	O
and	O
interferon	O
-	O
inducible	O
genes	O
.	O

These	O
data	O
suggest	O
that	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	O
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Overproduction	O
of	O
NFKB2	B-PRGE
(	O
lyt	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
:	O
a	O
mechanism	O
for	O
HTLV	O
-	O
I	O
Tax	B-PRGE
-	O
mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	B-PRGE
protein	O
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	B-PRGE
is	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-PRGE
(	O
lyt	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
are	O
overexpressed	O
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	B-PRGE
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B-PRGE
-	O
dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B-PRGE
(	O
p100	B-PRGE
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B-PRGE
(	O
p52	B-PRGE
)	O
form	O
,	O
induction	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-PRGE
precursor	I-PRGE
is	O
physically	O
associated	O
with	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
with	O
Tax	B-PRGE
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	B-PRGE
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
NFKB2	B-PRGE
alters	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

Autoregulation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transactivator	O
RelA	B-PRGE
(	O
p65	B-PRGE
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O

RelA	B-PRGE
(	O
p65	B-PRGE
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50	B-PRGE
-	O
p65	B-PRGE
NF	O
-	O
kappa	O
B	O
complex	O
and	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
.	O

After	O
cellular	O
activation	O
,	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
-	O
induced	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	B-PRGE
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	B-PRGE
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
but	O
also	O
with	O
other	O
ankyrin	O
motif	O
-	O
rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B2	I-PRGE
(	O
p100	B-PRGE
)	O
and	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B1	I-PRGE
(	O
p105	B-PRGE
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B-PRGE
-	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
RelA	B-PRGE
-	O
p100	B-PRGE
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
activation	O
;	O
(	O
iii	O
)	O
p100	B-PRGE
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B-PRGE
-	O
mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B-PRGE
and	O
p100	B-PRGE
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	O
localization	O
signal	O
of	O
RelA	B-PRGE
,	O
which	O
is	O
required	O
for	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
binding	O
;	O
(	O
v	O
)	O
p100	B-PRGE
inhibition	O
of	O
RelA	B-PRGE
function	O
requires	O
the	O
C	O
-	O
terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B-PRGE
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
alpha	I-PRGE
,	O
nuclear	O
RelA	B-PRGE
stimulates	O
p100	B-PRGE
mRNA	O
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

Calcineurin	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	O
kappa	O
B	O
/	O
MAD3	B-PRGE
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O

The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK	O
-	O
506	O
)	O
.	O

Calcineurin	O
,	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
is	O
the	O
FK	O
-	O
506	O
-	O
and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
partially	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
elements	O
IL	O
-	O
2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	B-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
IL	O
-	O
2E	O
(	O
which	O
binds	O
NF	O
-	O
AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
element	O
.	O

Calcineurin	O
stimulates	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	O
kappa	O
B	O
/	O
MAD3	B-PRGE
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK	O
-	O
506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	O
-	O
dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O

Activation	O
of	O
the	O
interleukin	B-PRGE
6	I-PRGE
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	O
factors	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	O
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	O
interleukin	B-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	O
(	O
LAM	O
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	O
release	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
a	O
dose	O
-	O
response	O
manner	O
.	O

LAM	O
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

Both	O
LAM	O
-	O
and	O
LPS	O
-	O
inducible	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-	O
158	O
to	O
-	O
49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
assay	O
.	O

Two	O
nuclear	O
factor	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
(	O
positions	O
-	O
153	O
to	O
-	O
145	O
and	O
-	O
83	O
to	O
-	O
75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
positions	O
-	O
72	O
to	O
-	O
63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
by	O
both	O
LAM	O
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
sites	O
mediate	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	O
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O

Calcineurin	O
activates	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
in	O
synergy	O
with	O
either	O
protein	O
kinase	O
C	O
or	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
in	O
T	O
cells	O
.	O

Two	O
cis	O
-	O
acting	O
elements	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
gene	O
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM	O
-	O
kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
and	O
a	O
PMA	O
/	O
A23187	O
-	O
induced	O
NF	O
-	O
AT	O
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	O
transcription	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
.	O

Cotransfection	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
-	O
or	O
AP	O
-	O
1	O
(	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
/	O
c	B-PRGE
-	I-PRGE
Fos	I-PRGE
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
significantly	O
augmented	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
containing	O
the	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
the	O
CLE0	O
(	O
AP	O
-	O
1	O
/	O
NF	O
-	O
AT	O
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2	B-PRGE
+	I-PRGE
/	I-PRGE
calmodulin	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
phosphatase	I-PRGE
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
promoter	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF	O
-	O
kappa	O
B	O
-	O
,	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
AT	O
-	O
binding	O
sequences	O
is	O
required	O
for	O
induction	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
gene	O
through	O
PKC	O
-	O
and	O
Ca2	O
+	O
-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	O
receptor	O
-	O
dependent	O
transcription	O
.	O

Interaction	O
between	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
and	O
glucocorticoid	B-PRGE
receptor	I-PRGE
(	O
GR	B-PRGE
)	O
-	O
mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	O
activating	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B-PRGE
-	O
dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O

TPA	O
-	O
GR	B-PRGE
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR	B-PRGE
-	O
responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
-	I-PRGE
transferase	I-PRGE
expression	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	B-PRGE
DNA	O
-	O
binding	O
domain	O
,	O
whereas	O
amino	O
-	O
or	O
carboxyl	O
-	O
terminal	O
domains	O
were	O
dispensable	O
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	O
.	O

Increased	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
and	O
jun	B-PRGE
-	I-PRGE
D	I-PRGE
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP	O
-	O
1	O
/	O
TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	B-PRGE
acetyl	I-PRGE
-	I-PRGE
transferase	I-PRGE
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

The	O
ability	O
of	O
Jun	O
proteins	O
to	O
cooperate	O
with	O
GR	B-PRGE
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
jun	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
or	O
jun	B-PRGE
-	I-PRGE
D	I-PRGE
expression	O
vectors	O
,	O
which	O
augmented	O
GR	B-PRGE
-	O
dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O

Conversely	O
,	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
and	O
jun	B-PRGE
-	I-PRGE
B	I-PRGE
transfection	O
blunted	O
GR	B-PRGE
-	O
dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O

The	O
presence	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
had	O
a	O
negative	O
influence	O
on	O
GR	B-PRGE
function	O
and	O
correlated	O
with	O
the	O
cell	O
-	O
specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	O
with	O
respect	O
to	O
GR	B-PRGE
;	O
high	O
basal	O
expression	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
as	O
well	O
as	O
AP	O
-	O
1	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O

Furthermore	O
overexpression	O
of	O
exogenous	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-PRGE
-	O
dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O

We	O
propose	O
that	O
Jun	O
plays	O
a	O
bifunctional	O
role	O
on	O
GR	B-PRGE
-	O
dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell	O
-	O
specific	O
microenvironment	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
appear	O
to	O
be	O
influential	O
.	O

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
HL	O
-	O
60	O
cell	O
differentiation	O
.	O

The	O
results	O
demonstrate	O
that	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
,	O
designated	O
HL	O
-	O
60	O
/	O
vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
,	O
induces	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c	B-PRGE
-	I-PRGE
fms	I-PRGE
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL	O
-	O
60	O
/	O
vinc	O
revertant	O
(	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
expression	O
,	O
suggests	O
that	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
fra	B-PRGE
-	I-PRGE
1	I-PRGE
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL	O
-	O
60	O
/	O
vinc	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
,	O
whereas	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
is	O
attenuated	O
in	O
the	O
HL	O
-	O
60	O
/	O
vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL	O
-	O
60	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
.	O

Activity	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
Y	O
-	O
peptide	O
was	O
markedly	O
diminished	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	O
-	O
mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun	O
/	O
fos	O
early	O
response	O
gene	O
expression	O
.	O

Initiation	B-PRGE
binding	I-PRGE
repressor	I-PRGE
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-PRGE
h5	I-PRGE
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	B-PRGE
binding	I-PRGE
repressor	I-PRGE
[	O
corrected	O
]	O
(	O
IBR	B-PRGE
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-PRGE
h5	I-PRGE
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	B-PRGE
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B-PRGE
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B-PRGE
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	B-PRGE
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	B-PRGE
and	O
IBF	B-PRGE
.	O

IBR	B-PRGE
is	O
a	O
503	O
-	O
amino	O
-	O
acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99	O
.	O
0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
alpha	B-PRGE
-	I-PRGE
Pal	I-PRGE
factor	I-PRGE
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	B-PRGE
and	O
erected	B-PRGE
wing	I-PRGE
gene	I-PRGE
product	O
(	O
EWG	B-PRGE
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	B-PRGE
and	O
IBF	B-PRGE
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	B-PRGE
/	O
F	B-PRGE
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	O
species	O
.	O

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR	B-PRGE
/	O
F	B-PRGE
harbors	O
the	O
DNA	O
-	O
binding	O
/	O
dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR	B-PRGE
/	O
F	B-PRGE
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	O
.	O

An	O
inhibitory	O
,	O
"	O
dominant	O
-	O
negative	O
,	O
"	O
form	O
of	O
the	O
calcineurin	B-PRGE
catalytic	I-PRGE
(	I-PRGE
A	I-PRGE
)	I-PRGE
subunit	I-PRGE
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	B-PRGE
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B-PRGE
(	I-PRGE
B	I-PRGE
)	I-PRGE
subunit	I-PRGE
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	O
-	O
dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
"	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
"	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B-PRGE
B	I-PRGE
subunit	I-PRGE
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B-PRGE
subunit	I-PRGE
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
"	O
rescued	O
"	O
by	O
overexpression	O
of	O
transfected	O
B	B-PRGE
subunit	I-PRGE
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	B-PRGE
A	I-PRGE
and	O
B	B-PRGE
subunits	I-PRGE
.	O

Modulation	O
of	O
endogenous	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
proportion	O
of	O
HIV	O
-	O
infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
.	O

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
was	O
noted	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
induced	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
but	O
not	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
(	I-PRGE
ra	I-PRGE
)	I-PRGE
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	O
IL	O
-	O
1	O
was	O
involved	O
in	O
LPS	O
-	O
mediated	O
viral	O
production	O
.	O

In	O
this	O
regard	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
inhibited	O
LPS	O
plus	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up	O
-	O
regulation	O
of	O
endogenous	O
IL	B-PRGE
-	I-PRGE
1ra	I-PRGE
production	O
.	O

Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	O
produced	O
viral	O
inducer	O
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
)	O
and	O
an	O
inhibitor	O
(	O
IL	B-PRGE
-	I-PRGE
1ra	I-PRGE
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
promoter	O
-	O
reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
cis	O
-	O
regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B-PRGE
or	O
antibodies	O
to	O
CD3	O
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	O
antibodies	O
or	O
B7	O
-	O
positive	O
(	O
B	O
cells	O
)	O
or	O
B7	O
-	O
negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis	O
-	O
elements	O
.	O

Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
transcriptional	O
regulation	O
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis	O
-	O
elements	O
in	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2	B-PRGE
+	I-PRGE
-	I-PRGE
modulating	I-PRGE
cyclophilin	I-PRGE
ligand	I-PRGE
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2	B-PRGE
+	I-PRGE
-	I-PRGE
modulating	I-PRGE
cyclophilin	I-PRGE
ligand	I-PRGE
(	O
CAML	B-PRGE
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B-PRGE
B	I-PRGE
-	O
binding	O
protein	O
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	O
factors	O
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
CAML	B-PRGE
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	B-PRGE
'	O
s	O
putative	O
membrane	O
-	O
spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	O
C	O
-	O
terminal	O
tail	O
of	O
CAML	B-PRGE
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N	O
-	O
terminal	O
hydrophilic	O
domain	O
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	O
protein	O
motif	O
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O

Interactions	O
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	B-PRGE
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation	O
-	O
dependent	O
,	O
T	O
cell	O
-	O
specific	O
transacting	O
factors	O
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	B-PRGE
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O

Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	B-PRGE
I	I-PRGE
footprinting	O
indicated	O
that	O
nuclear	O
factors	O
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter	O
-	O
proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter	O
-	O
distal	O
site	O
,	O
META	O
(	O
D	O
+	O
)	O
,	O
within	O
the	O
400	O
-	O
base	O
pair	O
META	O
region	O
.	O

Nuclear	O
factors	O
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D	O
-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D	O
+	O
)	O
.	O

META	O
(	O
D	O
+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA	O
-	O
sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
targets	O
did	O
not	O
compete	O
for	O
the	O
META	O
(	O
D	O
+	O
)	O
binding	O
factor	O
(	O
s	O
)	O
.	O

The	O
SV40	B-PRGE
core	O
sequence	O
competed	O
for	O
META	O
(	O
D	O
+	O
)	O
binding	O
factors	O
,	O
but	O
META	O
(	O
D	O
+	O
)	O
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	B-PRGE
probe	O
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D	O
+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell	O
-	O
type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	O
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Monocytic	O
cell	O
type	O
-	O
specific	O
transcriptional	O
induction	O
of	O
collagenase	O
.	O

Interstitial	O
collagenase	O
(	O
MMP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
,	O
a	O
metalloproteinase	O
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	O
I	O
collagen	O
fibrils	O
.	O

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	O
collagen	O
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	O
expression	O
is	O
cell	O
-	O
type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	O
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	O
alter	O
fibroblast	O
collagenase	O
expression	O
.	O

Since	O
promoter	O
elements	O
controlling	O
collagenase	O
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS	O
-	O
or	O
zymosan	O
-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A	O
-	O
binding	O
protein	O
-	O
3	O
site	O
(	O
-	O
83	O
to	O
-	O
91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-	O
102	O
to	O
-	O
105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O

Mutagenesis	O
of	O
the	O
activator	O
protein	O
-	O
1	O
[	O
AP	O
-	O
1	O
]	O
site	O
at	O
-	O
72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS	O
/	O
zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
like	O
site	O
at	O
-	O
20	O
to	O
-	O
10	O
had	O
no	O
effect	O
.	O

Nuclear	O
extracts	O
from	O
LPS	O
-	O
and	O
zymosan	O
-	O
treated	O
cells	O
showed	O
strong	O
AP	O
-	O
1	O
activity	O
by	O
gel	O
-	O
shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP	O
-	O
1	O
complexes	O
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP	O
-	O
1	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	O
transcription	O
in	O
macrophagelike	O
cells	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	O
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
generation	O
,	O
on	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

(	O
2E	O
)	O
-	O
3	O
-	O
[	O
5	O
-	O
(	O
2	O
,	O
3	O
-	O
Dimethoxy	O
-	O
6	O
-	O
methyl	O
-	O
1	O
,	O
4	O
-	O
benzoquinoyl	O
)	O
]	O
-	O
2	O
-	O
nonyl	O
-	O
2	O
-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
gene	O
and	O
on	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF	O
-	O
alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted	O
-	O
type	O
placental	B-PRGE
alkaline	I-PRGE
phosphatase	I-PRGE
(	O
PLAP	B-PRGE
)	O
reporter	O
gene	O
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1	O
.	O
4	O
-	O
kb	O
human	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
.	O

A	O
stable	O
transformant	O
of	O
the	O
PLAP	B-PRGE
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	B-PRGE
activity	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B	O
-	O
1	O
,	O
kappa	O
B	O
-	O
2	O
,	O
kappa	O
B	O
-	O
3	O
,	O
kappa	O
B	O
-	O
4	O
)	O
in	O
human	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
.	O

By	O
using	O
mutated	O
promoter	O
-	O
PLAP	B-PRGE
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF	O
-	O
kappa	O
B	O
sites	O
were	O
necessary	O
for	O
induction	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double	O
-	O
stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF	O
-	O
kappa	O
B	O
consisting	O
of	O
p50	B-PRGE
/	O
p65	B-PRGE
heterodimer	O
bound	O
to	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
recognition	O
sites	O
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
expression	O
.	O

E3330	O
decreased	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
/	O
or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Western	O
blotting	O
analysis	O
with	O
anti	O
-	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	O
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
which	O
is	O
an	O
inhibitory	O
protein	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
role	O
of	O
p16	B-PRGE
in	O
the	O
E2F	O
-	O
dependent	O
thymidine	B-PRGE
kinase	I-PRGE
regulation	O
.	O

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	B-PRGE
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	B-PRGE
,	O
the	O
inhibitor	O
of	O
cyclin	B-PRGE
-	I-PRGE
dependent	I-PRGE
-	I-PRGE
kinase	I-PRGE
-	I-PRGE
4	I-PRGE
and	O
6	B-PRGE
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B-PRGE
protein	I-PRGE
by	O
cyclin	B-PRGE
-	I-PRGE
dependent	I-PRGE
kinases	I-PRGE
4	I-PRGE
and	O
6	B-PRGE
prevents	O
its	O
interaction	O
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	B-PRGE
kinase	I-PRGE
.	O

Although	O
a	O
role	O
of	O
p16	B-PRGE
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	O
-	O
mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-PRGE
kinase	I-PRGE
in	O
phytohemagglutinin	B-PRGE
-	O
stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16	B-PRGE
-	O
negative	O
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
.	O

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B-PRGE
kinase	I-PRGE
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	B-PRGE
kinase	I-PRGE
mRNA	O
expression	O
.	O

Transient	O
expression	O
of	O
p16	B-PRGE
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B-PRGE
protein	I-PRGE
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	O
of	O
p16	B-PRGE
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	B-PRGE
kinase	I-PRGE
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	B-PRGE
protein	I-PRGE
and	O
decrease	O
of	O
free	O
E2F	O
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	B-PRGE
kinase	I-PRGE
promoter	O
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	B-PRGE
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	B-PRGE
protein	I-PRGE
.	O

Rel	B-PRGE
-	O
deficient	O
T	O
cells	O
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B-PRGE
3	I-PRGE
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
.	O

The	O
c	B-PRGE
-	I-PRGE
rel	I-PRGE
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
family	O
of	O
transcription	O
factors	O
.	O

Mice	O
lacking	O
Rel	B-PRGE
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B-PRGE
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	O
surface	O
activation	O
markers	O
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel	B-PRGE
-	O
/	O
-	O
T	O
cells	O
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
)	I-PRGE
chain	I-PRGE
(	O
CD25	B-PRGE
)	O
,	O
CD69	B-PRGE
and	O
L	B-PRGE
-	I-PRGE
selectin	I-PRGE
(	O
CD62	B-PRGE
)	O
is	O
normal	O
in	O
mitogen	O
-	O
activated	O
Rel	B-PRGE
-	O
/	O
-	O
T	O
cells	O
,	O
but	O
cytokine	O
production	O
is	O
impaired	O
.	O

In	O
Rel	B-PRGE
-	O
/	O
-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
,	O
and	O
gamma	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
were	O
only	O
2	O
-	O
to	O
3	O
-	O
fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-PRGE
stimulated	O
Rel	B-PRGE
-	O
/	O
-	O
T	O
cells	O
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	O
.	O

Exogenous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti	O
-	O
CD3	O
-	O
and	O
anti	O
-	O
CD28	B-PRGE
-	O
treated	O
Rel	O
-	O
/	O
-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen	O
-	O
activated	O
Rel	B-PRGE
-	O
/	O
-	O
T	O
cells	O
,	O
lipopolysaccharide	O
-	O
stimulated	O
Rel	B-PRGE
-	O
/	O
-	O
macrophages	O
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

These	O
findings	O
establish	O
that	O
Rel	B-PRGE
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
.	O

Human	O
T	O
lymphotropic	O
virus	O
-	O
I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	O
expression	O
of	O
the	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
,	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

Animal	O
lectins	O
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
a	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
previously	O
designated	O
as	O
epsilon	B-PRGE
BP	I-PRGE
(	O
IgE	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
)	O
,	O
CBP35	B-PRGE
,	O
Mac	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
L	B-PRGE
-	I-PRGE
29	I-PRGE
,	O
and	O
L	B-PRGE
-	I-PRGE
34	I-PRGE
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

Galectin	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	O
,	O
with	O
the	O
notable	O
exception	O
of	O
B	O
and	O
T	O
lymphocytes	O
.	O

We	O
now	O
report	O
that	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-	O
I	O
-	O
infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6T	O
,	O
HUT	O
102	O
,	O
K3T	O
,	O
MT	O
-	O
2	O
,	O
and	O
SLB	O
-	O
I	O
,	O
but	O
is	O
not	O
expressed	O
in	O
non	O
-	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
cell	O
lines	O
such	O
as	O
Jurkat	O
,	O
CEM	O
,	O
and	O
MOLT	O
-	O
4	O
.	O

In	O
addition	O
,	O
the	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
level	O
was	O
markedly	O
increased	O
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV	O
-	O
I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O

The	O
up	O
-	O
regulation	O
of	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
were	O
found	O
in	O
the	O
S1T	O
and	O
ATL	O
-	O
1K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV	O
-	O
I	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
the	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
was	O
significantly	O
up	O
-	O
regulated	O
by	O
expression	O
vectors	O
encoding	O
the	O
40	O
-	O
kd	O
Tax	B-PRGE
protein	O
,	O
a	O
potent	O
transactivator	O
in	O
HTLV	O
-	O
I	O
.	O

Analysis	O
of	O
various	O
Tax	B-PRGE
mutants	O
suggested	O
that	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
promoter	O
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic	O
-	O
AMP	O
-	O
responsive	O
element	O
binding	O
protein	O
/	O
activation	O
transcription	O
factor	O
family	O
of	O
transcription	O
factors	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
induction	O
.	O

Transfection	O
of	O
human	O
promonocytic	O
U	O
-	O
937	O
cells	O
with	O
an	O
HTLV	O
-	O
I	O
Tax	B-PRGE
expression	O
vector	O
induced	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
expression	O
in	O
this	O
cell	O
line	O
.	O

Functionally	O
,	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
was	O
shown	O
to	O
activate	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
in	O
Jurkat	O
T	O
cells	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV	O
-	O
I	O
Tax	B-PRGE
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV	O
-	O
I	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B-PRGE
response	O
element	O
within	O
the	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
correlates	O
with	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
molecules	O
such	O
as	O
CD28	B-PRGE
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
produce	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-PRGE
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	O
factor	O
of	O
mitogenic	O
-	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
MATp35	O
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
.	O

Induction	O
of	O
NF	O
-	O
MATp35	O
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B-PRGE
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF	O
-	O
MATp35	O
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	O
-	O
MATp35	O
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF	O
-	O
MATp35	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
MATp35	O
shows	O
excellent	O
correlation	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
.	O

Preassociation	O
of	O
STAT1	B-PRGE
with	O
STAT2	B-PRGE
and	O
STAT3	B-PRGE
in	O
separate	O
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B-PRGE
or	O
STAT2	B-PRGE
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	O
protein	O
.	O

Similarly	O
,	O
STAT1	B-PRGE
-	O
STAT3	B-PRGE
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O

STAT1	B-PRGE
and	O
STAT2	B-PRGE
or	O
STAT1	B-PRGE
and	O
STAT3	B-PRGE
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	B-PRGE
-	O
STAT2	B-PRGE
signaling	O
complex	O
.	O

Newly	O
translated	O
STAT1	B-PRGE
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B-PRGE
and	O
STAT3	B-PRGE
,	O
but	O
we	O
show	O
that	O
STAT2	B-PRGE
and	O
STAT3	B-PRGE
exist	O
in	O
separate	O
heterocomplexes	O
with	O
STAT1	B-PRGE
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B-PRGE
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Inhibition	O
of	O
p105	B-PRGE
processing	O
by	O
NF	O
-	O
kappaB	O
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
involves	O
proteasome	O
-	O
mediated	O
processing	O
of	O
the	O
NF	B-PRGE
-	I-PRGE
kappaB1	I-PRGE
p105	B-PRGE
precursor	O
protein	O
,	O
which	O
generates	O
the	O
p50	B-PRGE
subunit	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
processing	O
of	O
p105	B-PRGE
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	B-PRGE
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	B-PRGE
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	B-PRGE
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	B-PRGE
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	B-PRGE
or	O
other	O
NF	O
-	O
kappaB	O
subunits	O
,	O
including	O
RelA	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
that	O
physically	O
interact	O
with	O
p105	B-PRGE
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	B-PRGE
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	O
-	O
kappaB	O
subunits	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	B-PRGE
undergoes	O
degradation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B-PRGE
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B-PRGE
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	B-PRGE
are	O
differentially	O
regulated	O
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
of	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O

To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	B-PRGE
or	O
the	O
adult	B-PRGE
globin	I-PRGE
developmental	O
program	O
.	O

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	O
-	O
E2	O
(	O
or	O
AP	O
-	O
1	O
)	O
and	O
GATA	B-PRGE
-	I-PRGE
1	I-PRGE
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	B-PRGE
or	O
the	O
adult	B-PRGE
globin	I-PRGE
genes	I-PRGE
are	O
expressed	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	B-PRGE
or	O
the	O
adult	B-PRGE
globin	I-PRGE
program	O
.	O

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma	B-PRGE
-	I-PRGE
and	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma	B-PRGE
-	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	B-PRGE
or	O
the	O
adult	B-PRGE
globin	I-PRGE
gene	O
.	O

Interleukin	B-PRGE
10	I-PRGE
induced	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	O
protein	O
kinases	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
the	O
expression	O
of	O
the	O
protooncogene	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	O
CD20	B-PRGE
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

RNA	O
was	O
extracted	O
by	O
phenol	O
/	O
chloroform	O
and	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2	O
-	O
4	O
fold	O
increase	O
of	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
2	O
hrs	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
declined	O
to	O
basal	O
levels	O
.	O

The	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
dose	O
-	O
dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng	O
/	O
ml	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

The	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
effect	O
on	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
induced	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
was	O
observed	O
.	O

In	O
addition	O
,	O
H	O
-	O
7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
kinases	O
,	O
significantly	O
blocked	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
mediated	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
induces	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
expression	O
in	O
human	O
B	O
-	O
cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine	O
/	O
threonine	O
kinases	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
stimulates	O
human	O
B	O
-	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	O
-	O
CD3	O
mAb	O
OKT3	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	O
-	O
protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
protein	O
family	O
,	O
the	O
p50	B-PRGE
/	O
p65	B-PRGE
(	O
Rel	B-PRGE
A	I-PRGE
)	O
heterodimeric	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
are	O
able	O
so	O
inhibit	O
NF	O
-	O
kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
up	O
-	O
regulation	O
of	O
CD80	B-PRGE
Ag	I-PRGE
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	O
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
the	O
anti	O
-	O
CD28	B-PRGE
mAb	O
CLB	O
-	O
CD28	O
/	O
1	O
restores	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	O
inhibited	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	O
-	O
regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	B-PRGE
,	O
produced	O
by	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
can	O
inhibit	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Vitamin	O
D3	O
-	O
and	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	O
vitamin	B-PRGE
D3	I-PRGE
receptor	I-PRGE
,	O
retinoic	O
acid	O
receptors	O
,	O
and	O
retinoid	O
X	O
receptors	O
in	O
U	O
-	O
937	O
cells	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	O
and	O
VitD3	O
receptor	O
network	O
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-	O
and	O
VitD3	O
-	O
signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
RA	O
and	O
VitD3	O
receptors	O
[	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
,	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
and	O
VitD3	B-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
]	O
in	O
the	O
U	O
-	O
937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR	B-PRGE
/	O
RXR	O
DNA	O
-	O
binding	O
complexes	O
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element	O
-	O
driven	O
reporter	O
construct	O
.	O

Several	O
DNA	O
-	O
binding	O
complexes	O
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O

Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B-PRGE
beta	I-PRGE
/	O
RXR	O
DNA	O
binding	O
,	O
activated	O
RARE	O
-	O
dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA	O
-	O
stimulated	O
formation	O
of	O
RAR	B-PRGE
beta	I-PRGE
/	O
RXR	O
heterodimers	O
,	O
favoring	O
VDR	B-PRGE
/	O
RXR	O
binding	O
to	O
the	O
RARE	O
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B-PRGE
and	O
CD49f	B-PRGE
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U	O
-	O
937	O
cell	O
differentiation	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA	O
-	O
stimulated	O
,	O
RARE	O
-	O
mediated	O
transcription	O
nor	O
the	O
induced	O
RAR	B-PRGE
-	I-PRGE
beta	I-PRGE
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid	O
-	O
induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	O
-	O
mediated	O
signal	O
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation	O
-	O
inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

Calcium	O
-	O
dependent	O
immediate	O
-	O
early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha	B-PRGE
-	I-PRGE
ras	I-PRGE
.	O

The	O
induction	O
of	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
fos	I-PRGE
,	O
and	O
c	B-PRGE
-	I-PRGE
jun	I-PRGE
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	O
kinases	O
.	O

p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
,	O
a	O
guanine	O
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T	O
-	O
cell	O
signal	O
transduction	O
through	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
.	O

The	O
involvement	O
of	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	O
-	O
AT	O
.	O

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
)	O
and	O
their	O
correlated	O
consequences	O
.	O

The	O
expression	O
of	O
activated	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O

This	O
inhibition	O
of	O
calcium	O
-	O
activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	O
in	O
this	O
regulation	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B-PRGE
(	I-PRGE
ras	I-PRGE
)	O
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
and	O
protein	O
production	O
.	O

These	O
results	O
suggest	O
that	O
p2l	B-PRGE
(	I-PRGE
ras	I-PRGE
)	I-PRGE
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid	O
-	O
and	O
Fas	B-PRGE
-	O
mediated	O
cytotoxicity	O
.	O

Fas	B-PRGE
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

Restimulation	O
of	O
T	O
cell	O
blasts	O
up	O
-	O
regulates	O
Fas	B-PRGE
and	O
Fas	B-PRGE
ligand	I-PRGE
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	B-PRGE
-	O
mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
,	O
whereas	O
etoposide	O
-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
and	O
adenovirus	O
E1B	B-PRGE
19K	I-PRGE
did	O
not	O
interfere	O
with	O
anti	O
-	O
Fas	B-PRGE
killing	O
.	O

In	O
contrast	O
,	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	O
cells	O
normally	O
express	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B-PRGE
-	O
mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Interferons	O
induce	O
normal	O
and	O
aberrant	O
retinoic	B-PRGE
-	I-PRGE
acid	I-PRGE
receptors	I-PRGE
type	I-PRGE
alpha	I-PRGE
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	O
markers	O
.	O

Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	B-PRGE
-	I-PRGE
acid	I-PRGE
receptor	I-PRGE
type	I-PRGE
alpha	I-PRGE
(	O
RAR	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
)	O
and	O
the	O
leukemia	B-PRGE
-	I-PRGE
specific	I-PRGE
retinoic	I-PRGE
acid	I-PRGE
receptor	I-PRGE
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
and	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Up	O
-	O
regulation	O
of	O
RAR	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
and	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
gene	O
expression	O
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
,	O
i	O
.	O
e	O
.	O
,	O
granulocyte	B-PRGE
-	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
receptor	I-PRGE
mRNA	O
and	O
leukocyte	B-PRGE
alkaline	I-PRGE
phosphatase	I-PRGE
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	O
of	O
the	O
myeloid	O
surface	O
markers	O
CD11b	B-PRGE
and	O
CD33	B-PRGE
.	O

The	O
IFN	O
-	O
dependent	O
increase	O
in	O
RAR	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	B-PRGE
-	I-PRGE
RAR	I-PRGE
positive	O
cells	O
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

An	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
response	O
element	O
in	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	O
Stat5	B-PRGE
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
and	O
a	O
GATA	O
family	O
protein	O
.	O

Expression	O
of	O
the	O
human	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
)	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
gene	O
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non	O
-	O
consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non	O
-	O
consensus	O
GAS	O
motif	O
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

Multiple	O
factors	O
including	O
Stat5	B-PRGE
,	O
Elf	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
HMG	B-PRGE
-	I-PRGE
I	I-PRGE
(	I-PRGE
Y	I-PRGE
)	I-PRGE
and	O
GATA	O
family	O
proteins	O
bind	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	O
family	O
protein	O
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
.	O

Thus	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2R	I-PRGE
alpha	I-PRGE
promoter	O
activity	O
requires	O
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	O
and	O
negative	O
regulatory	O
factors	O
.	O

Active	O
suppression	O
of	O
the	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
-	O
encoding	O
AIR	O
-	O
1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
expression	O
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O

Class	O
II	O
molecules	O
are	O
not	O
expressed	O
in	O
plasma	O
cells	O
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell	O
-	O
specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
(	O
CIITA	B-PRGE
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR	O
-	O
1	O
locus	O
derived	O
from	O
CIITA	B-PRGE
-	O
expressing	O
cells	O
do	O
not	O
express	O
CIITA	B-PRGE
-	O
specific	O
transcripts	O
.	O

Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	B-PRGE
coding	O
sequence	O
under	O
the	O
control	O
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
product	O
across	O
species	O
barriers	O
.	O

Interestingly	O
,	O
in	O
CIITA	B-PRGE
-	O
transfected	O
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
heterodimer	O
was	O
not	O
observed	O
.	O

This	O
result	O
was	O
not	O
attributable	O
to	O
lack	O
of	O
HLA	B-PRGE
-	I-PRGE
DQ	I-PRGE
alpha	I-PRGE
or	O
-	B-PRGE
DQ	I-PRGE
beta	I-PRGE
transcription	O
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA	B-PRGE
-	O
transfected	O
hybrids	O
,	O
although	O
at	O
reduced	O
levels	O
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	B-PRGE
-	O
independent	O
mechanism	O
.	O

Silencing	O
of	O
human	O
fetal	B-PRGE
globin	I-PRGE
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	O
beta	O
-	O
globin	O
gene	O
activator	O
protein	O
EKLF	B-PRGE
.	O

Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O

A	O
switch	O
from	O
human	B-PRGE
fetal	I-PRGE
(	I-PRGE
gamma	I-PRGE
)	I-PRGE
-	I-PRGE
to	O
adult	B-PRGE
(	I-PRGE
beta	I-PRGE
)	I-PRGE
-	I-PRGE
globin	I-PRGE
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	B-PRGE
Kruppel	I-PRGE
-	I-PRGE
like	I-PRGE
factor	I-PRGE
(	O
EKLF	B-PRGE
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O

To	O
examine	O
the	O
role	O
of	O
EKLF	B-PRGE
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
we	O
interbred	O
EKLF	B-PRGE
heterozygotes	O
(	O
+	O
/	O
-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
yeast	O
artificial	O
chromosome	O
transgene	O
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B-PRGE
,	O
while	O
human	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
transcripts	O
are	O
elevated	O
approximately	O
5	O
-	O
fold	O
.	O

Impaired	O
silencing	O
of	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
expression	O
identifies	O
EKLF	B-PRGE
as	O
the	O
first	O
transcription	O
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
to	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
switch	O
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	B-PRGE
mediates	O
an	O
adult	O
stage	O
-	O
specific	O
interaction	O
between	O
the	O
beta	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma	B-PRGE
-	I-PRGE
globin	I-PRGE
gene	O
.	O

Nasal	O
NK	O
-	O
and	O
T	O
-	O
cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
.	O

Nasal	O
T	O
/	O
NK	O
-	O
cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T	O
-	O
cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Both	O
NK	O
-	O
and	O
T	O
-	O
cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK	O
-	O
cell	O
and	O
4	O
as	O
T	O
-	O
cell	O
tumours	O
.	O

ISH	O
for	O
EBV	O
-	O
encoded	O
small	O
non	O
-	O
polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O

RT	O
-	O
PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	O
EBNAI	B-PRGE
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	O
membrane	O
proteins	O
,	O
LMP1	B-PRGE
and	O
2	B-PRGE
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	B-PRGE
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1	B-PRGE
+	O
and	O
LMP1	B-PRGE
-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

Although	O
2	O
early	O
lytic	O
transcripts	O
,	O
BZLF1	B-PRGE
and	O
BHRF1	B-PRGE
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	O
of	O
ZEBRA	B-PRGE
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	O
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

Down	O
-	O
regulation	O
of	O
immunogenic	O
proteins	O
(	O
EBNA2	B-PRGE
-	O
EBNA6	B-PRGE
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T	O
-	O
cell	O
surveillance	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140	O
-	O
kDa	O
protein	O
designated	O
Sp140	B-PRGE
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Sp140	B-PRGE
was	O
similar	O
to	O
Sp100	B-PRGE
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O

The	O
carboxyl	O
portion	O
of	O
Sp140	B-PRGE
contained	O
a	O
zinc	O
-	O
finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	B-PRGE
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	B-PRGE
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	B-PRGE
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O

The	O
location	O
of	O
Sp140	B-PRGE
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B-PRGE
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20	O
-	O
methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
'	O
s	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20	O
-	O
epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon	O
-	O
20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20	O
-	O
methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20	O
-	O
methyl	O
-	O
and	O
20	O
-	O
methyl	O
-	O
23	O
-	O
eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Both	O
compounds	O
show	O
about	O
2	O
-	O
fold	O
lower	O
affinity	O
to	O
the	O
VD	B-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30	O
-	O
fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300	O
-	O
fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF	O
-	O
7	O
cells	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10	O
-	O
fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium	O
-	O
mobilizing	O
potency	O
as	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	O
element	O
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	O
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	B-PRGE
receptor	I-PRGE
(	O
AR	B-PRGE
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-	O
508	O
to	O
-	O
501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
AR	B-PRGE
mRNA	O
was	O
upregulated	O
in	O
LNCaP	O
but	O
not	O
in	O
either	O
PC	O
-	O
3	O
or	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CREB	B-PRGE
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	B-PRGE
-	O
CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B-PRGE
.	O

The	O
ability	O
to	O
regulate	O
AR	B-PRGE
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
human	O
cells	O
.	O

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O

Treatment	O
of	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
(	O
the	O
heterodimer	O
p50	B-PRGE
/	O
p65	B-PRGE
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O

Western	O
blot	O
analysis	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
subunits	O
(	O
IkappaB	O
)	O
demonstrated	O
that	O
both	O
IkappaB	B-PRGE
-	I-PRGE
alpha	I-PRGE
proteolysis	O
and	O
p105	B-PRGE
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p	O
-	O
bromophenacyl	O
-	O
bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF	O
-	O
kappaB	O
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O

Moreover	O
,	O
ACH	O
-	O
2	O
cells	O
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
in	O
the	O
supernatants	O
.	O

The	O
importance	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
in	O
NF	O
-	O
kappaB	O
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappaB	O
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
HOCl	O
was	O
detected	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	O
-	O
kappaB	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
.	O

Thymocytes	O
control	O
the	O
CD4	B-PRGE
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O

We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	B-PRGE
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	O
the	O
CD4	B-PRGE
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

The	O
5	O
'	O
-	O
positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4	B-PRGE
-	O
CD8	O
-	O
double	O
-	O
negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double	O
-	O
positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4	O
+	O
CD8int	O
/	O
-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	B-PRGE
gene	O
,	O
is	O
required	O
for	O
CD4	B-PRGE
gene	O
expression	O
in	O
this	O
population	O
.	O

The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	B-PRGE
silencer	O
which	O
inhibits	O
CD4	B-PRGE
gene	O
expression	O
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down	O
-	O
regulate	O
CD4	B-PRGE
gene	O
expression	O
.	O

Unexpectedly	O
,	O
the	O
CD4	B-PRGE
silencer	O
is	O
also	O
active	O
in	O
CD4	B-PRGE
+	O
CD8int	O
/	O
-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti	O
-	O
silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	B-PRGE
expression	O
in	O
this	O
cell	O
population	O
.	O

Altogether	O
,	O
the	O
CD4	B-PRGE
gene	O
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

Triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
differentially	O
modulates	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti	O
-	O
HLA	O
-	O
DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm	O
-	O
6	O
and	O
BV173	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O

Secreted	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
neutralizing	O
antibodies	O
did	O
not	O
upregulate	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

In	O
contrast	O
,	O
released	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
Sc	O
-	O
I	O
,	O
and	O
Raji	O
cells	O
induced	O
by	O
mAb	O
L243	O
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	O
surface	O
HLA	O
-	O
DR	O
antigens	O
;	O
(	O
c	O
)	O
secreted	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
gene	O
expression	O
.	O

BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O

Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

The	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	O
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
.	O

METHODS	O
:	O
THP	O
-	O
1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O

Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O

Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
chloramphenicol	B-PRGE
acetyl	I-PRGE
transferase	I-PRGE
(	O
CAT	B-PRGE
)	O
or	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
.	O

RESULTS	O
:	O
Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
protein	O
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS	O
-	O
stimulated	O
control	O
cells	O
.	O

Cytomegalovirus	O
IE	O
gene	O
products	O
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
activity	O
in	O
both	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
CAT	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
luciferase	O
activity	O
in	O
LPS	O
-	O
stimulated	O
CMV	O
transfected	O
cells	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	O
immediate	O
early	O
gene	O
products	O
significantly	O
enhanced	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
LPS	O
-	O
stimulated	O
cells	O
.	O

The	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
luciferase	O
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoter	O
responsive	O
to	O
IL	O
-	O
1	O
,	O
TNF	B-PRGE
alpha	I-PRGE
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

The	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
enhance	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O

Homodimerization	O
of	O
the	O
human	O
interleukin	B-PRGE
4	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
chain	I-PRGE
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
gamma	I-PRGE
chain	I-PRGE
.	O

The	O
cytokines	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
-	O
binding	O
IL	B-PRGE
-	I-PRGE
4Ralpha	I-PRGE
chain	I-PRGE
,	O
which	O
is	O
shared	O
with	O
the	O
IL	O
-	O
13R	O
,	O
and	O
the	O
IL	B-PRGE
-	I-PRGE
2Rgamma	I-PRGE
(	I-PRGE
gammac	I-PRGE
)	I-PRGE
chain	I-PRGE
,	O
which	O
is	O
shared	O
with	O
IL	B-PRGE
-	I-PRGE
7R	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
9R	I-PRGE
,	O
and	O
IL	O
-	O
15R	O
.	O

IL	B-PRGE
-	I-PRGE
4	I-PRGE
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	B-PRGE
chain	I-PRGE
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	B-PRGE
chain	I-PRGE
may	O
involve	O
signaling	O
via	O
the	O
IL	O
-	O
13R	O
.	O

Alternatively	O
,	O
the	O
IL	B-PRGE
-	I-PRGE
4Ralpha	I-PRGE
chain	I-PRGE
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	B-PRGE
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL	B-PRGE
-	I-PRGE
4Ralpha	I-PRGE
induces	O
Janus	B-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
Jak1	B-PRGE
)	O
activation	O
,	O
STAT6	B-PRGE
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1	B-PRGE
-	O
binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL	B-PRGE
-	I-PRGE
4Ralpha	I-PRGE
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	B-PRGE
CD8alpha	I-PRGE
/	I-PRGE
IL	I-PRGE
-	I-PRGE
4Ralpha	I-PRGE
receptor	I-PRGE
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
4Ralpha	I-PRGE
chain	I-PRGE
is	O
sufficient	O
to	O
transduce	O
Jak1	B-PRGE
-	O
dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	O
-	O
I	O
Tax	B-PRGE
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Tax1	B-PRGE
,	O
a	O
transcriptional	O
trans	O
-	O
activator	O
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB	O
/	O
ATF	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
SRF	B-PRGE
.	O

This	O
Tax1	B-PRGE
-	O
induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B-PRGE
-	O
inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B-PRGE
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4	B-PRGE
+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
SRF	B-PRGE
pathways	O
is	O
also	O
required	O
.	O

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	B-PRGE
receptor	I-PRGE
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	B-PRGE
receptor	I-PRGE
(	O
hMR	B-PRGE
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729	O
-	O
Lys984	O
of	O
hMR	B-PRGE
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	B-PRGE
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	B-PRGE
form	O
and	O
the	O
transformed	O
MR	B-PRGE
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	B-PRGE
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	B-PRGE
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	B-PRGE
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	B-PRGE
complex	O
and	O
the	O
antibody	O
-	O
MR	B-PRGE
complex	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	B-PRGE
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	B-PRGE
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729	O
-	O
Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J	O
.	O
Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol	O
.	O
57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729	O
-	O
Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	B-PRGE
alpha	I-PRGE
.	O

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	B-PRGE
alpha	I-PRGE
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	O
-	O
positive	O
cells	O
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-	O
gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-PRGE
deltaepsilongamma	I-PRGE
and	O
TCR	B-PRGE
zeta	I-PRGE
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	B-PRGE
zeta	I-PRGE
chain	I-PRGE
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	B-PRGE
kinase	I-PRGE
p56	I-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	O
of	O
p65	B-PRGE
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta	O
-	O
chain	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	O
cytokines	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-PRGE
zeta	I-PRGE
chain	I-PRGE
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	O
-	O
chain	O
.	O

An	O
isotype	O
-	O
specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
.	O

Patients	O
with	O
one	O
type	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-PRGE
II	I-PRGE
transactivator	I-PRGE
(	O
CIITA	B-PRGE
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA	O
-	O
DR	O
,	O
-	O
DQ	O
,	O
and	O
-	O
DP	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DP	O
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	B-PRGE
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA	O
-	O
DQ	O
,	O
but	O
not	O
HLA	O
-	O
DR	O
or	O
-	O
DP	O
transcription	O
.	O

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	B-PRGE
,	O
might	O
control	O
HLA	O
-	O
DQ	O
expression	O
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	B-PRGE
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	O
-	O
DQ	O
in	O
another	O
CIITA	B-PRGE
-	O
deficient	O
cell	O
line	O
,	O
RJ2	O
.	O
2	O
.	O
5	O
.	O

In	O
addition	O
,	O
no	O
CIITA	B-PRGE
protein	O
is	O
detectable	O
in	O
clone	O
13	O
nuclear	O
extracts	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2	O
.	O
2	O
.	O
5	O
restored	O
expression	O
of	O
the	O
HLA	O
-	O
DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2	O
.	O
2	O
.	O
5	O
DQB	O
gene	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA	O
-	O
DQ	O
isotype	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
which	O
functions	O
independently	O
of	O
CIITA	B-PRGE
.	O

Induction	O
of	O
cytokine	O
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin	O
-	O
stimulated	O
platelets	O
.	O

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	O
induction	O
by	O
leukocyte	O
-	O
platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte	O
-	O
platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	B-PRGE
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+	O
/	O
-	O
16	O
versus	O
35	O
+	O
/	O
-	O
9	O
;	O
P	O
=	O
.	O
003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin	B-PRGE
-	O
stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
,	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
(	I-PRGE
MCP	I-PRGE
)	I-PRGE
-	I-PRGE
1	I-PRGE
in	O
unfractionated	O
leukocytes	O
.	O

After	O
4	O
hours	O
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	O
by	O
268	O
+	O
/	O
-	O
36	O
%	O
and	O
210	O
+	O
/	O
-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
content	O
had	O
increased	O
by	O
170	O
+	O
/	O
-	O
8	O
%	O
.	O

Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O

Inhibition	O
of	O
binding	O
by	O
anti	O
-	O
P	B-PRGE
selectin	I-PRGE
antibodies	O
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	O
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte	O
-	O
platelet	O
adhesion	O
is	O
increased	O
.	O

Binding	O
of	O
activated	O
platelets	O
induces	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
leukocytes	O
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte	O
-	O
platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

The	O
class	B-PRGE
II	I-PRGE
trans	I-PRGE
-	I-PRGE
activator	I-PRGE
CIITA	B-PRGE
interacts	O
with	O
the	O
TBP	B-PRGE
-	O
associated	O
factor	O
TAFII32	B-PRGE
.	O

The	O
class	B-PRGE
II	I-PRGE
trans	I-PRGE
-	I-PRGE
activator	I-PRGE
(	O
CIITA	B-PRGE
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
proteins	O
.	O

Its	O
N	O
-	O
terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha	O
-	O
helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	O
-	O
helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	B-PRGE
.	O

Moreover	O
,	O
a	O
CIITA	B-PRGE
protein	O
in	O
which	O
both	O
functional	O
alpha	O
-	O
helices	O
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

This	O
activation	O
domain	O
of	O
CIITA	B-PRGE
interacts	O
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	O
,	O
TAFII32	B-PRGE
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N	O
-	O
terminal	O
deletions	O
of	O
CIITA	B-PRGE
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B-PRGE
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	B-PRGE
and	O
CIITA	B-PRGE
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O

Regulation	O
by	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O

Biosynthesis	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O

Functional	O
analysis	O
of	O
monocytic	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-	O
182	O
to	O
-	O
37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	O
in	O
response	O
to	O
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-	O
182	O
to	O
-	O
162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1	B-PRGE
/	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
site	O
,	O
and	O
region	O
II	O
(	O
-	O
119	O
to	O
-	O
88	O
)	O
contained	O
CRE	O
and	O
NF	O
-	O
kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O

In	O
unstimulated	O
THP	O
-	O
1	O
,	O
CRE	O
-	O
binding	O
protein	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
complexes	O
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	O
site	O
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
-	O
containing	O
complexes	O
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	O
factors	O
to	O
the	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
p50	B-PRGE
/	O
p65	B-PRGE
,	O
respectively	O
.	O

The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
complexes	O
and	O
p50	B-PRGE
/	O
p65	B-PRGE
.	O

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
promoter	O
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O

Involvement	O
of	O
Rel	O
,	O
Fos	B-PRGE
,	O
and	O
Jun	B-PRGE
proteins	O
in	O
binding	O
activity	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
CD28	B-PRGE
response	O
element	O
/	O
AP	O
-	O
1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O

CD28	B-PRGE
is	O
an	O
important	O
costimulatory	O
molecule	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	B-PRGE
leads	O
to	O
high	O
level	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-PRGE
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
by	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
/	O
Rel	O
family	O
members	O
as	O
well	O
as	O
an	O
uncharacterized	O
transcription	O
factor	O
called	O
CD28	B-PRGE
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
make	O
up	O
the	O
CD28	B-PRGE
response	O
complex	O
transcription	O
factor	O
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	B-PRGE
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP	O
-	O
1	O
-	O
binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE	O
/	O
AP	O
-	O
1	O
sequence	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP	O
-	O
1	O
site	O
.	O

Of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
tested	O
,	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
contains	O
predominantly	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	B-PRGE
and	O
RelA	B-PRGE
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	O
.	O

c	B-PRGE
-	I-PRGE
Fos	I-PRGE
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
are	O
also	O
found	O
in	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP	O
-	O
1	O
-	O
binding	O
sites	O
influence	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
activity	O
in	O
CD28	B-PRGE
-	O
costimulated	O
T	O
cells	O
.	O

c	B-PRGE
-	I-PRGE
Myb	I-PRGE
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B-PRGE
.	O

The	O
Zfh	O
family	O
of	O
zinc	O
finger	O
/	O
homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	B-PRGE
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh	O
-	O
1	O
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	B-PRGE
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	B-PRGE
blocks	O
the	O
activity	O
of	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	B-PRGE
and	O
transcriptional	O
activation	O
by	O
c	B-PRGE
-	I-PRGE
Myb	I-PRGE
/	O
Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-PRGE
integrin	I-PRGE
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

GABP	O
factors	O
bind	O
to	O
a	O
distal	O
interleukin	B-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
enhancer	O
and	O
contribute	O
to	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	O
mediated	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induction	O
.	O

Triggering	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
-	O
CD3	O
complex	O
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2	O
+	O
-	O
dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	O
kinase	O
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
(	B-PRGE
IL	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
gene	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Prominent	O
protein	O
kinase	O
cascades	O
are	O
those	O
that	O
activate	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O

We	O
show	O
here	O
that	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP	O
-	O
Erk	O
cascade	O
,	O
contributes	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induction	O
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-	O
502	O
to	O
-	O
413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
.	O

Induction	O
of	O
this	O
distal	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
enhancer	O
differs	O
from	O
induction	O
of	O
the	O
proximal	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
enhancer	O
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2	O
+	O
signals	O
.	O

In	O
DNA	O
-	O
protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	O
factors	O
GABP	B-PRGE
alpha	I-PRGE
and	O
-	B-PRGE
beta	I-PRGE
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets	O
-	O
like	O
factors	O
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
enhancer	O
,	O
while	O
overexpression	O
of	O
both	O
GABP	O
factors	O
enhanced	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
promoter	O
-	O
enhancer	O
induction	O
.	O

Overexpression	O
of	O
BXB	B-PRGE
,	O
a	O
constitutive	O
active	O
version	O
of	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
Erk	O
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	O
-	O
mediated	O
promoter	O
-	O
enhancer	O
induction	O
.	O

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c	B-PRGE
-	I-PRGE
Raf	I-PRGE
-	O
induced	O
phosphorylation	O
of	O
GABP	O
factors	O
(	O
E	O
.	O
Flory	O
,	O
A	O
.	O
Hoffmeyer	O
,	O
U	O
.	O
Smola	O
,	O
U	O
.	O
R	O
.	O
Rapp	O
,	O
and	O
J	O
.	O
T	O
.	O
Bruder	O
,	O
J	O
.	O
Virol	O
.	O
70	O
:	O
2260	O
-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	O
factors	O
to	O
the	O
Raf	O
-	O
mediated	O
enhancement	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
induction	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	O
eotaxin	B-PRGE
gene	O
.	O

Eotaxin	B-PRGE
is	O
an	O
eosinophil	O
specific	O
beta	O
-	O
chemokine	O
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Its	O
expression	O
is	O
stimulus	O
-	O
and	O
cell	O
-	O
specific	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	B-PRGE
gene	O
.	O

Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	O
eotaxin	B-PRGE
gene	O
expression	O
and	O
/	O
or	O
mediating	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	O
with	O
nuclear	O
factors	O
like	O
NF	B-PRGE
-	I-PRGE
IL6	I-PRGE
,	O
AP	O
-	O
1	O
,	O
a	O
NF	O
-	O
kappa	O
-	O
B	O
like	O
consensus	O
sequence	O
and	O
gamma	B-PRGE
-	I-PRGE
interferon	I-PRGE
-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/	O
Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
in	O
human	O
THP	O
-	O
1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50	O
/	O
p65	O
containing	O
NF	O
-	O
kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL	O
-	O
8	O
.	O

This	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O

The	O
oxLDL	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	O
prevented	O
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	O
of	O
I	B-PRGE
kappa	I-PRGE
B	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
expression	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
class	B-PRGE
II	I-PRGE
trans	I-PRGE
-	I-PRGE
activator	I-PRGE
(	O
CIITA	B-PRGE
)	O
is	O
a	O
bi	O
-	O
or	O
multi	O
-	O
functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	B-PRGE
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O

CD30	B-PRGE
-	O
dependent	O
degradation	O
of	O
TRAF2	B-PRGE
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	B-PRGE
is	O
a	O
cell	O
-	O
surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

CD30	B-PRGE
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	B-PRGE
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B-PRGE
1	I-PRGE
tumor	I-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
TNFR1	B-PRGE
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	O
-	O
binding	O
sites	O
within	O
the	O
CD30	B-PRGE
cytoplasmic	O
domain	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B-PRGE
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B-PRGE
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O

During	O
CD30	B-PRGE
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-PRGE
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	B-PRGE
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-PRGE
and	O
the	O
associated	O
protein	O
TRAF1	B-PRGE
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	B-PRGE
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	B-PRGE
.	O

Depletion	O
of	O
intracellular	O
TRAF2	B-PRGE
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death	O
-	O
inducing	O
receptors	O
such	O
as	O
TNFR1	B-PRGE
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
TRAF2	B-PRGE
was	O
found	O
to	O
potentiate	O
TNFR1	B-PRGE
-	O
mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	B-PRGE
,	O
as	O
well	O
as	O
other	O
TRAF	O
-	O
binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

TNFalpha	B-PRGE
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV	O
-	O
1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O

Activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	B-PRGE
.	O

Ctx	O
combined	O
with	O
TNFalpha	B-PRGE
or	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-PRGE
antigen	I-PRGE
production	O
in	O
U1	O
promonocytic	O
cells	O
.	O

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-	O
mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	B-PRGE
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
cooperate	O
differently	O
with	O
the	O
cAMP	O
/	O
PKA	O
activation	O
pathway	O
to	O
induce	O
HIV	O
-	O
1	O
expression	O
in	O
U1	O
cells	O
.	O

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP	O
-	O
1	O
-	O
dependent	O
transcription	O
.	O

TNFalpha	B-PRGE
as	O
well	O
as	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP	O
-	O
1	O
-	O
mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B-PRGE
and	O
the	O
cAMP	O
/	O
PKA	O
pathway	O
.	O

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
cannot	O
bind	O
CREB	O
/	O
ATF	O
homodimers	O
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV	O
-	O
1	O
DSE	O
bind	O
heterodimers	O
composed	O
of	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
proteins	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
product	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
engages	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	O
-	O
kappaB	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B-PRGE
is	O
a	O
constitutively	O
activated	O
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
.	O

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	O
residues	O
beyond	O
TES1	O
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	O
interacting	O
proteins	O
,	O
including	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
death	I-PRGE
domain	I-PRGE
protein	I-PRGE
(	O
TRADD	B-PRGE
)	O
.	O

TRADD	B-PRGE
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	O
-	O
type	O
TES2	O
and	O
not	O
with	O
isoleucine	O
-	O
mutated	O
TES2	O
.	O

TRADD	B-PRGE
associated	O
with	O
wild	O
-	O
type	O
LMP1	B-PRGE
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	B-PRGE
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	B-PRGE
constitutively	O
associated	O
with	O
LMP1	B-PRGE
in	O
EBV	O
-	O
transformed	O
cells	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B-PRGE
and	O
TES2	B-PRGE
synergistically	O
mediated	O
high	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	B-PRGE
appropriates	O
TRADD	B-PRGE
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	O
inducible	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
in	O
precursor	O
B	O
lymphocytes	O
.	O

The	O
POU	O
transcription	O
factors	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
regulate	O
the	O
activity	O
of	O
octamer	O
-	O
dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	O
genes	O
.	O

Unlike	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
is	O
restricted	O
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	O
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
an	O
LPS	O
-	O
responsive	O
member	O
of	O
the	O
Rel	O
transcription	O
factor	O
family	O
.	O

Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
gene	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
unaffected	O
.	O

The	O
finding	O
that	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
under	O
NF	O
-	O
kappaB	O
control	O
highlights	O
an	O
important	O
cross	O
-	O
talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	O
factor	O
families	O
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O

Paternal	O
expression	O
of	O
WT1	B-PRGE
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	B-PRGE
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
WT1	B-PRGE
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i	O
.	O
e	O
.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	B-PRGE
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	B-PRGE
and	O
H19	B-PRGE
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B-PRGE
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	B-PRGE
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue	O
-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
OBF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF	O
-	O
kappa	O
B	O
,	O
E47	B-PRGE
)	O
.	O

By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell	O
-	O
expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O

Regulation	O
of	O
Id3	B-PRGE
cell	O
cycle	O
function	O
by	O
Cdk	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
dependent	O
phosphorylation	O
.	O

The	O
functions	O
of	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
in	O
activating	O
differentiation	O
-	O
linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	O
family	O
of	O
HLH	O
proteins	O
.	O

These	O
bHLH	O
antagonists	O
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	O
targets	O
in	O
inactive	O
heterodimers	O
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	O
regulatory	O
(	O
E	O
box	O
)	O
sequences	O
.	O

Recently	O
,	O
cyclin	B-PRGE
E	I-PRGE
-	O
Cdk2	B-PRGE
-	O
and	O
cyclin	B-PRGE
A	I-PRGE
-	O
Cdk2	B-PRGE
-	O
dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	B-PRGE
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	B-PRGE
in	O
abrogating	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E	O
.	O
Hara	O
,	O
M	O
.	O
Hall	O
,	O
and	O
G	O
.	O
Peters	O
,	O
EMBO	O
J	O
.	O
16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell	O
-	O
cycle	O
-	O
regulated	O
phosphorylation	O
of	O
Id3	B-PRGE
alters	O
the	O
specificity	O
of	O
Id3	B-PRGE
for	O
abrogating	O
both	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E	O
-	O
box	O
-	O
dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild	O
-	O
type	O
Id3	B-PRGE
,	O
an	O
Id3	B-PRGE
Asp5	O
mutant	O
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	B-PRGE
Ala5	O
mutant	O
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	O
-	O
type	O
Id3	B-PRGE
protein	O
.	O

Cdk2	B-PRGE
-	O
dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B-PRGE
and	O
modulates	O
its	O
target	O
bHLH	O
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	B-PRGE
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	O
heterodimer	O
-	O
dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	B-PRGE
and	O
Id	O
-	O
bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B-PRGE
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
Th1	O
cells	O
and	O
by	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
Th2	O
cells	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	B-PRGE
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	B-PRGE
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	B-PRGE
induction	O
was	O
completely	O
inhibited	O
by	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B-PRGE
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up	O
-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	O
of	O
IkappaBalpha	B-PRGE
expression	O
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	O
natural	O
antibodies	O
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O

Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1	O
.	O
5	O
dynes	O
/	O
cm2	O
)	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U	O
/	O
ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	O
molecules	O
and	O
chemoattractants	O
.	O

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF	O
-	O
kappa	O
B	O
(	O
p65	B-PRGE
subunit	O
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
this	O
setting	O
.	O

At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O

Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl	O
-	O
phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte	O
-	O
endothelium	O
interaction	O
possibly	O
through	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF	O
-	O
kappaB	O
induction	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
alpha	I-PRGE
expression	O
.	O

The	O
binding	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	O
nuclear	O
expression	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
activation	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
2R	I-PRGE
)	I-PRGE
alpha	I-PRGE
chain	I-PRGE
gene	O
,	O
and	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL	O
-	O
2R	O
signaling	O
in	O
the	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O

Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8	O
+	O
T	O
-	O
PLL	O
expressed	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
and	O
beta	B-PRGE
chains	O
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
2Ralpha	I-PRGE
expression	O
on	O
culture	O
with	O
exogeneous	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Northern	O
blot	O
analysis	O
failed	O
to	O
detect	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	O
,	O
suggesting	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
revealed	O
that	O
recombinant	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF	O
-	O
kappaB	O
components	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
and	O
KBF1	B-PRGE
in	O
these	O
cells	O
.	O

IL	B-PRGE
-	I-PRGE
2	I-PRGE
binding	O
analysis	O
demonstrated	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL	O
-	O
2Rs	O
on	O
the	O
leukemia	O
cells	O
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high	O
-	O
affinity	O
IL	O
-	O
2Rs	O
.	O

These	O
results	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
CD8	O
+	O
T	O
-	O
PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	O
T	O
-	O
cell	O
-	O
line	O
-	O
expressing	O
wild	O
-	O
type	O
and	O
mutated	O
CD4	B-PRGE
receptors	I-PRGE
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	B-PRGE
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
induced	O
apoptosis	O
(	O
J	O
.	O
Corbeil	O
,	O
M	O
.	O
Tremblay	O
,	O
and	O
D	O
.	O
D	O
.	O
Richman	O
,	O
J	O
.	O
Exp	O
.	O
Med	O
.	O
183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	B-PRGE
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O

To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	B-PRGE
cytoplasmic	O
tail	O
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2	O
.	O
01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	B-PRGE
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
(	O
mutated	O
at	O
the	O
dicysteine	O
motif	O
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild	O
-	O
type	O
CD4	B-PRGE
.	O

The	O
differences	O
between	O
wild	O
-	O
type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
or	O
NF	O
-	O
kappaB	O
activation	O
.	O

Initial	O
signaling	O
through	O
the	O
CD4	B-PRGE
receptor	I-PRGE
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8	O
-	O
2	O
,	O
which	O
binds	O
to	O
CD4	B-PRGE
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	B-PRGE
-	O
Fas	B-PRGE
ligand	I-PRGE
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	B-PRGE
MAb	O
(	O
ZB	O
-	O
4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	B-PRGE
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B-PRGE
-	O
Fas	B-PRGE
ligand	I-PRGE
interaction	O
,	O
does	O
not	O
require	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B-PRGE
dimerization	O
.	O

NF	O
-	O
kappaB	O
only	O
partially	O
mediates	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
activation	O
of	O
B	O
cells	O
.	O

The	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
LMP1	B-PRGE
)	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O

LMP1	B-PRGE
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
activation	O
markers	O
.	O

LMP1	B-PRGE
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
one	O
through	O
interactions	O
with	O
TRAF	O
proteins	O
and	O
the	O
other	O
with	O
the	O
TRADD	O
protein	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF	O
-	O
kappaB	O
induction	O
in	O
the	O
up	O
-	O
regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CD71	B-PRGE
by	O
LMP1	B-PRGE
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B-PRGE
activates	O
transcription	O
from	O
p50	B-PRGE
/	O
p65	B-PRGE
-	O
and	O
c	B-PRGE
-	I-PRGE
Rel	I-PRGE
-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	O
IkappaB	O
mutant	O
.	O

ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CD71	B-PRGE
are	O
nevertheless	O
up	O
-	O
regulated	O
by	O
LMP1	B-PRGE
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	O
IkappaB	O
.	O

Furthermore	O
,	O
LMP1	B-PRGE
-	O
induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-PRGE
is	O
unable	O
to	O
activate	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	O
that	O
LMP1	B-PRGE
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF	O
-	O
kappaB	O
.	O

Relationship	O
between	O
IkappaBalpha	B-PRGE
constitutive	O
expression	O
,	O
TNFalpha	B-PRGE
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B-PRGE
into	O
lymphoblastoid	O
cells	O
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B-PRGE
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	O
cell	O
cycle	O
analysis	O
after	O
BrdU	O
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in	O
-	O
situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O

No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-PRGE
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	O
clones	O
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	B-PRGE
transfected	O
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	B-PRGE
treatment	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B-PRGE
treatment	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	O
cells	O
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B-PRGE
gene	O
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B-PRGE
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	O
.	O

Uncoupling	O
activation	O
-	O
dependent	O
HS1	B-PRGE
phosphorylation	O
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	B-PRGE
and	O
CD28	B-PRGE
.	O

CD3	O
,	O
CD2	B-PRGE
,	O
and	O
CD28	B-PRGE
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	B-PRGE
,	O
Cbl	B-PRGE
,	O
p85	O
phosphoinositide	O
3	O
-	O
kinase	O
,	O
and	O
the	O
Src	B-PRGE
family	O
kinases	O
Lck	B-PRGE
and	O
Fyn	B-PRGE
.	O

Ligation	O
of	O
CD3	O
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-PRGE
,	O
a	O
75	O
-	O
kDa	O
hematopoietic	O
cell	O
-	O
specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O

We	O
have	O
examined	O
changes	O
in	O
HS1	B-PRGE
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	O
,	O
CD2	B-PRGE
,	O
and	O
CD28	B-PRGE
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti	O
-	O
CD28	B-PRGE
mAb	O
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	B-PRGE
ligands	O
CD80	B-PRGE
or	O
CD86	B-PRGE
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-PRGE
in	O
Jurkat	O
T	O
cells	O
.	O

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-PRGE
was	O
induced	O
by	O
mitogenic	O
pairs	O
of	O
anti	O
-	O
CD2	B-PRGE
mAbs	O
capable	O
of	O
activating	O
the	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
.	O

Costimulation	O
through	O
CD28	B-PRGE
and	O
/	O
or	O
CD2	B-PRGE
did	O
not	O
modulate	O
the	O
CD3	O
-	O
dependent	O
phosphorylation	O
of	O
HS1	B-PRGE
.	O

In	O
vivo	O
studies	O
indicated	O
that	O
CD3	O
-	O
induced	O
HSI	B-PRGE
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	B-PRGE
family	O
tyrosine	O
kinase	O
Lck	B-PRGE
and	O
the	O
tyrosine	O
phosphatase	O
CD45	B-PRGE
,	O
did	O
not	O
require	O
MEK1	B-PRGE
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	B-PRGE
,	O
and	O
CD2	B-PRGE
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	B-PRGE
.	O

Furthermore	O
,	O
activation	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-PRGE
was	O
not	O
required	O
for	O
NFAT	O
transcriptional	O
activation	O
.	O

IL	B-PRGE
-	I-PRGE
7	I-PRGE
reconstitutes	O
multiple	O
aspects	O
of	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
-	O
mediated	O
signaling	O
.	O

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
is	O
currently	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-PRGE
protein	I-PRGE
kinase	I-PRGE
(	I-PRGE
JAK	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
JAK3	B-PRGE
,	O
STAT5	O
,	O
and	O
STAT6	B-PRGE
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
.	O

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	O
-	O
sensitive	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
mutant	O
were	O
examined	O
.	O

Whereas	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
had	O
little	O
or	O
no	O
effect	O
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	O
-	O
Abl	O
kinase	O
inactivation	O
.	O

IL	B-PRGE
-	I-PRGE
7	I-PRGE
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Myc	I-PRGE
,	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
that	O
occur	O
upon	O
loss	O
of	O
v	O
-	O
Abl	O
kinase	O
activity	O
.	O

IL	B-PRGE
-	I-PRGE
7	I-PRGE
did	O
not	O
maintain	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
-	O
mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
.	O

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
signaling	O
pathways	O
in	O
transformation	O
by	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
signaling	O
cannot	O
substitute	O
for	O
an	O
active	O
v	B-PRGE
-	I-PRGE
Abl	I-PRGE
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O

p21ras	B-PRGE
initiates	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
not	O
phosphatidyl	O
inositol	O
3	O
kinase	O
/	O
PKB	B-PRGE
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	B-PRGE
is	O
activated	O
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
Ras	O
-	O
related	O
GTPase	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PtdIns	O
3	O
-	O
kinase	O
)	O
.	O

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B-PRGE
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	O
/	O
threonine	O
kinase	O
Akt	B-PRGE
/	O
PKB	B-PRGE
.	O

The	O
role	O
of	O
PtdIns	O
3	O
-	O
kinase	O
in	O
Ras	O
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3	O
-	O
kinase	O
to	O
initiate	O
the	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	B-PRGE
/	O
PKB	B-PRGE
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP	O
-	O
1	O
complexes	O
.	O

PtdIns	O
3	O
-	O
kinase	O
signals	O
cannot	O
mimic	O
p21ras	B-PRGE
and	O
induce	O
the	O
Rac	O
mediated	O
responses	O
of	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	O
or	O
Ras	O
activation	O
of	O
AP	O
-	O
1	O
is	O
dependent	O
on	O
PtdIns	O
3	O
-	O
kinase	O
.	O

PKB	B-PRGE
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	B-PRGE
signals	O
are	O
unable	O
to	O
induce	O
Akt	B-PRGE
/	O
PKB	B-PRGE
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	O
function	O
required	O
for	O
Akt	B-PRGE
/	O
PKB	B-PRGE
activation	O
in	O
response	O
to	O
the	O
TCR	O
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3	O
-	O
kinase	O
and	O
Akt	B-PRGE
/	O
PKB	B-PRGE
are	O
not	O
universal	O
Ras	O
effector	O
molecules	O
.	O

Ras	O
can	O
initiate	O
Rac	B-PRGE
-	I-PRGE
1	I-PRGE
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
.	O

Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	O
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3	O
/	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	O
expression	O
of	O
TCRzeta	B-PRGE
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
that	O
are	O
associated	O
with	O
the	O
TCR	O
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	B-PRGE
containing	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
complexes	O
have	O
been	O
noted	O
.	O

These	O
defects	O
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	B-PRGE
,	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	O
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	O
therapy	O
[	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
IFN	B-PRGE
alpha	I-PRGE
-	O
containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	B-PRGE
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
were	O
determined	O
by	O
Western	O
blots	O
of	O
T	O
-	O
cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	O
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
.	O

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	O
treatment	O
were	O
also	O
investigated	O
.	O

TCRzeta	B-PRGE
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
were	O
detected	O
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B-PRGE
(	O
P	O
=	O
0	O
.	O
029	O
)	O
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
(	O
P	O
=	O
0	O
.	O
029	O
)	O
but	O
not	O
CD3epsilon	B-PRGE
(	O
P	O
=	O
0	O
.	O
131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
IFN	B-PRGE
alpha	I-PRGE
-	O
based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	B-PRGE
increased	O
significantly	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	O
of	O
TCRzeta	B-PRGE
or	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B-PRGE
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

Abnormal	O
NFkappaB	O
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
and	O
/	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O

Activation	O
of	O
NFkappaB	O
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	O
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	O
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	O
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-PRGE
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-PRGE
levels	O
were	O
present	O
although	O
kappaB	O
binding	O
was	O
not	O
inducible	O
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	B-PRGE
and	O
p56	B-PRGE
(	I-PRGE
lck	I-PRGE
)	I-PRGE
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B-PRGE
associated	O
molecules	O
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	O
-	O
based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	O
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
IFN	B-PRGE
alpha	I-PRGE
-	O
based	O
treatment	O
.	O

This	O
alteration	O
in	O
NFkappaB	O
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta	B-PRGE
-	O
associated	O
signaling	O
elements	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

Transcriptional	O
regulation	O
of	O
lysosomal	B-PRGE
acid	I-PRGE
lipase	I-PRGE
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	O
factors	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
.	O

Human	O
lysosomal	B-PRGE
acid	I-PRGE
lipase	I-PRGE
(	O
LAL	B-PRGE
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	B-PRGE
-	O
mRNA	O
is	O
induced	O
.	O

This	O
induction	O
is	O
dependent	O
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O

The	O
cell	O
type	O
-	O
specific	O
increase	O
in	O
LAL	B-PRGE
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O

In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-	O
182	O
bp	O
and	O
-	O
107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
to	O
the	O
LAL	B-PRGE
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	O
LAL	B-PRGE
expression	O
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B-PRGE
acid	I-PRGE
lipase	I-PRGE
(	O
LAL	B-PRGE
)	O
expression	O
in	O
THP	O
-	O
1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	B-PRGE
and	O
AP	O
-	O
2	O
.	O

A	O
nongenomic	O
mechanism	O
for	O
progesterone	O
-	O
mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K	O
+	O
channels	O
,	O
Ca2	O
+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage	O
-	O
gated	O
and	O
calcium	O
-	O
activated	O
K	O
+	O
channels	O
(	O
KV	O
and	O
KCa	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2	O
+	O
signaling	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
-	O
driven	O
gene	O
expression	O
are	O
inhibited	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2	O
+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2	O
+	O
signals	O
,	O
but	O
not	O
the	O
Ca2	O
+	O
transient	O
after	O
TCR	O
stimulation	O
.	O

K	O
+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	O
and	O
KCa	O
channels	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K	O
+	O
channels	O
,	O
reducing	O
both	O
Kv1	B-PRGE
.	I-PRGE
3	I-PRGE
and	O
charybdotoxin	O
-	O
resistant	O
components	O
of	O
KV	O
current	O
and	O
KCa	O
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	O
KV	O
channels	O
expressed	O
in	O
cell	O
lines	O
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	O
voltage	O
-	O
gated	O
Na	O
+	O
channel	O
,	O
an	O
inward	O
rectifier	O
K	O
+	O
channel	O
,	O
or	O
on	O
lymphocyte	O
Ca2	O
+	O
and	O
Cl	O
-	O
channels	O
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K	O
+	O
channels	O
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone	O
-	O
induced	O
immunosuppression	O
.	O

Role	O
of	O
IKK1	B-PRGE
and	O
IKK2	B-PRGE
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O

Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
transcription	O
factor	O
family	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
1	O
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	B-PRGE
and	O
IKK2	B-PRGE
.	O

Phosphorylation	O
of	O
the	O
IkappaB	O
cytoplasmic	O
inhibitors	O
,	O
IkappaBalpha	B-PRGE
,	O
IkappaBbeta	B-PRGE
,	O
and	O
IkappaBepsilon	B-PRGE
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
proteins	O
into	O
the	O
nucleus	O
.	O

At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	O
activity	O
in	O
human	O
monocytes	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	O
and	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	B-PRGE
,	O
a	O
dominant	O
negative	O
mutant	O
IKK1	B-PRGE
(	O
K44M	O
)	O
,	O
or	O
wild	O
type	O
IKK2	B-PRGE
did	O
not	O
affect	O
LPS	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
monocytic	O
cells	O
.	O

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B-PRGE
inhibited	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
IKK2	B-PRGE
.	O

Effects	O
of	O
overexpression	O
of	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
on	O
NFkappaB	O
activation	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
and	O
stress	O
-	O
activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O

The	O
association	O
and	O
activation	O
of	O
the	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
protein	O
kinase	O
(	O
IRAK	O
)	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL	O
-	O
1	O
signal	O
transduction	O
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6	O
.	O
1	O
overexpressing	O
human	O
(	O
h	O
)	O
IRAK	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL	O
-	O
1	O
signaling	O
.	O

Overexpression	O
of	O
hIRAK	O
enhanced	O
IL	O
-	O
1	O
-	O
stimulated	O
activation	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N	O
-	O
IRAK	O
)	O
specifically	O
inhibited	O
IL	O
-	O
1	O
-	O
dependent	O
NFkappaB	O
activity	O
.	O

In	O
clones	O
stably	O
overexpressing	O
hIRAK	O
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	O
correlated	O
with	O
a	O
low	O
basal	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL	O
-	O
1	O
-	O
dependent	O
manner	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose	O
-	O
response	O
curve	O
of	O
IL	O
-	O
1	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	O
directly	O
triggers	O
NFkappaB	O
-	O
mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
:	O
permanent	O
overexpression	O
of	O
IRAK	O
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
SAP	O
kinases	O
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Decreased	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O

IL	O
-	O
12	O
is	O
a	O
75	O
-	O
kDa	O
heterodimeric	O
cytokine	O
composed	O
of	O
two	O
covalently	O
linked	O
p35	B-PRGE
and	O
p40	B-PRGE
chains	O
.	O

This	O
pro	O
-	O
inflammatory	O
cytokine	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

Thus	O
,	O
IL	O
-	O
12	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti	O
-	O
inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
.	O

ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL	O
-	O
12	O
heterodimer	O
as	O
well	O
as	O
p40	B-PRGE
monomer	O
by	O
human	O
monocytic	O
cells	O
.	O

This	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
12p40	I-PRGE
mRNA	O
expression	O
.	O

Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	B-PRGE
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
and	O
binding	O
to	O
the	O
p40	B-PRGE
-	O
kappaB	O
site	O
in	O
the	O
p40	B-PRGE
promoter	O
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	B-PRGE
gene	O
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
ASA	O
leads	O
to	O
down	O
-	O
regulation	O
of	O
IL	O
-	O
12	O
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

Membrane	O
-	O
associated	O
lymphotoxin	O
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pathway	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	O
molecule	O
expression	O
and	O
cytokine	O
secretion	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell	O
-	O
mediated	O
EC	O
activation	O
.	O

METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
or	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)	I-PRGE
-	I-PRGE
8	I-PRGE
promoters	O
or	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
.	O

In	O
addition	O
,	O
a	O
dominant	O
-	O
negative	O
mutant	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
I	I-PRGE
(	O
TNFRI	B-PRGE
)	O
expression	O
vector	O
was	O
co	O
-	O
transfected	O
in	O
inhibition	O
studies	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Co	O
-	O
culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
activity	O
.	O

NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p50	B-PRGE
and	O
p65	B-PRGE
)	O
.	O

Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
LTalpha	B-PRGE
)	O
but	O
not	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Furthermore	O
,	O
LTalpha	B-PRGE
was	O
secreted	O
in	O
NK	O
:	O
EC	O
co	O
-	O
cultures	O
.	O

Co	O
-	O
transfection	O
with	O
dominant	O
-	O
negative	O
mutant	O
TNFRI	B-PRGE
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti	O
-	O
human	O
LT	O
sera	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B-PRGE
,	O
leading	O
to	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
transcription	O
of	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	O
TNFRI	B-PRGE
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
.	O

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-	O
associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	B-PRGE
activator	I-PRGE
of	I-PRGE
NF	I-PRGE
-	I-PRGE
kappaB	I-PRGE
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O

Receptor	B-PRGE
activator	I-PRGE
of	I-PRGE
NF	I-PRGE
-	I-PRGE
kappaB	I-PRGE
(	O
RANK	B-PRGE
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O

Its	O
cognate	O
ligand	O
(	O
RANKL	B-PRGE
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B-PRGE
with	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
associated	I-PRGE
factors	I-PRGE
(	I-PRGE
TRAFs	I-PRGE
)	I-PRGE
1	I-PRGE
,	O
2	B-PRGE
,	O
3	B-PRGE
,	O
5	B-PRGE
,	O
and	O
6	B-PRGE
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	O
/	O
RANK	B-PRGE
interaction	O
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	B-PRGE
cytoplasmic	O
tail	O
.	O

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	B-PRGE
-	O
dependent	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
NH2	O
-	O
terminal	O
kinase	O
activities	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O

In	O
particular	O
,	O
TRAF6	B-PRGE
interacted	O
with	O
membrane	O
-	O
proximal	O
determinants	O
distinct	O
from	O
those	O
binding	O
TRAFs	B-PRGE
1	I-PRGE
,	O
2	B-PRGE
,	O
3	B-PRGE
,	O
and	O
5	B-PRGE
.	O

When	O
this	O
membrane	O
-	O
proximal	O
TRAF6	B-PRGE
interaction	O
domain	O
was	O
deleted	O
,	O
RANK	B-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
signaling	O
was	O
completely	O
inhibited	O
while	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
NH2	O
-	O
terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2	O
-	O
terminal	O
truncation	O
mutant	O
of	O
TRAF6	B-PRGE
inhibited	O
RANKL	B-PRGE
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	B-PRGE
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O

Regulation	O
of	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
transcription	O
by	O
Epstein	O
-	O
Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	O
proteins	O
via	O
their	O
interaction	O
with	O
RBP	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	O
proteins	O
on	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

Using	O
RT	O
-	O
PCR	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
was	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
EBV	O
-	O
transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O

The	O
up	O
-	O
regulation	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
EBV	B-PRGE
nuclear	I-PRGE
proteins	I-PRGE
2	I-PRGE
,	O
3	B-PRGE
,	O
4	B-PRGE
,	O
and	O
6	B-PRGE
genes	I-PRGE
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-	O
300	O
region	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B-PRGE
nuclear	I-PRGE
proteins	I-PRGE
3	I-PRGE
and	O
6	B-PRGE
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	O
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O

In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF	O
-	O
kappaB	O
,	O
only	O
RBP	O
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
could	O
be	O
demonstrated	O
in	O
EBV	O
-	O
transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
latent	B-PRGE
membrane	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
led	O
to	O
activation	O
of	O
NF	O
-	O
kappaB	O
that	O
was	O
capable	O
of	O
binding	O
the	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
promoter	O
.	O

The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up	O
-	O
regulate	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
expression	O
,	O
possibly	O
by	O
using	O
RBP	O
,	O
NF	O
-	O
kappaB	O
,	O
or	O
both	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Characterization	O
of	O
the	O
human	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
.	O

Potential	O
role	O
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
gene	O
expression	O
in	O
monocytes	O
.	O

To	O
characterize	O
the	O
human	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O

A	O
TATA	O
-	O
like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	O
for	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	O
to	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
promoter	O
activity	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

Egr	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
serum	B-PRGE
response	I-PRGE
factor	I-PRGE
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+	O
265	O
and	O
+	O
448	O
,	O
respectively	O
.	O

Because	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
we	O
propose	O
that	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
important	O
for	O
the	O
regulation	O
of	O
elk	B-PRGE
-	I-PRGE
1	I-PRGE
transcription	O
in	O
differentiating	O
monocytes	O
.	O

Functional	O
association	O
of	O
Nmi	B-PRGE
with	O
Stat5	O
and	O
Stat1	B-PRGE
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
IFNgamma	B-PRGE
-	O
mediated	O
signaling	O
.	O

Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	B-PRGE
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	B-PRGE
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	B-PRGE
-	I-PRGE
Myc	I-PRGE
interactor	I-PRGE
.	O

We	O
further	O
show	O
that	O
Nmi	B-PRGE
interacts	O
with	O
all	O
STATs	O
except	O
Stat2	B-PRGE
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IFNgamma	B-PRGE
,	O
and	O
demonstrate	O
that	O
Nmi	B-PRGE
augments	O
STAT	O
-	O
mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O

Interestingly	O
,	O
Nmi	B-PRGE
lacks	O
an	O
intrinsic	O
transcriptional	O
activation	O
domain	O
;	O
instead	O
,	O
Nmi	B-PRGE
enhances	O
the	O
association	O
of	O
CBP	O
/	O
p300	O
coactivator	O
proteins	O
with	O
Stat1	B-PRGE
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP	O
/	O
p300	O
can	O
augment	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
and	O
IFNgamma	B-PRGE
-	O
dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B-PRGE
can	O
potentiate	O
STAT	O
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	O
-	O
specific	O
transcription	O
factors	O
.	O
